fluorouracil has been researched along with Cancer of Liver in 3965 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)." | 9.51 | Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022) |
| "A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies." | 9.41 | A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021) |
| "Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC)." | 9.34 | Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. ( Artru, P; Dahan, L; De La Fouchardière, C; Guimbaud, R; Jouve, JL; Lepage, C; Montérymard, C; Pellerin, O; Pernot, S; Raoul, JL; Sefrioui, D; Smith, D; Taieb, J; Tougeron, D, 2020) |
| "Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC)." | 9.30 | Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. ( Boucher, KM; Garrido-Laguna, I; McGregor, K; Orgain, N; Sharma, S; Stenehjem, DD; Thorne, K; Wade, ML; Weis, J; Weldon Gilcrease, G; Whisenant, J, 2019) |
| "Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit." | 9.30 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 9.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior." | 9.27 | Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 9.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)." | 9.24 | A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017) |
| "Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare." | 9.22 | Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016) |
| "This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial." | 9.20 | Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015) |
| "The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)." | 9.20 | Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 9.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC)." | 9.19 | Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. ( Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 9.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)." | 9.19 | Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014) |
| "Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically." | 9.17 | A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. ( Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 9.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| "The purpose of this prospective, nonrandomized, controlled study was to compare the regimen of continuously administering trastuzumab and capecitabine (HX) with the regimen of lapatinib plus capecitabine (LX) for metastatic breast cancer (MBC) patients who are resistant to trastuzumab and have previously received taxane treatment." | 9.17 | Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. ( Bian, L; Jiang, Z; Wang, T; Zhang, S, 2013) |
| "The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib." | 9.17 | Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013) |
| "To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin." | 9.17 | Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013) |
| "The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer." | 9.17 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 9.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "The aim of this phase II study was to investigate the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic breast cancer (MBC) patients heavily pretreated with anthracyclines, taxanes, vinorelbine, gemcitabine, and capecitabine." | 9.16 | Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. ( Hu, XC; Jia, Z; Sun, S; Wang, BY; Wang, LP; Yang, XY; Zhang, J; Zhang, QL, 2012) |
| "Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
| "To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)." | 9.16 | Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 9.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 9.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)." | 9.15 | Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011) |
| "We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 9.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
| "This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)." | 9.15 | Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 9.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)." | 9.14 | Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 9.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "Studies indicate that adjuvant 5-fluorouracil (5-FU) with folinic acid (FA) in colorectal cancer patients with completely resectable liver-limited metastases (LMCRC) offers clinical benefit over surgery alone." | 9.14 | A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. ( Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M, 2009) |
| "To assess the resectability rate of patients with initially unresectable liver-only metastases from colorectal cancer (CRC) after treatment with irinotecan/capecitabine." | 9.14 | A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. ( Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J, 2010) |
| "PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer." | 9.14 | Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. ( Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM, 2010) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 9.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| "Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach." | 9.14 | Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010) |
| "This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC)." | 9.14 | Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ( Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M, 2010) |
| "Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R(0) resection, but potentially resectable after tumor reduction, were given FOLFIRINOX: oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), bolus fluorouracil 400 mg/m(2) and fluorouracil 46-h continuous IV infusion 2,400 mg/m(2), every 2 weeks for a maximum of 12 cycles." | 9.13 | Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. ( Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 9.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 9.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "To examine whether carbogen and nicotinamide increases 5-fluorouracil (5-FU) delivery to colorectal cancer metastases." | 9.12 | Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. ( Aboagye, EO; Gupta, N; Hoskin, PJ; Jones, T; Kötz, B; Osman, S; Phillips, R; Price, PM; Saleem, A; Vernon, C; Wasan, H, 2006) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 9.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)." | 9.12 | Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 9.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 9.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer." | 9.12 | Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007) |
| "The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches." | 9.12 | Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 9.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 9.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 9.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)." | 9.11 | Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 9.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 9.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 9.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 9.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "HLA-A2-positive patients with confirmed newly diagnosed metastatic colorectal cancer and elevated serum carcinoembryonic antigen (CEA) were randomized to receive three cycles of standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) and vaccinations with CEA-derived CAP-1 peptide admixed with different adjuvants [CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2 (IL-2), CAP-1/dSLIM/IL-2, and CAP-1/IL-2]." | 9.11 | Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. ( Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 9.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| "We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment." | 9.10 | Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 9.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics." | 9.10 | Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003) |
| "To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC)." | 9.10 | Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. ( Baum, U; Brückl, W; Fuchs, F; Günther, K; Hahn, EG; Hanke, B; Hohenberger, W; Merkel, S; Ott, R; Papadopoulos, T; Reck, T; Riedel, C; Wein, A, 2003) |
| " We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver." | 9.10 | Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 9.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| " irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer." | 9.10 | Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003) |
| "We investigated the pharmacokinetics (PK), preliminary clinical results and toxicity of chronomodulated oxaliplatin (OHP) plus 5-fluorouracil (5-FU) without folinic acid (FA) in 13 patients with metastatic colorectal cancer." | 9.10 | Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. ( Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Infante, L; La Grotta, G; Passera, R, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "Twenty-two patients with unresectable liver metastases from colorectal cancer were treated with continuous HAI of 300 mg/m2 5-fluorouracil for 5 days a week and 6 mg/m2 cisplatin for 2 hours on 5 consecutive days a week." | 9.10 | Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Tajima, T; Toh, Y; Yamamoto, M, 2002) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 9.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated." | 9.10 | Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 9.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer." | 9.10 | Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. ( Amadori, D; Cruciani, G; Giovanis, P; Marangolo, M; Nicolini, M; Oliverio, G; Panzini, I; Pasquini, E; Ravaioli, A; Rossi, A; Tassinari, D; Turci, D; Zumaglini, F, 2002) |
| "This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma." | 9.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
| "To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy." | 9.09 | Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999) |
| "Previous studies demonstrated that chemotherapy with either cisplatin, vincristine, and fluorouracil (regimen A) or cisplatin and continuous infusion doxorubicin (regimen B) improved survival in children with hepatoblastoma." | 9.09 | Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. ( Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; King, DR; Krailo, MD; Liu-Mares, W; Ortega, JA; Quinn, JJ; Reynolds, M; Sensel, MG, 2000) |
| "The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy." | 9.09 | Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 9.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| "Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2)." | 9.09 | Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ( Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001) |
| "A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma." | 9.08 | 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995) |
| "A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil (FU) with both leucovorin (LV) and cisplatin (CDDP) against liver metastases of colorectal cancer was devised." | 9.08 | [A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer]. ( Fukada, D; Kato, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tsuji, K; Umemoto, T, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 9.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| "Between September 1990 and August 1994, 11 patients (pts) with liver metastases (mets) from colorectal cancer were treated with continuous hepatic arterial infusion chemotherapy of 5-fluorouracil (FU) plus leucovorin (LV)." | 9.08 | [Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer]. ( Ban, K; Higashi, H; Imanari, T; Ishihara, S; Kitazaki, M; Masuda, K; Matsumoto, M; Noma, M; Ota, M; Shida, H, 1995) |
| "A carboplatin and 5-fluorouracil (CF) chemotherapy protocol was designed to evaluate tumor response and toxicity in patients with metastatic nasopharyngeal carcinoma (NPC)." | 9.08 | Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. ( Chan, AT; Johnson, PJ; Lee, WY; Leung, SF; Leung, TW; Teo, PM; Yeo, W, 1996) |
| "Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide." | 9.08 | Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 9.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy." | 9.08 | Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). ( Asselain, B; Beuzeboc, P; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Palangié, T; Pierga, JY; Pouillart, P; Scholl, S, 1998) |
| "We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19." | 9.07 | Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993) |
| "25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)." | 9.07 | Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993) |
| "Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days." | 9.07 | Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993) |
| " This prospective phase II study evaluates the efficacy and toxicity of hepatic arterial infusion of 5-Fluorouracil (5-FU) via an implantable Infusaid pump in previously untreated patients with localised but unresectable hepatic metastases from colorectal cancer." | 9.07 | Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver. ( Boyle, FM; Levi, JA; Smith, RC, 1993) |
| "Treatment results in advanced colorectal cancer have improved during the last decade since the incorporation of agents like folinic acid, PALA, or interferon as active biomodulation of 5-fluorouracil (5-FU), the most potent drug in this disease." | 9.07 | A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. ( Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2." | 9.07 | Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial. ( Günther, E; Hinrichs, HF; Hirschmann, WD; Koniczek, KH; Natt, F; Sondern, W; Steinke, B; Wagner, T; Wander, HE; Werdier, D, 1992) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 9.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver." | 9.07 | Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 9.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver." | 9.07 | Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 9.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 9.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 8.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| "New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)." | 8.82 | [Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004) |
| "Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs." | 8.80 | Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 8.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy." | 8.79 | Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994) |
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 8.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| "A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen." | 8.77 | [Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989) |
| "Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)." | 8.31 | Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023) |
| "Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown." | 8.31 | Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023) |
| "0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)." | 8.12 | Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 8.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| "Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)." | 8.12 | One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022) |
| "Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells." | 8.02 | [Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021) |
| " The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown." | 8.02 | Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021) |
| " sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)." | 8.02 | Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021) |
| "To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)." | 8.02 | Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021) |
| "The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)." | 7.96 | Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020) |
| "Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 7.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
| "The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk." | 7.91 | Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019) |
| "Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab." | 7.91 | Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. ( Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W, 2019) |
| "5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer." | 7.91 | 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019) |
| "A case of hyperammonemia induced by chemotherapy, including high-dose fluorouracil(5-FU), for advanced unresectable large intestinal cancer has been reported." | 7.91 | [Case of Hyperammonemia Induced by High-Dose Fluorouracil]. ( Abe, M; Hagiwara, A; Kusakabe, A; Mafune, K; Saito, M, 2019) |
| "To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 7.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs." | 7.88 | Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018) |
| "The combination of platinum with 5-fluorouracil has scarcely been studied in metastatic breast cancer." | 7.88 | Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. ( Biagioni, C; Biganzoli, L; DI Leo, A; Malorni, L; McCartney, A; Moretti, E; Pestrin, M; Risi, E; Rossi, L; Sanna, G, 2018) |
| "5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)." | 7.88 | lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018) |
| "We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats." | 7.88 | Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018) |
| "Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)." | 7.85 | The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017) |
| "This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)." | 7.85 | The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017) |
| "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose." | 7.85 | Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 7.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| " Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism." | 7.83 | Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016) |
| "To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 7.83 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016) |
| "This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China." | 7.83 | FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 7.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| " Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)." | 7.81 | Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015) |
| " The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)." | 7.81 | Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015) |
| "To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)." | 7.81 | Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 7.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
| "5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)." | 7.80 | The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014) |
| "Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 7.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
| "To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 7.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
| "This study proposed a conception of individualized chemotherapy based on organ selectivity of drug distribution by retrospectively comparing the effect of vinorelbine and capecitabine in patients with metastatic breast cancer." | 7.80 | Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer. ( Cao, R; Liu, C; Liu, XH; Man, YN; Wu, XZ, 2014) |
| "Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)." | 7.80 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014) |
| "5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma." | 7.80 | Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014) |
| " The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells." | 7.80 | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014) |
| "Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC)." | 7.80 | Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. ( Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D, 2014) |
| "We report a case of a trastuzumab-resistant human epidermal growth factor receptor-2(HER2)-positive breast cancer patient with extensive liver metastases and associated impaired liver function, who showed an excellent response to the combination of trastuzumab and capecitabine." | 7.79 | [Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report]. ( Fujiuchi, N; Misumi, M; Nakamiya, N; Osaki, A; Saeki, T; Shigekawa, T; Sugitani, I; Sugiyama, M; Takeuchi, H, 2013) |
| "The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma." | 7.79 | Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 7.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma." | 7.79 | Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013) |
| "Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable." | 7.79 | Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013) |
| "To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)." | 7.79 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 7.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 7.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
| "We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 7.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 7.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)." | 7.78 | Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012) |
| "Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro." | 7.78 | Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 7.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| "Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols." | 7.78 | Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012) |
| "A 55-year-old woman with a 3-year and 4-month history of liver metastasis from breast cancer underwent chemotherapy with capecitabine and cyclophosphamide for following 10-months." | 7.78 | [Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer]. ( Ishikawa, T; Tukamoto, Y; Yasaki, S; Yoshii, F; Yuasa, N, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 7.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| "The aim was to evaluate activity and toxicity of hepatic arterial infusion of oxaliplatin in combination with capecitabine in patients with metastatic breast cancer with liver metastases and limited extrahepatic disease." | 7.78 | Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer. ( Bergenfeldt, M; Hermann, KL; Jensen, BK; Jensen, BV; Nelausen, KM; Nielsen, DL; Nørgaard, H; Pfeiffer, P; Vestermark, LW, 2012) |
| "Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is a promising treatment for colorectal, breast and gastric cancers, but often causes hand-foot syndrome (HFS), the most common dose-limiting toxicity." | 7.78 | Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. ( Azuma, Y; Fujiwara, Y; Hata, K; Hirakawa, A; Makino, Y; Morikawa, N; Ryushima, Y; Sai, K; Saito, Y; Tohkin, M; Udagawa, R; Yamamoto, H; Yokote, N, 2012) |
| "Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 7.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 7.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 7.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
| "Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings." | 7.77 | Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011) |
| "This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 7.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)." | 7.77 | Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011) |
| "To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.77 | Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011) |
| "We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches." | 7.77 | Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| "To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms." | 7.77 | Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011) |
| "Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization." | 7.77 | Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011) |
| "We report a 55-year-old female with liver metastases from breast cancer who responded to lapatinib and capecitabine combination therapy as third-line." | 7.77 | [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy]. ( Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H, 2011) |
| "We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)." | 7.77 | [A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 7.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 7.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 7.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| "Capecitabine + docetaxel combination therapy proves highly effective against the advanced or recurrent breast cancer." | 7.76 | [An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6]. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T, 2010) |
| "Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in advanced colorectal cancer patients." | 7.76 | Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. ( Auman, JT; Deal, AM; Hoskins, JM; Hudson, ML; Ibrahim, JG; McLeod, HL; Meyers, MO; Muhale, F; O'Neil, BH; Thorne, LB; Walko, CM; Watson, RG; Yu, J, 2010) |
| "We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)." | 7.76 | MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010) |
| "This retrospective study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU) for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy." | 7.76 | Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. ( Arai, Y; Aramaki, T; Boku, N; Inaba, Y; Kichikawa, K; Matsuoka, M; Nishiofuku, H; Otsuji, T; Sato, Y; Tanaka, T, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 7.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer." | 7.75 | Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009) |
| "Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 7.75 | Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009) |
| "We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)." | 7.75 | Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009) |
| "Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)." | 7.75 | Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009) |
| "In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis." | 7.75 | Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009) |
| "The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)." | 7.75 | Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009) |
| "We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC)." | 7.74 | Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. ( Alessandroni, P; Baldi, G; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B, 2008) |
| "Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo." | 7.74 | [Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 7.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)." | 7.74 | Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007) |
| " The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis." | 7.74 | Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007) |
| "This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients." | 7.74 | Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007) |
| "We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration." | 7.74 | Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 7.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003." | 7.74 | [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007) |
| "We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor." | 7.74 | Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007) |
| "We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results." | 7.74 | Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007) |
| "Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis." | 7.74 | Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| "Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| "Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease." | 7.74 | [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. ( Fujii, H; Inoue, A; Inoue, M; Inoue, S; Kunitomo, K; Takahashi, H, 2008) |
| "The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)." | 7.74 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008) |
| "Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma." | 7.73 | Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005) |
| "To determine whether the nonselective and relatively inexpensive nonsteroidal anti-inflammatory drug ibuprofen would be effective in inhibiting colorectal cancer and might improve mortality in a mouse model." | 7.73 | Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 7.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)." | 7.73 | Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005) |
| "We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 7.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
| "We identified genes related to 5-fluorouracil (5-FU) sensitivity in colorectal cancer and utilized these genes for predicting the 5-FU sensitivity of liver metastases." | 7.73 | Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. ( Endo, I; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Kunisaki, C; Matsuyama, R; Momiyama, N; Shimada, H; Shimizu, D; Suzuki, H; Togo, S, 2006) |
| "A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation." | 7.73 | Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006) |
| " In this study, we evaluated the correlation between sensitivity to 5-fluorouracil (5-FU) and the mRNA expression level of several 5-FU-related metabolic enzymes [thymidylate synthase, dihydropyrimidine dehydrogenase (DPD), thymidylate phosphorylase (TP), orotate phosphoribosyl transferase, and uridine phosphorylase] in primary colorectal cancer and synchronous liver metastases from ten patients to investigate how colorectal cancer acquires 5-FU resistance during liver metastases." | 7.73 | Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. ( Endo, Y; Kaizuka, M; Kurumi, Y; Mekata, E; Okumura, K; Shiomi, H; Tani, T, 2006) |
| "Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated." | 7.73 | The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006) |
| "The author reports the successful treatment of an 85-year-old recurrent breast cancer patient with low-dose capecitabine." | 7.73 | [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine]. ( Honma, H, 2006) |
| "We present two cases of multiple liver metastases from colorectal cancer, which did not respond to hepatic arterial infusion (HAI) using 5-fluorouracil (5-FU 1250 mg/body weekly) alone, but responded to HAI using 5-fluorouracil (5-FU 750 mg/body weekly) and l-leucovorin (l-LV 50 mg/body weekly) achieving a complete response (CR)." | 7.73 | [Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin]. ( Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kato, S; Sugihara, K; Uetake, H; Yasuno, M, 2006) |
| "The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal and thromboembolic events were reported in two US trials." | 7.72 | Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. ( Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C, 2003) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 7.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| " In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)." | 7.72 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 7.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "Expression of thymidylate synthase (TS) and the 5-fluorouracil (5-FU) metabolic enzymes, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), and uridine phosphorylase (UP), has been reported to be associated with the sensitivity to 5-FU-based chemotherapy in colorectal cancer." | 7.72 | Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. ( Inokuchi, M; Shirota, Y; Sugihara, K; Tajima, M; Uetake, H; Yamada, H, 2004) |
| "To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression." | 7.72 | Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004) |
| "The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases." | 7.72 | Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. ( Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M, 2004) |
| "We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival." | 7.72 | Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 7.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use." | 7.72 | A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 7.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis." | 7.72 | Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004) |
| "Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma." | 7.72 | Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004) |
| "To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination." | 7.72 | [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 7.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)." | 7.72 | [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004) |
| "Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 7.72 | Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004) |
| "This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)." | 7.71 | Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002) |
| "Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer." | 7.71 | Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002) |
| "We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously." | 7.71 | [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 7.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| "To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU." | 7.71 | Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002) |
| "We evaluated the effect of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer." | 7.71 | [Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Sakita, I; Soma, I; Yoshida, T, 2002) |
| "A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)." | 7.71 | [A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 7.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions." | 7.71 | [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001) |
| "The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)." | 7.71 | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002) |
| "A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)." | 7.71 | [A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 7.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "This case can be considered the first documented Irinotecan-induced immune thrombocytopenia." | 7.70 | Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998) |
| "Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)." | 7.70 | 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998) |
| "The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs." | 7.70 | Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999) |
| "A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]." | 7.70 | [A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999) |
| "In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system." | 7.70 | Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999) |
| "Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)." | 7.70 | [Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999) |
| "Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies." | 7.70 | Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000) |
| "The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease." | 7.70 | Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000) |
| "We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)." | 7.69 | [A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994) |
| "We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats." | 7.69 | Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994) |
| "From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy." | 7.69 | [5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994) |
| "Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break." | 7.69 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996) |
| "5-Fluorouracil (5-FU) is the most widely used cytotoxic drug in oncology and the only one useful in the management of colorectal cancer - a leading cause of cancer death worldwide." | 7.68 | The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. ( Collins, DJ; Cunningham, D; Findlay, MP; Glaholm, J; Leach, MO; Mansi, JL; McCready, VR; Payne, GS, 1993) |
| "The development of pellagra in a patient treated with 5-fluorouracil for malignant disease is reported." | 7.68 | Pellagra secondary to 5-fluorouracil. ( Begent, RH; Dooley, JS; Ostlere, LS; Rustin, MH; Stevens, HP, 1993) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 7.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| "A total of 51 fully evaluable patients with advanced and intensively pretreated breast cancer were treated with a combination chemotherapy of ifosfamide plus mesna, methotrexate and 5-fluorouracil." | 7.68 | Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer. ( Becher, R; Höfeler, H; Kloke, O; May, D; Niederle, N; Richter, R; Scheulen, ME; Schmidt, CG; Wandl, U, 1991) |
| "Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP)." | 7.68 | 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. ( Brugieres, L; Droz, JP; Gicquel, C; Parmentier, C; Schlumberger, M; Travagli, JP, 1991) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 7.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 7.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 7.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma." | 7.67 | Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 7.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 7.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| " In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation." | 7.67 | [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987) |
| "An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia." | 7.67 | Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 7.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| "Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0." | 7.66 | [Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982) |
| "A heparinized catheter was used for the regional infusion of 5-fluorouracil in seven patients with liver metastases." | 7.66 | Heparinized catheters for long-term intraarterial infusion of 5-fluorouracil in liver metastases. ( Forsberg, L; Owman, T; Tylén, U, 1979) |
| "Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed." | 6.90 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019) |
| "Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited." | 6.87 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018) |
| "This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy." | 6.80 | Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015) |
| "The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 6.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15." | 6.79 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)." | 6.77 | Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012) |
| "Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 6.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
| " This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX." | 6.75 | A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 6.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation." | 6.74 | Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. ( Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA, 2009) |
| "Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease." | 6.74 | Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. ( Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Jassem, J; Li, RK; Mukhopadyay, P; Pivot, XB; Roché, HH; Thomas, ES, 2009) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 6.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| "From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 6.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 6.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 6.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)." | 6.71 | Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003) |
| "A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy." | 6.71 | Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 6.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| " Pharmacokinetic studies were performed on cycle 1 and 2 to assess the best sequence and detect any interaction between the two drugs." | 6.71 | Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. ( Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S, 2004) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 6.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| "Pravastatin was administered at a daily dose of 40 mg." | 6.70 | Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001) |
| "Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients." | 6.70 | A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001) |
| "In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance." | 6.70 | Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001) |
| "Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible." | 6.69 | Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 6.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| " These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU." | 6.68 | A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995) |
| " The dosage was as follows: group A received FA i." | 6.68 | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 6.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 6.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 6.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| " 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity." | 6.67 | Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992) |
| "In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation." | 6.50 | Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014) |
| "For instance, in patients with colorectal cancer, higher enzyme activity of topoisomerase-I seems to be predictive of a better response to irinotecan." | 6.43 | Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. ( Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM, 2005) |
| "Colorectal cancer is a leading cause of cancer death worldwide." | 6.42 | Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. ( Gill, S; Goldberg, RM, 2004) |
| "The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor." | 6.41 | [Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002) |
| "We report on a series of 10 patients with carcinoid tumors metastatic to the liver who were treated with long-term octreotide acetate therapy (100 to 500 micrograms three times a day), sequential intra-arterial 5-fluorouracil (5-FU) infusions, and hepatic tumor chemoembolization." | 6.17 | Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. ( Diaco, DS; Fletcher, WS; Hajarizadeh, H; Mueller, CR; Pommier, RF; Woltering, EA, 1995) |
| "Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer." | 5.91 | Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023) |
| "Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage." | 5.91 | MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023) |
| "5-Fluorouracil (5-FU) has been widely applied in treating cancers." | 5.72 | CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022) |
| "Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu." | 5.72 | Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022) |
| "To report the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI)." | 5.69 | Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. ( Cao, MR; Chen, HW; Cheng, Y; Deng, JD; Deng, M; Fang, CK; Guan, RG; Guo, RP; Guo, ZX; Huang, HK; Jiang, YC; Lei, QC; Li, JB; Li, Q; Li, SH; Lin, WP; Ling, YH; Lu, LH; Luo, R; Mei, J; Wang, QX; Wei, W; Wen, YH; Zhao, RC; Zheng, L; Zhong, C; Zou, JW, 2023) |
| "Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents." | 5.62 | Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021) |
| "The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure." | 5.56 | Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020) |
| "5-Fluorouracil (5-Fu) is a widely used as an anticancer drug." | 5.56 | CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020) |
| "Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion." | 5.56 | Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats. ( Bausys, A; Feldbacher, N; Hoefler, G; Kolb-Lenz, D; Leber, B; Maneikyte, J; Schemmer, P; Stiegler, P; Strupas, K, 2020) |
| " The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC." | 5.56 | Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020) |
| " Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level." | 5.56 | Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020) |
| "Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)." | 5.51 | Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022) |
| "This trial investigates the addition of panitumumab to chemotherapy with fluorouracil/folinic acid and oxaliplatin (FOLFOX) in a 2:1 randomised, controlled, open-label, phase II trial in RAS wild-type colorectal cancer patients with R0/1-resected liver metastases." | 5.51 | FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). ( Fischer V Weikersthal, L; Fuchs, M; Heinemann, V; Held, S; Jacobasch, L; Jung, A; Junghanß, C; Kaczirek, K; Kaiser, F; Karthaus, M; Kasper, S; Keitel, V; Kiani, A; Lerchenmüller, C; Lorenzen, S; Modest, DP; Moosmann, N; Sent, D; Stintzing, S; Uhlig, J, 2022) |
| "However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed." | 5.51 | Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019) |
| "SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu." | 5.51 | Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 5.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "5-Fluorouracil (5-FU) is a widely used antitumor drug." | 5.51 | Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019) |
| "Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity." | 5.48 | Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 5.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties." | 5.43 | Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016) |
| "Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 5.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
| "Dioscin is a natural steroid saponin that presents in various plants." | 5.43 | Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016) |
| "Although hyperammonemia is a known side effect of 5-FU that can cause serious pathological conditions, only a few cases have been reported." | 5.42 | [Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis]. ( Iida, T; Isshiki, H; Kaneto, H; Murakami, K; Naganawa, Y; Sasaki, H; Satoh, S; Shimizu, H; Tani, M; Wagatsuma, K, 2015) |
| "Most liver metastases from colorectal cancer (CRC) are unresectable at diagnosis." | 5.42 | Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. ( Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E, 2015) |
| "Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence." | 5.42 | MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 5.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "Hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China." | 5.41 | Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. ( Du, Z; He, M; Kan, A; Lai, Z; Li, Q; Liu, S; Shen, J; Shi, M; Xu, L, 2023) |
| "A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies." | 5.41 | A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021) |
| "The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor." | 5.39 | Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor." | 5.39 | PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013) |
| "Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma." | 5.39 | Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013) |
| "A 77-year-old man with colon cancer and multiple metastases to the liver and lungs underwent resection of the primary tumor and D3 lymph node dissection." | 5.39 | [A case of advanced colon cancer with atrial fibrillation and the use of dabigatran for safe chemotherapy using fluoropyrimidine-based antitumor agents]. ( Adachi, A; Nakajima, M; Uchisako, H; Uchiyama, T, 2013) |
| "The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor." | 5.39 | Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection." | 5.39 | Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013) |
| "The only drug that improves survival in hepatocellular carcinoma is sorafenib." | 5.38 | Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012) |
| "Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice." | 5.38 | Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012) |
| "The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 5.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
| "Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU." | 5.38 | 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012) |
| "The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC." | 5.38 | Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012) |
| "To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 5.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
| "There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus." | 5.37 | Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| "Histological examinations revealed squamous cell carcinoma." | 5.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL." | 5.37 | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011) |
| "Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil." | 5.37 | Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 5.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "Capecitabine was started after the occurrence of new multiple lesions; complete regression was reached, which has now lasted over three years with continued capecitabine treatment." | 5.36 | [Long-term response of liver metastases of breast cancer to capecitabine--case report]. ( Macková, D, 2010) |
| "A 51-year-old patient had recurrent breast cancer with liver metastases." | 5.36 | [A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective]. ( Hata, K; Hirai, I; Maebeya, S; Miki, Y; Oota, F; Tanaka, T; Tanino, H, 2010) |
| "Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways." | 5.36 | Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 5.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 5.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)." | 5.35 | Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008) |
| ": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options." | 5.35 | Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009) |
| "Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC)." | 5.34 | Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. ( Artru, P; Dahan, L; De La Fouchardière, C; Guimbaud, R; Jouve, JL; Lepage, C; Montérymard, C; Pellerin, O; Pernot, S; Raoul, JL; Sefrioui, D; Smith, D; Taieb, J; Tougeron, D, 2020) |
| "The phase III West Japan Oncology Group (WJOG) 4407G study showed noninferiority of folinic acid, bolus/continuous fluorouracil, and irinotecan plus bevacizumab to modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin 6 plus bevacizumab in progression-free survival (PFS) as first-line chemotherapy for patients with metastatic colorectal cancer." | 5.34 | Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study. ( Hironaka, S; Hosokawa, A; Kusaba, H; Matsuda, C; Morita, S; Muro, K; Okamura, S; Shinozaki, K; Shirakawa, T; Tamura, T; Tsuda, M; Tsuda, T; Tsushima, T; Ueda, S; Yamashita, H; Yamazaki, K, 2020) |
| " In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC." | 5.34 | Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007) |
| "However, severe hyperbilirubinemia (grade 3/4) has not been previously reported in association with this chemotherapeutic agent." | 5.34 | Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. ( Fakih, MG; Gupta, B; LeVea, C; Litwin, A, 2007) |
| "5-fluorouracil (5-FU) is a basic agent used in chemotherapy." | 5.34 | Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007) |
| "Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 5.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
| "Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor." | 5.33 | [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005) |
| "Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation." | 5.33 | 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005) |
| "Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude." | 5.33 | Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases. ( Anselmi, E; Bertè, R; Bidin, L; Cavanna, L; Civardi, G; Lazzaro, A; Moroni, CF; Palladino, MA; Rodinò, C; Vallisa, D, 2005) |
| "For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33." | 5.33 | [Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 5.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 5.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
| " Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen." | 5.33 | Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. ( Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ, 2006) |
| "The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal." | 5.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
| "Between July 1999 and August 2001, 95 cancer patients were evaluated." | 5.32 | Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? ( Carnaghi, C; Castagna, L; Fallini, M; Magagnoli, M; Masci, G; Pedicini, V; Santoro, A; Sarina, B; Zucali, PA, 2003) |
| "Median time to disease progression was 9." | 5.32 | Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003) |
| "The patient was diagnosed with advanced gastric cancer (type-3) with lymphangitis carcinomatosa of the lung." | 5.32 | [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1]. ( Kawabata, H; Murata, A; Nakajima, H; Takase, I; Watanabe, T, 2003) |
| "A syngeneic rat model of hepatocellular carcinoma was used." | 5.32 | [Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003) |
| "Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used." | 5.32 | The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004) |
| "Patients with liver metastases of colorectal cancer were treated with 5-FU (500/600 mg/m)+folinic acid with or without trimetrexate." | 5.32 | 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. ( Heerschap, A; Kamm, YJ; van den Bergh, EJ; Wagener, DJ, 2004) |
| "The prognosis of breast cancer patients with liver metastases is extremely poor." | 5.32 | Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. ( Jassem, J; Sosińska-Mielcarek, K; Zaucha, R, 2004) |
| "The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein." | 5.32 | Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004) |
| "For women with metastatic breast cancer, complete remission is uncommon, and stable disease is a reasonable goal of successful therapy." | 5.31 | Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment. ( Hara, Y; Hikosaka, Y; Iwase, H; Kobayashi, S; Toyama, T; Yamashita, H, 2001) |
| "The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 5.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
| "Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC)." | 5.30 | Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. ( Boucher, KM; Garrido-Laguna, I; McGregor, K; Orgain, N; Sharma, S; Stenehjem, DD; Thorne, K; Wade, ML; Weis, J; Weldon Gilcrease, G; Whisenant, J, 2019) |
| "First-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI)." | 5.30 | Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). ( Bendell, J; Hochster, HS; Hurwitz, HI; Lee, JJ; Lenz, HJ; Nicholas, A; Palma, JF; Price, R; Reeves, JA; Scappaticci, F; Somer, B; Sommer, N; Tan, BR; Xiong, H, 2019) |
| "Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit." | 5.30 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 5.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 5.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "Five cases of colorectal cancer with unresectable liver metastases treated from April 1992 to April 1993 in Osaka National Hospital were summarized in this paper." | 5.29 | [Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases]. ( Imamura, H; Kanoh, T; Kikkawa, N; Miyazaki, M; Nakayama, T; Tamaki, Y; Taniguchi, K; Tohno, K; Utsunomiya, T, 1993) |
| "Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)." | 5.28 | [Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990) |
| "Chemotherapy for liver metastasis of breast cancer has rarely been found effective." | 5.28 | [Clinical efficacy of ifosfamide for liver metastasis of breast cancer]. ( Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y, 1990) |
| "In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior." | 5.27 | Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018) |
| "The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC)." | 5.27 | AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. ( Aravantinos, G; Bafaloukos, D; Efstratiou, I; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeropoulou, L; Karavasilis, V; Kentepozidis, N; Koliou, GA; Kotoula, V; Koumakis, G; Laschos, K; Pectasides, D; Pentheroudakis, G; Petraki, C; Poulios, C; Samantas, E; Sgouros, J; Souglakos, I; Tikas, I; Voutsina, A; Vrettou, E; Zarkavelis, G, 2018) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 5.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 5.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 5.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)." | 5.24 | A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017) |
| "The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma." | 5.24 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. ( Al-Batran, SE; Arnold, D; Bechstein, W; Berkhoff, S; Egger, M; Fischbach, W; Grimm, K; Hartmann, JT; Höffkes, HG; Hofheinz, RD; Homann, N; Illerhaus, G; Jäger, E; Koenigsmann, M; Kraus, TW; Luley, KB; Martens, UM; Mayer, F; Messmann, H; Moehler, M; Mönig, S; Pauligk, C; Post, S; Prasnikar, N; Probst, S; Ronellenfitsch, U; Schmalenberg, H; Stoehlmacher, J, 2017) |
| "In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]." | 5.24 | First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). ( Abad, A; Aranda, E; Carrato, A; Dueñas, R; Escudero, P; Gallego, J; García-Paredes, B; Gómez, A; González, E; Grávalos, C; Longo-Muñoz, F; Losa, F; Manzano, JL; Massuti, B; Pericay, C; Rivera, F; Safont, MJ; Valladares-Ayerbes, M, 2017) |
| "The hepatic artery infusion (HAI) of irinotecan, oxaliplatin and 5-fluorouracil with intravenous cetuximab achieved outstanding efficacy in previously treated patients with initially unresectable liver metastases from colorectal cancer." | 5.24 | Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). ( Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J, 2017) |
| "The combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients with extensive liver metastases and prior treatment." | 5.24 | Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. ( Bouchahda, M; Chatelut, E; Etienne-Grimaldi, MC; Focan, C; Innominato, P; Karaboué, A; Lévi, F; Milano, G; Paintaud, G, 2017) |
| " Additionally, resveratrol showed a great potential against breast cancer mainly due to its ability to exert both anti-estrogenic and estrogenic effects (based on the concentration) and because it has a high affinity for estrogen receptors ERα and Erβ." | 5.22 | Combination Therapy Using Polyphenols: An Efficient Way to Improve Antitumoral Activity and Reduce Resistance. ( Ene, AG; Ficai, A; Ficai, D; Vladu, AF, 2022) |
| "The purpose of this study was to assess the efficacy and tolerance of induction chemotherapy combining LV5FU2 with increased doses of irinotecan adapted to UGT1A1 genotyping and cetuximab in untreated potentially resectable liver metastases of colorectal cancer." | 5.22 | High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT). ( Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X, 2016) |
| "Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare." | 5.22 | Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016) |
| "This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial." | 5.20 | Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015) |
| "The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)." | 5.20 | Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015) |
| "In vitro and pre-clinical studies have suggested that addition of the diet-derived agent curcumin may provide a suitable adjunct to enhance efficacy of chemotherapy in models of colorectal cancer." | 5.20 | Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. ( Berry, DP; Brown, K; Cai, H; Dennison, A; Garcea, G; Greaves, P; Griffin-Teal, N; Higgins, JA; Howells, LM; Irving, G; Iwuji, C; James, MI; Karmokar, A; Lloyd, DM; Metcalfe, M; Morgan, B; Patel, SR; Steward, WP; Thomas, A, 2015) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 5.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "To compare the efficacy and safety of chemoembolization alone or chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC), including oxaliplatin (OXA), 5-fluorouracil (5-FU) and folinic acid (CF), in inoperable hepatocellular carcinoma (HCC) without distant metastasis." | 5.20 | Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. ( Chen, H; Gao, S; Guo, JH; Liu, P; Xu, HF; Yang, RJ; Zhang, PJ; Zhu, X, 2015) |
| "The MTD of (90)Y delivered in conjunction with capecitabine in the setting of intrahepatic cholangiocarcinoma or metastatic disease confined to the liver exceeds 170 Gy." | 5.19 | Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. ( Benson, AB; Gates, VL; Habib, A; Hickey, R; Kircher, S; Lewandowski, RJ; Mulcahy, MF; Newman, S; Nimeiri, H; Salem, R; Vouche, M, 2014) |
| "To evaluate panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated wild-type (WT) KRAS exon 2 (codons 12 and 13) metastatic colorectal cancer (mCRC)." | 5.19 | PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal ( Canon, JL; Fasola, G; Go, WY; Hecht, JR; Karthaus, M; Oliner, KS; Rivera, F; Schwartzberg, LS; Yu, H, 2014) |
| "The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC)." | 5.19 | Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. ( Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 5.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC)." | 5.19 | Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. ( Bai, Y; Cheng, Y; Fan, J; Jian, Z; Li, J; Liang, H; Liang, J; Liang, L; Qin, S; Rau, KM; Shen, L; Sun, Y; Wu, G; Yang, TS; Zhang, Y, 2014) |
| " Because previous studies showed that long-term telbivudine treatment improved renal function in chronic hepatitis B virus (HBV) infected patients, we conducted a case-control study to evaluate the clinical outcome of telbivudine preemptive therapy in HBV-related advanced HCC patients treated by combination chemotherapy comprising 5-fluorouracil, mitoxantrone and cisplatin (FMP)." | 5.19 | Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. ( Chang, ML; Chen, YC; Chien, RN; Hsu, CW; Lin, CL; Yeh, C; Yeh, CT, 2014) |
| "The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)." | 5.19 | Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014) |
| "Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically." | 5.17 | A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. ( Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 5.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| "After resection of their primary tumors, patients with KRAS wild-type synchronous nonresectable liver-limited metastases from colorectal cancer were randomly assigned to receive chemotherapy (FOLFIRI [fluorouracil, leucovorin, and irinotecan] or mFOLFOX6 [modified fluorouracil, leucovorin, and oxaliplatin]) plus cetuximab (arm A) or chemotherapy alone (arm B)." | 5.17 | Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. ( Liu, TS; Qin, XY; Ren, L; Wei, Y; Xu, B; Xu, J; Ye, LC; Ye, QH; Yu, Y; Zai, SY; Zhu, DX, 2013) |
| "Newly diagnosed K-RAS wild-type colorectal cancer patients with unresectable liver-only metastases were treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) plus cetuximab every 2 weeks for a maximum of 12 cycles." | 5.17 | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. ( Baek, JY; Hong, YS; Ji, JH; Kang, HJ; Kim, KP; Kim, SY; Kim, TW; Lee, J; Park, SH; Park, YS; Shim, BY; Shin, SJ, 2013) |
| "The purpose of this prospective, nonrandomized, controlled study was to compare the regimen of continuously administering trastuzumab and capecitabine (HX) with the regimen of lapatinib plus capecitabine (LX) for metastatic breast cancer (MBC) patients who are resistant to trastuzumab and have previously received taxane treatment." | 5.17 | Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. ( Bian, L; Jiang, Z; Wang, T; Zhang, S, 2013) |
| "The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib." | 5.17 | Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013) |
| "To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin." | 5.17 | Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013) |
| "The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer." | 5.17 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013) |
| "The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer." | 5.17 | FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013) |
| "Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer." | 5.17 | Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. ( Bechstein, WO; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mauer, M; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Tanis, E; Van Cutsem, E; Walpole, ET, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 5.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "The aim of this phase II study was to investigate the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic breast cancer (MBC) patients heavily pretreated with anthracyclines, taxanes, vinorelbine, gemcitabine, and capecitabine." | 5.16 | Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. ( Hu, XC; Jia, Z; Sun, S; Wang, BY; Wang, LP; Yang, XY; Zhang, J; Zhang, QL, 2012) |
| "Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
| "To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)." | 5.16 | Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 5.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "The primary objective of this study is to evaluate the safety, tolerance, and pharmacokinetic profile of liver-directed therapy with drug-eluting beads irinotecan (DEBIRI) in combination with systemic modified FOLFOX in the treatment of unresectable liver metastases in chemotherapy-naive patients with colorectal cancer." | 5.16 | Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ( Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D, 2012) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 5.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC)." | 5.15 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. ( Bokemeyer, C; Bondarenko, I; Celik, I; de Braud, F; Hartmann, JT; Koralewski, P; Schlichting, M; Schuch, G; Zubel, A, 2011) |
| "Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)." | 5.15 | Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011) |
| "We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer." | 5.15 | XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. ( Cassidy, J; Clarke, S; Díaz-Rubio, E; Figer, A; Gilberg, F; Koski, S; Rittweger, K; Saltz, L; Scheithauer, W; Wong, R, 2011) |
| "We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 5.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
| "This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)." | 5.15 | Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 5.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule." | 5.14 | Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. ( Bellone, G; Bertetto, O; Chiappino, I; Ciuffreda, L; Giacobino, A; Milanesi, E; Novarino, A; Rahimi, F; Satolli, MA, 2009) |
| "This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)." | 5.14 | Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 5.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "Studies indicate that adjuvant 5-fluorouracil (5-FU) with folinic acid (FA) in colorectal cancer patients with completely resectable liver-limited metastases (LMCRC) offers clinical benefit over surgery alone." | 5.14 | A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. ( Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M, 2009) |
| "To assess the resectability rate of patients with initially unresectable liver-only metastases from colorectal cancer (CRC) after treatment with irinotecan/capecitabine." | 5.14 | A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. ( Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J, 2010) |
| "PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer." | 5.14 | Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. ( Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM, 2010) |
| " Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer." | 5.14 | Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI- ( Alberts, SR; Bolton, JS; Dentchev, T; Lai, LL; Mahoney, MR; Molina, R; Nagorney, DM; O'Connell, MJ; Roh, MS; Schwarz, RE; Smyrk, TC; Wagman, L; Weiland, TL, 2010) |
| "Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma." | 5.14 | A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 5.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| "Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach." | 5.14 | Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010) |
| "This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC)." | 5.14 | Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ( Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M, 2010) |
| "In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy to the infusional FOLFOX-6 regimen in first-line treatment of metastatic colorectal cancer (mCRC)." | 5.14 | Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6. ( Bennouna, J; Conroy, T; Dominguez, S; Douillard, JY; Ducreux, M; Faroux, R; Florentin, V; Hebbar, M; Lledo, G; Perrocheau, G; Ychou, M, 2010) |
| "Stages I-III colorectal cancer patients (n = 753) were randomized to receive either surgery alone (control arm), surgery plus postoperative portal venous infusion of 5-FU 500 mg/m(2) plus heparin given for 24 hours for seven consecutive days plus mitomycin C 10 mg/m(2) given on the first day (arm 2), or surgery and the same chemotherapy regimen administered by peripheral venous route (arm 3)." | 5.13 | Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. ( Aeberhard, P; Harder, F; Herrmann, R; Laffer, U; Lorenz, M; Maibach, R; Metzger, U; Zuber, M, 2008) |
| "To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer." | 5.13 | Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008) |
| "Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R(0) resection, but potentially resectable after tumor reduction, were given FOLFIRINOX: oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), bolus fluorouracil 400 mg/m(2) and fluorouracil 46-h continuous IV infusion 2,400 mg/m(2), every 2 weeks for a maximum of 12 cycles." | 5.13 | Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. ( Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M, 2008) |
| "Food and Drug Administration reviewed a single, open-label, multicenter trial in which 463 patients with epidermal growth factor receptor-expressing metastatic colorectal cancer who had progressed on or following treatment with a regimen containing a fluoropyrimidine, oxaliplatin, and irinotecan were randomized (1:1) to receive best supportive care (BSC) with or without panitumumab (6 mg/kg every other week) administered until disease progression or intolerable toxicity." | 5.13 | U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. ( Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 5.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 5.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "To examine whether carbogen and nicotinamide increases 5-fluorouracil (5-FU) delivery to colorectal cancer metastases." | 5.12 | Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. ( Aboagye, EO; Gupta, N; Hoskin, PJ; Jones, T; Kötz, B; Osman, S; Phillips, R; Price, PM; Saleem, A; Vernon, C; Wasan, H, 2006) |
| "We determined whether hepatic intra-arterial infusion of 5-fluorouracil (5-FU) in patients with synchronous hepatic metastases from colorectal cancer, in whom the primary lesion was resectable but hepatic metastatic lesions were non-resectable helped improve survival time when administered on the basis of the results of the anticancer drug sensitivity test." | 5.12 | Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Yanagi, Y, 2006) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 5.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "In a multicenter trial, we randomly assigned 173 patients with completely resected (R0) hepatic metastases from colorectal cancer to surgery alone and observation (87 patients) or to surgery followed by 6 months of systemic adjuvant chemotherapy with a fluorouracil and folinic acid monthly regimen (86 patients)." | 5.12 | Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. ( Bedenne, L; Belghiti, J; Bosset, JF; Bouche, O; Bugat, R; Elias, D; Guimbaud, R; Lazorthes, F; Nordlinger, B; Piedbois, P; Portier, G; Rougier, P; Saric, J, 2006) |
| "To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)." | 5.12 | Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 5.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 5.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50." | 5.12 | A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. ( Ben-Josef, E; Desai, SP; El-Rayes, BF; Greenson, JK; Griffith, KA; Huang, EH; Knol, JA; McGinn, CJ; Philip, PA; Zalupski, MM, 2007) |
| "A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer." | 5.12 | Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007) |
| "The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches." | 5.12 | Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 5.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)." | 5.11 | Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 5.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 5.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)." | 5.11 | Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 5.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 5.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS) in patients with metastatic colorectal cancer (MCRC)." | 5.11 | Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. ( Alberts, SR; Delaunoit, T; Findlay, BP; Fuchs, C; Goldberg, RM; Green, E; Krook, J; Morton, RF; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2005) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 5.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 5.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin." | 5.11 | Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005) |
| "HLA-A2-positive patients with confirmed newly diagnosed metastatic colorectal cancer and elevated serum carcinoembryonic antigen (CEA) were randomized to receive three cycles of standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) and vaccinations with CEA-derived CAP-1 peptide admixed with different adjuvants [CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2 (IL-2), CAP-1/dSLIM/IL-2, and CAP-1/IL-2]." | 5.11 | Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. ( Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 5.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| "Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma." | 5.11 | Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005) |
| "To estimate the disease-response rate, proportion of patients whose tumors can be made resectable, event-free survival (EFS), and toxicity in children with unresectable or metastatic hepatoblastoma (HB) after sequential treatment with the following: (1) carboplatin (CARBO); (2) CARBO, vincristine, and fluorouracil (CARBO-VCR-5-FU); and (3) high-dose cisplatin and etoposide (HDDP-ETOP)." | 5.10 | Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. ( Bowman, LC; Douglass, EC; Finegold, MJ; Katzenstein, HM; London, WB; Plaschkes, J; Reynolds, M, 2002) |
| "We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment." | 5.10 | Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 5.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics." | 5.10 | Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003) |
| "To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC)." | 5.10 | Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. ( Baum, U; Brückl, W; Fuchs, F; Günther, K; Hahn, EG; Hanke, B; Hohenberger, W; Merkel, S; Ott, R; Papadopoulos, T; Reck, T; Riedel, C; Wein, A, 2003) |
| " We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver." | 5.10 | Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003) |
| "The purpose of this study was to evaluate the prognostic value of quantitative dynamic FDG PET studies in patients with metastastic colorectal cancer receiving FOLFOX (fluorouracil, folinic acid and oxaliplatin) chemotherapy." | 5.10 | PET-FDG as predictor of therapy response in patients with colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Rudi, J; Strauss, LG, 2003) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 5.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| " irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer." | 5.10 | Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003) |
| "We investigated the pharmacokinetics (PK), preliminary clinical results and toxicity of chronomodulated oxaliplatin (OHP) plus 5-fluorouracil (5-FU) without folinic acid (FA) in 13 patients with metastatic colorectal cancer." | 5.10 | Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. ( Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Infante, L; La Grotta, G; Passera, R, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "Twenty-two patients with unresectable liver metastases from colorectal cancer were treated with continuous HAI of 300 mg/m2 5-fluorouracil for 5 days a week and 6 mg/m2 cisplatin for 2 hours on 5 consecutive days a week." | 5.10 | Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Tajima, T; Toh, Y; Yamamoto, M, 2002) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 5.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated." | 5.10 | Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 5.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer." | 5.10 | Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. ( Amadori, D; Cruciani, G; Giovanis, P; Marangolo, M; Nicolini, M; Oliverio, G; Panzini, I; Pasquini, E; Ravaioli, A; Rossi, A; Tassinari, D; Turci, D; Zumaglini, F, 2002) |
| "This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma." | 5.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
| "To determine surgical resectability, event-free survival (EFS), and toxicity in children with hepatocellular carcinoma (HCC) randomized to treatment with either cisplatin (CDDP), vincristine, and fluorouracil (regimen A) or CDDP and continuous-infusion doxorubicin (regimen B)." | 5.10 | Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Liu-Mares, W; Malogolowkin, MH; Newman, K; Ortega, JA; Quinn, JJ; Reynolds, M; Sensel, MG, 2002) |
| "The purpose of this Phase II study was to determine the response rate, the toxicity, and the effect on survival of the combination of cisplatin, doxorubicin, 5-fluorouracil, and alpha-IFN (PIAF) in advanced unresectable hepatocellular carcinoma." | 5.09 | Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. ( Chan, AT; Ho, SK; Johnson, PJ; Lau, WY; Leung, NW; Leung, TW; Liew, CT; Mok, TS; Patt, YZ; Tang, AM; Yeo, W; Yu, SC, 1999) |
| "To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy." | 5.09 | Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999) |
| "We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone." | 5.09 | Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999) |
| "Previous studies demonstrated that chemotherapy with either cisplatin, vincristine, and fluorouracil (regimen A) or cisplatin and continuous infusion doxorubicin (regimen B) improved survival in children with hepatoblastoma." | 5.09 | Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. ( Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; King, DR; Krailo, MD; Liu-Mares, W; Ortega, JA; Quinn, JJ; Reynolds, M; Sensel, MG, 2000) |
| "To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.09 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M, 2000) |
| "The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy." | 5.09 | Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000) |
| "A multicenter phase II trial was initiated in order to evaluate the weekly, high-dose 24-hour infusion of 5-fluorouracil (5-FU) plus folinic acid (FA) in patients with unresectable colorectal cancer hepatic metastases." | 5.09 | Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. ( Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 5.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| "Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2)." | 5.09 | Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ( Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001) |
| "A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma." | 5.08 | 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995) |
| "A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil (FU) with both leucovorin (LV) and cisplatin (CDDP) against liver metastases of colorectal cancer was devised." | 5.08 | [A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer]. ( Fukada, D; Kato, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tsuji, K; Umemoto, T, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 5.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| "Between September 1990 and August 1994, 11 patients (pts) with liver metastases (mets) from colorectal cancer were treated with continuous hepatic arterial infusion chemotherapy of 5-fluorouracil (FU) plus leucovorin (LV)." | 5.08 | [Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer]. ( Ban, K; Higashi, H; Imanari, T; Ishihara, S; Kitazaki, M; Masuda, K; Matsumoto, M; Noma, M; Ota, M; Shida, H, 1995) |
| "A phase I and pharmacokinetic trial was performed between October 1993 and June 1994 to determine the maximum-tolerated dose of hepatic arterial infusion (HAI) of fluorouracil (5-FU) and intravenous (IV) leucovorin (folinic acid; FA) in patients with hepatic metastases from colorectal cancer." | 5.08 | Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. ( Buckels, J; Budden, J; Doughty, J; Kerr, DJ; Ledermann, JA; McArdle, CS; Neoptolemos, J; Seymour, M; Taylor, I, 1995) |
| "A carboplatin and 5-fluorouracil (CF) chemotherapy protocol was designed to evaluate tumor response and toxicity in patients with metastatic nasopharyngeal carcinoma (NPC)." | 5.08 | Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. ( Chan, AT; Johnson, PJ; Lee, WY; Leung, SF; Leung, TW; Teo, PM; Yeo, W, 1996) |
| "The primary objective of this study was to determine the response rate of patients with metastatic colorectal cancer to combined therapy with 5-fluorouracil (5-FU), leucovorin, and intravenous azidothymidine (AZT), a thymidine nucleoside analog." | 5.08 | Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. ( Akerley, W; Beitz, J; Bigley, J; Browne, M; Clark, J; Cole, B; Cummings, F; Darnowski, J; Kennedy, T; Sikov, W; Wanebo, H; Weitberg, A, 1996) |
| "Evidence suggests that interferon-alpha (IFN-alpha) augments the antineoplastic activity of 5-fluorouracil (5-FU) in human adenocarcinoma cell lines in vitro and may enhance the efficacy of 5-FU in patients with advanced colorectal carcinoma." | 5.08 | Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. ( Benson, AB; Bushunow, PW; Dutcher, JP; Flynn, PJ; Hansen, R; Kirkwood, J; Lipsitz, S; Sparano, JA; Wadler, S, 1996) |
| "Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide." | 5.08 | Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 5.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "One hundred ninety-five women (141 eligible) whose disease was in CR or in CR except for bone metastases following six cycles (6 months) of doxorubicin-containing induction treatment were randomized to receive cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, and halotestin [CMF(P)TH] or observation." | 5.08 | Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. ( Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D, 1998) |
| "Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy." | 5.08 | Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). ( Asselain, B; Beuzeboc, P; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Palangié, T; Pierga, JY; Pouillart, P; Scholl, S, 1998) |
| "We conducted a randomized, controlled trial comparing 5-fluorouracil (5-FU) with or without biological response modifiers (BRMs) as a maintenance therapy for hepatocellular carcinoma (HCC) after treatment with percutaneous ethanol injection (PEI), transcatheter arterial embolization (TAE) or arterial infusion of antitumor agents (AI)." | 5.07 | Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. ( Fukuda, S; Moriya, N; Sakata, Y; Sasaki, D; Suto, T; Watanabe, Y; Yoshida, Y, 1994) |
| "We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19." | 5.07 | Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993) |
| "A prospective, controlled randomized trial of hepatic arterial infusion of 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin C (MMC) [FAM group] versus 5-FU, epirubicin (EPIR) and MMC [FEM group] in patients with unresectable liver metastasis from colorectal cancer is reported." | 5.07 | [A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group]. ( Kunii, Y; Mashiko, H; Momono, S; Muto, I; Nakagawa, K; Ouchi, A; Shiiba, K; Wada, M; Yamamoto, K; Yamazaki, T, 1993) |
| "25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)." | 5.07 | Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993) |
| "Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days." | 5.07 | Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993) |
| " This prospective phase II study evaluates the efficacy and toxicity of hepatic arterial infusion of 5-Fluorouracil (5-FU) via an implantable Infusaid pump in previously untreated patients with localised but unresectable hepatic metastases from colorectal cancer." | 5.07 | Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver. ( Boyle, FM; Levi, JA; Smith, RC, 1993) |
| "Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy)." | 5.07 | Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. ( Desai, DC; Desouza, LJ; Dhir, V; Dinshaw, KA; Jagannath, P; Mohandas, KM; Nagral, A; Sharma, V; Swaroop, VS, 1992) |
| "Treatment results in advanced colorectal cancer have improved during the last decade since the incorporation of agents like folinic acid, PALA, or interferon as active biomodulation of 5-fluorouracil (5-FU), the most potent drug in this disease." | 5.07 | A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. ( Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2." | 5.07 | Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial. ( Günther, E; Hinrichs, HF; Hirschmann, WD; Koniczek, KH; Natt, F; Sondern, W; Steinke, B; Wagner, T; Wander, HE; Werdier, D, 1992) |
| "The mechanisms of biochemical modulation of 5-fluorouracil (5-FU) cytotoxicity by folinic acid (FA) have been elucidated, and the clinical use of this combination has improved response rates and survival in patients with metastatic colorectal cancer." | 5.07 | A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. ( Bauer, L; Budd, GT; Bukowski, RM; Gibson, V; Inoshita, G; Murthy, S; Prestifilippo, J; Sergi, JS; Yalavarthi, P, 1992) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 5.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver." | 5.07 | Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 5.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver." | 5.07 | Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991) |
| "Fourteen patients (group A) with unresectable metastasis to the liver from colorectal cancers (11 patients) and gastric cancers (3 patients) were treated with the combined application of hyperthermia and intra-hepato-arterial (IHA) chemotherapy with cisplatinum and 5-fluorouracil." | 5.07 | A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil. ( Hamazoe, R; Hirooka, Y; Kaibara, N; Maeta, M; Murakami, A, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 5.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion." | 5.06 | Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. ( Beart, RW; Fitzgibbons, RJ; Leigh, JE; Moertel, CG; van Heerden, JA; Wieand, HS; Windschitl, HE; Wolff, BG, 1990) |
| "The effect of hepatic irradiation (RT) after intraarterial 5-fluorouracil (5-FU) was evaluated in 37 randomized patients with colorectal adenocarcinoma hepatic metastases." | 5.06 | Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study. ( Demets, D; Lee, JW; Ramirez, G; Stephenson, JA; Wiley, AL; Wirtanen, GW, 1989) |
| "We included one randomised clinical trial with 61 participants (43 male and 18 female) with colorectal cancer with liver metastases: 22 received transarterial embolisation (TAE; hepatic artery embolisation), 19 received transarterial chemoembolisation (TACE; 5-fluorouracil hepatic artery infusion chemotherapy with degradable microspheres), and 20 received 'no active therapeutic intervention' as a control." | 5.05 | Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. ( Bala, MM; Kleijnen, J; Mitus, JW; Pedziwiatr, M; Riemsma, RP; Storman, D; Swierz, MJ; Wolff, R, 2020) |
| "In a prospective clinical trial, 39 patients with advanced hepatocellular carcinoma were randomized to receive either Adriamycin (20 patients) or a combination of 5-fluorouracil, methotrexate, cyclophosphamide, and vincristine (19 patients)." | 5.05 | Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. ( Choi, TK; Lee, NW; Wong, J, 1984) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 5.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a randomized treatment schedule." | 5.04 | 5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. ( Bateman, JR; Durkin, WJ; Link, JS; Paroly, WS; Peters, RL, 1977) |
| "A new method for intermittent hepatic arterial flow arrest has been used in combination with intraarterial 5-fluorouracil (5-Fu) for the treatment of secondary liver neoplasms in 12 patients." | 5.04 | Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs. ( Aronsen, KF; Hellekant, C; Holmberg, J; Rothman, U; Teder, H, 1979) |
| "The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer." | 4.95 | FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. ( Barni, S; Ghidini, M; Passalacqua, R; Petrelli, F; Russo, A; Tomasello, G, 2017) |
| " Here, we review the case of a 76-year-old male rectal cancer patient with liver metastasis who suffered extensive bowel necrosis after administration of 5-fluorouracil-based chemotherapy with bevacizumab, and required a subtotal colectomy and end-ileostomy." | 4.91 | Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature. ( Endo, K; Furukawa, J; Hoshino, Y; Ito, H; Kimata, M; Kobayashi, K; Masugi, Y; Ogata, Y; Shinozaki, H; Takada, S; Terauchi, T, 2015) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 4.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| "We report a case of long-term survival of a patient who received low-dose 5-fluorouracil and cisplatin (FP) systemic chemotherapy and underwent partial resection of the lung for a tumor thrombus in the inferior caval vein (IVC) and multiple lung metastases from recurrent hepatocellular carcinoma (HCC)." | 4.90 | [A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma]. ( Akasu, I; Fukushima, G; Kataoka, H; Kondo, K; Magata, H; Marutsuka, H; Nakamura, K; Otani, K; Sato, Y; Yano, K; Yonei, A, 2014) |
| " For colorectal liver metastases (mCRC), in a salvage setting, response was 79% for (90)Y-RE combined with 5-fluorouracil/leucovorin (5-FU/LV), and 79% when combined with 5-FU/LV/oxaliplatin or 5-FU/LV/irinotecan, and in a first-line setting 91% and 91%, respectively." | 4.85 | Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. ( Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA, 2009) |
| " We diagnosed 5-fluorouracil (5FU)-induced hyperammonemia." | 4.85 | [A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer]. ( Fujita, J; Hirata, T; Kinjyo, F; Kobashikawa, K; Matayoshi, R; Nakamura, M; Ohshiro, M; Takaki, R; Tamura, J, 2009) |
| "5-fluorouracil (5-FU) plus leucovorin (LV) therapy is the most widely used regimen with a high evidence as the first-line treatment for advanced colorectal cancer (CRC), as well as CPT-11 as the second-line." | 4.82 | [Chemotherapy for colorectal carcinoma]. ( Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H, 2003) |
| "For advanced colorectal cancer (ACC), 5-fluorouracil (5-FU) based chemotherapy has been the standard for some decades." | 4.82 | Systemic treatment of advanced colorectal carcinoma. ( Punt, CJ; van Laarhoven, HW, 2004) |
| "New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)." | 4.82 | [Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004) |
| "Although 5-fluorouracil (5-FU) has been used to treat advanced colorectal cancer for 45 years, the drug has only a modest response rate and impact on survival." | 4.80 | Therapy for advanced colorectal cancer. ( Benson, AB, 1998) |
| "Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs." | 4.80 | Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 4.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "Oxaliplatin in combination with fluorouracil/folinic acid is an effective treatment option for patients with metastatic colorectal cancer, both as a first-line therapy and in patients refractory to previous chemotherapy." | 4.80 | Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. ( Clemett, D; Culy, CR; Wiseman, LR, 2000) |
| "Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy." | 4.79 | Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994) |
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 4.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| "A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen." | 4.77 | [Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989) |
| "Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)." | 4.31 | Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023) |
| "Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown." | 4.31 | Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023) |
| "0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)." | 4.12 | Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 4.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| "Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)." | 4.12 | One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022) |
| "Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells." | 4.02 | [Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021) |
| "FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of colorectal cancer (CRC) and hepatocellular carcinoma (HCC)." | 4.02 | Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. ( Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021) |
| "Combination therapy of tegafur/uracil (UFT) and leucovorin (LV) is widely used to treat colorectal cancers." | 4.02 | Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. ( Endo, Y; Hirashita, T; Inomata, M; Itoh, H; Iwao, M; Iwashita, Y; Masuda, T; Shiraiwa, K; Suzuki, Y; Tada, K; Tanaka, R; Uchida, H, 2021) |
| " The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown." | 4.02 | Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021) |
| "This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with modified FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) as an alternative treatment option in advanced hepatocellular carcinoma (HCC) patients with failed or unsuitability for transarterial chemoembolization (TACE)." | 4.02 | Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. ( Chen, MP; Chen, RX; Chen, Y; Ge, NL; Hsu, SJ; Luo, JF; Ren, ZG; Wang, Y; Wang, YH; Xu, X; Yin, X; Zhang, L; Zhao, ZY, 2021) |
| "This study aimed to utilize cholesterol conjugation of 5-fluorouracil (5-FUC) and liposomal formulas to enhance the partitioning of 5-FU into low density lipoprotein (LDL) to target hepatocellular carcinoma (HCC)." | 4.02 | Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition. ( Al Meanazel, AT; Al Meanazel, OT; Alanazi, FK; Alanazi, SA; Alomrani, AH; Badran, MM; Elzayat, E; Harisa, GI, 2021) |
| " sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)." | 4.02 | Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021) |
| "To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)." | 4.02 | Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021) |
| "The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)." | 3.96 | Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020) |
| "The authors sought to forecast survival and enhance treatment decisions for patients with liver metastatic colorectal cancer by using on-treatment radiomics signature to predict tumor sensitiveness to irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) alone (F) or in combination with cetuximab (FC)." | 3.96 | Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. ( Dercle, L; Eggleton, P; Lu, L; Piessevaux, H; Qian, M; Schwartz, LH; Tejpar, S; Zhao, B, 2020) |
| "Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 3.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
| "This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice." | 3.96 | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. ( Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2020) |
| "This study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed." | 3.96 | Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. ( Aparicio, T; Barbier, E; Ben Abdelghani, M; Bennouna, J; Boige, V; Borel, C; Bouché, O; Desseigne, F; Dohan, A; Faroux, R; François, E; Gallix, B; Genet, D; Ghiringhelli, F; Guiu, B; Hoeffel, C; Jacquot, S; Jouve, JL; Khemissa-Akouz, F; Le Malicot, K; Lepage, C; Phelip, JM; Reinhold, C; Rinaldi, Y; Seitz, JF; Soyer, P; Suc, E; Taieb, J; Texereau, P, 2020) |
| "Currently, 5-fluorouracil (5-FU) resistance became a major obstacle to its clinical use for patients with hepatocellular carcinoma (HCC)." | 3.91 | H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA. ( Li, F; Li, Z; Wang, J; Wei, N; Wu, N; Zhang, H, 2019) |
| "The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk." | 3.91 | Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019) |
| "Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab." | 3.91 | Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. ( Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W, 2019) |
| " In this study, a biotin-/lactobionic acid-modified poly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol) (BLPP) copolymer was synthesized, and curcumin- and 5-fluorouracil-loaded nanoparticles (BLPPNPs/C + F) were prepared to enhance the treatment of hepatocellular carcinoma." | 3.91 | Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma. ( Gao, X; Ji, Y; Jian, X; Li, Z; Liu, Z; Ni, W; Sun, S; Wu, L, 2019) |
| "5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer." | 3.91 | 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019) |
| "Bile salts (GCDA) promoted the proliferation of hepatocellular carcinoma (HCC) cells (HepG2 and QGY-7703), and GCDA treatment reduced the chemosensitivity of 5-fluorouracil (5FU) in HepG2 and QGY-7703 cells." | 3.91 | Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. ( Jin, X; Li, X; Liao, M; Wang, C; Xiao, X; Yang, M; Zhang, Y; Zhao, J, 2019) |
| "A case of hyperammonemia induced by chemotherapy, including high-dose fluorouracil(5-FU), for advanced unresectable large intestinal cancer has been reported." | 3.91 | [Case of Hyperammonemia Induced by High-Dose Fluorouracil]. ( Abe, M; Hagiwara, A; Kusakabe, A; Mafune, K; Saito, M, 2019) |
| "Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies." | 3.88 | Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study. ( Gonoi, W; Hashimoto, M; Kondoh, C; Kuroyanagi, H; Matoba, S; Nishioka, Y; Ozaki, Y; Shindoh, J; Takano, T; Tanabe, Y, 2018) |
| "We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease." | 3.88 | KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. ( Alesse, E; Bruera, G; Calvisi, G; Cannita, K; Cocciolone, V; Cortellini, A; Dal Mas, A; Ficorella, C; Mastroiaco, V; Ricevuto, E; Tessitore, A; Zazzeroni, F, 2018) |
| "To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 3.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs." | 3.88 | Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018) |
| "The combination of platinum with 5-fluorouracil has scarcely been studied in metastatic breast cancer." | 3.88 | Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. ( Biagioni, C; Biganzoli, L; DI Leo, A; Malorni, L; McCartney, A; Moretti, E; Pestrin, M; Risi, E; Rossi, L; Sanna, G, 2018) |
| "5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)." | 3.88 | lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018) |
| "We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats." | 3.88 | Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018) |
| " We found that the downregulation or complete depletion of SND1 enhanced the apoptosis levels of HepG2 and SMMC-7721 cells upon stimulation with 5-Fu (5-fluorouracil), a chemotherapeutic drug for HCC (hepatocellular carcinoma)." | 3.88 | SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. ( Cui, X; Gao, X; Qian, B; Ren, Y; Su, C; Yang, J; Yao, X; Yao, Z; Zhao, C, 2018) |
| " Interestingly, the panel also revealed that he had mismatch-repair(MMR)deficiency with MSH2 mutation, which is reported as a possible cause of resistance to 5-fluorouracil in colorectal cancer." | 3.88 | [A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer]. ( Hotta, S; Ichikawa, H; Kameyama, H; Maruyama, S; Miura, K; Nagahashi, M; Nakano, M; Nogami, H; Shimada, Y; Tajima, Y; Takii, Y; Tanaka, K; Wakai, T; Yamada, S, 2018) |
| "More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease." | 3.86 | Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. ( Arnold, D; Edelmann, T; Glockzin, G; Hildebrandt, B; Hollerbach, S; Illerhaus, G; Königsrainer, A; Richter, M; Schlitt, HJ; Schmoll, HJ; Stein, A; Wienke, A, 2012) |
| "Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)." | 3.85 | The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017) |
| " A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon." | 3.85 | Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE. ( Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K, 2017) |
| "This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)." | 3.85 | The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017) |
| "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose." | 3.85 | Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 3.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| " Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism." | 3.83 | Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016) |
| " We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients." | 3.83 | Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Kim, MJ; Kim, SH; Kim, TY; Lee, DW; Lee, KH; Oh, DY, 2016) |
| "Three human hepatocellular carcinoma cell lines--HepG2, Hep3B and HuH-7--were pre- and post-treated with doxorubicin, 5-fluorouracil (5-FU) and cisplatin." | 3.83 | Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. ( Farmer, RW; Li, Y; Martin, RC; Yang, Y, 2016) |
| "To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 3.83 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016) |
| "This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China." | 3.83 | FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 3.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| " Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)." | 3.81 | Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015) |
| " Herein, we report that NPs conjugated with antibody against GRP78 (mAb GRP78-NPs) inhibit the adhesion, invasion, and metastasis of hepatocellular carcinoma (HCC) and promote drug delivery of 5-fluorouracil into GRP78 high-expressed human hepatocellular carcinoma cells." | 3.81 | Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78. ( Li, H; Liu, L; Shi, Y; Su, C; Su, R; Wang, G; Zhao, L, 2015) |
| " The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)." | 3.81 | Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015) |
| "To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)." | 3.81 | Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015) |
| "Seventy-three patients with liver cirrhosis (LC) and advanced HCC (aHCC) received hepatic arterial infusion chemotherapy (HAIC: leucovorin (LV) at 12 mg/h, cisplatin (CDDP) at 10 mg/h and 5-fluorouracil (5-FU) at 250 mg/22 h) via the proper hepatic artery every 5 days for 4 weeks using a catheter connected to a subcutaneous drug delivery system." | 3.81 | VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy. ( Matsui, D; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y, 2015) |
| "To summarize the experience of the chemotherapy regimen cisplatin + fluorouracil + vincristine (C5V) for hepatoblastoma, and analyze the factors associated the outcome." | 3.81 | [Outcome of hepatoblastoma: experience with 63 patients received chemotherapy with the regimen C5V]. ( Dong, K; Li, K; Liu, B; Liu, G; Xiao, X, 2015) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 3.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
| "Systemic FOLFOX (folinic acid (leucovorin (LV)), 5-fluorouracil (5-FU), and oxaliplatin), FOLFIRI (LV, 5-FU, and irinotecan), or FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) chemotherapy regimens and additional molecular-target treatments, including anti-vascular endothelial growth factor, anti-epidermal growth factor receptor, and anti-multi-kinase antibodies, have been recommended for unresectable recurrent colorectal cancers." | 3.81 | Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer. ( Fujimoto, D; Goi, T; Kimura, Y; Koneri, K; Morikawa, M; Naruse, T; Yamaguchi, A, 2015) |
| "12 patients with unresectable liver metastases from colorectal cancer were enrolled and received neoadjuvant FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab therapy." | 3.81 | Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. ( Amato, DM; Avallone, A; Catalano, O; Filice, S; Fusco, R; Granata, V; Izzo, F; Nasti, G; Petrillo, A, 2015) |
| " Here, we report the effect of an APN inhibitor 4cc in enhancing sensitivity of hepatocellular carcinoma (HCC) cell lines and xenograft model in response to 5-fluorouracil (5-FU) in vivo and in vitro." | 3.81 | Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition. ( Dai, G; Duan, Y; Shi, LH; Sun, ZP; Wang, XJ; Xu, WF; Zhang, J; Zhang, XR, 2015) |
| "Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC)." | 3.80 | A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. ( Chang, ML; Hsu, CL; Hung, CF; Liang, KH; Lin, CC; Yeh, CT, 2014) |
| "5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)." | 3.80 | The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014) |
| "Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 3.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
| "To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 3.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
| "This study proposed a conception of individualized chemotherapy based on organ selectivity of drug distribution by retrospectively comparing the effect of vinorelbine and capecitabine in patients with metastatic breast cancer." | 3.80 | Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer. ( Cao, R; Liu, C; Liu, XH; Man, YN; Wu, XZ, 2014) |
| " Decreases in the rates of ascites and jaundice were confirmed by ultrasound and bilirubin levels." | 3.80 | Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study. ( Lu, K; Qiao, WB; Sun, D; Yin, H; You, QS; Zhang, HY, 2014) |
| "To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping." | 3.80 | FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. ( Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS, 2014) |
| "Chemotherapy-induced intestinal mucositis (CIM) is a major dose-limiting side effect, resulting from the nonspecific cytoablative actions of chemoagents, including 5-fluorouracil (5-FU) and irinotecan (CPT-11)." | 3.80 | IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.). ( Chan, GL; Gao, J; Han, W; Qian, L; Wang, X; Wu, M; Yu, Y; Zhang, Y; Zhu, S, 2014) |
| "Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)." | 3.80 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014) |
| "In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma." | 3.80 | Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. ( Dangi, R; Gulbake, A; Hurkat, P; Jain, A; Jain, SK; Shilpi, S, 2014) |
| "5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma." | 3.80 | Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014) |
| " The authors report a case of radiation recall resulting from an interaction between radiation delivered during a fluoroscopically guided hepatic chemoembolization for treatment of metastatic carcinoid tumor and the oral chemotherapeutic agents capecitabine and temozolomide administered 7 weeks later." | 3.80 | Radiation recall after a transarterial hepatic chemoembolization. ( Sands, MJ; Wunderle, KA, 2014) |
| "49 consecutive patients bearing unresectable metastatic colorectal cancer and who experienced failure to oxaliplatin- and irinotecan-based chemotherapy were treated with oxaliplatin (85 mg/m(2)), irinotecan (180 mg/m(2)), leucovorin (400 mg/m(2)), and fluorouracil (400 mg/m(2) bolus then 2,400 mg/m(2)) repeated every 2 weeks." | 3.80 | FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. ( Chaix, M; Ghiringhelli, F; Lorgis, V; Vincent, J, 2014) |
| " The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells." | 3.80 | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014) |
| "Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC)." | 3.80 | Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. ( Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D, 2014) |
| "Children with hepatocellular carcinoma (HCC) were treated on a prospective, randomized trial and were then analyzed to determine whether children with the fibrolamellar (FL) histologic variant of HCC have a more favorable presentation, increased surgical resectability, greater response to therapy, and improved outcome compared with children who have typical HCC." | 3.80 | Fibrolamellar hepatocellular carcinoma in children and adolescents. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Malogolowkin, MH; Newman, K; Ortega, JA; Qu, W; Quinn, JJ; Reynolds, M; Sensel, MG, 2003) |
| "We report a case of a trastuzumab-resistant human epidermal growth factor receptor-2(HER2)-positive breast cancer patient with extensive liver metastases and associated impaired liver function, who showed an excellent response to the combination of trastuzumab and capecitabine." | 3.79 | [Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report]. ( Fujiuchi, N; Misumi, M; Nakamiya, N; Osaki, A; Saeki, T; Shigekawa, T; Sugitani, I; Sugiyama, M; Takeuchi, H, 2013) |
| "The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma." | 3.79 | Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| "We retrospectively analyzed ABCG2 expression levels in patients with metastatic colorectal cancer (CRC) to investigate the interaction between ABCG2 expression and the tumor response to oxaliplatin and 5-fluorouracil (FOLFOX)." | 3.79 | Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence. ( Chang, SC; Chen, WS; Li, AF; Lin, CC; Lin, HH; Lin, JK; Lin, PC; Yang, SH, 2013) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 3.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma." | 3.79 | Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013) |
| "Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable." | 3.79 | Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013) |
| "To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)." | 3.79 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013) |
| " Our study found that the expression of miR-27a was down-regulated in the multidrug-resistant hepatocellular carcinoma cell line BEL-7402/5-fluorouracil (BEL/5-FU) compared with its parental BEL-7402 cell line, while the MDR1/P-glycoprotein expression was elevated." | 3.79 | MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. ( Chen, Z; Hu, T; Huang, C; Li, J; Lv, X; Ma, T; Xu, T; Zhang, L, 2013) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 3.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "To explore the potential of iodized linoleic acid (ILA) and its 5-fluoro-deoxyuridine ester (IFU) to inhibit hepatocellular carcinoma (HCC) cells in vitro and tumors in vivo." | 3.79 | [A preliminary study of the inhibitive efficacy of iodized linoleic acid and its fluorodeoxyuridine ester in hepatocellular cancer]. ( Dai, ZY; Jiang, YB; Kuang, CX; Li, KC; Zeng, XY, 2013) |
| "A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 3.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
| "Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits." | 3.79 | Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. ( Lee, HJ; Lee, SH; Oh, MJ, 2013) |
| "We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 3.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 3.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients." | 3.79 | The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. ( Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S, 2013) |
| "We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver." | 3.79 | Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. ( Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA, 2013) |
| "Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)." | 3.78 | Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012) |
| " Swiss mice inoculated with hepatoma HepA(22) or sarcoma 180 (S(180)) cells were treated with ShD or 5-fluorouracil (5Fu)." | 3.78 | Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice. ( BaoJie, G; GuangZhi, Y; LiHua, L; Long, S; Wei, X; Yang, Z; YanYong, H; YingLi, W, 2012) |
| "FOLFOXIRI demonstrated higher efficacy compared to 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer." | 3.78 | Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. ( Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E, 2012) |
| "Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro." | 3.78 | Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012) |
| "5-Fluorouracil (5-FU) chemotherapy is the first choice treatment for advanced hepatocellular carcinoma (HCC), and resistance is the major obstacle to successful treatment." | 3.78 | Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. ( Kasamatsu, A; Kobayashi, E; Sakurada, T; Sato, N; Sunaga, M; Tanzawa, H; Uchibori, K; Ueda, S; Uzawa, K; Yokota, S; Yoshikawa, M, 2012) |
| "The aim of the present study was to design a targeted delivery system of 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)." | 3.78 | Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. ( Hassanzadeh, F; Khadem, M; Sadeghi, H; Varshosaz, J, 2012) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 3.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| "Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols." | 3.78 | Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012) |
| "A 55-year-old woman with a 3-year and 4-month history of liver metastasis from breast cancer underwent chemotherapy with capecitabine and cyclophosphamide for following 10-months." | 3.78 | [Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer]. ( Ishikawa, T; Tukamoto, Y; Yasaki, S; Yoshii, F; Yuasa, N, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 3.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| "The aim was to evaluate activity and toxicity of hepatic arterial infusion of oxaliplatin in combination with capecitabine in patients with metastatic breast cancer with liver metastases and limited extrahepatic disease." | 3.78 | Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer. ( Bergenfeldt, M; Hermann, KL; Jensen, BK; Jensen, BV; Nelausen, KM; Nielsen, DL; Nørgaard, H; Pfeiffer, P; Vestermark, LW, 2012) |
| "Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is a promising treatment for colorectal, breast and gastric cancers, but often causes hand-foot syndrome (HFS), the most common dose-limiting toxicity." | 3.78 | Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. ( Azuma, Y; Fujiwara, Y; Hata, K; Hirakawa, A; Makino, Y; Morikawa, N; Ryushima, Y; Sai, K; Saito, Y; Tohkin, M; Udagawa, R; Yamamoto, H; Yokote, N, 2012) |
| "A colorectal cancer patient receiving chemotherapy (5-fluorouracil and oxaliplatin) plus bevacizumab developed acute, severe thrombocytopenia." | 3.78 | A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia. ( Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dior, M; Goldwasser, F; Mir, O; Perkins, G, 2012) |
| "We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)." | 3.78 | Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. ( Aloia, TA; Andreou, A; Brouquet, A; Chen, SS; Curley, SA; Garrett, C; Kopetz, S; Maru, DM; Overman, MJ; Shindoh, J; Vauthey, JN; Zimmitti, G, 2012) |
| "Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 3.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 3.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 3.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
| "5-Fluorouracil remains widely used in colorectal cancer treatment more than 40 years after its development." | 3.77 | Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? ( Griffiths, JR; Howe, FA; Ladroue, C; Lofts, F; McIntyre, DJ; Stubbs, M, 2011) |
| "Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings." | 3.77 | Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011) |
| "This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011) |
| " The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer." | 3.77 | Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. ( Chatelut, E; Delord, JP; Duret, A; Etienne, MC; Falandry, C; Freyer, G; Lledo, G; Merrouche, Y; Milano, G; Rebischung, C, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 3.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)." | 3.77 | Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011) |
| "To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.77 | Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011) |
| "Cytotoxic activity of artemisinin and derivatives in the presence and absence of holo-transferrin and expression of genes involved in resistance of cancer cells were investigated in human cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines in vitro." | 3.77 | Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. ( Chaijaroenkul, W; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2011) |
| "The antivascular endothelial growth factor monoclonal antibody bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) is a standard first-line treatment option for metastatic colorectal cancer." | 3.77 | Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. ( Boc, M; Ocvirk, J; Rebersek, M, 2011) |
| "We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches." | 3.77 | Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| "Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC)." | 3.77 | Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results. ( Jung, G; Kim, BH; Kim, JS; Kim, NY; Lee, KJ; Park, SJ; Park, YM; Yeon, JW; Yun, HK, 2011) |
| "To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms." | 3.77 | Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011) |
| "Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization." | 3.77 | Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011) |
| "We report a 55-year-old female with liver metastases from breast cancer who responded to lapatinib and capecitabine combination therapy as third-line." | 3.77 | [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy]. ( Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H, 2011) |
| "We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)." | 3.77 | [A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 3.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 3.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 3.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| " However, it has also been reported that 5-fluorouracil (5-FU) exacerbates liver damage in patients with liver cirrhosis (LC)." | 3.76 | Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Matsui, T; Momiyama, K; Nagai, H; Shinohara, M; Shizawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2010) |
| "Capecitabine + docetaxel combination therapy proves highly effective against the advanced or recurrent breast cancer." | 3.76 | [An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6]. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T, 2010) |
| "Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in advanced colorectal cancer patients." | 3.76 | Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. ( Auman, JT; Deal, AM; Hoskins, JM; Hudson, ML; Ibrahim, JG; McLeod, HL; Meyers, MO; Muhale, F; O'Neil, BH; Thorne, LB; Walko, CM; Watson, RG; Yu, J, 2010) |
| " Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU- and neocarzinostatin-dependent cFLIP(L) and cFLIP(S) down-regulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL." | 3.76 | ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. ( Barilà, D; Giaccari, D; Mingardi, M; Santini, S; Stagni, V, 2010) |
| "We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)." | 3.76 | MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010) |
| "Data on patients with colorectal cancer who received FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) treatment between June 2005 and June 2009 were retrieved from the prospective cohort database of the Outpatient Oncology Unit of the Kyoto University Hospital." | 3.76 | Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. ( Chiba, T; Fukushima, M; Hazama, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mori, Y; Nagayama, S; Nishimura, T; Sakai, Y; Teramukai, S; Yanagihara, K; Yoshimura, K, 2010) |
| "This retrospective study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU) for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy." | 3.76 | Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. ( Arai, Y; Aramaki, T; Boku, N; Inaba, Y; Kichikawa, K; Matsuoka, M; Nishiofuku, H; Otsuji, T; Sato, Y; Tanaka, T, 2010) |
| "We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP)." | 3.76 | [A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi]. ( Doki, Y; Eguchi, H; Hashimoto, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 3.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy." | 3.75 | Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009) |
| "In patients suffering from colorectal cancer liver metastases, 5-fluorouracil-based chemotherapy plus oxaliplatin ensures superior response rates at the cost of hepatic injury." | 3.75 | Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Klinger, M; Koelblinger, C; Tamandl, D, 2009) |
| "The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer." | 3.75 | Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009) |
| " Additionally, unsupervised clustering using the MMP/TIMP profile of N=25 colorectal cancer liver metastases was performed and the response to palliative 5-fluorouracil (5-FU)-based chemotherapy was assessed using radiological response criteria." | 3.75 | Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. ( Brueckl, WM; Croner, RS; Dimmler, A; Dorlaque, L; Gentner, B; Hahn, EG; Hohenberger, W; Roedel, F; Wein, A; Wirtz, RM; Zeittraeger, I, 2009) |
| "Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 3.75 | Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009) |
| "As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined treatment (cisplatin, gemcitabine, 5-FU)." | 3.75 | Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. ( Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B, 2009) |
| "We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)." | 3.75 | Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009) |
| "Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)." | 3.75 | Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009) |
| "One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens." | 3.75 | [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009) |
| "The combination therapy of interferon (IFN)-alpha and 5-fluorouracil (5-FU) improved the prognosis of the patients with hepatocellular carcinoma (HCC)." | 3.75 | Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamamoto, H, 2009) |
| "In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis." | 3.75 | Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009) |
| "The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)." | 3.75 | Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009) |
| "We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC)." | 3.74 | Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. ( Alessandroni, P; Baldi, G; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B, 2008) |
| "Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo." | 3.74 | [Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008) |
| " When the total dose of 5-fluorouracil reached 21,200 mg and the total dose of oxaliplatin reached 880 mg after about 100 days of treatment, epiphora developed." | 3.74 | [Epiphora in a patient receiving FOLFOX therapy]. ( Iwagami, E; Niimi, M; Ono, Y; Tanaka, E; Uto, N; Yamato, M; Yatsuda, C, 2008) |
| "5-fluorouracil (5-FU) and oxaliplatin play important roles in chemotherapy for patients with colorectal cancer." | 3.74 | Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. ( Azuma, M; Danenberg, KD; Danenberg, PV; Enomoto, M; Higuchi, T; Iida, S; Kobayashi, H; Lenz, HJ; Mori, R; Omori, A; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 3.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)." | 3.74 | Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007) |
| " The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis." | 3.74 | Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007) |
| "This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients." | 3.74 | Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007) |
| "The aim of this study is to evaluate the safety and efficacy of hepatic artery infusion (HAI) of 5-fluorouracil (5FU) for patients with liver metastases from colorectal carcinoma after radiological placement of infusion catheters." | 3.74 | Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters. ( Hirayama, I; Horikoshi, H; Motegi, K; Saito, T; Sameshima, S; Sawada, T; Tomozawa, S, 2007) |
| "We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration." | 3.74 | Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007) |
| "To evaluate the effect of combined antisense oligonucleotides targeting midkine (MK-AS) and chemotherapeutic drugs [cisplatin(DDP), 5-fluorouracil (5-FU) and adriamycin (ADM)] on inhibition of HepG2 cell proliferation, and to analyze the efficacy of MK-AS used in combined ADM in in situ human hepatocellular carcinoma (HCC) model." | 3.74 | Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma. ( Dai, LC; He, JF; Lu, YL; Ping, JL; Wang, X; Yao, X, 2007) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 3.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003." | 3.74 | [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "We report a 59-year-old woman diagnosed with metastasic colorectal cancer who developed immune hemolytic anemia during FOLFOX chemotherapy (oxaliplatin/leucovorin/5-fluorouracil)." | 3.74 | Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. ( Albiol, S; Cobo, F; De Celis, G; Latorre, X; Pereira, A; Pujadas, J, 2007) |
| "We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor." | 3.74 | Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007) |
| "We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results." | 3.74 | Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007) |
| "A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer." | 3.74 | Regression of radiation-induced macular edema after systemic bevacizumab. ( Bakri, SJ; Pulido, JS; Solano, JM, 2007) |
| "To investigate the multicellular resistance of human hepatocellular carcinoma HepG2 cells in three-dimensional culture to delisheng, 5-fluorouracil and adriamycin, and the possible molecular mechanisms of delisheng." | 3.74 | Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. ( Cui, J; Guo, YH; Nan, KJ; Tian, T; Wang, L; Zhao, N, 2007) |
| "Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis." | 3.74 | Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| "Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| " Here, we examined the role p53 plays in the antitumour effect of combination treatment with pegylated interferon (PEG-IFN)-alpha and 5-fluorouracil (5-FU), which has been shown to effectively treat advanced hepatocellular carcinoma (HCC)." | 3.74 | Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. ( Fukuta, N; Hagiwara, S; Hayakawa, S; Kimura, M; Kudo, M; Munakata, H; Nagashima, M; Nakatani, T; Sakaguchi, Y, 2007) |
| "To observe changes of sensitivity to 5'-deoxy-5-fluorouridine (5'-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP)." | 3.74 | [Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase]. ( Fan, J; Liu, YK; Sun, RX; Tang, ZY; Xiao, YS; Ye, SL; Zhao, Y; Zhou, J, 2007) |
| "Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease." | 3.74 | [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. ( Fujii, H; Inoue, A; Inoue, M; Inoue, S; Kunitomo, K; Takahashi, H, 2008) |
| "The chemotherapy regimen suitable for advanced colorectal cancer patients previously treated with 5 fluorouracil (5FU); oxaliplatin and irinotecan remains an unresolved issue." | 3.74 | A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. ( Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E, 2008) |
| "Transcatheter treatment for liver metastases from breast cancer was given to 55 patients (1995-2006): hepatic artery infusion (HAI) with 5-fluorouracil, doxorubicin and carboplatin--11; hepatic artery oil chemoembolization (HAOC) with doxorubicin--14; taxotere (Docetaxel)--17; HAI+HAOC--13." | 3.74 | [Transcatheter treatment of liver metastases from breast cancer]. ( Gasanov, ISh; Generalov, MI; Polikarpov, AA; Tarazov, PG, 2008) |
| "The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)." | 3.74 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008) |
| "Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma." | 3.73 | Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005) |
| "To determine whether the nonselective and relatively inexpensive nonsteroidal anti-inflammatory drug ibuprofen would be effective in inhibiting colorectal cancer and might improve mortality in a mouse model." | 3.73 | Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005) |
| "We examined Drg1 expression by immunohistochemistry in 131 patients with metastatic colorectal cancer enrolled in a clinical trial of adjuvant fluorouracil-based therapy from 1991 to 1995." | 3.73 | Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. ( Cordon-Cardo, C; Drobnjak, M; Gonen, M; Hummer, A; Kemeny, N; Motwani, M; Schwartz, GK; Shah, MA, 2005) |
| "The effect of tacrolimus (FK506) and 5-fluorouracil (5-FU) on hepatocellular carcinoma remains elusive." | 3.73 | Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721. ( Cao, XW; Ding, GS; Fu, ZR, 2005) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 3.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)." | 3.73 | Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005) |
| "We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 3.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
| "We identified genes related to 5-fluorouracil (5-FU) sensitivity in colorectal cancer and utilized these genes for predicting the 5-FU sensitivity of liver metastases." | 3.73 | Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. ( Endo, I; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Kunisaki, C; Matsuyama, R; Momiyama, N; Shimada, H; Shimizu, D; Suzuki, H; Togo, S, 2006) |
| "Hepatic arterial infusion chemotherapy with levofolinate (l-leucovorin) and fluorouracil regimen was performed using an implanted port system on unresectable hepatic metastasis patients with colorectal cancer." | 3.73 | [Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer]. ( Fujino, H; Hata, K; Kitamura, N; Kobuchi, T; Maruhashi, K; Nakamura, T; Shimomatsuya, T; Shiraishi, S, 2006) |
| "A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation." | 3.73 | Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006) |
| " In this study, we evaluated the correlation between sensitivity to 5-fluorouracil (5-FU) and the mRNA expression level of several 5-FU-related metabolic enzymes [thymidylate synthase, dihydropyrimidine dehydrogenase (DPD), thymidylate phosphorylase (TP), orotate phosphoribosyl transferase, and uridine phosphorylase] in primary colorectal cancer and synchronous liver metastases from ten patients to investigate how colorectal cancer acquires 5-FU resistance during liver metastases." | 3.73 | Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. ( Endo, Y; Kaizuka, M; Kurumi, Y; Mekata, E; Okumura, K; Shiomi, H; Tani, T, 2006) |
| "Interferon (IFN) combined with 5-Fluorouracil (5-FU) treatment has recently been reported to show beneficial effects in patients with advanced hepatocellular carcinoma." | 3.73 | Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. ( Iwasaki, Y; Koike, K; Sakaguchi, K; Shiraha, H; Shiratori, Y; Suzuki, M; Takaki, A; Tatsukawa, M, 2006) |
| "Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated." | 3.73 | The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006) |
| " Anti-proliferative effects of single treatment with IFN-alpha subtypes or 5-fluorouracil (FU), and of combined treatment with each IFN-alpha subtype and 5-FU were examined on three hepatocellular carcinoma cell lines, HepG2, HLE and PLC/PRF/5." | 3.73 | Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells. ( Arai, N; Ariyasu, H; Ariyasu, T; Fujioka, N; Fukuda, S; Ikeda, M; Ikegami, H; Kurimoto, M; Ohta, T; Tanimoto, T; Yamamoto, S, 2006) |
| "The author reports the successful treatment of an 85-year-old recurrent breast cancer patient with low-dose capecitabine." | 3.73 | [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine]. ( Honma, H, 2006) |
| "We present two cases of multiple liver metastases from colorectal cancer, which did not respond to hepatic arterial infusion (HAI) using 5-fluorouracil (5-FU 1250 mg/body weekly) alone, but responded to HAI using 5-fluorouracil (5-FU 750 mg/body weekly) and l-leucovorin (l-LV 50 mg/body weekly) achieving a complete response (CR)." | 3.73 | [Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin]. ( Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kato, S; Sugihara, K; Uetake, H; Yasuno, M, 2006) |
| "The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal and thromboembolic events were reported in two US trials." | 3.72 | Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. ( Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C, 2003) |
| "To investigate the toxicities, biodistribution and anticancer effect of 5-fluorouracil controlled release implant (5-FUCI) on Walker 256 carcinosarcoma cells in Wistar rats." | 3.72 | Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats. ( Cao, J; Chen, JW; He, YC; Pan, DY; Qiao, JG, 2003) |
| "Hepatic intra-arterial infusion chemotherapy of 5-fluorouracil (5-FU) or fluorodeoxyuridine (FUDR) has been a treatment option for liver metastasis from colorectal cancer." | 3.72 | Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. ( Ishikawa, K; Makuuchi, H; Masuda, T; Murayama, C; Nakamura, T; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2003) |
| "The significance of hepatic arterial infusion chemotherapy for unresectable liver metastases from colorectal cancer was evaluated in 50 patients, who received either of the following regimens: 1 shot 5-FU + epirubicin + MMC (FAM group); hepatic arterial infusion of 5-FU for 2 hours + MMC (MF group); hepatic arterial infusion of 5-FU for 2 hours (5-FU group)." | 3.72 | [Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer]. ( Hirakawa, K; Kosaka, K; Nishihara, T; Nishino, H; Ohira, M; Yamada, N, 2003) |
| "In metastatic colorectal cancer the oral 5-fluorouracil (5FU) prodrug capecitabine is used with increasing frequency as an alternative to i." | 3.72 | In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. ( Heerschap, A; Kamm, YJ; Klomp, DW; Punt, CJ; van Laarhoven, HW, 2003) |
| "To study the effect of wild type (wt) p53 gene transfection on drug resistant human hepatocellular carcinoma (HCC) cells induced by 5-Fluorouracil (5-FU)." | 3.72 | Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. ( Li, YX; Lin, ZB; Tan, HR, 2004) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 3.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases." | 3.72 | [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. ( Fujio, N; Fukuda, Y; Koyama, I; Mayumi, K; Osugi, H; Takatori, H; Terakura, M; Tsukazaki, T; Tsukazaki, Y, 2004) |
| " In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)." | 3.72 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 3.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "Expression of thymidylate synthase (TS) and the 5-fluorouracil (5-FU) metabolic enzymes, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), and uridine phosphorylase (UP), has been reported to be associated with the sensitivity to 5-FU-based chemotherapy in colorectal cancer." | 3.72 | Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. ( Inokuchi, M; Shirota, Y; Sugihara, K; Tajima, M; Uetake, H; Yamada, H, 2004) |
| "To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression." | 3.72 | Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004) |
| "The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases." | 3.72 | Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. ( Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M, 2004) |
| "We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival." | 3.72 | Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 3.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use." | 3.72 | A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 3.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis." | 3.72 | Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004) |
| "Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma." | 3.72 | Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004) |
| "To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination." | 3.72 | [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 3.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)." | 3.72 | [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004) |
| " To evaluate the therapeutic effectiveness and safety of oxaliplatin combined with 5-fluorouracil and leucovorin on the patients with gastric carcinoma after palliative gastric resection, we analyzed all of the cases of gastric adenocarcinoma undergone palliative gastric resection in our Cancer Center in recent years." | 3.72 | [Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer]. ( Chen, YB; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ, 2004) |
| "Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 3.72 | Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004) |
| " In 25 patients with HCC, in vitro chemosensitivity to 5-fluorouracil (5-FU), epirubicin (EPI), and cisplatin (CDDP) was examined by CD-DST, and 5-FU, EPI, and paclitaxel (PTX) were examined in 38 patients with breast cancer." | 3.72 | [In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures]. ( Abumiya, K; Kamachi, H; Kamiyama, N; Kamiyama, T; Khor, LW; Kobayashi, H; Kurauchi, N; Matsushita, M; Nakagawa, T; Nakajima, H; Nakanishi, K; Taguchi, K; Takahashi, H; Takahashi, M; Todo, S; Tsukahara, M; Watanabe, K, 2004) |
| "This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)." | 3.71 | Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002) |
| "Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer." | 3.71 | Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously." | 3.71 | [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 3.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| "To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU." | 3.71 | Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002) |
| "We evaluated the effect of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer." | 3.71 | [Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Sakita, I; Soma, I; Yoshida, T, 2002) |
| "We administered interleukin (IL)-2 with mitomycin C (MMC) and 5-fluorouracil (5-FU) by hepatic arterial infusion for the treatment of liver recurrence from colorectal cancer." | 3.71 | [Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer]. ( Hazama, S; Iizuka, N; Matsuoka, K; Oka, M; Takano, N; Tangoku, A; Yoshimura, K, 2002) |
| "A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)." | 3.71 | [A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001) |
| "In our institution, patients with multiple unresectable liver metastases from colorectal cancer have received 24-h continuous arterial infusion therapy of 5-fluorouracil (5-FU) 250 mg/body/day every 2 weeks for the past 11 years." | 3.71 | [Results and limitations of arterial infusion therapy for liver metastases from colorectal cancer]. ( Mori, T; Ohue, M; Takahashi, K; Yamaguchi, T, 2001) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 3.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "For patients with incurable stage IV colorectal cancer, minimally symptomatic primary tumours were left in situ and 5-fluorouracil-based chemotherapy was administered systemically." | 3.71 | Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. ( Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT, 2001) |
| "We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions." | 3.71 | [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001) |
| "The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)." | 3.71 | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002) |
| "A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)." | 3.71 | [A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 3.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| " High DPD mRNA levels in liver metastasis and advanced colorectal cancer may have clinical importance for 5-fluorouracil-based chemosensitivity." | 3.71 | Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. ( Ichikawa, W; Nihei, Z; Shirota, Y; Sugihara, K; Uetake, H; Yamada, H, 2002) |
| "Dynamic PET and [18F]fluorouracil (18F-FU) were used in patients with liver metastases from colorectal cancer to examine the pharmacokinetics of the drug up to 120 min after intravenous and intra-arterial injection of the same dose of fluorouracil (FU)." | 3.70 | Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Doll, J; Hohenberger, P; Irngartinger, G; Oberdorfer, F; Schlag, P; Strauss, LG; van Kaick, G, 1998) |
| "It has been observed previously that the pulmonary metastases of colorectal adenocarcinoma are less responsive to therapy with fluorouracil (FUra) as compared with other sites of metastasis (liver, local)." | 3.70 | Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. ( Banerjee, D; Bertino, JR; Danenberg, KD; Danenberg, PV; Fu, J; Gorlick, R; Jhanwar, S; Kemeny, N; Klimstra, D; Longo, GS; Metzger, R; Miles, JS; Salonga, D, 1998) |
| "This case can be considered the first documented Irinotecan-induced immune thrombocytopenia." | 3.70 | Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998) |
| "Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)." | 3.70 | 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998) |
| "Between 1990 and 1997, 227 patients with hepatocellular carcinoma were treated by intrahepatic arterial injection of a Lipiodol-Epirubicin-Mitomycin C emulsion followed by intermittent hepatic artery infusion of Epirubicin, Mitomycin C and 5-FU, employing an implantable subcutaneous infusion port." | 3.70 | [Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma]. ( An, M; Hamada, E; Ikawa, M; Matsumoto, Y; Miura, T; Murata, M; Nakasato, S; Takagi, S; Terakado, H; Watanabe, K, 1998) |
| "We studied the effect of immunotherapy using recombinant interleukin-2 (rIL-2) in combination with a differentiating agent, sodium butyrate (NaBut), on experimental 5-fluorouracil (5-FU)-resistant liver metastasis from colorectal cancer in rats." | 3.70 | Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance. ( Cordel, S; Douillard, JY; Dupas, B; Meflah, K, 1998) |
| " However, new chemotherapy, based on the synergistic antitumor activities of 5-fluorouracil (5-FU) and cisplatin (CDDP) producing biochemical modulation in solid cancers diagnosed as adenocarcinoma, has recently been reported to be effective." | 3.70 | Biochemical modulation therapy for pancreatic cancer. ( Denno, R; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takashima, T; Yamamitsu, S, 1998) |
| "The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs." | 3.70 | Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999) |
| "A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]." | 3.70 | [A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999) |
| "In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system." | 3.70 | Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999) |
| "Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)." | 3.70 | [Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999) |
| "Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies." | 3.70 | Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000) |
| "The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease." | 3.70 | Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000) |
| "Continuous systemic infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (500 mg/body/day) was performed for advanced hepatocellular carcinoma (HCC) after hepatectomy with diffuse lung metastases and multiple intrahepatic metastases." | 3.70 | [Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 2000) |
| "This study was designed to examine the optimal regimen of 5-fluorouracil (5-FU), uracil and degradable starch microspheres (DSM) to prevent the hepatic metastasis of colorectal cancer." | 3.69 | Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer. ( Fujii, K; Hanaue, H; Kurosawa, T; Mitomi, T; Nakasaki, H; Tajima, T; Yasuda, S, 1994) |
| "We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)." | 3.69 | [A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994) |
| " We present herein the cases of three patients with multiple liver metastases from colorectal cancer in whom complete remission was achieved by treatment with an HAI of IL-2 in combination with mitomycin C (MMC) and 5-fluorouracil (5-FU)." | 3.69 | Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases. ( Akabane, Y; Koh, K; Kurooka, K; Nakajima, I; Ohnishi, H; Okuno, K; Shindo, K; Yasutomi, M, 1994) |
| "We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats." | 3.69 | Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994) |
| "From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy." | 3.69 | [5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994) |
| "The optimal schedule for the administration of 5-fluorouracil (5-FU) in the management of advanced colorectal cancer remains to be determined." | 3.69 | Bioavailability of subcutaneous 5-fluorouracil: a case report. ( Carlin, W; Dunlop, DJ; Eatock, MM; Soukop, M; Watson, DG, 1996) |
| "Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break." | 3.69 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996) |
| "Although intrahepatic infusion therapy with 5-fluorouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others." | 3.69 | p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. ( Benhattar, J; Cerottini, JP; Givel, JC; Metthez, G; Saraga, E, 1996) |
| "Twelve patients with liver metastases of breast cancer were treated with hepatic arterial infusion chemotherapy using 20-30 mg/body of epi-adriamycin (epi-ADM) every 2 weeks and continuous infusion of 250 mg/body/day of 5-fluorouracil (5-FU)." | 3.69 | [Intra-arterial infusion chemotherapy for liver metastases from breast cancer]. ( Furukawa, J; Kinuta, M; Maruhashi, S; Maruyama, H; Masuda, N; Matsui, S; Okamura, J; Ooi, H; Takiguchi, S; Tateishi, H; Tokunaga, M; Yano, H; Yayoi, E, 1996) |
| "A patient with advanced unresectable fibrolamellar hepatocellular carcinoma is reported, who was treated with cisplatinum, epirubicin and 5-fluorouracil combination chemotherapy." | 3.69 | Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy. ( Bower, M; Habib, N; Newlands, ES, 1996) |
| "The case history is reported of a 51-year-old man with metastatic colonic carcinoma who was receiving a continuous 5-fluorouracil infusion via a central venous catheter and who developed cardiac perforation and pericardial effusion." | 3.69 | Cardiac perforation associated with continuous infusional chemotherapy. ( Cooper, RA; James, RD; Taylor, KJ, 1996) |
| " In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial." | 3.69 | Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995) |
| "5-Fluorouracil (5-FU) is the most widely used cytotoxic drug in oncology and the only one useful in the management of colorectal cancer - a leading cause of cancer death worldwide." | 3.68 | The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. ( Collins, DJ; Cunningham, D; Findlay, MP; Glaholm, J; Leach, MO; Mansi, JL; McCready, VR; Payne, GS, 1993) |
| "A total of 77 patients with advanced colorectal cancer, including postoperative patients with liver, lung and peritoneal metastases, were treated with single or multiple injections of monoclonal antibody A7-neocarzinostatin (A7-NCS)." | 3.68 | Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer. ( Honda, M; Kitamura, K; Noguchi, A; Otsuji, E; Takahashi, T; Yamaguchi, T, 1993) |
| "The development of pellagra in a patient treated with 5-fluorouracil for malignant disease is reported." | 3.68 | Pellagra secondary to 5-fluorouracil. ( Begent, RH; Dooley, JS; Ostlere, LS; Rustin, MH; Stevens, HP, 1993) |
| "Arterial infusion chemotherapy of EPF (etoposide, cisplatin, and 5-fluorouracil) or EAP (etoposide, Adriamycin, and cisplatin) was carried out in 28 cases of advanced hepatocellular carcinoma (HCC) between January 1988 and December 1990, and assessment was made of the anticancer efficacy of each treatment method." | 3.68 | Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. ( Midorikawa, H; Saito, Y; Sasaki, T; Takekawa, SD; Tarusawa, K; Yodono, H, 1992) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 3.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| " Regarding HAI, transcatheter hepatic arterial embolization (TAE) was applied in two cases (hepatocellular carcinoma: 1; metastasis: 1) and 5-fluorouracil (continuous) combined with leucovorin (one shot) therapy (LV + 5-FU) was given to one metastatic case." | 3.68 | [Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy]. ( Arai, K; Iwasaki, Y; Kitamura, M; Miyashita, K; Mori, T; Okamoto, A, 1991) |
| "A total of 51 fully evaluable patients with advanced and intensively pretreated breast cancer were treated with a combination chemotherapy of ifosfamide plus mesna, methotrexate and 5-fluorouracil." | 3.68 | Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer. ( Becher, R; Höfeler, H; Kloke, O; May, D; Niederle, N; Richter, R; Scheulen, ME; Schmidt, CG; Wandl, U, 1991) |
| " One patient had severe ileitis caused by intravenous administration of 5-fluorouracil; the other had severe duodenitis caused by infusion of 5-floxuridine into the hepatic artery by an implanted pump." | 3.68 | Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings. ( Hiehle, JF; Levine, MS, 1991) |
| "Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP)." | 3.68 | 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. ( Brugieres, L; Droz, JP; Gicquel, C; Parmentier, C; Schlumberger, M; Travagli, JP, 1991) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 3.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 3.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 3.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "An investigation was carried out into the effects of lipiodol-transcatheter arterial chemoembolization (L-TACE) therapy on hepatocellular carcinoma (HCC) and metastatic liver cancer, as well as the effects of oral 5-fluorouracil administration after L-TACE." | 3.67 | Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms. ( Hashimoto, N; Inoue, J; Kawai, S; Makino, M; Masuzawa, M; Mikuriya, S; Oda, T; Shimamura, Y; Takahashi, A; Yumoto, Y, 1989) |
| "In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma." | 3.67 | Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 3.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined." | 3.67 | [Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 3.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| " In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation." | 3.67 | [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987) |
| "Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg)." | 3.67 | [5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration]. ( Suenaga, M, 1988) |
| "Fifty-four patients with unresectable malignant liver tumors (14 of hepatocellular carcinoma, 40 of metastasis to the liver from gastric or colo-rectal cancer) were treated with intra-hepato-arterial (IHA) injections of cis-diamminedichloroplatinum (II) (CDDP) plus 5-fluorouracil (5-FU)." | 3.67 | [Hepatic arterial chemotherapy combined with hyperthermia or arterial embolization in unresectable liver tumor]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeda, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T; Wakatsuki, T, 1988) |
| "An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia." | 3.67 | Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 3.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| "Twenty-two patients with disseminated adenocarcinoma of the large bowel received therapy with 5-fluorouracil 800-1000 mg/m2 as a 24 h infusion for 4 consecutive days with 60 mg/m2 intravenous folinic acid administered every 6 hours." | 3.67 | Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. ( Higano, C; Mortimer, JE, 1988) |
| "Thirty-eight patients with advanced colorectal adenocarcinoma were treated with the following regimen: N5-10-methyltetrahydrofolate (MTHF) (200 mg/m2/day) and 5-fluorouracil (5-FU) (375 mg/m2/day) given concomitantly, consecutively for 5 days, every 4 weeks, in order to evaluate the potential advantage derived from the biochemical enhancement of cytotoxic activity of 5-FU by high-dose reduced folates." | 3.67 | Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. ( Bruzzone, M; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Tagarelli, G, 1985) |
| " An improvement of the chemotherapy of hepatocellular carcinoma with adriamycin or 5-fluorouracil and a reduction of side effects has been achieved by intra-arterial administration of the drugs." | 3.66 | [Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)]. ( Gerok, W; Holstege, A; Keppler, D; Pausch, J, 1981) |
| "The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors." | 3.66 | [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983) |
| "Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0." | 3.66 | [Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982) |
| "Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined." | 3.66 | [Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer]. ( Hattori, M; Horiike, N; Kanaoka, M; Ohta, Y; Onji, M; Yamashita, Y; Yoshida, T, 1982) |
| "In 2 patients with the malignant carcinoid syndrome, a Swam-Ganz balloon tip, flow-directed catheter was used to occlude hepatic arterial flow and perfuse hepatic metastases with 5-fluorouracil." | 3.66 | Hepatic artery occlusion with perfusion in the treatment of carcinoid syndrome. ( Costanzi, JJ; Helmer, RE; Morettin, LB, 1981) |
| "Twenty-two patients with adenocarcinoma metastatic to the liver were treated with rapid fractionation whole-liver irradiation (1350-2100 rads in 300-rad fractions) with simultaneous intrahepatic 5-fluorouracil (10-15 mg/kg/day) and intrahepatic Adriamycin 2." | 3.66 | Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study. ( Cassidy, M; Friedman, M; Levine, M; Phillips, T; Resser, KJ; Spivack, S, 1979) |
| "A heparinized catheter was used for the regional infusion of 5-fluorouracil in seven patients with liver metastases." | 3.66 | Heparinized catheters for long-term intraarterial infusion of 5-fluorouracil in liver metastases. ( Forsberg, L; Owman, T; Tylén, U, 1979) |
| "Since 1970, 38 patients with multiple primary or secondary liver neoplasms have been treated by hepatic artery ligation and distal cytotoxic infusion with fluorouracil." | 3.65 | Hepatic artery ligation and cytotoxic infusion in treatment of liver neoplasms. ( Gulesserian, HP; Safaie-Shirazi, S; Zike, WL, 1975) |
| "Nine patients with extensive bilateral hepatic metastases of colorectal cancer were treated with hepatic artery ligation and continuous infusion of 5-fluorouracil (5-FU)." | 3.65 | Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. ( Eilber, FR; Holmes, EC; Morton, DL; Ramming, KP; Sparks, FC, 1976) |
| "The case of a young man with hypogonadism, who was treated for five years withmethyltestosterone and who developed hepatocellular carcinoma, is discussed." | 3.65 | Hepatocellular carcinoma in association with androgen therapy. ( Goodman, MA; Laden, AM, 1977) |
| "Cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone were administered for 165, 28-day cycles to 33 patients with metastatic breast cancer." | 3.65 | Leucovorin in combination chemotherapy of breast cancer. ( Corder, MP; Flannery, EP; Herbst, KD; Justice, GR; Sheets, RF; Stone, WH, 1977) |
| "Forty-four patients with metastatic breast cancer were treated with monthly courses of cyclophosphamide, methotrexate and 5-fluorouracil." | 3.65 | Cyclic combination chemotherapy for metastatic breast cancer. ( Biran, S; Brufman, G; Hochman, A; Krasnokuki, D, 1977) |
| " A case is presented of hemangiosarcoma of theliver and spleen treated effectively by hepatic artery ligation, splenectomy, and postoperative intraportal infusion of 5-fluorouracil, as indicated by the regression of hepatic tumors on postoperative scanning and arteriograpms." | 3.65 | Hemangiosarcoma of liver and spleen treated by hepatic artery ligation, intraportal infusion chemotherapy, and splenectomy. ( Inokuchi, K; Nagasue, N; Ogawa, Y, 1976) |
| "Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2 intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle." | 3.65 | Combination chemotherapy for advanced breast cancer: response and effect on survival. ( Canellos, GP; Chabner, BA; DeVita, VT; Gold, GL; Schein, PS; Young, RC, 1976) |
| "Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
| "The majority of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage." | 3.30 | Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. ( Cheng, S; Guo, W; Huo, L; Jiang, D; Lau, WY; Liu, C; Mao, F; Shi, J; Sun, J; Zhang, F; Zhou, L, 2023) |
| "Main eligibility criteria are colorectal cancer, unresectable liver metastasis, no extra-hepatic metastases except pulmonary nodules if ≤3 and <10 mm, ECOG performance status 0 or 1." | 3.11 | Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. ( Audemar, F; De Baere, T; Ducreux, M; Gallois, C; Khemissa Akouz, F; Lapuyade, B; Lecaille, C; Lepage, C; Louafi, S; Mineur, L; Monterymard, C; Pellerin, O; Pernot, S; Simon, M; Smith, D; Taieb, J; Thirot-Bidault, A; Tougeron, D, 2022) |
| " Patients exhibiting EWL had worse survival and higher frequencies of adverse events." | 3.11 | Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022) |
| "Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development." | 3.01 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. ( Iwamoto, H; Kawaguchi, T; Niizeki, T; Shimose, S; Shirono, T, 2023) |
| "The treatment of colorectal cancer (CRC) has evolved and become more personalized during the past several years." | 3.01 | Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. ( Damato, A; Dottorini, L; Ghidini, A; Ghidini, M; Iaculli, A; Luciani, A; Petrelli, F; Tomasello, G, 2023) |
| " We conducted this phase Ib/II study to assess the safety and efficacy of anti-PD-1 antibody camrelizumab in combination with FOLFOX4 for treatment-naive advanced hepatocellular carcinoma (aHCC)." | 3.01 | Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. ( Chen, Z; Li, H; Liu, Y; Meng, Z; Qin, S; Ren, Z; Wang, L; Xiong, J; Zhang, X; Zou, J, 2021) |
| "Arginine is an important nutrient for hepatocellular carcinoma (HCC)." | 3.01 | Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. ( Abou-Alfa, GK; Akce, M; Bomalaski, JS; Chen, YY; Cohen, SA; El Dika, I; Feng, YH; Harding, JJ; Ho, CL; Huang, WT; Johnston, A; Lee, DW; Lim, HY; Meyer, T; O'Reilly, EM; Qin, S; Ryoo, BY; Sarker, D; Tan, B; Yang, TS; Yen, CJ, 2021) |
| " The purpose of this study is to investigate the efficacy of lobaplatin in combination with 5-fluorouracil (5-FU) and doxorubicin on AFP and treatment of primary carcinoma of the liver by transhepatic arterial chemotherapy and embolization (TACE)." | 2.94 | Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization. ( Chen, L; Chen, Y; Li, W; Yang, Q; Zeng, C, 2020) |
| "Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed." | 2.90 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019) |
| "Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors." | 2.90 | Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. ( Dajani, O; Glimelius, B; Guren, TK; Hamfjord, J; Johansen, JS; Kure, EH; Lingjærde, OC; Pallisgaard, N; Pfeiffer, P; Sorbye, H; Spindler, KG; Tveit, KM, 2019) |
| "Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited." | 2.87 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018) |
| "The treatment of colorectal cancer liver metastases has seen significant improvement in recent years and, for certain patients, the long-term survival and even cure are possible." | 2.82 | Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. ( Naher, SK; Samoon, Z; Sjoquist, KM; Zalcberg, J, 2022) |
| "Patients with liver-only metastatic colorectal cancer (mCRC) who are not candidates for potentially curative resection may become resectable with more aggressive chemotherapy regimens." | 2.82 | A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. ( Bendell, JC; Boccia, R; Earwood, C; Gian, V; Lane, CM; Lipman, A; LoCicero, R; Meluch, A; Moskowitz, M; Peyton, JD; Waterhouse, D; Zakari, A, 2016) |
| "We assessed circulating tumor cells (CTCs) as a prognostic biomarker in patients treated with a 4-drug regimen." | 2.80 | Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. ( Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW, 2015) |
| "This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy." | 2.80 | Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015) |
| "The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 2.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years." | 2.79 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. ( Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J, 2014) |
| "Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15." | 2.79 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014) |
| "The aim of this study was the evaluation of pharmacokinetic parameters, biomarkers, clinical outcome, and imaging parameters in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI plus sunitinib." | 2.79 | FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. ( Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D, 2014) |
| "Patients (pts) with metastatic rectal cancer and symptomatic primary, require local and systemic control." | 2.79 | Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer. ( Bressel, M; Chander, S; Cooray, P; Heriot, A; Hicks, R; Jefford, M; Leong, T; MacKay, JR; McClure, B; McKendrick, J; Michael, M; Ngan, SY; Steel, M; Zalcberg, J, 2014) |
| " We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC." | 2.78 | A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. ( Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J, 2013) |
| "Adults with primary metastasized rectal cancer were enrolled." | 2.78 | Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. ( Beets, GL; Beukema, JC; de Jong, KP; Gelderblom, AJ; Havenga, K; Hospers, GA; Nagtegaal, ID; Rutten, HJ; Tamas, K; van de Velde, CJ; van Dijk, TH; Wiggers, T, 2013) |
| "Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m(2)) on days 1 and 15 followed by leucovorin (20 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1, 8, and 15." | 2.78 | Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. ( El-Hadaad, HA; Wahba, HA, 2013) |
| "To compare the effect of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma (HCC)." | 2.78 | [Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience]. ( Bao, LW; Jiang, XF; Jin, XJ; Lin, JJ; Lu, LJ; Wu, W, 2013) |
| " We conducted a phase II trial to confirm the pharmacokinetic parameters from 3-Tesla dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as surrogate biomarkers of BV + FOLFIRI regimen efficacy in colorectal cancer with liver metastases." | 2.77 | Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. ( Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Miyake, M; Nakajima, T; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Tateishi, U; Yamada, Y, 2012) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)." | 2.77 | Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012) |
| "We randomly assigned 287 Stage III colorectal cancer patients after curative resection between 2002 and 2008 to receive 2 cycles of HAIC plus 4 cycles of systemic chemotherapy (combined therapy) or 6 cycles of systemic chemotherapy alone (monotherapy)." | 2.77 | Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection. ( Bao, Y; Feng, WM; Huang, SX; Tang, CW; Tao, YL; Wang, Y; Zheng, YY, 2012) |
| "The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome." | 2.76 | A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011) |
| "To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer." | 2.76 | [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011) |
| "Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative." | 2.76 | Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. ( Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T, 2011) |
| "Stage IV colorectal cancer encompasses a broad patient population in which both curative and palliative management strategies may be used." | 2.75 | Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. ( Ashley, S; Brown, G; Chau, I; Cunningham, D; Gillbanks, A; Karanjia, N; Mudan, SS; Norman, AR; Watkins, DJ, 2010) |
| "Grade 3 neutropenia was seen in seven patients and grade 4 in one patient." | 2.75 | Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. ( Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T, 2010) |
| "HAI oxaliplatin combined with systemic 5-fluorouracil, leucovorin, and bevacizumab had antitumor activity in patients with advanced cancer and liver metastases, and the current results indicated that this combination warrants further study." | 2.75 | A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. ( Bedikian, AY; Camacho, LH; Eng, C; Fu, S; Hong, D; Kurzrock, R; Lim, JA; Ng, C; Tsimberidou, AM; Wallace, M; Wen, S; Wheler, J, 2010) |
| "Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 2.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
| " This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX." | 2.75 | A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010) |
| "Liver perfusion chemotherapy (LPC) for pancreatic cancer has been rarely undertaken in a postoperative adjuvant setting." | 2.74 | Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. ( Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N, 2009) |
| "Twelve subjects with metastatic colorectal cancer within the liver failing first-line chemotherapy were treated in four cohorts with a single dose (3 x 10(6) to 1 x 10(8) particles) of NV1020, a multimutated, replication-competent HSV." | 2.74 | A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. ( Bhargava, A; Brody, L; Brown, K; Covey, A; Fong, Y; Getrajdman, G; Jarnagin, W; Karrasch, M; Kemeny, N; Kim, T; Mescheder, A; Schwartz, L, 2009) |
| "This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers." | 2.74 | Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Lee, KW; Lee, MH; Lee, NS; Oh, DY; Park, SR; Song, HS, 2009) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 2.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "The incidence of liver metastasis in group A was 34% which was lower than 50% in group B." | 2.74 | Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009) |
| "A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(-1), capecitabine 1300 mg m(-2) daily for 2 weeks and gemcitabine 1000 mg m(-2) weekly 2 times; cycles were repeated every 21 days." | 2.74 | Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. ( Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J, 2009) |
| "Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy." | 2.74 | [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. ( Dai, H; Yan, D, 2009) |
| " This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
| "Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation." | 2.74 | Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. ( Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA, 2009) |
| "Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease." | 2.74 | Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. ( Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Jassem, J; Li, RK; Mukhopadyay, P; Pivot, XB; Roché, HH; Thomas, ES, 2009) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| " This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events." | 2.73 | [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis]. ( Chen, G; Ding, PR; Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, GQ; Wu, XJ; Zhou, ZW, 2007) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 2.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| "From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 2.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Gemcitabine was given at 1,000 mg/m(2) weekly for 3 weeks followed by 1 week rest then 5-6 weeks of radiotherapy and concurrent CI 5FU (200 mg/m(2)/day)." | 2.73 | 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. ( Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y, 2008) |
| "364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group)." | 2.73 | Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. ( Bechstein, WO; Bethe, U; Collette, L; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Praet, M; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Van Cutsem, E; Walpole, ET, 2008) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 2.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| "Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients." | 2.73 | Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. ( Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R, 2007) |
| "There was a significant difference in adverse effect and toxicity such as naupathia,fever, swirl, asthenia observed between two groups (P < 0." | 2.73 | [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer]. ( Li, T; Li, ZW; Wen, HC, 2007) |
| "For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX)." | 2.72 | Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. ( Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R, 2021) |
| " The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81." | 2.72 | Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006) |
| "Patients with invasive ductal pancreatic cancer who underwent radical surgery with clear histological margins at 11 Japanese institutions were enrolled and randomly assigned to one of two groups: surgery-alone group (no further treatment after surgery) and the surgery + chemotherapy group [two courses of postoperative adjuvant systemic chemotherapy with cisplatin (80 mg/m(2), Day 1) and 5-fluorouracil (500 mg/m(2)/day, Days 1-5)]." | 2.72 | A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. ( Kakizoe, T; Kiuchi, T; Kosuge, T; Mukai, K, 2006) |
| "Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group)." | 2.72 | Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer. ( Chang, HM; Ha, HK; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, KH; Lee, MG; Ryu, MH; Yu, CS, 2006) |
| " We thus conducted a phase I/II study of gemcitabine and infusional 5-FU in Japanese patients to determine a recommended dosage for this combination and clarify efficacy and toxicity." | 2.72 | A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. ( Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H, 2006) |
| " A weekly 5 hour-administration of 5-FU (1500 mg) which was repeated for 8 weeks showed a comparable effect to a continuous infusion group with an identical total dosage of 5-FU." | 2.72 | [Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life]. ( Hoshino, H; Iwazawa, T; Kanoh, T; Kimura, Y; Matsushita, M; Miyazaki, S; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H, 2006) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 2.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first-line treatment for patients with locally advanced/metastatic breast carcinoma." | 2.71 | Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. ( Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M, 2003) |
| "Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)." | 2.71 | Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003) |
| "A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy." | 2.71 | Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003) |
| "Thirteen patients had limited extrahepatic cancer." | 2.71 | A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. ( Blind, PJ; Gustavsson, B; Hafström, L; Lindnér, P; Naredi, P; Oman, M, 2003) |
| "To evaluate the effect of tamoxifen (TAM) combined with a somatostatin analogue, octretide (OCT) on advanced liver cancer and whether tamoxifen combined with OCT is superior to regular chemotherapeutic agents 5-Fu and mitomycin C (MMC)." | 2.71 | Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. ( Chen, JW; Huo, YC; Pan, DY; Qiao, JG; Shi, HA; Zhou, YK, 2003) |
| ") infusion] alone, OXA combined with 5-FU (1000 mg/m2/day, continuous i." | 2.71 | Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. ( Boige, V; Bouché, O; Breau, JL; Bugat, R; Cvitkovic, E; Ducreux, M; Etienne, PL; Mitry, E; Morvan, F; Ould-Kaci, M; Rougier, P; Seitz, JF; Tigaud, JM, 2004) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 2.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| " We decided on a recommended dose of cisplatin of 4 mg/m(2)/day because the dosage was one level under the maximum-tolerated dose." | 2.71 | Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). ( Hirakawa, K; Hirata, K; Mitachi, Y; Nakata, B; Shirasaka, T; Tsuji, A; Yamamitsu, S, 2004) |
| " Pharmacokinetic studies were performed on cycle 1 and 2 to assess the best sequence and detect any interaction between the two drugs." | 2.71 | Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. ( Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S, 2004) |
| " Pharmacokinetic parameters were studied during the first cycle of dose levels 1 and 2 (500 mg/m2." | 2.71 | A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. ( Brown, G; Chak, K; Chan, AT; Johnson, P; Leung, TW; Mok, TS; Moyses, C; Wong, H; Yeo, W, 2004) |
| "Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer." | 2.71 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004) |
| "Over 80% of hepatocellular carcinoma (HCC) patients are HBV carriers; however, the incidence of HBV reactivation during CT has not been well-reported." | 2.71 | Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. ( Chan, AT; Chan, PS; Ho, WM; Johnson, PJ; Lam, KC; Leung, TW; Ma, B; Mo, FK; Mok, TS; Wong, WL; Yeo, W; Zee, B, 2004) |
| " Pharmacokinetic analyses for both BAY 12-9566 and 5-fluorouracil were performed." | 2.71 | An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. ( Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005) |
| "To evaluate the clinical efficacy of capecitabine combined with transcatheter arterial chemoembolization (TACE) for advanced liver cancer." | 2.71 | [Capecitabine combined with TACE for advanced liver cancer]. ( Chen, AJ; Hu, MD; Li, L; Li, XY; Ran, JH; Sun, F; Tang, JH, 2004) |
| "Thirty-eight unresectable small hepatocellular carcinoma patients with diameter | 2.71 | [Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xia, JL; Yang, BW; Yie, SL; Zhang, BH, 2004) |
| "Dex combined with GS markedly decreased the occurrence ratio and lasting time of the symptoms such as nausea, vomiting, fever and pain, and protected the function of liver as compared with the placebo (P<0." | 2.71 | [Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial]. ( Chen, Z; Feng, YL; Li, B; Ling, CQ; Yu, CQ; Zhu, DZ, 2005) |
| "A total of 156 gastric cancer patients were randomized into 3 groups, and underwent the combined therapy (treatment group 1), intraoperative chemotherapy (treatment group 2), and peritoneal lavage with distilled water (control group), respectively." | 2.71 | [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer]. ( Bi, JW; Fang, GE; Hua, JD; Nie, MM; Shen, XJ; Wei, G; Xue, XC, 2005) |
| "Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs." | 2.71 | Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. ( Boige, V; Delperro, JR; Ducreux, M; Elias, D; Gamelin, E; Husseini, F; Jacob, JH; Laplanche, A; Lasser, P; Luboinski, M; Quenet, F; Viret, F; Ychou, M, 2005) |
| "Forty patients with rectal cancer (T3-T4 and/or N+) received radiotherapy (1." | 2.71 | Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. ( Aydin, S; Baurain, JF; Canon, JL; Coche, JC; Coster, B; Duck, L; Gilbeau, L; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Octave-Prignot, M; Remouchamps, V; Scalliet, P; Sempoux, C; Van Maele, P, 2005) |
| "In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity." | 2.71 | A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. ( Bailey, W; Dowling, R; Gibbs, P; Liechtenstein, M; Lim, L; Little, A; Shapiro, JD; Smith, D; Yip, D, 2005) |
| "Standard chemotherapy for advanced gastric cancer remains undefined." | 2.71 | [A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer]. ( Cai, XC; Chen, Q; Chen, YG; Fan, NF; Guo, ZQ; Lu, X; Ouyang, XN; Wu, XA; Xu, S; Yang, JW; Zhang, YH, 2005) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor." | 2.70 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002) |
| "Febrile neutropenia was observed in 10% of patients and 2." | 2.70 | Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. ( Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P, 2002) |
| "In four patients with disease progression per bidimensional and unidimensional criteria, the response was stable disease per volumetric criteria." | 2.70 | CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. ( Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE, 2002) |
| "Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection." | 2.70 | Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001) |
| "At present, only few animal experiment has been reported about the pharmacokinetic of peritoneal chemotherapy." | 2.70 | [Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ( Li, ZJ; Lin, AD; Qu, MW; Sun, HY; Wang, FJ; Wang, JY, 2002) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 2.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| "Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis." | 2.70 | [Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis]. ( Ahn, SH; Cheong, JY; Chon, CY; Han, KH; Kim, JS; Lee, DY; Moon, YM; Seong, JS; Youn, YH, 2002) |
| "Pravastatin was administered at a daily dose of 40 mg." | 2.70 | Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001) |
| "The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with dailyx5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metastatic colorectal cancer (CRC) patients." | 2.70 | A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. ( Balbiani, L; Bella, S; Blajman, C; Cazap, E; Chacón, M; Cóppola, F; Giglio, R; Lastiri, F; Mickiewicz, E; Montiel, M; Perazzo, F; Pujol, F; Recondo, G; Richardet, E; Rodger, J; Schmilovich, A; Simon, J; Van Kooten, M; Vilanova, M; Wasserman, E; Zori Comba, A, 2001) |
| "Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients." | 2.70 | A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001) |
| "In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance." | 2.70 | Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001) |
| "Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)." | 2.70 | Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. ( Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002) |
| "Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible." | 2.69 | Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998) |
| "The 24 patients with advanced colorectal cancer were divided into 2 groups randomly and both were treated with 5-FU 250 mg/day by continuous hepatic arterial infusion for three weeks." | 2.69 | [Method of preventing hepatic artery occlusion during continuous intrahepatic arterial infusion chemotherapy of 5-FU]. ( Ishida, H; Ishikawa, K; Itoh, I; Iwase, H; Kameya, T; Makuuchi, H; Mukai, M; Ohtaki, M; Sadahiro, S; Suzuki, T; Tajima, T; Tokunaga, N; Yasuda, S, 1998) |
| " However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin." | 2.69 | Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv ( Apolone, G; Couvreur, ML; Curran, D; De Waele, B; Doci, R; Labianca, R; Lasser, P; Marsoni, S; Nakajima, T; Nitti, D; Pector, JC; Rauschecker, H; Rougier, P; Sahmoud, T; Wils, J, 1998) |
| "Liver metastasis from breast cancer has a poor prognosis." | 2.69 | A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. ( Adachi, I; Ando, J; Aoyama, H; Enomoto, K; Fukutomi, T; Ikeda, T; Kanda, K; Ogita, M; Sano, M; Shimoyama, M; Tabei, T; Takashima, S; Tominaga, T, 1999) |
| "The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | 2.69 | [Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
| "Nonresectable colorectal cancer metastases in the liver respond to chemotherapy in 20-25% only." | 2.69 | Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. ( Bangard, M; Bangard, N; Bender, H; Biersack, HJ; Metten, N; Mezger, J; Schomburg, A, 1999) |
| "Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years." | 2.69 | Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. ( Bjarnason, GA; Cripps, C; Fields, AL; Goel, R; Hrincu, A; Jensen, JL; Kerr, IA; Khoo, KE; Warner, E, 1999) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 2.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "In patients with carcinoid tumor, a combination of cisplatin (150 mg) and doxorubicin (50 mg) was used." | 2.69 | Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. ( Ajani, JA; Carrasco, CH; Chuang, V; Dumas, P; Kim, YH; Lawrence, D; Richli, W; Wallace, S, 1999) |
| "Twelve colorectal cancer patients with small volume disease metastatic to the liver (all lesions < or = 2." | 2.69 | Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. ( Angerstein, C; Becker, H; Becker, W; Béhé, M; Behr, TM; Blumenthal, RD; Fayyazi, A; Goldenberg, DM; Hiddemann, W; Liersch, T; Ringe, B; Salib, AL; Sharkey, RM; Wörmann, B, 1999) |
| "Twenty-two colorectal cancer patients (infusion group) in Dukes' C stage were given hepatic arterial infusion of 5-FU (500 mg/body for 1 hr per week, repeated 50 times) and peroral UFT-E (2." | 2.69 | [Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer]. ( Fujioka, M; Idezuki, Y; Inokuma, S; Ishida, H; Kamano, T; Kishi, T; Kondo, K; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Shimomura, K; Suzuki, T; Takeuchi, I; Yamada, H, 1999) |
| " Also, groups receiving a dosage of 15 g or greater of 5-FU showed prolonged survival rates." | 2.69 | [Cooperative study of intraarterial preventive chemotherapy after resection of hepatic metastasis from colorectal cancer]. ( Hamada, H; Ishizaki, A; Itou, Y; Kassai, S; Katsuki, Y; Kimura, J; Kino, S; Kusano, M; Nakasaki, H; Suzuki, K; Suzuki, S; Tsuji, Y; Tsujita, K; Watanabe, M; Yamamoto, Y, 1999) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | 2.69 | Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000) |
| "Five patients, two with gastric cancer and three with colorectal cancer, who had metastatic tumor nodules in their livers were studied dynamically in vivo after 5-FU injection." | 2.69 | Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ( Presant, CA; Shani, J; Waluch, V; Weitz, I; Wiseman, CL; Wolf, W, 2000) |
| "Four cases of gigantic hepatocellular carcinoma, considered by surgeons to be inoperable, were treated with repeated transcatheter chemoembolization (TOCE) until the serum alfafetoprotein reduced to normal or less than half of the original level or until the tumor reduced to less than half of the original size documented by CT scan and angiogram." | 2.69 | Gigantic hepatocellular carcinoma, treated by transcatheter oily chemoembolization (TOCE) and wedge hepatic resection. ( Eurvilaichit, C; Kanjanapitak, A; Leopairut, J, 2000) |
| "Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT." | 2.69 | Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2000) |
| "A pharmacokinetic population approach was used to analyze the data from 21 patients with colorectal cancer." | 2.69 | Dose and time dependencies of 5-fluorouracil pharmacokinetics. ( Boisdron-Celle, M; Bugat, R; Canal, P; Chatelut, E; Erdociain, E; Féty-Deporte, R; Gamelin, E; Guimbaud, R; Lafont, T; McLeod, HL; Terret, C, 2000) |
| "2 of the 7 (29%) patients with hepatoma responded." | 2.68 | Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. ( Cunningham, D; Ellis, PA; Hickish, T; Hill, A; Nicolson, M; Norman, A; O'Brien, ME, 1995) |
| "courses in 15 patients with cancer of different origins." | 2.68 | Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. ( Gabizon, AA; Gorodetsky, R; Mou, X; Vexler, AM, 1995) |
| "Out of 213 consecutive cases of colorectal cancer patients, 39 patients had liver metastasis (31 synchronous metastases and 8 metachronous metastases)." | 2.68 | [Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer]. ( Ariga, T; Kinoshita, H; Maruyama, T; Ooshima, I; Ozaki, M; Shimada, H; Shouko, T; Takeda, A; Yoshimura, S, 1995) |
| "In the present study, repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy was performed in patients with unresectable tumors of the liver." | 2.68 | [Efficacy of repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy for unresectable tumors of the liver]. ( Hashimoto, N; Hayashi, T; Kohno, H; Kubota, H; Nagasue, N; Ono, T; Uchida, M; Yamanoi, A, 1995) |
| "To evaluate the efficacy of intra-arterial chemotherapy combined with hyperthermia for metastatic liver cancer, our cooperative study group carried out a randomized clinical trial comparing intra-arterial chemotherapy alone and intra-arterial chemotherapy combined with hyperthermia." | 2.68 | [A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer]. ( Hiraoka, M; Itani, K; Kondo, M; Miura, K; Noguchi, M; Tanaka, Y; Watanabe, N; Yoshikawa, T, 1995) |
| "Fourteen advanced gastric cancer patients allocated to RT and Control group randomly and received each amino acid as protein source for 7 days TPN with 5-FU administration." | 2.68 | [Clinical evaluation of anticancer effect of methionine-depleting total parenteral nutrition with 5-fluorouracil and/or mitomycin C]. ( Endo, M; Goseki, N; Kando, F; Maruyama, M; Nagai, K; Shimoju, K; Wada, Y, 1995) |
| "These findings suggest that colorectal cancer with aneuploidy and a DI above 1." | 2.68 | Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. ( Hoshino, K; Kaibara, N; Kimura, O; Kurayoshi, K; Makino, M; Sugezawa, A, 1995) |
| "Forty-nine patients with metastatic breast cancer were enrolled; 41 were eligible." | 2.68 | Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B. ( Kennedy, BJ; Kiang, DT; Korzun, AH; Nowak, BS; Perry, MC; Schilling, A; Wood, W; Younger, J, 1995) |
| "Women with resected T1-3N1,2 primary breast cancer and > or = 10 positive axillary lymph nodes referred for possible trial participation were evaluated for this report." | 2.68 | Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. ( Crump, M; Girouard, C; Goss, PE; Prince, M, 1996) |
| " These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU." | 2.68 | A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995) |
| " The dosage was as follows: group A received FA i." | 2.68 | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996) |
| "Forty-six patients with colorectal cancer were studied for the effects of intraportal chemotherapy in terms of the administered dose of 5-FU." | 2.68 | [The effect of intraportal chemotherapy in terms of administered dose of 5-FU]. ( Akaishi, O; Hanai, A; Kikuchi, K; Matsuzaki, H; Miyake, H; Oikawa, H; Ozasa, T; Seo, K; Tanaka, K; Tsukikawa, S; Yamaguchi, S; Yamamura, T, 1996) |
| "The liver metastases of gastric cancer without unresectable primary tumors and hepatectomy were divided into two groups, 16 HAIC cases (11 synchronous, 5 metachronous metastases) and 23 systemic chemotherapeutic cases (10 synchronous, 13 metachronous metastases)." | 2.68 | [Evaluation of hepatic arterial infusion chemotherapy for gastric cancer]. ( Kawai, H; Kawasaki, S; Maruyama, S; Morisue, S; Morokoshi, Y; Otani, J; Soda, M; Suga, M; Uemura, T; Yamamoto, M; Yoshizane, K, 1996) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 2.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Unresectable hepatocellular carcinoma is related to a poor prognosis." | 2.68 | Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. ( Colleoni, M; Liessi, G; Manente, P; Mastrapasqua, G; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 2.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "The response rate was 56." | 2.68 | [Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]. ( Aiba, K; Araki, H; Chung, Y; Hirata, K; Saji, S; Sasaki, K; Shirasaka, T; Sowa, M; Tanaka, M; Toge, T; Wada, H; Yamamitsu, S; Yasumoto, K, 1997) |
| "5-Fluorouracil (5-FU) was delivered via a surgically placed hepatic artery catheter." | 2.68 | A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. ( Buckles, J; Budden, J; Gallagher, HJ; Howell, JD; Kerr, DJ; Ledermann, JA; McArdle, CS; Taylor, I, 1997) |
| "Ninety-four patients with primary liver cancer have been treated with electrochemical therapy (ECT) in our hospital." | 2.67 | Electrochemical therapy of 74 cases of liver cancer. ( Wang, HL, 1994) |
| "Recurrence of gastric cancer or colon cancer was observed in some patients who received 5-fluorouracil (5-FU) high-dose continuous Methotrexate (MTX)-Leucovorin (LV) therapy (FML therapy) previously." | 2.67 | [Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer]. ( Fujihara, T; Inokuchi, T; Kawano, K; Kimoto, K; Mori, F; Tamura, Y; Yoshioka, Y, 1994) |
| "Second-line therapy of patients with colorectal cancer metastatic to the liver is unsatisfactory." | 2.67 | Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. ( Bakal, CW; Cynamon, J; Haynes, H; Kaleya, R; Martinelli, DJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1994) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 2.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| " 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity." | 2.67 | Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992) |
| "A total of 49 patients with metastatic renal cell cancer underwent recombinant interferon-alpha 2a therapy combined with chemotherapy." | 2.67 | Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. ( Amato, R; Dexeus, FH; Fitz, K; Kilbourn, R; Logothetis, CJ; Sella, A; Wallace, S, 1992) |
| "Seventeen patients with colorectal cancer who failed local chemotherapy received 5-FU as a 4-hour infusion, preceded by a bolus of FA and IFN." | 2.67 | A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ( Boese-Landgraf, J; Boewer, C; Hilgenfeld, RU; Hoksch, B; Knauf, WU; Kreuser, ED; Matthias, M; Oldenkott, B; Schalhorn, A; Zeitz, M, 1992) |
| "Eleven patients with rectum cancer and four patients with colon cancer were treated according to the following schedule: 9 million units IFN-alpha subcutaneous three times a week; 500 mg/m2 5-FU via an intravenous bolus 1 hour after the initiation of a 2-hour infusion of 500 mg/m2 of FA, once a week." | 2.67 | Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a. ( Bernhard, H; Klein, O; Knuth, A; Meyer zum Büschenfelde, KH, 1992) |
| "Significant improvement in dysphagia was recorded in 76% patients with complete response in 47 cases ranging from 6 to 27 months." | 2.67 | The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study. ( Desai, PB; Deshpande, R; Dinshaw, KA; Malliat, MK; Pendse, AM; Sharma, V; Telang, CS; Vege, SS, 1991) |
| "Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease." | 2.66 | The actual management of colorectal liver metastases. ( Dorcaratto, D; Garcés-Albir, M; Huerta Álvaro, M; Muñoz-Forner, E; Pérez-Santiago, L; Roselló Keranën, S; Sabater, L, 2020) |
| "Hepatocellular carcinoma is known to have a doubling time of approximately 41 days." | 2.66 | 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. ( Fishman, EK; Guse, C; Klein, JL; Leibel, SA; Leichner, PK; Order, SE; Stillwagon, GB, 1989) |
| "Forty-seven patients with hepatocellular cancer were treated in a randomised trial comparing adriamycin + VM 26 + 5-Fluorouracil (5-FU) to mAMSA + VM 26 + 5-FU." | 2.66 | Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. ( Bezwoda, WR; Derman, DP; Kew, M; Weaving, A, 1987) |
| "In rectosigmoid cancer the group on 5-FU included 26 patients who showed a response rate of 19% (5/26)." | 2.66 | Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. ( Kolarić, K; Potrebica, V; Stanovnik, M, 1986) |
| " The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg." | 2.65 | [Joint clinical Phase II study of SF-SP]. ( Hanatani, Y; Sato, H; Sato, T, 1984) |
| "A PR of hepatic metastases was noted in eight patients (35%) with a median and mean duration of response of 4." | 2.64 | Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. ( Buroker, T; Correa, J; Fraile, R; Samson, M; Vaitkevicius, VK, 1976) |
| "Fifty consecutive patients with colorectal cancer but no evidence of secondary deposits in the liver were included in an ongoing controlled clinical trial of adjuvant liver perfusion aimed at reducing the incidence of hepatic metastases." | 2.64 | Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial. ( Brooman, P; Rowling, JT; Taylor, I, 1977) |
| "route." | 2.64 | A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. ( Bruckner, HW; Hahn, RG; Moertel, CG; Schutt, AJ, 1975) |
| "Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2." | 2.55 | Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. ( Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017) |
| "Primary liver cancer, mainly consisting of hepatocellular carcinoma (HCC), is one of common malignancies worldwide, and prevalent among the Chinese population." | 2.53 | Progress in systemic therapy of advanced hepatocellular carcinoma. ( Gong, XL; Qin, SK, 2016) |
| "The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset." | 2.53 | Unresectable liver metastases in colorectal cancer: review of current strategies. ( Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T, 2016) |
| "Colorectal cancer is the third most common cancer, with recent advances in the management of unresectable metastatic lesions." | 2.50 | Options for metastatic colorectal cancer beyond the second line of treatment. ( Foubert, F; Matysiak-Budnik, T; Touchefeu, Y, 2014) |
| "The treatment of metastatic colorectal cancer (mCRC) has evolved considerably in the last decade, currently allowing most mCRC patients to live more than two years." | 2.50 | Role of cetuximab in first-line treatment of metastatic colorectal cancer. ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation." | 2.50 | Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014) |
| " We started combination chemotherapy with 5-fluorouracil, Leucovorin and oxaliplatin(modified FOLFOX6)at a 20% lower than standard dosage for safety." | 2.49 | [A case of metastatic colorectal cancer with icterus due to multiple liver metastases treated effectively by FOLFOX plus bevacizumab]. ( Fukuda, K; Koja, S; Terasawa, T; Yasuda, K, 2013) |
| "He was diagnosed with interstitial pneumonitis induced by irinotecan or panitumumab." | 2.48 | [A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy]. ( Abe, T; Ando, M; Kato, T; Nakashima, H; Shindo, J; Shiraki, A; Yamamoto, K; Yukita, Y, 2012) |
| "Liver metastasis from colorectal cancer has become a common disease associated with the increase of primary colorectal cancer in Japan." | 2.48 | Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective. ( Shimada, Y, 2012) |
| "Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control." | 2.48 | [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure]. ( Endo, T; Hasegawa, H; Hoshino, G; Hoshino, H; Hoshino, Y; Ishii, Y; Kitagawa, Y; Matsunaga, A; Ochiai, H; Seo, Y; Shigeta, K, 2012) |
| "A 62-year-old woman being treated for chronic hepatitis C and high blood pressure was shown by computed tomography to have tumors in the lateral and medial segments of her liver, and in her right breast." | 2.48 | [Liver arterial infusion chemotherapy with adjuvant trastuzumab for the simultaneous treatment of liver and breast cancer-a case report]. ( Akashi, M; Fujii, T; Inoue, Y; Momosaki, S; Nakayama, Y; Nishida, R; Saitsu, H; Shirouzu, K; Takahashi, H; Takahashi, R; Takami, Y; Takayoshi, K; Uchino, K, 2012) |
| "Metastatic colorectal cancer has evolved from a paradigm that was previously centered upon the use of systemic chemotherapy to one of multimodality therapy." | 2.47 | Surgical therapies in metastatic colorectal cancer with a potential for cure. ( Chua, TC; Esquivel, J; Koong, HN; Liauw, W, 2011) |
| "Atypical carcinoid tumors of the uterine cervix represent rare neuroendocrine tumors and are highly aggressive, showing early lymphatic invasion and hematogenous distant metastases." | 2.47 | Atypical metastatic carcinoid of the uterine cervix and review of the literature. ( Imamura, Y; Katayama, K; Kotsuji, F; Sato, K; Yamaguchi, A; Yoshida, Y, 2011) |
| "Patients with UICC stage II colon cancer and microsatellite instability (MSI) apparently experience a better prognosis but do not profit from an adjuvant CT with 5-FU/FA alone." | 2.47 | [Multimodal therapy for colon cancer: state of the art]. ( Link, KH; Weber, T, 2011) |
| " The question to be addressed is how and when to apply intensified systemic therapy with adequate dosage and intensity as well as acceptable treatment-associated toxicity." | 2.47 | [Rectal cancer: current status of multimodal therapy--when and how?]. ( Becker, H; Gaedcke, J; Ghadimi, BM; Hess, C; Liersch, T; Rödel, C, 2011) |
| "We report a case of renal tubular acidosis (RTA) secondary to capecitabine, oxaliplatin, and cetuximab administration in a 63-year-old woman with liver metastasis from colon carcinoma who had partial treatment response." | 2.46 | Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. ( Meirovitz, A; Sonnenblick, A, 2010) |
| "The prognosis of metastatic colorectal cancer remains poor despite advances made in recent years, particularly with new treatments directed towards molecular targets." | 2.46 | Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. ( Díaz-Rubio, E; García-Foncillas, J, 2010) |
| "A form of non-alcoholic steatohepatitis (NASH) related to chemotherapy and otherwise known as chemotherapy-associated steatohepatitis (CASH) is closely linked to irinotecan-based therapy and is associated with inferior outcomes following hepatic surgery mainly due to hepatic insufficiency and poor regeneration." | 2.45 | Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. ( Khan, AZ; Makuuchi, M; Morris-Stiff, G, 2009) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "Liver metastases from colorectal cancer (CRC) have a poor prognosis." | 2.45 | Treatment of colorectal liver metastases: a review. ( Hendlisz, A; Van den Eynde, M, 2009) |
| "The successful management of rectal cancer requires a multidisciplinary approach, with treatment decisions based on precise patient evaluations by a group of clinicians, including surgeons, gastroenterologists, medical and radiation oncologists, radiologists, and pathologists." | 2.45 | The multidisciplinary management of rectal cancer. ( Hoffe, SE; Meredith, KL; Shibata, D, 2009) |
| "Floxuridine (FUDR) is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction." | 2.45 | The role of floxuridine in metastatic liver disease. ( Kemeny, NE; Power, DG, 2009) |
| "Resectability of liver-limited colorectal cancer metastases should be considered as an endpoint for all patients." | 2.44 | Regional chemotherapy for liver-limited metastatic colorectal cancer. ( Healey-Bird, BR; Kemeny, NE; Power, DG, 2008) |
| "The majority of primary liver cancer is hepatocellular carcinoma (HCC)." | 2.44 | Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. ( Nagai, H; Sumino, Y, 2008) |
| "Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
| "Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting." | 2.44 | [Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007) |
| "The role of surgery in advanced colorectal cancer in the elderly is restricted to the relief of bowel obstruction and where appropriate resection of hepatic metastasis." | 2.44 | Treatment of advanced colorectal cancer in the elderly. ( Audisio, RA; Bruce, C; Köhne, CH, 2007) |
| "Metastatic colorectal cancer (CRC) is most frequently seen in the liver." | 2.44 | Advances in neoadjuvant therapy for colorectal cancer with liver metastases. ( Barone, C; Kemeny, NE; Pozzo, C, 2008) |
| "For instance, in patients with colorectal cancer, higher enzyme activity of topoisomerase-I seems to be predictive of a better response to irinotecan." | 2.43 | Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. ( Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM, 2005) |
| "The treatment of hepatoblastoma is an example of the great advances made in paediatric oncology over the past few decades." | 2.43 | Hepatoblastoma: an oncological review. ( Perilongo, G; Roebuck, DJ, 2006) |
| "About 50% of patients with colorectal cancer (CCR) are destined to develop hepatic metastases during the course of the disease." | 2.43 | Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. ( Biasco, G; Brandi, G; Derenzini, E; Ercolani, G; Grazi, G; Pantaleo, MA; Ravaioli, M, 2006) |
| "The modern treatment of colorectal cancer." | 2.43 | [The modern treatment of colorectal cancer. Present and future]. ( András, C; Farczádi, E; Szántó, J, 2006) |
| "In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer." | 2.43 | First- and second-line therapy of metastatic colorectal cancer. ( Grothey, A; Terstriep, S, 2006) |
| "Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures." | 2.42 | Palliative treatment of patients with colorectal cancer. ( Glimelius, B, 2003) |
| "Half of the patients with colorectal cancer present with liver metastases at some point in their illness." | 2.42 | Hepatic resection after down-staging of unresectable hepatic colorectal metastases. ( Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Huguet, E; Kunstlinger, F; Levi, F, 2003) |
| "No case of epidermoid (squamous cell) cancer of the colon has been previously described in a pregnant woman." | 2.42 | [Colon cancer in pregnancy]. ( Fermeaux, V; Mathonnet, M, 2003) |
| "Colorectal cancer is a leading cause of cancer death world-wide." | 2.42 | Review article: colorectal cancer chemotherapy. ( Gill, S; Goldberg, RM; Thomas, RR, 2003) |
| "Fluorouracil has been the mainstay of treatment in this setting for the past few decades." | 2.42 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer. ( Gill, S; Goldberg, RM, 2004) |
| "Survival in patients with advanced colorectal cancer is on a positive trajectory." | 2.42 | Current strategies in previously untreated advanced colorectal cancer. ( Goldberg, RM; Penland, SK, 2004) |
| "Patients with colorectal cancer commonly succumb to the sequelae of hepatic metastases." | 2.42 | Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. ( Barber, FD; Kurzrock, R; Mavligit, G, 2004) |
| "Colorectal cancer is a leading cause of cancer death worldwide." | 2.42 | Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. ( Gill, S; Goldberg, RM, 2004) |
| "Patients with hepatocellular carcinoma (HCC) frequently show early recurrence even after hepatic resection and local ablation therapy." | 2.42 | [Chemotherapy for hepatocellular carcinoma]. ( Ikeda, M; Okusaka, T; Ueno, H, 2004) |
| "The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor." | 2.41 | [Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002) |
| "Progression of colorectal cancer can occur primarily isolated in the liver." | 2.41 | Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. ( Gog, C; Heinrich, S; Lorenz, M; Müller, HH; Petrowsky, H; Staib-Sebler, E; Vetter, G, 2000) |
| "In advanced colorectal cancer, liver metastases are a major problem." | 2.41 | Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. ( Giaccone, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM, 2000) |
| " Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies." | 2.41 | [The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. ( Monden, T; Tono, T, 2000) |
| "A significant number of patients with colorectal cancer will present with hepatic metastases as their only site of metastatic disease." | 2.41 | Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma. ( Alberts, SR, 2000) |
| "A case of AFP producing early gastric cancer successfully treated with a small dose of CDDP and 5-FU therapy administered intermittedly is reported with a review of the literature." | 2.41 | [A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy]. ( Aoki, T; Fujimitsu, Y; Koyanagi, Y; Moritani, M; Niido, T; Shinohara, M; Tsuchida, A, 2001) |
| "The treatment of advanced colorectal cancer has long been a dilemma for clinicians." | 2.41 | Randomized clinical trials in advanced and metastatic colorectal carcinoma. ( Dangelica, MI; Nissan, A; Shoup, MC, 2002) |
| "Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist." | 2.40 | The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. ( Neoptolemos, JP; Rougier, P, 1997) |
| "The recurrence rate of resected gastric cancer with curative intent was around 20%." | 2.40 | [Treatment of recurrent gastric cancer]. ( Sakata, Y; Tsushima, K, 1998) |
| "This article describes two cases of colorectal cancer in adolescents and reviews the literature regarding this rare condition." | 2.40 | Colorectal cancer in adolescents. ( Renaut, AJ; Shankar, A; Taylor, I; Whelan, J, 1999) |
| "Sixty-six patients with colorectal cancer were studied regarding effects of prevention of hepatic recurrence in completely performed portal infusion chemotherapy." | 2.40 | [Is portal infusion chemotherapy uneffective for hepatic recurrence after resection for colorectal cancer?]. ( Akaishi, O; Tsukikawa, S; Yabe, K; Yamaguchi, S; Yamamura, T, 1999) |
| "We report herein a case of rectal carcinoid with multiple liver metastasis successfully treated with hepatic arterial infusion of methotrexate (MTX) and 5-fluorouracil (5-FU)." | 2.40 | [A case of liver metastases of rectal carcinoid successfully treated with hepatic arterial infusion of methotrexate and 5-fluorouracil]. ( Idezuki, Y; Ishida, H; Nakada, H; Suzuki, T; Tada, M; Takeuchi, I, 1999) |
| "Fifty per cent of patients with colorectal cancer develop hepatic metastases but only a minority are candidates for potentially curative surgical resection." | 2.39 | Hepatic artery chemotherapy for colorectal liver metastases. ( Jorgensen, JO; McCall, JL; Morris, DL, 1995) |
| "A patient with recurrent breast cancer, who was diagnosed with eyelid metastasis as a part of systemic metastases and in whom systemic chemotherapy was markedly effective, is reported." | 2.39 | Eyelid metastasis from breast cancer showing marked response to chemotherapy. ( Abe, K; Adachi, I; Kaneko, A; Narabayashi, M; Tokue, Y; Tsuda, H; Watanabe, T; Yin, DF; Zhang, GJ, 1995) |
| "The pharmacokinetic advantage of a novel system to noninvasively isolate the hepatic venous outflow and infuse high doses of chemotherapy (doxorubicin or 5-FU) is discussed and compared with intravenous infusion and intra-arterial infusion without hepatic venous detoxification." | 2.39 | Isolated liver perfusion for liver metastases: pharmacokinetic advantage? ( Dixon, K; Ravikumar, TS, 1996) |
| " The pharmacokinetic rationales were based on the theories of "first pass effect" and "increased local concentration without first pass effect" advocated by Dr." | 2.38 | [Pharmacokinetics in arterial infusion chemotherapy]. ( Arai, Y; Ariyoshi, Y; Kido, C, 1993) |
| "Hepatocellular carcinoma is a rapidly fatal disease in most patients." | 2.37 | Medical treatment of hepatocellular carcinoma. ( Friedman, M; Nerenstone, S, 1987) |
| "Certainly in treatment of the carcinoid tumor surgery has a well-established curative and palliative potential." | 2.36 | Treatment of the carcinoid tumor and the malignant carcinoid syndrome. ( Moertel, CG, 1983) |
| "Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
| "Hepatic metastasis is usually quite resistant to conventional systemic chemotherapy." | 2.36 | Nonsystemic treatment of metastatic tumors of the liver--a review. ( Lee, YT, 1978) |
| "Treatments for patients suffering from pancreatic cancer with oligo-hepatic metastasis have always been a cause of certain controversy." | 1.91 | Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. ( Lou, J; Lu, W; Tang, K; Wang, L, 2023) |
| "Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer." | 1.91 | Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023) |
| "Molecular targeted therapy combined with immunotherapy significantly improves the prognosis of patients with advanced liver cancer." | 1.91 | Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. ( Gao, W; Guo, Z; Li, H; Li, M; Liu, C; Liu, D; Mu, H; Si, T; Xing, W; Yang, X; Yu, H; Zhang, K; Zhang, W; Zou, Q, 2023) |
| "Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage." | 1.91 | MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023) |
| "RNA sequencing of primary colorectal cancer specimens vs adjacent liver tissue vs synchronous and asynchronous liver metastases." | 1.91 | Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids. ( Blandino, G; Canu, V; Caricato, M; Cioce, M; Crescenzi, A; Diodoro, MG; Donzelli, S; Fanciulli, M; Fazio, VM; Fumagalli, MR; Goeman, F; Grazi, GL; La Porta, C; Levrero, M; Morrone, A; Orlandi, G; Palcau, AC; Pulito, C; Rutigliano, D; Sacconi, A; Strano, S; Verri, M; Zapperi, S, 2023) |
| "Combining colorectal resection with HAI pump implantation is a safe surgical approach for management of unresectable CRLM." | 1.72 | Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases. ( Allen, PJ; Creasy, JM; Lan, B; Lidsky, ME; Mantyh, CR; Migaly, J; Moore, C; Sharib, J; Thacker, JKM; Turley, MC; Zani, S, 2022) |
| " The primary endpoint was overall survival (OS), while the secondary endpoints were progression-free survival and adverse effects." | 1.72 | Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study. ( Hibi, T; Ishii, M; Itano, O; Itano, S; Iwamoto, H, 2022) |
| "5-Fluorouracil (5-FU) has been widely applied in treating cancers." | 1.72 | CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022) |
| "Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu." | 1.72 | Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022) |
| "Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a history of liver disease." | 1.72 | Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. ( Akce, M; Draper, A; El-Rayes, B; Guadagno, J; Kang, S; Magliocca, J; Pectasides, M; Roccaro, G; Sellers, M; Zheng, W, 2022) |
| " We analysed the pharmacokinetic profile of the less toxic photoform ("ring-closed" dithienylethene) of the compound in tumors, plasma, and healthy liver." | 1.72 | Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data. ( Afonin, S; Babii, O; Borysko, P; Dovbynchuk, T; Dziubenko, N; Garmanchuk, LV; Gorbach, O; Khranovska, N; Komarov, IV; Kuznietsova, H; Schober, T; Shtanova, LY; Tolstanova, G; Ulrich, AS; Veselsky, SP; Yanchuk, PI, 2022) |
| "Against Meth A fibrosarcoma solid tumor system, L-MTP-PE showed slight but statistically significant elongation of survival days against 5-FU monotherapy in spite of its non-effect on tumor growth, when combined with 5-FU." | 1.72 | Effects of Liposome-Entrapped Muramyl Tripeptide Phosphatidylethanolamine (L-MTP-PE) on the Tumor Growth and Survival of Mice Bearing Syngeneic Tumor in Combination with a Chemotherapeutic or Immunomodulatory Agent. ( Abe, S; Tanaka, M, 2022) |
| "The development of liver cancer is strongly tied with fibrosis and cirrhosis that alters the microenvironmental landscape, especially ECM composition." | 1.72 | Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment. ( Fang, X; Gong, L; Guan, XY; Lam, KO; Lam, RHW; Lee, AW; Liu, B; Luo, J; Ren, J; Tiu, YC; Yan, Q; Yang, Y; Zhang, Y, 2022) |
| "Hazard ratios for overall survival and disease progression were 0." | 1.72 | A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. ( Cheng, S; Gu, J; Jiang, D; Lau, WY; Liu, C; Mao, F; Shen, L; Shi, J; Sun, J; Wang, N; Zhou, L, 2022) |
| "Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment." | 1.72 | The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. ( Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022) |
| "To evaluate the clinical efficacy of targeted therapy and immunotherapy combined with hepatic arterial infusion chemotherapy (HAIC) of FOLFOX and lipiodol embolization in the treatment of unresectable hepatocellular carcinoma." | 1.72 | Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma. ( Chen, D; Chen, Y; Hu, XL; Huang, DB; Li, XQ; Lin, ZP; Xu, SX; Zhang, J; Zhong, H; Zou, XG, 2022) |
| "A total of 48 consecutive patients with colorectal cancer (CRC) with hepatic metastasis were retrospectively reviewed, and factors such as metastatic tumor vascular microenvironment, chemotherapy response and hepatic resection, were analyzed." | 1.62 | Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response. ( Ichikawa, D; Iino, H; Okamoto, H; Shiba, S; Sudoh, M, 2021) |
| "Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents." | 1.62 | Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021) |
| "Treatment of liver cancer with conventional method bears several side effects, thus to undertake these side effects as a formulation challenge, it is necessary to develop novel target-specific drug delivery system for the effective and better localization of drug into the proximity of target with restricting the movement of the drug in normal tissues." | 1.62 | Mannose Conjugated Starch Nanoparticles for Preferential Targeting of Liver Cancer. ( Jain, AK; Mishra, K; Sahu, H; Thareja, S, 2021) |
| "A 68-year-old man having a descending colon cancer with multiple metastases of up to 9." | 1.62 | [A Case of Colon Cancer with Synchronous Multiple Metastases Successfully Treated with Combined Chemotherapy]. ( Hasegawa, K; Isogai, J; Kaneko, J; Maejima, K; Maejima, S; Otomo, M; Takatsuno, Y, 2021) |
| "We used pancreatic, liver and colon cancer cell lines and isolated CSCs using Aldefluor technology to analyze PARP-1 expression." | 1.62 | Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study. ( Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D, 2021) |
| "Although the colorectal cancer (CRC) mortality rates are decreasing in virtue of CRC screening and improved therapeutic methods, CRC is still a leading cause of cancer deaths." | 1.56 | Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer. ( Chen, H; Huang, L; Li, Z; Liu, J; Shen, R; Shi, H; Tao, J; Wang, T; Zhang, Y, 2020) |
| "Over 50% of colorectal cancer patients develop resistance after a transient response to therapy." | 1.56 | Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. ( Cao, Y; Li, Q; Liu, Y; Zhang, Y; Zhou, J, 2020) |
| "5-Fluorouracil (5-FU) is a broad-spectrum anticancer drug, but its clinical application is limited due to drug resistance and toxic side effects." | 1.56 | Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent. ( Fang, X; Shen, A, 2020) |
| "The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure." | 1.56 | Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020) |
| "We report a case with steatohepatitis mimicking liver metastasis as toxicity that was not seen in study patient population." | 1.56 | Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis. ( Bozkurt Duman, B; Çil, T, 2020) |
| "Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy." | 1.56 | Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. ( Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ, 2020) |
| "Pathological diagnosis was carcinoid, se, ly2, v0, n1." | 1.56 | [A Case of Malignant Lymphoma Undergoing HAI Treatment for Multiple Liver Metastases of Carcinoid That Appeared about Nine Years after Resection of Rectal Carcinoid with Liver Metastases]. ( Gofuku, J; Hasuike, Y; Higuchi, I; Ishikawa, A; Miyamoto, M; Mori, Y; Tokunaga, M; Tsuchida, Y; Urano, N, 2020) |
| "Liver cancer is a major threat to human life and health, and chemotherapy has been the standard non-surgical treatment for liver cancer." | 1.56 | Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. ( Dong, C; Jiang, K; Li, R; Lv, J; Sun, R; Wang, L; Wang, Q; Yin, Z; Zhang, J; Zhou, Y, 2020) |
| "5-Fluorouracil (5-Fu) is a widely used as an anticancer drug." | 1.56 | CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020) |
| "Efficient hepatocellular carcinoma (HCC) therapy remains a significant challenge due to the unsatisfactory targeting efficiency of nanoparticles (NPs) with either a passive targeting or a single active targeting property." | 1.56 | Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy ( He, DX; Huang, C; Huang, W; Liu, Y; Long, J; Tan, XW; Tang, S; Wei, H; Xiang, Y; Yu, CY; Zhou, Y, 2020) |
| "Here, we report the case of a Lynch syndrome PDA patient with an exceptional response to a single cycle of pembrolizumab immunotherapy." | 1.56 | Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma. ( Khan, GN; Patil, NR, 2020) |
| "IORT using the INTRABEAM radiation system combined with portal vein infusion chemotherapy is promising for select patients with PVTT." | 1.56 | INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. ( Han, M; He, Y; Liang, H; Shao, Z; Song, X, 2020) |
| "Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion." | 1.56 | Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats. ( Bausys, A; Feldbacher, N; Hoefler, G; Kolb-Lenz, D; Leber, B; Maneikyte, J; Schemmer, P; Stiegler, P; Strupas, K, 2020) |
| "The study includes the total of 60 colorectal cancer metastases operated patients, divided into two groups of 30 patients: the group of patients who were treated with "bevacizumab plus FOLFOX IV" protocol as a neoadjuvant therapy - prior to liver metastases surgery and the control group, patients with the liver resection done without previous neoadjuvant chemotherapy." | 1.56 | Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer. ( Gmijovic, M; Pecic, V; Stojanovic, M, 2020) |
| "By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC)." | 1.56 | Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. ( Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY, 2020) |
| " The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC." | 1.56 | Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020) |
| "Patient-derived gastric cancer was established in nude mice from the patient' s surgical tumor specimen." | 1.56 | A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy. ( Bouvet, M; Higuchi, T; Hoffman, RM; Kawaguchi, K; Nishino, H; Park, JH; Sugisawa, N; Tashiro, Y; Unno, M; Yamamoto, J, 2020) |
| " Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level." | 1.56 | Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020) |
| "In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed." | 1.56 | Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. ( Alawi, M; David, K; Ewald, F; Fischer, L; Indenbirken, D; Izbicki, JR; Jücker, M; Juhl, H; Molloy, MP; Nashan, B; Omidi, M; Sauter, G; Schlüter, H; Simon, R; Smit, DJ; Spohn, M; Voß, H; Wurlitzer, M, 2020) |
| "This paper discussed the synergistic anti-tumor effect of Shuangdan Capsules combined with 5-fluorouracil(5-FU) on human liver cancer cell line Huh-7 and tumor bearing mice." | 1.56 | [Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice]. ( Chen, XW; Ding, WB; Ning, Q; Song, J; Xia, Z; Zhou, XW, 2020) |
| " Using the CCK-8 and Colony formation assay, the anti-proliferation effect of 5-FU combined with Huaier was observed." | 1.51 | The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. ( Che, C; Dong, B; Dong, C; Fu, Z; Liang, R; Ma, K; Wang, H; Wang, X; Zhang, R; Zhao, C, 2019) |
| "However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed." | 1.51 | Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019) |
| "Patients with advanced hepatocellular carcinoma (HCC) have a poor oncologic outcome." | 1.51 | Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. ( Cho, CW; Lee, BH; Lee, DS; Yun, SS, 2019) |
| "SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu." | 1.51 | Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019) |
| "Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes." | 1.51 | Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. ( Amor Divino, PH; Bonadio, RC; Capareli, FC; Hoff, PM; Kruger, JAP; Lima, KCA; Obando, JSM; Recchimuzzi, DZ; Saragiotto, DF, 2019) |
| "BACKGROUND Liver cancer is one of the most common malignancies around the world and one of the major causes of cancer related mortality." | 1.51 | Anticancer Action of Psilostachyin-A in 5-Fluorouracil-Resistant Human Liver Carcinoma are Mediated Through Autophagy Induction, G2/M Phase Cell Cycle Arrest and Inhibiting Extracellular-Signal-Regulated Kinase/Mitogen Activated Protein Kinase (ERK/MAPK) ( Huang, J; Huang, L; Liu, J; Liu, Y; Shi, C; Wang, G; Wang, J; Xu, X, 2019) |
| "We report 2 cases of advanced colorectal cancer achieving complete response by FOLFOXIRI plus bevacizumab." | 1.51 | [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report]. ( Aizawa, M; Endo, S; Isohata, N; Nemoto, D; Nemoto, T; Oshibe, I; Saito, T; Soeta, N; Takayanagi, D; Togashi, K; Utano, K, 2019) |
| " No statistical differences were observed in treatment-related adverse events, hospital admissions, or further treatment lines between age groups." | 1.51 | Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. ( Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 1.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "Although hepatectomy for metastatic colorectal cancer (mCRC) prolongs survival in up to 40% of people, recurrence rates approach 70%." | 1.51 | Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study. ( Hanai, T; Hayashi, T; Ikeda, Y; Kato, Y; Katsuno, H; Koide, Y; Maeda, K; Masumori, K; Matsuoka, H; Morise, Z; Nakajima, S; Sugioka, A; Tanahashi, Y; Tanaka, C; Uyama, I, 2019) |
| "Distant metastasis still remained a major concern in pCR patients following nCRT and TME." | 1.51 | Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019) |
| "5-Fluorouracil (5-FU) is a widely used antitumor drug." | 1.51 | Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic drug used to treat cancer, including CRC." | 1.51 | Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer. ( Lee, JH; Lee, SW, 2019) |
| "Even for right colon cancer, anti-EGFR antibodies might be effective if RAS is wild-type." | 1.51 | [Long-Term Effectiveness of Chemotherapy Containing mFOLFOX6 plus Panitumumab and 5-FU/l-LV plus Panitumumab after Primary Tumor Resection in a Case of Ascending Colon Carcinoma and Multiple Hepatic Metastases]. ( Akita, N; Gomyo, Y; Ikeno, T; Kitahama, T; Miyamoto, H; Okada, I, 2019) |
| "Thus, pancreatic cancer of the tail often presents late with a very poor prognosis." | 1.51 | The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report. ( Rahman, M; Washington, L, 2019) |
| "Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor." | 1.51 | Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. ( Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B, 2019) |
| "Our study included 90 cases of colorectal cancer liver metastasis resected after preoperative chemotherapy." | 1.51 | Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis. ( Akagi, Y; Akiba, J; Fujita, F; Fukahori, M; Goto, Y; Hisaka, T; Ishikawa, H; Kawahara, R; Kinugasa, T; Miwa, K; Mizobe, T; Naito, Y; Nakashima, O; Nomura, Y; Okuda, K; Sakai, H; Tanaka, H; Tanigawa, M; Yano, H; Yasunaga, M, 2019) |
| "Forty patients with metastatic colorectal cancer receiving FOLFOX4 chemotherapy with or without bevacizumab and 40 healthy volunteers were included in the study." | 1.48 | Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment. ( Aleknavicius, E; Baltruskeviciene, E; Didziapetriene, J; Kazbariene, B; Krikstaponiene, A; Stratilatovas, E; Suziedelis, K; Venceviciene, L, 2018) |
| "We reported a patient survived more than 7years after undergoing hepatectomy accompanied by tumor thrombectomy in the main trunk of the portal vein after preoperative hepatic arterial chemotherapy for hepatocellular carcinoma combined with tumor thrombus in the main portal vein." | 1.48 | [A Case of a Long-Term Survivor Who Underwent Surgical Intervention for Hepatocellular Carcinoma Combined with Tumor Thrombus in the Main Trunkof the Portal Vein]. ( Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R, 2018) |
| "Early disease progression in the chemotherapy to LR interval occurred in approximately 15% of patients and was associated with extremely poor survival." | 1.48 | Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? ( Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L, 2018) |
| "Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity." | 1.48 | Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018) |
| "The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the major portal vein (PV) is extremely poor." | 1.48 | Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap ( Hatano, E; Uemoto, S; Yamamoto, M; Yamaue, H, 2018) |
| "A 56-year-old woman was diagnosed with rectal cancer and liver metastases(Stage IV), and underwent low anterior resection and laparoscopic partial hepatectomy." | 1.48 | [Primary Small Bowel Tumor with Simultaneous Lung Metastases from Rectal Cancer - A Case Report]. ( Hayashi, H; Hyodo, M; Inoue, Y; Lefor, AK; Okada, M; Ota, G; Sato, H; Shinohara, S; Tsukahara, M; Yasuda, Y, 2018) |
| "Bio-GC nanoparticles targeted liver and liver cancer cell in vitro and in vivo, and this was confirmed by confocal laser scanning and small animal imaging system." | 1.48 | Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo. ( Cheng, M; Liu, B; Ma, D; Zhi, K; Zhu, W, 2018) |
| "In order to reduce the frequency and the severity of oxaliplatin-related sensory-neuropathy and preserve antitumor efficacy, we performed alternating 4 mFOLFOX6 and 4 FOLFIRI cycles, in combination with bevacizumab, in patients with metastatic colorectal cancer." | 1.48 | [A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab]. ( O'hara, H; Yamamoto, H, 2018) |
| "This study investigated the anti-hepatoma activity of different extracts from A." | 1.46 | Studies on anti-hepatoma activity of Annona squamosa L. pericarp extract. ( Cao, YZ; Chen, JW; Chen, Y; Chen, YY; Li, FQ; Li, X; Lu, JH; Peng, CX; Zhu, XL, 2017) |
| "HAIC offers a safe and effective salvage treatment strategy in heavily pretreated patients with LMBC and no further treatment options." | 1.46 | Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters. ( Bogner, S; Peis, MW; Reinboldt, MP; Schuler, M; Tewes, M; Theysohn, JM; Welt, A, 2017) |
| "Stage IV squamous cell carcinoma of the anus outcomes are poor, but first-line chemotherapy can enable good response rates." | 1.46 | Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. ( Benezery, K; Cavaglione, G; Doyen, J; Evesque, L; Follana, P; François, E; Reure, J; Tuan Falk, A, 2017) |
| "Restoring oxygen in metastatic colon cancer through ITPP inhibits tumor spread and markedly improves animal survival; an effect that is enhanced through the application of subsequent chemotherapy." | 1.46 | The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice. ( Clavien, PA; Graf, R; Humar, B; Kachaylo, E; Kron, P; Lehn, JM; Limani, P; Linecker, M; Nicolau, C; Schneider, MA; Tschuor, C; Ungethuem, U, 2017) |
| "Liver fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) and is a strong predictor of hepatocellular carcinoma (HCC) development and progression." | 1.46 | A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells. ( Fukumitsu, K; Ishii, T; Katayama, H; Kawai, T; Kita, S; Kojima, H; Minami, T; Miyauchi, Y; Ogiso, S; Sasaki, N; Uemoto, S; Yamaoka, R; Yasuchika, K; Yasuda, K; Yoshitoshi-Uebayashi, EY, 2017) |
| " In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy)." | 1.46 | Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. ( Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Seong, J; Song, JE; Song, K; Won, JY, 2017) |
| "The most common sites of metastases were liver (63%) and peritoneum (22%)." | 1.46 | Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017) |
| "The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy." | 1.46 | Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. ( Andrikou, K; Bianconi, M; Bittoni, A; Bracci, R; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Mandolesi, A; Scarpelli, M; Scartozzi, M, 2017) |
| "Rectal cancer is a malignant disease requiring multidisciplinary management." | 1.46 | Management of rectal cancer: the 2016 French guidelines. ( Bridoux, V; Brouquet, A; de Chaisemartin, C; Kirzin, S; Lakkis, Z; Lefevre, JH; Maggiori, L; Manceau, G; Panis, Y, 2017) |
| "CTCs in 2 (10%) of 20 breast carcinomas, more than 1 CTC was detected before adjuvant therapy, and both cases showed a decrease to 0 after chemotherapy." | 1.46 | Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation. ( Kinoshita, S; Shimada, T; Takeyama, H; Uchida, K, 2017) |
| "Cetuximab has activity against colorectal cancers." | 1.46 | Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. ( Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S, 2017) |
| "Several microdevices for liver cancer culture and evaluation of the drug cytotoxicity have been reported." | 1.46 | Studies of anticancer drug cytotoxicity based on long-term HepG2 spheroid culture in a microfluidic system. ( Brzozka, Z; Chudy, M; Dybko, A; Kwapiszewska, K; Zuchowska, A, 2017) |
| "Both patients presented with colorectal cancer with synchronous liver metastasis." | 1.46 | A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases. ( Aydin, N; Berber, E; Dural, C; Okoh, AK; Taskin, HE; Yazici, P; Yigitbas, H, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 1.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties." | 1.43 | Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016) |
| "For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment." | 1.43 | Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin. ( Ohi, H; Ozaki, T; Seki, H; Yabusaki, H, 2016) |
| "Metastatic liver disease from colorectal cancer is a significant clinical problem." | 1.43 | The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis. ( Denys, A; Devun, F; Dutreix, M; Herath, NI; Herbette, A; Lienafa, MC; Sun, JS, 2016) |
| "She was diagnosed with descending colon cancer with lymph node and liver metastases." | 1.43 | [A Case of Liver Metastasis of Descending Colon Cancer with a Pathological Complete Response to mFOLFOX6]. ( Ito, T; Kawamoto, K; Kawamoto, Y; Koda, Y; Ome, Y; Saga, K, 2016) |
| "MSFCs, CD90+ liver cancer cells (CD90+ LCCs), and parental MHCC97H cells were treated with no drug, LY294002 alone, 5-FU alone, or both drugs together and then compared in terms of stem cell-related gene expression, proliferation, and invasion." | 1.43 | Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity. ( Li, LQ; Lu, SD; Peng, NF; Peng, YC; Xie, ZB; You, XM; Zhong, JH, 2016) |
| "Oesophageal cancer is a highly aggressive disease with about 50% of patients presenting with advanced or metastatic disease at initial diagnosis." | 1.43 | Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review. ( Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F, 2016) |
| "Gastroscopy revealed that the gastric cancer had disappeared." | 1.43 | [A Case of Double Cancer of Initially Unresectable Sigmoid Colon Cancer and Advanced Gastric Cancer Treated with Curative Resection after mFOLFOX6 Therapy]. ( Aoki, K; Endo, M; Ikenaga, S; Mitsuhashi, Y; Miura, T; Shibasaki, I; Suto, A; Tomiura, S; Yoshikawa, T, 2016) |
| "The treatment efficacy of unresectable hepatocellular carcinoma (HCC) is still not promising." | 1.43 | Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. ( Bao, Y; Dai, Y; Dong, X; Feng, W; Shen, J; Tang, C; Zhang, J; Zheng, Y, 2016) |
| " Implanting sustained-release 5-FU into hepatic cross-section and omentum majus after primary liver cancer resection is proved to be safe as it has little impact on related indexes." | 1.43 | Safety of implanting sustained-release 5-fluorouracil into hepatic cross-section and omentum majus after primary liver cancer resection. ( Chen, J; Hua, L; Ren, X; Wang, C; Yao, K; Zhang, J; Zhang, L, 2016) |
| "The histological diagnosis was tubular adenocarcinoma (tub2-1), int, INF a, pMP, ly0, v0, pDM0, pPM0, R0." | 1.43 | [A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab]. ( Aomatsu, N; Dozaiku, T; Hanno, H; Hirakawa, T; Hirooka, T; Iwauchi, T; Kawamura, M; Morimoto, J; Nakazawa, K; Nishii, T; Takayanagi, S; Takeda, O; Takeuchi, K; Uchima, Y; Yukawa, Y, 2016) |
| "Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 1.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
| "Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%." | 1.43 | Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. ( Choi, GH; Choi, JS; Han, DH; Han, KH; Joo, DJ; Kim, MS; Kim, SI; Park, YN; Seong, J, 2016) |
| "A 68-year-old man was diagnosed with rectal cancer on colonoscopy and liver metastasis of rectal cancer on abdominal computed tomography(CT)." | 1.43 | [A Case of Liver Metastasis from Colorectal Cancer That Showed a Pathological Complete Response to mFOLFOX6 plus Cetuximab]. ( Chihara, T; Endo, S; Ikenaga, M; Konishi, K; Nakagawa, T; Nakashima, S; Nishijima, J; Ohta, K; Yamada, T, 2016) |
| "BACKGROUND Hepatocellular carcinoma (HCC) causes many deaths worldwide every year, especially in Asia." | 1.43 | Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. ( He, B; Hu, X; Liu, J; Liu, S; Wang, H, 2016) |
| "Dioscin is a natural steroid saponin that presents in various plants." | 1.43 | Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016) |
| "We report 2 cases of metastatic rectal cancer patients who received chemotherapy with FOLFOXIRI plus bevacizumab(Bev)." | 1.43 | [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab]. ( Aomatsu, N; Hirakawa, T; Iwauchi, T; Morimoto, J; Nagashima, D; Nakazawa, K; Nishii, T; Takeuchi, K; Tei, S; Uchima, Y; Wang, E; Yamakoshi, Y, 2016) |
| "A 75-year-old man was diagnosed with sigmoid colon cancer with multiple liver metastases at our hospital in May 2010." | 1.43 | [Long-Term Survival in a Case of Sigmoid Colon Cancer with Multiple Liver Metastases Treated with Repeated Hepatectomies]. ( Fujii, H; Hokutou, D; Inoue, T; Kawaguchi, C; Koyama, F; Nakajima, Y; Nakamoto, T; Nakamura, Y; Nomi, T; Obara, S; Sasaki, Y; Ueda, T; Yamato, I; Yasuda, S; Yoshikawa, T, 2016) |
| "Liver cancer is one of the most drug-resistant cancer types, and cancer stem cells are related to drug resistance." | 1.42 | JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. ( Ahn, YH; Jee, HG; Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, JH; Lee, M; Park, SY; Yoon, JH; Yu, SJ, 2015) |
| "A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007." | 1.42 | Hepatic arterial infusion in hepatocellular carcinoma: a single center experience. ( Dvorak, J; Ferko, A; Kamaradova, K; Krajina, A; Melichar, B, 2015) |
| " By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up." | 1.42 | A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015) |
| "Patients with KRAS wild-type metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled." | 1.42 | Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. ( Bortlíček, Z; Kubáčková, K; Linke, Z; Pikus, T; Pokorná, P; Prausová, J; Vyzula, R, 2015) |
| "She was diagnosed with descending colon cancer with multiple liver metastases, and was referred to our department." | 1.42 | [Preoperative chemotherapy with modified FOLFOX + panitumumab for the treatment of descending colon cancer with multiple liver metastases - a case study]. ( Iwaya, A; Manabe, S; Yagi, Y; Yamazaki, T, 2015) |
| "The clinicopathological parameters and adverse effects were similar between the 2 groups (P > 0." | 1.42 | Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. ( Burns, M; Hong, Y; Lei, X; Li, JL; Li, QL; Li, YG; Liu, C; Liu, HC; Liu, JS; Qiu, XX; Wang, XH; Wu, QF; Xia, M; Xiao, H; Xu, RC; Zhu, HZ; Zuo, CH, 2015) |
| "To investigate the cooperative effect of Bifidobacteria lipoteichoic acid (BLTA) combined with 5-fluorouracil on tumor cells growth and apoptosis in mice bearing H22." | 1.42 | Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis. ( Guo, B; Wang, Y; Xie, N, 2015) |
| "Although hyperammonemia is a known side effect of 5-FU that can cause serious pathological conditions, only a few cases have been reported." | 1.42 | [Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis]. ( Iida, T; Isshiki, H; Kaneto, H; Murakami, K; Naganawa, Y; Sasaki, H; Satoh, S; Shimizu, H; Tani, M; Wagatsuma, K, 2015) |
| "In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy." | 1.42 | [Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015) |
| " The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients." | 1.42 | Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. ( Kanazawa, S; Katsui, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Onishi, H; Sakaguchi, K; Shiraha, H; Takaki, A; Takeuchi, Y; Wada, N; Yamamoto, K; Yasunaka, T, 2015) |
| "Nineteen hepatic cancer cell lines, 50 cases of adjacent tissue and 149 cases of HCC samples were employed." | 1.42 | Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. ( Brock, MV; Guo, M; Herman, JG; Li, X; Liang, P; Tao, Q; Yu, J, 2015) |
| "Metastasis of colorectal cancer (CRC) in an adrenal gland develops in 1." | 1.42 | [Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava]. ( Andreĭtseva, OI; Gritsiuta, AI; Kalinin, DV; Kharazov, AF; Vishnevskiĭ, AV; Zhavoronkova, OI, 2015) |
| "Stage III colon cancer is currently treated as an entity with a unified therapeutic principle." | 1.42 | A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. ( Deng, G; He, J; Ma, J; Pei, H; Shen, H; Wu, X; Zeng, S; Zhang, S; Zhang, Y, 2015) |
| "Colon cancer in pregnancy is uncommon." | 1.42 | Chemotherapeutic treatment of colorectal cancer in pregnancy: case report. ( Al-Khatani, K; Al-Mohaisen, F; Makoshi, Z; Perrott, C, 2015) |
| "Most liver metastases from colorectal cancer (CRC) are unresectable at diagnosis." | 1.42 | Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. ( Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E, 2015) |
| "Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence." | 1.42 | MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015) |
| " Compared with either agent alone, a low dose of Dox combined with eAFP-VISA-BikDD induced better antitumor effect and prolonged longer survival of mice in two orthotopic liver cancer xenograft models." | 1.42 | Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. ( Chen, HY; Dai, HY; Hung, MC; Lai, WC; Li, LY, 2015) |
| "From January 2008 to December 2013, 107 gastric cancer patients with synchronous liver metastasis attending the four participating centers were enrolled in this multicenter, ambispective, controlled cohort study." | 1.42 | Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. ( Chen, L; Cheng, HD; Cui, JX; Li, JY; Liu, SF; Lu, CR; Shen, WS; Xi, HQ, 2015) |
| "Cucurbitacin B is a plant-derived tetracyclic triterpenoid, which has been used for a variety of cancers, especially human hepatoma." | 1.42 | Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells. ( Chen, D; Hu, H; Huang, Z; Qiao, M; Sun, Y; Zhang, J; Zhao, X; Zhou, J, 2015) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 1.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "Luteolin may inhibit tumor angiogenesis and tumor cell proliferation by down-regulation of LFA- 3 and PCNA and up-regulation of ICAM-1 in tumor tissue of tumor-bearing mice, thereby achieving its anti-tumor effect." | 1.42 | Effect of luteolin on gene expression in mouse H22 hepatoma cells. ( Bao, LD; Gan, HM; Guo, HP; Niu, JX; Ren, JJ, 2015) |
| "The SCAN colorectal cancer systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for colorectal cancer in Singapore." | 1.42 | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer. ( , 2015) |
| "After disease progression, a second line based on FOLFIRI-aflibercept was started achieving an initial partial response followed by a long-lasting disease stability with a good tolerability." | 1.42 | [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]. ( Aroldi, F; Zaniboni, A, 2015) |
| "A patient in his 70s was diagnosed with rectal cancer (pT3, pN1, cM0, and pStage IIIa) for which he underwent low anterior resection of the rectum and received adjuvant therapy with UFT/LV." | 1.42 | [A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab]. ( Goya, T; Hanaka, J; Kanamura, S; Nakayama, H; Takahashi, M; Takahashi, S; Wakamatsu, T, 2015) |
| "Approximately 20% of the patients with colorectal cancer have distant metastasis during diagnosis." | 1.42 | Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients. ( Albayrak, D; Cicin, I; Erdogan, B; Hacibekiroglu, I; Kodaz, H; Tozkir, H; Turkmen, E; Uzunoglu, S, 2015) |
| "HUVEC and human hepatoma cells (MHCC97H) were cultured, respectively, and then the MHCC97H cells were co-cultured with conditioned medium from HUVEC (EC-CM) with Transwell system." | 1.42 | [Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells]. ( Feng, C; Luo, Q; Song, G; Sun, J; Yang, X, 2015) |
| "Triptolide is a diterpenoid epoxide isolated from the herb Tripterygium wilfordii, which has long been used as a natural medicine in China for many diseases including cancer." | 1.40 | Triptolide sensitizes liver cancer cell lines to chemotherapy in vitro and in vivo. ( Hu, S; Li, Y, 2014) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| "The presented patient with stage IV rectal cancer and liver metastases was in a unique situation linked to its inclusion in a reversed treatment and the use of neoadjuvant chemotherapy alone." | 1.40 | Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer. ( Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C, 2014) |
| "Metastasized rectal cancer has long been considered incurable." | 1.40 | A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. ( Albertsson, M; Holmqvist, A; Jung, M; Sun, XF, 2014) |
| "Patients with cT2-4N0-2M0 distal rectal cancer treated with CRT (50." | 1.40 | Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. ( Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; Sabbagh, C; São Julião, GP, 2014) |
| "A 67-year-old man diagnosed with colorectal cancer in 2008 presented in April 2011 to Appalachian Regional Healthcare Cancer Center with obstructive jaundice and weight loss." | 1.40 | Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction. ( Craig, J; Elsoueidi, R; Mourad, H; Richa, EM, 2014) |
| "Biological characteristics of colorectal cancer liver metastases (CRCLM) are increasingly recognized as major determinants of patient outcome." | 1.40 | Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. ( Christophi, C; Lau, LF; Lee, ST; Muralidharan, V; Scott, AM; Williams, DS, 2014) |
| "Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability." | 1.40 | Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014) |
| "Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC." | 1.40 | Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014) |
| "The formation of liver metastases in colorectal cancer patients is the primary cause of patient death." | 1.40 | Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells. ( Ahn, JH; Hong, SW; Kim, JS; Kim, SJ; Lee, HJ; Yu, HK, 2014) |
| "He was diagnosed with sigmoid cancer with multiple liver and lung metastases." | 1.40 | [A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs]. ( Hasegawa, Y; Hatanaka, M; Iwata, H, 2014) |
| "We present a case of recurrent gastric cancer in which stable disease status was achieved for four months due to treatment with capecitabine/cisplatin (CDDP)after the failure of multiple anticancer drugs including S-1/CDDP." | 1.40 | [A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP]. ( Sakamoto, K; Sakashita, K; Sawada, R; Sunami, T; Tauchi, J; Yukimoto, K, 2014) |
| "The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship." | 1.40 | Colon cancer, version 3.2014. ( Bekaii-Saab, T; Benson, AB; Chan, E; Chen, YJ; Cooper, HS; Engstrom, PF; Enzinger, PC; Fenton, MJ; Freedman-Cass, DA; Fuchs, CS; Gregory, KM; Grem, JL; Hunt, S; Kamel, A; Leong, LA; Lin, E; Messersmith, W; Mulcahy, MF; Murphy, JD; Nurkin, S; Rohren, E; Ryan, DP; Saltz, L; Sharma, S; Shibata, D; Skibber, JM; Sofocleous, CT; Stoffel, EM; Stotsky-Himelfarb, E; Venook, AP; Willett, CG, 2014) |
| "Patients with colorectal cancer who received adjuvant CAPOX from January 2005 to August 2011 were reviewed." | 1.40 | Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. ( Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE, 2014) |
| "PP blocked colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC(50)), ranging from 0." | 1.40 | The impact of pyrvinium pamoate on colon cancer cell viability. ( Germer, CT; Hüttenrauch, M; Krummenast, F; Linnebacher, M; Mühling, B; Otto, C; Thalheimer, A; Uthe, FW; Wiegering, A, 2014) |
| " A c-myc antisense oligodeoxynucleotide can increase the sensitivity of liver cancer cells to 5-fluorouracil and decrease the dosage of the agent necessary for efficacy, providing an experimental basis for the clinical therapy of liver cancer." | 1.40 | Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil. ( Cai, H; Chen, YR; Guo, TK; He, J; Li, W; Yang, XJ; Yuan, Y, 2014) |
| "However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011." | 1.40 | [A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy]. ( Kigawa, G; Matsubara, T; Matsumiya, A; Mizukami, H; Nemoto, H; Saito, M; Tanaka, J; Tate, G; Umemoto, T, 2014) |
| "Irinotecan (CPT-11) was used as a chemotherapeutic agent in 24 patients, gemcitabine (GEM) in 24 and doxorubicin in 59." | 1.40 | Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY, 2014) |
| "To observe the antitumor effect of Stihopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells, and study the mechanism." | 1.40 | [Antitumor effect of Stichopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells]. ( Chen, D; Dai, H; Song, Y, 2014) |
| " Changes in liver function before and after the initial TACE procedure and hepatobiliary severe adverse events (SAEs) were compared." | 1.40 | Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. ( Li, X; Luo, X; Tsauo, J; Wang, X; Wang, Z; Zhang, H; Zhao, H, 2014) |
| "For locally unresectable hepatocellular carcinoma (HCC) patients, concurrent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment." | 1.40 | Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. ( Choi, JS; Han, KH; Kim, JK; Kim, JW; Kim, KS; Lee, IJ; Park, YN; Seong, J, 2014) |
| " Radiofrequency ablation (RFA) is a safe and effective technique for treatment of isolated liver metastasis." | 1.40 | Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer. ( Agarwal, A; Butler-Bowen, H; Daly, KP; Saif, MW, 2014) |
| "A 77-year-old woman was diagnosed with gastric cancer complicated by multiple liver metastases and peritoneal dissemination." | 1.40 | [Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report]. ( Choda, Y; Harano, M; Idani, H; Kanazawa, T; Matsukawa, H; Ninomiya, M; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Tokumoto, N, 2014) |
| "There has been no disease recurrence 75 months after the initial surgery." | 1.40 | [Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report]. ( Kakizawa, N; Kato, T; Noda, H; Rikiyama, T; Toyama, N; Watanabe, F, 2014) |
| "A colonoscopy detected KRAS wild-type rectal cancer." | 1.40 | [A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)]. ( Aisu, Y; Ando, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T, 2014) |
| "She was diagnosed with sigmoid colon cancer by colonoscopy and multiple liver metastases by ultrasonography." | 1.40 | [A case of long-term survival following chemotherapy after laparoscopic resection of sigmoid colon cancer with multiple liver metastases]. ( Arai, I; Hayashi, N; Inoue, S; Ohashi, I; Tamura, C; Wakasa, T, 2014) |
| "In patients with metastatic gastric cancer, the prognosis is poor with a median overall survival of 11 months since curative treatments are excluded; however, this case illustrated that a personalized treatment with chemotherapy and surgery can allow a curative strategy in selected patients with HER2-negative advanced gastric cancer." | 1.40 | Advanced gastric cancer with liver and lymph node metastases successfully resected after induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil. ( Anselmi, E; Banchini, F; Bodini, FC; Capelli, P; Cavanna, L; Michieletti, E; Stroppa, EM; Zangrandi, A, 2014) |
| "To study the synergistic effect on hepatoma cell(SMMC-7721) and the reduction killing effect on normal liver cells(LO-2) treated with sodium cantharidinate (SCA) in combination with fluorouracil(5-FU) or cisplatin(DDP) as well as the related mechanism." | 1.40 | [Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism]. ( Chen, MJ; Xu, DQ; Zhang, X; Zhao, FM; Zhao, RL; Zhou, KF, 2014) |
| "All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy." | 1.40 | Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer. ( Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S, 2014) |
| " The use of combined neoadjuvant chemotherapy is safe before hepatic resection." | 1.39 | Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment. ( Baranyai, ZS; Besznyák, I; Bursics, A; Dede, K; Jakab, F; Landherr, L; Mersich, T; Salamon, F; Zaránd, A, 2013) |
| "The prognosis of hepatocellular carcinoma (HCC) with macroscopic vascular invasion is extremely poor even after hepatic resection." | 1.39 | Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Nitta, H, 2013) |
| "The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor." | 1.39 | Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013) |
| "A 29-year-old woman with colon cancer and synchronous liver metastasis underwent a two-stage liver resection by the ALPPS technique because of an extremely small future liver remnant." | 1.39 | ALPPS procedure with the use of pneumoperitoneum. ( Machado, MA; Makdissi, FF; Surjan, RC, 2013) |
| "Stage III rectal cancer was found in 64." | 1.39 | Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. ( Arbea, L; Arredondo, J; Baixauli, J; Beorlegui, C; Chopitea, A; Hernández-Lizoáin, JL; Rodríguez, J; Sola, JJ, 2013) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor." | 1.39 | PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013) |
| " Histological analyses of organs did not exhibit adverse effects attributable to the test article." | 1.39 | Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques. ( Abel, T; Bach, P; Buchholz, CJ; Coulibaly, C; Heidmeier, S; Lauer, UM; Mühlebach, MD; Plesker, R; Seifried, J; Völker, I, 2013) |
| "Sorafenib can inhibit not only the tumor growth and lung metastsis in the nude mouse models, but also reduce the expression of multidrug resistance proteins P-gp and Topo IIa as well." | 1.39 | [Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil]. ( Shen, HJ; Wang, YH; Xu, J, 2013) |
| "The genome expression profiles of colorectal cancer tissues were examined using DNA microarray analysis, and differential gene expression was identified using a significance analysis of the microarray." | 1.39 | Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis. ( Chi, P; Huang, S; Huang, Y; Li, S; Lin, H; Lu, X; Pan, J; Shen, S; Xu, Z, 2013) |
| "SLN-curcumin and LDH-5-Fu were determined to be 100 and 60 nm by Transmission Electron Microscopy detection, and the loading efficiency were 28%±2." | 1.39 | Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line. ( Gao, B; Liu, H; Wang, S; Wu, X; Xiao, Y; Xie, Q; Zhu, R, 2013) |
| "The growth of H22 hepatoma transplantation tumor was inhibited more obviously in the combination group and the 5-Fu group than in the control group (P <0." | 1.39 | [Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma]. ( Jia, Q; Wang, ZP; Wang, ZX; Wu, LC; Zhang, WD; Zhang, YY; Zheng, AH, 2013) |
| "We report a case of advanced relapsed colon cancer, which had multiple liver and spleen metastasis, controlled for about two years by capecitabine therapy." | 1.39 | [A case of relapsed colon cancer successfully treated by capecitabine]. ( Hashimoto, T; Kimura, S; Toyono, M; Usuba, O; Yokoyama, M, 2013) |
| "Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma." | 1.39 | Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013) |
| "She was diagnosed as colon cancer with hepatic metastasis." | 1.39 | [A case of metastatic colon cancer effectively treated by XELOX and IRIS]. ( Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M, 2013) |
| "Because the gastric cancer was HER2-positive, she was treated with trastuzumab plus capecitabine plus cisplatin(XP)chemotherapy as third-line treatment." | 1.39 | [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment]. ( Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T, 2013) |
| "Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port." | 1.39 | Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013) |
| "Eighteen patients with rectal cancer and synchronous liver metastases, who had undergone laparoscopic colorectal resection and simultaneous treatment for liver metastases, were retrospectively reviewed." | 1.39 | The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy. ( Chen, F; Chen, K; Ding, XM; Hu, BS; Leng, JJ; Tan, HM; Tan, JW; Zhu, Z, 2013) |
| "As oxaliplatin is a standard agent in colorectal cancer therapy today, all clinicians and pathologists should be aware of such non-neoplastic lesions as one of the rare differential diagnoses of metastatic liver tumor, to prevent overtreatment." | 1.39 | Oxaliplatin-induced liver injury mimicking metastatic tumor on images: a case report. ( Endo, Y; Fujisawa, M; Kai, K; Matsukawa, A; Matsumoto, Y; Nobuhisa, T; Notohara, K; Sato, S; Uchino, K; Watanabe, T, 2013) |
| "A 77-year-old man with colon cancer and multiple metastases to the liver and lungs underwent resection of the primary tumor and D3 lymph node dissection." | 1.39 | [A case of advanced colon cancer with atrial fibrillation and the use of dabigatran for safe chemotherapy using fluoropyrimidine-based antitumor agents]. ( Adachi, A; Nakajima, M; Uchisako, H; Uchiyama, T, 2013) |
| "Celecoxib can enhance the antitumor effect of capecitabine by inhibiting the expressions of COX-2 and NF-ΚB p65 in mice bearing H22 implanted tumor." | 1.39 | [Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism]. ( Guo, HQ; Liu, YY; Yang, SJ; Yao, SN; Yao, ZH; Yuan, YD; Zhao, Y, 2013) |
| "Here, we used the chitosan and hepatoma cell-specific binding molecule, glycyrrhetinic acid (GA), to synthesize glycyrrhetinic acid-modified chitosan (GA-CTS)." | 1.39 | Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo. ( Chen, H; Cheng, M; Gao, X; Han, J; He, B; Li, Y; Wang, Y; Xu, H; Zhang, Z, 2013) |
| "Metastatectomy in colorectal cancer (CRC) is now a standard of care with improved survival reported." | 1.39 | Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. ( Beeke, C; Bishnoi, S; Karapetis, CS; Maddern, G; Padbury, R; Padman, S; Price, TJ; Townsend, AR, 2013) |
| "The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor." | 1.39 | Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013) |
| " The clinical efficacy and bevacizumab-related adverse reactions were observed." | 1.39 | [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. ( Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY, 2013) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection." | 1.39 | Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013) |
| "Furthermore pathogenesis of liver fibrosis is not well known." | 1.39 | A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer. ( Jeong, HY; Kang, DY; Kang, GH; Kim, SH; Lee, BS; Lee, ES; Lee, HY; Moon, HS; Sung, JK, 2013) |
| "A 44-year-old man with advanced hepatocellular carcinoma (HCC) was admitted to our institution." | 1.39 | [A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk]. ( Kanbara, Y; Tai, K; Terai, S, 2013) |
| "She underwent curative resection for sigmoid colon cancer( T4a, N2, M0, Stage IIIC)." | 1.39 | [Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer]. ( Baba, H; Iida, S; Ishiguro, M; Ishikawa, T; Iwata, N; Kikuchi, A; Kobayashi, H; Okazaki, S; Sugihara, K; Takahashi, H; Uetake, H, 2013) |
| "Human colon cancer cell lines, transfected with human chorionic gonadotropin and luciferase, were injected orthotopically into the caecal wall of severe combined immunodeficient mice, intrasplenically or subcutaneously." | 1.39 | Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. ( Francia, G; Hackl, C; Kerbel, RS; Man, S; Milsom, C; Xu, P, 2013) |
| "A 57-year-old male with lower esophageal cancer underwent subtotal esophagectomy with lymphadenectomy." | 1.39 | Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. ( Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T, 2013) |
| "These results suggest that HR + RFA after effective chemotherapy is a safe procedure with low local recurrence at the RFA site and is a potentially effective treatment option for patients with initially unresectable CRLM." | 1.39 | Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Kikuchi, K; Kuroki, H; Mima, K; Miyamoto, Y; Nakagawa, S; Okabe, H; Sakamoto, Y; Watanabe, M, 2013) |
| "Patients with colorectal cancer (CRC) and liver metastases benefit from perioperative chemotherapy and liver resection." | 1.39 | Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. ( Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F, 2013) |
| "Major postoperative complications were independently associated with major (≥ 3 segments) resections (57%) and perioperative blood transfusion." | 1.39 | Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. ( Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS, 2013) |
| "Combined resection of colorectal cancer with surgery for synchronous liver metastases (LM) still remains controversial because of the possible higher morbidity rate, the necessity of an adequate abdominal approach for both resections and the impact on oncological results." | 1.39 | Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases. ( Belghiti, J; Bretagnol, F; Farges, O; Hatwell, C; Panis, Y, 2013) |
| "We report on an 86-year-old woman with colon cancer with liver metastasis who was treated with 5-fluorouracil, folinic acid, and bevacizumab." | 1.39 | Cervical extravasation of bevacizumab. ( Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dréanic, J; Goldwasser, F; Mir, O; Perkins, G, 2013) |
| "Capecitabine was given concomitantly at a dose of 600 mg/m2 twice daily during radiotherapy." | 1.39 | Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ, 2013) |
| "Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival." | 1.39 | Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy? ( Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Okada, N, 2013) |
| "The only drug that improves survival in hepatocellular carcinoma is sorafenib." | 1.38 | Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012) |
| "A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy." | 1.38 | Perirenal hematoma associated with bevacizumab treatment. ( Hayashi, H; Nakagawa, K; Okamoto, I, 2012) |
| "Clinicopathological data of 257 cM1 gastric cancer patients who underwent an operation at Seoul National University Hospital from January 1999 to December 2004 were reviewed." | 1.38 | The value of palliative gastrectomy in gastric cancer with distant metastasis. ( Chang, YR; Han, DS; Kim, SH; Kim, WH; Kong, SH; Lee, HJ; Yang, HK, 2012) |
| "The prognosis for hepatocellular carcinoma (HCC) along with portal vein tumor thrombi (PVTT) is poor, and surgery has not been considered an option." | 1.38 | Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. ( Liu, B; Liu, J; Ou, Q; Wang, Y; Zhang, D, 2012) |
| "Sarcopenia was present in 30% (6/20) of patients with reduction in tumor size posttreatment, and in 52% (14/27) of patients with increased tumor size (P = 0." | 1.38 | Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. ( Baracos, VE; Fu, S; Hong, D; Kurzrock, R; Parsons, HA; Pontikos, M; Tsimberidou, AM; Wen, S, 2012) |
| "RFA combined with chemotherapy is a promising treatment for NPC metastatic liver disease with improved local response, PFS, and OS compared to current chemotherapy protocols." | 1.38 | Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes. ( Cai, XY; Cai, YC; Cao, Y; Jiang, WQ; Jin, Y; Shi, YX; Tan, YT, 2012) |
| "The patient was a 60-year-old man with cancer of the rectum, with huge multiple hepatic metastases." | 1.38 | [Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report]. ( Bando, Y; Katakawa, M; Ogata, S; Tagami, Y, 2012) |
| "Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy." | 1.38 | Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. ( Bae, SH; Cha, JH; Choi, BG; Choi, JY; Chun, HJ; Jang, JW; Kim, HL; Woo, HY; Yoon, SK; Youn, JM, 2012) |
| "We report a case of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) that developed in a patient with cholangiocarcinoma after receiving oxaliplatin-based chemotherapy." | 1.38 | Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, MK; Nam, TS; Shim, HJ; Yoon, JY, 2012) |
| "5-fluorouracil (5-FU) was administered continuously for 24 h from day 1 to day 5 every 2-4 wk via an injection reservoir." | 1.38 | Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? ( Fujita, K; Imajo, K; Kato, S; Kirikoshi, H; Kobayashi, N; Kubota, K; Maeda, S; Mawatari, H; Nakajima, A; Saito, S; Suzuki, K; Yoneda, M, 2012) |
| "Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulin-like growth factor (IGF)-1 levels." | 1.38 | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. ( Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY, 2012) |
| "Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice." | 1.38 | Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012) |
| "She was diagnosed as advanced sigmoid colon cancer with multiple metastases of lung, liver, and left hydronephrosis." | 1.38 | [A case of pathologically by complete response in advanced sigmoid colon cancer with multiple metastases of lung and Liver, left hydronephrosis after chemotherapy including bevacizumab/FOLFOX6]. ( Hasegawa, H; Kubo, H; Miyahara, M; Nishiyama, M; Tada, K; Yamashita, Y, 2012) |
| "A 31-year-old man with sigmoid colon cancer with concomitant simultaneous multiple liver metastases had received FOLFIRI (leucovorin, fluorouracil and irinotecan) and FOLFOX6 (leucovorin, fluorouracil and oxaliplatin) after an ordinary sigmoidectomy." | 1.38 | Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. ( Kawahara, H; Kitamura, H; Onda, S; Saito, R; Toyama, Y; Ushigome, T; Watanabe, K; Yanaga, K; Yanagisawa, S; Yoshida, S, 2012) |
| "Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super- selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups." | 1.38 | Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. ( Hu, Y; Li, H; Li, N; Zhou, Y, 2012) |
| "The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 1.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
| "Moreover, circulating tumor cells were demonstrated by flow cytometry." | 1.38 | [Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012]. ( Horger, M; Jaschonek, K; Kanz, L; Kopp, HG; Kurth, R; Mayer, F; Orgel, M, 2012) |
| "We report here a case of reversible posterior leukoencephalopathy syndrome(RPLS)induced by modified FOLFOX6(mFOLFOX6)." | 1.38 | [A case of reversible posterior leukoencephalopathy syndrome(RPLS)induced by modified FOLFOX6]. ( Araki, K; Kaneta, T; Matsunaga, M; Miwa, K; Nagashima, F; Nakayama, H; Noguchi, T; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2012) |
| "HAI can be a treatment of choice for esophageal cancer when metastasis is limited to the liver." | 1.38 | [Multimodality therapy containing hepatic arterial infusion chemotherapy for liver metastasis of esophageal cancer-a case report]. ( Hasegawa, H; Ikebe, M; Kitamura, M; Saitoh, G, 2012) |
| "We experienced a rare case of intussusception due to sigmoid colon cancer during chemotherapy." | 1.38 | [A case of intussusception due to sigmoid colon cancer during mFOLFOX6 therapy]. ( Fukino, N; Kano, H; Kawasaki, A; Kida, K; Kuboi, Y; Mimatsu, K; Oida, T, 2012) |
| "Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU." | 1.38 | 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012) |
| "The majority of patients with gastric cancer in developing countries present with advanced disease." | 1.38 | Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. ( Guven, M; Inal, A; Işikdogan, A; Kaplan, MA; Kuçukoner, M; Nas, N; Urakci, Z; Yunce, M, 2012) |
| "The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes." | 1.38 | How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
| "The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC." | 1.38 | Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012) |
| "The metastatic liver cancer was a huge tumor occupying the right hepatic lobe and caudate lobe." | 1.38 | [A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. ( Hasegawa, H; Hashimoto, T; Kabashima, A; Kitagawa, M; Kitamura, M; Kudo, K; Nakamura, T; Shoji, F; Teramoto, S, 2012) |
| "To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 1.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
| "Hyporexia/anorexia is a relevant clinical problem affecting the quality of life of many cancer patients." | 1.37 | Steroids, cancer and vertebral fractures: a dreaded combination. ( Uña Cidón, E, 2011) |
| "Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths." | 1.37 | Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011) |
| "The impact of diabetes mellitus on the treatment of hepatocellular carcinoma, especially chemotherapy, is uncertain." | 1.37 | Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. ( Fang, JL; Feng, YH; Huang, WT; Lin, CY; Tsao, CJ; Wu, CL, 2011) |
| "There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus." | 1.37 | Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| " Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events." | 1.37 | Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. ( Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011) |
| "Next, we showed that nine human colon cancer cell lines established from primary tumors or metastases expressed OX1R mRNA and underwent important apoptosis on orexin-A challenge." | 1.37 | Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. ( Bedossa, P; Descatoire, V; El Firar, A; Fasseu, M; Henin, D; Laburthe, M; Lehy, T; Paradis, V; Rouyer-Fessard, C; Voisin, T; Walker, F, 2011) |
| "FOLFOX plus bevacizumab therapy can be given safely to hemodialytic patients with no reduction in the dose of oxaliplatin if hemodialysis is performed soon after the administration of oxaliplatin and the dosing interval is extended to 3 weeks." | 1.37 | Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ( Chiba, T; Ezoe, Y; Horimatsu, T; Mashimo, Y; Miyamoto, S; Morita, S; Muto, M, 2011) |
| "Histological examinations revealed squamous cell carcinoma." | 1.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "A 50-year-old man with advanced rectal cancer and multiple liver metastases experienced DIC during third-line treatment with cetuximab plus irinotecan, following 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab and 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab." | 1.37 | A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab. ( Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T, 2011) |
| "Here, we report on 2 patients with colorectal cancer and severe liver dysfunction secondary to hepatic metastases." | 1.37 | Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction. ( Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C, 2011) |
| "About 50% of patients with primary colorectal cancer (CRC) will develop liver metastases (CLM)." | 1.37 | Type IV collagen as a tumour marker for colorectal liver metastases. ( Hafström, L; Naredi, P; Nyström, H; Sund, M, 2011) |
| "For the metastatic colorectal cancer LLD population with K-ras wild-type genotype, mean overall survival estimates were 37." | 1.37 | Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. ( Asseburg, C; Frank, M; Griebsch, I; Hartmann, JT; Köhne, CH; Mittendorf, T; Mohr, A; Osowski, U; Schulten, J, 2011) |
| "5-fluorouracil was used as a positive control group, and fluorescence-activated cell-sorting cytometry was used to measure the apoptosis rate of HepG2 cells and the expression of Bcl-2 and caspase-8 proteins." | 1.37 | Hepatocellular carcinoma HepG2 cell apoptosis and caspase-8 and Bcl-2 expression induced by injectable seed extract of Coix lacryma-jobi. ( Jia, ZX; Lu, Y; Lu, ZQ; Wu, WJ; Zhang, BY, 2011) |
| "Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL." | 1.37 | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011) |
| "Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil." | 1.37 | Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011) |
| " A concentration- or dose-response relationship was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity." | 1.37 | Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo. ( Cai-Hong, Z; Fang, M; Jin-Hua, J; Li, H; Ning, W; Qing-Duan, W; Xiao-Juan, G; Yan, Z, 2011) |
| "Metastatic colorectal cancer has a low cure rate." | 1.37 | Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer. ( Afonso, S; Afonso, V; Stefano, E; Viani, G, 2011) |
| "The prognosis of patients with advanced colorectal cancer with icterus is dismally poor, and adequate chemotherapy for these patients has not been established yet." | 1.37 | FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. ( Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T, 2011) |
| "Seven patients with rectal cancers which were difficult to ensure surgical margins for because of huge tumors(over 60mm in diameter), invasion to other organs, or severe nodal metastases, were treated with preoperative chemotherapy consisting of 2-10 courses of mFOLFOX6." | 1.37 | [Pilot study of preoperative mFOLFOX6 chemotherapy for advanced rectal cancers which were difficult to ensure surgical margins]. ( Fuyuhiro, Y; Hirakawa, K; Inoue, T; Kashiwagi, S; Maeda, K; Nagahara, H; Nakamoto, K; Noda, E, 2011) |
| "A 65-year-old male experiencing the recurrence of a solitary sigmoid cancer liver tumor was treated with bevacizumab (Bev)/XELOX chemotherapy, because he had refused surgical resection." | 1.37 | [Recurrent liver sigmoid cancer responding remarkably to neoadjuvant chemotherapy using bevacizumab/XELOX: report of a case]. ( Hamasu, S; Konishi, S; Manaka, D; Nishitai, R; Sakamoto, K; Uehara, M, 2011) |
| "The subject was 28 patients of colorectal cancer with synchronous unresectable liver metastasis who received mFOLFOX6 as a first-line treatment from 2005 to 2010." | 1.37 | [Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer]. ( Amano, K; Chikatani, K; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Iwama, T; Kumamoto, K; Kuwabara, K; Ohsawa, T; Okada, N; Sobajima, J; Tajima, Y, 2011) |
| "Cumulative risks of recurrence were 10." | 1.37 | [Recurrance of disappearing colorectal liver metastases after mFOLFOX6 regimen]. ( Haga, N; Ishibashi, K; Ishida, H; Kumamoto, K; Okada, N; Ono, T, 2011) |
| "The outcomes and management of colorectal cancer (CRC) hepatic metastasis have undergone many evolutionary changes." | 1.37 | Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. ( Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC, 2011) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 1.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "Malignant glucagonoma is an exceptional pancreatic endocrine tumour, with frequent dermatologic symptoms, diabetes and degradation of the general health status." | 1.36 | [Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency]. ( de Mestier, L; Dove, P; Hammel, P; Hentic, O; Lévy, P; Ruszniewski, P, 2010) |
| "Colonoscopy detected rectal cancer and sigmoid al polyps." | 1.36 | [A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy]. ( Baba, K; Ishigami, S; Kitazono, M; Matsushita, D; Natsugoe, S; Ogawa, H; Shinchi, H; Ueno, S, 2010) |
| "We report a resected case of ascending colon cancer with left supraclavicular and paraaortic lymph nodes and liver metastases which completely responded in terms of metastases but not the primary tumor to FOLFOX4 therapy." | 1.36 | [A case of advanced ascending colon cancer, curatively resected after complete response in left supraclavicular and paraaortic lymph nodes and liver metastases to FOLFOX4 therapy]. ( Fuji, H; Furumoto, K; Ito, D; Kogire, M; Kojima, H; Mizuno, R; Mori, T; Okuno, M; Takaya, H, 2010) |
| "Histological response of colorectal cancer liver metastases to chemotherapy may be graded based on the extent of tumor regression." | 1.36 | Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D, 2010) |
| "Capecitabine was started after the occurrence of new multiple lesions; complete regression was reached, which has now lasted over three years with continued capecitabine treatment." | 1.36 | [Long-term response of liver metastases of breast cancer to capecitabine--case report]. ( Macková, D, 2010) |
| "A 35-year-old woman with recurrent breast cancer with liver metastasis was treated with classical CMF because they had been resistant to anthracycline, taxane and vinorelbine." | 1.36 | [A case of recurrent breast cancer with life-threatening liver metastasis remarkably responding to classical CMF]. ( Chishima, T; Hasegawa, S; Ichikawa, Y; Ishikawa, T; Shimizu, D, 2010) |
| "A 51-year-old patient had recurrent breast cancer with liver metastases." | 1.36 | [A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective]. ( Hata, K; Hirai, I; Maebeya, S; Miki, Y; Oota, F; Tanaka, T; Tanino, H, 2010) |
| "In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy." | 1.36 | Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. ( Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L, 2010) |
| "We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W)." | 1.36 | Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. ( Aiura, K; Kitagawa, Y; Matsui, J; Takahashi, S; Ueda, M, 2010) |
| "A close inspection showed progressive stomach cancer with lymph node metastasis." | 1.36 | [A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6]. ( Ishida, T; Iwasaki, T; Kanemitsu, K; Okuda, T; Tanaka, K; Toyokawa, A, 2010) |
| "42%; P = ." | 1.36 | Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. ( Abdalla, EK; Capussotti, L; Contreras, CM; Curley, SA; Kishi, Y; Kopetz, S; Maru, DM; Motta, M; Ravarino, N; Ribero, D; Risio, M; Vauthey, JN; Zorzi, D, 2010) |
| "However, the role of CSCs in colorectal cancer metastasis is unclear." | 1.36 | A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. ( Cheung, LW; Chow, AK; Chu, AC; Lam, CS; Lan, HY; Lan, XR; Law, WL; Ng, L; Pang, R; Poon, JT; Poon, RT; Tan, VP; Wong, BC; Yau, TC, 2010) |
| "CASE 2: A 67-year-old male with colon cancer and liver and lung metastases was referred to our Dept." | 1.36 | [Two cases of unstable angina in patients treated with bevacizumab]. ( Okada, Y; Okura, Y; Takii, Y, 2010) |
| "Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways." | 1.36 | Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010) |
| "Established human hepatocellular carcinoma adriamycin (ADM) multi-drug resistant cell sub-lines models Bel-7402/ADMV, Bel-7402/ADML and Bel-7402/ADMS by three methods of in vitro concentration gradient increased induction, nude mice liver-implanted induction and subcutaneous-implanted induction respectively." | 1.36 | Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. ( Gong, R; Meng, X; Xiong, M; Zhong, X, 2010) |
| "5-fluorouracil was used as a positive control." | 1.36 | Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. ( Chaijaroenkul, W; Itharat, A; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2010) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 1.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| "Most colorectal cancer patients with liver metastases are not resectable upon initial diagnosis." | 1.36 | [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection]. ( Chin, K; Fujimoto, Y; Hatake, K; Ichimura, T; Matsusaka, S; Mitsuhashi, K; Mizunuma, N; Ogura, M; Ozaka, M; Saiura, A; Shinozaki, E; Suenaga, M; Yamamoto, N, 2010) |
| "Six patients of esophageal cancer with liver metastasis and without extra-hepatic metastasis were enrolled." | 1.36 | [Regional treatment of esophageal liver metastasis by intra-arterial low-dose 5-FU therapy]. ( Akutsu, Y; Kaiho, T; Kono, T; Matsubara, H; Natsume, T; Ohira, G; Okazumi, S; Ota, T; Saito, H; Sato, A; Shuto, K; Tohma, T; Uesato, M, 2010) |
| "A 61-year-old female who had sigmoid colon cancer with unresectable multiple lung and liver metastases underwent sigmoidectomy." | 1.36 | [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure]. ( Fujimoto, T; Itagaki, H; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Umehara, A; Yano, Y; Yokomizo, H; Yoshimatsu, K, 2010) |
| "Sigmoidectomy was performed for sigmoid colon cancer in January 2002." | 1.36 | [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]. ( Doki, Y; Hirose, H; Ikeda, M; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S, 2010) |
| "Recent advances in chemotherapy for colorectal cancer prolonged survival." | 1.36 | [Roles of hepatectomy for colorectal liver metastases with necrotic foci caused by prior anti-cancer therapies]. ( Inoue, T; Ishikawa, H; Ko, S; Kunishige, T; Mukogawa, T; Nakamoto, T; Nishiwada, T; Watanabe, A, 2010) |
| "The patient was diagnosed as idiopathic thrombocytopenic purpura (ITP) by several examinations but medical control including steroids failed." | 1.36 | [Idiopathic thrombocytopenic purpura during chemotherapy for liver metastasis of rectal cancer]. ( Ebisui, C; Ide, Y; Kinuta, M; Mikami, K; Momozane, T; Mukai, R; Murakami, M; Murata, K; Nagase, H; Nishigaki, T; Okada, K; Owada, Y; Yamada, M; Yanagisawa, T; Yokouchi, H, 2010) |
| "We report here a case of rectal cancer with synchronous multiple liver metastases successfully treated with a combined chemotherapy of modified FOLFOX6 (mFOLFOX6) and bevacizumab." | 1.36 | [A case of rectal cancer with synchronous multiple liver metastases successfully treated with combined chemotherapy of modified FOLFOX6 and bevacizumab]. ( Andou, S; Kitamura, Y; Tokunou, K; Toshimitsu, H; Tsushimi, K; Yamamoto, T, 2010) |
| "However, G-CSF-producing colorectal cancer (CRC) has never been reported in the English literature." | 1.35 | Granulocyte-colony stimulating factor producing rectal cancer. ( Akamo, Y; Funahashi, H; Ochi, N; Sakamoto, M; Satoh, M; Sawai, H; Takahashi, H; Takayama, S; Takeyama, H; Wakasugi, T; Yasuda, A, 2008) |
| "Final diagnosis of a pleomorphic liposarcoma was made by the routine histology and further identified by Oil Red O stain." | 1.35 | Mesojejunoileac liposarcoma with intrahepatic metastasis in a dog. ( Chang, SC; Liao, JW, 2008) |
| "To observe the effects of the anti-liver cancer pharmacodynamic action of the Rougan Jiedu formula through the experiments of inhibiting cell proliferation of the tumour cell in vitro." | 1.35 | [The study of Rougan Jiedu formula anti-liver cancer in vivtro]. ( Li, H; Wu, CJ, 2008) |
| "Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), methylenetetrahydrofolate reductase polymorphism (677C>T, 1298A>C), thymidylate synthase (TS) activity, dihydropyrimidine dehydrogenase activity, folylpolyglutamate synthase activity, and p53 protein expression." | 1.35 | K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. ( Benchimol, D; Chazal, M; Delpero, JR; Etienne-Grimaldi, MC; Formento, JL; Formento, P; François, E; Francoual, M; Laurent-Puig, P; Letoublon, C; Milano, G; Pezet, D; Renée, N; Seitz, JF, 2008) |
| "Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed." | 1.35 | Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. ( Codecà, C; Di Maria, G; Fazio, N; Ferrari, D; Fiore, J; Foa, P; Luciani, A; Maggioni, M; Oldani, S, 2008) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 1.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "In patients with metastatic colorectal cancer (mCRC), several prognostic factors such as performance status (PS), number of metastatic sites, carcinoembryonic antigen (CEA), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) have been reported." | 1.35 | Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. ( Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008) |
| "d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)." | 1.35 | Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008) |
| "We report a 59-year-old woman with rectal cancer who underwent low anterior resection in March 2007." | 1.35 | [A case with liver resection of metastasis from rectal cancer after FOLFOX4+bevacizumab treatment]. ( Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Uemura, T, 2008) |
| "The basaloid squamous cell carcinoma of the esophagus is highly malignant with poor prognosis." | 1.35 | [Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus]. ( Chen, JX; Tang, Q; Zheng, YD; Zhu, HN, 2008) |
| "Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach." | 1.35 | Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. ( Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE, 2009) |
| "Tree 1-7 on human hepatoma cell line HepG2 cultured in vitro." | 1.35 | [Cytotoxicity of the secondary metabolites of Marine Mangrove Fungus Paecilomyces sp. tree 1-7 on human hepatoma cell line HepG2]. ( Cai, XL; Gao, JP; Li, Q; Lin, YC; She, ZG; Wen, L, 2008) |
| "Of 55 patients with colorectal cancer, 20 had no metastasis and the other 35 had distant metastasis." | 1.35 | Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. ( Akagi, Y; Hattori, S; Kage, M; Kawahara, A; Kuwano, M; Mizobe, T; Ono, M; Shirouzu, K; Yanagawa, T, 2009) |
| "A 62-year-old male presents with colon cancer that has metastasized to both lobes of the liver." | 1.35 | Sequential or combination chemotherapy for a patient with mCRC? ( Arnold, D, 2008) |
| "Recently, standard therapies for either gastric cancer or colorectal cancer have been established through the development of multidrug systemic chemotherapy and the appearance of molecular targeting drugs." | 1.35 | [Hepatic artery infusion chemotherapy to three liver metastasis cases in which systemic chemotherapy was impossible or ineffective]. ( Ando, K; Emi, Y; Endo, K; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Saeki, H; Sugiyama, M, 2008) |
| "The subjects were 13 colorectal cancer patients who had undergone resection of the primary tumor, and showed multiple, unresectable liver metastases and severe liver dysfunction." | 1.35 | [Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction]. ( Iizawa, H; Ikeda, E; Ishiyama, K; Mori, N; Saito, K; Sakurai, N; Sato, T; Suto, T; Takano, N, 2009) |
| "Serum levels of 5-fluorouracil(5-FU)were measured in a patient receiving pharmacokinetic modulation chemotherapy( PMC), with 5-FU, as well as a combination of oxaliplatin and infusional 5-FU plus leucovorin(FOLFOX)." | 1.35 | [Pharmacokinetic monitoring of 5-fluorouracil may improve the clinical benefit with an individualized regimen-a case report]. ( Asakura, T; Hatakeyama, K; Kanda, J; Muneoka, K; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2009) |
| "There were upper gastrointestinal hemorrhage in 3 cases, hepatic failure in 4, pulmonary embolism in 1, cholecystitis in 4, hepatic encephalopathy in 2, gastric perforation in 1, and intrahepatic biloma in 2 cases." | 1.35 | [Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma]. ( Feng, B; Liang, SN; Liu, LL; Su, HY; Xu, K; Zhao, GS, 2008) |
| "We report here two cases of interstitial lung disease occurring in association with the use of this combination chemotherapy." | 1.35 | [Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX)]. ( Kato, S; Miyate, Y; Ogasawara, N; Ohori, H; Suzuki, M; Takahashi, M, 2009) |
| "Floxuridine was conjugated to polyethylenimine-beta-cyclodextrin to form prodrug PEI-beta-CyD-Fd." | 1.35 | [Preparation of floxuridine loaded polycation and its antitumor activity]. ( Chen, D; Jiang, QY; Lu, X; Tang, GP; Wang, QQ; Yu, H; Zhao, DJ; Zhou, J, 2009) |
| "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licensed for the treatment of breast and gastrointestinal cancers." | 1.35 | Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. ( Kolluri, RB; Raouf, S; Tipples, K, 2009) |
| " Transcatheter arterial chemoembolization is a standard treatment option for patients with unresectable HCC, especially when combined with other therapies." | 1.35 | A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization. ( Liu, J; Sui, J; Tian, G, 2009) |
| "Hepatocellular carcinoma was the second most frequent malignancy to be observed--23 patients (18." | 1.35 | [Advanced hepatic resection for malignancy]. ( Kotel'nikov, AG; Patiutko, IuI; Pylev, AL; Sagaĭdak, IV, 2009) |
| "The patient was diagnosed stageIV rectal cancer and resected primary focus and lymph node metastasis." | 1.35 | [A successfully resected case of rectal cancer with liver metastases treated with mFOLFOX6 and bevacizumab]. ( Fujino, Y; Fujita, T; Kanaji, S; Kanbara, Y; Kawasaki, K; Kobayashi, I; Nakamura, T; Ohno, M; Osawa, M; Tsuchida, S; Ueno, K, 2009) |
| "To determine the influence of HBx gene RNA interference combined with chemotherapy on stable hepatocellular carcinoma cells growth and its apoptosis mechanism." | 1.35 | [Effect of HBx gene RNA interference combined with chemotherapy on hepatocellular carcinoma cells]. ( He, X; He, Y; Lei, J; Sun, H; Wang, W, 2009) |
| ": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options." | 1.35 | Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009) |
| "To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE)." | 1.35 | [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. ( Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK, 2009) |
| "5-Fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle." | 1.35 | Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? ( Rajebi, MR; Saif, MW; Shahrokni, A, 2009) |
| "Once interstitial pneumonia has occurred, cessation of the regimen is mandatory, and high-dose corticosteroid treatment is commonly given to rescue patients from this potentially lethal complication." | 1.35 | Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). ( Hatakeyama, K; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakai, T, 2009) |
| "We experienced this AFP-producing gastric cancer in which CR was possible by FLEP." | 1.35 | [Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case]. ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T, 2009) |
| "Drug-induced interstitial pneumonitis was suspected, and Pneumocystis carini pneumonia was considered in the differential diagnosis." | 1.35 | [A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer]. ( Baba, N; Ishigami, S; Kitaguchi, K; Nakauchi, M; Nakayama, Y; Ohe, H; Sakikubo, M; Taira, K; Tamura, J; Ura, K; Yoshikawa, A, 2009) |
| "NAC by FOLFOX for liver metastasis of colorectal cancer showed a high reduction rate, and there was a little influence to hepatectomy indicating that FOLFOX could be an effective therapy." | 1.35 | [Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis]. ( Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M, 2009) |
| "We thought a gastric cancer patient with liver metastasis who didn't have an uncontrollable other organ metastasis was a good target for this regimen." | 1.35 | [Evaluation of hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer]. ( Kawahira, H; Matsubara, H; Nabeya, Y; Natsume, T; Ohira, G; Ota, T; Saito, H; Sato, A; Shuto, K, 2009) |
| "A man in his fifties with rectal cancer underwent low anterior resection in another Hospital in January 2006." | 1.35 | [A case of liver metastasis of rectal cancer demonstrating complete response for more than two years to mFOLFOX6]. ( Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Oshima, S; Sakamoto, T, 2009) |
| "We report a case of rectal cancer with unresectable multiple liver metastases, which was worried about the transition from liver dysfunction to liver failure." | 1.35 | [A case of advanced rectal cancer with severe liver dysfunction due to multiple liver metastases]. ( Enomoto, M; Fujimori, Y; Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kobayashi, H; Oda, G; Okazaki, S; Sugihara, K; Tsukamoto, S; Uetake, H; Yasuno, M, 2009) |
| "We report a case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor." | 1.35 | [A case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor]. ( Hazama, S; Nakatsu, H; Oka, M; Tokuhisa, Y; Tomochika, S; Yoshida, S; Yoshino, S, 2009) |
| "A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT." | 1.35 | [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009) |
| "All 35 patients had metastatic pancreatic cancer (94% liver, 6% lung sites)." | 1.35 | The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. ( Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J, 2008) |
| "However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear." | 1.35 | Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. ( Higami, K; Ikehara, T; Kanayama, M; Matsui, T; Miki, K; Miyaki, D; Momiyama, K; Nagai, H; Sumino, Y; Watanabe, M, 2008) |
| "Neoadjuvant chemotherapy for metastatic colorectal cancer may render some unresectable patients resectable, affording these patients the possibility of prolonged survival." | 1.35 | [A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6]. ( Fukuda, H; Hirokawa, S; Nagata, T; Sawada, S; Tazawa, K; Tsukada, K; Uotani, H; Yamagishi, F, 2008) |
| " Although this patient could accept it relatively safely without any severe side effect, the optimal dosage and the timing of hemodialysis for inoperable metastatic colorectal cancer patients should be determined by a further study using more cases." | 1.35 | [Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ( Ehara, K; Hasebe, S; Hashimoto, M; Hayashi, M; Igarashi, M; Ito, T; Katori, H; Kinoshita, Y; Matoba, S; Matsuda, M; Mine, S; Moriyama, J; Sato, M; Sawada, T; Toda, S; Tsutsumi, K; Udagawa, H; Ueno, M; Watanabe, G; Yokoyama, T, 2008) |
| "Ninety-six resections for colorectal cancer hepatic metastases performed from July 2001 to July 2003 (93% > or =2 segments) were reviewed." | 1.34 | Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. ( Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A, 2007) |
| "About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases." | 1.34 | Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? ( Amisano, M; Bouzari, H; Capussotti, L; Massucco, P; Muratore, A; Sperti, E; Zorzi, D, 2007) |
| "We developed a recombinant defective adenovirus with an insert of gene encoding extracellular domain of mouse Flt3L (Ad-mFlt3L) under control of cytomegalovirus promoter to investigate the biological efficacy of Flt3L in combination with chemotherapeutical drug, 5-FU, in eliciting an effective anti-cancer immunity in mouse hepatoma and colon cancer model systems." | 1.34 | Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. ( Dai, J; Fan, X; Guo, Y; Hou, S; Kou, G; Li, B; Li, J; Lin, B; Ma, J; Qian, W; Wang, H; Wu, M; Zhang, D; Zhao, J, 2007) |
| "Liver metastases are the most common cause of death in gastric ECs, and their control is very important for improving the poor prognosis associated with the disease." | 1.34 | A successful treatment for metastatic liver tumors from endocrine carcinoma of the stomach. ( Fujiyama, Y; Nishimura, M, 2007) |
| "Here, we report the case of a sigmoid colon cancer patient with initially unresectable hepatic metastases showing a prolonged survival (6." | 1.34 | [A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases]. ( Gega, M; Hashimoto, A; Ikeuchi, H; Kuno, T; Noda, M; Oshima, T; Tanaka, K; Tsukamoto, K; Yagyuu, T; Yamamura, T; Yanagi, H; Yoshikawa, R, 2007) |
| "Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes." | 1.34 | Male breast cancer with mandibular metastasis. A case report. ( Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S, 2007) |
| " In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC." | 1.34 | Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007) |
| "However, severe hyperbilirubinemia (grade 3/4) has not been previously reported in association with this chemotherapeutic agent." | 1.34 | Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. ( Fakih, MG; Gupta, B; LeVea, C; Litwin, A, 2007) |
| "A case of colorectal cancer in a 60-year-old man became resectable after downstaging was achieved with mFOLFOX 6 for multiple liver metastases from colorectal cancer." | 1.34 | [A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer]. ( Abe, T; Aoki, T; Ishizaki, T; Katsumata, K; Koyanagi, Y; Tsuchida, A; Wada, T, 2007) |
| "Cell proliferation assay in human hepatoma cells (HepG 2) was performed using 5-FU and/or various IFNs-alpha (C-IFN, Intron A, OIF)." | 1.34 | [Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells]. ( Fan, XY; Iwaki, K; Kai, S; Kitano, S; Ohta, M; Shibata, K; Uchida, H, 2007) |
| "Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
| "Case 1 was a 71-year-old woman with a hepatocellular carcinoma (HCC), 45 mm in diameter, with liver cirrhosis." | 1.34 | [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy]. ( Hirashita, T; Nakashima, K; Sakai, I; Sakai, M, 2007) |
| " The authors administered arterial infusion of 5-fluorouracil (5-FU) combined with concurrent radiation therapy to enhance the antitumor effect of chemotherapy." | 1.34 | Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study. ( Anai, H; Kichikawa, K; Morimoto, K; Sakaguchi, H; Tamamoto, T; Tanaka, T; Yamamoto, K, 2007) |
| "Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease." | 1.34 | Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. ( Arita, S; Ariyama, H; Baba, E; Kusaba, H; Miki, R; Mitsugi, K; Nakano, S; Noshiro, H; Ogami, N; Qin, B; Shibata, Y; Yao, T, 2007) |
| " In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen." | 1.34 | [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| "All patients died from neoplastic disease progression despite further chemotherapy at 6, 17 and 31 months following the diagnosis of NRH." | 1.34 | Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? ( Canon, JL; Ceratti, A; Gigot, JF; Horsmans, Y; Hubert, C; Humblet, Y; Machiels, JP; Rahier, J; Sempoux, C, 2007) |
| "All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed." | 1.34 | [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. ( Chen, L; Fan, Y; Fu, L; Guo, XJ; Lang, RG; Sun, YL, 2007) |
| "The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed." | 1.34 | [Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer]. ( Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD, 2007) |
| "In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice." | 1.34 | Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007) |
| "Treatment with capecitabine and erlotinib in gemcitabine-refractory patients was associated with an overall objective radiologic response rate of 10% and a median survival duration of 6." | 1.34 | Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. ( Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX, 2007) |
| "Liver metastasis is an important prognostic factor in colorectal cancer." | 1.34 | Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency. ( Higuchi, R; Koda, K; Kosugi, C; Sugimoto, M; Suzuki, M; Takenoue, T; Tezuka, T; Watayo, Y; Yagawa, Y; Yamamoto, S; Yamazaki, M; Yasuda, H, 2007) |
| "A 59-year-old man who had rectal cancer, multiple liver metastases and para-aortic LN metastasis underwent a laparoscopic rectal anterior resection." | 1.34 | [A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11]. ( Ide, Y; Kinuta, M; Maruyama, K; Murata, K; Ohta, H; Okada, K; Yasumoto, T; Yokouchi, H, 2007) |
| "5-fluorouracil (5-FU) is a basic agent used in chemotherapy." | 1.34 | Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007) |
| "Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 1.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
| "The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor." | 1.33 | Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. ( Aoyama, K; Ishikawa, T; Kawaguchi, K; Kimura, T; Kurokawa, F; Okita, K; Omori, K; Sakaida, I; Tajima, K; Takami, T; Terai, S; Tsuchiya, M; Yamasaki, T; Yokoyama, Y, 2005) |
| "Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor." | 1.33 | [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005) |
| " 5-FU serum concentrations were higher at night time and the peak concentration of 5-FU was obtained at 3 a." | 1.33 | [Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| "A 72-year-old man who had multiple hepatocellular carcinoma underwent eight times intrahepatic arterial chemotherapies of SMANCS and two times percutaneous ethanol injection (PEIT) therapies over three years, but new diffuse lesions appeared in the liver." | 1.33 | [A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU]. ( Arima, T; Horino, K; Inoue, M; Kimura, M; Kuhara, H; Nishimura, T; Uemura, K; Yamada, K, 2005) |
| "Treatment for advanced stages of hepatocellular carcinoma (HCC) remains unsatisfactory." | 1.33 | The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. ( Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S, 2005) |
| "Twenty-three patients with colorectal cancer and isolated liver metastases were enrolled in this trial." | 1.33 | Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver. ( Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M, 2005) |
| "Drug treatment of colorectal cancer has made impressive progress during the past 10 years." | 1.33 | [Systemic therapy for colorectal cancer]. ( Jäger, D; Knuth, A; Pestalozzi, BC, 2005) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "An in situ human hepatocellular carcinoma model was established in mice livers orthotopically." | 1.33 | Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. ( Lin, RX; Lü, QJ; Tuo, CW; Wang, SQ; Zhang, W, 2005) |
| "Severe steatohepatitis can be associated with preoperative administration of irinotecan or oxaliplatin, especially in the obese." | 1.33 | Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. ( Fernandez, FG; Goodwin, JW; Hawkins, WG; Linehan, DC; Ritter, J; Strasberg, SM, 2005) |
| "Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation." | 1.33 | 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005) |
| "The prognosis of hepatocellular carcinoma (HCC) with tumor thrombosis of the main trunk or major branches of the portal vein (mPVTT) is extremely poor, even if it is curatively resected." | 1.33 | Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. ( Mimura, T; Niguma, T; Tutui, N, 2005) |
| "While 5-Fu causes mainly apoptosis in hepatoma cells, the anticancer mechanism of paclitaxel is predominantly through induction of necrosis." | 1.33 | [Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells: a comparative study]. ( He, JB; Ji, MF; Li, XL; Yu, YL, 2005) |
| "Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude." | 1.33 | Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases. ( Anselmi, E; Bertè, R; Bidin, L; Cavanna, L; Civardi, G; Lazzaro, A; Moroni, CF; Palladino, MA; Rodinò, C; Vallisa, D, 2005) |
| " These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval." | 1.33 | [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005) |
| "Hepatocellular carcinoma (HCC) and pancreatic cancer are at the forefront of chemotherapy-resistant tumors with poor prognosis." | 1.33 | 5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. ( Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Tada, M; Yokosuka, O, 2005) |
| "A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt." | 1.33 | [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005) |
| "She was diagnosed with advanced cecal cancer with simultaneous multiple liver metastases." | 1.33 | [A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy]. ( Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y, 2005) |
| "Diffused hepatoma was involved in the posterior lobe, and tumor thrombus extended into the main portal vein (Vp4)." | 1.33 | [A case report of hepatocellular carcinoma (Vp4)--an attempt to reduce residual tumor thrombus using combination therapy (hepatic arterial infusion, hepatic arterial embolization and radiation)]. ( Ebisui, C; Fujimoto, T; Fujiwara, S; Fukuchi, N; Hasuike, Y; Hayashi, N; Izumiyama, K; Kida, H; Koshino, T; Sakita, I; Tsujie, M; Yoshida, T, 2005) |
| "For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33." | 1.33 | [Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005) |
| "Patients with bilobar colorectal cancer metastases to the liver present a unique problem in terms of resection." | 1.33 | Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved. ( Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL, 2006) |
| "The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history." | 1.33 | 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 1.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "To study the effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer." | 1.33 | [Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]. ( Chen, G; Lin, SX; Lu, ZH; Ren, JQ; Tang, SX; Wan, DS; Wang, GQ; Ye, YL; Zhou, ZW, 2006) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 1.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
| "A 73-year-old man was admitted for sigmoid colon cancer with multiple hepatic metastases." | 1.33 | [A case of hepatic metastases of sigmoid colon cancer which completely responded to systemic l-leucovorin/5-FU therapy and oral LV/UFT combination therapy]. ( Ishigame, T; Ishii, Y; Okayama, H; Takahashi, M, 2006) |
| "Most pulmonary metastases of hepatic cancer were hypervascular and the lipiodol deposited well in the nodules; during the follow-up, the nodules shrunk significantly and kept stable." | 1.33 | [Blood supply of pulmonary metastases and its clinical significance]. ( Chen, YX; Jiang, GM; Tian, F; Zhao, JW, 2006) |
| " Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen." | 1.33 | Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. ( Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ, 2006) |
| "Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m(2) over 30 min on day 1 combined with leucovorin 200 mg/m(2) over 2 h followed by 5-fluorouracil 400 mg/m(2) as bolus and 600 mg/m(2) as a 22-hour infusion on day 1 and 2." | 1.33 | Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. ( Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U, 2006) |
| " 3DCRT was given with the field covering the tumor with a generous margin." | 1.33 | [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma]. ( Chen, Z; Cheng, WW; Jiang, GL; Lin, JH; Liu, LM; Meng, ZQ; Zhang, XJ; Zhou, ZH, 2006) |
| "The growth and metastasis of human gastric cancer implanted in SCID mice were significantly inhibited in SU6668 group and combined group, especially in combined group." | 1.33 | [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]. ( Jiang, XT; Tao, HQ; Zou, SC, 2006) |
| "The failure to treat gastric cancer is often due to the recurrence or dismal metastasis of cancer and the poor response to traditional chemotherapeutic or radiotherapeutic regimens." | 1.33 | [Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice]. ( Wang, B; Wang, N; Wang, YJ, 2006) |
| " We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer." | 1.33 | [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. ( Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006) |
| "The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease." | 1.33 | A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. ( Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Martínez Banaclocha, N; Pons Sanz, V; Rodríguez Lescure, A, 2006) |
| "The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal." | 1.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
| "As leukopenia was seen after the first cycle, the administration doses were reduced and GTX has been continued for a total 13 cycles." | 1.33 | [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. ( Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H, 2006) |
| "An advanced colon cancer of the cecum was found with a colonoscopy." | 1.33 | [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. ( Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Miyake, Y; Oshima, K; Oshima, S; Yamamoto, H, 2006) |
| "Recently, we reported the beneficial effects of intra arterial 5-FU infusion chemotherapy combined with interferon-alpha (IFN-alpha/5-FU combined chemotherapy) for advanced hepatocellular carcinoma (HCC)." | 1.33 | [Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study]. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H, 2006) |
| " Only the initial 1 course was administered with 5-FU (500 mg/body) as an inpatient, and further courses were performed as an outpatient with no severe adverse events." | 1.33 | A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases. ( Fujiwara, T; Gochi, A; Kagawa, S; Tanaka, N; Teraishi, F; Uno, F, 2006) |
| "We report a case of advanced hepatocellular carcinoma (HCC)." | 1.33 | [Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL]. ( Amano, M; Fujita, M; Hayashida, H; Higaki, N; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M; Yamashita, S, 2006) |
| "The histological diagnosis was undifferentiated carcinoma of sigmoid colon." | 1.33 | [A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy]. ( Iwazawa, T; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H, 2006) |
| " Resection of liver metastases from SBA combined with neoadjuvant and adjuvant chemotherapy can result in extended disease-free survival and should undergo further investigation." | 1.33 | Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report. ( Eigenbrod, T; Klebl, F; Kullmann, F, 2006) |
| "Between July 1999 and August 2001, 95 cancer patients were evaluated." | 1.32 | Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? ( Carnaghi, C; Castagna, L; Fallini, M; Magagnoli, M; Masci, G; Pedicini, V; Santoro, A; Sarina, B; Zucali, PA, 2003) |
| "The prognosis and QOL of unresectable pancreatic cancer are very poor." | 1.32 | [A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1]. ( Endo, W; Fujito, T; Goda, F; Hojo, S; Maeura, Y; Matsuyama, J; Yamazaki, K; Yano, Y, 2003) |
| "Median time to disease progression was 9." | 1.32 | Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003) |
| "Liver metastasis from colorectal cancer remains an oncological challenge." | 1.32 | Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy. ( Blair, SL; Chu, DZ; Cullinane, C; Dean, G; Grant, M; Schwarz, RE; Wagman, L, 2003) |
| " The effects of 18 covariables on pharmacokinetic parameters were also studied in a univariate correlation analysis." | 1.32 | Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. ( De Vries, EG; Groen, HJ; Maring, JG; Piersma, H; Uges, DR; van Dalen, A, 2003) |
| "The patient was diagnosed with advanced gastric cancer (type-3) with lymphangitis carcinomatosa of the lung." | 1.32 | [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1]. ( Kawabata, H; Murata, A; Nakajima, H; Takase, I; Watanabe, T, 2003) |
| "Drugs pharmacokinetic control is a usual practice in case of flat continuous infusions." | 1.32 | [Modeling 5-FU clearance during a chronomodulated infusion]. ( Chevalier, V; Chevrier, R; Chollet, P; Cure, H; Kwiatkowski, F; Richard, D, 2003) |
| "A syngeneic rat model of hepatocellular carcinoma was used." | 1.32 | [Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003) |
| " Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)." | 1.32 | [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003) |
| "Primary hepatic squamous cell carcinoma is rare." | 1.32 | A case report of primary hepatic squamous cell carcinoma that remarkably responded to low dose arterial injection of anti-cancer drugs. ( Kaji, R; Nagata, E; Okabe, Y; Sasaki, N; Sata, M; Tateishi, I; Ueno, T; Yoshida, T, 2003) |
| " Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation." | 1.32 | [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy]. ( Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003) |
| "The prognosis of advanced hepatocellular carcinoma remains poor." | 1.32 | Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2003) |
| "5 patients with colorectal cancer with multiple liver metastases underwent resection of primary lesions." | 1.32 | [Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer]. ( Abe, N; Ishii, Y; Itou, T; Nakayama, K; Takahashi, M, 2003) |
| "Human hepatoma HepG2 cells were treated with 5-Fu at the concentrations of 1X10(-1), 1X10(-2), 1X10(-3), 1X10(-4), 1X10(-5) mol/L and for 1, 2, 4, 8, 16, 24 hours, respectively." | 1.32 | Caspase-8 in apoptosis of hepatoma cell induced by 5-fluorouracil. ( Yang, LY; Yi, TB, 2003) |
| "Nineteen patients with far advanced hepatocellular carcinoma received transarterial hepatic chemotherapy." | 1.32 | [Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy]. ( Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Kitamura, S; Masuda, F; Masutani, S; Obana, T; Ohnishi, H; Saeki, N; Shimizu, J; Takamura, M; Tatsuta, M; Tomotsu, K; Yura, M, 2003) |
| "We performed radiofrequency ablation (RFA) therapy combined with intrahepatic arterial infusion chemotherapy for 7 patients with liver metastasis from colorectal cancer." | 1.32 | [Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Oosaki, T; Otsuka, S; Sakata, T; Takahashi, M, 2003) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor." | 1.32 | [A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha]. ( Danno, M; Dono, K; Hatanaka, T; Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Monden, M; Nagano, H; Nakamori, S; Naoi, Y; Ohshima, S; Sakon, M; Tsujie, M; Umeshita, K; Yamamoto, H, 2003) |
| "We report a rectal cancer case with liver and lung metastases treated successfully with this protocol." | 1.32 | [A case of liver and lung metastases of rectal cancer responding well to 5-FU hepato-arterial infusion (HAI) with combined use of oral UFT]. ( Ebuchi, M; Hasegawa, K; Kato, K; Maruyama, M; Nagahama, T; Shinoura, H; Takashima, I, 2003) |
| "The patient was a 55-year-old man with sigmoid colon cancer and multiple hepatic metastases, 5 cm in diameter, in both lobes of the liver." | 1.32 | [A case of multiple hepatic metastases from colorectal cancer effectively treated by arterial infusion therapy with Leucovorin/5-FU]. ( Goi, T; Hirono, Y; Hirose, K; Iida, A; Ishida, M; Katayama, K; Kimura, T; Maeda, H; Murakami, M; Yamaguchi, A, 2003) |
| "Etodolac did not increase the inhibitory effect of 5-FU on cell proliferation." | 1.32 | Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. ( Hirakawa, K; Matsunaga, N; Nishiguchi, Y; Nishino, H; Ohira, M; Seki, S; Tachimori, A; Yamada, N, 2004) |
| "Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used." | 1.32 | The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004) |
| "To investigate the effect of a phosphorothioate antisense oligodeoxynucleotide "ASOND" combined with cis-Diamminedichloroplatinum (DDP), 5-fluorouracil (5-FU) and adriamycin (ADM) respectively on inhibiting the proliferation of HepG2 cells." | 1.32 | [Synergism of an antisense oligodeoxynucleotides targeted to hTERT in combination with chemotherapeutic drugs on inhibiting the proliferation of HepG2 cells]. ( Du, QY; Wang, SQ; Yang, Y, 2003) |
| "Twenty-five consecutive patients with rectal cancer were included, with tumor stages (c)T(2-4)N(x)M(0), during the period 1997-1999." | 1.32 | 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. ( Alvarez, E; Arranz, JA; Calvo, FA; Carreras, JL; Desco, M; Domper, M; Martínez-Lázaro, R; Matute, R, 2004) |
| "Patients with liver metastases of colorectal cancer were treated with 5-FU (500/600 mg/m)+folinic acid with or without trimetrexate." | 1.32 | 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. ( Heerschap, A; Kamm, YJ; van den Bergh, EJ; Wagener, DJ, 2004) |
| "A 58-year-old man who had colon cancer with liver and multiple lung metastases underwent ileocecal resection on May 10, 2002." | 1.32 | [A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11]. ( Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T, 2004) |
| " He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11." | 1.32 | [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. ( Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004) |
| "Four patients had primary liver cancers." | 1.32 | A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy. ( Danenberg, K; Danenberg, P; Formentini, A; Hillenbrand, A; Kornmann, M; Salonga, D; Sander, S; Staib, L, 2004) |
| "Colon and rectal cancer are in France a challenging problem in public health, reaching the second place in cancer related deaths." | 1.32 | [Colorectal cancer: what should be the management of primary tumour?]. ( Delpero, JR; Lelong, B; Moutardier, V, 2004) |
| "Rare reports of intestinal obstruction have been confined to the stiff plastic and stainless-steel stents." | 1.32 | A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). ( Ho, HS; Ong, HS, 2004) |
| "We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin." | 1.32 | [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. ( Aoki, T; Ichimiya, H; Kato, K; Katsumata, K; Okada, K; Wakana, Y, 2004) |
| "The expression of the FasL gene in colorectal cancer cells is related to immune evasion to escape from being killed by immune cells, showing stronger drug-resistance, and it facilitates hepatic metastasis." | 1.32 | Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma. ( An, P; Cai, HY; Li, SY; Wei, JC; Yu, B; Zuo, FY, 2004) |
| "We report a patient with metastatic colon cancer who developed a hypersensitivity reaction to oxaliplatin during the sixth cycle of combination chemotherapy with oxaliplatin, high-dose 5-fluorouracil and leucovorin." | 1.32 | Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. ( Chang, MC; Chang, YF; Hsieh, RK; Huang, MJ; Lim, KH; Lin, HC; Lin, J; Su, YW, 2004) |
| "In patients with liver metastases from colorectal cancer, survival can be increased by hepatic resection." | 1.32 | Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. ( Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D, 2004) |
| "The prognosis of breast cancer patients with liver metastases is extremely poor." | 1.32 | Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. ( Jassem, J; Sosińska-Mielcarek, K; Zaucha, R, 2004) |
| " S-1 has safe and potent antitumor effects in patients with gastric cancer via these respective functions." | 1.32 | Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis. ( Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Okazaki, H; Oshitani, N; Sasaki, E; Shiba, M; Suto, R; Tanigawa, T; Tominaga, K; Watanabe, T, 2004) |
| "Sigmoidectomy was performed for sigmoid colon cancer in 1991." | 1.32 | [A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy]. ( Beppu, T; Doi, K; Egami, H; Ishiko, T; Morinaga, H; Nakagawa, M; Sugiyama, S; Tanaka, H; Yamane, T, 2004) |
| "For synchronous liver metastases from rectal cancer, after extirpation of the primary lesion, a transcatheter arterial embolization was postoperatively performed 3 times at 6-month intervals." | 1.32 | [Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report]. ( Ishimaru, S; Kanayama, T, 2004) |
| "To study the anti-tumor effect of resveratrol and in combination with 5-FU on murine liver cancer." | 1.32 | Effect of resveratrol and in combination with 5-FU on murine liver cancer. ( Meng, KW; Pan, CE; Qin, XL; Sun, ZJ; Wu, SL; Yu, L, 2004) |
| "After surgical resection of colon cancer, he suffered a multiple liver metastasis." | 1.32 | [A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery]. ( Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T, 2004) |
| "The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein." | 1.32 | Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004) |
| "Pancreatic cancer is considered a disease with a poor prognosis even if aggressive resection is performed." | 1.32 | Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. ( Inoue, S; Kaneko, T; Kawase, Y; Nakao, A; Nakayama, S; Takeda, S, 2004) |
| "The prognosis of gastric cancer with liver metastasis is very poor." | 1.32 | [Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion]. ( Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Shirouzu, K; Takeda, J; Yano, S, 2004) |
| "Docetaxel will be a key drug for the gastric cancer." | 1.32 | [A case report of the 8 year survivor--unresectable liver metastases from advanced gastric cancer (Stage IV) were completely responsive, after 4 years from a total sequential gastrectomy, combining docetaxel treatment to regress the recurrence]. ( Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Ohshima, S; Tsujie, M; Yamamoto, H, 2004) |
| "Case 1: A 67-year-old male with gastric cancer." | 1.32 | [Three successful case reports of advanced gastric cancer with chemotherapy]. ( Fukunaga, K; Kawai, M; Kotobuki, T; Niinobu, T; Taniguchi, H; Yamamoto, M, 2004) |
| "We performed radio-frequency ablation (RFA) therapy combined with intra-arterial chemotherapy for a 71-year old female gastric cancer patient with liver metastasis." | 1.32 | [A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy]. ( Imaizumi, H; Kamei, K; Kosaka, T; Nakano, Y; Takashima, S; Ueno, K; Usami, K, 2004) |
| "Sigmoid colon cancer and hepatocellular cancer (S5, S6, S8) were diagnosed before surgery." | 1.32 | [The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient]. ( Hamada, H; Katsuki, Y; Takada, J; Tsuji, Y, 2004) |
| "To explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence." | 1.32 | [The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence]. ( Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004) |
| "Advanced pancreatic cancer is mainly treated by chemotherapy with poor prognosis." | 1.32 | [Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer]. ( Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX, 2004) |
| "Twenty patients with advanced gastric cancer received biweekly regimen of CF/5-FU/PTX (200 mg/m(2) of CF, intravenous infusion for 2 h, day 1; 500 mg/m(2) of 5-FU, intravenous injection, day 1; 1 500 mg/m(2) of 5-FU, intravenous infusion for 46 h, day 1, 2; 90 mg/m(2) of PTX, intravenous infusion for 3 h,day 1)." | 1.32 | [Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer]. ( Feng, JF; Lu, JW; Sun, XF, 2004) |
| "Twenty-four patients with advanced gastric cancer who had been treated by multiple chemotherapy regimens presenting poor responses were allotted." | 1.32 | [Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer]. ( Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ, 2004) |
| "We report a patient with esophageal cancer with concomitant liver metastasis in whom complete response was achieved by chemoradiation therapy." | 1.31 | Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy. ( Hiramoto, J; Murakami, S; Nagayama, K; Nakada, T; Sakabe, S; Tsuruta, Y, 2002) |
| "We report a case of inoperable gastric cancer with multiple liver metastases, which responded significantly to the short-term administration of TS-1 following intravenous FMP therapy." | 1.31 | [Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization]. ( Chinzei, T; Okada, Y; Tasaka, K; Tomofuji, Y, 2002) |
| "We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
| "During the follow-up, an elevated squamous cell carcinoma antigen (SCC Ag) level led to restaging computed tomography scans, which confirmed recurrent metastatic disease in the liver." | 1.31 | Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. ( Bolton, M; Copur, S; Frankforter, S; Fruehling, RM; Ledakis, P; Mleczko, KL; Muhvic, J; Norvell, M; Novinski, D; VanWie, E, 2001) |
| " Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co." | 1.31 | [A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin]. ( Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002) |
| "Six patients with metastatic liver cancer (H3) and abnormal laboratory data for liver function underwent intra-hepatic arterial infusion (H." | 1.31 | [Hepatic arterial infusion of high-dose 5-FU to liver metastases--case reports of 6 patients with abnormal laboratory data on liver function]. ( Inoue, M; Ishikawa, H; Nakayama, T; Oshima, S; Yukawa, M, 2002) |
| "We report a case of primary liver carcinoid." | 1.31 | [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes]. ( Hasuike, Y; Takeda, Y; Tujinaka, T; Ueda, S; Yoshida, K, 2002) |
| "Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)." | 1.31 | [Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC]. ( Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002) |
| "The prognosis of patients with advanced hepatoma is grim." | 1.31 | Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. ( Goto, T; Hoshida, Y; Kato, N; Moriyama, M; Omata, M; Otsuka, M; Seki, N; Shiratori, Y; Taniguchi, H, 2002) |
| "The VIPoma syndrome is rare." | 1.31 | Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. ( Barbier, JP; Berger, A; Carnot, F; Cellier, C; Cuillerier, E; Haddad, C; Landi, B; Siauve, N; Yaghi, C, 2000) |
| " In this study, the pharmacokinetic parameters of 5-FU are monitored in six patients, who received two chemotherapeutic courses of 2,600 mg/m2 BSA 5FU over 24 h, one course with 700 mg/m2 BSA amifostine prior to the 5-FU infusion and the other without." | 1.31 | Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma. ( Fuhlroth, J; Martens-Lobenhoffer, J; Ridwelski, K, 2000) |
| "5-fluorouracil (1,000 mg) was administered via the catheter 24 hours/week using an implantable vascular device and a small disposable pump in his home." | 1.31 | [A case of multiple liver metastases from colon cancer successfully operated after intraarterial chemotherapy performed in home]. ( Koh, T; Kunishima, S; Taniguchi, H; Yamagishi, H; Yamaguchi, A, 2000) |
| "Treatment of a patient with carcinoid metastases in the liver is discussed." | 1.31 | Targeted chemoembolization of tumors with poly(2-hydroxyethyl methacrylate) particles. ( Adamyan, A; Gumargalieva, K; Guseinov, E; Horák, D; Kokov, L; Skuba, N; Tchjao, A; Titova, M; Trostenyuk, N; Tsvirkun, V; Vishnevskii, V, 2000) |
| "We report a case of far advanced breast cancer showing an excellent response to chemo-endocrine therapy." | 1.31 | [A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy]. ( Hayashi, K; Kasuga, Y; Kondo, R; Munakata, Y; Nishimura, H; Takasuna, K, 2000) |
| "Methylene blue injection was used to identify anomalous arterial anatomy, which was found in 26 of 95 patients (27%), and significant extrahepatic 'access', which was seen in 25 patients (26%) after initial placement." | 1.31 | Hepatic artery access ports: recognizing and avoiding the problems. ( Cannan, RJ; Stubbs, RS; Wickremesekera, JK, 2000) |
| "Most nonendocrine pancreatic neoplasms are adenocarcinomas of ductal cell or acinar origin." | 1.31 | Squamous cell carcinoma of the pancreas with cystic degeneration. ( Colarian, J; Fowler, D; Poolos, S; Schor, J, 2000) |
| "Under a diagnosis of locally advanced breast cancer (T4bN2M1, stage IV) with liver metastases, we attempted sequential neoadjuvant chemotherapy." | 1.31 | [A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer]. ( Fukuda, H; Fukuda, K; Kim, YH; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T, 2000) |
| "We report a case of advanced rectal cancer accompanied by unresectable liver metastasis in which remission has been achieved for 7 years." | 1.31 | [A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective]. ( Baba, H; Kikunaga, H; Matsudo, A; Miura, H; Morisue, A; Nakai, H; Osakabe, Y; Sotome, K; Takao, M, 2000) |
| "We encountered a case of unresectable colon cancer that disappeared following pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)]. ( Asahara, T; Nakahara, H; Nakahara, M; Okajima, M; Yano, M, 2000) |
| "A case of hepatocellular carcinoma (HCC) complicated by tumor thrombosis of the main trunk is presented." | 1.31 | Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2000) |
| "Our experience of arterial infusion chemotherapy combined with regional hyperthermia in the treatment of non-resectable pancreatic cancer was presented." | 1.31 | [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival]. ( Endo, Y; Ikeda, H; Matumoto, Y; Miura, T, 2000) |
| " Intermittent hepatic arterial infusion of high-dose 5-FU was started on a weekly schedule and oral UFT was added as pharmacokinetic modulating chemotherapy 4 weeks after the initial chemotherapy." | 1.31 | [A successful case of preoperative intermittent hepatic arterial infusion of high-dose 5-FU and pharmacokinetic modulating chemotherapy against unresectable liver metastasis of colon cancer]. ( Hamazaki, K; Inagaki, M; Kawashima, T; Morichika, T; Sadamori, H; Shima, Y; Tanaka, N; Uetsuka, H; Yagi, T, 2000) |
| "For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival." | 1.31 | [Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers]. ( Hirakawa, K; Nishino, H; Ohira, M; Shimizu, S; Tamamori, Y; Tanaka, H; Yamada, N, 2000) |
| "A total of 18 patients (13: colon cancer, 5: gastric cancer) with multiple liver metastases (H3) underwent hepatic arterial infusion chemotherapy (HAI) using an implanted arterial port with portable syringe pumps in our outpatient clinic." | 1.31 | [Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases]. ( Fukunaga, M; Goda, F; Maeba, T; Maeta, H; Mihara, T; Mori, S; Ohkawa, M; Okada, H; Okano, K; Senda, S; Uchida, Y; Usuki, H; Wakabayashi, H, 2000) |
| "We have experienced a case of advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-fluorouracil (5-FU), mitomycin C (MMC) and peroral administration of 5-FU." | 1.31 | Advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-FU, MMC and peroral administration of 5-FU: a case report. ( Aoyagi, K; Koufuji, K; Murakami, N; Shirouzu, K; Takeda, J; Terasaki, Y; Yamasaki, Y; Yano, S, 2000) |
| "A 67-year-old female with rectal cancer and multiple liver metastases underwent low anterior resection by total mesorectal excision (TME), cholecystectomy and hepatic arterial cannulation in June 1995." | 1.31 | [Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)]. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2001) |
| "Capecitabine may inhibit the growth and metastasis of HCC." | 1.31 | [The expression of platelet-derived endothelial cell growth factor in liver cancer]. ( Fan, J; Tang, Z; Zhou, J, 2000) |
| "A 77-year-old man who had advanced gastric cancer with multiple liver metastases was treated by combined chemotherapy with 5-fluorouracil and low-dose cisplatin for 1 and half courses (1 course = 4 weeks)." | 1.31 | [A case of advanced gastric cancer complicated with liver metastases responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin, with UFT and low-dose cisplatin for maintenance on an outpatient basis]. ( Ikeda, S; Iwamoto, M; Nagata, S; Niiya, F; Shirouzu, K, 2001) |
| "Human colon cancer cells (KM12SM) were injected into the cecal wall of the nude rats." | 1.31 | [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]. ( Akagi, Y; Kobayashi, H; Matono, K; Miyagi, Y; Nakagawa, M; Nozoe, Y; Ogata, Y; Sasatomi, T; Shirouzu, K, 2001) |
| " The chemotherapy consisted of protracted infusion of 5-fluorouracil (5-FU), combined with infusion of nedaplatin (NDP)." | 1.31 | [A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy]. ( Eguchi, J; Ito, H; Ito, T; Kaneko, K; Kitahara, T; Konishi, K; Kurahashi, T; Mitamura, K; Yamamoto, T, 2001) |
| "A 63-year-old male with advanced esophageal cancer was admitted to our hospital." | 1.31 | [Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report]. ( Kumada, K; Makuuchi, M; Midorikawa, T; Nemoto, H; Sanada, Y; Sasaya, S; Takeuchi, S; Takizawa, K; Uemichi, O; Yamaguchi, M; Yoshizawa, Y, 2001) |
| "A malignant carcinoid syndrome was present in 8 patients." | 1.31 | [Surgical and adjuvant therapy of neuroendocrine tumors of the gastrointestinal tract and their metastases. A retrospective analysis of personal patient group]. ( Hallfeldt, KK; Jückstock, H; Ladurner, R; Mussack, T; Schmidbauer, S; Trupka, AW, 2001) |
| " This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues." | 1.31 | Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001) |
| "We reported a case of hepatocellular carcinoma (HCC) with multiple lymph node metastases." | 1.31 | [Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases]. ( Beppu, T; Fujiyama, S; Hirota, M; Ishiko, T; Ishiodori, H; Matsuda, T; Ogawa, M; Omuraya, M; Yamashita, Y, 2001) |
| "For women with metastatic breast cancer, complete remission is uncommon, and stable disease is a reasonable goal of successful therapy." | 1.31 | Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment. ( Hara, Y; Hikosaka, Y; Iwase, H; Kobayashi, S; Toyama, T; Yamashita, H, 2001) |
| "Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis, and the development of new therapeutic strategies is necessary." | 1.31 | Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. ( Kaneko, S; Kobayashi, K; Urabe, T, 2002) |
| "If hepatic reserve is satisfactory, an aggressive surgical approach combined with chemotherapy seems to be of benefit for patients having HCC with tumor thrombus in the MPV, IVC, or EBD." | 1.31 | Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. ( Aoyagi, S; Eriguchi, N; Fukuda, S; Imamura, I; Imamura, M; Okuda, K, 2002) |
| "The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 1.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
| "We performed PMC-CPT-11 therapy (modified pharmacokinetic modulating chemotherapy plus irinotecan, or modified PMC) in a case of sigmoid colon cancer with local invasion and multiple hepatic metastases." | 1.31 | [A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy]. ( Chang, W; Kondo, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Oriyama, T, 2002) |
| "To the best of our knowledge no anaphylactic reaction secondary to folinic acid (FA) administration has ever been reported before." | 1.31 | Anaphylactic shock secondary to intravenous administration of folinic acid: a first report. ( Benchalal, M; Fingerhut, A; Fouere, S; Yahchouchy-Chouillard, E, 2002) |
| "We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | 1.31 | [Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin]. ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
| "Though treatment of recurrent gastric cancer with liver metastasis is often ineffective, this case suggests that a combination therapy of cisplatin and carmofur might be effective." | 1.30 | [A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur]. ( Inomata, Y; Inoue, K; Kuroda, T; Mizutani, H; Sakuyama, T; Tadaoka, N; Takahashi, N; Yamada, T; Yoshinaga, K, 1997) |
| "The purpose of our study was to develop a pharmacokinetic model to quantify the intracellular 5-fluorouracil (5-FU) concentration in liver metastases, which is expected to be closely correlated to therapy response." | 1.30 | Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ( Bellemann, ME; Brix, G; Dimitrakopoulou-Strauss, A; Haberkorn, U; Kissel, J; Lorenz, WJ; Port, R; Strauss, LG, 1997) |
| "He was diagnosed as rectal cancer with multiple liver metastases." | 1.30 | [A case of multiple liver metastasis and local recurrence from rectal cancer effectively treated by arterial infusion chemotherapy using low-dose 5-fluorouracil, cisplatin and LV]. ( Endo, Y; Kodama, M; Naitoh, H; Okauchi, H; Tani, T; Yamasaki, M, 1997) |
| "This suggested that the therapy for a breast cancer patient with distant metastasis must be considered according to the region of recurrence." | 1.30 | [A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer]. ( Ayabe, H; Hara, S; Hashizume, S; Itoyanagi, N; Oka, T; Shinguu, H; Tagawa, Y; Tooyama, H; Tou, K; Tsuji, H; Yamamoto, S; Yamazumi, K, 1997) |
| "We diagnosed the patient as recurrent breast cancer metastatic to liver, 14 years postoperatively." | 1.30 | [Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report]. ( Arai, K; Imai, R; Ito, K; Kojima, K; Muro, H; Nakagami, K; Nakajima, N; Nishimura, K; Onogawa, S; Suzuki, M; Tohyama, K; Umeda, Y, 1997) |
| " There seemed to be no correlation with the total dosage of 5-FU or the number of administrations." | 1.30 | [Complication due to arterial infusion chemotherapy for liver metastasis from colorectal cancer]. ( Hamada, H; Hashimoto, M; Katsuki, Y; Kawata, S; Kon, H; Sasaki, R; Tomita, I; Tsuji, Y; Yasuda, T, 1997) |
| "5-Fluorouracil, 2600 mg/m2, was administered concurrently with 100 mg/m2 leucovorin over 24 hours of continuous intravenous infusion." | 1.30 | Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience. ( Chen, PM; Chen, WS; Chiou, TJ; Fan, FS; Hsieh, RK; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, WS; Yen, CC, 1998) |
| "Fifty-five colorectal cancer patients who had continuous intraportal chemotherapy between 1990 and 1993 (treated group) and 130 colorectal cancer patients who did not have portal chemotherapy between 1982 and 1993 (untreated group) were studied to clarify the effects of continuous intraportal chemotherapy on the prognosis." | 1.30 | [Continuous intraportal chemotherapy for prevention of metachronous hepatic metastasis in colorectal cancer]. ( Adachi, W; Amano, J; Kajikawa, S; Koide, N; Koike, S; Kuroda, T; Mihara, M; Nakata, S; Watanabe, H; Yazawa, K, 1998) |
| "For 6 patients with advanced hepatocellular carcinoma (HCC) in whom TAE was inefficacious, we tried hepatic arterial infusion chemotherapy." | 1.30 | [Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)]. ( Aoyama, H; Asano, T; Fukunaga, T; Isono, K; Iwasaki, K; Kenmochi, T; Kobayashi, S; Kouno, T; Matsuzaki, H; Nakagouri, S; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1998) |
| "Many cases with metastatic hepatic cancer have a poor prognosis because of the appearance of extrahepatic lesions in spite of the fact that a partial response can be obtained by hepatic arterial infusion chemotherapy." | 1.30 | [Appearance of extrahepatic lesions in the superior lip and orbit of a patient with liver metastases of gastric cancer following partial response by hepatic arterial infusion chemotherapy]. ( Hasegawa, K; Ichikawa, T; Kawai, S; Kirihara, M; Kume, S; Maruo, H; Tominaga, S, 1998) |
| "For advanced pancreatic cancer, there is no typical chemotherapy regimen non single chemotherapeutic agent." | 1.30 | [Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis]. ( Kobayashi, A; Yamaguchi, M, 1998) |
| "Forty-four advanced colorectal cancer patients (15 women and 29 men; median age 63, range, 27-78 years) receiving a standard FU-folinic acid protocol were included." | 1.30 | Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. ( Chazal, M; Cheradame, S; Cure, H; Etienne, MC; Formento, JL; Formento, P; François, E; Francoual, M; Letoublon, C; Milano, G; Mousseau, M; Pezet, D; Richelme, H; Seitz, JF, 1997) |
| "Five different human hepatoma cell lines, Hep G2, Hep G2." | 1.30 | Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. ( Jiang, S; Kim, SJ; Lee, MO; Park, JH; Shin, EC; Song, MJ, 1999) |
| "The innate drug resistance of human hepatocellular carcinoma (HCC) Bel7402 cell line was studied in vitro." | 1.30 | The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. ( Huang, M; Liu, G, 1999) |
| "The human colorectal cancer cell line C170HM2 readily forms liver metastases in vivo." | 1.30 | A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. ( Jackman, AL; Morris, TM; Page, MJ; Rohlff, C; Skelton, L; Watson, SA, 1999) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| "Multiple liver and lung metastasis of breast cancer were diagnosed because of high CA 15/3 serum levels and normal gastrointestinal study." | 1.30 | [Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report]. ( Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M, 1999) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 1.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "Mitomycin C (20 mg) was injected through out the induced hypertension (1." | 1.30 | [A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II]. ( Arai, K; Iwasaki, Y; Kitamura, M; Nakajima, Y, 1999) |
| "Mitomycin C was injected for 10 minutes via implanted port, whose tip was located in the hepatic artery, when the mean systolic blood pressure rose to 50 percent above the level in the untreated state by intravenous administration of angiotensin II." | 1.30 | [Efficacy and problems of hepatic arterial chemotherapy with angiotensin II for liver metastasis from gastric cancer]. ( Arai, K; Iwasaki, Y; Ohashi, M; Takahashi, T, 1999) |
| "AFP gene expression in human hepatoma cells was determined by avidin-biotin-peroxidase complex (ABC) immunocytochemical method." | 1.30 | Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth. ( Wang, X; Xie, H; Zhang, R, 1999) |
| "Patients with hepatic metastases from rectal cancer treated with hepatic artery (HA) chemotherapy have a life expectancy great enough to be at risk for pelvic failure." | 1.29 | Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases. ( Andrews, JC; Cha, C; Ensminger, WD; Lawrence, TS; Robertson, JM, 1996) |
| "We present a patient with metastatic breast cancer treated with high-dose chemotherapy and bone marrow transplantation." | 1.29 | Clostridium septicum abscess in hepatic metastases: successful medical management. ( Ciaccia, D; Corey, GR; Peters, W; Thel, MC; Vredenburgh, JJ, 1994) |
| "Primary hepatocellular carcinoma is a very rare disease, especially in association with a pregnancy." | 1.29 | [Hepatocellular carcinoma in pregnancy]. ( Brucker, C; Debus-Thiede, G; Genz, T; Maassen, V; Schweiberer, L; Weiss, M, 1994) |
| "5-Fluorouracil was given as a continuous infusion during therapy." | 1.29 | Whole abdominal radiotherapy and concomitant 5-fluorouracil as adjuvant therapy in advanced colon cancer. ( Ben-Josef, E; Court, WS, 1995) |
| "A case of far advanced gastric cancer with multiple liver metastasis (H3) was treated with transarterial intermittent chemotherapy (5-FU: 250 mg/week, Farmorubicin: 10 mg/4 weeks, MMC: 4 mg/2 weeks) and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans." | 1.29 | [A case report of far advanced gastric cancer with multiple liver metastasis (H3) treated with transarterial intermittent chemotherapy and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans]. ( Fukuma, E; Goto, S; Imai, I; Ishiyama, J; Kano, N; Kasugai, H; Kera, J; Miyajima, N; Takeuchi, S; Yamakawa, T, 1995) |
| "Of 23 patients, 18 had carcinoid syndrome and 19 had elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) levels." | 1.29 | Transcatheter chemoembolization of progressive carcinoid liver metastasis. ( Breittmayer, F; De Baere, T; Ducreux, M; Elias, D; Indushekar, S; Lasser, P; Roche, A; Rougier, P; Therasse, E, 1993) |
| "A case of liver tumors metastasized by Sigmoid colon cancer was treated with intrahepatic arterial infusion of CDDP (10 mg) and 5-FU (250 mg) via subcutaneously implanted reservoir." | 1.29 | [Neoadjuvant chemotherapy of liver tumors metastasized by sigmoid colon cancer: a case report of CDDP/5-FU intraarterial infusion therapy followed by hepatectomy]. ( Inoue, J; Katoh, O; Kuroki, S; Kusaba, T; Sasatomi, K; Shimada, M; Tanaka, M; Tanikawa, K; Yamashita, F; Yutani, S, 1995) |
| "The other five patients with advanced stomach cancer who could not have so good nutrition were receiving home parental nutrition (HPN, 1,200 kcal/day) and continuous or intermittent 5-FU infusion (250-500 mg/body/day) using Lentinan at the same time." | 1.29 | [Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer]. ( Chibai, M; Inomata, Y; Isshi, K; Nakamura, Y; Sakuyama, T; Shimono, S; Tadaoka, N; Takahashi, N; Takamura, S; Yamada, T, 1994) |
| "A 75-year-old man with gastric cancer having multiple liver metastases was given intraarterial infusion therapy with sequential low-dose MTX (30 mg/body) and 5-FU (1,000 mg/body) for metastatic liver tumors one month after the primary gastric tumor was resected." | 1.29 | [A case report: multiple liver metastasis from gastric cancer responding to intraarterial infusion of sequential low-dose MTX and 5-FU]. ( Hamanaka, Y; Hazama, S; Oka, M; Suzuki, T; Tangoku, A; Tsurumi, M, 1994) |
| "Two cases of hepatic metastasis of colorectal cancer were treated effectively by intrahepatic-arterial infusion immunotherapy using OK-432 (2 KE/week or 2 weeks), recombinant IL-2 (35 x 10(4) JRU or 40 x 10(4) JRU/week or 2 weeks), MMC (4 mg/week or 2 weeks) and 5-FU (250 mg/day during admission, 250 mg/week or 2 weeks during outpatient treatment)." | 1.29 | [Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Kurosaka, Y; Matsushita, M; Takashima, S; Tomita, F, 1994) |
| "A case of metastatic carcinoid syndrome with hypoxaemia is described." | 1.29 | Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome. ( Bloom, SR; Greaves, JD; Hammond, PJ; Hughes, JM; Hussain, A; Wallis, SC; Young, ET, 1994) |
| "A 67-year-old man with advanced gastric cancer with multiple liver metastases was treated by a new combination chemotherapy using 5-FU, THP and MMC (FTM)." | 1.29 | [A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)]. ( Kusano, F; Maekawa, N; Sakai, Y; Sasaki, N; Tajiri, K; Tazawa, J; Yamamoto, C, 1994) |
| "We described a case of advanced gastric cancer with multiple liver metastases, who was placed on neoadjuvant chemotherapy using CDDP and 5-FU (FP therapy) with a marked reduction in tumor load." | 1.29 | [Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases]. ( Igarashi, S; Kurosu, Y; Mori, K; Niki, M; Nishimura, G; Oohara, M; Osada, H; Takamoto, Y; Tsuzuki, H; Ueda, H, 1994) |
| " Eighty per cent reduction of leucovorin dosage leads to a significant decrease in grade 2 and grade 3 haematological and gastrointestinal toxicity." | 1.29 | Local and systemic toxicity of intra-hepatic-arterial 5-FU and high-dose or low-dose leucovorin for liver metastases of colorectal cancer. ( Klotz, HP; Largiadèr, F; Weder, W, 1994) |
| "An advanced esophageal cancer patient with multiple liver metastases was treated with a combination of CDDP, 5-FU and THP-ADM." | 1.29 | [A case of nonresectable esophageal cancer treated by the combination of cisplatin, 5-fluorouracil and THP-adriamycin]. ( Anai, H; Ichiyoshi, Y; Matsuzaki, K; Minamisono, Y; Miura, O; Nagasaki, S; Toda, T, 1993) |
| "Effects of 5-fluorouracil (5-FU) and UFT on an experimental liver metastasis model were compared at equi-effective dosage levels against subcutaneous tumor of mouse colon 26." | 1.29 | Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells. ( Kosaki, G; Kurihara, M; Tominaga, T; Yoshida, Y, 1993) |
| "Nine gastric cancer patients with simultaneous liver metastases were given intermittent transarterial administration of chemotherapeutics (adriamycin, mitomycin C or 5-fluorouracil) and biological response modifiers (BRM; OK-432 and interleukin (IL) -2) after gastrectomy." | 1.29 | [Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer]. ( Azuma, S; Furuta, T; Kato, M; Kida, H; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Umemoto, T, 1993) |
| "Five cases of colorectal cancer with unresectable liver metastases treated from April 1992 to April 1993 in Osaka National Hospital were summarized in this paper." | 1.29 | [Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases]. ( Imamura, H; Kanoh, T; Kikkawa, N; Miyazaki, M; Nakayama, T; Tamaki, Y; Taniguchi, K; Tohno, K; Utsunomiya, T, 1993) |
| "Sixteen patients with breast cancer were administered epi-adriamycin (Epi-ADM) singly or in a combination of 5-FU and mitomycin C through both subclavicular artery and internal thoracic artery." | 1.29 | [Complications of intra-arterial chemo-infusion using implantable vascular access system]. ( Kikkawa, N; Takatsuka, Y; Tamaki, Y, 1993) |
| "Since 1980, 89 patients with colorectal cancer showed liver metastasis." | 1.29 | [Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer]. ( Akaike, M; Okamoto, T; Sugimasa, Y; Takemiya, S, 1993) |
| "In a 63-year-old male patient with gastric cancer having multiple liver metastases, the metastatic lesions responded well to postoperative staggered intraarterial infusion therapy with MTX and 5-FU." | 1.29 | [A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU]. ( Adachi, A; Nakano, Y; Ota, Y; Shirafuji, T; Yamaguchi, H; Yoshida, K, 1993) |
| "Mitomycin C 26 mg was given intravenously on the day of operation and 5-fluorouracil (5-FU) 150 mg/day orally since postoperative 14th day as adjuvant chemotherapy." | 1.29 | [A case of advanced gastric cancer with liver metastasis with no recurrence and long survival]. ( Kajiura, Y; Kondo, Y; Mitomi, T; Miyaji, M; Nakamura, K; Ogoshi, K; Tajima, T, 1996) |
| "A-68-year-old man had hepatocellular carcinoma (HCC) in the area of S6 segment which was resected surgically." | 1.29 | [A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer]. ( Fukuzawa, Y; Ikeda, H; Kato, K; Murata, K; Sawada, T; Tagaya, T; Takahashi, K; Takiya, S, 1996) |
| "Primary tumours were carcinoids in nine, gastrinomas in five, non-functioning pancreatic tumours in six and calcitonin-secreting tumours in two patients." | 1.29 | Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. ( Bernades, P; Menu, Y; Ruszniewski, P; Skinazi, F; Zins, M, 1996) |
| "The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival." | 1.29 | Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. ( Chase, JL; Curley, SA; Davidson, BS; DuBrow, RA; Hohn, DC; Izzo, F; Patt, Y, 1996) |
| "Twenty-two patients with colorectal cancer and synchronous unresectable hepatic metastases were treated by resection the primary tumour with concurrent insertion of an Infusaid infusaport system for regional chemoperfusion (hepatic arterial 20, portal venous 2)." | 1.29 | Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases. ( Clingan, PR; Dasappa, V; King, DW; King, J; Morris, DL; Ross, WB, 1996) |
| "In seven patients with advanced primary hepatocellular carcinoma the same therapeutic regime was used." | 1.28 | Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma. ( Cuan-Orozco, F; Kalk, JF; Koussouris, P; Mercado, MA; Paquet, KJ; Siemens, F, 1992) |
| " After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990." | 1.28 | [A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992) |
| "Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma." | 1.28 | [Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma]. ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992) |
| "Survival in patients with metastatic carcinoid tumors is dependent on control of tumor growth and adequate palliation of vasoactive amine-induced symptoms of flushing, diarrhea, wheezing, and valvular heart disease." | 1.28 | Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. ( Fletcher, WS; Hajarizadeh, H; Ivancev, K; Mueller, CR; Woltering, EA, 1992) |
| "Forty patients with unresectable liver cancer were treated by hepatic arterial infusion chemotherapy plus embolization (HAI+HAE)." | 1.28 | [Hepatic arterial infusion chemotherapy plus embolization for unresectable liver cancer--a report on 40 patients]. ( Wang, JH, 1992) |
| "5-fluorouracil (5-FU) was infused continuously through an Infuse-A-Port; 360 mg/m2/day for one week after operation, and 180 mg/m2/day for the following three weeks." | 1.28 | [Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer]. ( Kubota, Y; Masaki, T; Ooya, M; Sakaguchi, M; Sameshima, S; Sawada, T; Shinozaki, M; Tsuno, N; Uchiyama, M; Watanabe, T, 1992) |
| "We reported a case of metastatic liver cancer from rectal carcinoma, which was successfully treated by systemic continuous 5-Fluorouracil and intermittent Mitomycin C chemotherapy." | 1.28 | [A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy]. ( Noguchi, S; Shibata, N, 1992) |
| "Four cases of advanced hepatocellular carcinoma patients were treated by intra-portal infusion of 5-FU immediately after surgery." | 1.28 | [Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report]. ( Gotoda, A; Kamiyama, T; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Saito, M; Sato, N; Uchino, J; Une, Y, 1991) |
| "A care system for cancer bearing patients at a highly advanced stage should be informed by a better quality of life based on a life style of the patients and their families." | 1.28 | [Nutritional support for cancer bearing patients]. ( Yamada, S, 1991) |
| "Presence of hepatomegaly emerged as the more significant (P = 0." | 1.28 | Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. ( Ducreux, M; Elias, D; Lasser, PH; Lumbroso, J; Pignon, JP; Rougier, P; Ruffie, P; Tigaud, JM, 1991) |
| "Two groups of patients with colorectal cancer and remote metastases in the liver are presented: one received surgical treatment alone, the other combined therapy." | 1.28 | [A combined method for treating metastases of colorectal carcinoma to the liver]. ( Dimitrov, V; Dudunkov, Z; Kurtev, P; Kurteva, G; Ralchev, K, 1991) |
| "Chemosensitivity of hepatocellular carcinoma tissues from 72 patients to 6 antitumor agents was assayed using the succinate dehydrogenase inhibition test." | 1.28 | Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test. ( Akazawa, K; Kanematsu, T; Maehara, Y; Matsumata, T; Shirabe, K; Sugimachi, K, 1991) |
| "Eighty-three rats with isolated colon cancer underwent total colectomy; 40 of these rats with no metastases were randomized into two groups: surgery alone or surgery plus 5-FU (5 mg/kg body weight/day) for 5 days after surgery." | 1.28 | Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. ( Ballet, F; Delelo, R; Herve, JP; Nordlinger, B; Panis, Y; Puts, JP, 1991) |
| "(3) In hepatic metastasis of breast cancer, arterial infusion therapy was more effective, and the survival period was prolonged significantly." | 1.28 | [Loco-regional cancer therapy for hepatic metastasis]. ( Aogi, K; Jinushi, K; Sawamura, A; Toge, T, 1991) |
| "There are few reports about the methods, amounts, and kinds of dosage about intermittent intra-arterial chemotherapy of liver metastases from primal pathological type's squamous cell carcinoma." | 1.28 | [Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma]. ( Aoki, T; Kasuya, K; Kimura, K; Koyanagi, Y; Ozawa, T; Sato, S; Tsuchida, A; Yasuda, D; Yoshimatsu, A, 1991) |
| "Chemotherapy for colorectal cancer with liver metastases following surgical operation for primary tumor should be selected following surgical intervention." | 1.28 | [Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases]. ( Ishida, Y; Kojima, N; Kusumoto, S; Nakayoshi, A; Oka, H, 1991) |
| "With colorectal cancer, the therapeutic outcome for multiple hepatic metastasis extending to the bilateral lobe, even when various chemotherapies are administered, is extremely poor." | 1.28 | [Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer]. ( Gotohda, H; Katoh, M; Kinami, Y; Kumaki, T; Saitoh, H; Takashima, S; Takegawa, S; Tomita, F, 1991) |
| "Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection." | 1.28 | Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. ( Furusawa, M; Kakeji, Y; Maehara, Y; Sugimachi, K; Tomoda, H; Tsujitani, S; Watanabe, A, 1991) |
| "5-Fluorouracil (5-FU) was delivered in a dose-intensive schedule to 23 patients with metastatic or unresectable colorectal carcinoma." | 1.28 | A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma. ( Baker, L; Brodfuehrer, J; Kraut, M; Poplin, EA; Vaitkevicius, V, 1991) |
| "A case of iatrogenic sclerosing cholangitis secondary to hepatic intra-arterial 5-fluorouracil (5FU) and Mitomycin C (MMC) chemotherapy is described." | 1.28 | Serious chemical sclerosing cholangitis associated with hepatic arterial 5FU and MMC chemotherapy. ( Fukuzumi, S; Makuuchi, M; Moriya, Y; Terui, S, 1990) |
| "5-FU concentration in liver cancer lesion was 0." | 1.28 | [Tissue UFT distribution and histological changes following UFT administration in metastatic liver cancer cases]. ( Amemiya, A; Emoto, T; Fujii, M; Han, N; Itou, A; Iwasaki, T; Tsujimura, T; Yoshikawa, K, 1990) |
| "These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| "Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)." | 1.28 | [Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990) |
| "Chemotherapy for liver metastasis of breast cancer has rarely been found effective." | 1.28 | [Clinical efficacy of ifosfamide for liver metastasis of breast cancer]. ( Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y, 1990) |
| " Thus, both intraarterial and intraportal chemotherapy combined with decollateralization by silicone rubber sheeting seems to be effective for advanced cholangiocarcinoma and metastatic carcinoma." | 1.28 | [Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer]. ( Fukuda, I; Furukawa, H; Imaoka, S; Ishikawa, O; Masutani, S; Nagano, H; Ohashi, I; Oohigashi, H; Sasaki, Y; Yasuda, T, 1990) |
| "Two patients had primary hepatocellular cancer (HCC)." | 1.28 | Repeated dearterialization of hepatic tumors with an implantable occluder. ( Bengmark, S; Ekberg, H; Jeppsson, B; Lundstedt, C; Persson, BG; Tranberg, KG, 1990) |
| "Human hepatoma and melanoma tumor cells and normal melanocytes, keratinocytes, and fibroblasts were incubated for 2, 24, and 48 h with graded concentrations of cis-platinum (0." | 1.28 | Rapid chemosensitivity assay with human normal and tumor cells in vitro. ( Babich, H; Borenfreund, E; Martin-Alguacil, N, 1990) |
| "Six cases of unresectable hepatic cancer in infant were treated with intra-arterial infusion therapy." | 1.28 | [Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children]. ( Abe, T; Hamada, H; Hata, Y; Saito, H; Sasaki, F; Sato, N; Sawada, H; Tamura, M; Uchino, J; Une, Y, 1989) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "Fifty-five gastric cancer patients with liver metastasis received arterial infusion chemotherapy." | 1.28 | [Arterial infusion chemotherapy in patients with gastric cancer in liver metastasis and long-term survival after treatment]. ( Arai, K; Kitamura, M; Kosaki, G; Miyashita, K, 1989) |
| "Seven cases of liver cancer with replaced right hepatic artery were treated with arterial infusion therapy using implanted reservoir." | 1.28 | [Reservoir implanted arterial infusion therapy in liver cancer with replaced right hepatic artery]. ( Gondo, H; Ishimura, M; Kamiyama, T; Matsuoka, S; Misawa, K; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Tamura, M; Une, Y, 1989) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| " The dosage was 250 mg/day for 5-FU continuously, 10 mg/week for MMC and 5 KE/week for OK-432, respectively." | 1.28 | [Three cases of effective hepatic arterial infusion with OK-432, mitomycin C and 5-fluorouracil in liver metastasis from gastric cancer]. ( Hamada, H; Mori, N; Nakajima, I; Nakamura, T; Nakamura, Y; Tanaka, A; Wada, T; Yasutomi, M, 1989) |
| "The cases of primary hepatic cancer are 2 cases of hepatoma (413, 420 days) and 1 case of cancer of bile-duct (400 days)." | 1.28 | [Evaluation of long survival cases treated with intra-arterial cancer chemotherapy using implantable reservoirs]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1989) |
| "In the case of gall bladder cancer cell line (NOZ), combination of adriamycin and hyperthermia showed more effective inhibition for cell proliferation than MMC + hyperthermia and 5-FU + hyperthermia." | 1.28 | [Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro]. ( Fujise, K; Hasumura, S; Homma, S; Kameda, H; Matsuura, T; Nagamori, S; Niiya, M; Shimizu, K; Sujino, H, 1989) |
| "Lipiodol-ADM was injected for hepatocellular carcinoma every 2 months and MMC-5-FU was injected for liver metastasis of colorectal carcinoma every one or two weeks." | 1.28 | [Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma]. ( Adachi, W; Hanasaki, K; Horigome, N; Iida, F; Kajikawa, S; Kinosita, T; Kuroda, T; Sodeyama, H, 1989) |
| "In 24 cases of unresectable hepatocellular carcinoma, we performed hepatic arterial catheterization and intra-arterial infusion chemotherapy." | 1.28 | [Hepatic arterial infusion chemotherapy of hepatocellular carcinoma]. ( Amioka, K; Hara, H; Iga, C; Ishibashi, T; Isozaki, H; Morita, S; Nakata, E; Nishimura, J; Okajima, K; Tanimura, M, 1989) |
| "Of the 8 patients having hepatoma with increased AFP, all the patients showed a decrease of AFP following the therapy with an average ratio of 65% decrease." | 1.28 | [Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1989) |
| "Nineteen patients with primary hepatocellular carcinoma (7 were at Stage III and 11 were at Stage IV) and 14 patients with metastatic liver tumors (4 were at H2 and 9 were at H3 stages) received this newly developed anticancer methodology." | 1.28 | [The clinical studies of intermittent hepatic artery occlusion with infusion chemotherapy--19 cases of unresectable hepatocellular carcinoma and 14 cases of metastatic liver cancer]. ( Naito, A; Nakase, A; Tamura, K; Tarumi, T; Yamamoto, T; Yano, S, 1989) |
| "Case report of a 45-year-old woman with breast cancer who underwent mastectomy with axillary lymphonodectomy and radiation therapy." | 1.28 | [Ablative hormone therapy and chemotherapy of metastatic breast cancer]. ( Blaschke, U; Gerber, B; Kasch, R, 1989) |
| "Seven patients with metastatic colorectal cancer have been treated with a regimen involving an 120-hour continuous infusion of rIL-2, 3 x 10(6) mu/m2." | 1.28 | A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. ( Franks, CR; Hamblin, TJ; Inzani, V; Palmer, P; Sadullah, S; Stevenson, FK; van der Plas, J; Williamson, P, 1989) |
| "Overall median survival was 352 days in colon cancer and 449 days in gastric cancer." | 1.28 | [A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. ( Arai, Y; Endo, T; Kido, C; Miyake, Y; Sakamoto, K, 1989) |
| " When IHAI chemotherapy was combined with hyperthermic treatment, antitumor effects were generated in 3 of 6 metastatic patients from colorectal cancer, who had received no benefit from the IHAI chemotherapy alone." | 1.28 | [Intra-hepato-arterial chemotherapy combined with hyperthermic treatment: clinical results of metastatic cancer of the liver and effects on correct (but not at all necessary) hepatic blood flow]. ( Hamazoe, R; Inoue, Y; Koga, S; Maeta, M; Murakami, A; Shabana, M, 1989) |
| " 5-fluorouracil (5-FU) with a daily dosage of 1 g/m2/day was given continuously for 5 consecutive days at 3-week intervals." | 1.28 | Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy. ( Herrmann, R; Hohenberger, P; Räth, U; Schlag, P, 1989) |
| "A 24-year-old man with hepatocellular carcinoma presented with recurrent obstructive jaundice caused by bile duct invasion and distal migration of necrotic tumor fragments." | 1.27 | Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma. ( Albaugh, JS; Keeffe, EB; Krippaehne, WW, 1984) |
| "Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin." | 1.27 | [Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984) |
| " At this time the ITC therapy is used in combination with induced-hypertension-chemotherapy (IHC therapy)." | 1.27 | [The clinical effect of hyperthermia combined with induced hypertension chemotherapy]. ( Hayashida, S; Kobayashi, T; Sugimoto, K, 1984) |
| "Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment." | 1.27 | Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983) |
| "We found that this conversion in human tumors was catalyzed not by uridine phosphorylase but by thymidine phosphorylase." | 1.27 | [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. ( Hara, Y, 1984) |
| "Although both patients with hepatocellular cancer and the patient with a soft tissue sarcoma responded to the regimen, only 1 of 38 patients with adenocarcinoma had a favourable response." | 1.27 | Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer. ( Cedermark, BJ; Gunven, P; Hammarberg, C, 1983) |
| "A 9-year-old boy with non-resectable hepatocellular carcinoma was treated with irradiation and intra-hepatic arterial infusion of antitumor agents." | 1.27 | [HBs antigen-positive adult type liver cancer in a child with sustained remission induced by infusion of antineoplastic agents into the hepatic artery]. ( Hamawaki, M; Ito, Y; Iwata, K; Kikkawa, K; Kubonishi, S; Kuroiwa, Y; Matsuoka, K; Ohmura, T; Okano, K, 1983) |
| " Isolated hyperthermic liver perfusion at 40 degrees C with an average dosage of 1000 mg 5-FU was performed in 32 patients with liver metastases (29 colorectal carcinomas, 2 carcinoids, 1 primary hepatoma)." | 1.27 | [Isolated liver perfusion in advanced metastases of colorectal cancers]. ( Aigner, KR; Link, KH; Schoch, P; Schwemmle, K; Tonn, JC; Walther, H, 1984) |
| " Determination of 5-FU concentrations in blood, normal and tumor tissues following a long term administration of Tegafur was performed." | 1.27 | [Enzymatic conversion of tegafur in human tumor tissue]. ( Hara, Y; Kono, A; Sugata, S; Tanaka, M, 1983) |
| "We studied 161 gastric cancer patients with P0, H(+) and 51 colorectal cancer patients with P0, H(+) from among cancer patients of the digestive organs and obtained the following conclusions." | 1.27 | [Basic and clinical studies on metastatic cancer--with special reference of multidisciplinary treatment of gastric and colorectal cancer patients with hepatic metastasis]. ( Hanaoka, A; Isono, K; Kimura, M; Koide, Y; Okuyama, K; Onoda, S; Ryu, M; Satoh, H; Tohnosu, N; Yamamoto, Y, 1983) |
| "To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0." | 1.27 | [Intra-hepato-arterial administration of cis-diammine-dichloroplatinum II (CDDP) for primary or metastatic hepatic cancer]. ( Hirooka, Y; Kanayama, H; Koga, S; Maeta, M; Murakami, A; Oda, M; Osaki, Y, 1984) |
| "We report 19 patients with metastatic colon cancer whose bulk disease was limited to the liver, but was not amenable to surgical resection." | 1.27 | Hepatic artery ligation and portal vein infusion for liver metastases from colon cancer. ( Courter, S; Guy, JF; Guy, JT; Laufman, LR; Nims, TA, 1984) |
| "Eighty-four patients with advanced gastric cancer treated in four centres in Scotland between June 1980 and December 1982 were reviewed following treatment with 5-fluorouracil, adriamycin and mitomycin-C (FAM)." | 1.27 | Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. ( Allan, SG; Calman, KC; Carter, DC; Cunningham, D; Hutcheon, AW; Kaye, SB; McArdle, CS; Sangster, G; Smyth, JF; Soukop, M, 1984) |
| "Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz." | 1.27 | [Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas]. ( Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985) |
| "Thirty-two patients with inoperable hepatic cancer underwent intra-arterial hepatic infusion using mitomycin C (MMC) and 5-fluorouracil (5-FU) or intra-arterial hepatic chemoembolization using heated albumin microspheres containing MMC with an average diameter 45 +/- 8 micron." | 1.27 | Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. ( Endoh, F; Fujimoto, S; Miyazaki, M; Morimoto, Y; Okui, K; Takahashi, O, 1985) |
| "In the treatment of metastatic liver cancer, arterial chemotherapy and transarterial embolization are the major modality." | 1.27 | [Current status of diagnosis and treatment of metastatic liver cancer]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y, 1987) |
| "Twenty patients with malignant hepatoma were treated with sequential intraarterial doxorubicin (72-hour continuous infusion) followed by systemic 5-fluorouracil (5-FU) and semustine (methyl CCNU)." | 1.27 | Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine. ( Hahn, RG; Moertel, CG; O'Connell, MJ; Rubin, J, 1988) |
| "5-fluorouracil was effective only in patients without cirrhosis, with an overall response rate of 22%." | 1.27 | Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. ( Audisio, R; Bignami, P; Bonfanti, G; Bozzetti, F; Colombo, M; Doci, R; Gennari, L, 1988) |
| "Of the 8 patients with hepatoma with increased AFP, all the patients showed a decrease of AFP following therapy with an average decrease ratio of 64%." | 1.27 | [Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1988) |
| "A total of 850 patients with hepatocellular carcinoma seen during the last 8 years were analyzed retrospectively for survival in relation to treatment and disease stage." | 1.27 | Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. ( Hasegawa, H; Nakajima, Y; Obata, H; Ohnishi, K; Ohtsuki, T; Okazaki, N; Okuda, K; Tomimatsu, M, 1985) |
| "All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls." | 1.27 | Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985) |
| "407 cases of unresectable hepatocellular carcinoma (HCC) occurring from 1970 to March 1985, including 107 cases receiving conservative therapy, 176 cases receiving one-shot therapy and 124 cases receiving transcatheter arterial embolization (TAE) therapy, were studied and the efficacy of chemotherapy was compared with that of TAE therapy." | 1.27 | [One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kawazoe, Y; Kumagai, M; Tanikawa, K; Yamashita, K, 1985) |
| "Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil." | 1.27 | Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors. ( Koga, S; Maeta, M; Murakami, A; Wakatsuki, T; Yoshioka, H, 1985) |
| "5-Fluorouracil was injected by a fine needle under ultrasound guidance." | 1.27 | Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance. ( Livraghi, T; Ravetto, C; Solbiati, L; Suter, F, 1986) |
| "The mitomycin C and BCNU were alternated monthly at the start of each FUDR cycle." | 1.27 | Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. ( Cohen, AM; Higgins, J; Schaeffer, N, 1986) |
| "A 65-year-old man with gastric cancer showing multiple liver metastases was treated with recombinant interferon-gamma (KW-2202) and 5-fluorouracil (5-FU)." | 1.27 | [A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU]. ( Hisatsugu, T; Katano, M; Kitajima, Y; Sato, S; Uchida, Y; Yamamoto, H, 1987) |
| "Excisions of metastatic liver cancer were performed in 23 pts and 15 pts had nonresectable metastatic liver cancer." | 1.27 | [Results of intra-arterial infusion chemotherapy in colorectal cancer patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1988) |
| "A 75-year-old man with gastric cancer metastatic to the liver was treated by combined administration of Tegafur (800 mg/body/day), 5-fluorouracil (300 mg/body/day) and Mitomycin C (hepatic arterial infusion of 20 mg/body and intravenous infusion of 8 mg/body)." | 1.27 | [Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C]. ( Ito, T; Nehashi, Y; Sasaki, J; Sasaki, Y, 1988) |
| " There have been a number of reports relating the plasma levels of cytotoxic agents with pharmacodynamic parameters." | 1.27 | Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. ( Goldberg, JA; Kerr, DJ; McArdle, CS; McKillop, JH; Willmott, N, 1988) |
| "In analysing the anticancer effects of TBHT according to cancer site, a high efficacy was observed in patients with their main tumor in the lung, liver and lymph nodes." | 1.27 | [Clinical results and problems of total-body thermochemotherapy]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T, 1988) |
| "In patients with colorectal cancer metastatic to the liver, partial response (PR) rates in Regimens I and II were 38% and 62%, respectively." | 1.27 | Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers. ( Hamazoe, R; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawada, T; Shimizu, N, 1988) |
| "We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days." | 1.27 | High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. ( Astone, A; Barone, C; Cassano, A; Cavallaro, A; Garufi, C; Grieco, A; Netri, G; Noviello, MR; Ricevuto, E; Rossi, S, 1987) |
| "A case of pancreatic cancer with liver metastasis is reported, in which chemotherapy had a marked effect, with the responses clearly documented." | 1.27 | A case of pancreatic cancer with liver metastasis which responded to chemotherapy. ( Hijikata, A; Mukai, T; Nakamura, K; Ohkura, H; Saito, D; Tajiri, H; Yamaguchi, H; Yoshida, S; Yoshida, T; Yoshimori, M, 1987) |
| " The possible mechanisms of these toxic effects, as well as the drug interactions are briefly discussed." | 1.27 | Cardiotoxicity during chemotherapy for advanced gastroenteric tumors. ( Bisol, A; Ferrante, F; Fiori, G; Galeone, M; Raina, A, 1987) |
| "Patients with metastatic colorectal cancer confined to the liver received fluorodeoxyuridine (FUdR) through the hepatic artery or through the portal vein." | 1.27 | Tumor and liver drug uptake following hepatic artery and portal vein infusion. ( Daly, JM; Kemeny, N; Ridge, JA; Sigurdson, ER, 1987) |
| "5-Fluorouracil (5-FU) was microencapsulated with poly L-lactic acid by the organic phase separation technique." | 1.27 | [A new anticancer preparation, 5-fluorouracil-poly-L-lactic acid microcapsule, and its therapeutic evaluation]. ( Hirano, M; Iwa, T; Kawaura, Y; Kitagawa, S; Sakatoku, M; Yamada, T; Yamashita, R, 1986) |
| "The treatment schedule for disseminated breast carcinoma has been developed." | 1.27 | [4-component chemotherapy and radiation therapy of breast cancer]. ( Aplevich, NN; Gritsaĭ, AA; Kondrat'eva, AP; Lichinitser, MR; Vyshinskaia, GV, 1986) |
| "Eight hepatocellular cancer patients and eighteen metastatic liver cancer patients were treated with intrahepato-arterial infusion of CDDP (cis-diamminedichloro-platinum II) plus 5-FU (5-fluorouracil); CDDP (0." | 1.27 | [Intrahepatic-artery infusion of cis-diamminedichloroplatinum (II) and 5-fluorouracil in primary or metastatic liver cancer]. ( Ikeda, Y; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Wakatsuki, T, 1987) |
| "These included 7 cases of pancreatic cancer, 2 cases of gall bladder cancer with infiltration to the liver, and 3 cases of hepatoma." | 1.27 | [Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas]. ( Hasegawa, H; Takada, T; Uchiyama, K; Yasuda, H, 1985) |
| "Five patients with colorectal cancer and unresectable synchronous liver metastases have survived for over five years at this writing." | 1.27 | Long-term survivors of colorectal cancer with unresectable hepatic metastases. ( Fujimoto, S; Higuchi, M; Kitsukawa, Y; Miyazaki, M; Okui, K, 1985) |
| "A 61-year-old man with double colon cancers and a solitary hepatic metastasis underwent right hemicolectomy and catheterization of the proper hepatic artery in April 1979." | 1.27 | [A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy]. ( Itoh, J; Koyama, K; Masuda, T; Narisawa, T, 1985) |
| "Multimodality therapy for colorectal cancer is composed of surgery, chemotherapy and irradiation; and hyperthermia joins them recently." | 1.27 | [Multimodality therapy of colorectal cancer]. ( Fujimoto, S; Miyazaki, M; Okui, K, 1985) |
| "The Southwest Oncology Group conducted a pilot study in patients who had had total clinical resection of cancer of the colon and had a high risk of recurrence (Duke's C); the purpose of the study was to determine the toxic effects of intra-arterial chemotherapy combined with hepatic radiotherapy, in anticipation of their potential use in an adjuvant groupwide protocol." | 1.27 | Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study. ( Boyer, C; Janaki, L; McCracken, JD; Oishi, N; Weatherall, TJ, 1985) |
| "In 161 cases of gastric cancer with liver metastasis but without peritoneal dissemination, evaluations were executed to find effective treatment." | 1.27 | Evaluation of treatment for gastric cancer with liver metastasis. ( Isono, K; Juan, IK; Koide, Y; Ochiai, T; Okuyama, K; Onoda, S; Satoh, H; Yamamoto, Y, 1985) |
| "Twenty-nine patients with advanced colorectal cancer were treated with methotrexate (MTX) 200 mg/m2 followed 1 h later by fluorouracil (FU) (1000 mg/m2) and 24 h later by oral leucovorin 20 mg every 6 h for six doses." | 1.27 | A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. ( Ford, J; Margolese, R; Panasci, L, 1985) |
| "A 69-year-old man with a large hepatoma of the right lobe extending in part to the medial segment of the left lobe was treated by ligation of the right hepatic artery combined with continuous infusion of a total dose of 5500 mg og 5-fluorouracil (5-FU) into the left hepatic artery." | 1.26 | A non-resectable hepatoma after hepatic artery ligation combined with infusion chemotherapy--an eight-year survival. ( Hiraoka, T; Konno, T; Nakakuma, K; Tashiro, S; Yokoyama, I, 1981) |
| "5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma." | 1.26 | Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982) |
| "One patient with hepatocellular carcinoma had compete disappearance of all disease with chemotherapy alone." | 1.26 | Preoperative chemotherapy for unresectable primary hepatic malignancies in children. ( Siegel, MM; Siegel, SE; Stanley, P; Weinblatt, ME; Weitzman, JJ, 1982) |
| "Four patients with metastatic glucagonoma are described." | 1.26 | Glucagonoma and its angiographic diagnosis. ( Keller, FS; Lieberman, DA; Rösch, J; Wawrukiewicz, AS, 1982) |
| "A retrospective study of 37 colorectal cancer patients with synchronous liver metastases was made." | 1.26 | Comparative efficacy of antitumor treatment for liver metastases from colorectal cancer. ( Fujimoto, S; Kitsukawa, Y; Miyazaki, M; Okui, K, 1981) |
| "Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1." | 1.26 | [Clinical experiences with UFD-1]. ( Furue, H, 1982) |
| "Twenty-seven patients with liver metastasis from colorectal cancer were treated with intrahepatic arterial chemotherapy and external radiotherapy consisting of 5-fluorouracil (5-FU) (10 mg/kg/day for 8 days), adriamycin (5 mg/m2/day for 7 days) and methotrexate (MTX) (240 mg/m2/X1), combined with 2,100 rads of whole liver irradiation." | 1.26 | Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate. ( Friedman, MA; Phillips, TL; Resser, KJ; Volberding, PA, 1982) |
| " Twelve (33%) of the 36 patients reported adverse effects: gastrointestinal symptoms in 8, CNS symptoms in 3, and others in 1." | 1.26 | [TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers]. ( Arimori, S; Furue, H; Ikenaga, M; Iketa, T; Komita, T; Nagao, T; Ohki, S; Satoh, H; Watanabe, K; Yamamoto, S, 1982) |
| "The pharmacokinetic conditions for oral administration of 5-fluorouracil (5-FU) were investigated in 16 patients with malignant liver tumours." | 1.26 | Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. ( Almersjö, OE; Gustavsson, BG; Regårdh, CG; Wåhlén, P, 1980) |
| "Less than 20% of advanced colorectal cancers respond to chemotherapy." | 1.26 | Chemotherapy for gastrointestinal malignancy. ( Balint, JA; Van der Veer, LD, 1980) |
| "Gastrointestinal cancer has proved exceedingly resistant to chemotherapy efforts." | 1.26 | [Chemotherapy of gastrointestinal cancer (author's transl)]. ( Gropp, C; Havemann, K, 1978) |
| "A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems." | 1.26 | [Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976) |
| "N1-S1/FdUrd Novikoff hepatoma cells, which lack thymidine kinase activity, are resistant to 5-fluorouracil (FUra) as well as 5-fluorodeoxyuridine (FdUrd), suggesting that the pathway, FUra leads to FdUrd leads to FdUMP, is utilized for the conversion of FUra to FdUMP." | 1.26 | Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. ( Crumley, J; Wilkinson, DS, 1977) |
| " Maintenance therapy was carried out by the administration of these drugs at induction dosage alternated each week as a single 24 hourly intravenous infusion." | 1.26 | Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. ( Das, B; Jaiswal, MS; Misra, NC; Singh, RV, 1977) |
| "Oral fluorouracil was administered weekly to 12 consecutive patients with unresectable hepatoma." | 1.26 | Oral fluorouracil therapy of hepatoma. ( Kennedy, PS; Lane, M; Lehane, DE; Smith, FE, 1977) |
| "The podophyllotoxin derivative VP 16-213 was used as monotherapy in 6 patients and combined with 5-fluorouracil in another 6." | 1.26 | [Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)]. ( Brunner, KW; Cavalli, F; Gerber, A; Ryssel, HJ; Sonntag, RW; Tschopp, L, 1977) |
| " Comparison of the effects of single vs fractionated dosage was made on 2 types of experimental solid tumour with different growth, cell kinetic, histological and metastasizing properties." | 1.26 | Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts. ( Hopkins, HA; Looney, WB; Macleod, MS, 1978) |
| "A case of hepatocellular carcinoma in a young female is presented in which the apparent etiology was the use of oral contraceptives for 5 1/2 years." | 1.26 | Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. ( Gattanell, PN; Holland, JF; Perloff, M, 1978) |
| "A 45-year-old man with hepatocellular carcinoma who developed intravascular coagulation following complete tumor regression by chemotherapy is described." | 1.26 | Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report. ( Harada, T; Makisaka, Y; Nishimura, H; Okuda, K, 1978) |
| "A case of hepatocellular carcinoma associated with erythrocytosis is described." | 1.26 | Hepatocellular carcinoma associated with erythrocytosis. A nine year survival after successful chemotherapy and left lateral hepatectomy. ( Arima, M; Hattori, N; Kimura, K; Okazaki, N; Ozaki, H, 1979) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 1.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| "A group of 24 patients with colorectal cancer and another group of 28 patients with 13 different primaries were treated." | 1.26 | Treatment of hepatic metastases by percutaneous hepatic arterial infusion. ( Minton, JP; Petrek, JA, 1979) |
| "A case of primary hemangioendothelioma is presented." | 1.26 | Primary malignant hemangioendothelioma of the liver: survival following nonoperative treatment. ( El-Mahdi, A; Langley, JR; Rosato, FE, 1978) |
| "Two young women with cancer of the pancreas are described." | 1.26 | Cancer of the pancreas in young adults. ( Butterfield, D; Hobbs, JB; Kune, GA; Sali, A, 1978) |
| "Hepatic hypoglycemia is discussed and the literature is reviewed." | 1.26 | Hypoglycemia secondary to metastases to the liver. A case report and review of the literature. ( Chawla, SK; LoPresti, PA; Sossi, AJ; Soterakis, J; Younus, S, 1977) |
| "40 patients with primary or metastatic liver malignancies have been treated with hepatic dearterialization, 19 of them in combination with regional infusion with 5-fluoroacil." | 1.26 | Results of liver dearterialization combined with regional infusion of 5-fluorouracil for liver cancer. ( Almersjö, O; Bengmark, S; Hafström, L; Leissner, KH, 1976) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | 1.26 | Adriamycin in the treatment of cancer. ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| "The topography of the neoplasm had no influence on the I." | 1.25 | Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors. ( Dubois, JB; Serrou, B, 1975) |
| "Metastases were from colon cancer in 13 and from other primary cancers in 6." | 1.25 | Hepatic artery ligation and postoperative chemotherapy for hepatic metastases: clinical and pathophysiological results. ( Hallauer, WC; Morton, DL; Mosher, MB; Passaro, E; Rangel, D; Silverstein, MJ; Sparks, FC, 1975) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 1.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "5-Fluorouracil (5-FU) was administered to 8 patients with malignant liver tumours either by regional portal or general intravenous infusion." | 1.25 | Concentration of biologically active 5-fluorouracil in general circulation during continuous portal infusion in man: a preliminary report. ( Almersjö, O; Brandberg, A; Gustavsson, B, 1975) |
| "There was no clinical evidence of carcinoid syndrome." | 1.25 | 5-Hydroxyindole-secreting rectal carcinoid tumour. ( Cheetham, HD; Murray-Lyon, IM; Sandler, M; Watts, JA; Williams, R, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 713 (17.98) | 18.7374 |
| 1990's | 690 (17.40) | 18.2507 |
| 2000's | 1183 (29.84) | 29.6817 |
| 2010's | 1152 (29.05) | 24.3611 |
| 2020's | 227 (5.73) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 6 |
| Liu, C | 13 |
| Gong, C | 1 |
| Lin, W | 1 |
| Guo, C | 4 |
| El-Far, M | 1 |
| Elmegeed, GA | 1 |
| Eskander, EF | 1 |
| Rady, HM | 1 |
| Tantawy, MA | 1 |
| Sun, J | 9 |
| Yang, YS | 1 |
| Li, W | 8 |
| Zhang, YB | 1 |
| Wang, XL | 2 |
| Tang, JF | 1 |
| Zhu, HL | 1 |
| Tuncbilek, M | 1 |
| Guven, EB | 1 |
| Onder, T | 1 |
| Cetin Atalay, R | 1 |
| Fu, J | 2 |
| Liu, L | 10 |
| Huang, Z | 2 |
| Lai, Y | 1 |
| Ji, H | 1 |
| Peng, S | 2 |
| Tian, J | 2 |
| Zhang, Y | 29 |
| Dai, M | 2 |
| Yuan, X | 3 |
| Kang, J | 1 |
| Zhu, ZJ | 2 |
| Yue, RC | 1 |
| Yuan, H | 2 |
| Chen, BY | 2 |
| Zhang, WD | 4 |
| Liu, RH | 2 |
| Sun, QY | 2 |
| Zhang, H | 15 |
| Zhu, P | 4 |
| Liu, J | 22 |
| Yang, X | 14 |
| Xu, S | 4 |
| Yao, H | 3 |
| Jiang, J | 5 |
| Ye, W | 5 |
| Wu, X | 17 |
| Xu, J | 11 |
| Lin, Y | 7 |
| Wang, Y | 30 |
| Paterna, A | 1 |
| Borralho, PM | 1 |
| Gomes, SE | 1 |
| Mulhovo, S | 1 |
| Rodrigues, CM | 1 |
| Ferreira, MJ | 1 |
| Shaaban, S | 2 |
| Negm, A | 2 |
| Ashmawy, AM | 2 |
| Ahmed, DM | 1 |
| Wessjohann, LA | 2 |
| Giri, GF | 1 |
| Danielli, M | 1 |
| Marinelli, RA | 1 |
| Spanevello, RA | 1 |
| Cheng, ZY | 1 |
| Yao, GD | 3 |
| Guo, R | 7 |
| Huang, XX | 3 |
| Song, SJ | 3 |
| Bai, ZT | 1 |
| Wu, ZR | 1 |
| Xi, LL | 1 |
| Li, X | 14 |
| Chen, P | 2 |
| Wang, FQ | 1 |
| Meng, WB | 1 |
| Zhou, WC | 1 |
| Wu, XA | 2 |
| Yao, XJ | 1 |
| Zhang, M | 6 |
| Tian, JL | 1 |
| Wang, YX | 2 |
| Gao, PY | 1 |
| Wang, D | 3 |
| Li, LZ | 2 |
| Lin, B | 2 |
| Hawash, MM | 1 |
| Kahraman, DC | 1 |
| Eren, F | 1 |
| Cetin Atalay, R | 1 |
| Baytas, SN | 1 |
| Zhang, B | 7 |
| Wang, N | 4 |
| Zhang, C | 6 |
| Gao, C | 1 |
| Zhang, W | 12 |
| Chen, K | 6 |
| Wu, W | 4 |
| Chen, Y | 22 |
| Tan, C | 1 |
| Liu, F | 7 |
| Jiang, Y | 3 |
| Zhang, L | 13 |
| Zheng, C | 1 |
| Nie, X | 1 |
| Shi, D | 1 |
| Wei, G | 2 |
| Wang, J | 20 |
| Chen, YY | 2 |
| Cao, YZ | 1 |
| Li, FQ | 1 |
| Zhu, XL | 1 |
| Peng, CX | 1 |
| Lu, JH | 1 |
| Chen, JW | 4 |
| Sun, Q | 4 |
| Song, XY | 1 |
| Qi, XL | 1 |
| Xi, YF | 1 |
| Liang, C | 1 |
| Pei, S | 1 |
| Ju, W | 1 |
| Jia, M | 1 |
| Tian, D | 1 |
| Tang, Y | 3 |
| Mao, G | 2 |
| Chen, H | 14 |
| Yu, Z | 4 |
| Cheng, Z | 3 |
| Zhao, Z | 4 |
| Wu, G | 3 |
| Xie, N | 2 |
| Ling, Y | 2 |
| Gao, WJ | 1 |
| Ling, C | 1 |
| Meng, C | 1 |
| Qian, J | 2 |
| Liu, S | 7 |
| Gan, H | 1 |
| Wu, H | 2 |
| Tao, J | 2 |
| Dai, H | 3 |
| Ding, Y | 3 |
| Li, S | 11 |
| Ge, W | 1 |
| Liu, Z | 12 |
| Zhang, X | 13 |
| Wang, M | 3 |
| Chen, T | 1 |
| Zhang, Q | 5 |
| Qiu, J | 2 |
| Zhou, Q | 4 |
| Guan, M | 2 |
| Zou, Y | 3 |
| Huang, X | 5 |
| Zhao, Y | 8 |
| Chen, W | 4 |
| Gu, X | 1 |
| Tawfik, HO | 1 |
| Petreni, A | 1 |
| Supuran, CT | 1 |
| El-Hamamsy, MH | 1 |
| Okamoto, H | 1 |
| Shiba, S | 2 |
| Iino, H | 1 |
| Sudoh, M | 1 |
| Ichikawa, D | 6 |
| Yue, K | 1 |
| Hou, X | 2 |
| Jia, G | 1 |
| Zhang, J | 24 |
| Tan, L | 1 |
| Wang, X | 21 |
| Zhang, Z | 9 |
| Li, P | 3 |
| Xu, W | 3 |
| Suzuki, H | 7 |
| Niizeki, T | 5 |
| Shirono, T | 3 |
| Koteda, Y | 1 |
| Kinjyo, Y | 1 |
| Mizukami, N | 2 |
| Koda, M | 1 |
| Ota, S | 1 |
| Nakano, M | 10 |
| Okamura, S | 6 |
| Iwamoto, H | 8 |
| Shimose, S | 4 |
| Noda, Y | 4 |
| Kamachi, N | 2 |
| Kajiwara, A | 1 |
| Suda, K | 3 |
| Akiba, J | 4 |
| Yano, H | 13 |
| Kuromatsu, R | 5 |
| Koga, H | 4 |
| Torimura, T | 6 |
| Pan, Y | 5 |
| Mei, J | 4 |
| Chen, J | 9 |
| Zhang, D | 5 |
| Yi, M | 1 |
| Zhou, Z | 4 |
| Chen, M | 8 |
| Xu, L | 10 |
| Chen, S | 7 |
| Xu, B | 2 |
| Wu, Z | 6 |
| Wang, P | 3 |
| Yu, W | 3 |
| Wu, Y | 8 |
| Li, T | 4 |
| Guo, W | 4 |
| Zhu, J | 5 |
| Sidaway, P | 2 |
| Sofocleous, CT | 2 |
| D'Angelica, MI | 8 |
| Gebauer, F | 1 |
| Damanakis, AI | 1 |
| Popp, F | 1 |
| Quaas, A | 1 |
| Kütting, F | 1 |
| Lutz, K | 1 |
| Held, S | 3 |
| Deuß, B | 1 |
| Göser, T | 1 |
| Waldschmidt, D | 1 |
| Bruns, C | 1 |
| Turley, MC | 1 |
| Moore, C | 1 |
| Creasy, JM | 3 |
| Sharib, J | 1 |
| Lan, B | 1 |
| Thacker, JKM | 1 |
| Migaly, J | 1 |
| Zani, S | 3 |
| Allen, PJ | 7 |
| Mantyh, CR | 1 |
| Lidsky, ME | 5 |
| Buisman, FE | 2 |
| Filipe, WF | 1 |
| Galjart, B | 1 |
| Grünhagen, DJ | 2 |
| Homs, MYV | 1 |
| Moelker, A | 1 |
| Verhoef, C | 5 |
| Groot Koerkamp, B | 1 |
| Lyu, N | 5 |
| Li, JB | 3 |
| Lai, JF | 1 |
| Chen, QF | 1 |
| Li, SL | 2 |
| Deng, HJ | 1 |
| He, M | 7 |
| Mu, LW | 1 |
| Zhao, M | 9 |
| Peng, SH | 1 |
| Mbarak, HS | 1 |
| Li, YH | 7 |
| Ma, C | 1 |
| Shang, QL | 2 |
| Chen, Z | 12 |
| Bian, DJ | 2 |
| Xiao, EH | 2 |
| Yu, H | 6 |
| Qin, L | 3 |
| Jia, Z | 2 |
| Ni, C | 1 |
| Jiang, Z | 3 |
| Hou, Z | 3 |
| Liang, Z | 1 |
| Ychou, M | 9 |
| Rivoire, M | 4 |
| Thezenas, S | 3 |
| Guimbaud, R | 9 |
| Ghiringhelli, F | 5 |
| Mercier-Blas, A | 1 |
| Mineur, L | 4 |
| Francois, E | 6 |
| Khemissa, F | 1 |
| Chauvenet, M | 1 |
| Kianmanesh, R | 2 |
| Fonck, M | 1 |
| Houyau, P | 1 |
| Aparicio, T | 3 |
| Galais, MP | 2 |
| Audemar, F | 2 |
| Assenat, E | 1 |
| Lopez-Crapez, E | 1 |
| Jouffroy, C | 1 |
| Adenis, A | 3 |
| Adam, R | 21 |
| Bouché, O | 9 |
| Pernot, S | 6 |
| Pellerin, O | 5 |
| Monterymard, C | 2 |
| Smith, D | 6 |
| Lapuyade, B | 1 |
| Gallois, C | 2 |
| Khemissa Akouz, F | 1 |
| De Baere, T | 9 |
| Tougeron, D | 3 |
| Thirot-Bidault, A | 1 |
| Simon, M | 2 |
| Lecaille, C | 1 |
| Louafi, S | 1 |
| Lepage, C | 4 |
| Ducreux, M | 27 |
| Taieb, J | 13 |
| Taniguchi, A | 1 |
| Adachi, Y | 7 |
| Kimura, Y | 19 |
| Iitaka, D | 3 |
| Nagata, T | 2 |
| Iwata, G | 1 |
| Yamaoka, N | 1 |
| Kagawa, Y | 1 |
| Inoue, A | 2 |
| Nishizawa, Y | 1 |
| Kawai, K | 1 |
| Ohta, T | 5 |
| Hata, T | 5 |
| Naito, A | 3 |
| Komatsu, H | 3 |
| Miyazaki, Y | 1 |
| Tomokuni, A | 5 |
| Motoori, M | 4 |
| Fujitani, K | 7 |
| Kato, T | 18 |
| Takeda, Y | 28 |
| Murata, K | 8 |
| Zhang, WL | 1 |
| Zhou, C | 1 |
| Deng, YX | 1 |
| Hou, ZL | 1 |
| Zhang, LJ | 1 |
| Lin, JZ | 1 |
| Pan, ZZ | 3 |
| Lu, ZH | 4 |
| Peng, JH | 1 |
| Feng, GY | 1 |
| Cheng, Y | 5 |
| Shi, ZR | 1 |
| Khin, NY | 1 |
| De Silva, M | 1 |
| Clarke, S | 2 |
| Pavlakis, N | 3 |
| Rogan, CM | 1 |
| Ho-Shon, K | 1 |
| Lane, RJ | 1 |
| Jin, Z | 1 |
| Qiu, G | 1 |
| Xie, Q | 4 |
| Mi, S | 1 |
| Huang, J | 7 |
| Ishii, M | 4 |
| Itano, O | 2 |
| Hibi, T | 2 |
| Itano, S | 5 |
| Samoon, Z | 1 |
| Naher, SK | 1 |
| Sjoquist, KM | 2 |
| Zalcberg, J | 2 |
| Matsumura, M | 1 |
| Hasegawa, K | 18 |
| Oba, M | 4 |
| Yamaguchi, K | 8 |
| Uetake, H | 17 |
| Yoshino, T | 2 |
| Morita, S | 12 |
| Takahashi, K | 24 |
| Unno, M | 6 |
| Shimada, Y | 15 |
| Muro, K | 11 |
| Matsuhashi, N | 1 |
| Mori, M | 25 |
| Baba, H | 34 |
| Shimada, M | 6 |
| Mise, Y | 4 |
| Kawaguchi, Y | 6 |
| Kagimura, T | 2 |
| Ishigure, K | 2 |
| Saiura, A | 5 |
| Sugihara, K | 22 |
| Kokudo, N | 6 |
| Watanabe, G | 3 |
| Inoue, Y | 16 |
| Takahashi, Y | 9 |
| Kishi, Y | 3 |
| Suyama, K | 2 |
| Takayama, T | 13 |
| Noie, T | 1 |
| Nishioka, Y | 4 |
| Akamatsu, N | 2 |
| Arita, J | 2 |
| Matsumura, K | 1 |
| Yamamura, K | 1 |
| Miyamoto, H | 3 |
| Hara, Y | 7 |
| Oda, E | 1 |
| Akahoshi, S | 1 |
| Yoshida, K | 9 |
| Yuki, H | 1 |
| Motohara, T | 4 |
| Sakamoto, K | 10 |
| Komohara, Y | 1 |
| Beppu, T | 18 |
| Suzuki, K | 16 |
| Matsuo, K | 7 |
| Kikuchi, Y | 4 |
| Koda, K | 4 |
| Tanaka, K | 20 |
| Pu, Y | 2 |
| Yan, D | 6 |
| Tu, L | 2 |
| Cheng, L | 4 |
| Yu, J | 13 |
| Li, Z | 13 |
| Zheng, X | 3 |
| Sütcüoğlu, O | 1 |
| Ulaş Kahya, B | 1 |
| Özdemir, N | 1 |
| Yazıcı, O | 1 |
| Liu, N | 1 |
| Wang, Q | 9 |
| Hu, J | 2 |
| Yang, A | 1 |
| Wu, Q | 4 |
| Chen, Q | 3 |
| Yang, J | 8 |
| Li, H | 13 |
| Tao, Y | 2 |
| Wang, A | 1 |
| Sun, Y | 7 |
| Morinaga, J | 1 |
| Shirakawa, H | 2 |
| Walker, BS | 1 |
| Billingsley, KG | 1 |
| Sutton, TL | 1 |
| Kolbeck, KJ | 1 |
| Korngold, EK | 1 |
| Nabavizadeh, N | 1 |
| Dewey, EN | 1 |
| Herzig, DO | 1 |
| Lopez, CD | 1 |
| Mayo, SC | 2 |
| Ouyang, H | 1 |
| He, D | 1 |
| Liu, D | 4 |
| Pan, W | 1 |
| Li, Q | 22 |
| Xie, W | 1 |
| Yu, C | 2 |
| Kang, S | 1 |
| Magliocca, J | 1 |
| Sellers, M | 1 |
| Roccaro, G | 1 |
| Zheng, W | 2 |
| Pectasides, M | 1 |
| Draper, A | 1 |
| Guadagno, J | 1 |
| El-Rayes, B | 2 |
| Akce, M | 2 |
| Qu, Y | 2 |
| Chen, YZ | 1 |
| Maruyama, K | 5 |
| Tominaga, T | 4 |
| Nonaka, T | 1 |
| Moriyama, M | 4 |
| Oyama, S | 1 |
| Sawai, T | 2 |
| Nagayasu, T | 1 |
| Guo, J | 5 |
| Huang, L | 7 |
| Komarov, IV | 1 |
| Tolstanova, G | 1 |
| Kuznietsova, H | 1 |
| Dziubenko, N | 1 |
| Yanchuk, PI | 1 |
| Shtanova, LY | 1 |
| Veselsky, SP | 1 |
| Garmanchuk, LV | 1 |
| Khranovska, N | 1 |
| Gorbach, O | 1 |
| Dovbynchuk, T | 1 |
| Borysko, P | 1 |
| Babii, O | 1 |
| Schober, T | 1 |
| Ulrich, AS | 1 |
| Afonin, S | 1 |
| Yu, S | 6 |
| Sathiyaseelan, A | 1 |
| Saravanakumar, K | 1 |
| Wang, MH | 1 |
| Tiu, YC | 2 |
| Gong, L | 2 |
| Luo, J | 2 |
| Yang, Y | 9 |
| Lee, WM | 1 |
| Guan, XY | 3 |
| Tanaka, M | 22 |
| Abe, S | 3 |
| Narita, H | 1 |
| Kawaratani, H | 1 |
| Shibamoto, A | 1 |
| Takeda, S | 4 |
| Ozutsumi, T | 1 |
| Tsuji, Y | 23 |
| Fujinaga, Y | 1 |
| Kitagawa, K | 1 |
| Nishimura, N | 1 |
| Hokuto, D | 2 |
| Sho, M | 6 |
| Yoshiji, H | 2 |
| Lu, W | 2 |
| Wang, L | 20 |
| Lou, J | 1 |
| Tang, K | 1 |
| Judge, SJ | 2 |
| Cho, M | 3 |
| Gholami, S | 3 |
| Yan, Q | 1 |
| Ren, J | 1 |
| Fang, X | 2 |
| Liu, B | 6 |
| Lam, RHW | 1 |
| Lam, KO | 2 |
| Lee, AW | 1 |
| Matuszyk, J | 1 |
| Modest, DP | 4 |
| Karthaus, M | 3 |
| Kasper, S | 1 |
| Moosmann, N | 3 |
| Keitel, V | 1 |
| Kiani, A | 3 |
| Uhlig, J | 1 |
| Jacobasch, L | 1 |
| Fischer V Weikersthal, L | 1 |
| Fuchs, M | 1 |
| Kaiser, F | 2 |
| Lerchenmüller, C | 1 |
| Sent, D | 1 |
| Junghanß, C | 1 |
| Lorenzen, S | 2 |
| Kaczirek, K | 5 |
| Jung, A | 2 |
| Stintzing, S | 4 |
| Heinemann, V | 6 |
| Lai, Z | 3 |
| Bu, X | 3 |
| Xu, Y | 3 |
| Huang, Y | 9 |
| Wen, D | 3 |
| Wei, W | 5 |
| Kan, A | 3 |
| Shi, M | 10 |
| Liu, X | 6 |
| Liu, Q | 4 |
| Bao, X | 1 |
| Oranratnachai, S | 1 |
| Rattanasiri, S | 1 |
| Sirachainan, E | 1 |
| Tansawet, A | 1 |
| Raunroadroong, N | 1 |
| McKay, GJ | 1 |
| Attia, J | 1 |
| Thakkinstian, A | 1 |
| Shi, J | 3 |
| Jiang, D | 2 |
| Mao, F | 3 |
| Gu, J | 4 |
| Zhou, L | 2 |
| Shen, L | 3 |
| Lau, WY | 6 |
| Cheng, S | 3 |
| Vladu, AF | 1 |
| Ficai, D | 1 |
| Ene, AG | 1 |
| Ficai, A | 1 |
| Kibudde, S | 1 |
| Begg, W | 1 |
| Huang, P | 1 |
| Zhou, Y | 11 |
| Yang, G | 1 |
| Shi, G | 1 |
| Liu, Y | 19 |
| Qiao, Y | 1 |
| Zhou, M | 4 |
| An, C | 1 |
| Li, C | 6 |
| Xue, L | 1 |
| He, J | 3 |
| Ren, C | 1 |
| Fu, X | 2 |
| Sakamoto, S | 1 |
| Tagai, N | 1 |
| Kurebayashi, H | 1 |
| Sawai, K | 5 |
| Morikawa, M | 2 |
| Koneri, K | 4 |
| Tamaki, M | 1 |
| Murakami, M | 14 |
| Hirono, Y | 2 |
| Goi, T | 6 |
| Lin, X | 3 |
| Perrin, ML | 3 |
| Bardet, SM | 3 |
| Yardin, C | 3 |
| Durand Fontanier, S | 3 |
| Taibi, A | 3 |
| Li, SH | 2 |
| Wang, QX | 2 |
| Fang, CK | 2 |
| Lei, QC | 2 |
| Huang, HK | 2 |
| Cao, MR | 2 |
| Luo, R | 2 |
| Deng, JD | 2 |
| Jiang, YC | 2 |
| Zhao, RC | 2 |
| Lu, LH | 2 |
| Zou, JW | 2 |
| Deng, M | 3 |
| Lin, WP | 2 |
| Guan, RG | 2 |
| Wen, YH | 2 |
| Zheng, L | 4 |
| Guo, ZX | 2 |
| Ling, YH | 2 |
| Chen, HW | 2 |
| Zhong, C | 2 |
| Guo, RP | 2 |
| Yamagata, M | 2 |
| Nakajima, T | 7 |
| Aihara, T | 3 |
| Nishijima, N | 1 |
| Tomoo, Y | 1 |
| Matsuki, G | 1 |
| Fujikawa, M | 3 |
| Ichise, N | 1 |
| Kasai, M | 4 |
| Okamoto, R | 1 |
| Ikuta, S | 1 |
| Nakamoto, Y | 3 |
| Osaki, Y | 3 |
| Yanagi, H | 4 |
| Yamanaka, N | 2 |
| Kaneko, J | 6 |
| Isogai, J | 5 |
| Hayashi, K | 8 |
| Takatsuno, Y | 2 |
| Okamoto, S | 2 |
| Hayakawa, T | 2 |
| Maejima, K | 2 |
| Kawaguchi, T | 1 |
| Damato, A | 1 |
| Ghidini, M | 2 |
| Dottorini, L | 1 |
| Tomasello, G | 6 |
| Iaculli, A | 1 |
| Ghidini, A | 1 |
| Luciani, A | 2 |
| Petrelli, F | 2 |
| MasodKhooy, MJ | 1 |
| Farasat, M | 1 |
| Salehi Salmi, M | 1 |
| Mirzaei, H | 1 |
| Ogawa, T | 2 |
| Kawamoto, S | 3 |
| Yamamoto, K | 18 |
| Atarashi, M | 1 |
| Terashima, T | 4 |
| Kurogi, N | 1 |
| Abdel-Hamid, NM | 1 |
| ElNakeeb, NA | 1 |
| El-Senduny, FF | 1 |
| Abu-Serie, MM | 1 |
| Abdelfattah, EZA | 1 |
| Fu, Y | 1 |
| Peng, W | 2 |
| Yang, Z | 6 |
| Hu, Z | 3 |
| Pang, Y | 1 |
| Hu, D | 1 |
| Okano, M | 2 |
| Hara, T | 2 |
| Tanizaki, K | 1 |
| Takayama, O | 1 |
| Kim, Y | 1 |
| Imamoto, H | 2 |
| Hasegawa, J | 2 |
| Du, Z | 1 |
| Shen, J | 4 |
| Beechinor, RJ | 1 |
| Abidalhassan, MF | 1 |
| Small, DF | 1 |
| Hoang, HK | 1 |
| Lamba, R | 1 |
| Loehfelm, TW | 1 |
| Foster, CC | 1 |
| Koontz, MZ | 1 |
| Kim, EJ | 1 |
| Yang, F | 5 |
| Min, Y | 1 |
| Shi, L | 5 |
| Liu, M | 3 |
| Wang, K | 7 |
| Ke, S | 1 |
| Gong, Y | 1 |
| Lin, ZP | 1 |
| Hu, XL | 2 |
| Chen, D | 6 |
| Zou, XG | 1 |
| Zhong, H | 1 |
| Xu, SX | 1 |
| Li, XQ | 1 |
| Huang, DB | 1 |
| Kauffels, A | 1 |
| Nowack, H | 1 |
| Bohnenberger, H | 1 |
| Spitzner, M | 1 |
| Sprenger, T | 1 |
| Ghadimi, M | 1 |
| Sperling, J | 2 |
| Shao, H | 1 |
| Li, A | 1 |
| Ma, L | 2 |
| Zhang, K | 1 |
| Gao, W | 1 |
| Si, T | 1 |
| Zou, Q | 1 |
| Guo, Z | 2 |
| Li, M | 7 |
| Mu, H | 1 |
| Xing, W | 1 |
| Zaidi, MY | 1 |
| Nussbaum, DP | 1 |
| Hsu, SD | 2 |
| Strickler, JH | 2 |
| Uronis, HE | 2 |
| Nasef, SM | 1 |
| Khozemy, EE | 1 |
| Mahmoud, GA | 1 |
| Kataoka, K | 2 |
| Takeuchi, J | 1 |
| Ito, K | 13 |
| Beppu, N | 1 |
| Ceelen, W | 3 |
| Kanemitsu, Y | 2 |
| Ajioka, Y | 1 |
| Endo, I | 8 |
| Ikeda, M | 14 |
| Huang, C | 11 |
| Situ, Y | 1 |
| Ji, S | 1 |
| Xu, M | 2 |
| Cai, C | 1 |
| He, X | 3 |
| Shi, Y | 5 |
| Ma, J | 8 |
| Chen, KE | 1 |
| Chen, B | 2 |
| Liang, H | 5 |
| Lu, Y | 3 |
| Yang, C | 4 |
| Imai, K | 10 |
| Hamaya, S | 1 |
| Oura, K | 1 |
| Morishita, A | 1 |
| Masaki, T | 4 |
| Cioce, M | 1 |
| Fumagalli, MR | 1 |
| Donzelli, S | 1 |
| Goeman, F | 1 |
| Canu, V | 1 |
| Rutigliano, D | 1 |
| Orlandi, G | 1 |
| Sacconi, A | 1 |
| Pulito, C | 1 |
| Palcau, AC | 1 |
| Fanciulli, M | 1 |
| Morrone, A | 1 |
| Diodoro, MG | 1 |
| Caricato, M | 1 |
| Crescenzi, A | 1 |
| Verri, M | 1 |
| Fazio, VM | 1 |
| Zapperi, S | 1 |
| Levrero, M | 1 |
| Strano, S | 1 |
| Grazi, GL | 2 |
| La Porta, C | 1 |
| Blandino, G | 1 |
| Katipally, RR | 1 |
| Martinez, CA | 1 |
| Pugh, SA | 1 |
| Bridgewater, JA | 1 |
| Primrose, JN | 6 |
| Domingo, E | 1 |
| Maughan, TS | 1 |
| Talamonti, MS | 1 |
| Posner, MC | 1 |
| Weichselbaum, RR | 1 |
| Pitroda, SP | 1 |
| Lin, Q | 2 |
| Ding, K | 1 |
| Zhao, R | 2 |
| Wang, H | 14 |
| Wei, Y | 5 |
| Ren, L | 5 |
| Ye, Q | 2 |
| Cui, Y | 3 |
| He, G | 3 |
| Tang, W | 4 |
| Feng, Q | 2 |
| Zhu, D | 2 |
| Chang, W | 4 |
| Liang, L | 2 |
| Zhou, G | 1 |
| Liang, F | 4 |
| Ye, F | 3 |
| Fan, J | 11 |
| Verheij, FS | 2 |
| Kuhlmann, KFD | 2 |
| Silliman, DR | 2 |
| Soares, KC | 2 |
| Kingham, TP | 6 |
| Balachandran, VP | 4 |
| Drebin, JA | 3 |
| Wei, AC | 2 |
| Jarnagin, WR | 9 |
| Cercek, A | 6 |
| Kok, NFM | 2 |
| Kemeny, NE | 17 |
| Jiang, L | 1 |
| Pan, T | 3 |
| Lv, Q | 1 |
| Yuan, W | 1 |
| Qu, X | 3 |
| Luo, D | 1 |
| Wan, S | 2 |
| Cui, S | 1 |
| Zhang, F | 1 |
| Huo, L | 1 |
| Ghalambor, T | 1 |
| Cavnar, MJ | 1 |
| Merkow, RP | 1 |
| Dominguez-Rosado, I | 1 |
| Karanicolas, PJ | 1 |
| Rocha, FG | 1 |
| Fields, RC | 1 |
| Patel, RA | 1 |
| Kennecke, HF | 2 |
| Koerkamp, BG | 1 |
| Yopp, AC | 1 |
| Petrowsky, H | 3 |
| Mahalingam, D | 1 |
| Kemeny, N | 22 |
| D'Angelica, M | 5 |
| Brañes, A | 1 |
| Karanicolas, P | 1 |
| Malka, D | 9 |
| Verret, B | 1 |
| Faron, M | 4 |
| Caramella, C | 2 |
| Edeline, J | 1 |
| Bengrine-Lefevre, L | 1 |
| Dupont-Bierre, E | 1 |
| Goéré, D | 10 |
| Dartigues, P | 3 |
| Lacroix, L | 1 |
| Boige, V | 17 |
| Gelli, M | 4 |
| Pignon, JP | 5 |
| Asahina, Y | 2 |
| Takatori, H | 4 |
| Nio, K | 3 |
| Okada, H | 5 |
| Hayashi, T | 14 |
| Hashiba, T | 2 |
| Suda, T | 3 |
| Nishitani, M | 1 |
| Sugimoto, S | 1 |
| Honda, M | 8 |
| Kaneko, S | 7 |
| Yamashita, T | 10 |
| Wang, S | 2 |
| Qiu, Z | 1 |
| Zhu, C | 3 |
| Zhao, S | 3 |
| Qiu, W | 1 |
| Lv, J | 2 |
| Qi, W | 1 |
| Fu, Z | 2 |
| Ma, K | 2 |
| Dong, B | 1 |
| Zhao, C | 4 |
| Che, C | 1 |
| Dong, C | 5 |
| Zhang, R | 6 |
| Liang, R | 4 |
| Okumura, S | 2 |
| Goumard, C | 2 |
| Gayet, B | 1 |
| Fuks, D | 1 |
| Scatton, O | 1 |
| Wei, H | 3 |
| Pan, J | 3 |
| Pan, D | 1 |
| Gao, T | 1 |
| Huang, M | 4 |
| Ou, M | 1 |
| Zhong, W | 1 |
| Lee, BH | 1 |
| Lee, DS | 1 |
| Cho, CW | 1 |
| Yun, SS | 1 |
| Shindoh, J | 5 |
| Kobayashi, Y | 5 |
| Kinowaki, K | 1 |
| Gonoi, W | 3 |
| Yoshida, S | 9 |
| Tani, K | 1 |
| Matoba, S | 3 |
| Kuroyanagi, H | 2 |
| Hashimoto, M | 9 |
| Yao, Y | 1 |
| Fang, Z | 2 |
| Miao, QR | 3 |
| Ye, M | 2 |
| Bonadio, RC | 1 |
| Amor Divino, PH | 1 |
| Obando, JSM | 1 |
| Lima, KCA | 1 |
| Recchimuzzi, DZ | 1 |
| Kruger, JAP | 1 |
| Saragiotto, DF | 1 |
| Capareli, FC | 1 |
| Hoff, PM | 3 |
| Fukui, S | 1 |
| Kobayashi, K | 20 |
| Morita, M | 4 |
| Ito, S | 3 |
| Kuba, S | 1 |
| Sakimura, C | 1 |
| Kosaka, T | 4 |
| Abe, K | 6 |
| Yamanouchi, K | 1 |
| Kanetaka, K | 1 |
| Takatsuki, M | 2 |
| Eguchi, S | 3 |
| Wang, G | 5 |
| Xu, X | 7 |
| Shi, C | 1 |
| Jain, C | 1 |
| Syed, A | 1 |
| Gupta, N | 2 |
| Kambhoj, M | 1 |
| Rao, A | 2 |
| Singh, S | 1 |
| Jin, X | 2 |
| Li, B | 9 |
| Wang, C | 9 |
| Liao, M | 2 |
| Hu, X | 6 |
| Yang, M | 4 |
| Geissler, M | 1 |
| Rivera, F | 6 |
| Wilson, R | 1 |
| Loupakis, F | 14 |
| Price, T | 3 |
| Tracy, M | 1 |
| Burdon, P | 1 |
| Peeters, M | 6 |
| Oshiro, H | 1 |
| Tome, Y | 1 |
| Kiyuna, T | 1 |
| Yoon, SN | 1 |
| Lwin, TM | 1 |
| Han, Q | 1 |
| Tan, Y | 3 |
| Miyake, K | 1 |
| Higuchi, T | 11 |
| Sugisawa, N | 2 |
| Katsuya, Y | 1 |
| Park, JH | 4 |
| Zang, Z | 1 |
| Razmjooei, S | 1 |
| Bouvet, M | 2 |
| Clary, B | 1 |
| Singh, SR | 1 |
| Kanaya, F | 1 |
| Nishida, K | 2 |
| Hoffman, RM | 5 |
| Morine, Y | 1 |
| Ikemoto, T | 1 |
| Iwahashi, S | 1 |
| Saito, YU | 1 |
| Yamada, S | 9 |
| Takasu, C | 1 |
| Higashijima, J | 1 |
| Imura, S | 1 |
| Varshosaz, J | 2 |
| Fard, MM | 1 |
| Mirian, M | 1 |
| Hassanzadeh, F | 2 |
| Li, F | 1 |
| Wu, N | 1 |
| Wei, N | 1 |
| Wen, X | 1 |
| Ling, S | 2 |
| Shan, Q | 1 |
| Liu, P | 2 |
| Wei, X | 3 |
| Ding, W | 1 |
| Teng, X | 1 |
| Ganesh, K | 1 |
| Wu, C | 2 |
| O'Rourke, KP | 1 |
| Szeglin, BC | 1 |
| Zheng, Y | 5 |
| Sauvé, CG | 1 |
| Adileh, M | 1 |
| Wasserman, I | 1 |
| Marco, MR | 1 |
| Kim, AS | 1 |
| Shady, M | 1 |
| Sanchez-Vega, F | 1 |
| Karthaus, WR | 1 |
| Won, HH | 1 |
| Choi, SH | 3 |
| Pelossof, R | 1 |
| Barlas, A | 1 |
| Ntiamoah, P | 1 |
| Pappou, E | 1 |
| Elghouayel, A | 1 |
| Strong, JS | 1 |
| Chen, CT | 1 |
| Harris, JW | 1 |
| Weiser, MR | 1 |
| Nash, GM | 2 |
| Guillem, JG | 1 |
| Wei, IH | 1 |
| Kolesnick, RN | 1 |
| Veeraraghavan, H | 1 |
| Ortiz, EJ | 1 |
| Petkovska, I | 1 |
| Manova-Todorova, KO | 1 |
| Saltz, LB | 2 |
| Lavery, JA | 1 |
| DeMatteo, RP | 6 |
| Massagué, J | 1 |
| Paty, PB | 2 |
| Yaeger, R | 1 |
| Chen, X | 8 |
| Patil, S | 2 |
| Clevers, H | 1 |
| Berger, MF | 1 |
| Lowe, SW | 1 |
| Shia, J | 4 |
| Romesser, PB | 1 |
| Dow, LE | 1 |
| Garcia-Aguilar, J | 1 |
| Sawyers, CL | 1 |
| Smith, JJ | 1 |
| Allard, MA | 2 |
| Beghdadi, N | 1 |
| Yamashita, S | 6 |
| Kitano, Y | 2 |
| Kokudo, T | 1 |
| Yamashita, YI | 3 |
| Sa Cunha, A | 2 |
| Vibert, E | 2 |
| Elias, D | 18 |
| Cherqui, D | 2 |
| Palmieri, LJ | 1 |
| Dermine, S | 1 |
| Coriat, R | 4 |
| Shimmura, H | 1 |
| Kuramochi, H | 2 |
| Jibiki, N | 1 |
| Katagiri, S | 1 |
| Nishino, T | 2 |
| Araida, T | 1 |
| Wang, Z | 13 |
| Gu, C | 1 |
| Lang, Y | 1 |
| Zhu, X | 3 |
| Yang, H | 1 |
| Shi, H | 1 |
| Shen, R | 1 |
| Wang, T | 5 |
| Zhou, J | 10 |
| Cao, Y | 3 |
| Nakamura, M | 23 |
| Watanabe, T | 13 |
| Mashita, N | 1 |
| Tobinaga, J | 1 |
| Fukuyama, R | 1 |
| Wattenberg, MM | 1 |
| Asch, D | 1 |
| O'Dwyer, PJ | 8 |
| Domchek, SM | 1 |
| Nathanson, KL | 1 |
| Rosen, MA | 1 |
| Beatty, GL | 1 |
| Siegelman, ES | 1 |
| Reiss, KA | 1 |
| Law, HC | 1 |
| Lagundžin, D | 1 |
| Clement, EJ | 1 |
| Qiao, F | 1 |
| Wagner, ZS | 1 |
| Krieger, KL | 1 |
| Costanzo-Garvey, D | 1 |
| Caffrey, TC | 1 |
| Grem, JL | 2 |
| DiMaio, DJ | 1 |
| Grandgenett, PM | 1 |
| Cook, LM | 1 |
| Fisher, KW | 1 |
| Yu, F | 2 |
| Hollingsworth, MA | 1 |
| Woods, NT | 1 |
| Macarulla Mercadé, T | 1 |
| Chen, LT | 6 |
| Li, CP | 3 |
| Siveke, JT | 2 |
| Cunningham, D | 18 |
| Bodoky, G | 2 |
| Blanc, JF | 3 |
| Lee, KH | 9 |
| Dean, A | 1 |
| Belanger, B | 2 |
| Wang-Gillam, A | 2 |
| Ma, X | 3 |
| Qiu, Y | 2 |
| Zhu, L | 2 |
| Ma, D | 3 |
| Qin, Z | 1 |
| Sun, C | 1 |
| Shen, X | 1 |
| Han, L | 1 |
| Hu, M | 2 |
| Zhou, X | 3 |
| Guan, K | 1 |
| Öz, A | 1 |
| Server, S | 1 |
| Koyuncu Sökmen, B | 1 |
| Namal, E | 1 |
| İnan, N | 1 |
| Balcı, NC | 1 |
| Tamjidifar, R | 1 |
| Akbari, M | 1 |
| Tarzi, S | 1 |
| Sadeghzadeh, M | 1 |
| Abolghasemi, M | 1 |
| Poursaei, E | 1 |
| Shomali, N | 1 |
| Mahdavi, F | 1 |
| Chouliaras, K | 1 |
| Russell, G | 1 |
| Levine, E | 1 |
| Howerton, R | 1 |
| Votanopoulos, K | 1 |
| Clark, C | 1 |
| Shen, P | 1 |
| Shen, A | 1 |
| Dercle, L | 1 |
| Lu, L | 1 |
| Schwartz, LH | 3 |
| Qian, M | 1 |
| Tejpar, S | 3 |
| Eggleton, P | 1 |
| Zhao, B | 3 |
| Piessevaux, H | 1 |
| Rochlani, SP | 1 |
| Dahiwade, LK | 1 |
| Choudhari, PB | 1 |
| Sun, R | 2 |
| Li, R | 5 |
| Chu, H | 1 |
| Hao, D | 1 |
| Bozkurt Duman, B | 1 |
| Çil, T | 1 |
| Alanazi, SA | 2 |
| Harisa, GI | 4 |
| Badran, MM | 4 |
| Haq, N | 1 |
| Radwan, AA | 1 |
| Kumar, A | 2 |
| Shakeel, F | 1 |
| Alanazi, FK | 4 |
| Sato, Y | 19 |
| Inaba, Y | 16 |
| Aramaki, T | 4 |
| Sone, M | 2 |
| Morita, Y | 2 |
| Nishiofuku, H | 9 |
| Tanaka, T | 21 |
| Miyazaki, M | 15 |
| Matsueda, K | 3 |
| Arai, Y | 26 |
| Hori, A | 1 |
| Ohira, R | 1 |
| Nakamura, T | 15 |
| Ueda, S | 6 |
| Torii, M | 1 |
| Kennoki, N | 1 |
| Hori, S | 4 |
| Das, S | 1 |
| Allen, A | 1 |
| Berlin, J | 1 |
| Nemoto, T | 3 |
| Endo, S | 4 |
| Isohata, N | 1 |
| Takayanagi, D | 1 |
| Nemoto, D | 1 |
| Aizawa, M | 1 |
| Utano, K | 1 |
| Togashi, K | 1 |
| Oshibe, I | 1 |
| Soeta, N | 1 |
| Saito, T | 6 |
| Swierz, MJ | 1 |
| Storman, D | 1 |
| Riemsma, RP | 1 |
| Wolff, R | 1 |
| Mitus, JW | 1 |
| Pedziwiatr, M | 1 |
| Kleijnen, J | 1 |
| Bala, MM | 1 |
| Yamano, T | 2 |
| Kubo, S | 1 |
| Tomita, N | 2 |
| Toyama, T | 2 |
| Shimakami, T | 1 |
| Shimizu, R | 1 |
| Arai, K | 24 |
| Kawaguchi, K | 3 |
| Kitamura, K | 3 |
| Sakai, Y | 7 |
| Mizukoshi, E | 2 |
| Mao, J | 1 |
| Ding, J | 1 |
| Frydenberg, H | 1 |
| Harsem, NK | 1 |
| Ofigsbø, Å | 1 |
| Skoglund, H | 1 |
| Brændengen, M | 1 |
| Kaasa, S | 1 |
| Guren, MG | 2 |
| Xiang, DC | 1 |
| Yang, JY | 1 |
| Xu, YJ | 1 |
| Zhang, S | 8 |
| Zhang, CL | 1 |
| Sastre, J | 5 |
| Orden, V | 1 |
| Martínez, A | 1 |
| Bando, I | 1 |
| Balbín, M | 1 |
| Bellosillo, B | 1 |
| Palanca, S | 1 |
| Peligros Gomez, MI | 1 |
| Mediero, B | 1 |
| Llovet, P | 1 |
| Moral, VM | 1 |
| Viéitez, JM | 2 |
| García-Alfonso, P | 2 |
| Calle, SG | 1 |
| Ortiz-Morales, MJ | 1 |
| Salud, A | 1 |
| Quintero, G | 2 |
| Lopez, C | 1 |
| Díaz-Rubio, E | 6 |
| Aranda, E | 7 |
| Das, M | 1 |
| Li, L | 5 |
| Han, S | 2 |
| Pan, H | 1 |
| Cao, W | 3 |
| Noordam, L | 1 |
| Verstegen, MMA | 1 |
| Ma, B | 4 |
| Wang, W | 6 |
| Bolkestein, M | 1 |
| Doukas, M | 1 |
| Ma, Z | 2 |
| Bruno, M | 1 |
| Sprengers, D | 1 |
| Kwekkeboom, J | 1 |
| van der Laan, LJW | 1 |
| Smits, R | 1 |
| Peppelenbosch, MP | 1 |
| Pan, Q | 2 |
| Kitagawa, Y | 4 |
| Osumi, H | 1 |
| Shinozaki, E | 4 |
| Ota, Y | 2 |
| Nakayama, I | 1 |
| Suzuki, T | 20 |
| Wakatsuki, T | 5 |
| Ogura, M | 2 |
| Ooki, A | 1 |
| Takahari, D | 7 |
| Suenaga, M | 5 |
| Chin, K | 3 |
| Kim, SA | 1 |
| Kim, JW | 8 |
| Suh, KJ | 1 |
| Oh, HK | 2 |
| Cho, JY | 3 |
| Kim, DW | 1 |
| Cho, S | 1 |
| Kim, JH | 13 |
| Kim, K | 3 |
| Kang, SB | 2 |
| Jheon, S | 1 |
| Lee, KW | 5 |
| Okuno, M | 4 |
| Hatano, E | 7 |
| Toda, R | 1 |
| Nishino, H | 8 |
| Nakamura, K | 12 |
| Ishii, T | 5 |
| Seo, S | 3 |
| Taura, K | 3 |
| Yasuchika, K | 5 |
| Yazawa, T | 2 |
| Zaima, M | 3 |
| Kanazawa, A | 6 |
| Terajima, H | 3 |
| Kaihara, S | 2 |
| Inoue, N | 4 |
| Furumoto, K | 3 |
| Manaka, D | 5 |
| Tokuka, A | 1 |
| Furuyama, H | 3 |
| Doi, K | 8 |
| Hirose, T | 2 |
| Horimatsu, T | 4 |
| Hasegawa, S | 8 |
| Matsumoto, S | 7 |
| Uemoto, S | 6 |
| Shibata, K | 2 |
| Machiki, Y | 1 |
| Hiromatsu, T | 1 |
| Takara, D | 1 |
| Idetsu, A | 1 |
| Ohara, N | 1 |
| Okazaki, S | 3 |
| Ishikawa, T | 21 |
| Hasuike, Y | 26 |
| Higuchi, I | 5 |
| Mori, Y | 7 |
| Ishikawa, A | 6 |
| Urano, N | 1 |
| Gofuku, J | 1 |
| Tsuchida, Y | 1 |
| Miyamoto, M | 2 |
| Tokunaga, M | 2 |
| Jiang, K | 1 |
| Yin, Z | 1 |
| Chun, YJ | 1 |
| Kim, SG | 3 |
| Cho, SH | 2 |
| Kim, TW | 6 |
| Baek, JY | 2 |
| Park, YS | 8 |
| Hong, S | 2 |
| Chu, CW | 1 |
| Beom, SH | 2 |
| Jung, M | 4 |
| Shin, SJ | 5 |
| Ahn, JB | 7 |
| Ding, H | 3 |
| Kratz, JD | 1 |
| LoConte, NK | 1 |
| Shigesawa, T | 1 |
| Maehara, O | 2 |
| Suda, G | 2 |
| Natsuizaka, M | 3 |
| Kimura, M | 6 |
| Shimazaki, T | 1 |
| Yamada, R | 2 |
| Kitagataya, T | 1 |
| Nakamura, A | 1 |
| Ohara, M | 4 |
| Kawagishi, N | 1 |
| Umemura, M | 1 |
| Nakai, M | 3 |
| Sho, T | 2 |
| Morikawa, K | 1 |
| Ogawa, K | 11 |
| Ohnishi, S | 2 |
| Sugiyama, M | 3 |
| Mizokami, M | 1 |
| Takeda, H | 4 |
| Sakamoto, N | 2 |
| Bockorny, B | 1 |
| Semenisty, V | 1 |
| Macarulla, T | 1 |
| Borazanci, E | 1 |
| Wolpin, BM | 1 |
| Stemmer, SM | 1 |
| Golan, T | 1 |
| Geva, R | 2 |
| Borad, MJ | 1 |
| Pedersen, KS | 1 |
| Park, JO | 6 |
| Ramirez, RA | 1 |
| Abad, DG | 1 |
| Feliu, J | 2 |
| Muñoz, A | 1 |
| Ponz-Sarvise, M | 1 |
| Peled, A | 1 |
| Lustig, TM | 1 |
| Bohana-Kashtan, O | 1 |
| Shaw, SM | 1 |
| Sorani, E | 1 |
| Chaney, M | 1 |
| Kadosh, S | 1 |
| Vainstein Haras, A | 1 |
| Von Hoff, DD | 2 |
| Hidalgo, M | 2 |
| Owen, D | 1 |
| Lukovic, J | 1 |
| Hosni, A | 1 |
| Crane, CH | 2 |
| Hong, TS | 2 |
| Dawson, LA | 1 |
| Velec, M | 1 |
| Lawrence, TS | 5 |
| Hough, NE | 1 |
| Chapman, SJ | 1 |
| Flight, WG | 1 |
| Artru, P | 5 |
| Raoul, JL | 8 |
| De La Fouchardière, C | 2 |
| Dahan, L | 3 |
| Sefrioui, D | 1 |
| Jouve, JL | 3 |
| Yamamoto, J | 3 |
| Nomura, Y | 3 |
| Hashiguchi, Y | 1 |
| Shibasaki, M | 2 |
| Sakamoto, H | 2 |
| Yamagata, S | 1 |
| Aoyanagi, N | 1 |
| Kaneko, H | 5 |
| Koyama, H | 5 |
| Miyagawa, S | 2 |
| Nozawa, H | 2 |
| Yang, Q | 3 |
| Chen, L | 11 |
| Zeng, C | 1 |
| Moretto, R | 2 |
| Corallo, S | 1 |
| Belfiore, A | 1 |
| Rossini, D | 3 |
| Boccaccino, A | 1 |
| Lonardi, S | 4 |
| Centonze, G | 1 |
| Morano, F | 2 |
| Germani, MM | 1 |
| Morelli, L | 2 |
| Urbani, L | 3 |
| Brich, S | 1 |
| Marmorino, F | 4 |
| Prisciandaro, M | 2 |
| Aprile, G | 4 |
| Fassan, M | 2 |
| Cillo, U | 2 |
| Cattaneo, L | 1 |
| Fontanini, G | 3 |
| De Braud, F | 3 |
| Falcone, A | 15 |
| Milione, M | 3 |
| Pietrantonio, F | 6 |
| Cremolini, C | 8 |
| Jia, Y | 2 |
| Peng, L | 1 |
| Konishi, T | 2 |
| Yoshidome, H | 4 |
| Shimizu, H | 6 |
| Yoshitomi, H | 3 |
| Furukawa, K | 3 |
| Takayashiki, T | 3 |
| Kuboki, S | 3 |
| Takano, S | 4 |
| Ohtsuka, M | 4 |
| Grothey, A | 2 |
| Xiang, Y | 2 |
| Huang, W | 3 |
| Long, J | 2 |
| Tang, S | 2 |
| He, DX | 3 |
| Tan, XW | 2 |
| Yu, CY | 3 |
| Patil, NR | 1 |
| Khan, GN | 1 |
| Basu, A | 1 |
| Dydowiczová, A | 1 |
| Trosko, JE | 1 |
| Bláha, L | 1 |
| Babica, P | 1 |
| Goto, Y | 2 |
| Hisaka, T | 3 |
| Sakai, H | 2 |
| Takagi, K | 1 |
| Fukutomi, S | 1 |
| Akagi, Y | 8 |
| Okuda, K | 11 |
| Song, X | 2 |
| He, Y | 7 |
| Han, M | 1 |
| Shao, Z | 1 |
| Liu, T | 2 |
| Pérez-Santiago, L | 1 |
| Dorcaratto, D | 1 |
| Garcés-Albir, M | 1 |
| Muñoz-Forner, E | 1 |
| Huerta Álvaro, M | 1 |
| Roselló Keranën, S | 1 |
| Sabater, L | 1 |
| Napier, KJ | 1 |
| Reed, SA | 1 |
| Wong, TZ | 1 |
| Kim, CY | 1 |
| Wildman-Tobriner, B | 1 |
| Mercier, F | 1 |
| Kerioui, M | 1 |
| Desmée, S | 1 |
| Guedj, J | 1 |
| Krieter, O | 1 |
| Bruno, R | 1 |
| Boilève, A | 1 |
| De Cuyper, A | 1 |
| Larive, A | 1 |
| Mahjoubi, L | 1 |
| Najdawi, M | 1 |
| Tazdait, M | 1 |
| Tselikas, L | 2 |
| Smolenschi, C | 1 |
| Maneikyte, J | 1 |
| Bausys, A | 1 |
| Leber, B | 1 |
| Feldbacher, N | 1 |
| Hoefler, G | 1 |
| Kolb-Lenz, D | 1 |
| Strupas, K | 1 |
| Stiegler, P | 1 |
| Schemmer, P | 1 |
| Gmijovic, M | 1 |
| Pecic, V | 1 |
| Stojanovic, M | 1 |
| Higai, K | 1 |
| Mukozu, T | 3 |
| Matsui, D | 3 |
| Amanuma, M | 1 |
| Yoshimine, N | 1 |
| Ogino, Y | 2 |
| Matsui, T | 8 |
| Wakui, N | 4 |
| Shinohara, M | 5 |
| Momiyama, K | 7 |
| Daido, Y | 1 |
| Nagai, H | 13 |
| Igarashi, Y | 5 |
| Jain, AK | 1 |
| Sahu, H | 1 |
| Mishra, K | 1 |
| Thareja, S | 1 |
| Lee, JC | 1 |
| Woo, SM | 2 |
| Shin, DW | 1 |
| Kim, J | 2 |
| Yang, SY | 1 |
| Kim, MJ | 3 |
| Lee, WJ | 3 |
| Cha, HS | 1 |
| Park, P | 1 |
| Hwang, JH | 1 |
| Hosokawa, A | 5 |
| Yamazaki, K | 9 |
| Matsuda, C | 2 |
| Kusaba, H | 3 |
| Tsuda, M | 3 |
| Tamura, T | 5 |
| Shinozaki, K | 1 |
| Tsushima, T | 1 |
| Tsuda, T | 4 |
| Shirakawa, T | 1 |
| Yamashita, H | 5 |
| Hironaka, S | 2 |
| Liu, KC | 1 |
| Hao, YH | 1 |
| Lv, WF | 1 |
| Jia, WD | 1 |
| Ji, CS | 1 |
| Zhou, CZ | 1 |
| Cheng, DL | 1 |
| Xu, SB | 1 |
| Gao, ZG | 1 |
| Su, MX | 1 |
| Shi, CS | 1 |
| Kawaguchi, S | 1 |
| Terada, S | 1 |
| Shirane, N | 1 |
| Srouji, RM | 1 |
| Narayan, RR | 1 |
| Boerner, T | 1 |
| Seier, K | 1 |
| Gonen, M | 8 |
| Wei, A | 2 |
| Tashiro, Y | 2 |
| Jilek, JL | 1 |
| Tu, MJ | 1 |
| Yu, AM | 1 |
| AlQahtani, SA | 2 |
| Alomrani, AH | 2 |
| Voß, H | 1 |
| Wurlitzer, M | 1 |
| Smit, DJ | 1 |
| Ewald, F | 1 |
| Alawi, M | 1 |
| Spohn, M | 1 |
| Indenbirken, D | 1 |
| Omidi, M | 1 |
| David, K | 1 |
| Juhl, H | 1 |
| Simon, R | 1 |
| Sauter, G | 1 |
| Fischer, L | 1 |
| Izbicki, JR | 1 |
| Molloy, MP | 1 |
| Nashan, B | 1 |
| Schlüter, H | 1 |
| Jücker, M | 1 |
| Xu, D | 2 |
| Wu, J | 5 |
| Xie, M | 1 |
| Tang, R | 1 |
| Cheng, C | 2 |
| Lin, S | 1 |
| Luo, X | 5 |
| Zheng, J | 3 |
| Changou, CA | 1 |
| Shiah, HS | 2 |
| Luh, F | 1 |
| Liu, SH | 2 |
| Cheng, YC | 2 |
| Yen, Y | 2 |
| Nassar, A | 1 |
| Phelip, JM | 3 |
| Loriau, J | 1 |
| Michel, P | 1 |
| Penna, C | 2 |
| Brouquet, A | 4 |
| Benoist, S | 3 |
| Connell, LC | 1 |
| Sun, D | 6 |
| Bhat, SS | 1 |
| Mukherjee, D | 1 |
| Sukharamwala, P | 1 |
| Dehuri, R | 1 |
| Murali, A | 1 |
| Teja, BV | 1 |
| Otomo, M | 1 |
| Maejima, S | 4 |
| Sato, H | 6 |
| Ii, T | 1 |
| Rikiyama, N | 1 |
| Noguchi, A | 2 |
| Aoki, Y | 1 |
| Sato, J | 2 |
| Kikuchi, D | 1 |
| Yamanami, H | 1 |
| Otani, A | 1 |
| Inoue, M | 9 |
| Otani, T | 3 |
| Watanabe, N | 3 |
| Nakatsukasa, R | 1 |
| Hayashi, N | 9 |
| Urabe, S | 1 |
| Nakagawa, T | 8 |
| Michiura, T | 1 |
| Yamabe, K | 1 |
| Hewitt, DB | 1 |
| Pawlik, TM | 2 |
| Cloyd, JM | 2 |
| Mei, N | 1 |
| Zhao, N | 3 |
| Tian, T | 2 |
| Jiao, M | 1 |
| Ding, WB | 1 |
| Ning, Q | 3 |
| Xia, Z | 2 |
| Song, J | 3 |
| Zhou, XW | 1 |
| Chen, XW | 1 |
| Shiraiwa, K | 1 |
| Suzuki, Y | 6 |
| Uchida, H | 3 |
| Iwashita, Y | 2 |
| Tanaka, R | 5 |
| Iwao, M | 1 |
| Tada, K | 4 |
| Hirashita, T | 2 |
| Masuda, T | 11 |
| Endo, Y | 9 |
| Inomata, M | 1 |
| Itoh, H | 2 |
| Takei, S | 1 |
| Homma, Y | 1 |
| Matsuyama, R | 4 |
| Quinonero, F | 1 |
| Cepero, A | 1 |
| Urbano, D | 1 |
| Munoz-Gamez, JA | 1 |
| Martin-Guerrero, SM | 1 |
| Martin-Oliva, D | 1 |
| Prados, J | 1 |
| Melguizo, C | 1 |
| Ortiz, R | 1 |
| Zhu, Y | 3 |
| Ke, KB | 1 |
| Xia, ZK | 1 |
| Li, HJ | 1 |
| Su, R | 2 |
| Zhou, FM | 1 |
| Chen, R | 2 |
| Wu, SG | 1 |
| Zhao, H | 3 |
| Gu, P | 1 |
| Leung, KS | 1 |
| Wong, MH | 1 |
| Lu, G | 1 |
| Zhang, JY | 1 |
| Jiang, BH | 1 |
| Qiu, JG | 1 |
| Shi, XN | 1 |
| Lin, MC | 1 |
| Zhou, B | 1 |
| Yan, Z | 5 |
| Lv, M | 1 |
| González Astorga, B | 1 |
| Salvà Ballabrera, F | 1 |
| Aranda Aguilar, E | 1 |
| Élez Fernández, E | 1 |
| González Flores, E | 1 |
| Vera García, R | 1 |
| Fernández Montes, A | 2 |
| López Muñoz, AM | 1 |
| Salud Salvia, A | 1 |
| Hu, B | 2 |
| Sun, YF | 1 |
| Huang, XW | 2 |
| Cheng, JW | 1 |
| Huang, A | 1 |
| Zeng, HY | 2 |
| Qiu, SJ | 1 |
| Yang, XR | 1 |
| Villard, C | 1 |
| Habib, M | 1 |
| Nordenvall, C | 1 |
| Nilsson, PJ | 1 |
| Jorns, C | 1 |
| Sparrelid, E | 1 |
| Hsu, SJ | 1 |
| Chen, MP | 1 |
| Zhao, ZY | 1 |
| Yin, X | 2 |
| Ge, NL | 5 |
| Wang, YH | 6 |
| Luo, JF | 1 |
| Ren, ZG | 5 |
| Chen, RX | 2 |
| Elzayat, E | 1 |
| Al Meanazel, OT | 1 |
| Al Meanazel, AT | 1 |
| Zhu, Q | 2 |
| Hu, H | 2 |
| Zhu, H | 3 |
| Yang, B | 4 |
| He, Q | 1 |
| Yu, L | 4 |
| Zeng, S | 3 |
| Choi, HJ | 4 |
| Kim, HR | 3 |
| Lee, H | 1 |
| Lee, JS | 2 |
| Lee, HW | 3 |
| Park, JY | 13 |
| Kim, SU | 6 |
| Kim, DY | 10 |
| Ahn, SH | 11 |
| Han, KH | 16 |
| Seong, J | 10 |
| Won, JY | 2 |
| Kim, BK | 5 |
| Sreekumar, R | 1 |
| Al-Saihati, H | 1 |
| Emaduddin, M | 1 |
| Moutasim, K | 1 |
| Mellone, M | 1 |
| Patel, A | 1 |
| Kilic, S | 1 |
| Cetin, M | 1 |
| Erdemir, S | 1 |
| Navio, MS | 1 |
| Lopez, MA | 1 |
| Curtis, N | 1 |
| Yagci, T | 1 |
| Price, BD | 1 |
| Berx, G | 1 |
| Thomas, GJ | 1 |
| Tulchinsky, E | 1 |
| Mirnezami, A | 1 |
| Sayan, AE | 1 |
| Kelm, M | 1 |
| Schollbach, J | 1 |
| Anger, F | 1 |
| Wiegering, A | 2 |
| Klein, I | 1 |
| Germer, CT | 2 |
| Schlegel, N | 1 |
| Kunzmann, V | 1 |
| Löb, S | 1 |
| Fujisawa, A | 1 |
| Takahara, H | 1 |
| Kondo, Y | 5 |
| Akagami, M | 1 |
| Yokoyama, T | 4 |
| Takahara, N | 1 |
| Yoshino, S | 3 |
| Ushigome, M | 1 |
| Kaneko, T | 4 |
| Kagami, S | 1 |
| Nagashima, Y | 2 |
| Koda, T | 1 |
| Miura, Y | 3 |
| Kurihara, A | 5 |
| Funahashi, K | 2 |
| Nakata, C | 1 |
| Sugou, N | 1 |
| Qin, S | 6 |
| Ren, Z | 5 |
| Xiong, J | 1 |
| Meng, Z | 1 |
| Zou, J | 1 |
| Cao, J | 4 |
| Gui, S | 1 |
| Chu, X | 1 |
| Han, X | 1 |
| Li, J | 20 |
| Lai, J | 1 |
| Deng, H | 4 |
| Hu, Y | 2 |
| Xie, Y | 1 |
| Liu, H | 4 |
| Jin, M | 1 |
| Kong, L | 2 |
| Han, Y | 2 |
| Bayir Garbioglu, D | 1 |
| Demir, N | 1 |
| Ozel, C | 1 |
| Avci, H | 1 |
| Dincer, M | 1 |
| Harding, JJ | 2 |
| Yang, TS | 5 |
| Feng, YH | 2 |
| Yen, CJ | 1 |
| Ho, CL | 1 |
| Huang, WT | 2 |
| El Dika, I | 1 |
| Tan, B | 1 |
| Cohen, SA | 1 |
| Meyer, T | 4 |
| Sarker, D | 1 |
| Lee, DW | 2 |
| Ryoo, BY | 2 |
| Lim, HY | 5 |
| Johnston, A | 2 |
| Bomalaski, JS | 1 |
| O'Reilly, EM | 3 |
| Abou-Alfa, GK | 3 |
| Nagamatsu, H | 4 |
| Ogo, E | 1 |
| Erickson, NT | 1 |
| Ricard, I | 1 |
| von Weikersthal, LF | 1 |
| Lerch, MM | 1 |
| Decker, T | 2 |
| Heintges, T | 2 |
| Kahl, C | 2 |
| Kullmann, F | 3 |
| Scheithauer, W | 15 |
| Link, H | 1 |
| Höffkes, HG | 2 |
| Moehler, M | 8 |
| Gesenhues, AB | 1 |
| Theurich, S | 1 |
| Michl, M | 1 |
| Algül, H | 1 |
| Holch, JW | 1 |
| Okusaka, T | 6 |
| Furuse, J | 3 |
| Mitsunaga, S | 1 |
| Ueno, H | 6 |
| Morizane, C | 4 |
| Kobayashi, T | 15 |
| Ruers, T | 2 |
| Van Coevorden, F | 2 |
| Punt, CJ | 8 |
| Pierie, JE | 1 |
| Borel-Rinkes, I | 1 |
| Ledermann, JA | 3 |
| Poston, G | 4 |
| Bechstein, W | 4 |
| Lentz, MA | 1 |
| Mauer, M | 5 |
| Folprecht, G | 6 |
| Van Cutsem, E | 12 |
| Nordlinger, B | 16 |
| Vienot, A | 1 |
| Beinse, G | 1 |
| Louvet, C | 8 |
| de Mestier, L | 2 |
| Meurisse, A | 1 |
| Fein, F | 1 |
| Heyd, B | 2 |
| Cleau, D | 2 |
| d'Engremont, C | 1 |
| Dupont-Gossart, AC | 1 |
| Lakkis, Z | 3 |
| Tournigand, C | 2 |
| Rousseau, B | 1 |
| Neuzillet, C | 1 |
| Bonnetain, F | 2 |
| Borg, C | 4 |
| Vernerey, D | 1 |
| Matsuda, K | 1 |
| Namiki, T | 1 |
| Ueno, M | 7 |
| Hashimoto, T | 7 |
| Hanafusa, T | 1 |
| Yokozeki, H | 1 |
| Nanda, A | 1 |
| Suyila, Q | 1 |
| Xian, L | 1 |
| Xiulan, S | 1 |
| Lim, A | 1 |
| Le Sourd, S | 1 |
| Senellart, H | 2 |
| Luet, D | 1 |
| Douane, F | 1 |
| Perret, C | 1 |
| Bouvier, A | 1 |
| Métairie, S | 1 |
| Cauchin, E | 2 |
| Rougier, P | 23 |
| Matysiak-Budnik, T | 3 |
| Touchefeu, Y | 2 |
| Grbčić, P | 1 |
| Tomljanović, I | 1 |
| Klobučar, M | 1 |
| Kraljević Pavelić, S | 1 |
| Lučin, K | 1 |
| Sedić, M | 1 |
| Luo, N | 2 |
| Tian, Y | 5 |
| Yin, H | 4 |
| Xiao, C | 1 |
| Sheng, J | 1 |
| Li, Y | 26 |
| Tang, B | 5 |
| Al-Batran, SE | 2 |
| Homann, N | 1 |
| Pauligk, C | 1 |
| Illerhaus, G | 2 |
| Martens, UM | 1 |
| Stoehlmacher, J | 2 |
| Schmalenberg, H | 1 |
| Luley, KB | 1 |
| Prasnikar, N | 1 |
| Egger, M | 1 |
| Probst, S | 1 |
| Messmann, H | 1 |
| Fischbach, W | 2 |
| Hartmann, JT | 7 |
| Mayer, F | 2 |
| Koenigsmann, M | 1 |
| Arnold, D | 5 |
| Kraus, TW | 1 |
| Grimm, K | 1 |
| Berkhoff, S | 1 |
| Post, S | 1 |
| Jäger, E | 3 |
| Ronellenfitsch, U | 1 |
| Mönig, S | 1 |
| Hofheinz, RD | 3 |
| Miller-Phillips, L | 1 |
| Fischer von Weikersthal, L | 1 |
| Vehling-Kaiser, U | 1 |
| Seipelt, G | 1 |
| Stauch, M | 1 |
| Jagenburg, A | 1 |
| Kirchner, T | 1 |
| You, YN | 1 |
| Shiozaki, H | 3 |
| Lee, JE | 4 |
| Passot, G | 1 |
| Aloia, TA | 5 |
| Eng, C | 5 |
| Chang, G | 1 |
| Vauthey, JN | 19 |
| Conrad, C | 2 |
| Mao, H | 2 |
| Dai, G | 3 |
| Yu, X | 3 |
| Babaei, M | 1 |
| Abnous, K | 1 |
| Taghdisi, SM | 1 |
| Amel Farzad, S | 1 |
| Peivandi, MT | 1 |
| Ramezani, M | 1 |
| Alibolandi, M | 1 |
| Yang, S | 4 |
| Wang, XQ | 1 |
| Kanamori, M | 1 |
| Kurumiya, Y | 2 |
| Mizuno, K | 2 |
| Sekoguchi, E | 1 |
| Kobayashi, S | 20 |
| Fukami, Y | 1 |
| Kiriyama, M | 3 |
| Aoyama, H | 6 |
| Oiwa, T | 1 |
| Miyamura, K | 1 |
| Jinno, T | 1 |
| Nakashima, Y | 1 |
| Russo, A | 3 |
| Passalacqua, R | 1 |
| Barni, S | 3 |
| Thongkum, A | 1 |
| Li, YY | 1 |
| Wangpaichitr, M | 1 |
| Navasumrit, P | 1 |
| Parnlob, V | 1 |
| Sricharunrat, T | 1 |
| Bhudhisawasdi, V | 2 |
| Ruchirawat, M | 1 |
| Savaraj, N | 1 |
| Devarasetty, M | 2 |
| Wang, E | 2 |
| Soker, S | 2 |
| Skardal, A | 2 |
| Kong, Y | 4 |
| Mu, L | 3 |
| Lin, A | 1 |
| Wu, P | 4 |
| Duwe, G | 1 |
| Knitter, S | 1 |
| Pesthy, S | 1 |
| Beierle, AS | 1 |
| Bahra, M | 2 |
| Schmelzle, M | 1 |
| Schmuck, RB | 1 |
| Lohneis, P | 1 |
| Raschzok, N | 1 |
| Öllinger, R | 1 |
| Sinn, M | 2 |
| Struecker, B | 1 |
| Sauer, IM | 1 |
| Pratschke, J | 3 |
| Andreou, A | 3 |
| Yan, Y | 2 |
| Shen, Q | 2 |
| Cai, X | 2 |
| Tan, S | 2 |
| Carrato, A | 4 |
| Abad, A | 5 |
| Massuti, B | 3 |
| Grávalos, C | 1 |
| Escudero, P | 1 |
| Longo-Muñoz, F | 1 |
| Manzano, JL | 4 |
| Gómez, A | 3 |
| Safont, MJ | 1 |
| Gallego, J | 1 |
| García-Paredes, B | 2 |
| Pericay, C | 2 |
| Dueñas, R | 2 |
| Losa, F | 1 |
| Valladares-Ayerbes, M | 3 |
| González, E | 1 |
| Yuan, XF | 1 |
| Li, ZZ | 1 |
| Bao, SQ | 1 |
| Zhang, XL | 2 |
| Yang, YY | 1 |
| Fan, DM | 1 |
| Zhang, YZ | 1 |
| Wu, CX | 1 |
| Guo, HX | 1 |
| Zhang, YJ | 1 |
| Ye, Z | 1 |
| Xiong, DS | 1 |
| Tewes, M | 1 |
| Peis, MW | 1 |
| Bogner, S | 1 |
| Theysohn, JM | 1 |
| Reinboldt, MP | 1 |
| Schuler, M | 2 |
| Welt, A | 1 |
| De Stefano, A | 2 |
| Rosanova, M | 1 |
| Malapelle, U | 1 |
| Martini, M | 2 |
| De Falco, S | 1 |
| Attademo, L | 1 |
| Fiore, G | 1 |
| Cenci, T | 1 |
| Bellevicine, C | 1 |
| De Placido, S | 2 |
| Troncone, G | 1 |
| Carlomagno, C | 3 |
| Oishi, N | 2 |
| Sunagozaka, H | 2 |
| Yoshida, M | 2 |
| Shirasaki, T | 1 |
| Miyanouchi, K | 1 |
| Ishii, F | 1 |
| Yoshida, Y | 13 |
| Yamauchi, Y | 2 |
| Aisu, N | 2 |
| Kojima, D | 1 |
| Mera, T | 1 |
| Kato, D | 1 |
| Naito, K | 2 |
| Yasumoto, K | 2 |
| Kamigaki, T | 3 |
| Goto, S | 2 |
| Hamada, Y | 1 |
| Nimura, S | 1 |
| Kodama, S | 1 |
| Evesque, L | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Tuan Falk, A | 1 |
| Doyen, J | 1 |
| Reure, J | 1 |
| Cavaglione, G | 1 |
| Lian, Y | 1 |
| Gu, L | 1 |
| Gao, Z | 6 |
| Wang, PP | 2 |
| Luan, JJ | 1 |
| Xu, WK | 2 |
| Xu, DJ | 3 |
| Yang, CY | 1 |
| Zhu, YH | 1 |
| Wang, YQ | 1 |
| Lee, EJ | 1 |
| Yang, SH | 3 |
| Kim, KJ | 2 |
| Cha, H | 1 |
| Lee, SJ | 4 |
| Chun, KH | 1 |
| Hsiao, JH | 1 |
| Tsai, CC | 1 |
| Liang, TJ | 1 |
| Chiang, CL | 1 |
| Liang, HL | 3 |
| Chen, IS | 1 |
| Chen, YC | 2 |
| Chang, PM | 1 |
| Chou, NH | 1 |
| Wang, BW | 1 |
| Limani, P | 2 |
| Linecker, M | 2 |
| Schneider, MA | 1 |
| Kron, P | 2 |
| Tschuor, C | 2 |
| Kachaylo, E | 2 |
| Ungethuem, U | 2 |
| Nicolau, C | 2 |
| Lehn, JM | 2 |
| Graf, R | 2 |
| Humar, B | 2 |
| Clavien, PA | 4 |
| Xiao, N | 1 |
| Yu, K | 1 |
| Shan, S | 1 |
| Zheng, S | 1 |
| Baltruskeviciene, E | 1 |
| Kazbariene, B | 1 |
| Aleknavicius, E | 1 |
| Krikstaponiene, A | 1 |
| Venceviciene, L | 1 |
| Suziedelis, K | 1 |
| Stratilatovas, E | 1 |
| Didziapetriene, J | 1 |
| Zarei, O | 1 |
| Yaghoobi, MM | 1 |
| Choi, YR | 1 |
| Park, SJ | 3 |
| Hur, BY | 1 |
| Han, JK | 3 |
| Lévi, F | 14 |
| Karaboué, A | 3 |
| Saffroy, R | 1 |
| Desterke, C | 1 |
| Hebbar, M | 8 |
| Innominato, P | 3 |
| Carvalho, C | 2 |
| Focan, C | 5 |
| Bouchahda, M | 3 |
| Milano, G | 13 |
| Lemoine, A | 4 |
| Miyauchi, Y | 2 |
| Fukumitsu, K | 2 |
| Ogiso, S | 2 |
| Minami, T | 2 |
| Kojima, H | 4 |
| Yamaoka, R | 1 |
| Katayama, H | 2 |
| Kawai, T | 2 |
| Yoshitoshi-Uebayashi, EY | 1 |
| Kita, S | 2 |
| Yasuda, K | 5 |
| Sasaki, N | 3 |
| Song, JE | 1 |
| Jung, KS | 1 |
| Song, K | 2 |
| Miller, CL | 1 |
| Taylor, MS | 1 |
| Qadan, M | 2 |
| Deshpande, V | 2 |
| Worthington, S | 1 |
| Smalley, R | 1 |
| Collura, C | 1 |
| Ryan, DP | 5 |
| Allen, JN | 2 |
| Blaszkowsky, LS | 3 |
| Clark, JW | 4 |
| Murphy, JE | 1 |
| Parikh, AR | 1 |
| Berger, D | 1 |
| Tanabe, KK | 1 |
| Lillemoe, KD | 1 |
| Ferrone, CR | 2 |
| O'Neill, AF | 1 |
| Towbin, AJ | 1 |
| Krailo, MD | 5 |
| Xia, C | 1 |
| Gao, Y | 2 |
| McCarville, MB | 2 |
| Meyers, RL | 1 |
| McGahren, ED | 1 |
| Tiao, GM | 1 |
| Dunn, SP | 1 |
| Langham, MR | 1 |
| Weldon, CB | 2 |
| Finegold, MJ | 5 |
| Ranganathan, S | 1 |
| Furman, WL | 2 |
| Malogolowkin, M | 1 |
| Rodriguez-Galindo, C | 1 |
| Katzenstein, HM | 6 |
| Yuan, YF | 2 |
| Lin, HC | 2 |
| Li, BK | 1 |
| Wang, FH | 4 |
| Wang, ZQ | 5 |
| Ding, PR | 2 |
| Chen, G | 4 |
| Wu, XJ | 3 |
| Wan, DS | 5 |
| Sun, P | 1 |
| Yan, SM | 1 |
| Xu, RH | 5 |
| Kim, HB | 2 |
| Park, SG | 2 |
| Lal, H | 1 |
| Yadav, P | 1 |
| Jena, R | 1 |
| Jain, M | 1 |
| Moussallem, T | 1 |
| Lim, C | 1 |
| Osseis, M | 1 |
| Esposito, F | 1 |
| Lahat, E | 1 |
| Fuentes, L | 1 |
| Salloum, C | 1 |
| Azoulay, D | 10 |
| Mizandari, M | 1 |
| Paksashvili, N | 1 |
| Kikodze, N | 1 |
| Azrumelashvili, T | 1 |
| Pantsulaia, I | 1 |
| Shanava, K | 1 |
| Janikashvili, N | 1 |
| Chikovani, T | 1 |
| Dou, C | 2 |
| Fang, C | 1 |
| Li, D | 2 |
| Deng, C | 1 |
| Zhao, T | 1 |
| Wei, F | 1 |
| Yang, L | 7 |
| Kim, M | 1 |
| Fisher, DT | 1 |
| Powers, CA | 1 |
| Gabriel, EM | 1 |
| Korman, AM | 1 |
| Sexton, S | 1 |
| Gudkov, AV | 1 |
| Skitzki, JJ | 1 |
| He, C | 1 |
| Jing, Z | 1 |
| Xie, J | 1 |
| Ma, W | 2 |
| Pak, LM | 1 |
| Capanu, M | 4 |
| Chou, JF | 3 |
| Boucher, T | 1 |
| Cioffi, JH | 1 |
| Estes, DJ | 1 |
| Florou, V | 1 |
| Ardalan, B | 1 |
| Guo, XL | 3 |
| Hu, F | 3 |
| Fang, JM | 1 |
| Zhu, ZΖ | 1 |
| Wei, LΧ | 1 |
| Xu, Q | 3 |
| Jalili-Nik, M | 1 |
| Soltani, A | 1 |
| Moussavi, S | 1 |
| Ghayour-Mobarhan, M | 1 |
| Ferns, GA | 1 |
| Hassanian, SM | 1 |
| Avan, A | 1 |
| Velut, G | 1 |
| Kourie, RH | 1 |
| Amouyal, G | 1 |
| Sapoval, M | 1 |
| Pointet, AL | 2 |
| Landi, B | 2 |
| Zaimi, Y | 1 |
| Lepère, C | 2 |
| Kuramoto, K | 1 |
| Nitta, H | 5 |
| Miyata, T | 3 |
| Koga, Y | 1 |
| Kaida, T | 1 |
| Nakagawa, S | 5 |
| Okabe, H | 9 |
| Hayashi, H | 17 |
| Hashimoto, D | 6 |
| Chikamoto, A | 6 |
| Kikuchi, K | 4 |
| Torén, W | 1 |
| Ansari, D | 1 |
| Andersson, B | 1 |
| Spelt, L | 1 |
| Andersson, R | 2 |
| Cotte, AK | 1 |
| Aires, V | 1 |
| Fredon, M | 1 |
| Limagne, E | 1 |
| Derangère, V | 1 |
| Thibaudin, M | 1 |
| Humblin, E | 1 |
| Scagliarini, A | 1 |
| de Barros, JP | 1 |
| Hillon, P | 2 |
| Delmas, D | 1 |
| Aoyagi, H | 5 |
| Ito, H | 7 |
| Higuchi, K | 2 |
| Koseki, K | 1 |
| Watanabe, I | 2 |
| Tanaka, Y | 8 |
| Nishi, N | 3 |
| Nihei, Z | 5 |
| Ito, M | 1 |
| Osada, S | 1 |
| Gotoh, A | 1 |
| Yokoi, R | 1 |
| Tsuchiya, H | 2 |
| Sakuratani, T | 1 |
| Sasaki, Y | 18 |
| Okumura, N | 1 |
| Mukai, T | 3 |
| Hagino, S | 1 |
| Ozaki, Y | 1 |
| Kondoh, C | 1 |
| Tanabe, Y | 1 |
| Takano, T | 2 |
| Tessitore, A | 1 |
| Bruera, G | 3 |
| Mastroiaco, V | 1 |
| Cannita, K | 4 |
| Cortellini, A | 1 |
| Cocciolone, V | 1 |
| Dal Mas, A | 1 |
| Calvisi, G | 1 |
| Zazzeroni, F | 1 |
| Ficorella, C | 5 |
| Ricevuto, E | 5 |
| Alesse, E | 1 |
| Kodama, K | 1 |
| Kawaoka, T | 9 |
| Aikata, H | 10 |
| Uchikawa, S | 1 |
| Nishida, Y | 2 |
| Inagaki, Y | 2 |
| Hatooka, M | 4 |
| Morio, K | 4 |
| Nakahara, T | 3 |
| Murakami, E | 3 |
| Tsuge, M | 2 |
| Hiramatsu, A | 8 |
| Imamura, M | 9 |
| Kawakami, Y | 7 |
| Masaki, K | 2 |
| Honda, Y | 3 |
| Mori, N | 8 |
| Takaki, S | 8 |
| Tsuji, K | 7 |
| Kohno, H | 14 |
| Moriya, T | 4 |
| Nonaka, M | 2 |
| Hyogo, H | 4 |
| Aisaka, Y | 2 |
| Kimura, T | 7 |
| Nagata, Y | 1 |
| Chayama, K | 10 |
| Zykova, T | 1 |
| Zhu, F | 2 |
| Lim, DY | 1 |
| Yao, K | 2 |
| Roh, E | 1 |
| Yoon, SP | 1 |
| Kim, HG | 1 |
| Bae, KB | 1 |
| Wen, W | 1 |
| Shin, SH | 1 |
| Nadas, J | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Fujisaki, S | 1 |
| Takashina, M | 1 |
| Tomita, R | 1 |
| Sakurai, K | 4 |
| Vigano, L | 4 |
| Darwish, SS | 1 |
| Rimassa, L | 3 |
| Cimino, M | 1 |
| Carnaghi, C | 4 |
| Donadon, M | 2 |
| Procopio, F | 1 |
| Personeni, N | 2 |
| Del Fabbro, D | 1 |
| Santoro, A | 5 |
| Torzilli, G | 1 |
| Dong, L | 3 |
| Bai, C | 1 |
| Long, H | 1 |
| Lin, Z | 3 |
| Zucchelli, G | 2 |
| Mennitto, A | 1 |
| Pellegrinelli, A | 3 |
| Bergamo, F | 3 |
| Schirripa, M | 2 |
| Cardellino, GG | 2 |
| Mazzaferro, V | 1 |
| Gouveia, HS | 1 |
| Lopes, SO | 1 |
| Faria, AL | 1 |
| Duan, B | 1 |
| Guo, Y | 7 |
| Zhou, R | 1 |
| Bie, B | 1 |
| Berardi, G | 1 |
| De Man, M | 1 |
| Laurent, S | 4 |
| Smeets, P | 3 |
| Tomassini, F | 1 |
| Ariotti, R | 1 |
| Hoorens, A | 1 |
| van Dorpe, J | 1 |
| Varin, O | 1 |
| Geboes, K | 3 |
| Troisi, RI | 2 |
| Ishida, K | 3 |
| Tamura, A | 3 |
| Kato, K | 12 |
| Uesugi, N | 1 |
| Osakabe, M | 1 |
| Eizuka, M | 1 |
| Hasegawa, Y | 3 |
| Otsuka, K | 2 |
| Sasaki, A | 4 |
| Ehara, S | 2 |
| Sugai, T | 1 |
| Omichi, K | 1 |
| Mizuno, T | 1 |
| Tzeng, CD | 1 |
| Chun, YS | 2 |
| Katz, MHG | 1 |
| Halperin, D | 1 |
| Yao, J | 3 |
| Dasari, A | 1 |
| Ettrich, TJ | 1 |
| Ebert, M | 1 |
| Vogel, A | 1 |
| Witkowski, L | 1 |
| Seufferlein, T | 1 |
| Reinacher-Schick, A | 2 |
| Saito, A | 1 |
| Konishi, K | 6 |
| Fukunaga, M | 6 |
| Takiguchi, N | 1 |
| Nakai, S | 1 |
| Honda, S | 3 |
| Yukimoto, R | 1 |
| Okamoto, A | 3 |
| Takeoka, T | 1 |
| Matsuno, H | 2 |
| Okada, K | 15 |
| Ota, H | 15 |
| Yokoyama, S | 2 |
| Konishi, M | 2 |
| Tokoro, T | 1 |
| Hirose, A | 1 |
| Nakanuma, S | 1 |
| Okamoto, K | 7 |
| Kinoshita, J | 1 |
| Makino, I | 1 |
| Oyama, K | 3 |
| Miyashita, T | 2 |
| Tajima, H | 2 |
| Takamura, H | 2 |
| Ninomiya, I | 1 |
| Fushida, S | 1 |
| Powers, JM | 1 |
| Pacheco, MM | 1 |
| Wickiser, JE | 1 |
| Zheng, F | 2 |
| Long, Q | 1 |
| Qiu, H | 1 |
| Ge, Q | 1 |
| Luo, M | 2 |
| Deng, W | 2 |
| Ji, DG | 1 |
| Guan, LY | 1 |
| Ma, F | 1 |
| Liu, HY | 1 |
| Jia, QA | 1 |
| Kadel, D | 1 |
| Zhang, XF | 1 |
| Zhang, QB | 1 |
| Odisio, BC | 1 |
| Simoneau, E | 1 |
| Holmes, AA | 1 |
| Conrad, CH | 1 |
| Li, JW | 1 |
| Huang, CZ | 1 |
| Li, JH | 3 |
| Yuan, JH | 1 |
| Chen, QH | 1 |
| Zhang, WF | 1 |
| Xu, ZS | 1 |
| Liu, YP | 1 |
| Zhan, MX | 1 |
| Lu, LG | 1 |
| Ke, M | 1 |
| Dong, J | 1 |
| Lv, Y | 1 |
| Wu, R | 1 |
| Yamada, I | 2 |
| Iwadou, S | 1 |
| Horiguchi, S | 2 |
| Takahashi, H | 13 |
| Suzuki, E | 3 |
| Moriguchi, M | 3 |
| Otsuka, T | 1 |
| Asagi, A | 1 |
| Kojima, Y | 4 |
| Takada, R | 1 |
| Mizuno, N | 1 |
| Awai, K | 2 |
| Waki, K | 6 |
| Nagaoki, Y | 2 |
| Amano, H | 2 |
| Katamura, Y | 3 |
| Cai, H | 3 |
| Li, N | 2 |
| Ao, L | 1 |
| Zhao, W | 1 |
| Do, RK | 2 |
| Dika, IE | 1 |
| Hollywood, E | 2 |
| Uhlitskykh, K | 1 |
| Valentino, E | 1 |
| Wan, P | 1 |
| Hamilton, C | 1 |
| Feng, X | 1 |
| Bomalaski, J | 1 |
| Li, CF | 1 |
| Pentheroudakis, G | 1 |
| Kotoula, V | 1 |
| Koliou, GA | 1 |
| Karavasilis, V | 1 |
| Samantas, E | 1 |
| Aravantinos, G | 2 |
| Kalogeropoulou, L | 1 |
| Souglakos, I | 1 |
| Kentepozidis, N | 2 |
| Koumakis, G | 2 |
| Sgouros, J | 1 |
| Zarkavelis, G | 1 |
| Efstratiou, I | 1 |
| Laschos, K | 1 |
| Petraki, C | 1 |
| Tikas, I | 1 |
| Poulios, C | 1 |
| Voutsina, A | 2 |
| Goudopoulou, A | 1 |
| Bafaloukos, D | 1 |
| Vrettou, E | 1 |
| Kalogera-Fountzila, A | 1 |
| Pectasides, D | 1 |
| Fountzilas, G | 1 |
| Choi, JH | 1 |
| Chung, WJ | 5 |
| Bae, SH | 11 |
| Song, DS | 3 |
| Song, MJ | 6 |
| Kim, YS | 5 |
| Yim, HJ | 6 |
| Jung, YK | 1 |
| Suh, SJ | 2 |
| Cho, SB | 4 |
| Aimono, Y | 1 |
| Kamoshida, T | 1 |
| Okawara, A | 1 |
| Suzuki, S | 8 |
| Sakamoto, R | 1 |
| Saito, Y | 6 |
| Aoyama, Y | 2 |
| Rossi, L | 2 |
| Biagioni, C | 1 |
| McCartney, A | 1 |
| Moretti, E | 1 |
| Pestrin, M | 1 |
| Sanna, G | 1 |
| Risi, E | 1 |
| Malorni, L | 1 |
| DI Leo, A | 1 |
| Biganzoli, L | 1 |
| Benhaim, L | 3 |
| Deschamps, F | 3 |
| Yamaue, H | 2 |
| Yamamoto, M | 14 |
| Hubert, C | 2 |
| Lucidi, V | 2 |
| Weerts, J | 3 |
| Dili, A | 1 |
| Demetter, P | 1 |
| Massart, B | 1 |
| Komuta, M | 1 |
| Navez, J | 1 |
| Reding, R | 1 |
| Gigot, JF | 3 |
| Sempoux, C | 3 |
| Wu, L | 4 |
| Pan, C | 3 |
| R Ebrahim, A | 1 |
| El-Mesery, M | 1 |
| El-Karef, A | 1 |
| Eissa, LA | 1 |
| Sunakawa, Y | 2 |
| Yang, D | 1 |
| Cao, S | 2 |
| Moran, M | 1 |
| Astrow, SH | 1 |
| Hsiang, J | 1 |
| Stephens, C | 1 |
| Tsuji, A | 4 |
| Takahashi, T | 31 |
| Tanioka, H | 1 |
| Negoro, Y | 1 |
| Takagane, A | 2 |
| Tani, S | 2 |
| Yamaguchi, T | 19 |
| Eto, T | 1 |
| Fujii, M | 11 |
| Ichikawa, W | 5 |
| Lenz, HJ | 6 |
| Shinohara, S | 1 |
| Hyodo, M | 1 |
| Ota, G | 1 |
| Tsukahara, M | 2 |
| Okada, M | 1 |
| Lefor, AK | 1 |
| Yasuda, Y | 4 |
| Kusano, M | 3 |
| Aoyama, T | 2 |
| Okabayashi, K | 1 |
| Hirata, K | 12 |
| Nakamori, S | 22 |
| Asahara, T | 4 |
| Ohashi, Y | 4 |
| Yoshikawa, T | 11 |
| Sakamoto, J | 6 |
| Oba, K | 3 |
| Saji, S | 10 |
| Cheng, J | 1 |
| Qian, D | 1 |
| Ding, X | 2 |
| Song, T | 2 |
| Cai, M | 1 |
| Zhao, J | 10 |
| Pang, Q | 1 |
| Hao, X | 2 |
| Yuan, Z | 1 |
| Song, W | 2 |
| Collot, T | 1 |
| Fumet, JD | 1 |
| Klopfenstein, Q | 1 |
| Vincent, J | 2 |
| Bengrine, L | 1 |
| Tokunaga, R | 1 |
| Naseem, M | 1 |
| Lo, JH | 1 |
| Battaglin, F | 1 |
| Puccini, A | 1 |
| Berger, MD | 1 |
| Soni, S | 1 |
| Millstein, J | 1 |
| Weldon Gilcrease, G | 1 |
| Stenehjem, DD | 1 |
| Wade, ML | 1 |
| Weis, J | 1 |
| McGregor, K | 1 |
| Whisenant, J | 2 |
| Boucher, KM | 1 |
| Thorne, K | 1 |
| Orgain, N | 1 |
| Garrido-Laguna, I | 1 |
| Sharma, S | 3 |
| Cheng, M | 6 |
| Zhi, K | 1 |
| Zhu, W | 2 |
| Cui, X | 1 |
| Yao, X | 4 |
| Qian, B | 1 |
| Su, C | 3 |
| Ren, Y | 1 |
| Yao, Z | 2 |
| Gao, X | 4 |
| Tran Cao, HS | 1 |
| Bachet, JB | 1 |
| Lucidarme, O | 1 |
| Levache, CB | 1 |
| Barbier, E | 2 |
| Lecomte, T | 3 |
| Desauw, C | 2 |
| Brocard, F | 1 |
| Breysacher, G | 1 |
| Lagasse, JP | 1 |
| Di Fiore, F | 1 |
| Etienne, PL | 3 |
| Dupuis, OJM | 1 |
| Aleba, A | 1 |
| Satake, M | 4 |
| Yoshimatsu, K | 8 |
| Ito, Y | 8 |
| Imaizumi, R | 1 |
| Sano, M | 7 |
| Kodera, A | 1 |
| Miyano, Y | 1 |
| Koike, T | 3 |
| Yamada, Y | 11 |
| Okayama, S | 3 |
| Yokomizo, H | 7 |
| Usui, T | 1 |
| Shiozawa, S | 2 |
| Shimakawa, T | 2 |
| Katsube, T | 2 |
| Naritaka, Y | 4 |
| Ni, W | 1 |
| Ji, Y | 1 |
| Sun, S | 3 |
| Jian, X | 1 |
| O'hara, H | 1 |
| Yamamoto, H | 18 |
| Limaiem, F | 1 |
| Bouraoui, S | 1 |
| Abdel-Rahman, O | 2 |
| Xiao, X | 2 |
| Fanotto, V | 1 |
| Fornaro, L | 5 |
| Bordonaro, R | 1 |
| Rosati, G | 2 |
| Di Donato, S | 1 |
| Santini, D | 3 |
| Leone, F | 3 |
| Silvestris, N | 3 |
| Stragliotto, S | 1 |
| Scartozzi, M | 3 |
| Giampieri, R | 2 |
| Nichetti, F | 1 |
| Antonuzzo, L | 1 |
| Cinieri, S | 1 |
| Avallone, A | 2 |
| Pellegrino, A | 1 |
| Melisi, D | 1 |
| Vasile, E | 5 |
| Gerratana, L | 1 |
| Hurwitz, HI | 1 |
| Tan, BR | 1 |
| Reeves, JA | 1 |
| Xiong, H | 1 |
| Somer, B | 1 |
| Hochster, HS | 2 |
| Scappaticci, F | 1 |
| Palma, JF | 1 |
| Price, R | 1 |
| Lee, JJ | 1 |
| Nicholas, A | 1 |
| Sommer, N | 1 |
| Bendell, J | 1 |
| Bi, F | 2 |
| Gou, H | 1 |
| Wu, B | 2 |
| Qiu, M | 2 |
| Bang, YJ | 6 |
| Kang, YK | 3 |
| Ng, M | 1 |
| Chung, HC | 3 |
| Wainberg, ZA | 1 |
| Gendreau, S | 1 |
| Chan, WY | 1 |
| Xu, N | 1 |
| Maslyar, D | 1 |
| Meng, R | 1 |
| Chau, I | 9 |
| Ajani, JA | 5 |
| Yasuno, M | 9 |
| Ishiguro, M | 11 |
| Mizunuma, N | 5 |
| Komori, T | 2 |
| Miyata, G | 1 |
| Shiomi, A | 1 |
| Cui, R | 1 |
| Miao, R | 1 |
| Dong, Y | 3 |
| Fan, H | 1 |
| Niu, W | 1 |
| Qu, K | 2 |
| Peng, T | 1 |
| Ouyang, Y | 1 |
| Tong, K | 1 |
| Hubner, RA | 1 |
| de Jong, FA | 1 |
| Mirakhur, B | 1 |
| Martínez Lago, N | 1 |
| Covela Rúa, M | 1 |
| de la Cámara Gómez, J | 1 |
| González Villaroel, P | 1 |
| Méndez Méndez, JC | 1 |
| Jorge Fernández, M | 1 |
| Salgado Fernández, M | 1 |
| Reboredo López, M | 1 |
| Quintero Aldana, G | 1 |
| Luz Pellón Augusto, M | 1 |
| Graña Suárez, B | 1 |
| García Gómez, J | 1 |
| Hosomi, S | 1 |
| Akiyama, Y | 4 |
| Tanigawa, T | 6 |
| Kitamura, T | 1 |
| Umemura, K | 1 |
| Miura, T | 24 |
| Ishido, K | 1 |
| Sakamoto, Y | 4 |
| Kudo, D | 1 |
| Kimura, N | 1 |
| Morohashi, H | 2 |
| Hakamada, K | 1 |
| Matsui, S | 7 |
| Kajiyama, D | 1 |
| Kawaguchi, M | 2 |
| Ohira, K | 1 |
| Amagasa, H | 3 |
| Noguchi, T | 7 |
| Sugita, H | 1 |
| Ganno, H | 4 |
| Ami, K | 5 |
| Fukuda, A | 4 |
| Ando, M | 6 |
| Hotta, S | 2 |
| Kameyama, H | 4 |
| Tajima, Y | 7 |
| Ichikawa, H | 2 |
| Hanyu, T | 2 |
| Takizawa, K | 8 |
| Nagahashi, M | 3 |
| Sakata, J | 5 |
| Wakai, T | 11 |
| Miura, K | 3 |
| Nogami, H | 2 |
| Maruyama, S | 12 |
| Takii, Y | 2 |
| Rezkallah, KNM | 1 |
| Ahmed, A | 1 |
| Patel, S | 1 |
| Kozma, K | 1 |
| Matsuoka, H | 8 |
| Morise, Z | 2 |
| Tanaka, C | 1 |
| Ikeda, Y | 3 |
| Maeda, K | 11 |
| Masumori, K | 4 |
| Koide, Y | 8 |
| Katsuno, H | 2 |
| Tanahashi, Y | 1 |
| Nakajima, S | 2 |
| Hanai, T | 2 |
| Kato, Y | 3 |
| Sugioka, A | 2 |
| Uyama, I | 1 |
| Liu, YF | 1 |
| Ye, PJ | 2 |
| Gao, P | 2 |
| Li, ZP | 2 |
| Tang, SY | 1 |
| Tang, SS | 3 |
| Xiao, D | 1 |
| Zhan, P | 1 |
| Strowitzki, MJ | 1 |
| Radhakrishnan, P | 1 |
| Pavicevic, S | 1 |
| Scheer, J | 1 |
| Kimmer, G | 1 |
| Ritter, AS | 1 |
| Tuffs, C | 1 |
| Volz, C | 1 |
| Vondran, F | 1 |
| Harnoss, JM | 1 |
| Klose, J | 1 |
| Schmidt, T | 1 |
| Schneider, M | 1 |
| AlGhamdi, KM | 1 |
| Salem-Bekhit, MM | 1 |
| Ahmad, SF | 1 |
| Rizzo, A | 1 |
| Palloni, A | 1 |
| Frega, G | 1 |
| Abbati, F | 1 |
| De Lorenzo, S | 1 |
| Brocchi, S | 1 |
| Brandi, G | 4 |
| Lin, H | 2 |
| Lu, X | 6 |
| Chi, P | 2 |
| Liao, C | 1 |
| Xiao, H | 2 |
| Tao, A | 1 |
| He, Z | 2 |
| Xu, C | 1 |
| Zheng, K | 1 |
| Byun, HK | 1 |
| Kim, HJ | 3 |
| Im, YR | 1 |
| Imamura, YU | 1 |
| Fukubayashi, K | 1 |
| Ishiko, T | 6 |
| Pan, Z | 2 |
| Ozaki, K | 2 |
| Ikuta, Y | 1 |
| Akaboshi, S | 1 |
| Ogata, K | 4 |
| Matumoto, K | 1 |
| Kamio, T | 1 |
| Takamori, H | 8 |
| Cui, ZG | 1 |
| Zakki, SA | 1 |
| Sun, L | 1 |
| Feril, LB | 1 |
| Inadera, H | 1 |
| Larsen, FO | 2 |
| Jensen, BV | 3 |
| Nørgaard, HH | 1 |
| Hermann, HK | 1 |
| Larsen, PN | 1 |
| Markussen, A | 1 |
| Hogdall, E | 1 |
| Nielsen, D | 1 |
| Liu, XY | 1 |
| Liu, ZH | 1 |
| Bu, Z | 1 |
| Lu, C | 1 |
| Lai, H | 1 |
| Qin, Y | 2 |
| Xiao, M | 1 |
| Lee, JH | 6 |
| Lee, SW | 2 |
| Chai, Z | 1 |
| Asano, A | 1 |
| Nakagawa, K | 13 |
| Kobayashi, M | 21 |
| Hamfjord, J | 1 |
| Guren, TK | 1 |
| Dajani, O | 1 |
| Johansen, JS | 1 |
| Glimelius, B | 7 |
| Sorbye, H | 6 |
| Pfeiffer, P | 3 |
| Lingjærde, OC | 1 |
| Tveit, KM | 1 |
| Kure, EH | 1 |
| Pallisgaard, N | 1 |
| Spindler, KG | 1 |
| Zou, R | 1 |
| Fang, W | 1 |
| Tan, G | 1 |
| Le, Y | 1 |
| Goyal, L | 1 |
| Zhu, AX | 5 |
| Su, D | 1 |
| Zhou, T | 2 |
| Dohan, A | 1 |
| Gallix, B | 1 |
| Guiu, B | 2 |
| Le Malicot, K | 1 |
| Reinhold, C | 1 |
| Soyer, P | 1 |
| Bennouna, J | 3 |
| Borel, C | 1 |
| Faroux, R | 3 |
| Seitz, JF | 8 |
| Jacquot, S | 1 |
| Ben Abdelghani, M | 1 |
| Khemissa-Akouz, F | 1 |
| Genet, D | 1 |
| Rinaldi, Y | 1 |
| Desseigne, F | 2 |
| Texereau, P | 1 |
| Suc, E | 1 |
| Hoeffel, C | 1 |
| Burki, TK | 1 |
| Saade Lemus, P | 1 |
| Anderson, K | 1 |
| Smith, M | 2 |
| Bullock, A | 1 |
| Kitahama, T | 1 |
| Gomyo, Y | 1 |
| Okada, I | 1 |
| Akita, N | 2 |
| Ikeno, T | 1 |
| Rahman, M | 1 |
| Washington, L | 1 |
| Matoba, H | 1 |
| Hirakata, A | 1 |
| Yoshida, H | 9 |
| Seta, S | 1 |
| Makino, H | 5 |
| Maruyama, H | 3 |
| Ueda, J | 1 |
| Takata, H | 1 |
| Ueda, K | 1 |
| Yoshioka, M | 1 |
| Kusakabe, M | 2 |
| Asami, K | 1 |
| Hagiwara, A | 6 |
| Abe, M | 7 |
| Mafune, K | 1 |
| Saito, M | 5 |
| Kusakabe, A | 1 |
| Gbolahan, O | 1 |
| Hashemi-Sadraei, N | 1 |
| O'Neil, B | 1 |
| Pintova, S | 1 |
| Dharmupari, S | 1 |
| Moshier, E | 1 |
| Zubizarreta, N | 1 |
| Ang, C | 1 |
| Holcombe, RF | 1 |
| Matikas, A | 1 |
| Souglakos, J | 4 |
| Katsaounis, P | 1 |
| Kotsakis, A | 2 |
| Kouroupakis, P | 1 |
| Pantazopoulos, N | 1 |
| Nikolaidi, A | 1 |
| Messaritakis, I | 1 |
| Tzovara, I | 1 |
| Hatzidaki, D | 2 |
| Prinarakis, E | 1 |
| Georgoulias, V | 4 |
| Sung, PS | 1 |
| Yang, K | 2 |
| Oh, JS | 2 |
| Chun, HJ | 6 |
| Nam, HC | 1 |
| Jang, JW | 5 |
| Choi, JY | 9 |
| Yoon, SK | 9 |
| Liang, JY | 2 |
| Xing, BC | 1 |
| Oki, E | 5 |
| Emi, Y | 6 |
| Yamanaka, T | 1 |
| Nagasaka, T | 1 |
| Ojima, H | 1 |
| Kusumoto, T | 2 |
| Katayose, Y | 3 |
| Fujiwara, T | 3 |
| Hyodo, I | 3 |
| Maehara, Y | 10 |
| Yasuda, T | 15 |
| Tanaka, O | 4 |
| Hayashi, S | 6 |
| Nakahata, Y | 1 |
| Omatsu, T | 1 |
| Obora, A | 1 |
| Kojima, T | 2 |
| Matsuo, M | 1 |
| Yagi, N | 1 |
| Horvath, P | 1 |
| Beckert, S | 1 |
| Königsrainer, A | 2 |
| Nadalin, S | 1 |
| Königsrainer, I | 1 |
| Roberts, L | 1 |
| Ishikawa, H | 7 |
| Kawahara, R | 1 |
| Yasunaga, M | 1 |
| Kinugasa, T | 1 |
| Fujita, F | 1 |
| Mizobe, T | 2 |
| Fukahori, M | 2 |
| Miwa, K | 4 |
| Nakashima, O | 2 |
| Tanigawa, M | 1 |
| Naito, Y | 4 |
| Tanaka, H | 13 |
| Sato, T | 15 |
| Masada, T | 2 |
| Tatsumoto, S | 1 |
| Marugami, N | 2 |
| Otsuji, T | 5 |
| Kanno, M | 2 |
| Koyama, F | 3 |
| Kichikawa, K | 10 |
| Shigekawa, T | 1 |
| Takeuchi, H | 2 |
| Misumi, M | 1 |
| Nakamiya, N | 1 |
| Sugitani, I | 1 |
| Fujiuchi, N | 1 |
| Osaki, A | 1 |
| Saeki, T | 2 |
| Nakae, S | 1 |
| Mizojiri, G | 1 |
| Ishida, J | 1 |
| Harada, N | 2 |
| Haji, S | 1 |
| Toyoda, M | 2 |
| Senzaki, H | 1 |
| Dede, K | 3 |
| Mersich, T | 2 |
| Besznyák, I | 2 |
| Zaránd, A | 1 |
| Salamon, F | 1 |
| Baranyai, ZS | 1 |
| Landherr, L | 1 |
| Jakab, F | 2 |
| Bursics, A | 3 |
| Xiao, Z | 1 |
| Ko, HL | 1 |
| Goh, EH | 1 |
| Wang, B | 5 |
| Ren, EC | 1 |
| Sakabe, T | 2 |
| Kanki, K | 1 |
| Azumi, J | 1 |
| Gonda, K | 1 |
| Mizuta, Y | 1 |
| Yamada, D | 2 |
| Wada, H | 28 |
| Shomori, K | 1 |
| Nagano, H | 50 |
| Shiota, G | 1 |
| Robinson, SM | 3 |
| Mann, J | 3 |
| Manas, DM | 2 |
| Mann, DA | 3 |
| White, SA | 3 |
| van den Broek, MA | 1 |
| Vreuls, CP | 1 |
| Winstanley, A | 1 |
| Jansen, RL | 1 |
| van Bijnen, AA | 1 |
| Dello, SA | 1 |
| Bemelmans, MH | 1 |
| Dejong, CH | 1 |
| Driessen, A | 1 |
| Olde Damink, SW | 1 |
| Harvey, VJ | 1 |
| Sharples, KJ | 1 |
| Isaacs, RJ | 1 |
| Jameson, MB | 1 |
| Jeffery, GM | 1 |
| McLaren, BR | 1 |
| Pollard, S | 1 |
| Riley, GA | 1 |
| Simpson, AB | 1 |
| Hinder, VA | 1 |
| Scott, JN | 1 |
| Dzhelali, MV | 1 |
| Findlay, MP | 2 |
| Machado, MA | 1 |
| Makdissi, FF | 1 |
| Surjan, RC | 1 |
| Arredondo, J | 1 |
| Baixauli, J | 1 |
| Beorlegui, C | 1 |
| Arbea, L | 1 |
| Rodríguez, J | 2 |
| Sola, JJ | 1 |
| Chopitea, A | 1 |
| Hernández-Lizoáin, JL | 1 |
| Pluschnig, U | 1 |
| Schoppmann, SF | 1 |
| Preusser, M | 2 |
| Datler, P | 1 |
| Asari, R | 1 |
| Ba-Ssalamah, A | 1 |
| Schwameis, K | 1 |
| Birner, P | 1 |
| Zacherl, J | 1 |
| Hejna, M | 2 |
| Vañó-Galván, S | 2 |
| Longo, F | 2 |
| Grillo, E | 1 |
| Jaén, P | 2 |
| Katsura, Y | 2 |
| Akita, H | 4 |
| Hama, N | 4 |
| Kawamoto, K | 6 |
| Marubashi, S | 25 |
| Eguchi, H | 21 |
| Tanemura, M | 10 |
| Umeshita, K | 37 |
| Doki, Y | 20 |
| Heine, A | 1 |
| Schmiedel, A | 1 |
| Menschik, T | 1 |
| Held, SA | 1 |
| Erdmann, C | 1 |
| Brossart, P | 1 |
| Kim, DS | 2 |
| Yu, YD | 1 |
| Jung, SW | 1 |
| Ji, W | 1 |
| Suh, SO | 1 |
| Cohn, AL | 1 |
| Tabernero, J | 3 |
| Maurel, J | 2 |
| Nowara, E | 1 |
| Chuah, BYS | 1 |
| Kopp, MV | 1 |
| Sakaeva, DD | 1 |
| Mitchell, EP | 2 |
| Dubey, S | 1 |
| Hei, YJ | 1 |
| Galimi, F | 1 |
| McCaffery, I | 1 |
| Loberg, R | 1 |
| Cottrell, S | 1 |
| Choo, SP | 2 |
| Shan, L | 1 |
| van Dijk, TH | 1 |
| Tamas, K | 1 |
| Beukema, JC | 1 |
| Beets, GL | 1 |
| Gelderblom, AJ | 1 |
| de Jong, KP | 2 |
| Nagtegaal, ID | 1 |
| Rutten, HJ | 1 |
| van de Velde, CJ | 2 |
| Wiggers, T | 1 |
| Hospers, GA | 1 |
| Havenga, K | 1 |
| Qian, X | 1 |
| Xia, J | 3 |
| Wang, R | 2 |
| Chen, C | 3 |
| Miele, L | 1 |
| Garcia-Carbonero, R | 1 |
| Cassidy, J | 4 |
| Sobrero, A | 4 |
| Köhne, CH | 9 |
| Gladkov, O | 1 |
| Davidenko, I | 1 |
| Salazar, R | 1 |
| Vladimirova, L | 1 |
| Cheporov, S | 1 |
| Burdaeva, O | 1 |
| Samuel, L | 1 |
| Bulavina, I | 1 |
| Potter, V | 1 |
| Chang, YL | 1 |
| Lokker, NA | 1 |
| Nasti, G | 3 |
| Piccirillo, MC | 1 |
| Izzo, F | 3 |
| Ottaiano, A | 2 |
| Albino, V | 1 |
| Delrio, P | 1 |
| Romano, C | 1 |
| Giordano, P | 1 |
| Lastoria, S | 1 |
| Caracò, C | 1 |
| de Lutio di Castelguidone, E | 1 |
| Palaia, R | 1 |
| Daniele, G | 1 |
| Aloj, L | 1 |
| Romano, G | 1 |
| Iaffaioli, RV | 2 |
| Lin, PC | 1 |
| Lin, HH | 1 |
| Lin, JK | 6 |
| Lin, CC | 5 |
| Li, AF | 3 |
| Chen, WS | 4 |
| Chang, SC | 2 |
| Brodowicz, T | 3 |
| Ciuleanu, TE | 3 |
| Radosavljevic, D | 1 |
| Shacham-Shmueli, E | 3 |
| Vrbanec, D | 2 |
| Plate, S | 1 |
| Mrsic-Krmpotic, Z | 1 |
| Dank, M | 1 |
| Purkalne, G | 1 |
| Messinger, D | 2 |
| Zielinski, CC | 3 |
| Ran, L | 1 |
| Liu, G | 3 |
| Lin, C | 1 |
| Liao, G | 1 |
| Nakai, T | 1 |
| Okuno, K | 7 |
| Kitaguchi, H | 1 |
| Yamasaki, M | 3 |
| Truant, S | 5 |
| Sergent-Baudson, G | 1 |
| Cattan, S | 1 |
| Piessen, G | 1 |
| Pruvot, FR | 5 |
| Ye, LC | 2 |
| Liu, TS | 3 |
| Zhu, DX | 2 |
| Zai, SY | 1 |
| Ye, QH | 1 |
| Yu, Y | 2 |
| Qin, XY | 1 |
| Fushiya, N | 1 |
| Takagi, I | 1 |
| Akizuki, S | 1 |
| Ohnishi, A | 1 |
| Alberts, S | 1 |
| Schaller, G | 1 |
| Magge, D | 2 |
| Zureikat, AH | 2 |
| Bartlett, DL | 2 |
| Holtzman, MP | 1 |
| Choudry, HA | 1 |
| Beumer, JH | 1 |
| Pingpank, JF | 1 |
| Holleran, JL | 1 |
| Strychor, S | 1 |
| Cunningham, DE | 1 |
| Jones, HL | 1 |
| Zeh, HJ | 1 |
| Song, MQ | 1 |
| Lin, HZ | 1 |
| Hao, LH | 1 |
| Jiang, XJ | 1 |
| Li, ZY | 2 |
| Chen, YX | 3 |
| El-Hadaad, HA | 1 |
| Wahba, HA | 1 |
| de Amuriza-Chicharro, N | 1 |
| Gastalver-Martín, C | 1 |
| Cortijo-Cascajares, S | 1 |
| Ferrari-Piquero, JM | 1 |
| Vasilaki, A | 1 |
| Mathers, J | 1 |
| Burt, AD | 1 |
| Oakley, F | 2 |
| Mertens, J | 2 |
| De Bruyne, S | 2 |
| Van Damme, N | 2 |
| Troisi, R | 2 |
| Goethals, I | 1 |
| Van de Wiele, C | 2 |
| Osawa, G | 3 |
| Sagawa, M | 1 |
| Ji, JH | 1 |
| Park, SH | 5 |
| Lee, J | 7 |
| Hong, YS | 4 |
| Kim, KP | 1 |
| Kim, SY | 4 |
| Kang, HJ | 2 |
| Shim, BY | 1 |
| Völker, I | 1 |
| Bach, P | 1 |
| Coulibaly, C | 1 |
| Plesker, R | 1 |
| Abel, T | 1 |
| Seifried, J | 1 |
| Heidmeier, S | 1 |
| Mühlebach, MD | 1 |
| Lauer, UM | 3 |
| Buchholz, CJ | 1 |
| Caparello, C | 1 |
| Funel, N | 1 |
| Pollina, L | 2 |
| Salvatore, L | 3 |
| Morvillo, M | 1 |
| Antoniotti, C | 1 |
| Masi, G | 10 |
| Shen, HJ | 1 |
| Lin, JJ | 1 |
| Jiang, XF | 1 |
| Jin, XJ | 1 |
| Lu, LJ | 1 |
| Bao, LW | 1 |
| Shen, S | 1 |
| Xu, Z | 3 |
| Huang, S | 2 |
| Uygun, K | 1 |
| Bilici, A | 1 |
| Kaya, S | 1 |
| Oven Ustaalioglu, BB | 1 |
| Yildiz, R | 2 |
| Temiz, S | 1 |
| Seker, M | 1 |
| Aksu, G | 1 |
| Cabuk, D | 1 |
| Gumus, M | 1 |
| Bian, L | 1 |
| Kanekawa, T | 3 |
| Kanayama, M | 7 |
| Ishii, K | 4 |
| Sumino, Y | 10 |
| El Bouzidi, L | 1 |
| Mahiou-Leddet, V | 1 |
| Bun, SS | 2 |
| Larhsini, M | 1 |
| Abbad, A | 1 |
| Markouk, M | 1 |
| Fathi, M | 1 |
| Boudon, M | 1 |
| Ollivier, E | 1 |
| Bekkouche, K | 1 |
| Miao, L | 1 |
| Lv, C | 1 |
| Sun, H | 2 |
| Wei, S | 1 |
| Jiao, B | 1 |
| Derenzini, E | 3 |
| Pietrabissa, A | 2 |
| Pinna, AD | 2 |
| Ercolani, G | 2 |
| Pantaleo, MA | 2 |
| Di Girolamo, S | 2 |
| de Rosa, F | 2 |
| Biasco, G | 4 |
| Wu, K | 1 |
| Yan, W | 1 |
| Hu, L | 1 |
| Yuan, J | 2 |
| Jing, K | 1 |
| Guo, M | 2 |
| Walter, H | 1 |
| Thomas, AL | 1 |
| Zhu, R | 2 |
| Xiao, Y | 1 |
| Gao, B | 1 |
| Trusilova, EV | 1 |
| Besova, NS | 1 |
| Bagrova, SG | 1 |
| Gorbunova, VA | 2 |
| Stilidi, IS | 1 |
| Nered, SN | 1 |
| Tezuka, T | 2 |
| Hamada, C | 1 |
| Ishida, H | 28 |
| Ooshiro, M | 1 |
| Kawasaki, S | 3 |
| Mishima, H | 16 |
| Kaseb, AO | 1 |
| Patt, YZ | 10 |
| Roses, RE | 1 |
| Zimmitti, G | 3 |
| Lozano, RD | 3 |
| Hassan, MM | 3 |
| Hassabo, HM | 1 |
| Curley, SA | 11 |
| Abbruzzese, JL | 5 |
| Abdel-Wahab, M | 1 |
| Shaker, M | 1 |
| Abdel-Wahab, S | 1 |
| Elbassiony, M | 1 |
| Ellithy, M | 1 |
| Ahn, JS | 1 |
| Jeon, JR | 1 |
| Yoo, HS | 1 |
| Park, TK | 1 |
| Park, CK | 1 |
| Sinn, DH | 1 |
| Paik, SW | 1 |
| Zheng, AH | 1 |
| Wang, ZP | 4 |
| Wang, ZX | 2 |
| Wu, LC | 2 |
| Jia, Q | 4 |
| Zhang, YY | 2 |
| Murphy, AJ | 1 |
| Ayers, GD | 1 |
| Hilmes, MA | 1 |
| Mukherjee, K | 1 |
| Wilson, KJ | 1 |
| Allen, WM | 1 |
| Fernandez-Pineda, I | 1 |
| Shinall, MC | 1 |
| Davidoff, AM | 1 |
| Lovvorn, HN | 1 |
| Yokoyama, M | 9 |
| Kimura, S | 2 |
| Usuba, O | 1 |
| Toyono, M | 1 |
| Zhao, L | 5 |
| Sha, YY | 1 |
| Zhao, Q | 1 |
| Zhu, BB | 1 |
| Lu, ZJ | 2 |
| You, QD | 1 |
| Guo, QL | 1 |
| Doden, K | 1 |
| Shimizu, S | 4 |
| Tanaka, N | 8 |
| Yagi, D | 1 |
| Asaumi, Y | 2 |
| Hirano, Y | 1 |
| Miyanaga, T | 2 |
| Hattori, M | 3 |
| Hashizume, Y | 1 |
| Nishizawa, T | 1 |
| Kinoshita, S | 2 |
| Sakuno, T | 1 |
| Fujiyama, Y | 2 |
| Kikuchi, M | 1 |
| Takahashi, M | 23 |
| Murata, Y | 1 |
| Matsuura, T | 4 |
| Kanoshima, K | 1 |
| Kuwabara, H | 3 |
| Fuyuki, A | 1 |
| Tomeno, W | 1 |
| Taniguchi, R | 1 |
| Uchiyama, T | 2 |
| Kuriyama, H | 2 |
| Hata, Y | 6 |
| Artale, S | 2 |
| Marino, D | 1 |
| Cagnazzo, C | 1 |
| Cascinu, S | 6 |
| Pinto, C | 1 |
| Fornarini, G | 1 |
| Tampellini, M | 2 |
| Di Fabio, F | 1 |
| Sartore-Bianchi, A | 1 |
| De Carlis, L | 1 |
| Pugliese, R | 1 |
| Capussotti, L | 8 |
| Gioeni, L | 1 |
| Siena, S | 1 |
| Aglietta, M | 2 |
| Deng, L | 1 |
| Shen, H | 3 |
| He, SL | 1 |
| Sun, XJ | 1 |
| Zhu, XJ | 1 |
| Liu, LM | 2 |
| Dong, JC | 1 |
| Kim, HY | 2 |
| Lee, YJ | 2 |
| Lee, HG | 1 |
| Nicolaou, A | 2 |
| Ricke, J | 2 |
| Podrabsky, P | 1 |
| Seehofer, D | 2 |
| Gebauer, B | 1 |
| Pech, M | 1 |
| Neuhaus, P | 4 |
| Dörken, B | 2 |
| Riess, H | 6 |
| Hildebrandt, B | 6 |
| Zhu, Z | 1 |
| Tan, JW | 1 |
| Tan, HM | 1 |
| Hu, BS | 1 |
| Ding, XM | 1 |
| Leng, JJ | 1 |
| Chen, F | 1 |
| Foubert, F | 1 |
| Katayama, K | 8 |
| Yamaguchi, A | 8 |
| Lupinacci, RM | 1 |
| Simon, JM | 1 |
| Spano, JP | 2 |
| Menegaux, F | 1 |
| Uchino, K | 4 |
| Fujisawa, M | 1 |
| Nobuhisa, T | 1 |
| Matsumoto, Y | 11 |
| Kai, K | 2 |
| Sato, S | 10 |
| Notohara, K | 1 |
| Matsukawa, A | 1 |
| Yeh, CT | 4 |
| Liang, KH | 2 |
| Chang, ML | 2 |
| Hsu, CL | 2 |
| Hung, CF | 2 |
| Bai, Y | 2 |
| Thongprasert, S | 1 |
| Chao, Y | 4 |
| Kang, WK | 6 |
| Nakajima, M | 3 |
| Adachi, A | 3 |
| Uchisako, H | 1 |
| Terasawa, T | 2 |
| Koja, S | 1 |
| Fukuda, K | 8 |
| Yao, ZH | 1 |
| Yuan, YD | 1 |
| Liu, YY | 1 |
| Guo, HQ | 1 |
| Yao, SN | 1 |
| Yang, SJ | 1 |
| Jiang, H | 3 |
| Dong, Q | 1 |
| Shi, B | 2 |
| Gao, H | 1 |
| Kong, J | 1 |
| Nouso, K | 3 |
| Miyahara, K | 2 |
| Uchida, D | 2 |
| Kuwaki, K | 5 |
| Izumi, N | 1 |
| Omata, M | 5 |
| Ichida, T | 2 |
| Kudo, M | 5 |
| Ku, Y | 4 |
| Sakamoto, M | 3 |
| Matsui, O | 2 |
| Matsuyama, Y | 1 |
| Ma, T | 1 |
| Lv, X | 1 |
| Xu, T | 1 |
| Hu, T | 2 |
| Watanabe, K | 14 |
| Kawahara, H | 5 |
| Enomoto, H | 2 |
| Toyama, Y | 2 |
| Akiba, T | 2 |
| Yanaga, K | 3 |
| Li, KC | 1 |
| Zeng, XY | 1 |
| Kuang, CX | 1 |
| Jiang, YB | 1 |
| Dai, ZY | 1 |
| Lang, I | 3 |
| Marcuello, E | 5 |
| Lorusso, V | 2 |
| Ocvirk, J | 4 |
| Shin, DB | 3 |
| Jonker, D | 1 |
| Osborne, S | 1 |
| Andre, N | 1 |
| Waterkamp, D | 2 |
| Saunders, MP | 2 |
| Nasyrov, AR | 2 |
| Pirtskhalava, TL | 2 |
| Korovina, IaV | 2 |
| Tan-Shalaby, J | 1 |
| Yoon, EL | 1 |
| Yeon, JE | 1 |
| Lee, HJ | 6 |
| Kang, SH | 1 |
| Kang, K | 1 |
| Yoo, YJ | 1 |
| Byun, KS | 1 |
| He, B | 6 |
| Xu, H | 7 |
| Han, J | 7 |
| Kochi, M | 4 |
| Aoki, T | 20 |
| Hagiwara, K | 1 |
| Hironaka, K | 1 |
| Teranishi, F | 2 |
| Osuka, F | 1 |
| Takeuchi, M | 2 |
| Witort, E | 1 |
| Lulli, M | 1 |
| Carloni, V | 1 |
| Capaccioli, S | 1 |
| Padman, S | 1 |
| Padbury, R | 1 |
| Beeke, C | 1 |
| Karapetis, CS | 1 |
| Bishnoi, S | 1 |
| Townsend, AR | 2 |
| Maddern, G | 1 |
| Price, TJ | 5 |
| Fan, F | 3 |
| Geng, L | 1 |
| Welling, TH | 1 |
| Feng, M | 1 |
| Hwang, SY | 1 |
| Volk, ML | 1 |
| Zalupski, MM | 4 |
| Sonnenday, CJ | 1 |
| Poston, GJ | 5 |
| Schlag, PM | 5 |
| Bechstein, WO | 9 |
| Walpole, ET | 4 |
| Finch-Jones, M | 4 |
| Jaeck, D | 5 |
| Mirza, D | 3 |
| Parks, RW | 3 |
| Tanis, E | 3 |
| Gruenberger, T | 21 |
| Oh, MJ | 1 |
| Lee, SH | 3 |
| Iwamoto, S | 4 |
| Nakajima, A | 3 |
| Arimoto, A | 1 |
| Gu, W | 4 |
| Fang, FF | 2 |
| Huang, F | 1 |
| Cheng, BB | 3 |
| Yabushita, Y | 1 |
| Kumamoto, T | 4 |
| Taguri, M | 1 |
| Pascal, J | 1 |
| Ashley, CE | 1 |
| Brocato, TA | 1 |
| Butner, JD | 1 |
| Carnes, EC | 1 |
| Koay, EJ | 1 |
| Brinker, CJ | 1 |
| Cristini, V | 1 |
| Nakazawa, T | 1 |
| Murai, A | 1 |
| Nakadai, E | 1 |
| Tonouchi, A | 1 |
| Fujita, Y | 2 |
| Nakamura, J | 1 |
| Yi, JH | 2 |
| Kim, H | 3 |
| Choi, JS | 6 |
| Choi, GH | 2 |
| Baik, SH | 1 |
| Min, BS | 3 |
| Kim, NK | 5 |
| Agostini, V | 1 |
| Andreone, P | 1 |
| Bolondi, L | 1 |
| Serra, C | 1 |
| Sama, C | 1 |
| Golfieri, R | 2 |
| Gramenzi, A | 1 |
| Cucchetti, A | 1 |
| Trevisani, F | 1 |
| Hiraki, M | 2 |
| Nishimura, J | 2 |
| Shiomi, H | 2 |
| Uemura, M | 3 |
| Haraguchi, N | 2 |
| Takemasa, I | 5 |
| Mizushima, T | 5 |
| Isohashi, F | 1 |
| Yoshioka, Y | 5 |
| Guo, X | 4 |
| Yu, YY | 1 |
| Zhou, YH | 1 |
| Zhuang, RY | 1 |
| Cui, YH | 1 |
| Kajiura, S | 2 |
| Yoshita, H | 2 |
| Ueda, Y | 5 |
| Ueda, A | 3 |
| Mihara, H | 1 |
| Ando, T | 2 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 2 |
| Touil, Y | 1 |
| Igoudjil, W | 1 |
| Corvaisier, M | 2 |
| Dessein, AF | 1 |
| Vandomme, J | 1 |
| Monté, D | 2 |
| Stechly, L | 1 |
| Skrypek, N | 2 |
| Langlois, C | 1 |
| Grard, G | 1 |
| Millet, G | 2 |
| Leteurtre, E | 3 |
| Dumont, P | 1 |
| Ellis, LM | 6 |
| Formstecher, P | 2 |
| Van Seuningen, I | 3 |
| Gespach, C | 2 |
| Polakowska, R | 1 |
| Huet, G | 3 |
| Takeda, K | 7 |
| Nojiri, K | 3 |
| Mori, R | 3 |
| Taniguchi, K | 3 |
| Ueda, M | 4 |
| Akiyama, H | 4 |
| Ichikawa, Y | 5 |
| Ota, M | 5 |
| Oashi, K | 1 |
| Tsutsumida, A | 1 |
| Namikawa, K | 1 |
| Omata, W | 1 |
| Yamamoto, Y | 10 |
| Yamazaki, N | 1 |
| Pörneczi, B | 1 |
| Mester, G | 1 |
| Fekete, A | 1 |
| Kőszegi, G | 1 |
| Nakano, E | 1 |
| Kuroki, M | 1 |
| Kanno, N | 1 |
| Matsumura, Y | 3 |
| Miura, A | 3 |
| Hirakawa, H | 1 |
| Kang, GH | 1 |
| Moon, HS | 1 |
| Lee, ES | 2 |
| Kim, SH | 6 |
| Sung, JK | 1 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Lee, HY | 1 |
| Kang, DY | 1 |
| Hu, S | 1 |
| Cervantes, A | 2 |
| Sobrero, AF | 1 |
| Hotko, Y | 1 |
| André, T | 7 |
| Chan, E | 2 |
| Lordick, F | 3 |
| Strickland, AH | 2 |
| Wilson, G | 1 |
| Roman, L | 1 |
| Sidhu, R | 1 |
| Kim, YI | 6 |
| Park, JW | 3 |
| Kim, BH | 3 |
| Kim, TH | 1 |
| Koh, YH | 1 |
| Kim, CM | 2 |
| Tanaka, S | 11 |
| Matsumura, S | 1 |
| Murakata, A | 1 |
| Ban, D | 1 |
| Ochiai, T | 14 |
| Irie, T | 5 |
| Kudo, A | 1 |
| Nakamura, N | 1 |
| Tanabe, M | 1 |
| Arii, S | 8 |
| Kim, S | 1 |
| Dobi, E | 1 |
| Jary, M | 1 |
| Monnien, F | 1 |
| Curtit, E | 1 |
| Nguyen, T | 2 |
| Fratte, S | 1 |
| Lamfichekh, N | 1 |
| Nerich, V | 1 |
| Demarchi, M | 1 |
| Iyama, KI | 1 |
| Ogata, Y | 8 |
| Kakeji, Y | 5 |
| Samura, H | 2 |
| Tsuda, Y | 1 |
| Tomimaru, Y | 8 |
| Terai, S | 4 |
| Tai, K | 1 |
| Kanbara, Y | 2 |
| Yabe, N | 1 |
| Murai, S | 1 |
| Kitasato, K | 1 |
| Oto, I | 1 |
| Nakadai, J | 1 |
| Hasegawa, H | 11 |
| Kobayashi, H | 7 |
| Iida, S | 7 |
| Kikuchi, A | 3 |
| Iwata, N | 1 |
| Yoshida, T | 26 |
| Murayama, M | 2 |
| Kohno, T | 1 |
| Miyazawa, M | 2 |
| Shimazaki, A | 1 |
| Miyaki, A | 1 |
| Usuda, A | 1 |
| Asaka, S | 1 |
| Furukawa, H | 11 |
| Munakata, S | 1 |
| Kawabata, R | 2 |
| Nakata, K | 4 |
| Yamamoto, T | 18 |
| Kawase, T | 1 |
| Ohzato, H | 4 |
| Deguchi, K | 1 |
| Nishikawa, K | 2 |
| Iwase, K | 3 |
| Kawada, J | 1 |
| Aono, T | 3 |
| Nomura, M | 6 |
| Tamagawa, H | 3 |
| Deguchi, T | 1 |
| Higashi, S | 3 |
| Okumura, Y | 1 |
| Noguchi, Y | 1 |
| Takagi, M | 2 |
| Fukui, A | 1 |
| Bao, H | 1 |
| Yin, M | 1 |
| Wu, S | 3 |
| Tomoda, M | 1 |
| Nagata, N | 2 |
| Okuyama, Y | 1 |
| Andoh, H | 1 |
| Hazama, S | 6 |
| Yan, C | 1 |
| Fan, D | 1 |
| Xiong, D | 1 |
| Ledermann, J | 2 |
| Ruers, TJ | 3 |
| Jin, Y | 3 |
| Liang, X | 1 |
| Dai, Z | 1 |
| You, YK | 1 |
| Lee, MA | 2 |
| Yamanashi, T | 1 |
| Nishi, T | 1 |
| Toriumi, F | 1 |
| Koshida, Y | 1 |
| Mukai, K | 2 |
| Shimoyama, Y | 1 |
| Nagano, I | 1 |
| Niwa, M | 1 |
| Kanazawa, H | 1 |
| Matsumoto, N | 3 |
| Yoshinaka, H | 1 |
| Naiken, SP | 1 |
| Toso, C | 1 |
| Rubbia-Brandt, L | 4 |
| Thomopoulos, T | 1 |
| Roth, A | 4 |
| Mentha, G | 5 |
| Morel, P | 3 |
| Gervaz, P | 4 |
| Kato, H | 4 |
| Kawabe, H | 1 |
| Tomizawa, G | 1 |
| Horikawa, N | 1 |
| Yabuhita, K | 1 |
| Note, M | 1 |
| Zhang, SS | 2 |
| Zhao, QD | 2 |
| Zong, C | 1 |
| Guo, SW | 1 |
| Zhang, JW | 2 |
| Wu, MC | 2 |
| Wei, LX | 2 |
| Han, NY | 1 |
| Park, BJ | 1 |
| Sung, DJ | 1 |
| Lee, CH | 2 |
| Jang, YJ | 1 |
| Um, SH | 4 |
| Won, NH | 1 |
| Yang, KS | 1 |
| Holmqvist, A | 1 |
| Sun, XF | 2 |
| Albertsson, M | 1 |
| Tamura, S | 4 |
| Kubo, N | 6 |
| Ijichi, K | 1 |
| Tsuchihashi, K | 1 |
| Komoda, M | 1 |
| Ariyama, H | 3 |
| Akashi, K | 1 |
| Baba, E | 3 |
| Habr-Gama, A | 1 |
| Gama-Rodrigues, J | 1 |
| São Julião, GP | 1 |
| Proscurshim, I | 1 |
| Sabbagh, C | 1 |
| Lynn, PB | 1 |
| Perez, RO | 1 |
| Van Loon, K | 1 |
| Venook, AP | 7 |
| Liu, XH | 1 |
| Man, YN | 1 |
| Cao, R | 1 |
| Wu, XZ | 1 |
| Zha, Y | 1 |
| Gan, P | 1 |
| Yao, Q | 1 |
| Ran, FM | 1 |
| Tan, J | 1 |
| Raab, HR | 2 |
| Weitz, J | 4 |
| Stoehlmacher-Williams, J | 2 |
| Lang, H | 2 |
| Trarbach, T | 2 |
| Liersch, T | 4 |
| Ockert, D | 2 |
| Jaeger, D | 1 |
| Steger, U | 1 |
| Suedhoff, T | 1 |
| Rentsch, A | 1 |
| Elsoueidi, R | 1 |
| Craig, J | 1 |
| Mourad, H | 1 |
| Richa, EM | 1 |
| Lau, LF | 1 |
| Williams, DS | 1 |
| Lee, ST | 1 |
| Scott, AM | 1 |
| Christophi, C | 1 |
| Muralidharan, V | 1 |
| Calderaro, J | 1 |
| Zafrani, ES | 1 |
| Okur, A | 1 |
| Eser, EP | 1 |
| Yilmaz, G | 1 |
| Dalgiç, A | 1 |
| Akdemir, ÜÖ | 1 |
| Oğuz, A | 1 |
| Karadeniz, C | 1 |
| Akyol, G | 1 |
| Demiroğullari, B | 1 |
| Boyunağa, Ö | 1 |
| Pinarli, FG | 1 |
| Chirica, M | 1 |
| Tranchard, H | 1 |
| Balladur, P | 1 |
| de Gramont, A | 7 |
| Afchain, P | 2 |
| Paye, F | 1 |
| Rahbari, NN | 2 |
| Reissfelder, C | 2 |
| Schulze-Bergkamen, H | 3 |
| Jäger, D | 3 |
| Büchler, MW | 2 |
| Koch, M | 1 |
| Fujii, T | 4 |
| Asao, T | 2 |
| Tsutsumi, S | 2 |
| Wada, S | 1 |
| Araki, K | 3 |
| Watanabe, A | 6 |
| Tsukagoshi, M | 1 |
| Kuwano, H | 3 |
| Rong, Z | 1 |
| Martel, G | 1 |
| Vandenbroucke-Menu, F | 1 |
| Lapointe, R | 1 |
| Lu, K | 1 |
| Qiao, WB | 1 |
| Zhang, HY | 1 |
| You, QS | 1 |
| Yeh, YS | 2 |
| Huang, ML | 1 |
| Chang, SF | 1 |
| Chen, CF | 1 |
| Hu, HM | 1 |
| Wang, JY | 6 |
| DʼAngelica, MI | 1 |
| Correa-Gallego, C | 1 |
| Gewirtz, AN | 1 |
| Fong, Y | 13 |
| Sui, W | 1 |
| Hickey, R | 2 |
| Mulcahy, MF | 4 |
| Lewandowski, RJ | 1 |
| Gates, VL | 1 |
| Vouche, M | 1 |
| Habib, A | 1 |
| Kircher, S | 1 |
| Newman, S | 1 |
| Nimeiri, H | 1 |
| Benson, AB | 11 |
| Salem, R | 2 |
| Wang, WP | 1 |
| Zhu, S | 1 |
| Qian, L | 2 |
| Gao, J | 2 |
| Wu, M | 10 |
| Chan, GL | 1 |
| Han, W | 1 |
| Cao, D | 1 |
| Schwartzberg, LS | 1 |
| Fasola, G | 1 |
| Canon, JL | 3 |
| Hecht, JR | 2 |
| Oliner, KS | 1 |
| Go, WY | 2 |
| Dangi, R | 1 |
| Hurkat, P | 1 |
| Jain, A | 2 |
| Shilpi, S | 1 |
| Gulbake, A | 1 |
| Jain, SK | 1 |
| Ahn, JH | 1 |
| Yu, HK | 1 |
| Hong, SW | 1 |
| Kim, SJ | 2 |
| Kim, JS | 7 |
| Tang, J | 1 |
| Tao, ZH | 1 |
| Wan, JL | 1 |
| Liu, DL | 1 |
| Cui, JF | 1 |
| Sun, HC | 2 |
| Wu, WZ | 2 |
| Primrose, J | 1 |
| Falk, S | 1 |
| Valle, J | 2 |
| O'Reilly, D | 1 |
| Siriwardena, A | 1 |
| Hornbuckle, J | 1 |
| Peterson, M | 1 |
| Rees, M | 1 |
| Iveson, T | 1 |
| Hickish, T | 4 |
| Butler, R | 1 |
| Stanton, L | 1 |
| Dixon, E | 4 |
| Little, L | 1 |
| Bowers, M | 1 |
| Pugh, S | 1 |
| Garden, OJ | 2 |
| Maughan, T | 1 |
| Bridgewater, J | 2 |
| Nielsen, DL | 2 |
| Palshof, JA | 1 |
| Ogasawara, S | 4 |
| Chiba, T | 4 |
| Ooka, Y | 1 |
| Kanogawa, N | 1 |
| Motoyama, T | 1 |
| Tawada, A | 1 |
| Kanai, F | 2 |
| Yokosuka, AO | 1 |
| Iwata, H | 1 |
| Hatanaka, M | 1 |
| Barbazán, J | 1 |
| Muinelo-Romay, L | 1 |
| Vieito, M | 1 |
| Candamio, S | 2 |
| Díaz-López, A | 1 |
| Cano, A | 1 |
| Gómez-Tato, A | 1 |
| Casares de Cal, Mde L | 1 |
| Abal, M | 1 |
| López-López, R | 1 |
| Chie, EK | 1 |
| Jang, JY | 2 |
| Kim, SW | 1 |
| Han, SW | 5 |
| Oh, DY | 5 |
| Im, SA | 6 |
| Kim, TY | 6 |
| Ha, SW | 1 |
| Ganeshkumar, M | 1 |
| Ponrasu, T | 1 |
| Raja, MD | 1 |
| Subamekala, MK | 1 |
| Suguna, L | 1 |
| Sotelo, MJ | 1 |
| Aguado, C | 1 |
| Feng, QY | 1 |
| Chang, WJ | 1 |
| Xu, JM | 1 |
| Tang, H | 3 |
| Zhang, P | 3 |
| Xiang, Q | 4 |
| Yin, J | 5 |
| Lei, X | 6 |
| Mross, K | 2 |
| Scheulen, M | 1 |
| Strumberg, D | 3 |
| Kuhlmann, J | 1 |
| Kanefendt, F | 2 |
| Sörgel, F | 1 |
| Jaehde, U | 3 |
| Burkholder, I | 1 |
| Moritz, B | 2 |
| Büchert, M | 2 |
| Arao, T | 1 |
| Matsumoto, K | 2 |
| Kimura, H | 5 |
| Togashi, Y | 1 |
| Hirashima, Y | 2 |
| Horita, Y | 2 |
| Iwasa, S | 3 |
| Okita, NT | 1 |
| Honma, Y | 2 |
| Takashima, A | 3 |
| Hamaguchi, T | 3 |
| Nishio, K | 1 |
| Wang, F | 7 |
| Dai, W | 3 |
| Shen, M | 1 |
| Cheng, P | 1 |
| Lu, J | 4 |
| Tsai, WL | 1 |
| Lai, KH | 2 |
| Hsu, PI | 2 |
| Chan, HH | 1 |
| Chen, WC | 1 |
| Yu, HC | 2 |
| Tsay, FW | 1 |
| Wang, HM | 2 |
| Tsai, HC | 1 |
| Cheng, JS | 2 |
| Jiang, JX | 1 |
| Gao, S | 2 |
| Pan, YZ | 1 |
| Sun, CY | 1 |
| Luo, NQ | 1 |
| Zhang, ZH | 2 |
| Ma, Y | 3 |
| Sunami, T | 2 |
| Tauchi, J | 1 |
| Sakashita, K | 1 |
| Yukimoto, K | 1 |
| Sawada, R | 1 |
| Okabe, T | 1 |
| Hoshino, K | 4 |
| Sunose, Y | 1 |
| Takeyoshi, I | 1 |
| Hua, H | 1 |
| Qu, W | 2 |
| Wang, SS | 3 |
| Xie, X | 2 |
| Wong, CS | 1 |
| Choi, Y | 1 |
| Fung, MC | 1 |
| Sui, WW | 1 |
| Wunderle, KA | 1 |
| Sands, MJ | 1 |
| Vargas, GM | 1 |
| Parmar, AD | 1 |
| Sheffield, KM | 1 |
| Tamirisa, NP | 1 |
| Brown, KM | 1 |
| Riall, TS | 1 |
| Ren, M | 1 |
| Ye, L | 1 |
| Ren, S | 1 |
| Xu, K | 2 |
| Bekaii-Saab, T | 1 |
| Chen, YJ | 2 |
| Cooper, HS | 2 |
| Engstrom, PF | 3 |
| Enzinger, PC | 2 |
| Fenton, MJ | 1 |
| Fuchs, CS | 3 |
| Hunt, S | 1 |
| Kamel, A | 1 |
| Leong, LA | 3 |
| Lin, E | 2 |
| Messersmith, W | 1 |
| Murphy, JD | 1 |
| Nurkin, S | 1 |
| Rohren, E | 1 |
| Saltz, L | 5 |
| Shibata, D | 2 |
| Skibber, JM | 2 |
| Stoffel, EM | 1 |
| Stotsky-Himelfarb, E | 1 |
| Willett, CG | 2 |
| Gregory, KM | 1 |
| Freedman-Cass, DA | 1 |
| Koca, D | 2 |
| Ünal, OÜ | 1 |
| Öztop, I | 2 |
| Yılmaz, U | 2 |
| Dutton, SJ | 1 |
| Kenealy, N | 1 |
| Love, SB | 1 |
| Wasan, HS | 1 |
| Sharma, RA | 2 |
| Chaix, M | 1 |
| Lorgis, V | 1 |
| Altaf, R | 1 |
| Lund Brixen, A | 1 |
| Kristensen, B | 1 |
| Nielsen, SE | 1 |
| Park, SY | 2 |
| Yang, JM | 1 |
| Zhao, X | 3 |
| Ji, D | 1 |
| Hamann, S | 1 |
| Schütte, K | 1 |
| Ehninger, G | 1 |
| Rudloff, U | 1 |
| Langan, RC | 1 |
| Mullinax, JE | 1 |
| Beane, JD | 1 |
| Steinberg, SM | 1 |
| Beresnev, T | 1 |
| Webb, CC | 1 |
| Walker, M | 1 |
| Toomey, MA | 1 |
| Schrump, D | 1 |
| Pandalai, P | 1 |
| Stojadinovic, A | 1 |
| Avital, I | 1 |
| Uthe, FW | 1 |
| Hüttenrauch, M | 1 |
| Mühling, B | 1 |
| Linnebacher, M | 1 |
| Krummenast, F | 1 |
| Thalheimer, A | 1 |
| Otto, C | 1 |
| Wang, JX | 1 |
| Zhang, LY | 1 |
| Wang, DM | 1 |
| Yuan, Y | 3 |
| Yang, XJ | 1 |
| Guo, TK | 1 |
| Chen, YR | 1 |
| Battisti, S | 1 |
| Guida, FM | 1 |
| Pagliara, E | 1 |
| Tonini, G | 5 |
| Zobel, BB | 1 |
| Nemoto, H | 2 |
| Tate, G | 1 |
| Umemoto, T | 6 |
| Matsubara, T | 1 |
| Mizukami, H | 1 |
| Kigawa, G | 1 |
| Matsumiya, A | 1 |
| Tanaka, J | 5 |
| Dedić Plavetić, N | 1 |
| Rakušić, Z | 1 |
| Ozretić, D | 1 |
| Simetić, L | 1 |
| Krpan, AM | 1 |
| Bišof, V | 1 |
| Song, L | 1 |
| Zhao, DY | 1 |
| Guo, B | 2 |
| Simone, G | 1 |
| Partipilo, G | 1 |
| Scarpi, E | 1 |
| Brunetti, AE | 1 |
| Maiello, E | 4 |
| Paradiso, A | 1 |
| Mangia, A | 1 |
| Song, Y | 3 |
| Cheng, AL | 4 |
| Vaid, AK | 1 |
| Ma, BB | 1 |
| Teh, C | 1 |
| Bello, M | 2 |
| Charoentum, C | 1 |
| de Lima Lopes, G | 2 |
| Ho, GF | 1 |
| Kong, HL | 1 |
| Sriuranpong, V | 1 |
| Sudoyo, AW | 1 |
| Zhang, SZ | 1 |
| Ciardiello, F | 1 |
| Shaw, M | 1 |
| Goldstein, R | 1 |
| Yu, D | 1 |
| Gillmore, R | 1 |
| Thirlwell, C | 1 |
| O'Donoghue, P | 1 |
| Mayer, A | 1 |
| Michael, M | 2 |
| Chander, S | 1 |
| McKendrick, J | 1 |
| MacKay, JR | 1 |
| Steel, M | 1 |
| Hicks, R | 1 |
| Heriot, A | 1 |
| Leong, T | 1 |
| Cooray, P | 2 |
| Jefford, M | 1 |
| Bressel, M | 1 |
| McClure, B | 1 |
| Ngan, SY | 2 |
| Gu, Y | 3 |
| Luo, H | 1 |
| Ding, P | 1 |
| Lu, Z | 3 |
| Xu, R | 2 |
| Wan, D | 1 |
| Liang, J | 3 |
| Rau, KM | 1 |
| Jian, Z | 1 |
| Magata, H | 1 |
| Kondo, K | 5 |
| Otani, K | 1 |
| Yano, K | 1 |
| Yonei, A | 1 |
| Akasu, I | 1 |
| Marutsuka, H | 1 |
| Fukushima, G | 1 |
| Kataoka, H | 2 |
| Hua, HW | 1 |
| Jiang, F | 1 |
| Huang, Q | 1 |
| Liao, ZJ | 1 |
| Ding, G | 1 |
| Nagai, Y | 2 |
| Miyamoto, Y | 8 |
| Hirashima, K | 1 |
| Imamura, Y | 5 |
| Baba, Y | 7 |
| Lin, CL | 1 |
| Chien, RN | 1 |
| Yeh, C | 1 |
| Hsu, CW | 1 |
| Tsauo, J | 1 |
| Mulcahy, M | 1 |
| Putnam, SG | 1 |
| Jia, K | 1 |
| Feng, T | 1 |
| Xu, F | 2 |
| Lee, IJ | 2 |
| Kim, JK | 5 |
| Kim, KS | 3 |
| Park, YN | 2 |
| Pan, X | 3 |
| Osawa, T | 1 |
| Sano, T | 1 |
| Shimizu, Y | 4 |
| Senda, Y | 1 |
| Yamaura, H | 1 |
| Zagonel, V | 1 |
| Cortesi, E | 3 |
| Ronzoni, M | 2 |
| Spadi, R | 1 |
| Zaniboni, A | 5 |
| Buonadonna, A | 2 |
| Amoroso, D | 1 |
| Chiara, S | 3 |
| Boni, C | 1 |
| Allegrini, G | 5 |
| Boni, L | 2 |
| Kim, JB | 1 |
| Ahn, YH | 1 |
| Jee, HG | 1 |
| Yu, SJ | 1 |
| Lee, HS | 2 |
| Lee, M | 4 |
| Yoon, JH | 1 |
| Kim, YJ | 1 |
| Hu, XY | 1 |
| Guo, XJ | 2 |
| Guo, YB | 1 |
| Tokunaga, S | 2 |
| Shirabe, K | 4 |
| Ueno, S | 4 |
| Kuramoto, M | 1 |
| Kabashima, A | 2 |
| Takahashi, I | 2 |
| Natsugoe, S | 4 |
| Agarwal, A | 2 |
| Daly, KP | 1 |
| Butler-Bowen, H | 1 |
| Saif, MW | 8 |
| Patkowski, W | 1 |
| Stankiewicz, R | 1 |
| Grąt, M | 1 |
| Krasnodębski, M | 1 |
| Kornasiewicz, O | 1 |
| Krawczyk, M | 1 |
| Min, Z | 1 |
| Goldberg, RM | 11 |
| Hirata, H | 1 |
| Sugimachi, K | 10 |
| Sakimura, S | 1 |
| Uchi, R | 1 |
| Kurashige, J | 1 |
| Takano, Y | 2 |
| Nanbara, S | 1 |
| Shinden, Y | 1 |
| Iguchi, T | 2 |
| Atsumi, K | 1 |
| Doi, T | 6 |
| Hirakawa, M | 2 |
| Honda, H | 3 |
| Mimori, K | 2 |
| Choda, Y | 1 |
| Ninomiya, M | 2 |
| Kanazawa, T | 1 |
| Sato, D | 1 |
| Tokumoto, N | 1 |
| Harano, M | 2 |
| Matsukawa, H | 1 |
| Ojima, Y | 1 |
| Idani, H | 2 |
| Shiozaki, S | 1 |
| Okajima, M | 2 |
| Sebagh, M | 3 |
| Baillie, G | 1 |
| Faitot, F | 1 |
| Vitadello, F | 1 |
| Kameoka, S | 2 |
| Mochizuki, I | 1 |
| Kinugasa, Y | 1 |
| Kikuchi, T | 2 |
| Melichar, B | 4 |
| Dvorak, J | 2 |
| Ferko, A | 1 |
| Kamaradova, K | 1 |
| Krajina, A | 2 |
| Gibbs, P | 5 |
| Gebski, V | 2 |
| Van Buskirk, M | 1 |
| Thurston, K | 1 |
| Cade, DN | 2 |
| Van Hazel, GA | 5 |
| Takada, S | 1 |
| Hoshino, Y | 4 |
| Masugi, Y | 1 |
| Terauchi, T | 1 |
| Endo, K | 3 |
| Kimata, M | 1 |
| Furukawa, J | 9 |
| Shinozaki, H | 1 |
| Akinwande, O | 1 |
| Miller, A | 1 |
| Hayes, D | 1 |
| O'Hara, R | 1 |
| Tomalty, D | 2 |
| Martin, RC | 5 |
| Vandamme, M | 1 |
| Pauwels, W | 1 |
| Bleecker, JD | 1 |
| García Alfonso, P | 1 |
| Mudan, S | 4 |
| Lasserre, S | 1 |
| Hermann, F | 1 |
| Duran, AO | 2 |
| Karaca, H | 2 |
| Besiroglu, M | 1 |
| Bayoglu, IV | 1 |
| Menekse, S | 1 |
| Yapici, HS | 1 |
| Yazilitas, D | 1 |
| Bahceci, A | 1 |
| Uysal, M | 1 |
| Sevinc, A | 1 |
| Hacibekiroglu, I | 2 |
| Aksoy, A | 1 |
| Tanriverdi, O | 1 |
| Arpaci, E | 1 |
| Inanc, M | 2 |
| Dane, F | 1 |
| Ozkan, M | 3 |
| Neofytou, K | 1 |
| Giakoustidis, A | 1 |
| Smyth, EC | 1 |
| Desurmont, T | 1 |
| Duhamel, A | 1 |
| Jonckheere, N | 1 |
| Gosset, P | 1 |
| Duchene, B | 1 |
| Ramdane, N | 1 |
| Kubáčková, K | 1 |
| Bortlíček, Z | 3 |
| Pikus, T | 1 |
| Linke, Z | 1 |
| Pokorná, P | 1 |
| Vyzula, R | 4 |
| Prausová, J | 2 |
| Muroi, H | 1 |
| Satomura, H | 1 |
| Domeki, Y | 1 |
| Takada, A | 2 |
| Noda, H | 2 |
| Watanabe, F | 1 |
| Kakizawa, N | 1 |
| Toyama, N | 2 |
| Rikiyama, T | 3 |
| Yagi, Y | 1 |
| Yamazaki, T | 4 |
| Iwaya, A | 1 |
| Manabe, S | 1 |
| Koeberle, D | 1 |
| Betticher, DC | 1 |
| von Moos, R | 1 |
| Dietrich, D | 1 |
| Brauchli, P | 1 |
| Baertschi, D | 1 |
| Matter, K | 1 |
| Winterhalder, R | 1 |
| Borner, M | 3 |
| Anchisi, S | 1 |
| Moosmann, P | 1 |
| Kollar, A | 1 |
| Saletti, P | 2 |
| Frueh, M | 1 |
| Kueng, M | 1 |
| Popescu, RA | 1 |
| Schacher, S | 1 |
| Hess, V | 1 |
| Herrmann, R | 6 |
| Ihaya, T | 1 |
| Tao, L | 1 |
| Yang, JK | 1 |
| Zhao, AG | 1 |
| Zhu, YJ | 1 |
| Zuo, CH | 1 |
| Xia, M | 1 |
| Liu, JS | 1 |
| Qiu, XX | 1 |
| Xu, RC | 1 |
| Liu, HC | 1 |
| Li, JL | 1 |
| Li, YG | 1 |
| Li, QL | 1 |
| Hong, Y | 1 |
| Wang, XH | 1 |
| Zhu, HZ | 2 |
| Wu, QF | 1 |
| Burns, M | 1 |
| Qu, P | 1 |
| Yuan, P | 2 |
| Xing, J | 1 |
| Zhao, XL | 1 |
| Shang, SQ | 1 |
| Shen, HQ | 1 |
| Nipp, RD | 1 |
| Hwang, JS | 5 |
| Eun, JR | 2 |
| Marton, E | 1 |
| Liegl-Atzwanger, B | 1 |
| Wrba, F | 3 |
| Knittelfelder, R | 1 |
| Lindner, E | 1 |
| Streubel, B | 1 |
| Krebs, MG | 1 |
| Renehan, AG | 1 |
| Backen, A | 1 |
| Gollins, S | 1 |
| Hasan, J | 1 |
| Valle, JW | 1 |
| Morris, K | 1 |
| Beech, J | 1 |
| Ashcroft, L | 1 |
| Dive, C | 1 |
| Baba, K | 3 |
| Oshita, A | 1 |
| Kohyama, M | 1 |
| Inoue, S | 6 |
| Kuroo, Y | 1 |
| Nakamura, H | 9 |
| Sugiyama, Y | 7 |
| Tazaki, T | 1 |
| Sasaki, M | 7 |
| Daimaru, Y | 2 |
| Ohdan, H | 1 |
| Nakamitsu, A | 3 |
| Huang, WJ | 1 |
| Wang, HY | 1 |
| Wang, YF | 1 |
| Peng, BG | 2 |
| Marks, E | 1 |
| Rizvi, SM | 1 |
| Sarwani, N | 1 |
| El-Deiry, WS | 2 |
| Malik, H | 1 |
| Khan, AZ | 2 |
| Berry, DP | 5 |
| Cameron, IC | 1 |
| Pope, I | 1 |
| Sherlock, D | 2 |
| Helmy, S | 1 |
| Byrne, B | 1 |
| Thompson, M | 1 |
| Pulfer, A | 1 |
| Davidson, B | 1 |
| Bergen, ES | 1 |
| Berghoff, AS | 1 |
| Rudas, M | 1 |
| Bartsch, R | 1 |
| Hou, N | 1 |
| Cho, H | 2 |
| Nishiike, S | 1 |
| Takenaka, Y | 1 |
| Nakahara, S | 1 |
| Yasui, T | 1 |
| Hanamoto, A | 1 |
| Inohara, H | 1 |
| Shimizu, K | 8 |
| Iwatsuki, M | 1 |
| Sugiyama, S | 2 |
| Ando, Y | 2 |
| Kadokawa, Y | 1 |
| Aisu, Y | 1 |
| Honda, K | 6 |
| Nishiuchi, A | 1 |
| Kato, S | 10 |
| Machimoto, T | 1 |
| Asao, Y | 1 |
| Yoshimura, T | 3 |
| Gokita, K | 1 |
| Matsunaga, Y | 1 |
| Fujiya, K | 2 |
| Ohshima, N | 1 |
| Nagahama, T | 13 |
| Tei, S | 3 |
| Okada, Y | 5 |
| Ohashi, I | 2 |
| Arai, I | 3 |
| Tamura, C | 1 |
| Wakasa, T | 1 |
| Hashimoto, Y | 3 |
| Hosoi, M | 1 |
| Minagawa, M | 2 |
| Kosugi, S | 2 |
| Koyama, Y | 6 |
| Okada, A | 5 |
| Tomihara, H | 1 |
| Asaoka, T | 3 |
| So, S | 2 |
| Kido, M | 1 |
| Fukumoto, T | 2 |
| Takebe, A | 1 |
| Kinoshita, H | 7 |
| Kuramitsu, K | 1 |
| Tsugawa, D | 1 |
| Fukushima, K | 1 |
| Urade, T | 1 |
| Asari, S | 1 |
| Okazaki, T | 1 |
| Shinzeki, M | 1 |
| Matsumoto, I | 1 |
| Ajiki, T | 2 |
| Hokonohara, K | 1 |
| Takata, A | 1 |
| Noda, T | 14 |
| Imamura, H | 5 |
| Hirota, M | 4 |
| Oshima, K | 2 |
| Tanida, T | 1 |
| Hatano, H | 3 |
| Iwazawa, T | 7 |
| Akagi, K | 1 |
| Adachi, S | 2 |
| Dono, K | 26 |
| Jeongho, M | 1 |
| Hatanaka, N | 2 |
| Odagiri, K | 2 |
| Kurokawa, T | 6 |
| Honmyo, N | 1 |
| Irei, T | 2 |
| Tominaga, H | 2 |
| Turkeli, M | 1 |
| Aldemir, MN | 1 |
| Cayir, K | 1 |
| Simsek, M | 1 |
| Bilici, M | 1 |
| Tekin, SB | 1 |
| Yildirim, N | 1 |
| Bilen, N | 1 |
| Makas, I | 1 |
| Fujikawa, Y | 1 |
| Rino, Y | 2 |
| Uchiyama, M | 2 |
| Atsumi, Y | 1 |
| Tsuchida, K | 1 |
| Yamamoto, N | 6 |
| Oshima, T | 3 |
| Yukawa, N | 2 |
| Masuda, M | 3 |
| Iida, T | 1 |
| Wagatsuma, K | 1 |
| Tani, M | 2 |
| Sasaki, H | 2 |
| Naganawa, Y | 1 |
| Isshiki, H | 1 |
| Murakami, K | 7 |
| Satoh, S | 2 |
| Kaneto, H | 1 |
| Russolillo, N | 2 |
| Ratti, F | 1 |
| Langella, S | 2 |
| Cipriani, F | 1 |
| Aldrighetti, L | 1 |
| Ferrero, A | 2 |
| Lescut, N | 1 |
| Lepinoy, A | 1 |
| Schipman, B | 1 |
| Cerda, T | 1 |
| Guimas, V | 1 |
| Bednarek, C | 1 |
| Bosset, JF | 3 |
| Pilat, N | 1 |
| Grünberger, T | 1 |
| Längle, F | 1 |
| Mittlböck, M | 1 |
| Perisanidis, B | 1 |
| Kappel, S | 1 |
| Wolf, B | 1 |
| Starlinger, P | 2 |
| Kührer, I | 1 |
| Mühlbacher, F | 1 |
| Kandioler, D | 1 |
| Gonella, S | 1 |
| Gonella, F | 1 |
| Rodman, C | 1 |
| Atala, A | 1 |
| Onishi, H | 3 |
| Nakamura, S | 4 |
| Katsui, K | 1 |
| Wada, N | 3 |
| Morimoto, Y | 4 |
| Takeuchi, Y | 6 |
| Yasunaka, T | 1 |
| Miyake, Y | 7 |
| Shiraha, H | 5 |
| Takaki, A | 4 |
| Sakaguchi, K | 3 |
| Kanazawa, S | 2 |
| Matono, K | 2 |
| Tsuda, H | 2 |
| Ushijima, M | 2 |
| Uchida, S | 4 |
| Shirouzu, K | 9 |
| Yoshitoshi, EY | 1 |
| Mizumoto, M | 1 |
| Xie, XY | 1 |
| Le, F | 1 |
| Li, LX | 2 |
| Gan, YH | 4 |
| Zhang, JB | 2 |
| Xue, TC | 1 |
| Xia, JL | 4 |
| Zhang, BH | 2 |
| Ye, SL | 4 |
| Ozaslan, E | 1 |
| Bozkurt, O | 1 |
| Ucar, M | 1 |
| Berk, V | 1 |
| Elmali, F | 1 |
| Ogino, YU | 1 |
| Utsumi, H | 1 |
| Nagashima, K | 2 |
| Nara, S | 2 |
| Esaki, M | 1 |
| Shimada, K | 1 |
| Stremitzer, S | 1 |
| Stift, J | 1 |
| Singh, J | 1 |
| Gruenberger, B | 9 |
| Tamandl, D | 8 |
| Cavanna, L | 2 |
| Bodini, FC | 1 |
| Stroppa, EM | 1 |
| Banchini, F | 1 |
| Michieletti, E | 1 |
| Capelli, P | 1 |
| Zangrandi, A | 1 |
| Anselmi, E | 2 |
| Irving, GR | 1 |
| Iwuji, CO | 1 |
| Morgan, B | 3 |
| Steward, WP | 3 |
| Thomas, A | 2 |
| Brown, K | 3 |
| Howells, LM | 2 |
| Li, BL | 1 |
| Zhao, XH | 1 |
| Sun, HG | 1 |
| Zhou, CY | 1 |
| Li, K | 1 |
| Dong, K | 1 |
| Takahama, T | 1 |
| Takeda, M | 3 |
| Nishina, S | 1 |
| Schoellhammer, HF | 1 |
| Goldner, B | 1 |
| Merchant, SJ | 1 |
| Kessler, J | 1 |
| Gagandeep, S | 1 |
| Bencsikova, B | 1 |
| Halamkova, J | 1 |
| Ostrizkova, L | 1 |
| Kiss, I | 2 |
| Pavlik, T | 1 |
| Dusek, L | 2 |
| Valik, D | 1 |
| Zdrazilova-Dubska, L | 1 |
| Brock, MV | 1 |
| Tao, Q | 1 |
| Herman, JG | 1 |
| Liang, P | 2 |
| Vishnevskiĭ, AV | 1 |
| Andreĭtseva, OI | 1 |
| Kharazov, AF | 1 |
| Gritsiuta, AI | 1 |
| Kalinin, DV | 1 |
| Zhavoronkova, OI | 1 |
| Yoshioka, R | 1 |
| Abe, H | 3 |
| Okura, N | 1 |
| Amankwatia, EB | 1 |
| Chakravarty, P | 1 |
| Carey, FA | 1 |
| Weidlich, S | 1 |
| Steele, RJ | 1 |
| Munro, AJ | 1 |
| Wolf, CR | 1 |
| Smith, G | 1 |
| Tokka, A | 1 |
| Huiskens, J | 1 |
| van Gulik, TM | 1 |
| van Lienden, KP | 1 |
| Engelbrecht, MR | 1 |
| Meijer, GA | 1 |
| van Grieken, NC | 1 |
| Schriek, J | 1 |
| Keijser, A | 1 |
| Mol, L | 1 |
| Molenaar, IQ | 1 |
| Dejong, KH | 1 |
| Kazemier, G | 1 |
| Ruers, TM | 1 |
| de Wilt, JH | 2 |
| van Tinteren, H | 1 |
| Lei, Z | 1 |
| Wu, D | 3 |
| Si, A | 1 |
| Wan, X | 1 |
| Xia, Y | 2 |
| Shen, F | 2 |
| James, MI | 1 |
| Iwuji, C | 1 |
| Irving, G | 1 |
| Karmokar, A | 1 |
| Higgins, JA | 1 |
| Griffin-Teal, N | 1 |
| Greaves, P | 1 |
| Patel, SR | 1 |
| Dennison, A | 1 |
| Metcalfe, M | 1 |
| Garcea, G | 2 |
| Lloyd, DM | 1 |
| Ayez, N | 2 |
| van der Stok, EP | 1 |
| Rothbarth, J | 1 |
| van Meerten, E | 1 |
| Eggermont, AM | 3 |
| Cohn, A | 1 |
| Dakhil, S | 1 |
| Saleh, M | 1 |
| Piperdi, B | 1 |
| Cline-Burkhardt, M | 1 |
| Saeki, I | 1 |
| Yamasaki, T | 3 |
| Tanabe, N | 1 |
| Iwamoto, T | 1 |
| Matsumoto, T | 3 |
| Urata, Y | 1 |
| Hidaka, I | 1 |
| Takami, T | 2 |
| Uchida, K | 4 |
| Sakaida, I | 2 |
| Volovat, SR | 1 |
| Volovat, C | 1 |
| Negru, SM | 1 |
| Danciu, M | 1 |
| Scripcariu, V | 1 |
| Kocakova, I | 1 |
| Kocak, I | 1 |
| Büchler, T | 1 |
| Petruzelka, L | 1 |
| Kohoutek, M | 1 |
| Finek, J | 1 |
| Mohelnikova-Duchonova, B | 1 |
| Zhao, RL | 1 |
| Chen, MJ | 2 |
| Zhao, FM | 1 |
| Xu, DQ | 1 |
| Zhou, KF | 1 |
| Schneitler, S | 1 |
| Kröpil, P | 1 |
| Riemer, J | 1 |
| Antoch, G | 1 |
| Knoefel, WT | 1 |
| Häussinger, D | 1 |
| Graf, D | 1 |
| Deng, G | 2 |
| Pei, H | 1 |
| Makoshi, Z | 1 |
| Perrott, C | 1 |
| Al-Khatani, K | 1 |
| Al-Mohaisen, F | 1 |
| Liao, B | 1 |
| Morio, R | 1 |
| Fukuhara, T | 2 |
| Naeshiro, N | 2 |
| Miyaki, D | 3 |
| Takahashi, S | 15 |
| Mithieux, F | 1 |
| Marsot, J | 1 |
| Watkin, E | 1 |
| Lledo, G | 3 |
| Chalabreysse, P | 1 |
| Desramé, J | 1 |
| Scoggins, CR | 3 |
| Schreeder, M | 2 |
| Rilling, WS | 1 |
| Laing, CJ | 1 |
| Tatum, CM | 1 |
| Kelly, LR | 1 |
| Garcia-Monaco, RD | 1 |
| Sharma, VR | 1 |
| Crocenzi, TS | 1 |
| Strasberg, SM | 3 |
| Ho, MY | 1 |
| Renouf, DJ | 1 |
| Cheung, WY | 1 |
| Lim, HJ | 1 |
| Gill, S | 4 |
| Shakado, S | 3 |
| Iwata, K | 3 |
| Tsuchiya, N | 1 |
| Kunimoto, H | 2 |
| Yotsumoto, K | 2 |
| Fukunaga, A | 2 |
| Kuno, S | 1 |
| Iwashita, H | 2 |
| Hirano, G | 2 |
| Yokoyama, K | 2 |
| Morihara, D | 2 |
| Nishizawa, S | 1 |
| Takeyama, Y | 2 |
| Irie, M | 2 |
| Sohda, T | 2 |
| Kora, S | 1 |
| Yoshimitsu, K | 1 |
| Sakisaka, S | 2 |
| Yamaguchi, S | 7 |
| Suto, T | 3 |
| Yajima, R | 1 |
| Morita, H | 1 |
| Mukouzu, T | 1 |
| Seo, JH | 2 |
| Gurung, S | 1 |
| Fu, H | 1 |
| Zhang, WW | 1 |
| Gu, YH | 1 |
| Tanabe, A | 1 |
| Toda, T | 2 |
| Sakata, H | 1 |
| Ijichi, M | 1 |
| Kusaka, K | 1 |
| Bandai, Y | 1 |
| Park, MI | 1 |
| De Divitiis, C | 1 |
| Cassata, A | 1 |
| Nappi, A | 1 |
| Barretta, ML | 1 |
| He, LQ | 1 |
| Wu, YX | 1 |
| Wang, XS | 2 |
| Zu, X | 2 |
| Peng, C | 1 |
| Patyutko, YI | 1 |
| Kotelnikov, AG | 1 |
| Mamontov, KG | 1 |
| Podluzhny, DV | 1 |
| Ponomarenko, AA | 1 |
| Dai, HY | 1 |
| Chen, HY | 1 |
| Lai, WC | 1 |
| Hung, MC | 1 |
| Li, LY | 1 |
| Zhang, YF | 1 |
| Yang, HY | 1 |
| Xu, HF | 2 |
| Sang, XT | 1 |
| Zhong, SX | 1 |
| Mao, YL | 1 |
| Liu, SF | 1 |
| Lu, CR | 1 |
| Cheng, HD | 1 |
| Xi, HQ | 1 |
| Cui, JX | 1 |
| Li, JY | 1 |
| Shen, WS | 1 |
| Motawi, TK | 1 |
| El-Boghdady, NA | 1 |
| El-Sayed, AM | 1 |
| Helmy, HS | 1 |
| Garde-Noguera, J | 1 |
| Gil-Raga, M | 1 |
| Evgenyeva, E | 1 |
| García, JA | 1 |
| Llombart-Cussac, A | 1 |
| Camps-Herrero, C | 1 |
| Liang, Y | 1 |
| Bu, JG | 1 |
| Cheng, JL | 1 |
| Gao, WW | 1 |
| Xu, YC | 1 |
| Feng, J | 1 |
| Liang, WC | 1 |
| Chen, KQ | 1 |
| Ágoston, EI | 1 |
| Baranyai, Z | 1 |
| Kulka, J | 1 |
| Harsányi, L | 1 |
| Szász, AM | 1 |
| Seki, H | 4 |
| Ohi, H | 1 |
| Ozaki, T | 4 |
| Yabusaki, H | 1 |
| Julié, C | 2 |
| Emile, JF | 2 |
| Aust, D | 1 |
| Lutz, MP | 2 |
| Schlag, P | 15 |
| Fisseler, A | 1 |
| Fujita, N | 1 |
| Nishie, A | 1 |
| Asayama, Y | 1 |
| Ishigami, K | 1 |
| Ushijima, Y | 1 |
| Takayama, Y | 1 |
| Okamoto, D | 1 |
| Morita, K | 1 |
| Koto, K | 1 |
| Kubo, Y | 3 |
| Oda, Y | 2 |
| Gu, YJ | 1 |
| Li, HD | 1 |
| He, WB | 1 |
| Rui, L | 1 |
| Zheng, HC | 1 |
| Su, RJ | 1 |
| Isaakidou, A | 1 |
| Karantanos, T | 1 |
| Sioziou, A | 1 |
| Theodoropoulos, GE | 1 |
| Pektasides, D | 1 |
| Gazouli, M | 1 |
| Zhang, PJ | 1 |
| Guo, JH | 1 |
| Yang, RJ | 1 |
| Qiao, M | 1 |
| Naruse, T | 1 |
| Fujimoto, D | 1 |
| Cai, D | 1 |
| He, K | 2 |
| Chang, S | 1 |
| Tong, D | 2 |
| Muneoka, K | 7 |
| Shirai, Y | 7 |
| Kanda, J | 2 |
| Wakabayashi, H | 3 |
| Yamaguchi, M | 3 |
| Takahashi, G | 1 |
| Sawada, G | 1 |
| Moon, J | 1 |
| Nakahira, S | 2 |
| Do, C | 1 |
| Lipton, L | 1 |
| Tapner, MJ | 2 |
| Price, D | 4 |
| Bower, GD | 2 |
| Dowling, R | 3 |
| Lichtenstein, M | 2 |
| Matsumoto, H | 6 |
| Okumura, H | 3 |
| Murakami, H | 3 |
| Kubota, H | 5 |
| Higashida, M | 2 |
| Tsuruta, A | 1 |
| Tohyama, K | 2 |
| Hirai, T | 3 |
| Matsuda, S | 1 |
| Koketsu, H | 1 |
| Hayakawa, M | 2 |
| Park, KW | 2 |
| Seo, CJ | 1 |
| Yun, DY | 1 |
| Kim, MK | 2 |
| Kim, BS | 3 |
| Han, YS | 1 |
| Yuan, S | 1 |
| He, S | 2 |
| Granata, V | 1 |
| Fusco, R | 1 |
| Catalano, O | 1 |
| Filice, S | 1 |
| Amato, DM | 1 |
| Petrillo, A | 1 |
| Lévi, FA | 1 |
| Tumolo, S | 2 |
| Ajavon, Y | 1 |
| Castaing, D | 10 |
| Kunstlinger, F | 4 |
| Afshar, M | 1 |
| Oh, SK | 1 |
| Kim, HW | 1 |
| Kang, DH | 1 |
| Choi, CW | 1 |
| Choi, YY | 1 |
| Lim, HK | 1 |
| Goo, JJ | 1 |
| Choi, SY | 2 |
| Leon, O | 1 |
| Radu, C | 1 |
| Gunnlaugsson, A | 1 |
| Johnsson, A | 1 |
| Niu, JX | 1 |
| Guo, HP | 1 |
| Gan, HM | 1 |
| Bao, LD | 1 |
| Ren, JJ | 1 |
| Gao, Q | 2 |
| Shen, G | 3 |
| Herath, NI | 1 |
| Devun, F | 1 |
| Lienafa, MC | 1 |
| Herbette, A | 1 |
| Denys, A | 1 |
| Sun, JS | 1 |
| Dutreix, M | 1 |
| Sun, ZP | 1 |
| Shi, LH | 1 |
| Zhang, XR | 1 |
| Duan, Y | 1 |
| Xu, WF | 1 |
| Wang, XJ | 1 |
| Sakoda, M | 2 |
| Bi, T | 1 |
| Kim, KH | 2 |
| Cho, MS | 1 |
| Kim, TI | 1 |
| Koom, WS | 1 |
| Chatelut, E | 4 |
| Quesada, JL | 1 |
| Roblin, X | 1 |
| Pezet, D | 4 |
| Mendoza, C | 1 |
| Buc, E | 1 |
| Sumie, S | 8 |
| Tajiri, N | 1 |
| Aino, H | 2 |
| Satani, M | 1 |
| Matsugaki, S | 1 |
| Kurogi, J | 3 |
| Kajiwara, M | 3 |
| Aroldi, F | 2 |
| Cha, Y | 1 |
| Maccaroni, E | 1 |
| Mandolesi, A | 1 |
| Del Prete, M | 1 |
| Andrikou, K | 1 |
| Faloppi, L | 1 |
| Bittoni, A | 1 |
| Bianconi, M | 1 |
| Scarpelli, M | 1 |
| Bracci, R | 1 |
| Takeda, T | 2 |
| Miyake, M | 2 |
| Maeda, S | 4 |
| Miyamoto, A | 16 |
| Hirao, M | 3 |
| Sekimoto, M | 2 |
| Maeno, H | 1 |
| Munechika, T | 1 |
| Yonemitsu, K | 2 |
| Nomi, M | 1 |
| Okamoto, T | 2 |
| Nagao, S | 1 |
| Yanagisawa, J | 1 |
| Terada, I | 2 |
| Amaya, K | 2 |
| Kawahara, Y | 1 |
| Yamamoto, S | 9 |
| Kaji, M | 1 |
| Fujita, S | 4 |
| Yamauchi, J | 1 |
| Yasuta, S | 1 |
| Satoh, A | 1 |
| Ikeda, T | 5 |
| Matsuda, Y | 3 |
| Tsuchihara, K | 1 |
| Kondo, N | 1 |
| Ishiyama, S | 2 |
| Kaneko, K | 2 |
| Okada, T | 3 |
| Muto, I | 3 |
| Hasegawa, M | 4 |
| Kurosaki, I | 2 |
| Hanaka, J | 1 |
| Kanamura, S | 1 |
| Wakamatsu, T | 1 |
| Nakayama, H | 2 |
| Goya, T | 1 |
| Kawamoto, Y | 1 |
| Ome, Y | 1 |
| Koda, Y | 1 |
| Saga, K | 1 |
| Ito, T | 10 |
| Kakuta, S | 1 |
| Takayama, W | 4 |
| Kou, T | 2 |
| Satou, M | 1 |
| Sugaya, M | 1 |
| Boucher, TM | 1 |
| Fong, YC | 1 |
| Long, F | 1 |
| Shao, S | 1 |
| Granetto, C | 3 |
| Mancini, ML | 1 |
| Vitello, S | 1 |
| Bustreo, S | 1 |
| Barbara, C | 1 |
| Sheng, D | 1 |
| Hou, J | 1 |
| Hao, C | 1 |
| Zhu, B | 2 |
| Han, Z | 3 |
| Wei, L | 3 |
| Volk, AM | 1 |
| Fritzmann, J | 1 |
| Weber, GF | 1 |
| Tebbutt, NC | 3 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 2 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 2 |
| Ganju, V | 2 |
| Peng, YC | 1 |
| Lu, SD | 1 |
| Zhong, JH | 1 |
| Xie, ZB | 1 |
| You, XM | 1 |
| Peng, NF | 1 |
| Li, LQ | 1 |
| Yano, Y | 10 |
| Nakayama, M | 3 |
| Matsumoto, A | 3 |
| Fujimoto, T | 10 |
| Kodaz, H | 1 |
| Erdogan, B | 1 |
| Turkmen, E | 1 |
| Tozkir, H | 1 |
| Albayrak, D | 1 |
| Uzunoglu, S | 1 |
| Cicin, I | 1 |
| Ozdemir, O | 1 |
| Demir, D | 1 |
| Akdeniz, H | 1 |
| Kurt, M | 1 |
| Kim, HK | 1 |
| Shin, JK | 1 |
| Hong, HJ | 1 |
| Park, H | 1 |
| Hwang, SG | 1 |
| Rim, KS | 1 |
| Qi, H | 1 |
| Sun, MZ | 1 |
| Bendell, JC | 2 |
| Zakari, A | 1 |
| Peyton, JD | 1 |
| Boccia, R | 1 |
| Moskowitz, M | 1 |
| Gian, V | 1 |
| Lipman, A | 1 |
| Waterhouse, D | 2 |
| LoCicero, R | 1 |
| Earwood, C | 1 |
| Lane, CM | 2 |
| Meluch, A | 1 |
| Yuan, XJ | 1 |
| Tang, MJ | 1 |
| Li, ZL | 1 |
| Zou, X | 2 |
| Fang, YJ | 2 |
| Tou, JF | 1 |
| Zhang, KR | 1 |
| Li, WS | 1 |
| Wu, YM | 1 |
| Serrablo, A | 1 |
| Paliogiannis, P | 1 |
| Pulighe, F | 1 |
| Moro, SS | 1 |
| Borrego-Estella, V | 1 |
| Attene, F | 1 |
| Scognamillo, F | 1 |
| Hörndler, C | 1 |
| Feng, C | 1 |
| Luo, Q | 1 |
| Song, G | 1 |
| Farmer, RW | 1 |
| Kataoka, J | 1 |
| Sawahara, H | 1 |
| Nagahara, T | 1 |
| Iwamuro, M | 1 |
| Morimoto, H | 1 |
| Yagi, T | 2 |
| Stein, SM | 1 |
| James, ES | 1 |
| Deng, Y | 1 |
| Cong, X | 1 |
| Kortmansky, JS | 1 |
| Staugaard, C | 1 |
| Indukala, D | 1 |
| Boustani, AM | 1 |
| Patel, V | 1 |
| Cha, CH | 2 |
| Salem, RR | 1 |
| Chang, B | 1 |
| Lacy, J | 1 |
| Zhou, F | 1 |
| Bai, L | 1 |
| Aoki, K | 4 |
| Mitsuhashi, Y | 2 |
| Tomiura, S | 1 |
| Suto, A | 1 |
| Ikenaga, S | 1 |
| Shibasaki, I | 1 |
| Endo, M | 4 |
| Umehara, M | 1 |
| Umehara, Y | 1 |
| Murata, A | 2 |
| Nishikawa, S | 1 |
| Tokura, T | 1 |
| Matsuzaka, M | 1 |
| Morita, T | 3 |
| Lv, G | 1 |
| Li, E | 1 |
| Yamashita, M | 2 |
| Ogawa, H | 2 |
| Gotoh, K | 3 |
| Fan, L | 1 |
| Qi, F | 1 |
| Ou, S | 1 |
| Yi, X | 1 |
| Ni, B | 1 |
| Zheng, Z | 1 |
| Lei, L | 1 |
| Basso, M | 3 |
| Dadduzio, V | 1 |
| Ardito, F | 2 |
| Lombardi, P | 1 |
| Strippoli, A | 1 |
| Vellone, M | 3 |
| Orlandi, A | 1 |
| Rossi, S | 2 |
| Cerchiaro, E | 1 |
| Cassano, A | 6 |
| Giuliante, F | 5 |
| Barone, C | 8 |
| Tang, C | 1 |
| Feng, W | 1 |
| Bao, Y | 2 |
| Dong, X | 1 |
| Dai, Y | 1 |
| Hua, L | 1 |
| Ren, X | 1 |
| Shibano, N | 1 |
| Yukawa, Y | 1 |
| Uchima, Y | 2 |
| Kawamura, M | 2 |
| Takeda, O | 1 |
| Hanno, H | 1 |
| Takayanagi, S | 1 |
| Hirooka, T | 2 |
| Dozaiku, T | 1 |
| Aomatsu, N | 2 |
| Hirakawa, T | 2 |
| Iwauchi, T | 2 |
| Nishii, T | 2 |
| Morimoto, J | 3 |
| Nakazawa, K | 4 |
| Takeuchi, K | 5 |
| Wu, WR | 1 |
| Shi, XD | 1 |
| Yi, C | 1 |
| Xu, LB | 2 |
| Kuo, KK | 1 |
| Lee, KT | 2 |
| Chen, KK | 1 |
| Yang, YH | 1 |
| Lin, YC | 3 |
| Tsai, MH | 1 |
| Wuputra, K | 1 |
| Lee, YL | 1 |
| Ku, CC | 1 |
| Miyoshi, H | 2 |
| Nakamura, Y | 8 |
| Saito, S | 3 |
| Wu, CC | 2 |
| Chai, CY | 1 |
| Eckner, R | 1 |
| Steve Lin, CL | 1 |
| Wu, DC | 1 |
| Lin, CS | 1 |
| Yokoyama, KK | 1 |
| Yuan, F | 1 |
| Qiao, T | 1 |
| Peng, F | 1 |
| Etienne-Grimaldi, MC | 2 |
| Paintaud, G | 1 |
| Han, DH | 1 |
| Joo, DJ | 1 |
| Kim, MS | 2 |
| Kim, SI | 1 |
| Hiroshima, Y | 1 |
| Shuto, K | 4 |
| Kawaguchi, D | 1 |
| Yamada, M | 4 |
| Kasahara, K | 1 |
| Murakami, T | 9 |
| Hirano, A | 1 |
| Kosugi, C | 2 |
| Ishida, Y | 2 |
| Qi, J | 1 |
| Gou, Y | 1 |
| Lee, P | 1 |
| Du, B | 2 |
| Yang, XY | 3 |
| Yang, W | 1 |
| Pan, F | 1 |
| Wen, F | 1 |
| Schlegel, A | 1 |
| Jang, JH | 1 |
| Georgiopoulou, S | 1 |
| Dhir, M | 1 |
| Novak, S | 1 |
| Wen, S | 3 |
| Feng, D | 1 |
| Zang, Q | 1 |
| Li, G | 3 |
| Bauzone, M | 1 |
| Corfiotti, F | 1 |
| Renaud, F | 1 |
| El Amrani, M | 1 |
| Ikenaga, M | 5 |
| Ohta, K | 3 |
| Nakashima, S | 2 |
| Yamada, T | 9 |
| Chihara, T | 1 |
| Nishijima, J | 1 |
| Gong, XL | 1 |
| Qin, SK | 2 |
| van Doorn, L | 1 |
| Veelenturf, S | 1 |
| Binkhorst, L | 1 |
| Bins, S | 1 |
| Mathijssen, R | 1 |
| Gned, D | 1 |
| Baratelli, C | 1 |
| Brizzi, MP | 1 |
| Ottone, A | 1 |
| Alabiso, I | 1 |
| Bertaggia, C | 1 |
| Di Maio, M | 1 |
| Scagliotti, GV | 1 |
| Veltri, A | 1 |
| Huang, CW | 1 |
| Ma, CJ | 2 |
| Tsai, HL | 2 |
| Chen, CW | 1 |
| Huang, MY | 2 |
| Lu, CY | 1 |
| Wu, JY | 1 |
| Ahn, SJ | 1 |
| Nomi, T | 3 |
| Yamato, I | 3 |
| Yasuda, S | 8 |
| Obara, S | 2 |
| Kawaguchi, C | 3 |
| Kanehiro, H | 1 |
| Nakajima, Y | 15 |
| Chong, LC | 1 |
| Karapetis, C | 2 |
| Díez de Corcuera, I | 1 |
| Alcaide, J | 1 |
| García García, T | 1 |
| Vera, R | 1 |
| Sueur, B | 1 |
| Voron, T | 1 |
| Nagayama, S | 4 |
| Hida, K | 1 |
| Kawada, K | 1 |
| Matsuo, T | 2 |
| Tada, M | 4 |
| Nishitai, R | 2 |
| Mitsuyoshi, A | 1 |
| Yoshimura, K | 4 |
| Niimi, M | 2 |
| Yun, Q | 1 |
| Yang, JP | 1 |
| Yang, LL | 1 |
| Fu, SZ | 1 |
| Wu, JB | 1 |
| Zhang, G | 1 |
| Zeng, X | 1 |
| Manceau, G | 1 |
| Bridoux, V | 1 |
| Kirzin, S | 1 |
| Maggiori, L | 1 |
| de Chaisemartin, C | 1 |
| Lefevre, JH | 2 |
| Panis, Y | 4 |
| Zang, J | 1 |
| Gan, R | 1 |
| Zheng, H | 2 |
| Takeyama, H | 3 |
| Shimada, T | 1 |
| Ohnishi, H | 3 |
| Casagrande, M | 1 |
| Moretto R, R | 1 |
| Ferrari, L | 1 |
| Pilati, P | 2 |
| Sensi, E | 1 |
| Benahim, E | 1 |
| Sánchez-Velázquez, P | 1 |
| Töpel, I | 1 |
| Piso, P | 1 |
| Bertocchi, P | 1 |
| Prochilo, T | 1 |
| Meriggi, F | 1 |
| Beretta, GD | 2 |
| Parikh, A | 1 |
| Atreya, C | 1 |
| Korn, WM | 1 |
| Mehdizadeh, A | 1 |
| Somi, MH | 1 |
| Darabi, M | 1 |
| Farajnia, S | 1 |
| Akbarzadeh, A | 1 |
| Montazersaheb, S | 1 |
| Yousefi, M | 1 |
| Bonyadi, M | 1 |
| Stevenson, HL | 1 |
| Prats, MM | 1 |
| Sasatomi, E | 2 |
| Sun, G | 1 |
| Yang, T | 2 |
| Suzuki, N | 1 |
| Tokumitsu, Y | 1 |
| Kanekiyo, S | 2 |
| Tomochika, S | 2 |
| Tsunedomi, R | 1 |
| Tokuhisa, Y | 2 |
| Iida, M | 2 |
| Ueno, T | 4 |
| Neumann, UP | 2 |
| Zuchowska, A | 1 |
| Kwapiszewska, K | 1 |
| Chudy, M | 1 |
| Dybko, A | 1 |
| Brzozka, Z | 1 |
| Kou, P | 1 |
| Shao, W | 1 |
| Lan, X | 1 |
| Lu, S | 1 |
| Fan, X | 2 |
| Wu, F | 3 |
| Tu, J | 1 |
| Ji, J | 1 |
| Yamakoshi, Y | 1 |
| Nagashima, D | 1 |
| Ueda, T | 4 |
| Hokutou, D | 1 |
| Inoue, T | 9 |
| Nakamoto, T | 2 |
| Fujii, H | 4 |
| Noura, S | 2 |
| Shuto, T | 1 |
| Muratsu, A | 1 |
| Yasuyama, A | 1 |
| Matsumura, T | 1 |
| Koga, C | 1 |
| Kameda, C | 2 |
| Yoshikawa, M | 3 |
| Shimizu, J | 7 |
| Miwa, H | 1 |
| Kamiya, M | 1 |
| Yoneyama, K | 1 |
| Doi, Y | 1 |
| Shirai, J | 1 |
| Hatori, S | 1 |
| Yigitbas, H | 1 |
| Yazici, P | 1 |
| Taskin, HE | 1 |
| Okoh, AK | 1 |
| Dural, C | 1 |
| Aydin, N | 1 |
| Berber, E | 2 |
| Scevola, G | 1 |
| Loreni, G | 1 |
| Rastelli, M | 1 |
| Sposato, S | 1 |
| Ramponi, S | 1 |
| Miele, V | 1 |
| Husseini, F | 3 |
| Delord, JP | 3 |
| Fournel-Federico, C | 1 |
| Guitton, J | 1 |
| Erbs, P | 1 |
| Homerin, M | 1 |
| Halluard, C | 1 |
| Jemming, C | 1 |
| Orange, C | 1 |
| Limacher, JM | 1 |
| Kurtz, JE | 1 |
| Yang, QL | 1 |
| Li, NM | 1 |
| Xiang, L | 1 |
| Su, Y | 2 |
| Xia, Q | 2 |
| Del Rio, M | 3 |
| Mollevi, C | 1 |
| Bibeau, F | 2 |
| Vie, N | 2 |
| Selves, J | 1 |
| Roger, P | 1 |
| Gongora, C | 3 |
| Robert, J | 1 |
| Tubiana-Mathieu, N | 1 |
| Martineau, P | 3 |
| Marti, P | 1 |
| Merrouche, Y | 3 |
| Tigaud, JM | 3 |
| Rebischung, C | 2 |
| Lacouture, ME | 1 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 1 |
| Martínez C, J | 1 |
| Jarufe C, N | 1 |
| González D, R | 1 |
| Alvarez Z, M | 1 |
| Yasuda, A | 1 |
| Ochi, N | 1 |
| Takayama, S | 2 |
| Wakasugi, T | 1 |
| Funahashi, H | 2 |
| Sawai, H | 1 |
| Satoh, M | 1 |
| Akamo, Y | 2 |
| de Liguori Carino, N | 1 |
| van Leeuwen, BL | 1 |
| Ghaneh, P | 1 |
| Wu, A | 1 |
| Audisio, RA | 2 |
| Tibensky, I | 1 |
| Schmidt, J | 1 |
| Ryschich, E | 1 |
| Märten, A | 1 |
| Sieben, M | 1 |
| Herzer, K | 1 |
| Zeidler, M | 1 |
| Heinrichs, V | 1 |
| Leuchs, B | 1 |
| Cornelis, JJ | 1 |
| Galle, PR | 4 |
| Rommelaere, J | 1 |
| Leong, SS | 1 |
| Wee, J | 1 |
| Rajan, S | 1 |
| Toh, CK | 1 |
| Lim, WT | 1 |
| Hee, SW | 1 |
| Tay, MH | 1 |
| Poon, D | 1 |
| Tan, EH | 1 |
| King, J | 3 |
| Quinn, R | 1 |
| Glenn, DM | 1 |
| Janssen, J | 1 |
| Liaw, W | 1 |
| Morris, DL | 13 |
| Liao, JW | 1 |
| Mizuno, H | 2 |
| Sugiura, T | 2 |
| Udatsu, Y | 1 |
| Okazawa, M | 1 |
| Sugimura, K | 1 |
| Kusumoto, H | 1 |
| Kishimoto, T | 3 |
| Izukura, M | 1 |
| Nagamine, Y | 1 |
| Kajiura, K | 1 |
| Kohagura, F | 1 |
| Shinzato, S | 1 |
| Akiyama, M | 1 |
| Miyaaki, H | 1 |
| Miuma, S | 1 |
| Shibata, H | 2 |
| Fujimoto, M | 1 |
| Takeshita, S | 1 |
| Ozawa, E | 1 |
| Ichikawa, T | 2 |
| Nakao, K | 1 |
| Eguchi, K | 2 |
| Power, DG | 4 |
| Healey-Bird, BR | 1 |
| Wu, CJ | 1 |
| Lee, JL | 2 |
| Zang, DY | 1 |
| Kim, JG | 2 |
| Park, SR | 3 |
| Ryu, MH | 3 |
| Chang, HM | 3 |
| Baek, JH | 2 |
| Min, YJ | 1 |
| Osako, T | 1 |
| Tokudome, N | 2 |
| Sugihara, T | 2 |
| Iwase, T | 2 |
| Matsuura, M | 3 |
| Hatake, K | 5 |
| Formento, JL | 3 |
| Francoual, M | 2 |
| Formento, P | 2 |
| Renée, N | 3 |
| Laurent-Puig, P | 2 |
| Chazal, M | 4 |
| Benchimol, D | 2 |
| Delpero, JR | 6 |
| Letoublon, C | 4 |
| Kornprat, P | 1 |
| Schöllnast, H | 1 |
| Cerwenka, H | 1 |
| Werkgartner, G | 1 |
| Bernhardt, G | 1 |
| Mischinger, HJ | 1 |
| Laffer, U | 6 |
| Metzger, U | 7 |
| Aeberhard, P | 6 |
| Lorenz, M | 20 |
| Harder, F | 1 |
| Maibach, R | 1 |
| Zuber, M | 1 |
| Ferrari, D | 1 |
| Di Maria, G | 1 |
| Fazio, N | 1 |
| Codecà, C | 1 |
| Fiore, J | 1 |
| Oldani, S | 1 |
| Maggioni, M | 1 |
| Foa, P | 1 |
| Ehara, K | 2 |
| Tsutsumi, K | 2 |
| Kinoshita, Y | 2 |
| Mine, S | 2 |
| Udagawa, H | 2 |
| Hagihara, A | 1 |
| Graziano, F | 1 |
| Ruzzo, A | 1 |
| Catalano, V | 2 |
| Canestrari, E | 1 |
| Maltese, P | 1 |
| Bisonni, R | 1 |
| Baldi, G | 2 |
| Giordani, P | 1 |
| Alessandroni, P | 1 |
| Giustini, L | 1 |
| Vincenzi, B | 1 |
| Magnani, M | 1 |
| Granci, V | 1 |
| Kramar, A | 2 |
| Boissière-Michot, F | 1 |
| Thirion, A | 1 |
| Sagawa, T | 5 |
| Kobune, M | 1 |
| Takimoto, R | 1 |
| Fukaura, J | 1 |
| Iyama, S | 4 |
| Miyanishi, K | 5 |
| Matsunaga, T | 1 |
| Kato, J | 5 |
| Sasaki, K | 10 |
| Hamada, H | 14 |
| Niitsu, Y | 8 |
| Hirooka, M | 2 |
| Hiraoka, A | 1 |
| Kumagi, T | 1 |
| Uehara, T | 1 |
| Hiasa, Y | 2 |
| Horiike, N | 2 |
| Onji, M | 4 |
| Yin, Y | 1 |
| Weihrauch, MR | 2 |
| Stippel, D | 1 |
| Fries, JW | 1 |
| Bovenschulte, H | 1 |
| Coutelle, O | 1 |
| Hacker, U | 1 |
| Mitry, E | 8 |
| Fields, AL | 2 |
| Bleiberg, H | 6 |
| Labianca, R | 4 |
| Portier, G | 3 |
| Tu, D | 2 |
| Nitti, D | 8 |
| Torri, V | 1 |
| O'Callaghan, C | 1 |
| Langer, B | 2 |
| Martignoni, G | 1 |
| Lazorthes, F | 2 |
| Bedenne, L | 3 |
| Moore, MJ | 1 |
| Kawachi, Y | 2 |
| Nihei, K | 1 |
| Tsuchiya, Y | 2 |
| Yokoyama, N | 6 |
| Shimizu, T | 10 |
| Hatakeyama, K | 8 |
| Paré, L | 1 |
| Altés, A | 1 |
| del Río, E | 1 |
| Sedano, L | 1 |
| Salazar, J | 1 |
| Cortés, A | 1 |
| Barnadas, A | 2 |
| Baiget, M | 1 |
| Moriya, F | 2 |
| Basaki, Y | 1 |
| Kojiro, S | 2 |
| Fukahori, S | 1 |
| Ishizaki, H | 2 |
| Nishida, N | 2 |
| Matsuoka, K | 4 |
| Kojiro, M | 3 |
| Kuwano, M | 3 |
| Doh, KO | 1 |
| Patiutko, IuI | 3 |
| Poliakov, AN | 1 |
| Sagaĭdak, IV | 3 |
| Kotel'nikov, AG | 3 |
| Harshman, LC | 1 |
| Srinivas, S | 1 |
| Bursi, S | 1 |
| Antonuzzo, A | 1 |
| Pfanner, E | 2 |
| Di Paolo, A | 1 |
| Bocci, G | 1 |
| Del Tacca, M | 1 |
| Kunoki, N | 1 |
| Nishiyama, R | 1 |
| Ryuzaki, H | 1 |
| Oonishi, M | 1 |
| Uno, A | 1 |
| Ogawa, M | 7 |
| Ogihara, A | 1 |
| Sou, K | 1 |
| Kinukawa, N | 1 |
| Machida, N | 1 |
| Boku, N | 4 |
| Onozawa, Y | 1 |
| Fukutomi, A | 1 |
| Yasui, H | 2 |
| Taku, K | 1 |
| Asaka, M | 3 |
| Recchia, F | 2 |
| Candeloro, G | 1 |
| Necozione, S | 1 |
| Bratta, M | 1 |
| Bisegna, R | 1 |
| Rea, S | 1 |
| Shu, Y | 1 |
| Tang, HH | 1 |
| Liang, G | 1 |
| Conti, JA | 3 |
| Kendall, TJ | 1 |
| Bateman, A | 1 |
| Armstrong, TA | 1 |
| Papa-Adams, A | 1 |
| Packham, G | 1 |
| Benyon, RC | 1 |
| Iredale, JP | 1 |
| Yamaguchi, F | 1 |
| Kamitori, K | 1 |
| Sanada, K | 1 |
| Horii, M | 1 |
| Sui, L | 1 |
| Tokuda, M | 1 |
| Uemura, T | 2 |
| Fujimitsu, Y | 2 |
| Kure, N | 6 |
| Wang, ZH | 1 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Chen, JX | 1 |
| Tang, Q | 1 |
| Zhu, HN | 1 |
| Zheng, YD | 1 |
| Huh, JW | 1 |
| Park, YA | 1 |
| Jung, EJ | 1 |
| Lee, KY | 1 |
| Kwon, JE | 1 |
| Sohn, SK | 2 |
| Sakaguchi, H | 3 |
| Sueyoshi, S | 3 |
| Shinnkai, T | 1 |
| Flamen, P | 2 |
| Vanderlinden, B | 1 |
| Delatte, P | 2 |
| Ghanem, G | 1 |
| Ameye, L | 1 |
| Van Den Eynde, M | 3 |
| Hendlisz, A | 4 |
| Campbell, ML | 1 |
| Landry, CS | 1 |
| Slomiany, BA | 1 |
| Woodall, CE | 1 |
| McMasters, KM | 1 |
| Vente, MA | 1 |
| Wondergem, M | 1 |
| van der Tweel, I | 1 |
| van den Bosch, MA | 1 |
| Zonnenberg, BA | 1 |
| Lam, MG | 1 |
| van Het Schip, AD | 1 |
| Nijsen, JF | 1 |
| Cai, XL | 1 |
| Gao, JP | 1 |
| Wen, L | 1 |
| She, ZG | 1 |
| O'Neil, BH | 2 |
| Hoshikawa, K | 1 |
| Wakabayashi, G | 1 |
| Yatsuda, C | 1 |
| Ono, Y | 1 |
| Uto, N | 1 |
| Iwagami, E | 1 |
| Tanaka, E | 1 |
| Yamato, M | 1 |
| Kim, T | 3 |
| Bhargava, A | 1 |
| Schwartz, L | 3 |
| Brody, L | 1 |
| Covey, A | 1 |
| Karrasch, M | 1 |
| Getrajdman, G | 1 |
| Mescheder, A | 1 |
| Jarnagin, W | 6 |
| Enomoto, M | 6 |
| Azuma, M | 1 |
| Omori, A | 1 |
| Danenberg, KD | 5 |
| Danenberg, PV | 5 |
| Gutweiler, JR | 1 |
| Yu, DC | 1 |
| Kozakewich, HP | 1 |
| Marcus, KJ | 1 |
| Shamberger, RC | 1 |
| Christante, D | 1 |
| Pommier, S | 1 |
| Givi, B | 1 |
| Pommier, R | 1 |
| Kawahara, A | 1 |
| Hattori, S | 1 |
| Ono, M | 4 |
| Yanagawa, T | 1 |
| Kage, M | 1 |
| Small, RM | 1 |
| Lubezky, N | 2 |
| Shmueli, E | 1 |
| Figer, A | 2 |
| Aderka, D | 1 |
| Nakache, R | 2 |
| Klausner, JM | 2 |
| Ben-Haim, M | 2 |
| Hill, SE | 1 |
| Phillips, R | 2 |
| Francis, N | 1 |
| Agnew, K | 1 |
| Idelevich, E | 1 |
| Greif, F | 2 |
| Mavor, E | 1 |
| Miller, R | 1 |
| Kashtan, H | 1 |
| Susmalian, S | 1 |
| Ariche, A | 1 |
| Brenner, B | 2 |
| Baruch, NB | 1 |
| Dinerman, M | 1 |
| Shani, A | 1 |
| Maire, F | 2 |
| Hammel, P | 3 |
| Hentic, O | 3 |
| Couvelard, A | 2 |
| Rebours, V | 2 |
| Zappa, M | 2 |
| Raymond, E | 1 |
| Sauvanet, A | 1 |
| Lévy, P | 3 |
| Belghiti, J | 4 |
| Ruszniewski, P | 5 |
| Morris-Stiff, G | 1 |
| Makuuchi, M | 6 |
| Komatsu, S | 2 |
| Sonoyama, T | 6 |
| Ikoma, H | 3 |
| Okamura, H | 1 |
| Otsuji, E | 7 |
| Luo, K | 1 |
| Yoshida, N | 3 |
| Funada, T | 2 |
| Mamiya, T | 1 |
| Ohkubo, R | 1 |
| Kaiga, T | 2 |
| Pozzo, C | 6 |
| Masuzawa, T | 1 |
| Fujiwara, Y | 5 |
| Takiguchi, S | 3 |
| Yamazaki, M | 8 |
| Miyata, H | 3 |
| Nakajima, K | 1 |
| Nishida, T | 1 |
| Shima, T | 1 |
| Wakasa, K | 7 |
| Monden, M | 35 |
| Ishiguro, T | 7 |
| Kitaoka, T | 1 |
| Sakimoto, T | 1 |
| Miyazaki, T | 4 |
| Ishibashi, K | 13 |
| Matsuki, M | 1 |
| Ide, Y | 3 |
| Yasumoto, T | 2 |
| Yokouchi, H | 7 |
| Kinuta, M | 10 |
| Mikami, K | 2 |
| Ando, K | 3 |
| Saeki, H | 1 |
| Song, HS | 1 |
| Lee, NS | 1 |
| Choi, IS | 1 |
| Lee, MH | 1 |
| Kim, MA | 1 |
| Kim, WH | 2 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Takano, N | 2 |
| Ishiyama, K | 1 |
| Sakurai, N | 1 |
| Saito, K | 4 |
| Iizawa, H | 1 |
| Ikeda, E | 2 |
| Asakura, T | 2 |
| Zhang, JD | 1 |
| Shao, ZY | 2 |
| Liang, SN | 1 |
| Liu, LL | 1 |
| Su, HY | 1 |
| Feng, B | 1 |
| Zhao, GS | 1 |
| Xiao, YP | 1 |
| Luo, JG | 1 |
| Li, MQ | 1 |
| Liang, B | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 1 |
| Wang, BC | 1 |
| Yin, HR | 1 |
| Bai, YX | 1 |
| Zhang, HG | 1 |
| Jia, TZ | 1 |
| Jin, ML | 1 |
| Meredith, KL | 1 |
| Hoffe, SE | 1 |
| Kwon, HC | 3 |
| Oh, SY | 2 |
| Lee, DM | 1 |
| Lee, S | 2 |
| Roh, MS | 4 |
| Kim, DC | 1 |
| Park, KJ | 1 |
| Novarino, A | 2 |
| Satolli, MA | 2 |
| Chiappino, I | 3 |
| Giacobino, A | 3 |
| Bellone, G | 2 |
| Rahimi, F | 1 |
| Milanesi, E | 1 |
| Bertetto, O | 2 |
| Ciuffreda, L | 3 |
| Chayahara, N | 1 |
| Yamamori, M | 1 |
| Kadowaki, Y | 1 |
| Okuno, T | 1 |
| Miki, I | 1 |
| Nishisaki, H | 1 |
| Maeda, T | 4 |
| Okumura, K | 2 |
| Azuma, T | 1 |
| Kasuga, M | 1 |
| Sakaeda, T | 1 |
| Hirai, M | 1 |
| Viúdez, A | 1 |
| Gil-Bazo, I | 1 |
| Klinger, M | 4 |
| Eipeldauer, S | 3 |
| Hacker, S | 3 |
| Herberger, B | 5 |
| Dorfmeister, M | 2 |
| Koelblinger, C | 1 |
| Warmann, SW | 1 |
| Armeanu, S | 1 |
| Heigoldt, H | 1 |
| Ruck, P | 1 |
| Vonthein, R | 1 |
| Heitmann, H | 1 |
| Seitz, G | 1 |
| Lemken, ML | 2 |
| Bitzer, M | 1 |
| Fuchs, J | 1 |
| Yao, M | 2 |
| Ohori, H | 2 |
| Ogasawara, N | 1 |
| Suzuki, M | 7 |
| Miyate, Y | 1 |
| Inari, H | 1 |
| Chiba, A | 1 |
| Inaba, M | 1 |
| Ino, H | 2 |
| Yoshida, A | 2 |
| Haviland, D | 1 |
| Dematteo, R | 3 |
| Jin, C | 1 |
| Yao, L | 1 |
| Fu, DL | 1 |
| Yu, XJ | 1 |
| Ni, QX | 1 |
| Kitano, S | 4 |
| Hirohashi, S | 1 |
| Takahashi, A | 2 |
| Matsuoka, M | 4 |
| Takahama, J | 1 |
| Higashiura, W | 1 |
| Dittmar, Y | 1 |
| Voigt, R | 1 |
| Heise, M | 1 |
| Rabsch, A | 1 |
| Jandt, K | 1 |
| Settmacher, U | 1 |
| Cupini, S | 3 |
| Ricci, S | 4 |
| Brunetti, IM | 3 |
| Ferraldeschi, R | 1 |
| Naso, G | 1 |
| Filipponi, F | 2 |
| Goletti, O | 2 |
| Andreuccetti, M | 1 |
| Zhao, DJ | 1 |
| Jiang, QY | 1 |
| Wang, QQ | 1 |
| Tang, GP | 1 |
| Laurent, A | 2 |
| Maru, D | 2 |
| Shimamura, T | 1 |
| Sato, R | 2 |
| Cho, N | 1 |
| Moore, S | 1 |
| Tipples, K | 1 |
| Kolluri, RB | 1 |
| Raouf, S | 1 |
| Tian, G | 3 |
| Zhou, JS | 1 |
| Otsuka, S | 4 |
| Inagaki, M | 5 |
| Nishie, M | 2 |
| Hamano, R | 2 |
| Tokunaga, N | 5 |
| Tsunemitsu, Y | 2 |
| Miyoshi, K | 3 |
| Oosaki, T | 2 |
| Iwagaki, H | 1 |
| Shiina, M | 2 |
| Martinez-Balibrea, E | 1 |
| Martínez-Cardús, A | 1 |
| Musulén, E | 1 |
| Ginés, A | 1 |
| Plasencia, C | 1 |
| Neamati, N | 1 |
| Yan, F | 1 |
| Wang, XM | 1 |
| Sui, J | 1 |
| Azakami, T | 1 |
| Kenjo, M | 1 |
| Toyota, N | 4 |
| Gentner, B | 2 |
| Wein, A | 6 |
| Croner, RS | 1 |
| Zeittraeger, I | 1 |
| Wirtz, RM | 1 |
| Roedel, F | 1 |
| Dimmler, A | 1 |
| Dorlaque, L | 1 |
| Hohenberger, W | 8 |
| Hahn, EG | 7 |
| Brueckl, WM | 3 |
| Gómez Portilla, A | 1 |
| Cendoya, I | 1 |
| Olabarría, I | 1 |
| Martínez de Lecea, C | 1 |
| Gómez Martínez de Lecea, C | 1 |
| Gil, A | 1 |
| Martín, E | 1 |
| Muriel, J | 1 |
| Magrach, L | 1 |
| Romero, E | 1 |
| Lirola, A | 1 |
| Guede, N | 1 |
| Moraza, N | 1 |
| Fernández, E | 1 |
| Kvadatze, M | 1 |
| Valdovinos, M | 1 |
| Larrabide, I | 1 |
| Ruiz de Alegría, N | 1 |
| Fernández, JL | 1 |
| Castillo, C | 1 |
| Rua, O | 1 |
| Ulibarrena, MA | 1 |
| Cafferata, EG | 1 |
| Macció, DR | 1 |
| Lopez, MV | 1 |
| Viale, DL | 1 |
| Carbone, C | 1 |
| Mazzolini, G | 1 |
| Podhajcer, OL | 1 |
| Kripp, M | 1 |
| Ströbel, P | 1 |
| Dinter, D | 1 |
| Lukan, N | 1 |
| Hochhaus, A | 1 |
| Dalzell, JR | 1 |
| Samuel, LM | 1 |
| Chen, GG | 4 |
| Chan, UP | 1 |
| Bai, LC | 1 |
| Fung, KY | 1 |
| Tessier, A | 1 |
| To, AK | 1 |
| Merchant, JL | 1 |
| Lai, PB | 6 |
| Aussilhou, B | 1 |
| Dokmak, S | 1 |
| Faivre, S | 1 |
| Paradis, V | 2 |
| Vilgrain, V | 1 |
| Pylev, AL | 1 |
| Finn, RS | 1 |
| Naomoto, Y | 2 |
| Tanabe, S | 2 |
| Sakurama, K | 1 |
| Noma, K | 2 |
| Nishikawa, T | 1 |
| Motoki, T | 1 |
| Takaoka, M | 3 |
| Shirakawa, Y | 2 |
| Yamatsuji, T | 1 |
| Matsuoka, J | 2 |
| Fujita, T | 4 |
| Kawasaki, K | 2 |
| Ohno, M | 2 |
| Kanaji, S | 1 |
| Kobayashi, I | 4 |
| Ueno, K | 3 |
| Tsuchida, S | 2 |
| Osawa, M | 1 |
| Fujino, Y | 1 |
| Skof, E | 2 |
| Rebersek, M | 3 |
| Hlebanja, Z | 2 |
| Sato, A | 5 |
| Moriya, Y | 10 |
| Yoshioka, S | 4 |
| Matsuura, N | 1 |
| Matsubara, K | 1 |
| Vizio, B | 1 |
| Brondino, G | 1 |
| Addeo, A | 1 |
| Prati, A | 1 |
| Campra, D | 1 |
| Fronda, GR | 1 |
| Sorscher, SM | 1 |
| Waters, SH | 1 |
| Gillibrand, A | 1 |
| Berry, H | 1 |
| Kumar, S | 1 |
| Velikova, G | 1 |
| Dodwell, DJ | 1 |
| Perren, TJ | 1 |
| Bathe, OF | 2 |
| Ernst, S | 2 |
| Sutherland, FR | 1 |
| Butts, C | 2 |
| Bigam, D | 2 |
| Holland, D | 1 |
| Porter, GA | 1 |
| Koppel, J | 1 |
| Dowden, S | 2 |
| Moreno, C | 1 |
| Medina, J | 1 |
| Pérez-García, B | 1 |
| García-López, JL | 1 |
| Ashley, S | 2 |
| Lei, J | 1 |
| Knudsen, AR | 1 |
| Kannerup, AS | 1 |
| Mortensen, FV | 1 |
| Nielsen, DT | 1 |
| Okoshi, K | 1 |
| Furu, M | 1 |
| Yoshizawa, A | 1 |
| Toguchida, J | 1 |
| Javle, M | 1 |
| Garrett, C | 2 |
| Pande, A | 1 |
| Kuvshinoff, B | 1 |
| Litwin, A | 2 |
| Phelan, J | 1 |
| Gibbs, J | 1 |
| Iyer, R | 1 |
| Lee, JO | 2 |
| Bernardos García, C | 1 |
| Alarcón Del Agua, I | 1 |
| Casado Maestre, MD | 1 |
| Serrano Borrero, I | 1 |
| Alamo Martínez, JM | 1 |
| Thelen, A | 1 |
| Röcken, C | 1 |
| Jonas, S | 1 |
| Schmeding, M | 1 |
| Bova, R | 1 |
| Mohan, P | 1 |
| Sukumar, R | 1 |
| Surendran, R | 1 |
| Sathyabhama, C | 1 |
| Jayanthi, V | 1 |
| Navarro, M | 1 |
| Bokemeyer, C | 4 |
| Kwok-Keung Choi, C | 1 |
| Fujimoto, Y | 3 |
| Akasu, T | 3 |
| Mocellin, S | 2 |
| Pasquali, S | 1 |
| Yata, Y | 1 |
| Kanda, D | 1 |
| Takeuchi, S | 3 |
| Hatanaka, T | 2 |
| Iesaki, K | 1 |
| Yoshinaga, T | 1 |
| Kubota, J | 1 |
| Dong, NN | 1 |
| Wang, MY | 1 |
| Liu, ZF | 1 |
| Yoo, BK | 1 |
| Gredler, R | 2 |
| Vozhilla, N | 1 |
| Su, ZZ | 1 |
| Forcier, T | 1 |
| Shah, K | 2 |
| Saxena, U | 1 |
| Hansen, U | 1 |
| Fisher, PB | 2 |
| Sarkar, D | 2 |
| Grenader, T | 1 |
| Goldberg, A | 1 |
| Gabizon, A | 1 |
| Xiong, YQ | 1 |
| Zhu, XD | 1 |
| Zhuang, PY | 1 |
| Qin, LX | 1 |
| Tang, ZY | 5 |
| McIntosh, A | 1 |
| Hagspiel, KD | 1 |
| Al-Osaimi, AM | 1 |
| Northup, P | 1 |
| Caldwell, S | 1 |
| Berg, C | 1 |
| Angle, JF | 1 |
| Argo, C | 1 |
| Weiss, G | 1 |
| Rich, TA | 4 |
| Kuebler, JP | 1 |
| Goldstein, D | 2 |
| Olver, IN | 1 |
| Briggs, GM | 1 |
| Rossleigh, MA | 1 |
| Taylor, DJ | 1 |
| George, J | 1 |
| Malavasi, N | 2 |
| Ponti, G | 1 |
| Depenni, R | 2 |
| Bertolini, F | 2 |
| Zironi, S | 2 |
| Luppi, G | 2 |
| Conte, PF | 2 |
| Schmidt, C | 1 |
| Pivot, XB | 1 |
| Li, RK | 1 |
| Thomas, ES | 1 |
| Fein, LE | 1 |
| Chan, VF | 1 |
| Jassem, J | 3 |
| de Mendoza, FH | 1 |
| Mukhopadyay, P | 1 |
| Roché, HH | 1 |
| Cao, LQ | 2 |
| Xue, P | 1 |
| Jiao, XY | 1 |
| Peng, HP | 2 |
| Lu, HW | 1 |
| Zheng, Q | 1 |
| Chen, XL | 1 |
| Huang, XH | 1 |
| Fu, XH | 1 |
| Chen, JS | 4 |
| Li, QY | 1 |
| Yin, ZF | 1 |
| Wu, FC | 1 |
| Sun, HW | 1 |
| Chen, LH | 1 |
| Wei, CJ | 1 |
| Zheng, XK | 1 |
| Li, QS | 1 |
| Guan, J | 1 |
| Zhang, DS | 2 |
| Feng, F | 3 |
| Jiang, WQ | 5 |
| He, YJ | 4 |
| An, X | 4 |
| Xiang, XJ | 2 |
| Romano, O | 1 |
| Triboulet, JP | 1 |
| Soto Iglesias, S | 1 |
| Baltar Arias, R | 1 |
| Vázquez Rodríguez, S | 1 |
| Alvarez, M | 1 |
| Gómez Martínez, P | 1 |
| Alvarez Sánchez, MV | 1 |
| Vázquez Astray, E | 1 |
| Shoji, T | 1 |
| Matsuda, I | 2 |
| Misumi, K | 1 |
| Taniguchi, M | 2 |
| Yonekawa, H | 1 |
| Zhong, JL | 1 |
| Xue, X | 1 |
| Yue, P | 1 |
| Boostrom, SY | 1 |
| Nagorney, DM | 6 |
| Donohue, JH | 2 |
| Harmsen, S | 1 |
| Thomsen, K | 1 |
| Que, F | 1 |
| Kendrick, M | 1 |
| Reid-Lombardo, KM | 1 |
| Woo, HY | 3 |
| Choi, BG | 3 |
| Im, HU | 1 |
| Cheong, JY | 3 |
| Cho, SW | 2 |
| Jang, BK | 4 |
| Seo, YS | 2 |
| Ji, X | 1 |
| Cai, J | 1 |
| Wan, F | 1 |
| Zhong, B | 1 |
| Tucker, S | 1 |
| Townsend, A | 1 |
| Shahrokni, A | 1 |
| Rajebi, MR | 1 |
| Sun, B | 1 |
| Meng, Y | 1 |
| Gounaris, I | 1 |
| Ahmad, A | 1 |
| Nishigami, K | 1 |
| Kawami, H | 1 |
| Rose, M | 1 |
| Chu, E | 1 |
| Foo, A | 1 |
| Su, T | 1 |
| Mammano, E | 1 |
| Tessari, E | 1 |
| Lise, M | 5 |
| Masellis, AM | 1 |
| Sielaff, TD | 1 |
| Bender, GP | 1 |
| Arts, J | 1 |
| King, P | 1 |
| Mariën, A | 1 |
| Floren, W | 1 |
| Beliën, A | 1 |
| Janssen, L | 1 |
| Pilatte, I | 1 |
| Roux, B | 1 |
| Decrane, L | 1 |
| Gilissen, R | 1 |
| Hickson, I | 1 |
| Vreys, V | 1 |
| Cox, E | 1 |
| Bol, K | 1 |
| Talloen, W | 1 |
| Goris, I | 1 |
| Andries, L | 1 |
| Du Jardin, M | 1 |
| Janicot, M | 1 |
| Page, M | 1 |
| van Emelen, K | 1 |
| Angibaud, P | 1 |
| Dove, P | 1 |
| Amari, M | 1 |
| Ishida, T | 3 |
| Ohuchi, N | 1 |
| Azad, A | 1 |
| Chionh, F | 1 |
| Jayarajan, J | 1 |
| Arimura, Y | 1 |
| Yamashita, K | 5 |
| Okahara, S | 1 |
| Tanuma, T | 1 |
| Kodaira, J | 1 |
| Hokari, K | 1 |
| Tsukagoshi, H | 1 |
| Shinomura, Y | 1 |
| Hosokawa, M | 1 |
| Kim, ST | 2 |
| Lee, JK | 1 |
| Heo, JS | 1 |
| Choi, DW | 1 |
| Sharma, A | 2 |
| Upadhyay, AK | 1 |
| Bhat, MK | 2 |
| Kanamori, N | 1 |
| Takano, M | 1 |
| Tsuyuguchi, M | 1 |
| Nagasako, T | 1 |
| Kawamura, N | 2 |
| Tsuda, I | 1 |
| Meguro, J | 1 |
| Wu, FY | 1 |
| Huang, GS | 1 |
| Jiang, JW | 1 |
| Xu, XD | 1 |
| Peng, DY | 1 |
| Bercovitz, RS | 1 |
| Greffe, BS | 1 |
| Hunger, SP | 1 |
| Frilling, A | 1 |
| Konopke, R | 1 |
| Stroszczynski, C | 3 |
| Herrmann, T | 1 |
| Goekkurt, E | 1 |
| Parisi, F | 1 |
| Sun, HQ | 1 |
| He, XE | 1 |
| Wang, WL | 1 |
| Lei, JH | 1 |
| Moon, HJ | 1 |
| Kim, TN | 1 |
| Chang, JC | 1 |
| Kobashikawa, K | 1 |
| Tamura, J | 2 |
| Takaki, R | 1 |
| Ohshiro, M | 1 |
| Matayoshi, R | 1 |
| Hirata, T | 1 |
| Kinjyo, F | 1 |
| Fujita, J | 1 |
| Tang, L | 1 |
| Zhang, LH | 1 |
| Bu, ZD | 1 |
| Wu, AW | 1 |
| Zong, XL | 1 |
| Shan, F | 1 |
| Li, SX | 1 |
| Ren, H | 3 |
| Zhang, XP | 1 |
| Ji, JF | 1 |
| Kaibori, M | 2 |
| Ishizaki, M | 3 |
| Matsui, K | 3 |
| Yoshioka, K | 2 |
| Kwon, AH | 3 |
| Nakauchi, M | 1 |
| Nakayama, Y | 2 |
| Kitaguchi, K | 1 |
| Sakikubo, M | 1 |
| Ura, K | 1 |
| Taira, K | 2 |
| Ohe, H | 1 |
| Yoshikawa, A | 1 |
| Ishigami, S | 3 |
| Baba, N | 1 |
| Koehler, BC | 1 |
| Urbanik, T | 1 |
| Vick, B | 1 |
| Boger, RJ | 1 |
| Heeger, S | 1 |
| Schuchmann, M | 1 |
| Amano, R | 1 |
| Yamada, N | 6 |
| Noda, E | 2 |
| Muguruma, K | 1 |
| Yashiro, M | 1 |
| Onoda, N | 2 |
| Sawada, T | 12 |
| Nakata, B | 4 |
| Ohira, M | 4 |
| Hirakawa, K | 8 |
| Ota, T | 4 |
| Ohira, G | 3 |
| Natsume, T | 2 |
| Saito, H | 8 |
| Kawahira, H | 1 |
| Nabeya, Y | 1 |
| Matsubara, H | 4 |
| Okada, N | 12 |
| Kuwabara, K | 5 |
| Hatano, S | 6 |
| Kubota, S | 2 |
| Chika, N | 1 |
| Tamaru, J | 1 |
| Kikuoka, S | 1 |
| Takeuchi, I | 8 |
| Ishida, F | 2 |
| Ozawa, F | 1 |
| Minagawa, R | 2 |
| Hamatsu, T | 2 |
| Honbou, T | 1 |
| Ushijima, C | 2 |
| Ikebe, M | 3 |
| Kitamura, M | 17 |
| Miura, N | 1 |
| Doh, J | 1 |
| Akahori, T | 1 |
| Tamamoto, T | 2 |
| Shomura, H | 1 |
| Nakano, S | 11 |
| Akabane, H | 1 |
| Yanagida, N | 1 |
| Hanamoto, T | 1 |
| Kuji, M | 1 |
| Kita, K | 2 |
| Oikawa, F | 1 |
| Miyagi, H | 1 |
| Yoneya, R | 1 |
| Miyo, M | 1 |
| Kato, A | 3 |
| Sakamoto, T | 4 |
| Hoshi, M | 1 |
| Makari, Y | 1 |
| Oshima, S | 5 |
| Iijima, S | 8 |
| Kurokawa, E | 5 |
| Kikkawa, N | 20 |
| Iwakawa, K | 1 |
| Iwagak, H | 1 |
| Minami, Y | 3 |
| Ezumi, K | 1 |
| Tsukamoto, S | 1 |
| Fujimori, Y | 2 |
| Oda, G | 2 |
| Nakatsu, H | 1 |
| Oka, M | 9 |
| Iida, A | 4 |
| Mishima, T | 1 |
| Muto, T | 2 |
| Satoh, E | 1 |
| Maruyama, M | 16 |
| Uehira, D | 1 |
| Ebana, K | 1 |
| Ohinata, R | 1 |
| Koide, A | 2 |
| Sanada, T | 1 |
| Sakoma, T | 2 |
| Sobajima, J | 3 |
| Ohsawa, T | 10 |
| Inokuma, S | 6 |
| Takada, J | 6 |
| Kenno, S | 1 |
| Katsuki, Y | 16 |
| Wardley, AM | 1 |
| Pivot, X | 2 |
| Morales-Vasquez, F | 1 |
| Zetina, LM | 1 |
| de Fátima Dias Gaui, M | 1 |
| Reyes, DO | 1 |
| Barton, C | 1 |
| Button, P | 1 |
| Hersberger, V | 1 |
| Torres, AA | 1 |
| Alberts, SR | 6 |
| Mahoney, MR | 3 |
| O'Connell, MJ | 8 |
| Wagman, L | 2 |
| Smyrk, TC | 1 |
| Weiland, TL | 1 |
| Lai, LL | 1 |
| Schwarz, RE | 2 |
| Molina, R | 1 |
| Dentchev, T | 1 |
| Bolton, JS | 4 |
| de Haas, RJ | 2 |
| Wicherts, DA | 2 |
| Flores, E | 1 |
| Paule, B | 4 |
| Ishikawa, M | 3 |
| Hieda, M | 1 |
| Kakizawa, H | 2 |
| Fayaz, S | 1 |
| Vasishta, S | 1 |
| Motawy, M | 1 |
| Matsushita, D | 1 |
| Kitazono, M | 1 |
| Shinchi, H | 1 |
| Nobuhara, Y | 2 |
| Matuoka, T | 1 |
| Yo, T | 2 |
| Watkins, DJ | 1 |
| Mudan, SS | 1 |
| Karanjia, N | 1 |
| Brown, G | 4 |
| Norman, AR | 6 |
| Gillbanks, A | 1 |
| Sawayama, H | 1 |
| Toyama, E | 2 |
| Watanabe, M | 16 |
| Koizumi, Y | 1 |
| Kisaka, Y | 1 |
| Matsuura, B | 1 |
| Yamagami, T | 2 |
| Yoshimatsu, R | 1 |
| Miura, H | 2 |
| Nishimura, T | 5 |
| Ling, XL | 1 |
| Boxberger, F | 2 |
| Albrecht, H | 1 |
| Konturek, PC | 1 |
| Reulbach, U | 1 |
| Maennlein, G | 1 |
| Zhang, WM | 1 |
| Xie, B | 2 |
| Zheng, JH | 1 |
| Xu, ZY | 1 |
| Lin, JR | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Fedyanin, MY | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 1 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 1 |
| Tjulandin, SA | 1 |
| Takaya, H | 1 |
| Fuji, H | 1 |
| Mizuno, R | 1 |
| Mori, T | 20 |
| Ito, D | 1 |
| Kogire, M | 3 |
| Hsu, CH | 3 |
| Hsu, C | 1 |
| Toh, HC | 2 |
| Epstein, RJ | 1 |
| Hsiao, LT | 1 |
| Chen, PJ | 1 |
| Lin, ZZ | 1 |
| Chao, TY | 1 |
| Shizawa, K | 1 |
| Iida, K | 1 |
| Macková, D | 1 |
| Guo, JF | 1 |
| Xing, H | 1 |
| Zhu, GY | 1 |
| Nie, XY | 1 |
| Peng, J | 1 |
| Miyahira, T | 1 |
| Teruya, N | 1 |
| Matsuura, F | 1 |
| Murayama, S | 1 |
| Aka, H | 1 |
| Teruya, J | 1 |
| Hanashiro, N | 1 |
| Nishihara, M | 1 |
| Okushima, N | 1 |
| Toda, Y | 1 |
| Kiyuna, M | 1 |
| Sonnenblick, A | 1 |
| Meirovitz, A | 1 |
| Zaanan, A | 1 |
| Costes, L | 1 |
| Gauthier, M | 1 |
| Locher, C | 1 |
| Gornet, JM | 2 |
| Sobhani, I | 1 |
| Moulin, V | 1 |
| Deshaies, I | 1 |
| Dumont, F | 3 |
| Dromain, C | 3 |
| Maleux, G | 2 |
| Vaninbroukx, J | 1 |
| Heye, S | 1 |
| Oyen, R | 1 |
| Komori, H | 2 |
| Horino, K | 3 |
| Imsung, C | 1 |
| Ootao, R | 2 |
| Iyama, K | 1 |
| Shibaki, T | 1 |
| Morimoto, N | 1 |
| Chishima, T | 1 |
| Shimizu, D | 3 |
| Tanino, H | 2 |
| Hirai, I | 1 |
| Hata, K | 3 |
| Maebeya, S | 1 |
| Oota, F | 2 |
| Miki, Y | 1 |
| Ma, SH | 2 |
| Yip, J | 1 |
| Kinoshita, K | 1 |
| Akira, C | 1 |
| Watanebe, M | 1 |
| Uña Cidón, E | 1 |
| Andres, A | 3 |
| Majno, P | 1 |
| Umeda, T | 1 |
| Kubota, Y | 3 |
| Kawai, Y | 2 |
| Kurumi, Y | 2 |
| Tani, T | 7 |
| Takamoto, T | 1 |
| Sano, K | 1 |
| Maruyama, Y | 3 |
| Inoue, K | 10 |
| Ogata, S | 2 |
| Takemura, T | 2 |
| Morelli, MF | 2 |
| Santomaggio, A | 1 |
| De Galitiis, F | 2 |
| Tudini, M | 1 |
| Mancini, M | 2 |
| Pelliccione, M | 1 |
| Calista, F | 1 |
| Guglielmi, F | 1 |
| Martella, F | 1 |
| Lanfiuti Baldi, P | 2 |
| Porzio, G | 2 |
| Gebbia, N | 2 |
| Iacobelli, S | 2 |
| Marchetti, P | 4 |
| Pessaux, P | 1 |
| Panaro, F | 1 |
| Casnedi, S | 2 |
| Zeca, I | 1 |
| Marzano, E | 1 |
| Bachellier, P | 2 |
| Chenard, MP | 1 |
| Uehara, K | 2 |
| Ishiguro, S | 2 |
| Nishio, H | 3 |
| Ebata, T | 3 |
| Yokoyama, Y | 5 |
| Kokuryo, T | 1 |
| Tsunoda, N | 1 |
| Igami, T | 1 |
| Sugawara, G | 1 |
| Fukaya, M | 1 |
| Nagino, M | 2 |
| Zen, Y | 1 |
| Aiura, K | 1 |
| Matsui, J | 1 |
| Yasutome, M | 1 |
| Chua, TC | 2 |
| Liauw, W | 1 |
| Koong, HN | 1 |
| Esquivel, J | 1 |
| Sata, M | 12 |
| Gallagher, DJ | 1 |
| Van Huysse, J | 1 |
| Berrevoet, F | 1 |
| Vandenbossche, B | 1 |
| Sainz-Barriga, M | 1 |
| Vinci, A | 1 |
| Ricciardi, S | 1 |
| Bocchetti, T | 1 |
| Rogiers, X | 1 |
| de Hemptinne, B | 1 |
| Smyth, E | 1 |
| Lowery, M | 1 |
| Shamseddine, A | 1 |
| Al-Olayan, A | 1 |
| Naghy, M | 1 |
| Power, D | 1 |
| Saliba, T | 1 |
| Kelsen, D | 1 |
| Shah, MA | 2 |
| Izumi, Y | 2 |
| Ryotokuji, T | 1 |
| Monma, K | 2 |
| Fujiwara, J | 1 |
| Egashira, H | 1 |
| Wang, GP | 2 |
| Guan, YS | 1 |
| Jin, XR | 1 |
| Jiang, SS | 1 |
| Luo, F | 1 |
| Lee, DY | 5 |
| Shimura, T | 1 |
| Hirata, Y | 2 |
| Mabuchi, M | 1 |
| Mizoshita, T | 1 |
| Kubota, E | 1 |
| Tanida, S | 1 |
| Kamiya, T | 1 |
| Joh, T | 3 |
| Tsimberidou, AM | 2 |
| Fu, S | 3 |
| Ng, C | 2 |
| Lim, JA | 1 |
| Hong, D | 2 |
| Wheler, J | 1 |
| Bedikian, AY | 3 |
| Wallace, M | 1 |
| Camacho, LH | 2 |
| Kurzrock, R | 4 |
| Lambert, B | 2 |
| Vannoote, J | 1 |
| De Keukeleire, K | 1 |
| Verslype, C | 2 |
| Defreyne, L | 1 |
| Delaunoit, T | 2 |
| Paesmans, M | 1 |
| Van Laethem, JL | 1 |
| Toyokawa, A | 1 |
| Kanemitsu, K | 3 |
| Okuda, T | 1 |
| Iwasaki, T | 6 |
| Deguchi, Y | 2 |
| Kasugai, H | 2 |
| Ikehara, K | 1 |
| Hidaka, E | 1 |
| Kudo, SE | 1 |
| Sugimoto, K | 4 |
| Nagayasu, K | 1 |
| Niwa, K | 1 |
| Ono, S | 1 |
| Hata, M | 1 |
| Komiyama, H | 1 |
| Yaginuma, Y | 1 |
| Goto, M | 3 |
| Sengoku, H | 1 |
| Okuzawa, A | 1 |
| Tomiki, Y | 1 |
| Zorzi, D | 3 |
| Contreras, CM | 1 |
| Maru, DM | 3 |
| Kopetz, S | 5 |
| Ribero, D | 2 |
| Motta, M | 1 |
| Ravarino, N | 1 |
| Risio, M | 1 |
| Abdalla, EK | 6 |
| Pang, R | 1 |
| Law, WL | 1 |
| Chu, AC | 1 |
| Poon, JT | 1 |
| Lam, CS | 1 |
| Chow, AK | 1 |
| Ng, L | 1 |
| Cheung, LW | 1 |
| Lan, XR | 1 |
| Lan, HY | 1 |
| Tan, VP | 1 |
| Yau, TC | 1 |
| Poon, RT | 1 |
| Wong, BC | 1 |
| Liu, JH | 4 |
| Hsieh, YY | 1 |
| Hsu, YN | 1 |
| Chau, GY | 2 |
| Teng, HW | 1 |
| King, KL | 2 |
| Lin, TC | 4 |
| Tzeng, CH | 1 |
| Xi, T | 1 |
| Ueshima, K | 1 |
| Takita, M | 1 |
| Nagai, T | 1 |
| Tatsumi, C | 1 |
| Kitai, S | 2 |
| Ishikawa, E | 1 |
| Yada, N | 1 |
| Hagiwara, S | 3 |
| Chung, H | 1 |
| Agata, T | 1 |
| Noro, T | 1 |
| Shiota, M | 1 |
| Ozeki, S | 1 |
| Hatta, K | 1 |
| Okura, Y | 1 |
| Matsukawa, S | 1 |
| Shiratori, T | 1 |
| Kugimiya, M | 1 |
| Matsuo, S | 2 |
| Kaji, S | 1 |
| Tang, JT | 1 |
| Wang, JL | 1 |
| Fang, JY | 1 |
| Mounier-Boutoille, H | 1 |
| Boisdron-Celle, M | 2 |
| Galmiche, JP | 1 |
| Morel, A | 1 |
| Gamelin, E | 4 |
| Shao, ZL | 1 |
| Xiao, JB | 1 |
| Xia, T | 1 |
| Bester, L | 1 |
| Akther, J | 1 |
| Ishii, H | 2 |
| Tanaka, F | 1 |
| Ohkuma, M | 1 |
| Kim, HM | 2 |
| Takiuchi, D | 1 |
| Barnard, GF | 1 |
| García-Foncillas, J | 2 |
| Zhong, X | 1 |
| Xiong, M | 1 |
| Meng, X | 1 |
| Gong, R | 1 |
| Watson, RG | 1 |
| Muhale, F | 1 |
| Thorne, LB | 1 |
| Hoskins, JM | 1 |
| Meyers, MO | 1 |
| Deal, AM | 1 |
| Ibrahim, JG | 1 |
| Hudson, ML | 1 |
| Walko, CM | 1 |
| McLeod, HL | 2 |
| Auman, JT | 1 |
| Siquini, W | 1 |
| Galizia, E | 1 |
| Stortoni, P | 1 |
| Marmorale, C | 1 |
| Berardi, R | 1 |
| Fianchini, A | 1 |
| Lin, CY | 1 |
| Wu, CL | 1 |
| Fang, JL | 1 |
| Tsao, CJ | 1 |
| Mir, O | 3 |
| Cessot, A | 1 |
| Brezault, C | 4 |
| Ropert, S | 1 |
| Durand, JP | 1 |
| Cacheux, W | 2 |
| Chaussade, S | 4 |
| Goldwasser, F | 5 |
| McIntyre, DJ | 2 |
| Howe, FA | 2 |
| Ladroue, C | 1 |
| Lofts, F | 2 |
| Stubbs, M | 2 |
| Griffiths, JR | 2 |
| Song, XR | 1 |
| Luo, YF | 1 |
| He, ZY | 2 |
| Li, SZ | 1 |
| Li, JM | 1 |
| Hou, SX | 1 |
| Wei, YQ | 1 |
| Spigel, DR | 1 |
| Greco, FA | 2 |
| Shipley, D | 1 |
| Vazquez, ER | 1 |
| Clark, BL | 1 |
| Infante, JR | 1 |
| Burris, HA | 1 |
| Hainsworth, JD | 2 |
| Okamoto, I | 1 |
| Stagni, V | 1 |
| Mingardi, M | 1 |
| Santini, S | 1 |
| Giaccari, D | 1 |
| Barilà, D | 1 |
| Tagawa, ST | 1 |
| Milowsky, MI | 1 |
| Jeske, S | 1 |
| Mazumdar, M | 2 |
| Kung, S | 1 |
| Sung, M | 1 |
| Lehrer, D | 1 |
| Matulich, D | 1 |
| Selzer, J | 1 |
| Wright, JJ | 1 |
| Nanus, DM | 1 |
| Husein-ElAhmed, H | 1 |
| Aneiros-Fernandez, J | 1 |
| Arias-Santiago, S | 1 |
| Naranjo-Sintes, R | 1 |
| Mahavorasirikul, W | 2 |
| Viyanant, V | 2 |
| Chaijaroenkul, W | 2 |
| Itharat, A | 1 |
| Na-Bangchang, K | 2 |
| Zhang, T | 1 |
| Kong, D | 1 |
| Ru, T | 1 |
| Chon, YE | 1 |
| Cha, J | 1 |
| Chon, CY | 4 |
| Shin, SK | 1 |
| Snoeren, N | 1 |
| Voest, EE | 1 |
| Bergman, AM | 1 |
| Dalesio, O | 3 |
| Verheul, HM | 1 |
| Tollenaar, RA | 1 |
| van der Sijp, JR | 1 |
| Schouten, SB | 1 |
| Rinkes, IH | 1 |
| van Hillegersberg, R | 1 |
| López, R | 1 |
| Salgado, M | 1 |
| Reboredo, M | 1 |
| Grande, C | 1 |
| Méndez, JC | 1 |
| Jorge, M | 1 |
| Romero, C | 1 |
| de la Cámara, J | 1 |
| Garufi, C | 4 |
| Torsello, A | 1 |
| Ettorre, GM | 1 |
| Zeuli, M | 1 |
| Campanella, C | 1 |
| Vennarecci, G | 1 |
| Mottolese, M | 3 |
| Sperduti, I | 2 |
| Cognetti, F | 4 |
| Ye, C | 1 |
| Leung, BC | 1 |
| Ho, RL | 2 |
| Stoiber, N | 1 |
| Hauser, N | 1 |
| Stoiber, B | 1 |
| Hohl, MK | 1 |
| Sohn, C | 1 |
| Eichbaum, MH | 2 |
| Ciacio, O | 1 |
| Giacchetti, S | 4 |
| Guettier, C | 1 |
| Chan, TH | 1 |
| Zheng, BJ | 1 |
| Mitsuhashi, K | 1 |
| Matsusaka, S | 2 |
| Ichimura, T | 2 |
| Ozaka, M | 1 |
| Ramiscal, JA | 1 |
| Jatoi, A | 1 |
| Ozaki, I | 1 |
| Hamajima, H | 1 |
| Iwane, S | 1 |
| Eguchi, Y | 1 |
| Mizuta, T | 1 |
| Fernandez, KS | 1 |
| Baum, R | 1 |
| Fung, B | 1 |
| Yeager, N | 1 |
| Leonis, MA | 1 |
| Wagner, LM | 1 |
| Tiao, G | 1 |
| Ross, ME | 1 |
| Kim, MC | 1 |
| Jang, JS | 1 |
| Kwon, KA | 1 |
| Xia, LP | 1 |
| Wu, PH | 2 |
| Xia, JC | 1 |
| Guan, ZZ | 1 |
| Guo, GF | 1 |
| Zeng, YX | 1 |
| Kasai, K | 2 |
| Ushio, A | 2 |
| Kasai, Y | 3 |
| Sawara, K | 2 |
| Oikawa, K | 2 |
| Kuroda, H | 2 |
| Takikawa, Y | 2 |
| Kitano, T | 1 |
| Kanai, M | 2 |
| Hazama, M | 1 |
| Ishiguro, H | 1 |
| Yanagihara, K | 1 |
| Teramukai, S | 1 |
| Fukushima, M | 3 |
| Teke, Z | 1 |
| Nessar, G | 1 |
| Kiremitci, S | 1 |
| Aksoy, E | 1 |
| Elbir, OH | 1 |
| Kuwada, A | 2 |
| Kouyama, M | 2 |
| Uekami, S | 1 |
| Touge, K | 1 |
| Taogoshi, H | 2 |
| Fukuda, Y | 5 |
| Daimaru, H | 1 |
| Fasol, U | 1 |
| Arends, J | 1 |
| Hense, J | 1 |
| Fischer, R | 1 |
| Scheulen, ME | 2 |
| Samaras, P | 1 |
| Breitenstein, S | 1 |
| Haile, SR | 1 |
| Stenner-Liewen, F | 1 |
| Heinrich, S | 4 |
| Feilchenfeldt, J | 1 |
| Renner, C | 1 |
| Knuth, A | 6 |
| Pestalozzi, BC | 2 |
| Krieger, PM | 1 |
| Faybik, P | 1 |
| Fleischmann, E | 1 |
| Maresch, J | 1 |
| Messersmith, WA | 1 |
| Jimeno, A | 1 |
| Jacene, H | 1 |
| Kulesza, P | 1 |
| Laheru, DA | 1 |
| Kahn, Y | 1 |
| Spira, A | 1 |
| Dancey, J | 2 |
| Iacobuzio-Donahue, C | 2 |
| Donehower, RC | 1 |
| Carducci, M | 1 |
| Rudek, MA | 1 |
| Garcia, S | 1 |
| Panchal, AM | 1 |
| Lim, J | 1 |
| Hong, DS | 1 |
| Madoff, DC | 1 |
| Gayed, I | 1 |
| Hataji, K | 1 |
| Kawasaki, N | 1 |
| Shimobayashi, T | 1 |
| Inatsugi, N | 1 |
| Yoshikawa, S | 1 |
| Kuge, H | 1 |
| Yokotani, T | 1 |
| Yamaoka, K | 1 |
| Tatsumi, K | 1 |
| Saraya, T | 1 |
| Yamochi, Y | 1 |
| Yamanishi, K | 1 |
| Enomoto, Y | 1 |
| Nonomura, A | 1 |
| Kametaka, H | 1 |
| Koyama, T | 2 |
| Seike, K | 1 |
| Hasegawa, A | 1 |
| Kono, T | 3 |
| Tohma, T | 1 |
| Akutsu, Y | 1 |
| Uesato, M | 1 |
| Okazumi, S | 3 |
| Kaiho, T | 2 |
| Ono, H | 5 |
| Someno, Y | 2 |
| Katsuta, E | 2 |
| Saguchi, M | 2 |
| Takahata, T | 2 |
| Hamada, S | 2 |
| Matsuyama, T | 2 |
| Masuda, D | 2 |
| Hosokawa, T | 1 |
| Tokita, H | 1 |
| Kakimoto, M | 1 |
| Goto, H | 1 |
| Koshiishi, H | 1 |
| Okamura, T | 3 |
| Itagaki, H | 1 |
| Umehara, A | 3 |
| Fukuda, S | 6 |
| Ohue, M | 3 |
| Kano, S | 1 |
| Shingai, T | 4 |
| Kishi, K | 3 |
| Miyashiro, I | 2 |
| Ohigashi, H | 8 |
| Yano, M | 8 |
| Ishikawa, O | 9 |
| Miyoshi, N | 1 |
| Hirose, H | 1 |
| Ohnishi, T | 5 |
| Kanoh, T | 6 |
| Tono, T | 12 |
| Danno, K | 1 |
| Tsukao, Y | 1 |
| Inatome, J | 1 |
| Kagara, N | 1 |
| Taniguchi, H | 18 |
| Nakano, Y | 11 |
| Monden, T | 10 |
| Imaoka, S | 9 |
| Kagawa, S | 3 |
| Kimura, F | 4 |
| Takeuchi, D | 2 |
| Ko, S | 1 |
| Mukogawa, T | 1 |
| Nishiwada, T | 1 |
| Kunishige, T | 1 |
| Honboh, T | 1 |
| Tsuchiya, M | 3 |
| Koike, J | 1 |
| Otsuka, Y | 2 |
| Shiokawa, H | 1 |
| Shimada, H | 9 |
| Owada, Y | 3 |
| Nishigaki, T | 2 |
| Nagase, H | 1 |
| Mukai, R | 1 |
| Momozane, T | 1 |
| Yanagisawa, T | 2 |
| Ebisui, C | 7 |
| Tokunou, K | 1 |
| Toshimitsu, H | 1 |
| Kitamura, Y | 2 |
| Andou, S | 1 |
| Tsushimi, K | 1 |
| Ottomo, S | 1 |
| Motoi, F | 1 |
| Egawa, S | 1 |
| Sasaki, I | 1 |
| Bondarenko, I | 1 |
| Schuch, G | 1 |
| Zubel, A | 1 |
| Celik, I | 1 |
| Schlichting, M | 1 |
| Koralewski, P | 1 |
| Seki, A | 2 |
| Sun, W | 1 |
| Sohal, D | 1 |
| Haller, DG | 1 |
| Mykulowycz, K | 1 |
| Rosen, M | 1 |
| Soulen, MC | 2 |
| Caparro, M | 1 |
| Teitelbaum, UR | 1 |
| Giantonio, B | 1 |
| Shaked, A | 3 |
| Reddy, R | 1 |
| Olthoff, K | 1 |
| Chun, CL | 1 |
| Eisenstat, S | 1 |
| Dormady, S | 1 |
| Lombard, C | 1 |
| Triadafilopoulos, G | 1 |
| Advani, PP | 1 |
| Fakih, MG | 4 |
| Freyer, G | 1 |
| Duret, A | 1 |
| Etienne, MC | 4 |
| Falandry, C | 1 |
| Wong, R | 2 |
| Barbachano, Y | 3 |
| Saffery, C | 1 |
| Khan, A | 2 |
| Wotherspoon, A | 1 |
| Strimpakos, AS | 1 |
| Thomas, J | 1 |
| Compton, S | 1 |
| Chua, YJ | 1 |
| Wang, LP | 1 |
| Zhang, QL | 1 |
| Hu, XC | 1 |
| Wang, BY | 1 |
| Adamo, V | 1 |
| Franchina, T | 1 |
| Minciullo, PL | 1 |
| Pace, E | 1 |
| Colonese, F | 1 |
| Ricciardi, GR | 1 |
| Saitta, S | 1 |
| Ferraro, M | 1 |
| Spatari, G | 1 |
| Gangemi, S | 1 |
| Sogabe, S | 1 |
| Komatsu, Y | 4 |
| Yuki, S | 2 |
| Kusumi, T | 1 |
| Hatanaka, K | 1 |
| Miyagishima, T | 1 |
| Iwanaga, I | 1 |
| Sakata, Y | 10 |
| Mete, E | 1 |
| Gul, HI | 1 |
| Cetin-Atalay, R | 1 |
| Das, U | 1 |
| Sahin, E | 1 |
| Gul, M | 1 |
| Kazaz, C | 1 |
| Dimmock, JR | 1 |
| Choi, YJ | 2 |
| Park, KH | 1 |
| Oh, SC | 1 |
| Shin, SW | 1 |
| Kim, YH | 5 |
| Sasako, M | 1 |
| Nashimoto, A | 3 |
| Kinoshita, T | 1 |
| Kobayashi, O | 1 |
| Asami, S | 2 |
| Endo, H | 1 |
| Dicksey, JS | 1 |
| Peters, WP | 1 |
| Palalay, M | 1 |
| Chang, AY | 2 |
| Sobočanec, S | 1 |
| Balog, T | 1 |
| Šariċ, A | 1 |
| Mačak-Šafranko, Ž | 1 |
| Štroser, M | 1 |
| Žarković, K | 1 |
| Žarković, N | 1 |
| Stojković, R | 1 |
| Ivanković, S | 1 |
| Marotti, T | 1 |
| Perrocheau, G | 1 |
| Conroy, T | 3 |
| Dominguez, S | 1 |
| Florentin, V | 1 |
| Douillard, JY | 4 |
| Shitara, K | 7 |
| Sawaki, A | 1 |
| Tajika, M | 1 |
| Kawai, H | 2 |
| Yokota, T | 4 |
| Ura, T | 3 |
| Pohlen, U | 1 |
| Buhr, HJ | 1 |
| Berger, G | 3 |
| Ritz, JP | 1 |
| Holmer, C | 1 |
| Tomita, M | 2 |
| Kuboi, K | 1 |
| Kameyama, N | 1 |
| Mitsuhashi, H | 1 |
| Sekimoto, Y | 1 |
| Uegami, S | 1 |
| Toge, K | 1 |
| Sato, K | 7 |
| Kotsuji, F | 1 |
| Ang, SF | 1 |
| Tan, SH | 1 |
| Poon, DY | 1 |
| Ong, SY | 1 |
| Foo, KF | 1 |
| Scarabelli, L | 1 |
| Fiocchi, F | 1 |
| Bagni, B | 1 |
| Del Giovane, C | 1 |
| Colucci, G | 4 |
| Gerunda, GE | 1 |
| Fontana, A | 1 |
| Pettorelli, E | 1 |
| Boc, M | 2 |
| Voisin, T | 1 |
| El Firar, A | 1 |
| Fasseu, M | 1 |
| Rouyer-Fessard, C | 1 |
| Descatoire, V | 1 |
| Walker, F | 1 |
| Bedossa, P | 2 |
| Henin, D | 1 |
| Lehy, T | 1 |
| Laburthe, M | 1 |
| Kim, JD | 1 |
| Zhong, Y | 1 |
| Luo, CL | 1 |
| An-Jun, Z | 1 |
| Lee, YS | 1 |
| Yoon, CJ | 1 |
| Shin, DY | 1 |
| Lee, YG | 1 |
| Kang, SG | 1 |
| Overman, MJ | 2 |
| Loyer, EM | 2 |
| Cooper, A | 1 |
| Garrett, CR | 1 |
| Chen, HC | 1 |
| Sung, CM | 1 |
| Pan, KT | 1 |
| Tseng, JH | 1 |
| Kang, SS | 1 |
| Cho, HA | 1 |
| Kang, WJ | 1 |
| Lee, JD | 1 |
| Boston, EA | 1 |
| Gaffney, EA | 1 |
| Xie, F | 1 |
| Deng, B | 1 |
| Giuliani, F | 3 |
| Mattioli, R | 1 |
| Manzione, L | 3 |
| Lopez, M | 3 |
| Parrella, P | 1 |
| Tommasi, S | 1 |
| Copetti, M | 1 |
| Daniele, B | 1 |
| Pisconti, S | 1 |
| Tuveri, G | 1 |
| Rodriguez, NA | 1 |
| Ascaso, FJ | 1 |
| Ferreira, A | 1 |
| Vieira, C | 1 |
| Rodrigues, A | 1 |
| Pereira, D | 1 |
| Rodrigues, H | 1 |
| Dávila, C | 1 |
| Bento, S | 1 |
| Miyamoto, S | 7 |
| Mashimo, Y | 1 |
| Ezoe, Y | 1 |
| Muto, M | 3 |
| Chuma, M | 1 |
| Taguchi, H | 1 |
| Nakanishi, M | 2 |
| Horimoto, H | 1 |
| Terashita, K | 1 |
| Sakuhara, Y | 1 |
| Abo, D | 1 |
| Tsukuda, Y | 1 |
| Tsunematsu, S | 1 |
| Hige, S | 1 |
| Kato, M | 7 |
| Shirato, H | 1 |
| Kosmider, S | 1 |
| Tan, TH | 1 |
| Yip, D | 2 |
| Long, S | 1 |
| GuangZhi, Y | 1 |
| BaoJie, G | 1 |
| YanYong, H | 1 |
| YingLi, W | 1 |
| LiHua, L | 1 |
| Fukui, T | 2 |
| Itoh, Y | 1 |
| Yoshioka, T | 2 |
| Kawada, S | 1 |
| Mizota, A | 2 |
| Kondo, C | 2 |
| Yun, M | 1 |
| Yoon, HI | 1 |
| Cho, HJ | 1 |
| Kitahara, H | 1 |
| Masumoto, J | 1 |
| Parker, AL | 1 |
| Maruta, F | 1 |
| Shimizu, A | 1 |
| Miwa, S | 1 |
| Kobayashi, N | 4 |
| Nakayama, J | 1 |
| Zhao, WY | 1 |
| Chen, DY | 1 |
| Qi, Q | 1 |
| Jiang, HR | 1 |
| Zhong, MZ | 1 |
| Huang, HY | 2 |
| Niu, JL | 2 |
| Zhao, LM | 1 |
| Lu, YH | 2 |
| Roderburg, C | 1 |
| do O, N | 1 |
| Fuchs, R | 1 |
| Bubenzer, J | 1 |
| Spannbauer, M | 1 |
| Luedde, T | 1 |
| Trautwein, C | 1 |
| Tischendorf, JJ | 1 |
| Nyström, H | 1 |
| Naredi, P | 3 |
| Hafström, L | 12 |
| Sund, M | 1 |
| Asseburg, C | 1 |
| Frank, M | 1 |
| Griebsch, I | 1 |
| Mohr, A | 1 |
| Osowski, U | 1 |
| Schulten, J | 1 |
| Mittendorf, T | 1 |
| Liao, WJ | 1 |
| Mei, MH | 1 |
| Qin, LL | 1 |
| Yuan, SG | 1 |
| Osuga, K | 3 |
| Zhang, BY | 1 |
| Jia, ZX | 1 |
| Wu, WJ | 1 |
| Lu, ZQ | 1 |
| Koski, S | 1 |
| Rittweger, K | 1 |
| Gilberg, F | 1 |
| O'Connor, JP | 1 |
| Rose, CJ | 1 |
| Jackson, A | 1 |
| Watson, Y | 1 |
| Cheung, S | 1 |
| Maders, F | 1 |
| Whitcher, BJ | 1 |
| Roberts, C | 1 |
| Buonaccorsi, GA | 1 |
| Thompson, G | 1 |
| Clamp, AR | 1 |
| Jayson, GC | 1 |
| Parker, GJ | 1 |
| Yim, DS | 2 |
| Zalinski, S | 1 |
| Mariette, C | 1 |
| Farges, O | 2 |
| Fang, F | 1 |
| Qin, W | 1 |
| Gallant, JN | 1 |
| Katz, SI | 1 |
| Dolloff, NG | 1 |
| Smith, CD | 1 |
| Abdulghani, J | 1 |
| Allen, JE | 1 |
| Dicker, DT | 1 |
| Hong, B | 1 |
| Navaraj, A | 1 |
| Tomuleasa, C | 3 |
| Soritau, O | 3 |
| Fischer-Fodor, E | 1 |
| Pop, T | 2 |
| Susman, S | 3 |
| Mosteanu, O | 2 |
| Petrushev, B | 3 |
| Aldea, M | 3 |
| Acalovschi, M | 1 |
| Irimie, A | 3 |
| Kacso, G | 3 |
| Farr, GH | 1 |
| Fitch, TR | 1 |
| Maples, WJ | 1 |
| Rubin, J | 8 |
| Fuloria, J | 1 |
| Steen, PD | 1 |
| Park, YM | 3 |
| Kim, NY | 1 |
| Yun, HK | 1 |
| Lee, KJ | 2 |
| Yeon, JW | 1 |
| Jung, G | 2 |
| Ning, W | 1 |
| Xiao-Juan, G | 1 |
| Cai-Hong, Z | 1 |
| Jin-Hua, J | 1 |
| Fang, M | 1 |
| Qing-Duan, W | 1 |
| Leite, D | 1 |
| Kater, FR | 1 |
| Afonso, S | 2 |
| Viani, G | 1 |
| Afonso, V | 1 |
| Stefano, E | 1 |
| de Melo, JV | 1 |
| Vieira de Melo, MS | 1 |
| Abad, MH | 1 |
| Bethke, A | 1 |
| Kühne, K | 1 |
| Platzek, I | 1 |
| Izumiya, M | 1 |
| Yamagishi, Y | 1 |
| Sakai, G | 1 |
| Funakoshi, S | 1 |
| Adachi, M | 1 |
| Higuchi, H | 1 |
| Takaishi, H | 1 |
| Sugiura, J | 1 |
| Irie, E | 1 |
| Ohmori, T | 1 |
| Oyamatsu, M | 1 |
| Shiraishi, O | 1 |
| Peng, YF | 1 |
| Tateishi, U | 1 |
| Akiyoshi, K | 1 |
| Okita, N | 1 |
| Shirao, K | 3 |
| Zhou, N | 1 |
| Trillet-Lenoir, V | 1 |
| Kraemer, S | 1 |
| Jeppesen, JB | 1 |
| Østerlind, K | 1 |
| Zang, Y | 1 |
| Zou, W | 1 |
| Shen, ZY | 1 |
| Polysalov, VN | 1 |
| Rutkin, IO | 1 |
| Krotova, OA | 1 |
| Tlostanova, MS | 1 |
| Nagahara, H | 1 |
| Kashiwagi, S | 1 |
| Fuyuhiro, Y | 1 |
| Nakamoto, K | 1 |
| Suzuki, C | 2 |
| Blomqvist, L | 1 |
| Sundin, A | 1 |
| Jacobsson, H | 1 |
| Byström, P | 1 |
| Berglund, Å | 1 |
| Nygren, P | 1 |
| Hiramatsu, K | 1 |
| Takeuchi, E | 1 |
| Mohammed, TA | 1 |
| Dennie, T | 1 |
| Holen, KD | 1 |
| Ferrarotto, R | 1 |
| Pathak, P | 1 |
| Overman, M | 1 |
| Nitzkorski, JR | 1 |
| Farma, JM | 1 |
| Watson, JC | 2 |
| Siripurapu, V | 1 |
| Matteotti, RS | 1 |
| Sigurdson, ER | 6 |
| Weber, T | 2 |
| Link, KH | 11 |
| Gaedcke, J | 1 |
| Hess, C | 1 |
| Becker, H | 2 |
| Rödel, C | 1 |
| Ghadimi, BM | 1 |
| Wang, JP | 1 |
| Edhemovic, I | 1 |
| Gadzijev, EM | 1 |
| Brecelj, E | 1 |
| Miklavcic, D | 1 |
| Kos, B | 1 |
| Zupanic, A | 1 |
| Mali, B | 1 |
| Jarm, T | 1 |
| Pavliha, D | 1 |
| Marcan, M | 1 |
| Gasljevic, G | 1 |
| Gorjup, V | 1 |
| Music, M | 1 |
| Vavpotic, TP | 1 |
| Cemazar, M | 1 |
| Snoj, M | 1 |
| Sersa, G | 1 |
| Baldi, GG | 1 |
| Tuzi, A | 1 |
| Rubie, C | 1 |
| Frick, VO | 1 |
| Ghadjar, P | 1 |
| Wagner, M | 1 |
| Justinger, C | 1 |
| Graeber, S | 1 |
| Kollmar, O | 1 |
| Schilling, MK | 1 |
| Ihara, E | 1 |
| Tomita, Y | 2 |
| Miyata, S | 1 |
| Sumida, Y | 1 |
| Ihara, Y | 1 |
| Misawa, T | 1 |
| Uehara, M | 1 |
| Konishi, S | 1 |
| Hamasu, S | 1 |
| Lam, VW | 1 |
| Spiro, C | 1 |
| Laurence, JM | 1 |
| Johnston, E | 1 |
| Hollands, MJ | 1 |
| Pleass, HC | 1 |
| Richardson, AJ | 1 |
| Liao, D | 1 |
| Muratore, A | 3 |
| Mellano, A | 1 |
| Hinchliffe, E | 1 |
| Allcock, RL | 1 |
| Mansoor, W | 1 |
| Myers, MA | 1 |
| Bioulac-Sage, P | 1 |
| Trillaud, H | 1 |
| Kuo, CH | 1 |
| Hou, MF | 1 |
| Chuang, SC | 1 |
| Lin, SR | 1 |
| Pilgrim, CH | 1 |
| Brettingham-Moore, K | 1 |
| Pham, A | 1 |
| Murray, W | 1 |
| Link, E | 1 |
| Usatoff, V | 1 |
| Evans, PM | 1 |
| Banting, S | 1 |
| Thomson, BN | 1 |
| Phillips, WA | 1 |
| Chien, SY | 1 |
| Kuo, SJ | 1 |
| Chen, YL | 1 |
| Chen, DR | 1 |
| Cheng, CY | 1 |
| Su, CC | 1 |
| Petrini, I | 1 |
| Lencioni, M | 1 |
| Ricasoli, M | 1 |
| Iannopollo, M | 1 |
| Orlandini, C | 1 |
| Oliveri, F | 1 |
| Bartolozzi, C | 1 |
| Zannino, D | 1 |
| Wilson, K | 1 |
| Simes, RJ | 1 |
| Robinson, BA | 1 |
| Broad, A | 1 |
| Ackland, SP | 1 |
| Chang, YR | 1 |
| Han, DS | 1 |
| Kong, SH | 1 |
| Yang, HK | 1 |
| Murata, S | 1 |
| Tamura, M | 3 |
| Fukunaga, K | 2 |
| Iida, H | 2 |
| Kakuno, A | 1 |
| Nishigami, T | 1 |
| Rho, JK | 1 |
| Rha, SY | 1 |
| Choi, SB | 1 |
| Park, MS | 3 |
| Ou, Q | 1 |
| Tian, L | 1 |
| Sheng, XF | 1 |
| Cao, JG | 1 |
| Abu-Ghanem, S | 1 |
| Novik, EF | 1 |
| Abu-Ghanem, Y | 1 |
| Man, S | 2 |
| Shelef, I | 1 |
| Gollub, MJ | 1 |
| Gultekin, DH | 1 |
| Akin, O | 1 |
| Fuqua, JL | 1 |
| Kuk, D | 1 |
| Weiser, M | 1 |
| Schrag, D | 1 |
| Goodman, K | 1 |
| Paty, P | 2 |
| Guillem, J | 1 |
| Temple, L | 1 |
| Poggi, G | 1 |
| Montagna, B | 1 |
| Melchiorre, F | 1 |
| Quaretti, P | 1 |
| Delmonte, A | 1 |
| Riccardi, A | 2 |
| Tagliaferri, B | 1 |
| Sottotetti, F | 1 |
| Di Cesare, P | 1 |
| Stella, MG | 1 |
| Villani, L | 1 |
| Zorzetto, M | 1 |
| Greco, G | 1 |
| Cornalba, G | 1 |
| Bernardo, G | 1 |
| Fei, Q | 1 |
| Niu, D | 1 |
| Sakai, A | 1 |
| Koganemaru, M | 1 |
| Abe, T | 5 |
| Iwamoto, R | 1 |
| Nonoshita, M | 1 |
| Uchiyama, D | 1 |
| Hayabuchi, N | 1 |
| Taniguchi, E | 1 |
| Masuda, H | 1 |
| Hashimoto, O | 1 |
| Barresi, V | 1 |
| Nakashima, E | 1 |
| Uchibori, K | 1 |
| Kasamatsu, A | 1 |
| Sunaga, M | 2 |
| Yokota, S | 1 |
| Sakurada, T | 1 |
| Kobayashi, E | 1 |
| Uzawa, K | 1 |
| Tanzawa, H | 1 |
| Sato, N | 8 |
| Tong, SW | 1 |
| Yang, YX | 1 |
| Hu, HD | 1 |
| Hu, P | 1 |
| Zhang, DZ | 1 |
| Enomoto, K | 2 |
| Kuwayama, T | 1 |
| Sugimoto, H | 1 |
| Ishiba, T | 1 |
| Chikatani, K | 1 |
| Amano, K | 2 |
| Kumamoto, K | 7 |
| Haga, N | 7 |
| Iwama, T | 5 |
| Ono, T | 8 |
| Honjou, H | 1 |
| Onouchi, T | 1 |
| Yakabi, K | 1 |
| Yamauchi, S | 2 |
| Umemoto, S | 1 |
| Takasaki, J | 1 |
| Watayoh, Y | 1 |
| Andoh, M | 1 |
| Vicentini, R | 1 |
| Nuzzo, G | 5 |
| Antonucci, A | 1 |
| Chan, KM | 1 |
| Chiang, JM | 1 |
| Lee, CF | 1 |
| Yu, MC | 1 |
| Lee, WC | 1 |
| Parsons, HA | 1 |
| Pontikos, M | 1 |
| Baracos, VE | 1 |
| Vigano', L | 1 |
| Lo Tesoriere, R | 1 |
| Biondani, P | 1 |
| Marchianò, A | 1 |
| Dotti, KF | 1 |
| Buzzoni, R | 3 |
| Di Bartolomeo, M | 3 |
| Cai, YC | 1 |
| Cai, XY | 1 |
| Tan, YT | 1 |
| Shi, YX | 3 |
| Yovino, S | 1 |
| Maidment, BW | 1 |
| Herman, JM | 1 |
| Pandya, N | 1 |
| Goloubeva, O | 1 |
| Wolfgang, C | 1 |
| Schulick, R | 1 |
| Laheru, D | 1 |
| Hanna, N | 1 |
| Alexander, R | 1 |
| Regine, WF | 2 |
| An, HJ | 1 |
| Yu, CS | 2 |
| Yun, SC | 1 |
| Kang, BW | 1 |
| Kim, JC | 2 |
| Xia, H | 1 |
| Jiang, X | 2 |
| Jiao, J | 1 |
| Shen, B | 1 |
| Collette, L | 2 |
| Feng, WM | 1 |
| Tang, CW | 1 |
| Huang, SX | 1 |
| Zheng, YY | 1 |
| Tao, YL | 1 |
| Chang, YY | 1 |
| Jiang, JK | 3 |
| Shindo, J | 1 |
| Shiraki, A | 1 |
| Nakashima, H | 1 |
| Yukita, Y | 1 |
| Tagami, Y | 1 |
| Katakawa, M | 1 |
| Bando, Y | 1 |
| Sahara, S | 1 |
| Kawai, N | 1 |
| Sato, M | 6 |
| Ikoma, A | 2 |
| Sanda, H | 1 |
| Minamiguchi, H | 1 |
| Shirai, S | 1 |
| Sonomura, T | 1 |
| Kasivisvanathan, V | 1 |
| Thapar, A | 1 |
| Oskrochi, Y | 1 |
| Picard, J | 1 |
| Leen, EL | 1 |
| Jiménez, R | 1 |
| Hijona, E | 1 |
| Emparanza, J | 1 |
| Alústiza, JM | 1 |
| Hijona, L | 1 |
| Macarulla, MT | 1 |
| Portillo, MP | 1 |
| Herreros-Villanueva, M | 1 |
| Beguiristain, A | 1 |
| Arenas, J | 1 |
| Bujanda, L | 1 |
| Kawaguchi, A | 1 |
| Kakuma, T | 1 |
| Shibata, Y | 2 |
| Tojima, Y | 1 |
| Tsuboi, K | 1 |
| Sakamoto, E | 1 |
| Kunieda, K | 7 |
| Suzumura, K | 1 |
| Naganuma, T | 1 |
| Sadeghi, H | 1 |
| Khadem, M | 1 |
| Roitman, M | 1 |
| Song, JR | 1 |
| Deng, WJ | 1 |
| Sun, K | 1 |
| Xie, XQ | 1 |
| Song, YJ | 1 |
| Arvold, ND | 1 |
| Fernandez-del Castillo, C | 1 |
| Niemierko, A | 1 |
| Kwak, EL | 2 |
| Wadlow, RC | 1 |
| Warshaw, AL | 1 |
| Benavides, M | 1 |
| Gil-Calle, S | 1 |
| Aparicio, J | 2 |
| González-Flores, E | 1 |
| Cabrera, E | 1 |
| Queralt, B | 1 |
| Gómez, MJ | 1 |
| Guasch, I | 1 |
| Etxeberría, A | 1 |
| Alfaro, J | 1 |
| Campos, JM | 1 |
| Reina, JJ | 1 |
| Seshimo, K | 1 |
| Oishi, M | 1 |
| Toshima, T | 2 |
| Ikeda, H | 4 |
| Yamamura, M | 3 |
| Kodera, M | 1 |
| Yamashita, Y | 9 |
| Fujita, H | 2 |
| Shibagaki, K | 1 |
| Matsuki, T | 1 |
| Takita, K | 1 |
| Nørgaard, H | 2 |
| Obi, S | 2 |
| Tateishi, R | 2 |
| Kanda, M | 2 |
| Arano, T | 1 |
| Enooku, K | 1 |
| Goto, E | 1 |
| Masuzaki, R | 1 |
| Nakagawa, H | 4 |
| Asaoka, Y | 1 |
| Yamashiki, N | 1 |
| Goto, T | 2 |
| Shiina, S | 2 |
| Koike, K | 2 |
| Kanzaki, M | 1 |
| Wada, J | 1 |
| Nakatsuka, A | 4 |
| Teshigawara, S | 1 |
| Terami, T | 1 |
| Katayama, A | 1 |
| Nasu, J | 1 |
| Hashimoto, A | 5 |
| Anai, H | 6 |
| Berindan, I | 1 |
| Cristea, V | 2 |
| Kim, DH | 2 |
| Goo, JM | 1 |
| Willmann, JK | 1 |
| Eo, JS | 1 |
| Paeng, JC | 1 |
| Choi, BI | 1 |
| Hidaka, T | 1 |
| Fujimura, T | 2 |
| Watabe, A | 1 |
| Haga, T | 1 |
| Onami, K | 1 |
| Mizuashi, M | 1 |
| Aiba, S | 1 |
| Youn, JM | 1 |
| Cha, JH | 1 |
| Kim, HL | 1 |
| Yoon, JY | 1 |
| Nam, TS | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Chung, IJ | 1 |
| Bae, WK | 1 |
| Dexiang, Z | 1 |
| Haifu, W | 1 |
| Yunshi, Z | 1 |
| Qinghai, Y | 1 |
| Shenyong, Z | 1 |
| Bo, X | 1 |
| Xiangou, P | 1 |
| Haohao, L | 1 |
| Lechi, Y | 1 |
| Tianshu, L | 1 |
| Jia, F | 3 |
| Xinyu, Q | 1 |
| Jianmin, X | 1 |
| Metzger, T | 1 |
| Tatum, C | 1 |
| Sharma, V | 3 |
| Dewdney, A | 1 |
| Yasaki, S | 1 |
| Tukamoto, Y | 1 |
| Yuasa, N | 2 |
| Yoshii, F | 1 |
| Ge, N | 2 |
| Gan, Y | 2 |
| Ye, S | 2 |
| Hackl, C | 1 |
| Francia, G | 1 |
| Milsom, C | 1 |
| Xu, P | 1 |
| Kerbel, RS | 1 |
| Márquez, E | 1 |
| Rodríguez, E | 1 |
| Pascual, J | 1 |
| Kirikoshi, H | 1 |
| Yoneda, M | 1 |
| Mawatari, H | 1 |
| Fujita, K | 1 |
| Imajo, K | 2 |
| Kubota, K | 1 |
| Ishibashi, N | 1 |
| Murakami, N | 5 |
| Kibe, S | 1 |
| Yahara, T | 1 |
| Lekakis, L | 1 |
| Tryfonopoulos, D | 1 |
| Pistamatzian, N | 1 |
| Panopoulos, C | 1 |
| Demiri, S | 1 |
| Efremidis, A | 1 |
| Ferdinande, L | 1 |
| Libbrecht, L | 1 |
| Ida, S | 1 |
| Jin, K | 1 |
| Lan, H | 1 |
| Han, N | 2 |
| Teng, L | 1 |
| Cao, F | 1 |
| Barroso, E | 1 |
| Laurent, C | 1 |
| Ijzermans, JN | 1 |
| Figueras, J | 2 |
| Mirza, DF | 2 |
| Isoniemi, H | 1 |
| Herrera, J | 1 |
| Sousa, FC | 1 |
| Pardo, F | 2 |
| Popescu, I | 1 |
| Shao, YY | 1 |
| Huang, CC | 1 |
| Lin, SD | 1 |
| Goyer, P | 1 |
| Hajjam, ME | 1 |
| Chen, XZ | 1 |
| Cao, ZY | 1 |
| Chen, TS | 1 |
| Zhang, YQ | 1 |
| Liu, ZZ | 1 |
| Su, YT | 1 |
| Liao, LM | 1 |
| Du, J | 1 |
| Varol, U | 1 |
| Karaca, B | 1 |
| Cakar, B | 1 |
| Sezgin, C | 1 |
| Karabulut, B | 1 |
| Uslu, R | 1 |
| Gulec, SA | 1 |
| Pennington, K | 2 |
| Wheeler, J | 1 |
| Barot, TC | 1 |
| Suthar, RR | 1 |
| Schwartzentruber, D | 1 |
| Trobaugh-Lotrario, AD | 1 |
| Tursi, A | 1 |
| Treska, V | 1 |
| Safranek, J | 1 |
| Lysak, D | 1 |
| Mirka, H | 1 |
| Skalicky, T | 1 |
| Slauf, F | 1 |
| Hes, O | 1 |
| Vestermark, LW | 1 |
| Jensen, BK | 1 |
| Nelausen, KM | 1 |
| Bergenfeldt, M | 1 |
| Hermann, KL | 1 |
| Yadunandam, AK | 1 |
| Yoon, JS | 1 |
| Seong, YA | 1 |
| Oh, CW | 1 |
| Kim, GD | 1 |
| Liang, RR | 1 |
| Qi, JA | 1 |
| Wang, ZD | 1 |
| Liu, PJ | 1 |
| Le, XF | 1 |
| Li, ZF | 1 |
| Azuma, Y | 1 |
| Sai, K | 1 |
| Udagawa, R | 1 |
| Hirakawa, A | 1 |
| Tohkin, M | 1 |
| Ryushima, Y | 1 |
| Makino, Y | 1 |
| Yokote, N | 1 |
| Morikawa, N | 1 |
| Takanashi, K | 3 |
| Katsuki, S | 2 |
| Waga, E | 2 |
| Shimodate, Y | 1 |
| Someya, T | 1 |
| Ohno, K | 2 |
| Fujita, M | 7 |
| Srivastava, J | 1 |
| Siddiq, A | 1 |
| Emdad, L | 1 |
| Santhekadur, PK | 1 |
| Shen, XN | 1 |
| Robertson, CL | 1 |
| Dumur, CI | 1 |
| Hylemon, PB | 1 |
| Mukhopadhyay, ND | 1 |
| Bhere, D | 1 |
| Ahmad, R | 1 |
| Giashuddin, S | 1 |
| Stafflinger, J | 1 |
| Subler, MA | 1 |
| Windle, JJ | 1 |
| Kubo, H | 2 |
| Nishiyama, M | 3 |
| Miyahara, M | 2 |
| Hoshino, H | 2 |
| Ishii, Y | 5 |
| Endo, T | 8 |
| Ochiai, H | 1 |
| Matsunaga, A | 1 |
| Shigeta, K | 1 |
| Seo, Y | 2 |
| Hoshino, G | 1 |
| Orza, A | 1 |
| Dudea, M | 1 |
| Florea, A | 1 |
| Pall, E | 1 |
| Berindan-Neagoe, I | 1 |
| Ushigome, T | 1 |
| Kitamura, H | 2 |
| Onda, S | 1 |
| Saito, R | 1 |
| Yanagisawa, S | 1 |
| Shiozaki, A | 2 |
| Fujiwara, H | 5 |
| Murayama, Y | 1 |
| Kuriu, Y | 1 |
| Kokuba, Y | 1 |
| Novarino, AM | 1 |
| Napoletano, R | 1 |
| Ceccarelli, M | 1 |
| Ciccone, G | 1 |
| Schena, M | 1 |
| Matsumori, T | 1 |
| Murakami, S | 3 |
| Araki, O | 1 |
| Goto, N | 1 |
| Adachi, K | 1 |
| Hayashi, M | 2 |
| Itani, T | 2 |
| Mimura, J | 1 |
| Hashimoto, K | 2 |
| Yan, S | 1 |
| Dior, M | 1 |
| Perkins, G | 2 |
| Dhooge, M | 2 |
| Bollet, MA | 1 |
| Servois, V | 1 |
| Zefkili, S | 1 |
| Farkhondeh, F | 1 |
| Baranger, B | 1 |
| Mariani, P | 1 |
| Alberda, WJ | 1 |
| Burger, JW | 1 |
| Nuyttens, JJ | 1 |
| Dwarkasing, RS | 1 |
| Willemssen, FE | 1 |
| Orgel, M | 1 |
| Horger, M | 1 |
| Kurth, R | 1 |
| Kanz, L | 3 |
| Jaschonek, K | 1 |
| Kopp, HG | 1 |
| Stein, A | 1 |
| Glockzin, G | 1 |
| Wienke, A | 1 |
| Edelmann, T | 1 |
| Hollerbach, S | 1 |
| Richter, M | 1 |
| Schlitt, HJ | 1 |
| Schmoll, HJ | 3 |
| Fang, P | 1 |
| Ding, CR | 1 |
| Cui, F | 1 |
| Jiao, SC | 1 |
| Matsunaga, M | 1 |
| Kaneta, T | 1 |
| Nagashima, F | 2 |
| Koike, S | 4 |
| Matsumura, H | 1 |
| Yokoi, K | 1 |
| Arai, M | 1 |
| Stiefelhagen, P | 1 |
| Ohtsu, A | 2 |
| Hamada, M | 1 |
| Okigami, M | 1 |
| Toiyama, Y | 1 |
| Matsushita, K | 3 |
| Saigusa, S | 1 |
| Okugawa, Y | 1 |
| Araki, T | 1 |
| Mohri, Y | 1 |
| Mizoguchi, A | 1 |
| Kusunoki, M | 6 |
| Palazzo, M | 1 |
| Goujon, G | 1 |
| Gillet, A | 1 |
| Mima, K | 1 |
| Kuroki, H | 1 |
| Ooi, H | 2 |
| Wan, T | 2 |
| Zha, B | 2 |
| Ye, T | 3 |
| Eveno, C | 1 |
| Honoré, C | 1 |
| Tzanis, D | 1 |
| Rangwala, F | 1 |
| Williams, KP | 1 |
| Smith, GR | 1 |
| Thomas, Z | 1 |
| Allensworth, JL | 1 |
| Lyerly, HK | 1 |
| Diehl, AM | 1 |
| Morse, MA | 1 |
| Devi, GR | 1 |
| Chen, SS | 1 |
| Uguen, T | 1 |
| Leconte, B | 1 |
| Desgrippes, R | 1 |
| Tchoundeu, B | 1 |
| Bretagne, JF | 2 |
| Manfredi, S | 1 |
| Constantinidou, A | 1 |
| Shurmahi, F | 1 |
| Asghar, U | 1 |
| Rao, S | 3 |
| Veltri, E | 1 |
| Zullo, A | 1 |
| Zoratto, F | 1 |
| Colonna, M | 1 |
| Di Seri, M | 1 |
| Giannarelli, D | 2 |
| Ruco, L | 1 |
| Romiti, A | 1 |
| Barucca, V | 1 |
| Adua, D | 1 |
| Tomao, S | 2 |
| Maisano, R | 1 |
| Azzarello, D | 1 |
| Maisano, M | 1 |
| Mafodda, A | 1 |
| Bottari, M | 1 |
| Egitto, G | 1 |
| Nardi, M | 1 |
| Wolf, PS | 1 |
| Bao, F | 1 |
| Tzeng, CW | 1 |
| Saitoh, G | 1 |
| Kida, K | 1 |
| Kawasaki, A | 1 |
| Mimatsu, K | 1 |
| Fukino, N | 1 |
| Kuboi, Y | 1 |
| Kano, H | 1 |
| Oida, T | 1 |
| Yoshida, R | 1 |
| Hijikawa, K | 1 |
| Yanagida, H | 1 |
| Kitade, H | 1 |
| Takada, H | 1 |
| Waseda, Y | 1 |
| Komai, Y | 1 |
| Yano, A | 1 |
| Fujii, Y | 4 |
| Noguchi, N | 1 |
| Kihara, K | 1 |
| Chen, SC | 1 |
| Ying, HY | 1 |
| Li, XY | 3 |
| Zhou, JF | 1 |
| Shao, YJ | 1 |
| Yang, XD | 1 |
| Ning, XH | 1 |
| Bai, CM | 1 |
| Hatwell, C | 1 |
| Bretagnol, F | 1 |
| Inal, A | 1 |
| Kaplan, MA | 1 |
| Kuçukoner, M | 1 |
| Urakci, Z | 1 |
| Guven, M | 1 |
| Nas, N | 1 |
| Yunce, M | 1 |
| Işikdogan, A | 1 |
| McCleary, NJ | 1 |
| Odejide, O | 1 |
| Szymonifka, J | 1 |
| Ryan, D | 1 |
| Hezel, A | 1 |
| Meyerhardt, JA | 2 |
| Kornmann, M | 7 |
| Staib, L | 4 |
| Wiegel, T | 1 |
| Kron, M | 1 |
| Henne-Bruns, D | 2 |
| Formentini, A | 3 |
| Lu, F | 1 |
| Hou, YQ | 1 |
| Yuan, ZJ | 1 |
| Sadahiro, S | 8 |
| Tanaka, A | 2 |
| Kamata, H | 1 |
| Koisumi, J | 1 |
| Rong, C | 1 |
| Antoniou, E | 1 |
| Mantas, D | 1 |
| Paraskeva, P | 1 |
| Dimitroulis, D | 1 |
| Smyrnis, A | 1 |
| Nikitakis, N | 1 |
| Labadariou, A | 1 |
| Tsavaris, N | 3 |
| Vernicos, P | 1 |
| Kostakis, A | 1 |
| Takahashi, R | 1 |
| Akashi, M | 1 |
| Nishida, R | 1 |
| Takami, Y | 1 |
| Saitsu, H | 1 |
| Momosaki, S | 2 |
| Takayoshi, K | 1 |
| Yang, BW | 2 |
| Yu, DS | 1 |
| Huang, XE | 2 |
| Lu, YY | 1 |
| Wu, XY | 2 |
| Xiang, J | 1 |
| Kong, WD | 1 |
| Cao, JM | 1 |
| Xu, TT | 1 |
| Lu, GM | 1 |
| Ling, CQ | 4 |
| Saridaki, Z | 1 |
| Androulakis, N | 3 |
| Vardakis, N | 2 |
| Vamvakas, L | 3 |
| Kabouraki, E | 1 |
| Kalbakis, K | 3 |
| Mavroudis, D | 3 |
| Xue, C | 1 |
| Huang, PY | 2 |
| Yu, QT | 1 |
| Pan, JJ | 1 |
| Liu, LZ | 1 |
| Song, XQ | 1 |
| Lin, SJ | 1 |
| Wu, JX | 1 |
| Zhao, HY | 1 |
| Liu, JL | 1 |
| Hu, ZH | 1 |
| Zhao, LP | 1 |
| Zhao, YY | 1 |
| Ma, YX | 1 |
| Pox, C | 1 |
| Schmiegel, W | 1 |
| Prenen, H | 1 |
| Knox, JJ | 1 |
| Voboril, Z | 1 |
| Malírová, E | 1 |
| Weiner, P | 1 |
| Nová, M | 1 |
| Ryska, A | 1 |
| Akiyoshi, T | 2 |
| Koga, R | 1 |
| Ikeda, A | 1 |
| Nagasue, Y | 1 |
| Oikawa, Y | 1 |
| Yamakawa, K | 1 |
| Fukunaga, Y | 1 |
| Yamamoto, C | 2 |
| Bonnet, S | 1 |
| Yue, XJ | 1 |
| Yu, XH | 1 |
| Fukushima, H | 1 |
| Brito, AF | 1 |
| Abrantes, AM | 1 |
| Pinto-Costa, C | 1 |
| Gomes, AR | 1 |
| Mamede, AC | 1 |
| Casalta-Lopes, J | 1 |
| Gonçalves, AC | 1 |
| Sarmento-Ribeiro, AB | 1 |
| Tralhão, JG | 1 |
| Botelho, MF | 1 |
| Dréanic, J | 1 |
| Boudou-Rouquette, P | 1 |
| Ye, X | 1 |
| Shao, L | 1 |
| Lin, BC | 1 |
| He, CX | 1 |
| Zhang, BB | 1 |
| Zhang, YP | 1 |
| Murao, S | 1 |
| Tsukamoto, T | 1 |
| Kodai, S | 1 |
| Yamazoe, S | 1 |
| Yamamoto, A | 2 |
| Nishiguchi, Y | 2 |
| Ikehara, T | 2 |
| Horii, K | 1 |
| Yamazaki, O | 1 |
| Kumagai, Y | 4 |
| Shioiri, M | 1 |
| Toura, I | 1 |
| Kudo, S | 1 |
| Nakanishi, T | 1 |
| Nishiyama, S | 1 |
| Takebe, S | 1 |
| Ohsaki, S | 1 |
| Makino, S | 2 |
| Wada, Y | 3 |
| Kato, R | 2 |
| Nakagomi, N | 1 |
| Tamai, M | 1 |
| Nakatake, R | 1 |
| Iwai, A | 1 |
| Matsushima, H | 1 |
| Kitagawa, M | 2 |
| Kudo, K | 2 |
| Shoji, F | 1 |
| Teramoto, S | 1 |
| Matsuzawa, T | 2 |
| Hua, XD | 1 |
| Winograd, E | 1 |
| Papoulas, M | 1 |
| Lahat, G | 1 |
| Klausner, J | 1 |
| Zhou, S | 2 |
| Duan, X | 1 |
| Kim, JY | 1 |
| Yoo, EJ | 1 |
| Kwon, JH | 3 |
| Kay, CS | 1 |
| Lichinitser, M | 1 |
| Suresh, AV | 1 |
| Manikhas, G | 1 |
| Shapiro, J | 1 |
| Rogowski, W | 1 |
| Warner, D | 1 |
| Jain, R | 1 |
| Fine, RL | 2 |
| Gulati, AP | 1 |
| Krantz, BA | 1 |
| Moss, RA | 1 |
| Schreibman, S | 1 |
| Tsushima, DA | 1 |
| Mowatt, KB | 1 |
| Dinnen, RD | 1 |
| Mao, Y | 1 |
| Stevens, PD | 1 |
| Schrope, B | 1 |
| Allendorf, J | 1 |
| Lee, JA | 1 |
| Sherman, WH | 1 |
| Chabot, JA | 1 |
| Hoshino, S | 1 |
| Naito, M | 1 |
| Miyake, T | 2 |
| Tanimura, S | 1 |
| Cirillo, M | 1 |
| Musola, M | 1 |
| Cassandrini, PA | 1 |
| Lunardi, G | 1 |
| Venturini, M | 2 |
| Nakada, T | 1 |
| Nagayama, K | 1 |
| Hiramoto, J | 1 |
| Tsuruta, Y | 2 |
| Sakabe, S | 1 |
| Itamoto, T | 2 |
| Nakahara, H | 3 |
| Tashiro, H | 1 |
| Haruta, N | 2 |
| Robertson, JM | 1 |
| Cha, C | 1 |
| Andrews, JC | 2 |
| Ensminger, WD | 5 |
| Bonino, F | 1 |
| Conte, P | 1 |
| Itoh, S | 2 |
| Takamatsu, M | 2 |
| Horimi, T | 2 |
| Zhang, A | 2 |
| Meyer, L | 2 |
| Puls, R | 1 |
| Bartels, B | 1 |
| Liu, LX | 1 |
| Zhang, WH | 1 |
| Jiang, HC | 1 |
| Zhu, AL | 1 |
| Wu, LF | 1 |
| Qi, SY | 1 |
| Piao, DX | 1 |
| Kelsen, DP | 2 |
| Ilson, D | 1 |
| O'Reilly, E | 1 |
| Zaknoen, S | 1 |
| Baum, C | 1 |
| Statkevich, P | 1 |
| London, WB | 2 |
| Douglass, EC | 7 |
| Reynolds, M | 8 |
| Plaschkes, J | 1 |
| Bowman, LC | 3 |
| Ezenfis, J | 1 |
| Clavero-Fabri, MC | 1 |
| Vaillant, JN | 1 |
| Ando, E | 8 |
| Yamashita, F | 7 |
| Yutani, S | 2 |
| Fukumori, K | 6 |
| Osterlund, P | 1 |
| Orpana, A | 1 |
| Elomaa, I | 1 |
| Repo, H | 1 |
| Joensuu, H | 1 |
| Tasaka, K | 1 |
| Tomofuji, Y | 1 |
| Chinzei, T | 1 |
| Takizawa, M | 1 |
| Hirano, M | 4 |
| Uno, Y | 1 |
| Kikkawa, H | 1 |
| Koyama, M | 1 |
| Watabe, S | 1 |
| Ohe, S | 1 |
| Kamio, Y | 1 |
| Chiba, M | 1 |
| Boucher, E | 1 |
| Corbinais, S | 1 |
| Brissot, P | 2 |
| Boudjema, K | 1 |
| Cantore, M | 3 |
| Rabbi, C | 2 |
| Guadagni, S | 2 |
| Zamagni, D | 2 |
| Aitini, E | 2 |
| Constenla, M | 1 |
| Garcia-Arroyo, R | 1 |
| Lorenzo, I | 1 |
| Carrete, N | 1 |
| Campos, B | 1 |
| Palacios, P | 1 |
| Yamamura, T | 11 |
| Yabe, K | 2 |
| Oka, H | 2 |
| Kouzuma, T | 1 |
| Wakayama, T | 1 |
| Sugiura, A | 1 |
| Hagiwara, M | 2 |
| Ohdate, K | 1 |
| Miyajima, N | 3 |
| Maeda, C | 1 |
| Okamura, R | 2 |
| Miyahara, T | 1 |
| Moriyama, Y | 2 |
| Gunji, A | 1 |
| Katsuramaki, T | 2 |
| Furuhata, T | 1 |
| Ohmura, T | 2 |
| Hata, F | 1 |
| Mukaiya, M | 3 |
| Hosoya, Y | 2 |
| Nihei, Y | 1 |
| Shoji, M | 1 |
| Sugita, M | 1 |
| Togo, S | 5 |
| Kunisaki, C | 2 |
| Akçali, Z | 1 |
| Akin, E | 1 |
| Ozyilkan, O | 1 |
| Mikami, Y | 2 |
| Kubozoe, T | 2 |
| Urakami, A | 2 |
| Kimoto, M | 2 |
| Tsunoda, T | 3 |
| Prasad, SR | 1 |
| Jhaveri, KS | 1 |
| Saini, S | 1 |
| Hahn, PF | 1 |
| Halpern, EF | 1 |
| Sumner, JE | 1 |
| Reid, T | 2 |
| Galanis, E | 2 |
| Abbruzzese, J | 2 |
| Sze, D | 2 |
| Wein, LM | 1 |
| Andrews, J | 2 |
| Randlev, B | 1 |
| Heise, C | 1 |
| Uprichard, M | 1 |
| Hatfield, M | 2 |
| Rome, L | 1 |
| Kirn, D | 2 |
| Fraker, DL | 2 |
| Soulen, M | 1 |
| Heidemann, E | 1 |
| Stoeger, H | 1 |
| Souchon, R | 1 |
| Hirschmann, WD | 2 |
| Bodenstein, H | 1 |
| Oberhoff, C | 1 |
| Fischer, JT | 1 |
| Schulze, M | 1 |
| Clemens, M | 2 |
| Andreesen, R | 1 |
| Mahlke, M | 1 |
| König, M | 1 |
| Scharl, A | 1 |
| Fehnle, K | 1 |
| Kaufmann, M | 2 |
| Aquino, A | 1 |
| Prete, SP | 1 |
| Balduzzi, A | 1 |
| Fossile, E | 1 |
| Formica, V | 1 |
| Torino, F | 1 |
| Bonmassar, L | 1 |
| Di Giacomo, A | 1 |
| Cappelletti, D | 1 |
| Cardillo, A | 1 |
| Graziani, G | 1 |
| Miyanari, N | 2 |
| Happich, K | 1 |
| Schirner, I | 1 |
| Jin, J | 3 |
| Wei, HL | 1 |
| Liu, GT | 1 |
| Sakon, M | 30 |
| Mainwaring, CJ | 1 |
| Naylor, E | 1 |
| Jerwood, S | 1 |
| Hall, V | 1 |
| Page, A | 1 |
| James, CM | 1 |
| Fishman, AD | 1 |
| Wadler, S | 5 |
| Bilchik, AJ | 2 |
| Wood, TF | 1 |
| Chawla, SP | 1 |
| Rose, DM | 1 |
| Chung, MH | 1 |
| Stern, SS | 1 |
| Foshag, LJ | 1 |
| Ramming, KP | 4 |
| Copur, S | 1 |
| Ledakis, P | 1 |
| Novinski, D | 1 |
| Mleczko, KL | 1 |
| Frankforter, S | 1 |
| Bolton, M | 1 |
| Fruehling, RM | 1 |
| VanWie, E | 1 |
| Norvell, M | 1 |
| Muhvic, J | 1 |
| Yamada, H | 8 |
| Shirota, Y | 4 |
| Hirayama, R | 2 |
| Lin, AD | 1 |
| Sun, HY | 1 |
| Qu, MW | 1 |
| Wang, FJ | 1 |
| Li, ZJ | 1 |
| Marsh, JC | 2 |
| Catalano, P | 1 |
| Graham, DL | 1 |
| Cornfeld, MJ | 1 |
| Miki, C | 2 |
| Ojima, E | 1 |
| Hatada, T | 1 |
| Salman, HS | 1 |
| Cynamon, J | 2 |
| Jagust, M | 1 |
| Bakal, C | 1 |
| Rozenblit, A | 2 |
| Kaleya, R | 2 |
| Negassa, A | 1 |
| Imasato, M | 1 |
| Okamura, J | 6 |
| Ebuchi, M | 13 |
| Takashima, I | 5 |
| Natsui, S | 1 |
| Shizawa, R | 1 |
| Nagahori, Y | 1 |
| Kumamoto, N | 1 |
| Hamaguchi, Y | 1 |
| Fukushima, T | 2 |
| Mogaki, M | 1 |
| Fukasawa, S | 1 |
| Kawahara, M | 1 |
| Nagahori, K | 1 |
| Hosoi, H | 1 |
| Ohara, T | 1 |
| Yasuda, D | 3 |
| Okamura, M | 1 |
| Natui, S | 1 |
| Nakazaki, H | 4 |
| Hasebe, Y | 3 |
| Takita, W | 3 |
| Seo, A | 2 |
| Takata, M | 1 |
| Teramoto, T | 5 |
| Hirano, K | 3 |
| Soma, I | 2 |
| Kanai, T | 4 |
| Fukuchi, N | 5 |
| Izawa, H | 2 |
| Sakita, I | 5 |
| Iizuka, N | 2 |
| Tangoku, A | 6 |
| Nakada, H | 7 |
| Ishizuka, N | 2 |
| Odaka, A | 4 |
| Hoshino, T | 4 |
| Murata, N | 4 |
| Fujito, T | 2 |
| Maeura, Y | 2 |
| Matsuyama, J | 2 |
| Hojo, S | 2 |
| Endo, W | 2 |
| Yukawa, M | 4 |
| Nakayama, T | 11 |
| Maruyama, N | 3 |
| Katsumoto, Y | 7 |
| Nakaguchi, K | 6 |
| Sue, F | 6 |
| Takemoto, H | 4 |
| Tsujino, T | 1 |
| Tujinaka, T | 1 |
| Nakajima, N | 8 |
| Matsuoka, S | 5 |
| Itoh, T | 4 |
| Maeda, Y | 8 |
| Osada, T | 4 |
| Sano, F | 2 |
| Schüll, B | 3 |
| Ulrich-Pur, H | 1 |
| Schmid, K | 1 |
| Raderer, M | 2 |
| Haider, K | 1 |
| Kwasny, W | 1 |
| Depisch, D | 2 |
| Schneeweiss, B | 2 |
| Lang, F | 2 |
| Kornek, GV | 4 |
| Schneider, T | 2 |
| Osl, F | 1 |
| Friess, T | 1 |
| Stockinger, H | 1 |
| Scheuer, WV | 1 |
| Seong, JS | 1 |
| Youn, YH | 1 |
| Moon, YM | 2 |
| Kamiyama, T | 6 |
| Matsushita, M | 8 |
| Kurauchi, N | 3 |
| Kamachi, H | 3 |
| Kondo, M | 13 |
| Ogata, T | 3 |
| Nishikawa, M | 1 |
| Todo, S | 3 |
| Arakawa, Y | 1 |
| Aiba, K | 2 |
| Watanabe, J | 1 |
| Okudaira, T | 1 |
| Seki, M | 2 |
| Honma, S | 1 |
| Iwasaki, Y | 15 |
| Yi, J | 2 |
| Liao, X | 2 |
| Barnett, KT | 1 |
| Malafa, MP | 1 |
| Hoffmann, T | 1 |
| Zanke, C | 2 |
| Hohl, H | 2 |
| Burg, H | 1 |
| Ehscheid, P | 1 |
| Schwindt, P | 1 |
| Adami, B | 2 |
| Schroeder, M | 3 |
| Klein, O | 4 |
| Baldus, M | 1 |
| Heike, M | 3 |
| Brown, TD | 4 |
| Schwinnen, I | 1 |
| Staib-Sebler, E | 7 |
| Gog, C | 4 |
| El-Ganainy, A | 1 |
| Gutt, C | 1 |
| Müller, HH | 9 |
| Nyati, MK | 1 |
| DeRemer, S | 1 |
| Parsels, J | 1 |
| Rehemtulla, A | 1 |
| Riedel, C | 3 |
| Brückl, W | 2 |
| Merkel, S | 1 |
| Ott, R | 3 |
| Hanke, B | 2 |
| Baum, U | 2 |
| Fuchs, F | 1 |
| Günther, K | 1 |
| Reck, T | 2 |
| Papadopoulos, T | 1 |
| Hoshida, Y | 3 |
| Otsuka, M | 3 |
| Kato, N | 3 |
| Shiratori, Y | 3 |
| Seki, N | 3 |
| Bonetti, A | 1 |
| Kerr, DJ | 13 |
| McArdle, CS | 15 |
| Taylor, I | 14 |
| Sherlock, DJ | 1 |
| Buckels, J | 2 |
| Mayer, D | 1 |
| Cain, D | 1 |
| Stephens, RJ | 1 |
| Janciauskiene, R | 1 |
| Juozaityte, E | 1 |
| Pavalkis, D | 1 |
| Shao, ZX | 1 |
| Cheng, ZG | 1 |
| Stoeltzing, O | 1 |
| Reinmuth, N | 1 |
| Parry, GC | 1 |
| Parikh, AA | 2 |
| McCarty, MF | 1 |
| Bucana, CD | 1 |
| Mazar, AP | 1 |
| Masci, G | 2 |
| Magagnoli, M | 2 |
| Zucali, PA | 2 |
| Castagna, L | 2 |
| Sarina, B | 1 |
| Pedicini, V | 2 |
| Fallini, M | 1 |
| Pulatov, DA | 2 |
| Durando, A | 1 |
| Garrone, O | 1 |
| Colozza, MA | 1 |
| Contu, A | 1 |
| Stevani, I | 1 |
| Genta, F | 1 |
| Bighin, C | 1 |
| Lambiase, A | 1 |
| Del Mastro, L | 1 |
| Goda, F | 3 |
| Yuste, AL | 2 |
| Segura, A | 1 |
| López-Tendero, P | 1 |
| Gironés, R | 1 |
| Pérez-Fidalgo, JA | 1 |
| Díaz, R | 1 |
| Calderero, V | 1 |
| Blair, SL | 1 |
| Grant, M | 1 |
| Chu, DZ | 1 |
| Cullinane, C | 1 |
| Dean, G | 1 |
| Sze, DY | 1 |
| Freeman, SM | 1 |
| Slonim, SM | 1 |
| Samuels, SL | 1 |
| Hicks, M | 1 |
| Ahrar, K | 1 |
| Gupta, S | 1 |
| Reid, TR | 1 |
| Proschek, D | 1 |
| Jauch, KW | 3 |
| Ridwelski, K | 6 |
| Gassel, HJ | 5 |
| Lehmann, U | 1 |
| Vestweber, KH | 1 |
| Padberg, W | 2 |
| Zamzow, K | 1 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 4 |
| Beerblock, K | 1 |
| Vaillant, JC | 2 |
| Cady, J | 1 |
| Maring, JG | 1 |
| Piersma, H | 1 |
| van Dalen, A | 1 |
| Groen, HJ | 1 |
| Uges, DR | 1 |
| De Vries, EG | 1 |
| Magnin, V | 1 |
| Moutardier, V | 2 |
| Giovannini, MH | 1 |
| Lelong, B | 2 |
| Giovannini, M | 3 |
| Viret, F | 3 |
| Monges, G | 2 |
| Bardou, VJ | 1 |
| Alzieu, C | 1 |
| Kamiyama, H | 1 |
| Miyazaki, K | 2 |
| Nagano, M | 1 |
| Suminaga, Y | 1 |
| Konishi, F | 1 |
| Hirai, R | 1 |
| Shimizu, N | 5 |
| Koinuma, K | 1 |
| Kaneko, Y | 1 |
| Malogolowkin, MH | 4 |
| Ortega, JA | 4 |
| Feusner, JH | 3 |
| Quinn, JJ | 4 |
| Newman, K | 3 |
| Haas, JE | 3 |
| Sensel, MG | 3 |
| Castleberry, RP | 3 |
| Dimitrakopoulou-Strauss, A | 5 |
| Strauss, LG | 10 |
| Rudi, J | 1 |
| Okamoto, N | 1 |
| Maruta, M | 2 |
| Takayanagi, N | 1 |
| Hirayama, Y | 1 |
| Sakamaki, S | 1 |
| Chiba, H | 2 |
| Oku, T | 4 |
| Huguet, E | 1 |
| Bismuth, H | 9 |
| Kelm, J | 1 |
| Ahlhelm, F | 1 |
| Weissenbach, P | 1 |
| Schliesing, P | 1 |
| Regitz, T | 1 |
| Deubel, G | 1 |
| Engel, C | 1 |
| Mazurchuk, R | 1 |
| Chaudhary, ND | 1 |
| Spernyak, J | 1 |
| Veith, J | 1 |
| Pera, P | 1 |
| Greco, W | 1 |
| Bernacki, RJ | 1 |
| Burmeister, BH | 1 |
| Schache, D | 1 |
| Burmeister, EA | 1 |
| Bell, A | 1 |
| Poulsen, MG | 1 |
| Mackintosh, J | 1 |
| Brooks, A | 1 |
| Clingan, P | 3 |
| Morris, D | 1 |
| Dahm, F | 1 |
| Selzner, N | 1 |
| Selzner, M | 1 |
| Komorizono, Y | 1 |
| Kohara, K | 1 |
| Oketani, M | 1 |
| Maeda, M | 4 |
| Shibathou, T | 1 |
| Shigenobu, S | 1 |
| Hiramine, Y | 1 |
| Yamasaki, N | 1 |
| Arima, T | 3 |
| Kazuaki, I | 1 |
| Yang, LY | 2 |
| Yi, TB | 2 |
| Yang, JQ | 1 |
| Sakurai, M | 1 |
| Yonemura, Y | 3 |
| Usuki, H | 2 |
| Ishimura, K | 1 |
| Yachida, S | 1 |
| Hagiike, M | 1 |
| Okano, K | 3 |
| Izuishi, K | 1 |
| Karasawa, Y | 1 |
| Maeta, H | 2 |
| Terashima, M | 4 |
| Irinoda, T | 1 |
| Nakaya, T | 1 |
| Yonezawa, H | 1 |
| Kanzaki, N | 1 |
| Ohtani, S | 1 |
| Kogure, M | 1 |
| Gotoh, M | 5 |
| Fusai, G | 1 |
| Davidson, BR | 2 |
| Shibata, T | 4 |
| Kikuchi, R | 1 |
| Oka, Y | 2 |
| Toyoda, H | 5 |
| Okada, S | 4 |
| Uchida, Y | 3 |
| Fallik, D | 1 |
| Jacob, J | 1 |
| Colin, P | 1 |
| Baulieux, J | 1 |
| Couzigou, P | 1 |
| Mahjoubi, R | 1 |
| Mahjoubi, M | 1 |
| Morenghi, E | 2 |
| Carola, E | 2 |
| Gilles-Amar, V | 1 |
| Krulik, M | 3 |
| Oman, M | 1 |
| Blind, PJ | 1 |
| Lindnér, P | 2 |
| Gustavsson, B | 10 |
| Uygur-Bayramiçli, O | 1 |
| Gemici, C | 1 |
| Kawabata, H | 1 |
| Takase, I | 1 |
| Nakajima, H | 2 |
| Kwiatkowski, F | 1 |
| Chevalier, V | 1 |
| Chevrier, R | 1 |
| Richard, D | 1 |
| Cure, H | 2 |
| Chollet, P | 1 |
| Rásó, E | 1 |
| Paku, S | 1 |
| Kopper, L | 1 |
| Tímár, J | 1 |
| Yan, DB | 1 |
| Klomp, DW | 3 |
| Van Laarhoven, HW | 4 |
| Kentgens, AP | 1 |
| Heerschap, A | 4 |
| Tokunaga, T | 1 |
| Sumimura, J | 1 |
| Yoshidome, K | 1 |
| Tsuboyama, N | 1 |
| Nagai, I | 1 |
| Yang, FC | 1 |
| Zheng, SS | 1 |
| Li, MW | 1 |
| Zeng, QL | 1 |
| Jiang, GP | 1 |
| Xie, HY | 1 |
| Zhai, L | 1 |
| Xing, L | 1 |
| He, YC | 1 |
| Pan, DY | 2 |
| Qiao, JG | 2 |
| Nanashima, A | 1 |
| Yamaguchi, H | 3 |
| Shibasaki, S | 1 |
| Morino, S | 1 |
| Yoshinaga, M | 1 |
| Nakagoe, T | 2 |
| Ayabe, H | 2 |
| Goloshchapov, RS | 1 |
| Kokov, LS | 1 |
| Vishnevskiĭ, VA | 1 |
| Ionkin, DA | 1 |
| Elagina, LV | 1 |
| Ichihara, T | 1 |
| Tenma, K | 1 |
| Itoh, M | 3 |
| Hibino, M | 1 |
| Kikuchi, I | 1 |
| Hosono, Y | 3 |
| Nomura, K | 1 |
| Oota, H | 2 |
| Kamimura, T | 4 |
| Kokufu, I | 2 |
| Tanei, T | 1 |
| Yano, T | 2 |
| Yamada, K | 4 |
| Flieger, D | 1 |
| Keller, R | 1 |
| Kaji, R | 1 |
| Tateishi, I | 1 |
| Nagata, E | 1 |
| Okabe, Y | 1 |
| Alimonti, A | 2 |
| Ferretti, G | 3 |
| Di Cosimo, S | 1 |
| Vecchione, A | 1 |
| Miyake, H | 2 |
| Takagi, T | 3 |
| Takamura, K | 1 |
| Tashiro, S | 3 |
| Mathonnet, M | 1 |
| Fermeaux, V | 1 |
| Teramoto, K | 1 |
| Kawamura, T | 2 |
| Mori, A | 1 |
| DAO, TL | 1 |
| GRINBERG, R | 1 |
| REED, ML | 1 |
| KUIPERS, FM | 1 |
| VAITKEVICIUS, VK | 6 |
| CLARK, MD | 1 |
| DRAKE, EH | 3 |
| EYLER, WR | 1 |
| BRENNAN, MJ | 1 |
| TALLEY, RW | 2 |
| POZNANSKI, AK | 1 |
| BRUSH, BE | 1 |
| SULLIVAN, RD | 3 |
| NORCROSS, JW | 1 |
| WATKINS, E | 2 |
| BOOTH, BA | 1 |
| SARTORELLI, AC | 1 |
| ANSFIELD, FJ | 12 |
| CURRERI, AR | 4 |
| FLETCHER, WS | 7 |
| CHANDLER, JJ | 1 |
| DONALDSON, SS | 1 |
| MCBRIDE, TJ | 1 |
| NOBLE, LC | 1 |
| CARR, MA | 1 |
| HULL, K | 1 |
| OLESON, JJ | 1 |
| SHERLOCK, P | 2 |
| KABAKOW, B | 1 |
| ALBAUM, H | 1 |
| ANTOPOL, W | 1 |
| BLINICK, G | 1 |
| SUSSMAN, L | 1 |
| GINZBURG, L | 1 |
| GREENSPAN, EM | 1 |
| HELSPER, JT | 2 |
| DEMOSS, EV | 1 |
| CAMMACK, KV | 1 |
| LINDEBOOM, GA | 1 |
| ROUSSELOT, LM | 3 |
| GROSSI, CE | 3 |
| SLATTERY, J | 2 |
| ROSSI, P | 2 |
| CONTE, AJ | 2 |
| RUZICKA, FF | 2 |
| PRYTZ, B | 1 |
| MORSE, PA | 1 |
| POTTER, VR | 1 |
| Zelek, L | 1 |
| Bugat, R | 4 |
| Ganem, G | 1 |
| Valleur, P | 1 |
| Dupuis, O | 1 |
| Aziza, T | 1 |
| Fagniez, PL | 1 |
| Auroux, J | 1 |
| Kobeiter, H | 1 |
| Tayar, C | 1 |
| Braud, AC | 1 |
| Haddad, E | 2 |
| Piolot, A | 1 |
| Buyse, M | 6 |
| Piedbois, P | 5 |
| Thomas, RR | 1 |
| Schramm, H | 4 |
| Hauss, J | 2 |
| Schäfer, H | 1 |
| Futamura, N | 1 |
| Matsutomo, M | 1 |
| Yasumura, M | 1 |
| Tateyama, K | 1 |
| Ishikawa, K | 5 |
| Makuuchi, H | 9 |
| Murayama, C | 3 |
| Tajima, T | 8 |
| Nagao, M | 1 |
| Takasaka, H | 1 |
| Nishikawa, N | 1 |
| Matsunaga, N | 2 |
| Akazawa, S | 2 |
| Yamashina, T | 1 |
| Nakazima, T | 1 |
| Sakurai, T | 1 |
| Kotake, K | 2 |
| Stippel, DL | 1 |
| Töx, U | 1 |
| Gossmann, A | 1 |
| Beckurts, KT | 1 |
| Hölscher, AH | 1 |
| Omura, K | 1 |
| Nakayama, K | 2 |
| Itou, T | 1 |
| Abe, N | 1 |
| Yoshizaki, N | 2 |
| Sumiyoshi, T | 2 |
| Ohira, N | 1 |
| Nishihori, Y | 1 |
| Ohi, M | 1 |
| Kondo, H | 3 |
| Huo, YC | 1 |
| Zhou, YK | 1 |
| Shi, HA | 1 |
| Masutani, S | 9 |
| Tatsuta, M | 5 |
| Masuda, F | 1 |
| Tomotsu, K | 3 |
| Yura, M | 2 |
| Obana, T | 1 |
| Kitamura, S | 2 |
| Saeki, N | 2 |
| Takamura, M | 2 |
| Fuchimoto, S | 2 |
| Sakata, T | 1 |
| Nakanishi, K | 2 |
| Shirakawa, K | 1 |
| Itoyama, S | 1 |
| Takeno, A | 1 |
| Tsujinaka, T | 10 |
| Kashiwazaki, M | 3 |
| Sawamura, T | 5 |
| Watayo, T | 1 |
| Nakata, H | 1 |
| Kito, A | 1 |
| Kunihiro, O | 2 |
| Kosaka, K | 1 |
| Nishihara, T | 2 |
| Tsujie, M | 5 |
| Ohshima, S | 2 |
| Naoi, Y | 4 |
| Danno, M | 1 |
| Shinoura, H | 1 |
| Maruyama, KT | 1 |
| Nagai, K | 4 |
| Ishigami, H | 1 |
| Handa, R | 3 |
| Nishisyo, I | 1 |
| Tamesa, T | 4 |
| Takemoto, N | 1 |
| Cattel, L | 1 |
| La Grotta, G | 2 |
| Infante, L | 1 |
| Passera, R | 1 |
| Arpicco, S | 1 |
| Brusa, P | 1 |
| Bumma, C | 1 |
| Bezulier, K | 1 |
| Fina, F | 1 |
| Roussel, M | 1 |
| Ciccolini, J | 2 |
| Martin, PM | 1 |
| Aubert, C | 2 |
| Barra, Y | 1 |
| Kamm, YJ | 2 |
| Siegelmann-Danieli, N | 1 |
| Stein, M | 2 |
| Bar-Ziv, J | 1 |
| Takada, T | 4 |
| Saito, E | 1 |
| Hiraide, Y | 1 |
| Maeda, H | 1 |
| Ishida, M | 6 |
| Hirose, K | 1 |
| Tachimori, A | 1 |
| Seki, S | 1 |
| Coleman, TA | 1 |
| Redger, CD | 1 |
| Hamill, RL | 1 |
| Dainer, P | 1 |
| Lai, YC | 1 |
| Shih, CY | 1 |
| Jeng, CM | 1 |
| Yang, SS | 1 |
| Hu, JT | 1 |
| Sung, YC | 1 |
| Liu, HT | 1 |
| Hou, SM | 1 |
| Wu, CH | 2 |
| Chen, TK | 1 |
| Antón, A | 2 |
| Massutti, B | 1 |
| Fenández-Martos, C | 1 |
| Gallén, M | 1 |
| Huarte, L | 1 |
| Balcells, M | 1 |
| Wu, TT | 1 |
| Kogure, T | 1 |
| Ueno, Y | 1 |
| Shimosegawa, T | 1 |
| Du, QY | 1 |
| Wang, SQ | 2 |
| Li, YX | 1 |
| Lin, ZB | 1 |
| Tan, HR | 1 |
| Furusawa, J | 1 |
| Mizumati, T | 1 |
| Iizuka, K | 1 |
| Yamaki, T | 3 |
| Yasuda, M | 2 |
| Li, JT | 1 |
| Ou, QJ | 1 |
| Wu, YC | 1 |
| Kawashima, R | 1 |
| Haisa, M | 1 |
| Uetsuka, H | 2 |
| Gunduz, M | 1 |
| Nagai, N | 1 |
| Saitoh, T | 2 |
| Fujio, N | 2 |
| Tsukazaki, T | 2 |
| Terakura, M | 1 |
| Mayumi, K | 1 |
| Koyama, I | 2 |
| Tsukazaki, Y | 2 |
| Osugi, H | 2 |
| Calvo, FA | 1 |
| Domper, M | 1 |
| Matute, R | 1 |
| Martínez-Lázaro, R | 1 |
| Arranz, JA | 1 |
| Desco, M | 1 |
| Alvarez, E | 1 |
| Carreras, JL | 1 |
| Fakih, M | 1 |
| Wang, TL | 1 |
| Diaz, LA | 1 |
| Romans, K | 1 |
| Bardelli, A | 1 |
| Saha, S | 1 |
| Galizia, G | 1 |
| Choti, M | 1 |
| Donehower, R | 1 |
| Parmigiani, G | 1 |
| Shih, IeM | 1 |
| Kinzler, KW | 1 |
| Vogelstein, B | 1 |
| Lengauer, C | 1 |
| Velculescu, VE | 1 |
| Choi, EA | 1 |
| Lei, H | 1 |
| Maron, DJ | 1 |
| Mick, R | 1 |
| Barsoum, J | 1 |
| Yu, QC | 1 |
| Wilson, JM | 1 |
| Spitz, FR | 1 |
| Woo, IS | 1 |
| Kang, JH | 3 |
| Lee, KS | 2 |
| Kubota, T | 3 |
| Sekido, H | 1 |
| Ould-Kaci, M | 1 |
| Breau, JL | 2 |
| Morvan, F | 1 |
| Cvitkovic, E | 2 |
| Schuell, B | 1 |
| Laengle, F | 1 |
| Penz, M | 1 |
| Karall, K | 1 |
| Emura, T | 1 |
| Murakami, Y | 1 |
| Nakagawa, F | 1 |
| Kitazato, K | 1 |
| Mitachi, Y | 1 |
| Yamamitsu, S | 5 |
| Shirasaka, T | 7 |
| Seeliger, H | 1 |
| Guba, M | 1 |
| Koehl, GE | 1 |
| Doenecke, A | 1 |
| Steinbauer, M | 1 |
| Bruns, CJ | 2 |
| Wagner, C | 1 |
| Frank, E | 1 |
| Geissler, EK | 1 |
| van den Bergh, EJ | 1 |
| Wagener, DJ | 2 |
| Qiu, F | 1 |
| Tsuchida, A | 7 |
| Hayashida, Y | 1 |
| Tamura, K | 3 |
| Kawakita, H | 1 |
| Kubouchi, T | 1 |
| Kinoshita, M | 1 |
| Kataba, Y | 1 |
| Morishita, Y | 3 |
| Kasakura, Y | 1 |
| Yagyu, T | 6 |
| Nakamura, E | 1 |
| Nozaki, H | 2 |
| Niida, M | 1 |
| Yasuoka, H | 1 |
| Nishimoto, Y | 1 |
| Watanabe, Y | 7 |
| Syouda, S | 1 |
| Kouno, T | 2 |
| Fukuhara, A | 1 |
| De Ridder, L | 1 |
| Slegers, G | 1 |
| De Gelder, V | 1 |
| Dierckx, RA | 1 |
| Thierens, H | 1 |
| Machiavelli, MR | 1 |
| Salum, G | 1 |
| Pérez, JE | 1 |
| Ortiz, EH | 1 |
| Romero, AO | 1 |
| Bologna, F | 1 |
| Vallejo, CT | 1 |
| Lacava, JA | 1 |
| Dominguez, ME | 1 |
| Leone, BA | 1 |
| Inokuchi, M | 1 |
| Tajima, M | 1 |
| van Etten, B | 1 |
| Hillenbrand, A | 1 |
| Sander, S | 1 |
| Salonga, D | 3 |
| Danenberg, K | 1 |
| Danenberg, P | 1 |
| Seelig, MH | 1 |
| Leible, M | 1 |
| Sänger, J | 1 |
| Berger, MR | 2 |
| Xiao, YS | 2 |
| Wu, ZQ | 1 |
| Sun, QM | 1 |
| Xue, Q | 1 |
| Liu, YK | 2 |
| Ganten, TM | 1 |
| Haas, TL | 1 |
| Sykora, J | 1 |
| Stahl, H | 1 |
| Sprick, MR | 1 |
| Fas, SC | 1 |
| Krueger, A | 1 |
| Weigand, MA | 1 |
| Grosse-Wilde, A | 1 |
| Stremmel, W | 2 |
| Krammer, PH | 2 |
| Walczak, H | 1 |
| Ho, HS | 1 |
| Ong, HS | 1 |
| Katsumata, K | 3 |
| Ichimiya, H | 1 |
| Wakana, Y | 1 |
| Taguchi, T | 3 |
| Li, SY | 1 |
| Yu, B | 1 |
| An, P | 1 |
| Wei, JC | 1 |
| Zuo, FY | 1 |
| Cai, HY | 1 |
| Quirino, M | 1 |
| Schinzari, G | 2 |
| Trigila, N | 2 |
| Oechsle, K | 1 |
| Reis, HE | 1 |
| Haag, C | 2 |
| Niederle, N | 2 |
| Wilke, HJ | 2 |
| Pflüger, KH | 1 |
| Batran, SA | 1 |
| Büchele, T | 1 |
| Chang, HK | 1 |
| Liau, CT | 1 |
| Chang, WC | 1 |
| Gil-Delgado, MA | 1 |
| Bastian, G | 1 |
| Guinet, F | 1 |
| Taillibert, S | 1 |
| Rocher, MA | 1 |
| Urien, S | 1 |
| Khayat, D | 3 |
| Kumada, T | 5 |
| Sone, Y | 5 |
| Kiriyama, S | 4 |
| Tanikawa, M | 1 |
| Hisanaga, Y | 1 |
| Kuzuya, T | 1 |
| Nonogaki, K | 1 |
| Yamauti, T | 1 |
| Kawase, N | 1 |
| Suganuma, T | 1 |
| Terauchi, R | 1 |
| Shikina, A | 1 |
| Aozasa, S | 1 |
| Utsunomiya, K | 1 |
| Fujino, K | 1 |
| Hase, K | 1 |
| Ghielmini, M | 1 |
| Martinoli, S | 4 |
| Goldhirsch, A | 1 |
| Lim, KH | 1 |
| Huang, MJ | 1 |
| Su, YW | 1 |
| Chang, YF | 1 |
| Lin, J | 1 |
| Chang, MC | 1 |
| Hsieh, RK | 3 |
| Penland, SK | 1 |
| Venook, A | 1 |
| Correale, P | 1 |
| Cerretani, D | 1 |
| Clerici, M | 1 |
| Messinese, S | 1 |
| Marsili, S | 1 |
| Petrioli, R | 1 |
| Cetta, F | 1 |
| Savelli, V | 1 |
| Guarnieri, A | 1 |
| Pinto, E | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Homma, H | 4 |
| Akiyama, T | 4 |
| Mezawa, S | 3 |
| Machida, T | 3 |
| Simizu, M | 1 |
| Matsukura, S | 1 |
| Samejima, R | 1 |
| Hidaka, K | 2 |
| Ema, T | 1 |
| Katayanagi, S | 3 |
| Chang, UI | 2 |
| Nam, SW | 2 |
| Mok, TS | 5 |
| Leung, TW | 7 |
| Moyses, C | 1 |
| Chan, AT | 7 |
| Yeo, W | 7 |
| Wong, H | 1 |
| Chak, K | 1 |
| Johnson, P | 1 |
| Henry, S | 1 |
| Machiels, JP | 3 |
| Baurain, JF | 2 |
| Duck, L | 2 |
| Sutherland, F | 1 |
| Walley, B | 1 |
| Ruether, D | 1 |
| Barber, FD | 1 |
| Mavligit, G | 2 |
| El-Saadani, MA | 1 |
| Teufel, A | 1 |
| Steinmann, S | 1 |
| Siebler, J | 1 |
| Höhler, T | 1 |
| Kershaw, MH | 1 |
| Jackson, JT | 1 |
| Haynes, NM | 1 |
| Teng, MW | 1 |
| Moeller, M | 1 |
| Hayakawa, Y | 2 |
| Street, SE | 1 |
| Cameron, R | 1 |
| Tanner, JE | 1 |
| Trapani, JA | 1 |
| Smyth, MJ | 1 |
| Darcy, PK | 1 |
| Hill, ME | 1 |
| Ross, PJ | 4 |
| Tebbutt, N | 1 |
| Oates, J | 2 |
| Shellito, P | 1 |
| Loibl, S | 1 |
| von Minckwitz, G | 1 |
| Schwedler, K | 1 |
| Schmidt, KA | 1 |
| Höper, D | 1 |
| Costa, SD | 1 |
| Munakata, M | 4 |
| Nozaki, T | 1 |
| Kawamura, S | 1 |
| Sawamura, N | 1 |
| Hiraga, H | 1 |
| Aguayo, A | 2 |
| Nooka, AK | 1 |
| Schnirer, II | 1 |
| Wolff, RA | 2 |
| Charnsangavej, C | 3 |
| Carlo, WF | 1 |
| Hummer, AJ | 1 |
| Sullivan, D | 2 |
| Oberfield, RA | 10 |
| Sampson, E | 1 |
| Heatley, GJ | 1 |
| Hotta, T | 1 |
| Johata, K | 1 |
| Sahara, M | 1 |
| Naka, T | 1 |
| Ochiai, M | 1 |
| Tanimura, H | 1 |
| Tsubota, YT | 1 |
| Polemonivi, N | 1 |
| O'Leary, E | 1 |
| Lloyd, TD | 1 |
| Dennison, AR | 1 |
| Miersch, A | 1 |
| Warschewske, G | 1 |
| Teichgräber, U | 1 |
| Lopez Hänninen, E | 1 |
| Felix, R | 1 |
| Hamada, A | 1 |
| Yamakado, K | 2 |
| Takaki, H | 2 |
| Akeboshi, M | 1 |
| Harting, MT | 1 |
| Blakely, ML | 1 |
| Herzog, CE | 1 |
| Lally, KP | 1 |
| Andrassy, RJ | 1 |
| Jiang, ZF | 1 |
| Song, ST | 1 |
| Zhang, SH | 1 |
| Yu, JX | 1 |
| Song, SY | 2 |
| Lee, SI | 1 |
| Noh, SH | 1 |
| Park, JN | 1 |
| Han, JY | 1 |
| Zaucha, R | 1 |
| Sosińska-Mielcarek, K | 1 |
| Tominaga, K | 1 |
| Okazaki, H | 1 |
| Suto, R | 1 |
| Hamaguchi, M | 1 |
| Sasaki, E | 1 |
| Shiba, M | 1 |
| Oshitani, N | 1 |
| Arakawa, T | 1 |
| Harada, O | 1 |
| Sasamoto, M | 1 |
| Shimaya, S | 1 |
| Nakagawa, M | 2 |
| Morinaga, H | 2 |
| Yamane, T | 1 |
| Egami, H | 2 |
| Kanayama, T | 2 |
| Ishimaru, S | 1 |
| Aozasa, K | 1 |
| Waters, JS | 1 |
| Topham, C | 1 |
| Middleton, G | 1 |
| Hill, M | 1 |
| Katopodis, R | 1 |
| Stewart, G | 1 |
| Oates, JR | 1 |
| Wu, SL | 1 |
| Sun, ZJ | 1 |
| Meng, KW | 1 |
| Qin, XL | 1 |
| Pan, CE | 1 |
| Guglielmi, A | 2 |
| Pella, N | 1 |
| Belvedere, O | 1 |
| Grossi, F | 2 |
| Frontini, L | 1 |
| Puglisi, F | 2 |
| Delvart, V | 2 |
| Pascal, G | 2 |
| Valeanu, A | 1 |
| Ghémard, O | 1 |
| Takada, K | 4 |
| Ishiwatari, H | 1 |
| Kogawa, T | 1 |
| Kurokawa, Y | 3 |
| Matoba, R | 1 |
| Ueno, N | 2 |
| Ishii, S | 1 |
| Nakayama, S | 1 |
| Kawase, Y | 1 |
| Nakao, A | 5 |
| Kawabe, T | 1 |
| Van Hazel, G | 2 |
| Blackwell, A | 1 |
| Anderson, J | 1 |
| Moroz, P | 1 |
| Bower, G | 2 |
| Cardaci, G | 1 |
| Gray, B | 3 |
| Tanimoto, K | 1 |
| Shimokuni, T | 1 |
| Ukon, K | 1 |
| Tsujimoto, H | 1 |
| Kawahara, K | 2 |
| Hiyama, K | 1 |
| Jin, CD | 1 |
| Kishin, R | 1 |
| Xing, X | 1 |
| Nikkuni, K | 1 |
| Nishimura, A | 6 |
| Bonnen, M | 1 |
| Crane, C | 1 |
| Skibber, J | 2 |
| Delclos, ME | 1 |
| Rodriguez-Bigas, M | 2 |
| Wong, A | 1 |
| Janjan, NA | 2 |
| Feig, BW | 1 |
| Lam, KC | 3 |
| Zee, B | 3 |
| Chan, PS | 1 |
| Mo, FK | 3 |
| Ho, WM | 4 |
| Wong, WL | 1 |
| Johnson, PJ | 6 |
| Goel, R | 2 |
| Chouinard, E | 1 |
| Stewart, DJ | 1 |
| Huan, S | 1 |
| Hirte, H | 1 |
| Stafford, S | 1 |
| Waterfield, B | 1 |
| Roach, J | 1 |
| Lathia, C | 1 |
| Agarwal, V | 1 |
| Humphrey, R | 1 |
| Walsh, W | 1 |
| Matthews, S | 1 |
| Seymour, L | 1 |
| Mochizuki, R | 1 |
| Gunji, Y | 2 |
| Miyazaki, S | 2 |
| Miyauchi, H | 1 |
| Chiba, S | 1 |
| Ohchi, T | 2 |
| Kikuchi, N | 1 |
| Ishimoto, T | 1 |
| Muranaka, T | 1 |
| Iwamoto, A | 1 |
| Tagi, T | 1 |
| Tamai, H | 1 |
| Yamagishi, H | 6 |
| Aoyagi, K | 2 |
| Koufuji, K | 2 |
| Yano, S | 4 |
| Miyagi, M | 1 |
| Imaizumi, T | 2 |
| Takeda, J | 2 |
| Niinobu, T | 6 |
| Kotobuki, T | 1 |
| Kawai, M | 3 |
| Matsumoto, G | 1 |
| Tsuruta, K | 1 |
| Ashikawa, K | 1 |
| Katayama, M | 1 |
| Noda, S | 3 |
| Hanai, A | 3 |
| Imaizumi, H | 1 |
| Kamei, K | 2 |
| Usami, K | 1 |
| Takashima, S | 6 |
| Ohbu, M | 1 |
| Tokuoka, M | 1 |
| Masuda, N | 2 |
| Araki, Y | 1 |
| Kikuchi, S | 3 |
| Sakakura, C | 3 |
| Inaba, S | 1 |
| Itoi, H | 1 |
| Mitsuishi, Y | 1 |
| Kishida, T | 1 |
| Koshino, T | 3 |
| Izumiyama, K | 3 |
| Damdinsuren, B | 9 |
| Li, HH | 1 |
| Duan, ZH | 1 |
| Zhang, HW | 1 |
| Sun, F | 1 |
| Chen, AJ | 1 |
| Hu, MD | 1 |
| Ran, JH | 1 |
| Tang, JH | 1 |
| Yie, SL | 1 |
| Gory-Delabaere, G | 1 |
| Bosquet, L | 1 |
| Bécouarn, Y | 2 |
| Chen, YB | 1 |
| Guan, YX | 1 |
| Zhan, YQ | 1 |
| Sun, XW | 1 |
| Li, YF | 1 |
| Xu, DZ | 1 |
| Schneeweiss, A | 1 |
| de Rossi, T | 1 |
| Bastert, G | 1 |
| Yagita, H | 1 |
| Zhou, JX | 1 |
| Hong, GB | 1 |
| Xu, LY | 1 |
| Xu, LF | 1 |
| Chen, YT | 1 |
| Jiang, RJ | 1 |
| Luo, JH | 1 |
| Feng, JF | 1 |
| Lu, JW | 1 |
| Kwon, KM | 2 |
| Park, KS | 2 |
| Cho, KB | 2 |
| Kim, GC | 2 |
| Nakata, S | 2 |
| Tomoda, K | 3 |
| Taguchi, K | 1 |
| Kamiyama, N | 1 |
| Khor, LW | 1 |
| Abumiya, K | 1 |
| Takezako, Y | 1 |
| Liu, JM | 2 |
| Wu, CW | 2 |
| Lan, C | 1 |
| Chung, TR | 1 |
| Lee, KD | 1 |
| Liu, TW | 2 |
| Peng, JW | 1 |
| Hitre, E | 1 |
| Wang, HE | 1 |
| Wu, HC | 1 |
| Kao, SJ | 1 |
| Tseng, FW | 1 |
| Wang, YS | 1 |
| Yu, HM | 1 |
| Chou, SL | 1 |
| Yen, SH | 2 |
| Chi, KH | 2 |
| Matsuda, M | 5 |
| Amemiya, H | 1 |
| Kono, H | 1 |
| Chang, MS | 1 |
| Izawa, S | 1 |
| Furuya, S | 1 |
| Takano, A | 1 |
| Hirohashi, Y | 2 |
| Sumi, K | 1 |
| Matsuyama, S | 1 |
| Sargent, DJ | 2 |
| Green, E | 1 |
| Krook, J | 1 |
| Fuchs, C | 3 |
| Ramanathan, RK | 1 |
| Williamson, SK | 1 |
| Morton, RF | 1 |
| Findlay, BP | 1 |
| Ishizu, K | 2 |
| Gohongi, T | 1 |
| Tokuuye, K | 1 |
| Nakai, R | 1 |
| Gunji, N | 1 |
| Akine, Y | 1 |
| Orii, K | 1 |
| Kurokawa, F | 1 |
| Aoyama, K | 1 |
| Tajima, K | 2 |
| Omori, K | 1 |
| Okita, K | 1 |
| Dou, J | 1 |
| Kai, S | 2 |
| Hirano, S | 1 |
| Ohta, M | 3 |
| Hiraoka, N | 1 |
| Hwang, JY | 1 |
| Lentz, F | 1 |
| Tran, A | 1 |
| Rey, E | 1 |
| Pons, G | 1 |
| Tréluyer, JM | 1 |
| Mei, JF | 1 |
| Shao, ZJ | 1 |
| He, ZM | 1 |
| Zhou, W | 1 |
| Sangha, S | 1 |
| Albert, A | 1 |
| Chang, AJ | 1 |
| Liu, TC | 1 |
| Wolfe, MM | 1 |
| Sekikawa, K | 2 |
| Ohki, S | 5 |
| Ohshima, T | 1 |
| Kanazawa, M | 1 |
| Takenoshita, S | 2 |
| Kuhara, H | 1 |
| Uemura, K | 1 |
| Ocker, M | 1 |
| Alajati, A | 1 |
| Ganslmayer, M | 1 |
| Zopf, S | 1 |
| Lüders, M | 1 |
| Neureiter, D | 1 |
| Schuppan, D | 1 |
| Herold, C | 1 |
| Sheng, Z | 1 |
| Ruan, YB | 1 |
| Guang, Y | 1 |
| Yang, ML | 1 |
| Landi, E | 1 |
| Feng, YL | 2 |
| Zhu, DZ | 1 |
| Yu, CQ | 1 |
| Ma, LW | 1 |
| Song, SB | 1 |
| Xiu, DR | 1 |
| Wang, JJ | 1 |
| Yang, XX | 1 |
| Jia, YM | 1 |
| Lin, CP | 1 |
| Lo, GH | 1 |
| Lin, CK | 1 |
| Chen, HH | 1 |
| Lo, CC | 1 |
| Tseng, HH | 1 |
| Ueki, K | 1 |
| Ishizuka, D | 1 |
| Wakakuwa, R | 1 |
| Sumitsuzi, A | 1 |
| Kamohara, H | 1 |
| Kuwahara, N | 1 |
| Hirota, T | 1 |
| Seium, Y | 1 |
| Stupp, R | 1 |
| Ruhstaller, T | 1 |
| Philippe, M | 1 |
| Allal, A | 1 |
| Trembleau, C | 1 |
| Bauer, J | 1 |
| Morant, R | 1 |
| Roth, AD | 3 |
| Fang, GE | 1 |
| Bi, JW | 1 |
| Shen, XJ | 1 |
| Nie, MM | 1 |
| Xue, XC | 1 |
| Hua, JD | 1 |
| Yin, XY | 3 |
| Lü, MD | 2 |
| Liang, LJ | 3 |
| Lai, JM | 1 |
| Li, DM | 2 |
| Kuang, M | 1 |
| Shiraki, K | 1 |
| Yamanaka, Y | 1 |
| Nakano, T | 1 |
| Ji, SH | 1 |
| Lim, DH | 1 |
| Park, BB | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Park, K | 1 |
| Hummer, A | 1 |
| Drobnjak, M | 1 |
| Motwani, M | 1 |
| Cordon-Cardo, C | 1 |
| Schwartz, GK | 1 |
| Brivio, F | 1 |
| Fumagalli, L | 1 |
| Fattori, L | 1 |
| Nespoli, L | 1 |
| Denova, M | 1 |
| Sargenti, E | 1 |
| Nespoli, A | 1 |
| Shimonov, M | 1 |
| Hayat, H | 1 |
| Chaitchik, S | 2 |
| Brener, J | 1 |
| Schachter, P | 1 |
| Czerniak, A | 1 |
| Comella, P | 1 |
| Massidda, B | 1 |
| Palmeri, S | 2 |
| Farris, A | 3 |
| Lucia, LD | 1 |
| Natale, D | 1 |
| Maiorino, L | 1 |
| Tafuto, S | 1 |
| Cataldis, GD | 1 |
| Casaretti, R | 1 |
| Kountouras, J | 1 |
| Zavos, C | 1 |
| Chatzopoulos, D | 1 |
| Cao, XW | 1 |
| Fu, ZR | 1 |
| Ding, GS | 1 |
| Lin, RX | 1 |
| Tuo, CW | 1 |
| Lü, QJ | 1 |
| Haruno, M | 2 |
| Shimamura, R | 1 |
| Ogawa, Y | 4 |
| Sakai, K | 3 |
| Fernandez, FG | 1 |
| Ritter, J | 1 |
| Goodwin, JW | 1 |
| Linehan, DC | 2 |
| Hawkins, WG | 2 |
| Hillemann, A | 1 |
| Brandenburg, B | 1 |
| Schmidt, U | 1 |
| Roos, M | 1 |
| Smirnow, I | 1 |
| Hildt, E | 1 |
| Gebbia, V | 2 |
| Paoletti, G | 2 |
| Borsellino, N | 1 |
| Cartenì, G | 1 |
| Pezzella, G | 1 |
| Romito, S | 1 |
| Inokuchi, K | 5 |
| Takeuchi, T | 1 |
| Zheng, JF | 1 |
| Wang, HD | 1 |
| Hishinuma, S | 2 |
| Tomikawa, M | 1 |
| Ozawa, I | 1 |
| Katano, S | 1 |
| Tsukiyama, I | 1 |
| Niguma, T | 1 |
| Mimura, T | 1 |
| Tutui, N | 1 |
| Di Battista, M | 1 |
| Qin, B | 2 |
| Mitsugi, K | 4 |
| Kuroiwa, T | 1 |
| Harada, M | 1 |
| Morse, M | 1 |
| Leonard, G | 1 |
| Blumgart, L | 2 |
| Laplanche, A | 1 |
| Lasser, P | 8 |
| Quenet, F | 2 |
| Jacob, JH | 1 |
| Delperro, JR | 1 |
| Luboinski, M | 1 |
| Faynsod, M | 1 |
| Wagman, LD | 2 |
| Longmate, J | 1 |
| Carroll, M | 1 |
| Yu, YL | 1 |
| Ji, MF | 1 |
| He, JB | 1 |
| Li, XL | 1 |
| Kawakami, H | 1 |
| Uno, T | 1 |
| Isobe, K | 1 |
| Aruga, T | 1 |
| Sudo, K | 1 |
| Saisho, H | 3 |
| Kawata, T | 1 |
| Bertè, R | 1 |
| Bidin, L | 1 |
| Civardi, G | 1 |
| Lazzaro, A | 1 |
| Moroni, CF | 1 |
| Palladino, MA | 1 |
| Rodinò, C | 1 |
| Vallisa, D | 1 |
| Choti, MA | 2 |
| Dilawari, RA | 1 |
| Enke, CA | 1 |
| Kiel, K | 1 |
| Knol, JA | 2 |
| Ludwig, KA | 1 |
| Martin, EW | 2 |
| Yeatman, TJ | 1 |
| Chiba, N | 1 |
| Sakayori, M | 1 |
| Kakudo, Y | 1 |
| Yamaura, G | 1 |
| Ishioka, C | 1 |
| Takeo, Y | 1 |
| Hanyu, F | 1 |
| Kawashima, K | 1 |
| Ikai, I | 1 |
| Shimahara, Y | 1 |
| Katoh, K | 1 |
| Kuroda, T | 5 |
| Nakasato, T | 1 |
| Satoh, C | 1 |
| Ohtsuka, K | 2 |
| Tsai, JY | 1 |
| Iannitti, D | 1 |
| Berkenblit, A | 1 |
| Akerman, P | 1 |
| Nadeem, A | 1 |
| Rathore, R | 1 |
| Harrington, D | 1 |
| Roye, D | 1 |
| Miner, T | 1 |
| Barnett, JM | 1 |
| Maia, C | 1 |
| Stuart, K | 2 |
| Safran, H | 1 |
| Chan, CH | 1 |
| Chang, JY | 1 |
| Whang-Peng, J | 2 |
| Mok, T | 1 |
| Lai, P | 1 |
| Lim, R | 1 |
| Koh, J | 3 |
| Wong, YY | 1 |
| King, A | 1 |
| Leow, CK | 1 |
| Ansén, S | 1 |
| Jurkiewicz, E | 1 |
| Geisen, C | 1 |
| Anderson, KS | 1 |
| Gracien, E | 1 |
| Schmidt, M | 1 |
| Wittig, B | 1 |
| Diehl, V | 1 |
| Wolf, J | 1 |
| Bohlen, H | 1 |
| Nadler, LM | 1 |
| Lin, ZY | 1 |
| Shen, YF | 1 |
| Mitsuyama, S | 1 |
| Anan, K | 1 |
| Yu, ZJ | 1 |
| Yu, JW | 1 |
| Cai, W | 1 |
| Yuan, HX | 1 |
| Chen, JP | 1 |
| Yao, DF | 1 |
| Jones, DH | 1 |
| Silberstein, PT | 1 |
| Lynch, H | 1 |
| Ternet, C | 1 |
| Kanda, T | 1 |
| Imazeki, F | 1 |
| Yokosuka, O | 1 |
| Nagao, K | 2 |
| Kurokohchi, K | 2 |
| Takaguchi, K | 1 |
| Kuriyama, S | 2 |
| Yokoyama, R | 1 |
| Akasaka, Y | 1 |
| Ohmori, K | 1 |
| Ueki, T | 1 |
| Umeno, M | 1 |
| Dai, J | 3 |
| Honhon, B | 1 |
| Coster, B | 1 |
| Coche, JC | 1 |
| Scalliet, P | 1 |
| Humblet, Y | 2 |
| Aydin, S | 1 |
| Kerger, J | 1 |
| Remouchamps, V | 1 |
| Van Maele, P | 1 |
| Gilbeau, L | 1 |
| Kirkove, C | 1 |
| Octave-Prignot, M | 1 |
| Kartheuser, A | 1 |
| Lim, L | 1 |
| Shapiro, JD | 1 |
| Little, A | 1 |
| Bailey, W | 1 |
| Liechtenstein, M | 1 |
| Naito, H | 1 |
| Hamada, T | 2 |
| Shinohara, T | 2 |
| Mino, K | 1 |
| Shibazaki, W | 1 |
| Minagawa, N | 1 |
| Orimo, T | 1 |
| Ichimura, W | 1 |
| Matsuoka, T | 2 |
| Morikage, N | 1 |
| Kuga, T | 1 |
| Horvath, WL | 1 |
| Sternfeld, WC | 1 |
| Dakhil, SR | 2 |
| Levitt, R | 1 |
| Rowland, K | 1 |
| Nair, S | 1 |
| Yu, SC | 3 |
| Hui, P | 2 |
| Wong, HT | 1 |
| Tang, A | 1 |
| Cunningham, SC | 1 |
| Cusnir, M | 1 |
| Burdick, RK | 1 |
| Van Echo, DA | 1 |
| Moesinger, R | 1 |
| Ayav, A | 1 |
| Habib, N | 3 |
| Jiao, LR | 1 |
| Ihara, T | 1 |
| Sugihara, S | 1 |
| Teshima, K | 1 |
| Anami, Y | 1 |
| Oguma, S | 2 |
| Sazawa, Y | 1 |
| Komiya, H | 1 |
| Izai, J | 1 |
| Mercier, C | 1 |
| Evrard, A | 1 |
| Boyer, JC | 1 |
| Richard, K | 1 |
| Dales, JP | 1 |
| Durand, A | 1 |
| Lacarelle, B | 1 |
| Paik, YH | 1 |
| Chang, YS | 1 |
| Lee, DK | 1 |
| Chung, JB | 1 |
| Yu, JS | 1 |
| Yoon, DS | 1 |
| Schmitz, R | 3 |
| Krakamp, B | 3 |
| Troidl, H | 1 |
| Akhurst, T | 1 |
| Kates, TJ | 1 |
| Yeung, H | 1 |
| Riedel, ER | 1 |
| Burt, BM | 1 |
| Larson, SM | 1 |
| Amano, M | 3 |
| Itani, Y | 1 |
| Nishikawa, Y | 3 |
| Higaki, N | 3 |
| Hayashida, H | 3 |
| Kida, H | 4 |
| Fujiwara, S | 2 |
| Shiba, Y | 1 |
| Umekita, N | 8 |
| Noda, K | 1 |
| Nokita, H | 1 |
| Horiuchi, H | 1 |
| Kawashima, Y | 1 |
| Fujishita, M | 1 |
| Aoyagi, S | 5 |
| Bazarragchaa, D | 1 |
| Tujie, M | 1 |
| Koro, T | 1 |
| Poh, SB | 1 |
| Bai, LY | 1 |
| Chen, PM | 4 |
| Mackay, HJ | 1 |
| Billingsley, K | 1 |
| Gallinger, S | 2 |
| Berry, S | 1 |
| Smith, A | 1 |
| Yeung, R | 1 |
| Pond, GR | 1 |
| Croitoru, M | 1 |
| Swanson, PE | 1 |
| Krishnamurthi, S | 1 |
| Siu, LL | 1 |
| Gurfinkel, R | 1 |
| Walfisch, S | 1 |
| Yang, JW | 1 |
| Chen, YG | 1 |
| Fan, NF | 1 |
| Guo, ZQ | 1 |
| Cai, XC | 1 |
| Zhang, YH | 1 |
| Ouyang, XN | 1 |
| Gao, WB | 1 |
| Han, JD | 1 |
| Du, M | 1 |
| Malani, AK | 1 |
| Gupta, C | 1 |
| Rangineni, S | 1 |
| Gupta, V | 1 |
| Horton, PJ | 1 |
| Chaudhury, PK | 1 |
| Znajda, TL | 1 |
| Martinie, JB | 1 |
| Rochon, C | 1 |
| Tzimas, GN | 1 |
| Metrakos, P | 1 |
| Tonouchi, H | 2 |
| Marcucci, L | 1 |
| Cerri, E | 1 |
| Viti, M | 1 |
| Yan, TD | 1 |
| Padang, R | 1 |
| Lee, Y | 1 |
| Han, SH | 1 |
| Kwon, SY | 1 |
| Kwon, OS | 1 |
| Kim, SS | 1 |
| Park, YH | 1 |
| Lee, JN | 1 |
| Bang, SM | 1 |
| Cho, EK | 1 |
| Roebuck, DJ | 1 |
| Perilongo, G | 1 |
| Kuroiwa, G | 1 |
| Uchikado, Y | 1 |
| Matsumoto, M | 7 |
| Setoyama, T | 1 |
| Takigawa, J | 1 |
| Haraguchi, Y | 2 |
| Aikou, T | 2 |
| Huang, SL | 1 |
| Zhang, XQ | 1 |
| Ying, L | 1 |
| Zhao, HF | 1 |
| Farker, K | 1 |
| Merkel, U | 1 |
| Wedding, U | 1 |
| Hippius, M | 1 |
| Höffken, K | 1 |
| Hoffmann, A | 1 |
| Yamamura, Y | 1 |
| Koizumi, W | 1 |
| Wang, MQ | 1 |
| Shao, RH | 1 |
| Ye, HY | 1 |
| Liu, FY | 1 |
| Cho, BC | 1 |
| Kim, CB | 1 |
| Sohn, JH | 1 |
| Lee, YC | 1 |
| Huang, CY | 1 |
| Vogelzang, NJ | 2 |
| Pu, YS | 1 |
| Leonard, GD | 1 |
| Momiyama, N | 1 |
| Hayasizaki, Y | 1 |
| Shimomatsuya, T | 1 |
| Kobuchi, T | 1 |
| Kitamura, N | 1 |
| Shiraishi, S | 1 |
| Fujino, H | 1 |
| Maruhashi, K | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Kainuma, S | 1 |
| Yamanaka, H | 1 |
| Ozawa, H | 4 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Kosuge, T | 1 |
| Kiuchi, T | 2 |
| Kakizoe, T | 1 |
| Niedzwiecki, D | 4 |
| Hollis, DR | 1 |
| Warren, RS | 3 |
| Naughton, MJ | 1 |
| Weeks, JC | 1 |
| Herndon, JE | 1 |
| Mayer, RJ | 4 |
| Diasio, R | 1 |
| Toi, M | 1 |
| Cardinale, D | 1 |
| Colombo, A | 2 |
| Colombo, N | 1 |
| Mekata, E | 1 |
| Kaizuka, M | 1 |
| Grazi, G | 1 |
| Ravaioli, M | 1 |
| Zhou, ZW | 2 |
| Wang, GQ | 2 |
| Ren, JQ | 2 |
| Tang, SX | 1 |
| Ye, YL | 1 |
| Lin, SX | 1 |
| Lim, TY | 1 |
| Sim, SJ | 1 |
| Choi, SJ | 1 |
| Choi, JW | 1 |
| Lee, KM | 1 |
| Won, JH | 1 |
| Yoo, BM | 1 |
| Hahm, KB | 1 |
| Toune, R | 1 |
| Unuma, T | 2 |
| Teratani, T | 1 |
| Miyakura, S | 1 |
| Vallbohmer, D | 1 |
| Park, S | 1 |
| Takasaki, K | 1 |
| Morese, R | 1 |
| Cianci, G | 1 |
| Di Rocco, ZC | 1 |
| De Tursi, M | 1 |
| Tinari, N | 1 |
| Tai, CJ | 1 |
| Chiou, HY | 1 |
| Pan, S | 1 |
| Liu, JD | 1 |
| Feng, LF | 2 |
| Zhong, M | 2 |
| Lei, XY | 2 |
| Zhu, BY | 2 |
| Liao, DF | 2 |
| Oh, HJ | 1 |
| Lee, SY | 1 |
| Kim, CW | 1 |
| Cha, SB | 1 |
| Byun, JY | 1 |
| András, C | 1 |
| Farczádi, E | 1 |
| Szántó, J | 1 |
| Sharma, D | 1 |
| Tang, Z | 2 |
| Alazmi, WM | 1 |
| McHenry, L | 1 |
| Watkins, JL | 1 |
| Fogel, EL | 1 |
| Schmidt, S | 1 |
| Sherman, S | 1 |
| Lehman, GL | 1 |
| Madary, A | 1 |
| Hewes, JC | 1 |
| Riddy, D | 1 |
| Morris, RW | 1 |
| Woodrooffe, AJ | 1 |
| Fuller, B | 1 |
| Jeon, SB | 1 |
| Chae, YS | 1 |
| Lee, KB | 1 |
| Shin, HJ | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Jung, HY | 1 |
| Moreno-Vega, AL | 1 |
| Fuentes-Pradera, J | 1 |
| Gordón-Santiago, Mdel M | 1 |
| Vargas-Machuca, JC | 1 |
| Ishigame, T | 1 |
| Okayama, H | 1 |
| Zhang, ZG | 1 |
| Song, C | 1 |
| Zhang, YN | 1 |
| Saleem, A | 2 |
| Kötz, B | 1 |
| Osman, S | 3 |
| Aboagye, EO | 2 |
| Vernon, C | 1 |
| Wasan, H | 1 |
| Jones, T | 2 |
| Hoskin, PJ | 1 |
| Price, PM | 3 |
| Kim, HC | 1 |
| Ha, HK | 1 |
| Lee, MG | 1 |
| Melloni, G | 1 |
| Doglioni, C | 1 |
| Bandiera, A | 1 |
| Carretta, A | 1 |
| Ciriaco, P | 1 |
| Arrigoni, G | 1 |
| Zannini, P | 1 |
| Beaven, AW | 1 |
| Terstriep, S | 1 |
| Matsuda, T | 4 |
| Ogino, K | 1 |
| Hiroyoshi, M | 2 |
| Toyama, H | 1 |
| Makita, D | 1 |
| Tsunemi, K | 1 |
| Moritomo, H | 1 |
| Katzenstein, H | 1 |
| Bowman, L | 1 |
| Finegold, M | 4 |
| Greffe, B | 1 |
| Rowland, J | 1 |
| Womer, RB | 1 |
| Berretta, M | 1 |
| Lleshi, A | 1 |
| Di Benedetto, F | 1 |
| Bearz, A | 1 |
| Spina, M | 1 |
| Tirelli, U | 1 |
| Ni, H | 1 |
| Terakawa, N | 1 |
| Satoi, S | 1 |
| Takai, S | 1 |
| Yanagimoto, H | 1 |
| Komiyama, Y | 1 |
| A-Hon, K | 1 |
| Kamiyama, Y | 1 |
| Kodaira, S | 3 |
| Hojo, K | 6 |
| Kunitomo, K | 2 |
| Isomoto, H | 1 |
| Yasutomi, M | 9 |
| Takemiya, S | 2 |
| Takiuchi, H | 1 |
| Jiang, GM | 1 |
| Zhao, JW | 1 |
| Tian, F | 1 |
| Romero, RZ | 1 |
| Morales, R | 1 |
| Garcia, F | 1 |
| Huarriz, M | 1 |
| Bandres, E | 1 |
| De la Haba, J | 1 |
| Shirado, A | 1 |
| Uto, H | 1 |
| Kusumoto, K | 1 |
| Hasuike, S | 1 |
| Nagata, K | 1 |
| Iwamitsu, A | 1 |
| Hori, T | 2 |
| Ibusuki, K | 1 |
| Ido, A | 1 |
| Tsubouchi, H | 1 |
| Funakoshi, A | 1 |
| Sumii, T | 1 |
| Alacacioglu, A | 1 |
| Yaren, A | 1 |
| Tarhan, O | 1 |
| Somali, I | 1 |
| Zhou, ZH | 1 |
| Cheng, WW | 1 |
| Meng, ZQ | 1 |
| Lin, JH | 1 |
| Zhang, XJ | 1 |
| Jiang, GL | 1 |
| Jiang, XT | 1 |
| Tao, HQ | 1 |
| Zou, SC | 1 |
| Vogt, T | 1 |
| Coras, B | 1 |
| Hafner, C | 1 |
| Landthaler, M | 1 |
| Reichle, A | 1 |
| Lui, WY | 1 |
| Tsay, SH | 1 |
| Nagaya, M | 1 |
| Tsukikawa, S | 4 |
| Yanagi, Y | 1 |
| Isogai, A | 2 |
| Cui, YL | 1 |
| Juzi, JT | 1 |
| Qian, BY | 1 |
| Hao, XS | 1 |
| Wang, YJ | 1 |
| Ohsuga, K | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Sonoda, K | 1 |
| Nishizaki, M | 1 |
| Uno, F | 2 |
| Teraishi, F | 2 |
| Gouchi, A | 2 |
| Sperti, E | 2 |
| Faggiuolo, R | 1 |
| Gerbino, A | 1 |
| Magnino, A | 1 |
| Ortega, C | 1 |
| Ferraris, R | 1 |
| Rijpkema, M | 1 |
| Kamm, YL | 1 |
| Barentsz, JO | 1 |
| Tatsukawa, M | 1 |
| Yoo, PS | 1 |
| Lopez-Soler, RI | 1 |
| Longo, WE | 1 |
| Fellague-Chebra, R | 1 |
| Flesch, M | 2 |
| Postel Vinay, S | 1 |
| Bidard, FC | 1 |
| Allen, JA | 1 |
| Adlakha, A | 1 |
| Bergethon, PR | 1 |
| Sakamoto, F | 1 |
| Toyoyama, H | 1 |
| Ikeda, N | 2 |
| Kamikado, C | 1 |
| Koshino, H | 1 |
| McNutt, MA | 1 |
| Giostra, E | 2 |
| Audard, V | 1 |
| Sartoretti, P | 1 |
| Dousset, B | 2 |
| Majno, PE | 2 |
| Soubrane, O | 2 |
| Terris, B | 1 |
| Sahajpal, A | 1 |
| Vollmer, CM | 1 |
| Chan, EK | 1 |
| Cattral, MS | 1 |
| Taylor, BR | 1 |
| Grant, DR | 1 |
| Greig, PD | 1 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Pons Sanz, V | 1 |
| Martínez Banaclocha, N | 1 |
| Guillén Ponce, C | 1 |
| Carrato Mena, A | 1 |
| Saric, J | 1 |
| Aloia, T | 1 |
| Plasse, M | 1 |
| Karam, V | 1 |
| Kalykaki, A | 2 |
| Agelaki, S | 2 |
| Tzardi, M | 1 |
| Kotsakis, AP | 1 |
| Gioulbasanis, J | 1 |
| Tsetis, D | 1 |
| Sfakiotaki, G | 2 |
| Chatzidaki, D | 1 |
| Oie, S | 1 |
| Terada, T | 1 |
| Fujioka, N | 1 |
| Ariyasu, T | 1 |
| Arai, N | 1 |
| Ariyasu, H | 1 |
| Tanimoto, T | 1 |
| Ikegami, H | 1 |
| Kurimoto, M | 1 |
| Bouzari, H | 1 |
| Amisano, M | 1 |
| Massucco, P | 1 |
| Oguro, A | 5 |
| Nanri, M | 2 |
| Ujiie, K | 1 |
| Koh, T | 3 |
| Yamazaki, J | 1 |
| Dai, LC | 2 |
| Lu, YL | 2 |
| Ping, JL | 2 |
| He, JF | 2 |
| de Geus-Oei, LF | 1 |
| Leer, JW | 1 |
| Corstens, FH | 1 |
| Oyen, WJ | 1 |
| Reinacher-Schick, AC | 1 |
| Popov, IP | 1 |
| Milicevic, M | 1 |
| Kecmanovic, D | 1 |
| Tomasevic, Z | 1 |
| Radosevic-Jelic, Lj | 1 |
| Borojevic, N | 1 |
| Micev, MT | 1 |
| Kezic, I | 1 |
| Kudo, T | 3 |
| Muto, O | 3 |
| Okada, R | 3 |
| Mitobe, S | 3 |
| Ishiguro, A | 1 |
| Sakuraba, H | 1 |
| Ikami, I | 3 |
| Honma, H | 1 |
| Satoh, D | 1 |
| Umeoka, T | 1 |
| Aoki, H | 2 |
| Onoda, T | 1 |
| Shiozaki, Y | 1 |
| Ohno, S | 2 |
| Higaki, K | 1 |
| Takakura, N | 1 |
| Ishii, E | 1 |
| Yabu, K | 1 |
| Kushihata, F | 1 |
| Yang, JJ | 1 |
| Wan, XR | 1 |
| Yanase, K | 1 |
| Ikenaka, Y | 1 |
| Noguchi, R | 1 |
| Kitade, M | 1 |
| Kaji, K | 1 |
| Yoshii, J | 1 |
| Namisaki, T | 1 |
| Asada, K | 1 |
| Tsujimoto, T | 1 |
| Akahane, T | 1 |
| Fukui, H | 2 |
| Baize, N | 1 |
| Gerard, B | 1 |
| Caroli-Bosc, F | 1 |
| Berthier, F | 1 |
| Legendre, H | 1 |
| Pector, JC | 7 |
| Shiozaki, K | 3 |
| Yabuuchi, S | 1 |
| Oikawa, M | 1 |
| Onogawa, T | 1 |
| Nakahara, O | 1 |
| Mizumoto, T | 2 |
| Hosaka, S | 1 |
| Ohtani, T | 1 |
| Ohsawa, G | 1 |
| Gonda, T | 2 |
| Gochi, A | 1 |
| Okabe, K | 1 |
| Hiroto, M | 1 |
| Higami, K | 2 |
| Okano, N | 1 |
| Matsumaru, K | 1 |
| Miki, K | 2 |
| Hwang, SJ | 1 |
| Lee, SD | 2 |
| Kim, GJ | 1 |
| Sin, CH | 1 |
| Nam, SH | 1 |
| Ghosn, M | 3 |
| Farhat, F | 1 |
| Kattan, J | 2 |
| Younes, F | 1 |
| Moukadem, W | 1 |
| Nasr, F | 1 |
| Chahine, G | 1 |
| Wang, CT | 1 |
| Cao, KJ | 1 |
| Xie, GF | 1 |
| Enoki, T | 1 |
| Kitada, K | 1 |
| Harada, E | 1 |
| Noshima, S | 1 |
| Hamano, K | 2 |
| Mauritz, R | 1 |
| van Groeningen, CJ | 8 |
| Smid, K | 5 |
| Jansen, G | 1 |
| Pinedo, HM | 10 |
| Peters, GJ | 8 |
| Kamoshita, N | 1 |
| Makita, F | 1 |
| Matsuzaki, Y | 1 |
| Kabeya, K | 1 |
| Neri, B | 1 |
| Pantaleo, P | 1 |
| Giommoni, E | 1 |
| Grifoni, R | 1 |
| Paoletti, C | 1 |
| Rotella, V | 1 |
| Pantalone, D | 1 |
| Taddei, A | 1 |
| Mercatelli, A | 1 |
| Tonelli, P | 1 |
| Hou, S | 1 |
| Kou, G | 1 |
| Qian, W | 1 |
| Blanshard, K | 1 |
| Nishimura, M | 1 |
| Sameshima, S | 2 |
| Horikoshi, H | 1 |
| Motegi, K | 1 |
| Tomozawa, S | 1 |
| Hirayama, I | 1 |
| Wang, XX | 1 |
| Zhou, ZM | 1 |
| Yuan, ZY | 1 |
| Li, LR | 1 |
| Noda, M | 3 |
| Kuno, T | 1 |
| Tsukamoto, K | 1 |
| Gega, M | 1 |
| Yagyuu, T | 1 |
| Yoshikawa, R | 3 |
| Ikeuchi, H | 1 |
| Minami, K | 1 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Miyahara, E | 2 |
| Noso, Y | 2 |
| Fogelman, DR | 1 |
| Schreibman, SM | 1 |
| Desai, M | 1 |
| Sherman, W | 1 |
| Strauss, J | 1 |
| Guba, S | 1 |
| Andrade, R | 1 |
| Chabot, J | 1 |
| Giantonio, BJ | 1 |
| Catalano, PJ | 1 |
| Meropol, NJ | 2 |
| Schwartz, MA | 1 |
| Imai, Y | 5 |
| Zhao, QZ | 1 |
| Dou, KF | 1 |
| Fontana, S | 1 |
| Ghilardi, R | 1 |
| Barbaglio, A | 1 |
| Amaddeo, P | 1 |
| Faldi, F | 1 |
| Pericotti, S | 1 |
| Giovannini, I | 1 |
| Iwata, S | 1 |
| Imai, S | 4 |
| Mochiduki, H | 1 |
| Imazeki, M | 1 |
| Taguchi, Y | 1 |
| Parks, R | 1 |
| Blumgart, LH | 2 |
| Malik, Z | 1 |
| Wisinski, KB | 1 |
| Mickle, M | 1 |
| Doci, R | 3 |
| Rosati, R | 1 |
| Gullo, G | 1 |
| Zuradelli, M | 1 |
| Abbadessa, G | 1 |
| Marcon, I | 1 |
| Garassino, I | 1 |
| Naganuma, A | 1 |
| Yanagisawa, M | 1 |
| Kosone, T | 1 |
| Arai, H | 1 |
| Takagi, H | 5 |
| Miao, J | 1 |
| Yun, JP | 1 |
| Chun, SY | 1 |
| Zheng, ZZ | 1 |
| Chak, EC | 1 |
| Xia, NS | 1 |
| Yoon, YJ | 1 |
| Kuroda, M | 1 |
| Urawa, N | 1 |
| Mifuji, R | 1 |
| Araki, J | 1 |
| Horiike, S | 1 |
| Furjita, N | 1 |
| Iwasa, M | 1 |
| Kaito, M | 1 |
| Gupta, B | 1 |
| LeVea, C | 1 |
| Emmanouilides, C | 1 |
| Christophylakis, C | 1 |
| Diamandidou, E | 1 |
| Touroutoglou, N | 1 |
| Chatzidakis, A | 1 |
| Chan, SL | 1 |
| Leung, NW | 2 |
| Lam, WY | 1 |
| Tang, JW | 1 |
| Chan, PK | 1 |
| Ishizaki, T | 1 |
| Koyanagi, Y | 6 |
| Wada, T | 4 |
| Matsuo, A | 1 |
| Fan, XY | 1 |
| Iwaki, K | 1 |
| Liu, ZS | 1 |
| Tang, SL | 1 |
| He, YM | 1 |
| Kuratomi, K | 1 |
| Bilancia, D | 1 |
| Germano, D | 1 |
| Dinota, A | 1 |
| Romano, R | 1 |
| Reggiardo, G | 1 |
| Schneider, BJ | 1 |
| Muler, JH | 1 |
| Philip, PA | 2 |
| Kalemkerian, GP | 1 |
| Griffith, KA | 2 |
| Ruutiainen, AT | 1 |
| Tuite, CM | 1 |
| Clark, TW | 1 |
| Mondschein, JI | 1 |
| Stavropoulos, SW | 1 |
| Trerotola, SO | 1 |
| Tan, MC | 1 |
| Siegel, BA | 1 |
| Nakashima, K | 6 |
| Sakai, M | 1 |
| Sakai, I | 1 |
| Hoshina, K | 1 |
| Kurita, M | 1 |
| Shida, D | 1 |
| Shinkai, H | 1 |
| Miyashita, M | 1 |
| Yao, YF | 1 |
| Morimoto, K | 1 |
| Miki, R | 1 |
| Ogami, N | 1 |
| Arita, S | 1 |
| Noshiro, H | 1 |
| Yao, T | 1 |
| Cobo, F | 1 |
| De Celis, G | 1 |
| Pereira, A | 1 |
| Latorre, X | 1 |
| Pujadas, J | 1 |
| Albiol, S | 1 |
| Harrop, R | 1 |
| Drury, N | 1 |
| Shingler, W | 1 |
| Chikoti, P | 1 |
| Redchenko, I | 1 |
| Carroll, MW | 1 |
| Kingsman, SM | 1 |
| Naylor, S | 1 |
| Melcher, A | 1 |
| Nicholls, J | 2 |
| Wassan, H | 1 |
| Anthoney, A | 1 |
| Inui, N | 1 |
| Hiyama, S | 1 |
| Morohashi, S | 1 |
| Odagiri, H | 1 |
| Horsmans, Y | 1 |
| Rahier, J | 1 |
| Ceratti, A | 1 |
| Chi, PD | 1 |
| Fan, YY | 1 |
| Wu, CY | 1 |
| Luo, HY | 1 |
| Fan, Y | 1 |
| Lang, RG | 1 |
| Sun, YL | 1 |
| Fu, L | 1 |
| Deguchi, A | 1 |
| Himoto, T | 1 |
| Yoneyama, H | 1 |
| Maeta, T | 1 |
| Kohi, F | 1 |
| Taminato, T | 1 |
| Chung, C | 1 |
| Joh, JW | 1 |
| Zhou, YD | 1 |
| Huan, HY | 1 |
| Guan, JH | 1 |
| Desai, SP | 1 |
| El-Rayes, BF | 1 |
| Ben-Josef, E | 2 |
| Greenson, JK | 1 |
| Huang, EH | 1 |
| McGinn, CJ | 1 |
| Bajetta, E | 3 |
| Celio, L | 1 |
| Ferrario, E | 1 |
| Denaro, A | 1 |
| Dotti, K | 1 |
| Mancin, M | 1 |
| Bajetta, R | 1 |
| Pusceddu, S | 1 |
| Solano, JM | 1 |
| Bakri, SJ | 1 |
| Pulido, JS | 1 |
| Iqbal, K | 1 |
| Chu, Q | 1 |
| Mei, Q | 1 |
| Eigenbrod, T | 1 |
| Klebl, F | 1 |
| Sunose, N | 1 |
| Tsuruo, T | 1 |
| Yamori, T | 1 |
| Nikaido, T | 1 |
| Murase, K | 1 |
| Araki, H | 2 |
| Blanchard, P | 1 |
| Huguet, F | 1 |
| Kawano, Y | 1 |
| Dupouy, N | 1 |
| Siperstein, AE | 1 |
| Ballem, N | 1 |
| Parikh, RT | 1 |
| D'Argento, E | 1 |
| Astone, A | 2 |
| Castaing, M | 1 |
| Pocard, M | 2 |
| Cui, J | 1 |
| Nan, KJ | 1 |
| Guo, YH | 1 |
| Imai, M | 2 |
| Kamimura, H | 2 |
| Tsuchiya, A | 2 |
| Togashi, T | 2 |
| Seki, K | 2 |
| Ohta, H | 4 |
| Terraz, S | 1 |
| Allal, AS | 1 |
| Uka, K | 3 |
| Miki, D | 3 |
| Jeong, SC | 2 |
| Kodama, H | 1 |
| Hasegawa, N | 1 |
| Kawabata, M | 1 |
| Abeshima, S | 1 |
| Kulke, MH | 1 |
| Muzikansky, A | 1 |
| Lawrence, C | 1 |
| Vega, ME | 1 |
| Alonso, V | 1 |
| Martinez-Villacampa, M | 1 |
| Meric, JB | 1 |
| Nakatani, T | 2 |
| Sakaguchi, Y | 1 |
| Nagashima, M | 1 |
| Fukuta, N | 1 |
| Hayakawa, S | 1 |
| Munakata, H | 1 |
| Tejani, MA | 1 |
| Sun, RX | 1 |
| Bruce, C | 1 |
| Mamada, Y | 1 |
| Taniai, N | 1 |
| Mizuguchi, Y | 1 |
| Kakinuma, D | 1 |
| Ishikawa, Y | 1 |
| Akimaru, K | 1 |
| Sugisaki, Y | 1 |
| Tajiri, T | 1 |
| Sugimoto, M | 1 |
| Yasuda, H | 2 |
| Takenoue, T | 1 |
| Higuchi, R | 1 |
| Watayo, Y | 1 |
| Yagawa, Y | 1 |
| Crump, M | 2 |
| Gluck, S | 1 |
| Stewart, D | 1 |
| Levine, M | 2 |
| Kirkbride, P | 1 |
| O'Reilly, S | 1 |
| Shore, T | 1 |
| Couban, S | 1 |
| Girouard, C | 2 |
| Marlin, S | 1 |
| Shepherd, L | 1 |
| Pritchard, KI | 1 |
| Armbrust, T | 1 |
| Sobotta, M | 1 |
| Füzesi, L | 1 |
| Grabbe, E | 1 |
| Ramadori, G | 2 |
| Roh, JK | 1 |
| Cha, SH | 1 |
| Tian, ZY | 1 |
| Du, GJ | 1 |
| Xie, SQ | 1 |
| Gao, WY | 1 |
| Wang, CJ | 1 |
| Jiang, JM | 1 |
| Liu, JY | 1 |
| Zhu, JR | 1 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Milella, M | 1 |
| Le, C | 1 |
| Gong, ZJ | 1 |
| Kong, G | 1 |
| Qing, DJ | 1 |
| Liang, YQ | 1 |
| Garrido, M | 1 |
| O'Brien, A | 1 |
| González, S | 1 |
| Clavero, JM | 1 |
| Orellana, E | 1 |
| Nakano, H | 3 |
| Oussoultzoglou, E | 1 |
| Rosso, E | 1 |
| Chenard-Neu, MP | 1 |
| Dufour, P | 2 |
| Mehta, NN | 1 |
| Ravikumar, R | 1 |
| Coldham, CA | 1 |
| Buckels, JA | 1 |
| Hubscher, SG | 1 |
| Bramhall, SR | 1 |
| Wigmore, SJ | 1 |
| Mayer, AD | 1 |
| Di Lorenzo, G | 1 |
| Rea, A | 1 |
| Pepe, S | 1 |
| Palmieri, G | 1 |
| Chirianni, A | 1 |
| Esposito, V | 1 |
| Montesarchio, V | 1 |
| Spry, N | 1 |
| Harvey, J | 1 |
| Macleod, C | 1 |
| Borg, M | 1 |
| Millar, JL | 1 |
| Graham, P | 1 |
| Zissiadis, Y | 1 |
| Kneebone, A | 1 |
| Carroll, S | 1 |
| Davies, T | 1 |
| Reece, WH | 1 |
| Iacopetta, B | 1 |
| Manekeller, S | 1 |
| Sioutis, M | 1 |
| Hirner, A | 1 |
| Minor, T | 1 |
| Coskun, U | 1 |
| Buyukberber, S | 1 |
| Yaman, E | 1 |
| Uner, A | 1 |
| Er, O | 1 |
| Dikilitas, M | 1 |
| Oguz, M | 1 |
| B, DY | 1 |
| Kaya, AO | 1 |
| Benekli, M | 1 |
| Nagatsuka, R | 1 |
| Kawabe, Y | 1 |
| Hirabayashi, Y | 1 |
| Fuchimoto, M | 1 |
| Iki, K | 2 |
| Zhai, BJ | 1 |
| Zhao, CL | 1 |
| Hu, K | 1 |
| Shen, DM | 1 |
| Beg, MS | 1 |
| Komrokji, RS | 1 |
| Ahmed, K | 1 |
| Safa, MM | 1 |
| Miki, H | 1 |
| Yoshimura, M | 1 |
| Uji, K | 1 |
| Suzuki, R | 1 |
| Komori, M | 1 |
| Copois, V | 1 |
| Bascoul-Mollevi, C | 1 |
| Denis, V | 1 |
| Bec, N | 1 |
| Robert, B | 1 |
| Fraslon, C | 1 |
| Conseiller, E | 1 |
| Molina, F | 1 |
| Larroque, C | 1 |
| Hu, WJ | 1 |
| Tomonaga, T | 1 |
| Ebara, M | 1 |
| Nomura, F | 1 |
| Gallego-Plazas, J | 1 |
| Menarguez-Pina, F | 1 |
| Pons-Sanz, V | 1 |
| Ballester-Navarro, I | 1 |
| von Delius, S | 1 |
| Lersch, C | 1 |
| Mayr, M | 1 |
| Stock, K | 1 |
| Schulte-Frohlinde, E | 1 |
| Schmid, RM | 1 |
| Eckel, F | 1 |
| Milandri, C | 1 |
| Calzolari, F | 1 |
| Passardi, A | 1 |
| Tison, C | 1 |
| Giampalma, E | 1 |
| Cecconetto, L | 1 |
| Kandutsch, S | 1 |
| Cottu, PH | 1 |
| Asselah, J | 1 |
| Lae, M | 1 |
| Pierga, JY | 2 |
| Diéras, V | 2 |
| Mignot, L | 1 |
| Sigal-Zafrani, B | 1 |
| Vincent-Salomon, A | 1 |
| Belmonte-Montes, C | 1 |
| Cosme-Reyes, C | 1 |
| Han, HS | 1 |
| Park, YI | 1 |
| Kook, MC | 1 |
| Choi, IJ | 1 |
| Kim, CG | 1 |
| Lee, JR | 1 |
| Cho, SJ | 1 |
| Oida, Y | 1 |
| Motojuku, M | 1 |
| Morikawa, G | 1 |
| Mukai, M | 3 |
| Giusti, RM | 1 |
| Shastri, K | 1 |
| Pilaro, AM | 1 |
| Cordoba-Rodriguez, R | 1 |
| Koti, K | 1 |
| Rothmann, M | 1 |
| Men, AY | 1 |
| Hughes, M | 1 |
| Keegan, P | 1 |
| Weiss, KD | 1 |
| Pazdur, R | 2 |
| Lieuw-a-Fa, M | 1 |
| Peringa, J | 1 |
| Leeksma, O | 1 |
| Terpstra, W | 1 |
| Zuckerman, DS | 1 |
| Hirono, S | 1 |
| Ina, S | 1 |
| Nishioka, R | 1 |
| Uchiyama, K | 2 |
| August, DA | 2 |
| Fukuda, H | 3 |
| Tazawa, K | 2 |
| Sawada, S | 3 |
| Uotani, H | 1 |
| Hirokawa, S | 1 |
| Yamagishi, F | 1 |
| Tsukada, K | 1 |
| Gensheimer, M | 1 |
| Jones, CA | 1 |
| Graves, CR | 1 |
| Merchant, NB | 1 |
| Lockhart, AC | 1 |
| Praet, M | 1 |
| Bethe, U | 1 |
| Trindade, F | 1 |
| Haro, R | 1 |
| Fariña, MC | 1 |
| Requena, L | 1 |
| Han, CJ | 1 |
| Kadikoylu, G | 1 |
| Yavasoglu, I | 1 |
| Barutca, S | 1 |
| Meydan, N | 1 |
| Bolaman, Z | 1 |
| Sasada, T | 1 |
| Denno, R | 3 |
| Mizukami, Y | 1 |
| Kohno, S | 2 |
| Takabayashi, A | 1 |
| Viel, E | 1 |
| Demarchi, MF | 1 |
| Chaigneau, L | 1 |
| Legat, C | 1 |
| Stein, U | 1 |
| Thiery-Vuillemin, A | 1 |
| Limat, S | 1 |
| Wei, WQ | 1 |
| Liu, DZ | 1 |
| Yang, LX | 1 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Tan, KL | 1 |
| Edwards, C | 1 |
| Dugan, U | 1 |
| Norton, L | 2 |
| Hudis, C | 1 |
| Schueller, J | 1 |
| Zielinski, C | 2 |
| Herbst, F | 1 |
| Funada, N | 1 |
| Toda, S | 1 |
| Moriyama, J | 1 |
| Katori, H | 1 |
| Igarashi, M | 1 |
| Hasebe, S | 1 |
| Kanemura, M | 1 |
| Polikarpov, AA | 1 |
| Gasanov, ISh | 1 |
| Tarazov, PG | 1 |
| Generalov, MI | 1 |
| Boeck, S | 1 |
| Wilkowski, R | 1 |
| Issels, RD | 1 |
| Schulz, C | 1 |
| Laessig, D | 1 |
| Haas, M | 1 |
| Golf, A | 1 |
| Hess, D | 1 |
| Koberle, D | 1 |
| Thurlimann, B | 1 |
| Pagani, O | 1 |
| Schonenberger, A | 1 |
| Mattmann, S | 1 |
| Rochlitz, C | 1 |
| Rauch, D | 1 |
| Schuller, JC | 1 |
| Ballabeni, P | 1 |
| Ribi, K | 1 |
| Shim, JH | 1 |
| Nam, BH | 1 |
| Punzengruber, R | 1 |
| Crivellari, D | 1 |
| Di Loreto, C | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Andreetta, C | 1 |
| Russo, S | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
| Saneto, H | 1 |
| White, RR | 1 |
| Munoz, JA | 1 |
| Raggio, G | 1 |
| Chunhu, Z | 1 |
| Suiyu, H | 1 |
| Meiqun, C | 1 |
| Guilin, X | 1 |
| Yunhui, L | 1 |
| Krailo, M | 1 |
| Saadati, H | 1 |
| Li, ZW | 1 |
| Wen, HC | 1 |
| Iyomasa, S | 1 |
| Sawasaki, N | 1 |
| Kyokane, T | 1 |
| Yuan, JN | 1 |
| Lee, WP | 1 |
| Lee, RC | 1 |
| Chang, FY | 1 |
| Duffy, A | 1 |
| Huitzil-Melendez, FD | 1 |
| Gyllenhaal, C | 1 |
| Alschuler, L | 1 |
| Rubin, D | 1 |
| Kranz, S | 1 |
| Roddy, GD | 1 |
| Block, KI | 1 |
| Farmer, RG | 1 |
| Filson, EJ | 1 |
| Buonocore, EA | 1 |
| Albaugh, JS | 1 |
| Keeffe, EB | 1 |
| Krippaehne, WW | 1 |
| Falkson, G | 9 |
| MacIntyre, JM | 2 |
| Moertel, CG | 15 |
| Johnson, LA | 1 |
| Scherman, RC | 1 |
| Sakatoku, M | 2 |
| Yamashita, R | 3 |
| Iwa, T | 2 |
| Balch, CM | 3 |
| Urist, MM | 2 |
| Shiraishi, K | 1 |
| Majima, Y | 2 |
| Sakemi, T | 1 |
| Sakai, T | 2 |
| Hirai, K | 5 |
| Ninomiya, F | 1 |
| Tanikawa, K | 6 |
| Akiharu, W | 1 |
| Higashi, T | 1 |
| Nakatsukasa, H | 1 |
| Fujiwara, M | 1 |
| Shiota, T | 1 |
| Nagashima, H | 2 |
| Ueoka, H | 1 |
| Kuroda, S | 1 |
| Ohnoshi, T | 1 |
| Kimura, I | 1 |
| Numoto, A | 1 |
| Hino, I | 1 |
| Tsuji, M | 2 |
| Frytak, S | 1 |
| Mattes, P | 3 |
| Betzler, M | 1 |
| Heinrich, UE | 1 |
| Bolkenius, M | 1 |
| Daum, R | 1 |
| Oppermann, HC | 1 |
| Mehls, O | 1 |
| Brandeis, WE | 1 |
| Theodors, A | 1 |
| Bukowski, RM | 4 |
| Lavery, I | 1 |
| Hewlett, JS | 3 |
| Livingston, RB | 1 |
| Buonocore, E | 1 |
| Wopfner, F | 3 |
| Rasenack, U | 1 |
| Caspary, W | 1 |
| Ohya, T | 2 |
| Sheen, MC | 1 |
| Huang, TJ | 1 |
| Sheen, PC | 1 |
| Ho, YH | 1 |
| Sheu, HM | 1 |
| Ou, SC | 1 |
| Chen, CY | 1 |
| Moser, K | 1 |
| Dittrich, C | 1 |
| Pirich, P | 1 |
| Choi, TK | 1 |
| Lee, NW | 1 |
| Wong, J | 1 |
| Hayashida, S | 1 |
| Markman, M | 2 |
| Barone, RM | 2 |
| Byfield, JE | 3 |
| Goldfarb, PB | 1 |
| Frankel, S | 2 |
| Ginn, C | 1 |
| Greer, S | 1 |
| Scarabelli, C | 1 |
| Campagnutta, E | 1 |
| Davis, HL | 6 |
| Huberman, MS | 2 |
| Peters, RE | 1 |
| Chuang, VP | 1 |
| Wallace, S | 4 |
| Hinterberger, R | 2 |
| Fischer, J | 1 |
| Preiss, J | 1 |
| Weigand, H | 1 |
| Weltz, MD | 1 |
| Perry, DJ | 1 |
| Blom, J | 1 |
| Butler, WM | 1 |
| Brückner, R | 1 |
| Rothmund, M | 1 |
| Al-Jurf, AS | 1 |
| Jochimsen, PR | 2 |
| Urdaneta, LF | 1 |
| Stagg, RJ | 2 |
| Lewis, BJ | 2 |
| Friedman, MA | 4 |
| Ignoffo, RJ | 1 |
| Hohn, DC | 5 |
| Manguso, L | 1 |
| Coraggio, F | 1 |
| Grimaldi, G | 1 |
| Zito, GA | 1 |
| Grimaldi, F | 1 |
| Vespoli, F | 1 |
| Gentile, B | 1 |
| Schlager, SI | 1 |
| Ohanian, SH | 4 |
| Oon, CJ | 1 |
| Chua, EJ | 1 |
| Foong, WC | 1 |
| Tan, LK | 1 |
| Yo, SL | 1 |
| Chang, CH | 1 |
| Ho, ST | 1 |
| Seah, CS | 1 |
| Volberding, PA | 2 |
| Cassidy, MJ | 1 |
| Resser, KJ | 3 |
| Wasserman, TH | 1 |
| Phillips, TL | 4 |
| Pausch, J | 2 |
| Holstege, A | 1 |
| Keppler, D | 2 |
| Gerok, W | 2 |
| Nixon, DW | 1 |
| Shlaer, SM | 1 |
| Nakakuma, K | 1 |
| Hiraoka, T | 3 |
| Konno, T | 1 |
| Yokoyama, I | 1 |
| Czerwiński, W | 4 |
| Young, D | 2 |
| Vine, E | 1 |
| Ghanbarpour, A | 1 |
| Shani, J | 4 |
| Siemsen, JK | 2 |
| Wolf, W | 4 |
| Evans, AE | 1 |
| Land, VJ | 1 |
| Newton, WA | 1 |
| Randolph, JG | 1 |
| Sather, HN | 1 |
| Tefft, M | 1 |
| Weinblatt, ME | 1 |
| Siegel, SE | 1 |
| Siegel, MM | 1 |
| Stanley, P | 1 |
| Weitzman, JJ | 1 |
| Joishy, SK | 1 |
| Bennett, JM | 1 |
| Balasegaram, M | 1 |
| Moertel, C | 2 |
| Carbone, PP | 2 |
| Penalba, C | 1 |
| Larouze, B | 1 |
| Mechali, D | 1 |
| Saimot, G | 1 |
| Coulaud, JP | 1 |
| Cedermark, BJ | 1 |
| Gunven, P | 1 |
| Hammarberg, C | 1 |
| Wawrukiewicz, AS | 1 |
| Rösch, J | 2 |
| Keller, FS | 1 |
| Lieberman, DA | 1 |
| Anttila, MI | 1 |
| Sotaniemi, EA | 2 |
| Kairaluoma, MI | 4 |
| Mokka, RE | 3 |
| Sundquist, HT | 1 |
| Niederhuber, JE | 1 |
| Kuroiwa, Y | 1 |
| Kikkawa, K | 1 |
| Kubonishi, S | 1 |
| Hamawaki, M | 1 |
| Matsuka, Y | 2 |
| Ejiri, T | 2 |
| Asano, K | 2 |
| Kanaoka, M | 1 |
| Ohta, Y | 4 |
| Hallengren, B | 1 |
| Dymling, JF | 1 |
| Manhem, P | 1 |
| Tennvall, L | 1 |
| Tibblin, S | 1 |
| Munehisa, T | 1 |
| Muro, T | 1 |
| Kohno, K | 1 |
| Furukawa, R | 1 |
| Ogino, T | 3 |
| Washtien, WL | 1 |
| Steele, G | 3 |
| Osteen, RT | 1 |
| Wilson, RE | 2 |
| Brooks, DC | 1 |
| Zamcheck, N | 1 |
| Ravikumar, TS | 4 |
| Spehn, J | 1 |
| Beyer, JH | 1 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 1 |
| Abel, U | 2 |
| Aigner, KR | 1 |
| Walther, H | 3 |
| Tonn, JC | 2 |
| Schoch, P | 1 |
| Schwemmle, K | 6 |
| Vogel, CL | 2 |
| Smalley, RV | 1 |
| Raney, M | 1 |
| Krauss, S | 1 |
| Carpenter, J | 1 |
| Velez-Garcia, E | 1 |
| Fishkin, E | 1 |
| Raab, S | 1 |
| Moore, MR | 1 |
| Stagg, M | 1 |
| Komov, DV | 2 |
| Roshchin, EM | 2 |
| Chernova, MV | 1 |
| Dolgushin, BI | 1 |
| Denck, H | 2 |
| Kojima, J | 1 |
| Kamada, T | 1 |
| Monna, J | 1 |
| Sugata, S | 1 |
| Kono, A | 1 |
| Ishibashi, H | 1 |
| Iguchi, K | 1 |
| Hashimoto, I | 1 |
| Kimoto, Y | 1 |
| Oota, J | 1 |
| Boulis-Wassif, S | 1 |
| Gerard, A | 6 |
| Loygue, J | 1 |
| Camelot, D | 1 |
| Duez, N | 4 |
| Reyes, JM | 1 |
| Okazaki, N | 5 |
| Yoshino, M | 1 |
| Okuyama, K | 4 |
| Isono, K | 4 |
| Satoh, H | 3 |
| Onoda, S | 3 |
| Tohnosu, N | 3 |
| Ryu, M | 1 |
| Hanaoka, A | 1 |
| Hanatani, Y | 1 |
| Kano, T | 3 |
| Kumashiro, R | 2 |
| Abe, Y | 2 |
| Notsuka, T | 2 |
| Tamada, R | 2 |
| Schlangen, J | 3 |
| Wils, J | 4 |
| Maeta, M | 8 |
| Koga, S | 8 |
| Kanayama, H | 1 |
| Oda, M | 1 |
| Murakami, A | 7 |
| Hirooka, Y | 2 |
| Shiomi, M | 1 |
| Saka, M | 2 |
| Katsu, K | 1 |
| Laufman, LR | 1 |
| Nims, TA | 1 |
| Guy, JT | 1 |
| Guy, JF | 1 |
| Courter, S | 1 |
| Bland, KI | 1 |
| Knutson, CO | 1 |
| Max, MH | 1 |
| Kish, JA | 1 |
| Weaver, A | 1 |
| Jacobs, J | 1 |
| Cummings, G | 1 |
| Al-Sarraf, M | 2 |
| Fornasiero, A | 1 |
| Cartei, G | 1 |
| Daniele, O | 1 |
| Fosser, V | 1 |
| Fiorentino, MV | 1 |
| Cadman, EC | 1 |
| Glick, JH | 1 |
| Cross, J | 1 |
| Horton, J | 1 |
| Taylor, SG | 1 |
| Soukop, M | 2 |
| Carter, DC | 1 |
| Smyth, JF | 1 |
| Allan, SG | 1 |
| Kaye, SB | 1 |
| Sangster, G | 1 |
| Calman, KC | 1 |
| Hutcheon, AW | 1 |
| Naus, A | 2 |
| Garvey, E | 1 |
| Kramer, R | 1 |
| Shapiro, CM | 1 |
| Bitran, JD | 1 |
| Shapiro, RA | 1 |
| Breithaupt, H | 1 |
| Aigner, K | 5 |
| Hechtel, R | 2 |
| Schulz, A | 1 |
| Kracht, J | 1 |
| Bengmark, S | 13 |
| Nobin, A | 1 |
| Jeppsson, B | 8 |
| Tranberg, KG | 5 |
| Tonn, J | 1 |
| Wenzl, A | 2 |
| Merker, G | 3 |
| Helling, HJ | 1 |
| Krahl, M | 2 |
| Lokich, JJ | 3 |
| Chen, TT | 1 |
| Khankhanian, N | 1 |
| Heilbrun, LK | 1 |
| McBride, CM | 3 |
| McMurtrey, MJ | 1 |
| Bodey, GP | 2 |
| Queisser, W | 1 |
| Schnitzler, G | 1 |
| Heim, ME | 1 |
| König, H | 1 |
| Katz, R | 1 |
| Fritze, D | 1 |
| Arnold, H | 1 |
| Henss, H | 1 |
| Trux, F | 1 |
| Hardy, TG | 1 |
| Aguilar, PS | 1 |
| Plasencia, G | 1 |
| Rusan, MS | 1 |
| Hartmann, RF | 1 |
| Stewart, WR | 1 |
| Castro, JR | 1 |
| Saunders, WM | 1 |
| Quivey, JM | 1 |
| Chen, GT | 1 |
| Collier, JM | 1 |
| Woodruff, KH | 1 |
| Lyman, JT | 1 |
| Twomey, P | 1 |
| Frey, C | 1 |
| Fujimoto, S | 7 |
| Kitsukawa, Y | 2 |
| Okui, K | 6 |
| Conroy, JF | 1 |
| Roda, PI | 1 |
| Brodsky, I | 1 |
| Kahn, SB | 1 |
| Bulova, SI | 1 |
| Pequignot, E | 1 |
| Cowan, JD | 1 |
| Easterbrock, J | 1 |
| Mills, GM | 1 |
| McCracken, JD | 2 |
| Kinami, Y | 4 |
| Shinmura, K | 1 |
| Takada, M | 2 |
| Sakuma, H | 1 |
| Nagakawa, T | 1 |
| Miyazaki, I | 4 |
| Suzuoka, M | 1 |
| Katayama, T | 1 |
| Monden, K | 2 |
| Hirano, T | 2 |
| Kono, Y | 1 |
| Ogasawara, K | 4 |
| Bada, K | 1 |
| Obaya, M | 1 |
| Fujioka, J | 1 |
| Takasan, H | 1 |
| Furue, H | 2 |
| Garvey, EC | 1 |
| Manganaro, M | 1 |
| Choy, DS | 1 |
| Newman, H | 1 |
| Vieta, J | 1 |
| Woods, RL | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Levi, JA | 2 |
| Brodie, GN | 1 |
| Valdivieso, M | 1 |
| Bonomi, PD | 1 |
| Chandra, G | 1 |
| Rossof, AH | 1 |
| Klaassen, D | 1 |
| Solan, A | 1 |
| Vogl, SE | 1 |
| Kaplan, BH | 1 |
| Berenzweig, M | 1 |
| Richard, J | 1 |
| Lanham, R | 1 |
| Mantravadi, RV | 1 |
| Spigos, DG | 1 |
| Tan, WS | 1 |
| Felix, EL | 1 |
| Tylén, U | 4 |
| Levine, AW | 1 |
| Donegan, WL | 4 |
| Irwin, M | 1 |
| Kies, MS | 1 |
| Schlesinger, T | 2 |
| Chlebowski, RT | 1 |
| Bateman, JR | 2 |
| Ausman, RK | 2 |
| Caballero, GA | 2 |
| Quebbeman, E | 1 |
| Ausman, DC | 1 |
| Granov, AM | 1 |
| Borisov, AE | 2 |
| Plotkin, LL | 1 |
| Zemlianoĭ, VP | 2 |
| Shelukhin, AP | 1 |
| Peetz, M | 1 |
| Swanson, J | 1 |
| Moseley, HS | 1 |
| Hiramoto, Y | 1 |
| Shiraishi, M | 1 |
| Inoue, F | 1 |
| Kodama, Y | 1 |
| Whitehouse, JM | 1 |
| Huttunen, R | 2 |
| Laitinen, S | 1 |
| Larmi, TK | 2 |
| Komita, T | 1 |
| Iketa, T | 1 |
| Arimori, S | 1 |
| Nagao, T | 2 |
| Ariel, IM | 4 |
| Padula, G | 3 |
| Dahl, E | 1 |
| Fredlund, P | 2 |
| Lesti, G | 1 |
| Andriani, G | 1 |
| Marinucci, R | 1 |
| Lance, JS | 1 |
| Hall, TC | 2 |
| Helmer, RE | 1 |
| Morettin, LB | 1 |
| Costanzi, JJ | 1 |
| Lokich, J | 1 |
| Kinsella, T | 1 |
| Perri, J | 1 |
| Malcolm, A | 1 |
| Clouse, M | 1 |
| Stone, RT | 1 |
| Jabour, A | 1 |
| Wilson, SE | 1 |
| Rangel, DM | 1 |
| Almersjö, OE | 1 |
| Gustavsson, BG | 1 |
| Regårdh, CG | 1 |
| Wåhlén, P | 1 |
| Van der Veer, LD | 1 |
| Balint, JA | 1 |
| Dahl, EP | 1 |
| Frelund, PE | 1 |
| Ellis, PA | 1 |
| Norman, A | 1 |
| Hill, A | 1 |
| O'Brien, ME | 1 |
| Nicolson, M | 1 |
| Norum, J | 1 |
| Schalhorn, A | 5 |
| Kühl, M | 1 |
| Rossion, I | 2 |
| Koch, B | 1 |
| Encke, A | 6 |
| Wiesner, J | 1 |
| Stéphan, F | 1 |
| Wallays, C | 1 |
| Clergue, F | 1 |
| Thel, MC | 1 |
| Ciaccia, D | 1 |
| Vredenburgh, JJ | 1 |
| Peters, W | 1 |
| Corey, GR | 1 |
| Brucker, C | 1 |
| Weiss, M | 1 |
| Schweiberer, L | 1 |
| Genz, T | 1 |
| Maassen, V | 1 |
| Debus-Thiede, G | 1 |
| Guyader, D | 1 |
| Duvauferrier, R | 1 |
| Bourguet, P | 2 |
| Bekhechi, D | 1 |
| Deugnier, YM | 1 |
| Gosselin, M | 1 |
| Wang, HL | 1 |
| Vexler, AM | 1 |
| Mou, X | 1 |
| Gabizon, AA | 1 |
| Gorodetsky, R | 1 |
| Lygidakis, NJ | 1 |
| Kosmidis, P | 2 |
| Ziras, N | 1 |
| Parissis, J | 1 |
| Kyparidou, E | 1 |
| Tetef, M | 1 |
| Doroshow, J | 1 |
| Akman, S | 1 |
| Coluzzi, P | 1 |
| Leong, L | 2 |
| Margolin, K | 1 |
| Morgan, RJ | 1 |
| Raschko, J | 1 |
| Shibata, S | 2 |
| Somlo, G | 1 |
| Court, WS | 1 |
| Fukao, K | 1 |
| Chikamori, F | 1 |
| Yuzawa, K | 1 |
| Shibuya, S | 1 |
| Nozue, M | 2 |
| Todoroki, T | 1 |
| Miya, K | 5 |
| Fukada, D | 4 |
| Takao, H | 5 |
| Aramaki, M | 3 |
| Kawano, K | 3 |
| Hanada, H | 1 |
| Maeshiro, T | 6 |
| Yamada, F | 3 |
| Awane, Y | 6 |
| Yanagi, I | 3 |
| Koga, A | 4 |
| Aso, K | 3 |
| Nishio, T | 2 |
| Shirotani, T | 2 |
| Kodama, T | 1 |
| So, H | 2 |
| Shibata, J | 5 |
| Nagashima, J | 2 |
| Tamaki, Y | 6 |
| Shin, E | 8 |
| Hoshima, M | 1 |
| Mugitani, T | 1 |
| Koishi, K | 1 |
| Masuyama, M | 3 |
| Miyata, K | 5 |
| Kohashi, S | 1 |
| Shiroto, H | 1 |
| Takahashi, N | 5 |
| Ikuta, K | 1 |
| Uchino, J | 7 |
| Ozaki, M | 4 |
| Ariga, T | 2 |
| Ooshima, I | 1 |
| Maruyama, T | 5 |
| Takeda, A | 3 |
| Yoshimura, S | 2 |
| Shouko, T | 1 |
| Koizumi, T | 1 |
| Mori, K | 7 |
| Osaku, M | 1 |
| Watahiki, Y | 1 |
| Hojyo, M | 2 |
| Kosaka, A | 5 |
| Maruo, H | 3 |
| Kido, S | 1 |
| Kida, M | 1 |
| Kojima, K | 3 |
| Akiyama, J | 1 |
| Hashimoto, N | 2 |
| Uchida, M | 2 |
| Yamanoi, A | 4 |
| Nagasue, N | 10 |
| Takami, M | 2 |
| Kitada, M | 2 |
| Tsukahara, Y | 2 |
| Murotani, M | 1 |
| Iihara, K | 2 |
| Ishiyama, J | 1 |
| Imai, I | 1 |
| Fukuma, E | 1 |
| Kano, N | 1 |
| Yamakawa, T | 1 |
| Kera, J | 1 |
| Itani, K | 1 |
| Hiraoka, M | 1 |
| Noguchi, M | 1 |
| Terada, J | 1 |
| Mizuno, I | 2 |
| Mohri, N | 2 |
| Inagaki, H | 1 |
| Manabe, T | 2 |
| Nabeyama, A | 2 |
| Sakagami, K | 1 |
| Van den Hout, BM | 1 |
| Taal, BG | 2 |
| Gortzak, E | 1 |
| Zoetmulder, FA | 1 |
| Boot, H | 1 |
| Evans, DB | 2 |
| Cleary, KR | 2 |
| Buchholz, DJ | 1 |
| Fenoglio, CJ | 2 |
| Collier, C | 1 |
| Peacock, JL | 1 |
| Goseki, N | 1 |
| Kando, F | 1 |
| Shimoju, K | 1 |
| Kohara, N | 1 |
| Kitaoka, F | 1 |
| Komuta, K | 1 |
| Motojima, K | 1 |
| Kanematsu, T | 6 |
| van der Wilt, CL | 3 |
| Marinelli, A | 2 |
| Cloos, J | 2 |
| Salminen, E | 1 |
| Nikkanen, V | 1 |
| Kimura, O | 1 |
| Kurayoshi, K | 1 |
| Sugezawa, A | 1 |
| Makino, M | 2 |
| Kaibara, N | 2 |
| Hisatomi, K | 1 |
| Nagafuchi, Y | 1 |
| Ohsato, K | 1 |
| Ji, T | 1 |
| Gu, Q | 1 |
| Nakasaki, H | 2 |
| Hanaue, H | 1 |
| Fujii, K | 2 |
| Mitomi, T | 3 |
| Kurosawa, T | 1 |
| Egami, I | 1 |
| Onda, M | 1 |
| Kelm, C | 1 |
| Henneking, K | 1 |
| Zimmermann, T | 1 |
| Vollerthun, M | 1 |
| Therasse, E | 1 |
| Breittmayer, F | 1 |
| Roche, A | 1 |
| Indushekar, S | 1 |
| Jardines, L | 1 |
| Callans, LS | 1 |
| Torosian, MH | 1 |
| Takenaka, K | 4 |
| Nishizaki, T | 1 |
| Korenaga, D | 1 |
| Hiroshige, K | 1 |
| Ilson, DH | 1 |
| Sirott, M | 1 |
| Heelan, R | 1 |
| Keresztes, R | 1 |
| Toya, N | 1 |
| Masaoka, N | 1 |
| Hirabayashi, T | 1 |
| Houya, Y | 1 |
| Matai, K | 1 |
| Stathopoulos, GP | 1 |
| Stergiou, GS | 1 |
| Perrea-Kostarelis, DN | 1 |
| Dontas, IA | 1 |
| Karamanos, BG | 1 |
| Karayiannacos, PE | 1 |
| Ambiru, S | 2 |
| Sørensen, P | 1 |
| Edal, AL | 1 |
| Madsen, EL | 1 |
| Fenger, C | 1 |
| Poulsen, MR | 1 |
| Petersen, OF | 1 |
| Culine, S | 1 |
| Theodore, C | 2 |
| Droz, JP | 4 |
| Diaco, DS | 1 |
| Hajarizadeh, H | 2 |
| Mueller, CR | 2 |
| Pommier, RF | 1 |
| Woltering, EA | 2 |
| Barberi-Heyob, M | 1 |
| Merlin, JL | 1 |
| Vigneron, M | 1 |
| Su, J | 1 |
| Zhen, YC | 1 |
| Qi, CQ | 1 |
| Hu, JL | 1 |
| Vaughn, D | 1 |
| Treat, J | 2 |
| McCall, JL | 1 |
| Jorgensen, JO | 1 |
| Kusaba, T | 2 |
| Kuroki, S | 1 |
| Inoue, J | 2 |
| Katoh, O | 1 |
| Sasatomi, K | 1 |
| Yabushita, K | 3 |
| Takada, O | 1 |
| Hasebe, K | 1 |
| Tsugawa, K | 1 |
| Kuroda, Y | 4 |
| Demachi, H | 2 |
| Olthoff, KM | 2 |
| Rosove, MH | 2 |
| Shackleton, CR | 2 |
| Imagawa, DK | 2 |
| Farmer, DG | 2 |
| Northcross, P | 2 |
| Pakrasi, AL | 2 |
| Martin, P | 2 |
| Goldstein, LI | 2 |
| Inokuchi, T | 1 |
| Fujihara, T | 1 |
| Mori, F | 1 |
| Tamura, Y | 2 |
| Kimoto, K | 1 |
| Sakuyama, T | 2 |
| Shimono, S | 1 |
| Takamura, S | 1 |
| Inomata, Y | 2 |
| Isshi, K | 1 |
| Chibai, M | 1 |
| Tadaoka, N | 2 |
| Furukawa, Y | 1 |
| Otani, Y | 3 |
| Ihara, A | 2 |
| Tsuji, R | 1 |
| Hiki, Y | 1 |
| Shinohara, K | 1 |
| Hu, GD | 1 |
| Li, XM | 1 |
| Huang, ZC | 1 |
| Hu, DY | 1 |
| Allegra, CJ | 1 |
| Chung, YS | 2 |
| Nitta, A | 1 |
| Hirayama, K | 1 |
| Kubo, T | 1 |
| Kiang, DT | 1 |
| Kennedy, BJ | 2 |
| Younger, J | 1 |
| Perry, MC | 1 |
| Schilling, A | 2 |
| Korzun, AH | 2 |
| Nowak, BS | 1 |
| Wood, W | 1 |
| Colleoni, M | 3 |
| Gaion, F | 1 |
| Liessi, G | 2 |
| Mastropasqua, G | 1 |
| Nelli, P | 2 |
| Manente, P | 2 |
| Riesener, KP | 2 |
| Winkeltau, G | 2 |
| Klemm, M | 1 |
| Schumpelick, V | 2 |
| Fried, G | 1 |
| Tsalik, M | 1 |
| Dale, J | 1 |
| Haim, N | 1 |
| Shida, H | 3 |
| Ban, K | 3 |
| Ishihara, S | 2 |
| Noma, M | 2 |
| Higashi, H | 4 |
| Kitazaki, M | 2 |
| Masuda, K | 3 |
| Imanari, T | 2 |
| Rexroth, G | 1 |
| Scotland, V | 1 |
| Zhang, GJ | 1 |
| Adachi, I | 2 |
| Yin, DF | 1 |
| Narabayashi, M | 1 |
| Tokue, Y | 1 |
| Kaneko, A | 1 |
| Lévy, E | 2 |
| Mishima, Y | 3 |
| Warren, HW | 3 |
| Anderson, JH | 4 |
| O'Gorman, P | 1 |
| Kane, E | 2 |
| Cooke, TG | 4 |
| Kabuto, T | 6 |
| Kameyama, M | 5 |
| Hiratsuka, M | 5 |
| Tomita, K | 1 |
| Ohashi, K | 1 |
| Ariyoshi, Y | 8 |
| Hoshino, M | 2 |
| Igarashi, W | 1 |
| Ohtake, T | 1 |
| Hatakeyama, Y | 2 |
| Abe, R | 2 |
| Misuta, K | 1 |
| Masui, H | 3 |
| Ike, H | 2 |
| Cho, G | 1 |
| Takatsuka, Y | 5 |
| Seshimo, A | 1 |
| Aratake, T | 1 |
| Kawase, A | 1 |
| Kirita, T | 1 |
| Higaki, T | 1 |
| Oishi, H | 1 |
| Nakata, Y | 1 |
| Kono, S | 1 |
| Tsurumi, M | 1 |
| Hamanaka, Y | 1 |
| Kawasaki, T | 2 |
| Okuyama, M | 1 |
| Satomi, T | 2 |
| Tomita, F | 3 |
| Kurosaka, Y | 1 |
| Kita, I | 2 |
| Komesu, I | 1 |
| Ohgami, N | 1 |
| Sou, H | 1 |
| Kumabe, T | 1 |
| Satoh, Y | 1 |
| Une, Y | 7 |
| Fujisawa, J | 1 |
| Civalleri, D | 4 |
| Håkansson, L | 1 |
| Arnaud, JP | 4 |
| Engarås, B | 1 |
| Holmberg, SB | 1 |
| Jönsson, PE | 4 |
| Tidebrant, G | 1 |
| Hussain, A | 1 |
| Young, ET | 1 |
| Greaves, JD | 1 |
| Hammond, PJ | 1 |
| Hughes, JM | 1 |
| Wallis, SC | 1 |
| Bloom, SR | 1 |
| Colin, R | 1 |
| Bordes, G | 1 |
| Bory, M | 1 |
| Ozawa, Z | 1 |
| Ozawa, T | 2 |
| Touno, T | 3 |
| Pizzorno, G | 1 |
| Bodden, W | 2 |
| Marsh, J | 1 |
| Strair, R | 2 |
| Pollack, J | 1 |
| Hendler, R | 1 |
| Hanna, J | 1 |
| D'Andrea, E | 1 |
| Maruhashi, Y | 1 |
| Hirose, S | 2 |
| Satomura, Y | 1 |
| Miwa, A | 1 |
| Nakanuma, Y | 1 |
| Bradley, C | 1 |
| Selby, P | 1 |
| Schlemmer, HP | 1 |
| Bachert, P | 3 |
| Semmler, W | 4 |
| Hohenberger, P | 11 |
| Lorenz, WJ | 4 |
| van Kaick, G | 5 |
| Begos, DG | 1 |
| Ballantyne, GH | 1 |
| Kusano, F | 1 |
| Maekawa, N | 1 |
| Tajiri, K | 1 |
| Tazawa, J | 1 |
| Kwan, W | 1 |
| Bjarnason, GA | 2 |
| Hamilton, P | 1 |
| Stein, TA | 1 |
| Burns, GP | 1 |
| Bailey, B | 1 |
| Citron, ML | 1 |
| Roos, JC | 1 |
| Teule, GJ | 1 |
| Castoldi, MC | 1 |
| Dellafiore, L | 1 |
| Pancera, G | 1 |
| Pierce, A | 1 |
| Mahaffey, W | 1 |
| Specht, S | 1 |
| Stemmler, N | 1 |
| Katoh, A | 2 |
| Nakajima, I | 4 |
| Akabane, Y | 1 |
| Kurooka, K | 2 |
| Koh, K | 2 |
| Shindo, K | 3 |
| Tsuzuki, H | 1 |
| Niki, M | 1 |
| Ueda, H | 2 |
| Takamoto, Y | 1 |
| Oohara, M | 1 |
| Igarashi, S | 2 |
| Osada, H | 1 |
| Nishimura, G | 2 |
| Kurosu, Y | 1 |
| Martinelli, DJ | 1 |
| Bakal, CW | 1 |
| Haynes, H | 1 |
| Wiernik, PH | 1 |
| Grandjouan, S | 1 |
| Fabri, MC | 1 |
| Miyauchi, T | 1 |
| Yamada, A | 2 |
| Fuji, N | 1 |
| Egeli, R | 3 |
| Arma, S | 2 |
| Barras, JP | 1 |
| Müller, W | 2 |
| Castiglione, M | 2 |
| Schroeder, R | 2 |
| Lamar, RE | 1 |
| Johnson, DH | 1 |
| Murphy, PB | 1 |
| Iwamiya, T | 2 |
| Yasui, M | 2 |
| Nonami, T | 3 |
| Harada, A | 3 |
| Hashimoto, S | 1 |
| Kajikawa, M | 1 |
| Hiraoka, E | 1 |
| Kido, C | 13 |
| Moriya, N | 2 |
| Sasaki, D | 2 |
| Yodono, H | 4 |
| Takekawa, SD | 2 |
| Tarusawa, K | 4 |
| Kanehira, J | 3 |
| Sasaki, T | 4 |
| Yakushiji, H | 2 |
| Kitahara, K | 2 |
| Tsutsumi, N | 1 |
| Iwanaga, A | 1 |
| Iyama, A | 1 |
| Fukagawa, H | 1 |
| Wen, YJ | 1 |
| Fujishima, H | 1 |
| Yoshimatsu, H | 1 |
| Niho, Y | 3 |
| Klotz, HP | 2 |
| Weder, W | 4 |
| Largiadèr, F | 4 |
| Rasi, G | 1 |
| Silecchia, G | 1 |
| Sinibaldi-Vallebona, P | 1 |
| Spaziani, E | 1 |
| Pierimarchi, P | 1 |
| Sivilia, M | 1 |
| Tremiterra, S | 1 |
| Garaci, E | 1 |
| Jochheim, C | 1 |
| Janning, P | 1 |
| Marggraf, U | 1 |
| Löffler, TM | 1 |
| Hasse, F | 1 |
| Linscheid, M | 1 |
| Takamura, A | 1 |
| Sakurai, Y | 2 |
| Horio, K | 1 |
| Yamano, M | 1 |
| Sawaguchi, Y | 1 |
| Hamblin, TJ | 2 |
| Sadullah, S | 2 |
| Williamson, P | 2 |
| Stevenson, J | 1 |
| Oskam, R | 1 |
| Palmer, P | 2 |
| Franks, CR | 2 |
| Brix, G | 3 |
| Bellemann, ME | 3 |
| Zabel, HJ | 1 |
| Chase, JL | 3 |
| Koster, RH | 1 |
| Weissman, DE | 1 |
| Balaban, EP | 1 |
| Graham, M | 1 |
| Perkins, S | 1 |
| Sheehan, RG | 1 |
| Frenkel, EP | 1 |
| Ross, M | 1 |
| Bull, J | 1 |
| Pruitt, B | 1 |
| Periman, P | 1 |
| Ruud, C | 1 |
| Xu, HB | 1 |
| Yan, XQ | 1 |
| de Takats, PG | 1 |
| Poole, CJ | 1 |
| Takei, Y | 1 |
| Di Tora, P | 2 |
| Mannella, E | 2 |
| Casaldi, V | 1 |
| Morandi, GB | 1 |
| Da Pian, PP | 2 |
| Padovani, A | 1 |
| Callopoli, A | 1 |
| Dimitrakopoulou, A | 2 |
| Clorius, JH | 2 |
| Ostertag, H | 1 |
| Heim, M | 1 |
| Oberdorfer, F | 3 |
| Helus, F | 1 |
| Haberkorn, U | 3 |
| Boese-Landgraf, J | 5 |
| Häring, R | 1 |
| Weber, B | 1 |
| Hopfenmüller, W | 1 |
| Hager, K | 1 |
| Ichiyoshi, Y | 1 |
| Miura, O | 1 |
| Matsuzaki, K | 1 |
| Minamisono, Y | 1 |
| Nagasaki, S | 1 |
| Nolè, F | 1 |
| Leach, MO | 1 |
| Collins, DJ | 1 |
| Payne, GS | 1 |
| Glaholm, J | 1 |
| Mansi, JL | 1 |
| McCready, VR | 1 |
| Kosaki, G | 2 |
| Kurihara, M | 2 |
| Azuma, S | 1 |
| Furuta, T | 1 |
| Tohno, K | 1 |
| Utsunomiya, T | 1 |
| Oikawa, H | 3 |
| Matsuzaki, H | 5 |
| Akaishi, O | 4 |
| Seo, K | 2 |
| Ozasa, T | 3 |
| Koishi, Y | 1 |
| Mukaijo, T | 1 |
| Shiiba, K | 2 |
| Ouchi, A | 2 |
| Kunii, Y | 3 |
| Momono, S | 3 |
| Mashiko, H | 2 |
| Wada, M | 3 |
| Mashima, H | 1 |
| Katano, M | 2 |
| Kishikawa, T | 1 |
| Hisatsugu, T | 2 |
| Akaike, M | 1 |
| Sugimasa, Y | 1 |
| Satou, T | 1 |
| Suganuma, Y | 2 |
| Torii, T | 1 |
| Ozawa, M | 1 |
| Toyama, K | 1 |
| Aoki, F | 1 |
| Cantor, AB | 1 |
| Glicksman, A | 2 |
| Sitzmann, JV | 1 |
| Abrams, R | 1 |
| Chiche, L | 1 |
| Itsubo, M | 1 |
| Foo, ML | 1 |
| Gunderson, LL | 2 |
| McLlrath, DC | 1 |
| van Heerden, JA | 2 |
| Robinow, JS | 1 |
| Kvols, LK | 1 |
| Garton, GR | 1 |
| Martenson, JA | 1 |
| Cha, SS | 1 |
| Lai, RQ | 1 |
| Gondo, H | 2 |
| Takeda, I | 3 |
| Sugiyama, K | 3 |
| Suga, T | 2 |
| Oki, H | 1 |
| Ijuin, H | 1 |
| Ban, S | 1 |
| Sakata, K | 1 |
| Ono, N | 1 |
| Noguchi, H | 1 |
| Itobayashi, E | 1 |
| Shimauchi, A | 1 |
| Lehner, B | 1 |
| Frohmüller, S | 1 |
| Yang, JC | 1 |
| Shlasko, E | 1 |
| Ritchey, JL | 1 |
| Landry, JG | 1 |
| White, DE | 1 |
| Rosenberg, SA | 1 |
| Lynes, AC | 1 |
| O'Shaughnessy, JA | 1 |
| Cowan, KH | 1 |
| Meyer, S | 2 |
| Vermorken, JB | 1 |
| Nieweg, MB | 1 |
| Cuesta, M | 1 |
| Lankelma, J | 1 |
| Kok, RM | 1 |
| Noordhuis, P | 2 |
| Hidalgo, OF | 1 |
| Rebollo, J | 1 |
| Bilbao, I | 1 |
| Tangco, E | 1 |
| Abuchaibe, O | 1 |
| Gomez, J | 1 |
| Bready, B | 1 |
| Levin, B | 3 |
| Sigurdson, E | 1 |
| Cohen, A | 2 |
| Seiter, K | 2 |
| Lincer, R | 1 |
| Botet, J | 2 |
| Chapman, D | 1 |
| Costa, P | 2 |
| Inutsuka, S | 1 |
| Kohnoe, S | 3 |
| Carstensen, JM | 1 |
| Burcharth, F | 1 |
| Boyle, FM | 1 |
| Smith, RC | 1 |
| Kuo, TH | 1 |
| Nishibori, H | 1 |
| Furukawa, T | 2 |
| Kase, S | 1 |
| Saikawa, Y | 1 |
| Kitajima, M | 3 |
| Komatsu, T | 1 |
| Ookubo, K | 1 |
| Spiers, EM | 1 |
| Potts, RC | 1 |
| Sharpe, SY | 1 |
| Newman, EL | 1 |
| Lavelle-Jones, M | 1 |
| Beck, JS | 1 |
| Cuschieri, A | 3 |
| Bumann, D | 1 |
| Crone-Münzebrock, W | 1 |
| Carl, U | 1 |
| Weh, HJ | 2 |
| Stevens, HP | 1 |
| Ostlere, LS | 1 |
| Begent, RH | 1 |
| Dooley, JS | 1 |
| Rustin, MH | 1 |
| Shirafuji, T | 1 |
| Neoptolemos, J | 1 |
| Seymour, M | 2 |
| Doughty, J | 1 |
| Budden, J | 2 |
| Staley, CA | 1 |
| Goss, PE | 1 |
| Prince, M | 1 |
| Eatock, MM | 1 |
| Carlin, W | 1 |
| Dunlop, DJ | 1 |
| Watson, DG | 2 |
| Tessitore, J | 1 |
| Huberman, M | 1 |
| Carlson, R | 1 |
| Allen-Mersh, T | 1 |
| O'Connell, M | 1 |
| Chang, A | 1 |
| Sondak, V | 1 |
| Kemeny, M | 1 |
| Petrelli, NJ | 1 |
| Rustum, YM | 1 |
| Blumenson, LE | 1 |
| Frank, C | 1 |
| Berghorn, E | 1 |
| Creaven, PJ | 1 |
| Findlay, M | 1 |
| Young, H | 1 |
| Iveson, A | 1 |
| Cronin, B | 1 |
| Pratt, B | 1 |
| Husband, J | 1 |
| Flower, M | 1 |
| Anand, A | 2 |
| Anand, N | 1 |
| Witham, M | 1 |
| Harnett, PR | 1 |
| Mughal, TI | 1 |
| Koriech, OM | 1 |
| Vaughn, DJ | 1 |
| Ooki, H | 1 |
| Samori, T | 1 |
| Babu, KG | 2 |
| Raud, C | 1 |
| Kumaraswamy, SV | 1 |
| Lalitha, N | 2 |
| Polyzos, A | 1 |
| Giannopoulos, A | 1 |
| Bacoyiannis, C | 1 |
| Papadimas, V | 1 |
| Kalahanis, N | 1 |
| Karatzas, G | 1 |
| Kosmas, C | 2 |
| Sakelaropoulos, N | 1 |
| Archimandritis, A | 1 |
| Papachristodoulou, A | 1 |
| Estes, NC | 2 |
| Giri, S | 1 |
| Fabian, C | 1 |
| Andreyev, HJ | 1 |
| Padhani, AR | 1 |
| Hill, AS | 1 |
| Webb, A | 2 |
| Sugahara, K | 2 |
| Tobe, T | 1 |
| Ohta, J | 1 |
| Maruiwa, M | 1 |
| Noutomi, M | 1 |
| Tokuhara, K | 1 |
| Inutsuka, K | 1 |
| Tanemura, H | 3 |
| Oshita, H | 1 |
| Kurimoto, H | 1 |
| Ono, K | 1 |
| Fuku, A | 1 |
| Miyaji, M | 1 |
| Ogoshi, K | 1 |
| Kajiura, Y | 1 |
| Saint-Marc, O | 1 |
| Pitre, J | 1 |
| Houssin, D | 1 |
| Chapuis, Y | 1 |
| Benhattar, J | 1 |
| Cerottini, JP | 1 |
| Saraga, E | 1 |
| Metthez, G | 1 |
| Givel, JC | 2 |
| Doughty, JC | 1 |
| Warren, H | 1 |
| Stewart, IS | 1 |
| Reid, AW | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Karaayvaz, M | 1 |
| Arat, AR | 1 |
| Larsson, PA | 1 |
| Carlsson, G | 1 |
| Spears, CP | 1 |
| Barthel, A | 1 |
| Leonhardt, U | 1 |
| Stöckmann, F | 1 |
| Kawaguchi, H | 1 |
| Unate, H | 1 |
| Nitta, K | 1 |
| Tsujitani, S | 2 |
| Takiya, S | 1 |
| Tagaya, T | 1 |
| Fukuzawa, Y | 1 |
| Leung, SF | 1 |
| Teo, PM | 1 |
| Lee, WY | 1 |
| Rasheshyam, D | 1 |
| Clark, J | 1 |
| Sikov, W | 1 |
| Cummings, F | 1 |
| Browne, M | 1 |
| Akerley, W | 1 |
| Wanebo, H | 1 |
| Weitberg, A | 1 |
| Kennedy, T | 1 |
| Cole, B | 1 |
| Bigley, J | 1 |
| Beitz, J | 1 |
| Darnowski, J | 1 |
| Porte, H | 1 |
| De Moulins, H | 1 |
| Gambiez, L | 2 |
| Wurtz, A | 1 |
| Quandalle, P | 2 |
| Kubo, R | 2 |
| Murase, M | 1 |
| Hibi, K | 1 |
| Akiyama, S | 1 |
| Hattori, T | 3 |
| Fukata, S | 1 |
| Hayashi, Y | 1 |
| Sawai, S | 1 |
| Ragnhammar, P | 1 |
| Blomgren, H | 1 |
| Skinazi, F | 1 |
| Zins, M | 1 |
| Menu, Y | 1 |
| Bernades, P | 1 |
| Pillasch, J | 5 |
| Weindel, M | 2 |
| Leder, G | 4 |
| Beger, HG | 8 |
| Matuo, H | 1 |
| Taketomi, A | 1 |
| Tomoda, H | 2 |
| Watabiki, Y | 2 |
| Shikata, A | 3 |
| Hoshiya, Y | 2 |
| Yorozuya, K | 1 |
| Arai, T | 5 |
| Okabe, S | 5 |
| Murase, N | 5 |
| Yabata, E | 1 |
| Endou, M | 1 |
| Yayoi, E | 1 |
| Maruhashi, S | 1 |
| Tateishi, H | 1 |
| Hojo, I | 1 |
| Fukunari, H | 1 |
| Iwanaga, T | 2 |
| Harmantas, A | 1 |
| Rotstein, LE | 1 |
| Aschele, C | 3 |
| Tixi, L | 1 |
| Davidson, BS | 1 |
| DuBrow, RA | 1 |
| Patt, Y | 1 |
| Blesing, CH | 1 |
| Shiomi, S | 1 |
| Kuroki, T | 1 |
| Hasegawa, I | 1 |
| Azuma, K | 1 |
| Ochi, H | 1 |
| Busuttil, RW | 1 |
| Dasappa, V | 1 |
| Ross, WB | 3 |
| King, DW | 1 |
| Clingan, PR | 5 |
| Ruffin, WK | 1 |
| Sparano, JA | 1 |
| Lipsitz, S | 2 |
| Hansen, R | 2 |
| Bushunow, PW | 1 |
| Kirkwood, J | 1 |
| Flynn, PJ | 1 |
| Dutcher, JP | 1 |
| Bower, M | 1 |
| Newlands, ES | 1 |
| Suga, M | 1 |
| Otani, J | 2 |
| Morisue, S | 1 |
| Yoshizane, K | 1 |
| Morokoshi, Y | 1 |
| Soda, M | 2 |
| Cooper, RA | 1 |
| James, RD | 1 |
| Taylor, KJ | 1 |
| Gabra, H | 1 |
| Cameron, DA | 1 |
| Lee, LE | 1 |
| Mackay, J | 1 |
| Leonard, RC | 1 |
| Ashikaga, K | 1 |
| Hanyu, N | 1 |
| Ishimura, H | 1 |
| Mariani, G | 1 |
| Di Sacco, S | 1 |
| Bonini, R | 1 |
| Di Luca, L | 1 |
| Buralli, S | 1 |
| Bonora, D | 1 |
| Baranowska-Kortylewicz, J | 1 |
| Adelstein, SJ | 1 |
| Kassis, AI | 1 |
| Dixon, K | 1 |
| Itoyanagi, H | 1 |
| Hirose, I | 1 |
| Hasumi, K | 2 |
| Eriguchi, M | 2 |
| Fenton-Lee, D | 1 |
| Phadke, K | 1 |
| Mastrapasqua, G | 1 |
| Vicario, G | 1 |
| Sgarbossa, G | 1 |
| Pancheri, F | 1 |
| Harstrick, A | 1 |
| Klaassen, U | 1 |
| Müller, C | 1 |
| Eberhardt, W | 1 |
| Korn, MW | 1 |
| Wilke, H | 2 |
| Seeber, S | 1 |
| Yoshinaga, K | 1 |
| Mizutani, H | 1 |
| Rafique, M | 1 |
| Adachi, W | 4 |
| Kajikawa, S | 4 |
| Yazawa, K | 2 |
| Sugenoya, A | 1 |
| Amano, J | 2 |
| Yukaya, H | 3 |
| Taniguch, K | 1 |
| Earlam, S | 1 |
| Glover, C | 3 |
| Davies, M | 1 |
| Fordy, C | 2 |
| Allen-Mersh, TG | 3 |
| Hoque, A | 2 |
| Lozano, R | 2 |
| Pozdur, R | 1 |
| Chase, J | 1 |
| Carrasco, H | 1 |
| Chuang, V | 2 |
| Delpassand, ES | 1 |
| Ellis, L | 2 |
| Curley, S | 2 |
| Roh, M | 3 |
| Jones, DV | 1 |
| Sowa, M | 2 |
| Miura, M | 1 |
| Terashima, Y | 1 |
| Yamazaki, S | 2 |
| Ikeyama, S | 1 |
| Taki, S | 1 |
| Yogita, S | 1 |
| Sanz-Altamira, PM | 1 |
| Spence, LD | 1 |
| Posner, MR | 1 |
| Perry, LJ | 2 |
| Stuart, KE | 2 |
| Schöffski, P | 1 |
| Prendiville, J | 1 |
| Howell, JD | 3 |
| Gallagher, H | 1 |
| Maguire, R | 1 |
| Ehrlich, PF | 1 |
| Greenberg, ML | 1 |
| Filler, RM | 1 |
| Wang, WS | 3 |
| Fan, FS | 3 |
| Chiou, TJ | 3 |
| Yen, CC | 3 |
| Hsu, H | 1 |
| Kissel, J | 2 |
| Port, R | 1 |
| Somma, L | 1 |
| Del Vecchio, M | 1 |
| Zunino, F | 1 |
| Bignami, P | 2 |
| Magnani, E | 1 |
| Zidani, R | 2 |
| Misset, JL | 5 |
| Esposito, M | 1 |
| De Cian, F | 1 |
| Balletto, N | 2 |
| Vannozzi, MO | 1 |
| Mondini, G | 1 |
| Carrabetta, S | 1 |
| Bocchio, MM | 1 |
| Cavazzini, G | 1 |
| Bertani, M | 1 |
| Pulica, C | 1 |
| Campo, S | 1 |
| Pari, F | 1 |
| Mambrini, A | 1 |
| Bezzi, A | 1 |
| Amadori, M | 1 |
| Smerieri, F | 1 |
| Metzger, R | 2 |
| Butzer, U | 3 |
| Leder, GH | 2 |
| Safi, F | 3 |
| Chung, Y | 1 |
| Toge, T | 4 |
| Mure, T | 1 |
| Imai, H | 1 |
| Onuma, E | 1 |
| Tadaoka, Y | 1 |
| Takeo, T | 1 |
| Kuwahara, H | 1 |
| Takamatsu, S | 2 |
| Sugano, N | 3 |
| Buckles, J | 1 |
| Gallagher, HJ | 1 |
| Morimoto, O | 1 |
| Baba, S | 1 |
| Miya, A | 1 |
| Hashizume, R | 1 |
| Arifuku, T | 1 |
| Nagaoka, S | 1 |
| Tomita, I | 3 |
| Kon, H | 2 |
| Sasaki, R | 2 |
| Kawata, S | 5 |
| Takao, T | 4 |
| Nishida, M | 2 |
| Takao, K | 1 |
| Sawamura, A | 2 |
| Kim, R | 1 |
| Aogi, K | 2 |
| Yamaguchi, Y | 1 |
| Hihara, J | 1 |
| Fukunaga, T | 2 |
| Iwasaki, K | 2 |
| Shinoto, K | 1 |
| Imazeki, H | 1 |
| Nishisho, I | 4 |
| Hosoki, T | 3 |
| Naitoh, H | 1 |
| Okauchi, H | 1 |
| Kodama, M | 1 |
| Oshima, I | 1 |
| Ioku, T | 1 |
| Iwashita, C | 1 |
| Shoko, T | 1 |
| Tsubaki, M | 2 |
| Hara, S | 1 |
| Hashizume, S | 1 |
| Itoyanagi, N | 1 |
| Tagawa, Y | 1 |
| Tsuji, H | 1 |
| Oka, T | 1 |
| Shinguu, H | 1 |
| Tou, K | 1 |
| Tooyama, H | 1 |
| Yamazumi, K | 1 |
| Onogawa, S | 1 |
| Nishimura, K | 2 |
| Umeda, Y | 1 |
| Imai, R | 1 |
| Nakagami, K | 1 |
| Muro, H | 1 |
| Ohno, T | 1 |
| Shibata, N | 2 |
| Ikeda, K | 2 |
| Hino, K | 1 |
| Masuyama, K | 1 |
| Okamoto, M | 2 |
| Fujimaki, M | 1 |
| Kakihara, N | 1 |
| Tazaki, N | 1 |
| Kida, T | 1 |
| Jibiki, M | 1 |
| Taniguchi, Y | 1 |
| Ikari, H | 1 |
| Ishibashi, T | 2 |
| Sugamura, Y | 1 |
| Kunizaki, T | 1 |
| Hirao, K | 1 |
| Chou, CW | 1 |
| Wu, MF | 1 |
| Tie, CM | 1 |
| Neoptolemos, JP | 1 |
| Wojtacki, J | 1 |
| Dziewulska-Bokiniec, A | 1 |
| Rolka-Stempniewicz, G | 1 |
| O'Hagan, S | 1 |
| Diamond, T | 1 |
| Streit, M | 1 |
| Stremetzne, S | 1 |
| Kerz, H | 1 |
| Strohbach, F | 1 |
| Zwiebel, FM | 1 |
| Hebart, H | 1 |
| Böthig, R | 1 |
| Kairies, M | 1 |
| Zillig, D | 1 |
| Schuchmann, S | 1 |
| Warnecke, S | 1 |
| Thiel, E | 1 |
| Kreuser, ED | 2 |
| Warzelhan, J | 1 |
| Tsushima, K | 3 |
| Koeda, K | 1 |
| Iwaya, T | 1 |
| Wakayama, H | 1 |
| Hotta, M | 1 |
| Oota, K | 1 |
| Thuss-Patience, P | 1 |
| Friedrich, M | 2 |
| Daniel, PT | 1 |
| Kretzschmar, A | 1 |
| Benter, T | 1 |
| Bauer, B | 1 |
| Dietz, R | 1 |
| Irngartinger, G | 1 |
| Doll, J | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Ouya, T | 1 |
| Ohwada, S | 1 |
| Gorlick, R | 1 |
| Miles, JS | 1 |
| Longo, GS | 1 |
| Banerjee, D | 1 |
| Klimstra, D | 1 |
| Jhanwar, S | 1 |
| Bertino, JR | 2 |
| Bandealy, MT | 1 |
| Gonin, R | 1 |
| Loehrer, PJ | 2 |
| Monaco, F | 1 |
| Einhorn, LH | 2 |
| Watanabe, H | 3 |
| Koide, N | 2 |
| Mihara, M | 1 |
| Roppongi, T | 1 |
| Kanno, K | 1 |
| Gerard, JP | 1 |
| Ayzac, L | 1 |
| Hun, D | 1 |
| Romestaing, P | 1 |
| Coquard, R | 1 |
| Ardiet, JM | 1 |
| Mornex, F | 1 |
| Gelman, RS | 1 |
| Pandya, KJ | 2 |
| Osborne, CK | 1 |
| Tormey, D | 1 |
| Cummings, FJ | 1 |
| Sledge, GW | 1 |
| Abeloff, MD | 1 |
| Chenoufi, N | 1 |
| Lescoat, G | 1 |
| Chan, KL | 1 |
| Tam, PK | 1 |
| Gottwald, T | 1 |
| Köveker, G | 1 |
| Büsing, M | 1 |
| Lauchart, W | 1 |
| Becker, HD | 1 |
| Pajkos, G | 1 |
| Szentpétery, L | 1 |
| Kristó, K | 1 |
| Izsó, J | 1 |
| Nepomniashchaia, SL | 1 |
| Topf, N | 1 |
| Worgall, S | 1 |
| Hackett, NR | 1 |
| Crystal, RG | 1 |
| Asano, T | 1 |
| Nakagouri, S | 1 |
| Kenmochi, T | 1 |
| Shutou, K | 1 |
| Shinotou, K | 1 |
| Kawasaki, R | 1 |
| Awatani, T | 1 |
| Bozec, L | 1 |
| Bierling, P | 1 |
| Fromont, P | 1 |
| Debat, P | 1 |
| Jouve, M | 1 |
| Asselain, B | 1 |
| Livartowski, A | 1 |
| Beuzeboc, P | 1 |
| Scholl, S | 1 |
| Dorval, T | 1 |
| Palangié, T | 1 |
| Garcia-Giralt, E | 1 |
| Pouillart, P | 1 |
| Kato, O | 1 |
| Bernath, AM | 1 |
| Schroeder, G | 1 |
| Fitzgibbons, RJ | 3 |
| Mailliard, JA | 2 |
| Burch, P | 1 |
| Colon-Otero, G | 1 |
| Krook, JE | 2 |
| Möhler, M | 1 |
| Gutzler, F | 1 |
| Raeth, U | 1 |
| Morandi, C | 1 |
| Colopi, S | 1 |
| Molani, L | 1 |
| Cantone, M | 1 |
| Gallo, E | 1 |
| Troiso, A | 1 |
| Mathurin, P | 1 |
| Rixe, O | 1 |
| Carbonell, N | 1 |
| Bernard, B | 1 |
| Cluzel, P | 1 |
| Bellin, MF | 1 |
| Opolon, P | 1 |
| Poynard, T | 1 |
| An, M | 1 |
| Terakado, H | 1 |
| Murata, M | 3 |
| Takagi, S | 3 |
| Ikawa, M | 1 |
| Hamada, E | 2 |
| Nakasato, S | 1 |
| Kujime, J | 1 |
| Yamagami, H | 2 |
| Kimura, J | 3 |
| Ohira, S | 3 |
| Iwase, H | 2 |
| Kameya, T | 1 |
| Itoh, I | 1 |
| Ohtaki, M | 2 |
| Nishishou, I | 2 |
| Sai, H | 2 |
| Adachi, T | 1 |
| Nagao, N | 1 |
| Takagi, Y | 2 |
| Sasaki, J | 3 |
| Tsutsui, M | 2 |
| Kirihara, M | 1 |
| Kawai, S | 2 |
| Tominaga, S | 1 |
| Kume, S | 1 |
| Iwai, T | 4 |
| Glenn, D | 1 |
| Rink, T | 1 |
| Schröder, O | 1 |
| Dietrich, C | 1 |
| Kirchner, J | 1 |
| Hör, G | 1 |
| Zeuzem, S | 1 |
| Baum, RP | 1 |
| Seymour, MT | 2 |
| Dietz, DW | 1 |
| Casillas, S | 1 |
| Jones, SC | 1 |
| Milsom, JW | 1 |
| Sahmoud, T | 1 |
| Curran, D | 1 |
| De Waele, B | 1 |
| Rauschecker, H | 1 |
| Marsoni, S | 1 |
| Apolone, G | 1 |
| Couvreur, ML | 1 |
| Kasperk, R | 1 |
| Pincemaille, B | 1 |
| Besançon, C | 1 |
| Balme, B | 1 |
| Devaux, Y | 1 |
| Thomas, L | 1 |
| Movsas, B | 1 |
| Hanlon, AL | 1 |
| Lanciano, R | 1 |
| Scher, RM | 1 |
| Weiner, LM | 1 |
| Hoffman, JP | 2 |
| Eisenberg, BL | 2 |
| Provins, S | 1 |
| Coia, LR | 1 |
| Kobayashi, A | 1 |
| Chimori, Y | 1 |
| Yamane, E | 1 |
| Nishioka, B | 1 |
| Chauffert, B | 2 |
| Bonnotte, B | 1 |
| Chvetzoff, G | 1 |
| Hocking, RA | 1 |
| Feng, Y | 1 |
| Nagawa, H | 1 |
| Koike, H | 1 |
| Kasai, H | 1 |
| Henderson, CA | 1 |
| Davies, MM | 1 |
| Jiang, W | 1 |
| Diasio, RB | 1 |
| Cheradame, S | 1 |
| Richelme, H | 1 |
| Mousseau, M | 1 |
| Gansauge, F | 2 |
| Hale, HL | 1 |
| Husband, JE | 1 |
| Gossios, K | 1 |
| Cordel, S | 2 |
| Dupas, B | 1 |
| Meflah, K | 2 |
| Rau, HG | 1 |
| Stieger, R | 2 |
| Jiang, S | 1 |
| Shin, EC | 1 |
| Lee, MO | 1 |
| Bulkley, GB | 1 |
| Oikawa, I | 2 |
| Takashima, T | 1 |
| Badalian, KhV | 1 |
| Tumanian, AO | 1 |
| Luna-Perez, P | 1 |
| Rodriguez-Coria, DF | 1 |
| Arroyo, B | 1 |
| Gonzalez-Macouzet, J | 1 |
| Suwa, H | 1 |
| Hosotani, R | 2 |
| Okino, T | 1 |
| Ohshio, G | 1 |
| Fukumoto, M | 1 |
| Stubbs, RS | 2 |
| Alwan, MH | 1 |
| Booth, MW | 1 |
| Bavisotto, LM | 1 |
| Patel, NH | 1 |
| Althaus, SJ | 1 |
| Coldwell, DM | 1 |
| Nghiem, HV | 1 |
| Thompson, T | 1 |
| Storer, B | 1 |
| Thomas, CR | 1 |
| Junginger, T | 2 |
| Saeger, HD | 2 |
| Yonekura, K | 1 |
| Sakukawa, R | 2 |
| Saiki, I | 2 |
| Masamune, R | 1 |
| Pillasch, AF | 1 |
| Sunelaitis, E | 3 |
| Schatz, M | 2 |
| Pressmar, J | 1 |
| Mabuchi, K | 1 |
| Kitaoka, H | 1 |
| Hirata, N | 1 |
| Kitaoka, U | 1 |
| Ogita, M | 1 |
| Ando, J | 1 |
| Tabei, T | 1 |
| Kanda, K | 1 |
| Fukutomi, T | 1 |
| Shimoyama, M | 1 |
| Serravezza, G | 1 |
| Lelli, G | 1 |
| Leo, S | 1 |
| Filippelli, G | 1 |
| Nicolella, G | 1 |
| Brandi, M | 1 |
| Rohlff, C | 1 |
| Watson, SA | 1 |
| Morris, TM | 1 |
| Skelton, L | 1 |
| Jackman, AL | 1 |
| Page, MJ | 1 |
| Yuasa, Y | 1 |
| Carrasco, CH | 3 |
| Cleary, K | 2 |
| Bender, H | 1 |
| Bangard, N | 1 |
| Metten, N | 1 |
| Bangard, M | 1 |
| Mezger, J | 1 |
| Schomburg, A | 1 |
| Biersack, HJ | 1 |
| Shankar, A | 2 |
| Loizidou, M | 1 |
| Burnstock, G | 1 |
| Port, RE | 3 |
| Zaers, J | 1 |
| Warner, E | 1 |
| Jensen, JL | 1 |
| Cripps, C | 1 |
| Khoo, KE | 1 |
| Kerr, IA | 1 |
| Hrincu, A | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Renaut, AJ | 1 |
| Whelan, J | 1 |
| Kreutz, F | 1 |
| Focan-Henrard, D | 2 |
| Lobelle, JP | 1 |
| Dallemagne, B | 2 |
| Jehaes, C | 2 |
| Markiewicz, S | 2 |
| Jasmin, C | 2 |
| Miller, M | 1 |
| Funahashi, Y | 1 |
| Koyanagi, N | 1 |
| Sonoda, J | 1 |
| Kitoh, K | 1 |
| Imamoto, E | 2 |
| Minami, M | 2 |
| Boku, Y | 1 |
| Inuma, S | 1 |
| Kaneda, K | 1 |
| Ho, SK | 1 |
| Liew, CT | 1 |
| Tang, AM | 2 |
| Twelves, C | 1 |
| Glynne-Jones, R | 1 |
| Schüller, J | 3 |
| Goggin, T | 1 |
| Roos, B | 1 |
| Banken, L | 1 |
| Utoh, M | 1 |
| Weidekamm, E | 1 |
| Reigner, B | 1 |
| Kakisaka, A | 2 |
| Goto, J | 1 |
| Ohara, K | 1 |
| Isizaki, A | 1 |
| Kino, S | 2 |
| Kasai, S | 2 |
| Fujitake, S | 1 |
| Shimizu, M | 1 |
| Tohyama, M | 1 |
| Kataoka, S | 1 |
| Rudroff, C | 1 |
| Altendorf-Hoffmann, A | 1 |
| Stangl, R | 2 |
| Scheele, J | 2 |
| Itzhaki, M | 1 |
| Gruia, G | 1 |
| Brienza, S | 2 |
| Alafaci, E | 1 |
| Bertheault-Cvitkovic, F | 2 |
| Reynes, M | 1 |
| Tokusasi, Y | 1 |
| Miyokawa, N | 1 |
| Leichman, CG | 1 |
| Jacobson, JR | 1 |
| Modiano, M | 1 |
| Daniels, JR | 1 |
| Doroshow, JH | 1 |
| Macdonald, JS | 2 |
| Debernardis, D | 2 |
| Baldo, C | 2 |
| Tunesi, G | 2 |
| Staccioli, MP | 1 |
| Brenna, A | 1 |
| Muretto, P | 1 |
| Catalano, G | 3 |
| Seno, H | 1 |
| Koshizuka, K | 1 |
| Hada, M | 1 |
| Muto, S | 1 |
| Hagiwara, J | 1 |
| Nakagomi, H | 1 |
| Takano, K | 1 |
| Kamiya, K | 1 |
| Tada, Y | 1 |
| Koehne, CH | 1 |
| Midgley, R | 1 |
| Dumas, P | 1 |
| Richli, W | 1 |
| Lawrence, D | 1 |
| Paulino, AC | 1 |
| Behr, TM | 1 |
| Salib, AL | 1 |
| Béhé, M | 1 |
| Angerstein, C | 1 |
| Blumenthal, RD | 1 |
| Fayyazi, A | 1 |
| Sharkey, RM | 1 |
| Ringe, B | 1 |
| Wörmann, B | 1 |
| Hiddemann, W | 2 |
| Goldenberg, DM | 1 |
| Becker, W | 1 |
| Itoh, K | 1 |
| Takayasu, Y | 3 |
| Hara, H | 2 |
| Nomura, E | 1 |
| Sako, S | 1 |
| Otani, M | 1 |
| Tanigawa, N | 2 |
| Fujioka, M | 2 |
| Kishi, T | 1 |
| Shimomura, K | 1 |
| Idezuki, Y | 3 |
| Kamano, T | 1 |
| Ishizaki, A | 1 |
| Kassai, S | 1 |
| Tsujita, K | 1 |
| Itou, Y | 1 |
| Oki, S | 1 |
| Ukei, T | 2 |
| Oozato, H | 2 |
| Udagawa, M | 2 |
| Ootsukasa, S | 1 |
| Utsumi, T | 1 |
| Senda, K | 1 |
| Ishihara, O | 1 |
| Morimoto, T | 1 |
| Azama, T | 2 |
| Okajima, S | 3 |
| Oohata, K | 1 |
| Tukamoto, H | 2 |
| Yoneyama, Y | 2 |
| Takanishi, K | 1 |
| Matsumoto, J | 1 |
| Kan, K | 1 |
| Kunishima, S | 3 |
| Shirasu, M | 1 |
| Kato, C | 1 |
| Sakumoto, H | 1 |
| Sumiyoshi, K | 1 |
| Takahahsi, T | 1 |
| Kane, T | 1 |
| Asano, M | 1 |
| Kasuya, K | 2 |
| Ohashi, M | 2 |
| Kure, M | 1 |
| Kohashi, T | 1 |
| Katayama, S | 1 |
| Fukuda, T | 1 |
| Dohi, K | 1 |
| Nisida, M | 2 |
| Ohtsukasa, S | 1 |
| Kishimoto, S | 1 |
| Wakahara, M | 1 |
| Ooshita, H | 1 |
| Kanno, A | 2 |
| Suhara, T | 1 |
| Nakata, T | 1 |
| Saitou, S | 1 |
| Takata, N | 1 |
| Harada, K | 1 |
| Yoshinaka, I | 1 |
| Ohara, E | 1 |
| Kawashima, N | 1 |
| Casazza, S | 1 |
| Antonelli, G | 1 |
| Lionetto, R | 1 |
| Maley, F | 1 |
| Larzillière, I | 1 |
| Brandissou, S | 1 |
| Breton, P | 1 |
| Lingoungou, A | 1 |
| Gargot, D | 1 |
| Ramain, JP | 1 |
| Harnois, C | 1 |
| Faivre, C | 1 |
| Lusinchi, A | 1 |
| Eschwege, F | 1 |
| Pierrefite-Carle, V | 2 |
| Baqué, P | 2 |
| Gavelli, A | 2 |
| Mala, M | 1 |
| Gugenheim, J | 1 |
| Bourgeon, A | 3 |
| Staccini, P | 2 |
| Rossi, B | 2 |
| Iwasa, H | 1 |
| Hirai, J | 1 |
| Morimoto, M | 1 |
| Sekiguchi, R | 1 |
| Moriyama, N | 1 |
| Cohen, AM | 3 |
| Shi, W | 1 |
| Brennan, MF | 1 |
| Turnbull, AD | 1 |
| Stockman, J | 1 |
| Thirion, P | 1 |
| Wolmark, N | 1 |
| Presant, CA | 1 |
| Waluch, V | 1 |
| Wiseman, CL | 1 |
| Weitz, I | 1 |
| Cellier, C | 1 |
| Yaghi, C | 1 |
| Cuillerier, E | 1 |
| Siauve, N | 1 |
| Berger, A | 1 |
| Carnot, F | 1 |
| Haddad, C | 1 |
| Barbier, JP | 1 |
| Martens-Lobenhoffer, J | 1 |
| Fuhlroth, J | 1 |
| Denimal, F | 1 |
| Karoui, M | 1 |
| Dewailly, V | 1 |
| Iwatani, Y | 1 |
| Sinmaru, H | 1 |
| Musha, N | 1 |
| Nihei, T | 1 |
| Sunami, E | 1 |
| Sando, N | 1 |
| Oka, K | 1 |
| Lampert, S | 1 |
| Reingruber, B | 1 |
| Vetter, G | 2 |
| Saguchi, T | 1 |
| Koizumi, K | 1 |
| Kakiuchi, H | 1 |
| Ashizawa, T | 1 |
| Nakao, N | 1 |
| Kubota, A | 1 |
| Smail, A | 1 |
| Cailliez, V | 1 |
| Block, A | 1 |
| Freund, CT | 1 |
| Chen, SH | 1 |
| Nguyen, KP | 1 |
| Windler, E | 1 |
| Woo, SL | 1 |
| Hochmuth, K | 1 |
| Horák, D | 2 |
| Guseinov, E | 2 |
| Vishnevskii, V | 2 |
| Adamyan, A | 2 |
| Kokov, L | 2 |
| Tsvirkun, V | 1 |
| Tchjao, A | 1 |
| Titova, M | 2 |
| Skuba, N | 2 |
| Trostenyuk, N | 2 |
| Gumargalieva, K | 1 |
| De Vreede, I | 1 |
| Steers, JL | 1 |
| Burch, PA | 1 |
| Rosen, CB | 1 |
| Haddock, MG | 1 |
| Burgart, L | 1 |
| Gores, GJ | 1 |
| Unno, J | 1 |
| Shirozaki, T | 1 |
| Arai, S | 1 |
| Okuyama, H | 1 |
| Hayashida, N | 1 |
| Kouda, S | 1 |
| Tadokoro, M | 1 |
| Ishikou, T | 1 |
| Touda, J | 1 |
| Miyazaki, O | 1 |
| Nosaka, S | 1 |
| Imanishi, Y | 1 |
| Enomoto, T | 1 |
| Tanaka, I | 1 |
| Nishimura, H | 2 |
| Takasuna, K | 1 |
| Kondo, R | 1 |
| Munakata, Y | 1 |
| Kasuga, Y | 1 |
| Palermo, JA | 1 |
| Richards, F | 1 |
| Lohman, KK | 1 |
| Lovelace, JV | 1 |
| Atkinson, J | 1 |
| Case, LD | 1 |
| White, DR | 2 |
| Blackstock, AW | 2 |
| Eurvilaichit, C | 1 |
| Kanjanapitak, A | 1 |
| Leopairut, J | 1 |
| King, DR | 1 |
| Liu-Mares, W | 2 |
| Shinkawa, H | 1 |
| Naka, S | 1 |
| Yasuhara, H | 1 |
| Nojiri, T | 1 |
| Furuya, Y | 1 |
| Okazaki, K | 1 |
| Yovine, A | 1 |
| Pelosi, E | 1 |
| Masaneo, I | 1 |
| Clara, R | 1 |
| Valetto, MR | 1 |
| Zanon, C | 1 |
| Grosso, M | 1 |
| Mussa, A | 1 |
| Bisi, G | 1 |
| Wickremesekera, JK | 1 |
| Cannan, RJ | 1 |
| Oh, CM | 1 |
| Kukitsu, T | 2 |
| Kusakabe, T | 1 |
| Abramson, RG | 1 |
| Rosen, MP | 1 |
| Brophy, DP | 1 |
| Raeburn, SL | 1 |
| Oevermann, K | 1 |
| Buer, J | 1 |
| Hoffmann, R | 1 |
| Franzke, A | 1 |
| Schrader, A | 1 |
| Patzelt, T | 1 |
| Kirchner, H | 1 |
| Atzpodien, J | 1 |
| Kollmannsberger, C | 1 |
| Quietzsch, D | 1 |
| Lingenfelser, T | 1 |
| Baronius, W | 1 |
| Hempel, V | 1 |
| Colarian, J | 1 |
| Fowler, D | 1 |
| Schor, J | 1 |
| Poolos, S | 1 |
| Ohkuma, K | 1 |
| Hisano, C | 1 |
| Kaji, Y | 1 |
| Masumoto, N | 1 |
| van Riel, JM | 4 |
| Giaccone, G | 3 |
| John, WJ | 1 |
| McGrath, P | 1 |
| Strodel, WE | 1 |
| Mohiuddin, M | 1 |
| Pugliese, P | 1 |
| Aschelter, AM | 1 |
| Nisticò, C | 1 |
| Giunta, S | 1 |
| Caterino, M | 1 |
| Cosimelli, M | 2 |
| Terzoli, E | 1 |
| Eichhorst, ST | 1 |
| Müller, M | 1 |
| Li-Weber, M | 1 |
| Angel, P | 1 |
| Terret, C | 1 |
| Erdociain, E | 1 |
| Féty-Deporte, R | 1 |
| Lafont, T | 1 |
| Canal, P | 1 |
| Ikeda, J | 1 |
| Kitano, H | 1 |
| Kikunaga, H | 1 |
| Sotome, K | 1 |
| Morisue, A | 1 |
| Matsudo, A | 1 |
| Nakai, H | 1 |
| Takao, M | 1 |
| Osakabe, Y | 1 |
| Nakahara, M | 1 |
| Teshima, T | 1 |
| Garner, PD | 1 |
| Hall, LD | 1 |
| Johnstone, PA | 1 |
| Matsuno, S | 1 |
| Ogasawara, T | 1 |
| Yamazaki, H | 2 |
| Köstler, WJ | 1 |
| Tomek, S | 1 |
| Wiltschke, C | 1 |
| Culy, CR | 1 |
| Clemett, D | 1 |
| Wiseman, LR | 1 |
| Matumoto, Y | 1 |
| Tominaga, M | 1 |
| Sendou, H | 1 |
| Kanoh, Y | 1 |
| Yasue, A | 2 |
| Shima, Y | 1 |
| Sadamori, H | 1 |
| Kawashima, T | 1 |
| Morichika, T | 1 |
| Hamazaki, K | 2 |
| Tamamori, Y | 2 |
| Shirata, Y | 1 |
| Kurisu, S | 1 |
| Taira, Y | 1 |
| Inoue, H | 1 |
| Kawano, T | 1 |
| Toukairin, Y | 2 |
| Shirasawa, H | 1 |
| Fujimori, A | 1 |
| Kuchide, M | 1 |
| Tomatsuri, N | 1 |
| Takekuni, K | 2 |
| Teshima, S | 1 |
| Miyashita, K | 5 |
| Sumi, H | 1 |
| Hosokawa, K | 1 |
| Ishikura, S | 1 |
| Bleeker, WA | 1 |
| Mulder, NH | 1 |
| Hermans, J | 1 |
| Otter, R | 1 |
| Plukker, JT | 1 |
| Okumoto, T | 1 |
| Kanaya, Y | 1 |
| Konovalova, NP | 1 |
| Volkova, LM | 1 |
| Codacci-Pisanelli, D | 1 |
| Seminara, P | 1 |
| Franchi, F | 1 |
| Vauthey, J | 1 |
| Sawaf, HB | 1 |
| Dubrow, R | 1 |
| Allen, P | 1 |
| Hoff, P | 1 |
| Lenzi, R | 1 |
| Lynch, P | 1 |
| Habib, NA | 1 |
| Sarraf, CE | 1 |
| Mitry, RR | 1 |
| Havlík, R | 1 |
| Kelly, M | 1 |
| Vernon, CC | 1 |
| Gueret-Wardle, D | 1 |
| El-Masry, R | 1 |
| Salama, H | 1 |
| Ahmed, R | 2 |
| Michail, N | 1 |
| Edward, E | 1 |
| Jensen, SL | 2 |
| Kumar, SK | 1 |
| Maeba, T | 1 |
| Mori, S | 1 |
| Mihara, T | 1 |
| Ohkawa, M | 1 |
| Senda, S | 1 |
| Terasaki, Y | 1 |
| Yamasaki, Y | 1 |
| Albers, SH | 1 |
| Cazemier, M | 1 |
| Meijer, S | 2 |
| Bleichrodt, R | 1 |
| van den Berg, FG | 1 |
| Watine, J | 1 |
| Soulage, C | 1 |
| Bras-Gonçalves, RA | 1 |
| Poirson-Bichat, F | 1 |
| De Pinieux, G | 1 |
| Pandrea, I | 1 |
| Arvelo, F | 1 |
| Ronco, G | 1 |
| Villa, P | 1 |
| Coquelle, A | 1 |
| Lesuffleur, T | 1 |
| Dutrillaux, B | 1 |
| Poupon, MF | 1 |
| Hisamatsu, T | 1 |
| Motohashi, Y | 1 |
| Ikezawa, T | 1 |
| Tatsuno, S | 1 |
| Mizuno, Y | 1 |
| Nishida, J | 1 |
| Naitoh, M | 1 |
| Hara, F | 1 |
| Mitunaga, S | 1 |
| Moriyama, S | 1 |
| Tuji, T | 1 |
| Furutani, S | 1 |
| Nawa, S | 1 |
| Ohtuka, K | 1 |
| Kashiyama, Y | 1 |
| Witte, RS | 1 |
| Cnaan, A | 1 |
| Mansour, EG | 1 |
| Barylak, E | 1 |
| Harris, JE | 1 |
| Schutt, AJ | 4 |
| Akiyama, N | 1 |
| Motegi, M | 1 |
| Sasamoto, H | 1 |
| Osawa, H | 1 |
| Wada, W | 1 |
| Niiya, F | 1 |
| Ikeda, S | 1 |
| Nagata, S | 1 |
| Iwamoto, M | 1 |
| Guo, WJ | 1 |
| Yu, EX | 1 |
| Khoubehi, B | 1 |
| Schofield, A | 1 |
| Leslie, M | 1 |
| Slevin, ML | 1 |
| Talbot, IC | 1 |
| Northover, JM | 1 |
| Yamasaki, E | 1 |
| Nagase, T | 1 |
| Inui, Y | 1 |
| Ito, N | 1 |
| Inada, M | 1 |
| Matsuzawa, Y | 1 |
| Kubishkin, V | 1 |
| Backus, HH | 2 |
| Dukers, DF | 2 |
| Vos, W | 2 |
| Bloemena, E | 2 |
| Wouters, D | 2 |
| Rosty, C | 1 |
| Beaune, P | 1 |
| Carceller, A | 1 |
| Blanchard, H | 1 |
| Champagne, J | 1 |
| St-Vil, D | 1 |
| Bensoussan, AL | 1 |
| Copur, MS | 1 |
| Capadano, M | 1 |
| Lynch, J | 1 |
| Goertzen, T | 1 |
| McCowan, T | 1 |
| Brand, R | 1 |
| Tempero, M | 1 |
| Mueller, HH | 1 |
| Mattes, E | 1 |
| Zori Comba, A | 1 |
| Blajman, C | 1 |
| Richardet, E | 1 |
| Bella, S | 1 |
| Vilanova, M | 1 |
| Cóppola, F | 1 |
| Van Kooten, M | 1 |
| Rodger, J | 1 |
| Giglio, R | 1 |
| Balbiani, L | 1 |
| Perazzo, F | 1 |
| Montiel, M | 1 |
| Chacón, M | 1 |
| Pujol, F | 1 |
| Mickiewicz, E | 1 |
| Cazap, E | 1 |
| Recondo, G | 1 |
| Lastiri, F | 1 |
| Simon, J | 1 |
| Wasserman, E | 1 |
| Schmilovich, A | 1 |
| Maindrault-Goebel, F | 1 |
| Gilles, V | 1 |
| Lotz, JP | 1 |
| Izrael, V | 1 |
| Wang, HS | 1 |
| Nozoe, Y | 1 |
| Sasatomi, T | 1 |
| Miyagi, Y | 1 |
| Tarao, H | 1 |
| Porta, C | 1 |
| Danova, M | 1 |
| Accurso, S | 1 |
| Tinelli, C | 1 |
| Girino, M | 1 |
| Szatkowska, L | 1 |
| Mazurkiewicz, M | 1 |
| Brzozowska, A | 1 |
| Nazmy El Assal, O | 1 |
| Cunningham, VJ | 1 |
| Kurahashi, T | 1 |
| Eguchi, J | 1 |
| Kitahara, T | 1 |
| Mitamura, K | 1 |
| Kern, W | 1 |
| Beckert, B | 1 |
| Lang, N | 1 |
| Stemmler, J | 2 |
| Beykirch, M | 1 |
| Stein, J | 1 |
| Goecke, E | 1 |
| Waggershauser, T | 1 |
| Braess, J | 1 |
| Llovet, JM | 1 |
| Ruff, P | 1 |
| Tassopoulos, N | 1 |
| Castells, L | 1 |
| Bruix, J | 1 |
| El-Hariry, I | 1 |
| Peachey, M | 1 |
| Valls, C | 1 |
| Rafecas, A | 1 |
| Fabregat, J | 1 |
| Ramos, E | 1 |
| Jaurrieta, E | 1 |
| Anzai, K | 1 |
| Momma, T | 1 |
| Sassa, M | 1 |
| Kimijima, I | 1 |
| Cyjon, A | 2 |
| Neuman-Levin, M | 1 |
| Rakowsky, E | 1 |
| Belinky, A | 1 |
| Atar, E | 1 |
| Hardoff, R | 1 |
| Sulkes, A | 1 |
| Tachibana, M | 3 |
| Kinugasa, S | 1 |
| Yoshimura, H | 1 |
| Fiorentini, G | 1 |
| De Giorgi, U | 1 |
| Giovanis, P | 2 |
| Marangolo, M | 2 |
| Yoshizawa, Y | 1 |
| Uemichi, O | 1 |
| Sasaya, S | 1 |
| Midorikawa, T | 1 |
| Sanada, Y | 1 |
| Kumada, K | 1 |
| Alliot, C | 1 |
| Messouak, D | 1 |
| Beets, C | 1 |
| Rapin, JP | 1 |
| Hishikawa, Y | 1 |
| Kimoto, T | 1 |
| Dhar, DK | 2 |
| Koji, T | 1 |
| Schmidbauer, S | 1 |
| Ladurner, R | 1 |
| Jückstock, H | 1 |
| Trupka, AW | 1 |
| Mussack, T | 1 |
| Hallfeldt, KK | 1 |
| Sarela, AI | 1 |
| Guthrie, JA | 1 |
| Ride, E | 1 |
| Guillou, PJ | 1 |
| O'Riordain, DS | 1 |
| Onishi, Y | 1 |
| Yajima, Y | 1 |
| Hayashi, C | 1 |
| Aoki, C | 1 |
| Miyazaki, A | 2 |
| Eda, Y | 1 |
| Xie, H | 1 |
| McSheehy, PM | 1 |
| Rodrigues, LM | 1 |
| Wadsworth, P | 1 |
| Price, NM | 1 |
| Nicholson, G | 1 |
| Müller, H | 1 |
| Nakchbandi, W | 1 |
| Chatzissavvidis, I | 1 |
| Valek, V | 2 |
| Stevenson, JP | 1 |
| Burke, D | 1 |
| Carnochan, P | 1 |
| Toukairin, H | 1 |
| Tokairin, Y | 2 |
| Omuraya, M | 1 |
| Ishiodori, H | 1 |
| Fujiyama, S | 1 |
| Tamagaki, S | 1 |
| Mitomo, M | 1 |
| Kawasaki, H | 2 |
| Sasaki, S | 1 |
| Nishijima, K | 1 |
| Kunimoto, Y | 1 |
| Habara, K | 1 |
| Fukumoto, S | 1 |
| Ishihara, K | 1 |
| Ohshita, H | 1 |
| Hatou, T | 1 |
| Tonomura, S | 1 |
| Tokura, H | 1 |
| Masamura, S | 1 |
| Matsui, A | 1 |
| Hojo, T | 1 |
| Mitsui, Y | 1 |
| Miyabe, R | 1 |
| Furukawa, S | 1 |
| Sasson, AR | 1 |
| Moritani, M | 1 |
| Niido, T | 1 |
| Fukue, M | 1 |
| Kodaira, Y | 1 |
| Monma, E | 1 |
| Takada, Y | 1 |
| Shidara, S | 1 |
| Ikezawa, K | 1 |
| Shimakura, S | 1 |
| Yashimura, H | 1 |
| Toh, Y | 1 |
| Marková, J | 1 |
| Tomásek, J | 1 |
| Boudný, J | 1 |
| Kala, Z | 1 |
| Hanke, I | 1 |
| Ostrízek, T | 1 |
| Leypold, J | 1 |
| Hikosaka, Y | 1 |
| Brossette, N | 1 |
| Saint Paul, MC | 1 |
| Köckerling, F | 1 |
| Martus, P | 1 |
| Hänsler, J | 1 |
| Bernatik, T | 1 |
| Becker, D | 1 |
| Auerbach, M | 1 |
| Elias, EG | 4 |
| Orford, J | 1 |
| Shrikhande, S | 1 |
| Friess, H | 1 |
| Kleeff, J | 1 |
| Tempia, A | 1 |
| Zimmermann, A | 1 |
| Zhu, K | 1 |
| Shan, H | 1 |
| Vadiaka, M | 1 |
| Koufos, C | 1 |
| Urabe, T | 1 |
| Corsi, DC | 1 |
| Ciaparrone, M | 1 |
| Zannoni, G | 1 |
| Specchia, M | 1 |
| Imamura, I | 1 |
| Eriguchi, N | 1 |
| Romel, L | 1 |
| Kemeny, MM | 3 |
| Adak, S | 1 |
| Smith, T | 1 |
| Oriyama, T | 1 |
| Kosaka, H | 1 |
| Chung, T | 1 |
| Dangelica, MI | 1 |
| Shoup, MC | 1 |
| Nissan, A | 1 |
| Dizon, DS | 1 |
| Oliver, L | 1 |
| Barbieux, I | 1 |
| LeCabellec, MT | 1 |
| Grégoire, M | 1 |
| Vallette, FM | 1 |
| Demedts, I | 1 |
| Tokura, N | 1 |
| Saito, N | 1 |
| Shirasaka, K | 1 |
| Koyasaki, N | 1 |
| Matsumura, A | 1 |
| Kamata, T | 1 |
| Tsuchiya, K | 1 |
| Takemura, N | 1 |
| Nakano, K | 1 |
| Osaka, Y | 1 |
| Sako, H | 1 |
| Ioka, Z | 1 |
| Nakane, Y | 1 |
| Daijo, H | 1 |
| Tomlinson, SK | 1 |
| Melin, SA | 1 |
| Higgs, V | 1 |
| Savage, P | 1 |
| Case, D | 1 |
| Benchalal, M | 1 |
| Yahchouchy-Chouillard, E | 1 |
| Fouere, S | 1 |
| Fingerhut, A | 1 |
| Sikma, MA | 1 |
| Coenen, JL | 1 |
| Kloosterziel, C | 1 |
| Hasselt, BA | 1 |
| Ravaioli, A | 1 |
| Pasquini, E | 1 |
| Rossi, A | 1 |
| Amadori, D | 1 |
| Cruciani, G | 1 |
| Tassinari, D | 1 |
| Oliverio, G | 1 |
| Turci, D | 1 |
| Zumaglini, F | 1 |
| Nicolini, M | 1 |
| Panzini, I | 1 |
| Misawa, K | 3 |
| Sano, H | 2 |
| Naka, M | 1 |
| Okawa, Y | 1 |
| Yoneyama, S | 1 |
| Nakanishi, Y | 1 |
| Morikawa, A | 1 |
| Okabe, R | 1 |
| Miyazawa, K | 1 |
| Suzuki, A | 1 |
| Sugiyama, A | 1 |
| Emoto, T | 2 |
| Yoshikawa, K | 2 |
| Naka, Y | 1 |
| Komaki, T | 1 |
| Mitchell, E | 1 |
| Abramson, N | 1 |
| Klencke, B | 1 |
| Ritch, P | 1 |
| Burnhan, JP | 1 |
| McGuirt, C | 1 |
| Bonny, T | 1 |
| Levin, J | 1 |
| Hohneker, J | 1 |
| Benjamin, I | 1 |
| Qin, C | 1 |
| Cheb, S | 1 |
| Zuo, G | 1 |
| Shen, W | 1 |
| Gopalakrishnan, TV | 1 |
| Thompson, EB | 1 |
| Segerling, M | 3 |
| Borsos, T | 3 |
| Zike, WL | 2 |
| Safaie-Shirazi, S | 1 |
| Gulesserian, HP | 2 |
| Umezawa, I | 1 |
| Komiyama, K | 1 |
| Kawakubo, Y | 1 |
| Nishiyama, Y | 1 |
| Swain, C | 1 |
| Abe, I | 1 |
| Prostman, TJ | 1 |
| Nakase, A | 5 |
| Honjo, I | 2 |
| Iwaki, A | 2 |
| Tanner, AR | 1 |
| Bolton, PM | 1 |
| Powell, LW | 1 |
| Kono, K | 1 |
| Sherman, DM | 1 |
| Weichselbaum, R | 1 |
| Order, SE | 5 |
| Cloud, L | 1 |
| Trey, C | 1 |
| Piro, AJ | 2 |
| Sundqvist, K | 1 |
| Hafström, LO | 2 |
| Rydén, S | 1 |
| Forsberg, L | 2 |
| Lunderquist, A | 1 |
| Mayr, AC | 1 |
| Chevrel, JP | 1 |
| Damsin, JP | 1 |
| Lebhar, E | 1 |
| Friedman, M | 2 |
| Cassidy, M | 1 |
| Phillips, T | 1 |
| Spivack, S | 1 |
| Pettavel, J | 3 |
| Morgenthaler, FR | 1 |
| Morgenthaler, F | 2 |
| Buroker, T | 1 |
| Samson, M | 1 |
| Correa, J | 1 |
| Fraile, R | 1 |
| Clouse, ME | 2 |
| Ryan, RB | 1 |
| McCaffrey, JA | 2 |
| Lee, YT | 2 |
| Rosowsky, A | 1 |
| Raso, V | 1 |
| Levin, DC | 1 |
| Glode, M | 1 |
| Come, S | 1 |
| Frei, E | 1 |
| Gropp, C | 1 |
| Havemann, K | 1 |
| Polio, J | 1 |
| Hamilton, T | 1 |
| Holton, CP | 1 |
| Burrington, JD | 1 |
| Hatch, EI | 1 |
| Shiu, MH | 2 |
| Fortner, JG | 2 |
| Brookhart, W | 1 |
| Allen, R | 1 |
| Looney, W | 1 |
| Hopkins, H | 1 |
| Kovacs, C | 1 |
| Morris, H | 1 |
| Kovacs, CJ | 6 |
| Hopkins, HA | 9 |
| Simon, RM | 1 |
| Looney, WB | 8 |
| Murad, F | 1 |
| Wilkinson, DS | 4 |
| Tlsty, TD | 1 |
| Hanas, RJ | 1 |
| Fujii, S | 1 |
| Okuda, H | 2 |
| Akazawa, A | 1 |
| Terui, S | 2 |
| Keczkes, K | 1 |
| Barker, DJ | 1 |
| Antonovic, R | 1 |
| Dotter, CT | 1 |
| Bast, RC | 1 |
| Greene, SL | 1 |
| Zbar, B | 1 |
| Rapp, HJ | 1 |
| Kirsch, WM | 2 |
| Van Buskirk, JJ | 2 |
| Schulz, DW | 1 |
| Tabuchi, K | 1 |
| Sparks, FC | 3 |
| Eilber, FR | 2 |
| Holmes, EC | 1 |
| Morton, DL | 3 |
| Umsawasdi, T | 1 |
| Chainuvati, T | 1 |
| Hitanant, S | 1 |
| Nilprabhassorn, P | 1 |
| Viranuvatti, V | 1 |
| Nüvemann, M | 1 |
| Fernholz, HJ | 1 |
| Frik, W | 1 |
| Schaffner, JG | 2 |
| Trefil, JS | 2 |
| Wakefield, JA | 2 |
| Zollinger, RM | 1 |
| Carey, LC | 1 |
| Sparks, J | 1 |
| Minton, JP | 3 |
| Crumley, J | 2 |
| Goodman, MA | 1 |
| Laden, AM | 1 |
| Misra, NC | 1 |
| Jaiswal, MS | 1 |
| Singh, RV | 1 |
| Das, B | 1 |
| Kennedy, PS | 1 |
| Lehane, DE | 1 |
| Smith, FE | 1 |
| Lane, M | 1 |
| Link, JS | 1 |
| Paroly, WS | 1 |
| Durkin, WJ | 1 |
| Peters, RL | 1 |
| Shirakabe, H | 1 |
| Izumi, T | 1 |
| Miyasaka, K | 1 |
| Ariyama, J | 1 |
| Ritenour, R | 1 |
| Greenberg, N | 1 |
| Schumm, DE | 1 |
| Webb, TE | 1 |
| Fegiz, G | 1 |
| Rosati, D | 1 |
| Tonelli, F | 1 |
| Donfrancesco, A | 1 |
| Cochrane, AM | 1 |
| Murray-Lyon, IM | 4 |
| Brinkley, DM | 1 |
| Williams, R | 4 |
| Tret'iakov, AV | 1 |
| Riazanov, EM | 1 |
| Filov, VA | 1 |
| Cory, JG | 1 |
| Grady, ED | 1 |
| Nolan, TR | 1 |
| Crumbley, AJ | 1 |
| Rosen, AR | 1 |
| Ryan, R | 1 |
| Metman, EH | 1 |
| Oberfield, R | 1 |
| Glouse, M | 1 |
| Baker, LH | 1 |
| Saiki, JH | 1 |
| Jones, SE | 1 |
| Brownlee, RW | 1 |
| Stephens, RL | 1 |
| Breuel, HP | 1 |
| Douwes, F | 1 |
| Bähre, M | 1 |
| San Luis, T | 1 |
| Emrich, D | 1 |
| Seligman, M | 1 |
| Groppe, CW | 1 |
| Weick, JK | 1 |
| Greenstreet, RL | 1 |
| Cavalli, F | 1 |
| Tschopp, L | 1 |
| Gerber, A | 1 |
| Sonntag, RW | 1 |
| Ryssel, HJ | 1 |
| Brunner, KW | 1 |
| Habs, M | 1 |
| Habs, G | 1 |
| Schmähl, D | 1 |
| Macleod, MS | 1 |
| Atkins, HL | 1 |
| Bradley-Moore, PR | 1 |
| Casella, V | 1 |
| Fowler, JS | 1 |
| Greenberg, D | 1 |
| Ido, T | 1 |
| Lambrecht, RM | 1 |
| MacGregor, R | 1 |
| Mantescu, C | 1 |
| Neirinckx, R | 1 |
| Som, P | 1 |
| Wolf, AP | 1 |
| Wodinsky, I | 1 |
| Meaney, K | 1 |
| Gattanell, PN | 1 |
| Perloff, M | 1 |
| Holland, JF | 1 |
| Harada, T | 1 |
| Makisaka, Y | 1 |
| Senzer, NN | 1 |
| Terrell, W | 1 |
| Pratt, CB | 2 |
| Lavin, P | 1 |
| Pretorius, FJ | 1 |
| Hobara, N | 2 |
| Ettinger, DS | 2 |
| Dragon, LH | 1 |
| Klein, J | 1 |
| Sgagias, M | 1 |
| Wellwood, JM | 1 |
| Cady, B | 2 |
| Ozaki, H | 1 |
| Arima, M | 1 |
| Hattori, N | 3 |
| Kimura, K | 4 |
| Kühböck, J | 1 |
| Aiginger, P | 1 |
| Pötzi, P | 1 |
| Corder, MP | 1 |
| Sheets, RF | 1 |
| Stone, WH | 1 |
| Flannery, EP | 1 |
| Justice, GR | 1 |
| Herbst, KD | 1 |
| Petrek, JA | 1 |
| Heal, JM | 1 |
| Schein, PS | 3 |
| Brooman, P | 1 |
| Rowling, JT | 1 |
| Grage, TB | 2 |
| Vassilopoulos, PP | 1 |
| Shingleton, WW | 2 |
| Jubert, AV | 2 |
| Aust, JB | 2 |
| Moss, SE | 2 |
| Aronsen, KF | 1 |
| Hellekant, C | 1 |
| Holmberg, J | 1 |
| Rothman, U | 1 |
| Teder, H | 2 |
| Delk, S | 1 |
| El-Domeiri, AA | 1 |
| Owman, T | 1 |
| Haida, K | 3 |
| Haida, S | 1 |
| Rowling, J | 1 |
| West, C | 2 |
| Farndon, JR | 1 |
| Shirazi, SS | 1 |
| Pearlman, NW | 1 |
| Kanashima, R | 1 |
| Inokughi, K | 1 |
| Bugarski, M | 1 |
| Vuletić, L | 1 |
| Boberić, J | 1 |
| Milosavljević, A | 1 |
| Dilparić, S | 1 |
| Tomin, R | 1 |
| Naumović, P | 1 |
| Ramirez, G | 14 |
| Langley, JR | 1 |
| Rosato, FE | 1 |
| El-Mahdi, A | 1 |
| Kune, GA | 1 |
| Hobbs, JB | 1 |
| Butterfield, D | 1 |
| Sali, A | 1 |
| Serrou, B | 1 |
| Dubois, JB | 1 |
| Younus, S | 1 |
| Soterakis, J | 1 |
| Sossi, AJ | 1 |
| Chawla, SK | 1 |
| LoPresti, PA | 1 |
| Biran, S | 1 |
| Krasnokuki, D | 1 |
| Hochman, A | 1 |
| Brufman, G | 1 |
| Schmidt, JD | 1 |
| Gibbons, RP | 1 |
| Johnson, DE | 1 |
| Prout, GR | 1 |
| Scott, WW | 1 |
| Murphy, GP | 1 |
| Almersjö, O | 7 |
| Leissner, KH | 2 |
| Cotino, HH | 1 |
| Zwaveling, A | 1 |
| Scialla, SJ | 1 |
| Miskoff, RA | 1 |
| Israel, L | 2 |
| De Jager, RL | 1 |
| Magill, GB | 1 |
| Golbey, RB | 1 |
| Krakoff, IH | 1 |
| Fischerman, K | 1 |
| Petersen, CF | 1 |
| Christensen, KC | 1 |
| Efsen, F | 1 |
| Kushnir, IN | 1 |
| Hahn, RG | 3 |
| Bruckner, HW | 4 |
| Jugdutt, BI | 1 |
| Turner, FW | 1 |
| Gallmeier, WM | 1 |
| Bruntsch, U | 1 |
| Schmidt, CG | 2 |
| Mosher, MB | 1 |
| Hallauer, WC | 1 |
| Silverstein, MJ | 1 |
| Rangel, D | 1 |
| Passaro, E | 1 |
| Creech, RH | 1 |
| Catalano, RB | 1 |
| Mastrangelo, MJ | 1 |
| Tobita, Y | 1 |
| Takino, T | 1 |
| Misawa, S | 1 |
| Kadono, A | 1 |
| Yamaguchi, N | 1 |
| Mittal, VK | 1 |
| Saharia, S | 1 |
| Singh, K | 1 |
| Wirtanen, GW | 8 |
| Johnson, RO | 1 |
| Bryan, GT | 3 |
| Manalo, FB | 1 |
| Borden, EC | 1 |
| Davis, TE | 1 |
| Esmili, M | 1 |
| Brandberg, A | 1 |
| van Dyk, JJ | 1 |
| van der Merwe, AM | 1 |
| Falkson, HC | 1 |
| Canellos, GP | 2 |
| DeVita, VT | 2 |
| Gold, GL | 2 |
| Chabner, BA | 2 |
| Young, RC | 2 |
| Congy, F | 1 |
| Pelletier, S | 1 |
| Langlois, P | 1 |
| Homsi, T | 1 |
| Emerit, J | 1 |
| Gewiese, B | 1 |
| Fobbe, F | 1 |
| Stiller, D | 1 |
| Gallkowski, U | 2 |
| Wolf, KJ | 1 |
| Kajanti, M | 1 |
| Pyrhönen, S | 1 |
| Mäntylä, M | 1 |
| Rissanen, P | 1 |
| Smith, FW | 1 |
| Heys, SD | 1 |
| Evans, NT | 1 |
| Roeda, D | 1 |
| Gvozdanovic, D | 1 |
| Eremin, O | 1 |
| Mallard, JR | 1 |
| Paquet, KJ | 1 |
| Kalk, JF | 1 |
| Cuan-Orozco, F | 1 |
| Siemens, F | 1 |
| Koussouris, P | 1 |
| Mercado, MA | 1 |
| Ito, J | 1 |
| Tanzawa, Y | 1 |
| Toda, N | 1 |
| Uta, Y | 1 |
| Tagawa, K | 1 |
| van Eeden, H | 1 |
| Burger, W | 1 |
| Ansell, SM | 1 |
| Flückiger, A | 1 |
| Schlup, P | 1 |
| Tarui, T | 1 |
| Sugata, F | 2 |
| Yoshiba, M | 2 |
| Kuniyasu, Y | 2 |
| Iwao, Y | 2 |
| Aikawa, H | 1 |
| Kuramoto, S | 1 |
| Hanawa, S | 1 |
| Yanagita, K | 1 |
| Yoshio, T | 1 |
| Cantor, A | 1 |
| Morioka, N | 1 |
| Okuda, Y | 1 |
| Midorikawa, H | 2 |
| Tsukui, M | 2 |
| Goto, K | 1 |
| Le Hello, C | 1 |
| Auvray, S | 1 |
| Letellier, P | 1 |
| Segol, P | 2 |
| Ivancev, K | 1 |
| Holmberg, A | 1 |
| Nose, H | 1 |
| Yoshimori, M | 2 |
| Dhir, V | 1 |
| Swaroop, VS | 1 |
| Mohandas, KM | 1 |
| Dinshaw, KA | 2 |
| Desai, DC | 1 |
| Nagral, A | 1 |
| Jagannath, P | 1 |
| Desouza, LJ | 1 |
| Wang, JH | 1 |
| Fedeli, A | 2 |
| Luzi Fedeli, S | 2 |
| Fowler, WC | 1 |
| Beheshti, MV | 1 |
| Denny, DF | 1 |
| Glickman, MG | 1 |
| Yoshimoto, H | 1 |
| Itoh, E | 1 |
| Alberto, P | 2 |
| Tabuchi, M | 1 |
| Fukawa, M | 1 |
| Imaizumi, N | 1 |
| Okushima, K | 1 |
| Fuchinoue, S | 1 |
| Teraoka, S | 1 |
| Agishi, T | 1 |
| Ota, K | 2 |
| Awano, T | 2 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Ooya, M | 1 |
| Shinozaki, M | 1 |
| Tsuno, N | 1 |
| Sakaguchi, M | 1 |
| Horigome, N | 2 |
| Hanasaki, K | 2 |
| Shiohara, E | 1 |
| Haba, Y | 1 |
| Kaneko, G | 1 |
| Ueshima, Y | 1 |
| Tsukuda, N | 1 |
| Hottenrott, C | 5 |
| Maier, P | 1 |
| Reimann, M | 1 |
| Inglis, R | 2 |
| Morere, JF | 1 |
| Boaziz, C | 1 |
| Sella, A | 1 |
| Logothetis, CJ | 1 |
| Fitz, K | 1 |
| Dexeus, FH | 1 |
| Amato, R | 1 |
| Kilbourn, R | 1 |
| Schöber, C | 1 |
| Köhne-Wömpner, CH | 1 |
| Stahl, M | 1 |
| Poliwoda, H | 1 |
| Steinke, B | 1 |
| Günther, E | 1 |
| Sondern, W | 1 |
| Koniczek, KH | 1 |
| Wander, HE | 1 |
| Natt, F | 1 |
| Wagner, T | 1 |
| Hinrichs, HF | 1 |
| Werdier, D | 1 |
| Hilgenfeld, RU | 1 |
| Matthias, M | 3 |
| Hoksch, B | 1 |
| Boewer, C | 1 |
| Oldenkott, B | 1 |
| Knauf, WU | 1 |
| Zeitz, M | 1 |
| Bernhard, H | 2 |
| Meyer zum Büschenfelde, KH | 3 |
| Nakashima, A | 1 |
| Kanzaki, T | 1 |
| Endoh, A | 1 |
| Sasahashi, N | 1 |
| Richter, EI | 1 |
| Schultheis, KH | 1 |
| Gebhardt, C | 1 |
| Wurzer, W | 1 |
| Brunet, R | 1 |
| Ravaud, A | 1 |
| Bussières, E | 1 |
| Lagarde, P | 1 |
| Komaki, R | 2 |
| Peters, T | 1 |
| Byhardt, RW | 1 |
| Order, S | 2 |
| Gallagher, MJ | 1 |
| Herskovic, A | 1 |
| Pederson, J | 1 |
| Kusano, H | 1 |
| Ifuku, M | 1 |
| Noguchi, S | 1 |
| Gray, BN | 2 |
| Anderson, JE | 1 |
| Burton, MA | 1 |
| Codde, J | 1 |
| Morgan, C | 1 |
| Klemp, P | 1 |
| Mizutani, J | 1 |
| Ueo, H | 1 |
| Nagabuchi, E | 3 |
| Gotoda, A | 2 |
| Mizuguchi, N | 1 |
| Ohyama, Y | 1 |
| Mukojima, T | 1 |
| Kumagai, T | 1 |
| Iwasaki, H | 1 |
| Tada, I | 4 |
| Takeyama, M | 1 |
| Yokomori, K | 1 |
| Asoh, S | 1 |
| Tuji, A | 1 |
| Kajanti, MJ | 1 |
| Pyrhönen, SO | 1 |
| el Hag, IA | 1 |
| Jakobsson, B | 1 |
| Stenram, U | 2 |
| Staines, A | 1 |
| Cullen, S | 1 |
| Guiney, EJ | 1 |
| Fitzgerald, RJ | 1 |
| Breatnach, F | 1 |
| Inoshita, G | 1 |
| Yalavarthi, P | 1 |
| Murthy, S | 1 |
| Gibson, V | 1 |
| Budd, GT | 1 |
| Sergi, JS | 1 |
| Bauer, L | 1 |
| Prestifilippo, J | 1 |
| Romero, JA | 1 |
| Alvarez-Vijande, R | 1 |
| Gil-Vernet, JM | 1 |
| Samsón, R | 1 |
| Fernández, I | 1 |
| Gutiérrez, R | 1 |
| Carretero, P | 1 |
| Becher, R | 1 |
| Höfeler, H | 1 |
| Kloke, O | 1 |
| May, D | 1 |
| Wandl, U | 1 |
| Richter, R | 1 |
| Tsuru, S | 1 |
| Shinomiya, N | 1 |
| Noritake, M | 1 |
| Nomoto, K | 1 |
| Keller, F | 1 |
| Roth, W | 1 |
| Dreicer, R | 1 |
| Love, RR | 1 |
| Martin, D | 1 |
| Urmacher, C | 1 |
| Kurtz, RC | 1 |
| Murray, M | 1 |
| Mulvihill, SJ | 1 |
| Grobman, BJ | 1 |
| Rayner, AA | 1 |
| Hiehle, JF | 1 |
| Levine, MS | 1 |
| Dawson, NA | 1 |
| Costanza, ME | 1 |
| Clamon, GH | 1 |
| Pollak, M | 1 |
| Carey, RW | 1 |
| Hochlaf, S | 1 |
| Mignon, M | 1 |
| Anzá, M | 1 |
| Durante, F | 1 |
| Porcellana, M | 1 |
| Cavaliere, P | 1 |
| Anfossi, A | 1 |
| Pilati, PL | 1 |
| Oberg, K | 1 |
| Eriksson, B | 1 |
| Lumbroso, J | 4 |
| Ruffie, P | 1 |
| Lasser, PH | 1 |
| Altendorf-Hofmann, A | 1 |
| Gall, FP | 1 |
| Dudunkov, Z | 1 |
| Dimitrov, V | 1 |
| Kurtev, P | 1 |
| Kurteva, G | 1 |
| Ralchev, K | 1 |
| Matsumata, T | 3 |
| Akazawa, K | 1 |
| Stillwagon, GB | 2 |
| Guse, C | 2 |
| Leibel, SA | 3 |
| Asbell, SO | 1 |
| Klein, JL | 3 |
| Leichner, PK | 3 |
| Pajak, T | 1 |
| Leibel, S | 1 |
| Asbell, S | 1 |
| Leichner, P | 1 |
| Ettinger, D | 1 |
| Stillwagon, G | 1 |
| Herpst, J | 1 |
| Haulk, T | 1 |
| Kopher, K | 2 |
| Puts, JP | 1 |
| Herve, JP | 1 |
| Delelo, R | 1 |
| Ballet, F | 1 |
| Tohyama, N | 2 |
| Jinushi, K | 2 |
| Korman, DB | 2 |
| Snimshchikov, VA | 1 |
| Dobroskok, LB | 1 |
| Maslova, IA | 1 |
| Mikaélian, SG | 1 |
| Pines, EV | 1 |
| Yoshimatsu, A | 2 |
| Di Lauro, L | 1 |
| Gionfra, T | 1 |
| Gandolfo, G | 1 |
| Ameglio, F | 1 |
| Chang, YC | 1 |
| Röthlin, M | 1 |
| Fukuda, I | 4 |
| Kojima, N | 1 |
| Kusumoto, S | 1 |
| Nakayoshi, A | 1 |
| Takegawa, S | 1 |
| Kumaki, T | 1 |
| Katoh, M | 1 |
| Gotohda, H | 1 |
| Saitoh, H | 1 |
| Kurosawa, H | 1 |
| Fukano, M | 2 |
| Tokitoh, T | 1 |
| Hamazoe, R | 6 |
| Satou, N | 1 |
| Furusawa, M | 1 |
| Shirayama, Y | 1 |
| Hirohata, T | 1 |
| Villar-Grimalt, A | 1 |
| Candel, MT | 1 |
| Delgado, F | 1 |
| García-Reinoso, J | 1 |
| Sanchis, C | 1 |
| Viciano, V | 1 |
| Asencio, F | 1 |
| Martínez-Abad, M | 1 |
| Aguilo, J | 1 |
| Sánchez, JJ | 1 |
| Rosell, R | 1 |
| Pastor, MC | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| Oller, B | 1 |
| Armengol, M | 1 |
| Salva, A | 1 |
| Ribas, M | 1 |
| Bauknecht, KJ | 1 |
| Ernst, H | 1 |
| Poplin, EA | 1 |
| Kraut, M | 1 |
| Baker, L | 1 |
| Brodfuehrer, J | 1 |
| Vaitkevicius, V | 1 |
| Rosen, H | 1 |
| Schiessel, R | 1 |
| Karall, M | 1 |
| Ernst, F | 1 |
| Sebesta, C | 1 |
| Kornek, G | 1 |
| Hentschel, E | 1 |
| Marczell, A | 1 |
| Chang, D | 1 |
| Nott, D | 1 |
| Jenkins, S | 1 |
| Faradji, A | 2 |
| Bohbot, A | 2 |
| Damonte, J | 2 |
| Eber, M | 1 |
| Laustriat, D | 1 |
| Goetz, J | 2 |
| Wiesel, ML | 2 |
| Follea, G | 2 |
| Piemont, Y | 1 |
| Schimpfle, B | 1 |
| Wolff, H | 2 |
| Mai, C | 1 |
| Lüning, M | 2 |
| Demuynck, B | 1 |
| Maisani, JE | 1 |
| Lagadec, B | 1 |
| Delfau, S | 1 |
| Varette, C | 1 |
| Gonzalez-Canali, G | 1 |
| Schlumberger, M | 1 |
| Brugieres, L | 1 |
| Gicquel, C | 1 |
| Travagli, JP | 1 |
| Parmentier, C | 1 |
| Willems, G | 3 |
| Delvaux, G | 3 |
| Depadt, G | 2 |
| Pendse, AM | 1 |
| Telang, CS | 1 |
| Vege, SS | 1 |
| Malliat, MK | 1 |
| Deshpande, R | 1 |
| Desai, PB | 1 |
| Braumann, D | 1 |
| Mainzer, K | 1 |
| Günzl, C | 1 |
| Lewerenz, B | 1 |
| Shatikhin, VA | 1 |
| Bachert-Baumann, P | 1 |
| Gückel, F | 1 |
| Ermark, F | 1 |
| Goshima, H | 1 |
| Yamazaki, Y | 1 |
| Kokehara, N | 1 |
| Oota, M | 1 |
| Ishida, N | 1 |
| Itou, F | 1 |
| Yamasaki, S | 1 |
| Yasui, K | 1 |
| Fukuzumi, S | 1 |
| Amemiya, A | 1 |
| Itou, A | 1 |
| Tsujimura, T | 1 |
| Kakuta, T | 3 |
| Sakurai, H | 1 |
| Fukunaga, J | 1 |
| Kitahama, H | 1 |
| Okuyama, A | 1 |
| Seki, T | 1 |
| Tsurui, K | 1 |
| Sasagawa, M | 1 |
| Noto, T | 1 |
| Mizutani, K | 1 |
| Ohtani, Y | 1 |
| Kawano, N | 1 |
| Houjo, K | 1 |
| Iijima, K | 1 |
| Hamahata, Y | 1 |
| Tsuchiya, S | 1 |
| Kudou, J | 1 |
| Ishibashi, O | 1 |
| Hirabayashi, N | 1 |
| Kirihara, Y | 1 |
| Takagami, S | 1 |
| Ryuji, K | 1 |
| Yorishima, T | 1 |
| Mazy, V | 1 |
| Longrée, L | 1 |
| Jacquet, N | 1 |
| Demoulin, JC | 1 |
| Gayral, F | 2 |
| Tuchmann, A | 1 |
| Iigo, M | 1 |
| Miwa, M | 1 |
| De Clercq, E | 1 |
| Martin, JK | 1 |
| Wieand, HS | 3 |
| Tschetter, LK | 1 |
| Schumacher, K | 1 |
| Roscher, R | 2 |
| Bittner, R | 1 |
| Hrushesky, WJ | 1 |
| Terz, JJ | 2 |
| Hill, LR | 1 |
| Beatty, JD | 1 |
| Kokal, WA | 1 |
| Riihimaki, DU | 2 |
| Obrist, R | 2 |
| Haenggi, ST | 1 |
| Heiman, D | 1 |
| Obrecht, JP | 2 |
| Fujii, N | 1 |
| Akimura, R | 1 |
| Izumi, R | 3 |
| Imai, T | 1 |
| Oike, E | 1 |
| Odaka, K | 1 |
| Narita, T | 1 |
| Tomida, A | 1 |
| Knöpfle, G | 1 |
| Leidig, P | 1 |
| Oohigashi, H | 1 |
| Persson, BG | 1 |
| Ekberg, H | 3 |
| Lundstedt, C | 2 |
| Kuwahara, A | 1 |
| Hirao, E | 1 |
| Shimoda, K | 1 |
| Tsao, SW | 1 |
| Ng, TB | 1 |
| Yeung, HW | 1 |
| Borenfreund, E | 1 |
| Babich, H | 1 |
| Martin-Alguacil, N | 1 |
| Hunt, TM | 2 |
| Flowerdew, AD | 2 |
| Birch, SJ | 1 |
| Williams, JD | 1 |
| Mullee, MA | 1 |
| North, ML | 1 |
| Bergerat, JP | 1 |
| Goldberg, JA | 5 |
| Stewart, I | 1 |
| Sueyama, H | 1 |
| Wilmott, N | 1 |
| McKillop, JH | 3 |
| Ludwig, C | 1 |
| Weber, W | 1 |
| Brunner, K | 1 |
| Koks, CH | 2 |
| Van der Kam, HJ | 1 |
| Brouwers, JR | 2 |
| Czejka, MJ | 1 |
| Jäger, W | 1 |
| Archer, SG | 1 |
| Hölting, T | 2 |
| Buhl, K | 2 |
| Schwarz, V | 3 |
| Herfarth, C | 3 |
| Beart, RW | 1 |
| Leigh, JE | 1 |
| Windschitl, HE | 1 |
| Wolff, BG | 1 |
| Willmott, N | 2 |
| Bates, CD | 1 |
| Amino, K | 1 |
| Mieno, K | 1 |
| Miura, S | 1 |
| Satoi, Y | 1 |
| Ohtaki, K | 1 |
| Shikata, J | 1 |
| Archer, S | 1 |
| Wereldsma, JC | 1 |
| Bruggink, ED | 1 |
| Meijer, WS | 1 |
| Roukema, JA | 1 |
| van Putten, WL | 1 |
| Hatta, Y | 1 |
| Sassa, T | 1 |
| Yoshikawa, N | 1 |
| Hirose, N | 1 |
| Funatomi, H | 1 |
| Taguchi, S | 1 |
| Endoh, F | 1 |
| Takahashi, O | 1 |
| Gutman, M | 1 |
| Rozin, RR | 1 |
| Lelcuk, S | 1 |
| Inbar, M | 1 |
| Molzahn, E | 1 |
| Gruenagel, HH | 1 |
| Freund, U | 1 |
| Gross, D | 1 |
| Erichsen, C | 1 |
| Christensson, PI | 1 |
| Yasui, Y | 1 |
| Hamada, F | 1 |
| Sanada, E | 1 |
| Urakubo, M | 1 |
| Okura, M | 1 |
| Akamatsu, Y | 1 |
| Orita, K | 2 |
| Smith, RA | 1 |
| Stubblefield, GC | 1 |
| Reagan, MT | 1 |
| Mikuriya, S | 1 |
| Oda, T | 2 |
| Shimamura, Y | 2 |
| Masuzawa, M | 1 |
| Yumoto, Y | 1 |
| Birsic, W | 1 |
| D'Oro, L | 1 |
| Charoensiri, S | 1 |
| Lele, SB | 1 |
| Piver, MS | 1 |
| Muraoka, A | 1 |
| Tokiwa, T | 1 |
| Strohmeyer, G | 1 |
| Porschen, R | 1 |
| Sasaki, F | 1 |
| Sawada, H | 1 |
| Bissat, A | 2 |
| Koella, C | 1 |
| Seybold, K | 1 |
| Barkanov, AI | 1 |
| Marks, HG | 1 |
| Marks, V | 1 |
| Kremer, B | 1 |
| Mai, M | 2 |
| Teshima, Y | 1 |
| Maruyama, J | 1 |
| Morikawa, E | 1 |
| Hida, J | 1 |
| Ko, K | 1 |
| Ishimura, M | 1 |
| Barras, J | 1 |
| Bär, HU | 1 |
| Schweizer, W | 1 |
| Ogasawara, H | 1 |
| Furukohri, N | 1 |
| Saitoh, S | 2 |
| Baba, T | 1 |
| Munakata, A | 1 |
| Mennigen, R | 1 |
| Barkun, J | 1 |
| Klauke, H | 1 |
| Sidibe, S | 2 |
| Jackson, DE | 1 |
| Bitter, R | 1 |
| Schumacher, KA | 1 |
| Gaus, W | 1 |
| Didolkar, MS | 2 |
| Kirkowa-Reimann, M | 1 |
| Planting, AS | 1 |
| Runhaar, EA | 1 |
| Verwey, J | 1 |
| Blijham, G | 1 |
| Neyt, JP | 1 |
| Kanda, Y | 2 |
| Futatsugi, K | 1 |
| Fujiki, T | 1 |
| Saifuku, K | 1 |
| Suzuki, F | 1 |
| Muraoka, M | 1 |
| Hasumura, S | 1 |
| Nagamori, S | 1 |
| Fujise, K | 1 |
| Homma, S | 1 |
| Sujino, H | 1 |
| Niiya, M | 1 |
| Kameda, H | 1 |
| Tarumi, T | 3 |
| Tsubuku, Y | 1 |
| Kenmizaki, H | 1 |
| Tatekawa, I | 1 |
| Ling, HY | 1 |
| Wang, NZ | 1 |
| Koura, Y | 1 |
| Kurisu, Y | 1 |
| Kuroi, K | 1 |
| Kai, Y | 1 |
| Shiga, T | 1 |
| Nishimaki, K | 1 |
| Kinosita, T | 1 |
| Sodeyama, H | 1 |
| Iida, F | 1 |
| Okajima, K | 1 |
| Isozaki, H | 1 |
| Nakata, E | 1 |
| Iga, C | 1 |
| Amioka, K | 1 |
| Tanimura, M | 1 |
| Mitarai, Y | 1 |
| Hurukawa, H | 1 |
| Horichi, H | 1 |
| Kitabayashi, K | 1 |
| Urade, M | 2 |
| Iyobe, T | 1 |
| Segawa, M | 1 |
| Mitsugi, O | 1 |
| Iimura, Y | 1 |
| Nagafuchi, E | 1 |
| Takekawa, S | 1 |
| Ye, WJ | 1 |
| Lorcerie, B | 1 |
| Faivre, J | 1 |
| Klepping, C | 1 |
| Martin, F | 1 |
| Mimura, H | 1 |
| Fishman, EK | 1 |
| Soga, K | 1 |
| Turuya, T | 1 |
| Toshima, M | 1 |
| Shibasaki, K | 1 |
| Matugi, H | 1 |
| Kawai, C | 1 |
| Asakura, H | 1 |
| Passalacqua, G | 1 |
| Rodorigo, C | 1 |
| Belli, L | 1 |
| Morgante, A | 1 |
| Rabitti, G | 1 |
| Kasch, R | 1 |
| Gerber, B | 1 |
| Blaschke, U | 1 |
| Benasso, M | 1 |
| Ferro, A | 1 |
| Bacigalupo, A | 1 |
| Toma, S | 1 |
| Vitriolo, S | 1 |
| Rosso, R | 2 |
| Merlano, M | 1 |
| Laurensse, EJ | 1 |
| de Quay, N | 1 |
| Cuttat, JF | 1 |
| Tevaearai, H | 1 |
| Chapuis, G | 1 |
| Albe, X | 1 |
| Vassilakos, P | 1 |
| Houvenaeghel, G | 1 |
| Guerinel, G | 1 |
| Carcassonne, Y | 1 |
| Inzani, V | 1 |
| Stevenson, FK | 1 |
| van der Plas, J | 1 |
| Petrelli, N | 1 |
| Douglass, HO | 2 |
| Herrera, L | 1 |
| Russell, D | 1 |
| Stablein, DM | 1 |
| Schinella, R | 1 |
| Green, MD | 1 |
| Muggia, FM | 1 |
| Martoni, A | 1 |
| Cricca, A | 1 |
| Guaraldi, M | 1 |
| Pannuti, F | 1 |
| Preiss, R | 1 |
| Sperling, P | 1 |
| Spain, M | 1 |
| McPherson, D | 1 |
| Akamatsu, H | 1 |
| Arisawa, Y | 2 |
| Takabayashi, T | 2 |
| Abe, O | 2 |
| Okubo, Y | 1 |
| Imajo, M | 1 |
| Yaegashi, K | 1 |
| Shabana, M | 1 |
| Akai, S | 1 |
| Wiley, AL | 2 |
| Stephenson, JA | 1 |
| Demets, D | 1 |
| Lee, JW | 1 |
| Räth, U | 1 |
| Remick, SC | 1 |
| Weese, JL | 2 |
| Willson, JK | 1 |
| Alberti, DB | 1 |
| Nieting, LM | 1 |
| Tutsch, KD | 1 |
| Fischer, PH | 1 |
| Ogita, S | 3 |
| Tokiwa, K | 3 |
| Lin, DY | 1 |
| Liaw, YF | 1 |
| Lee, TY | 1 |
| Lai, CM | 1 |
| Nerenstone, S | 1 |
| Hannigan, JF | 1 |
| Carter, SK | 1 |
| Simoncini, E | 1 |
| Marpicati, P | 1 |
| Marini, G | 1 |
| Bozzetti, F | 1 |
| Bonfanti, G | 1 |
| Audisio, R | 1 |
| Colombo, M | 1 |
| Gennari, L | 1 |
| Herlin, T | 1 |
| Norup, K | 1 |
| Storm, K | 1 |
| Ohhori, I | 1 |
| Kishimoto, W | 1 |
| Kuroe, K | 1 |
| Haba, T | 1 |
| Shioaki, Y | 1 |
| Itoh, A | 1 |
| Seiki, K | 1 |
| Shimotsuma, M | 1 |
| Nishioka, S | 1 |
| Yataka, I | 1 |
| Onoyama, Y | 1 |
| Kanno, T | 1 |
| Nakatsuka, H | 1 |
| Sawata, T | 2 |
| Kushima, K | 1 |
| Hashiba, M | 1 |
| Altimari, AF | 1 |
| Bhoopalam, N | 1 |
| O'Dorsio, T | 1 |
| Lange, CL | 1 |
| Sandberg, L | 1 |
| Prinz, RA | 1 |
| Quentmeier, A | 1 |
| Reichman, B | 1 |
| Vinciguerra, V | 1 |
| Michaelson, R | 1 |
| Rosenbluth, R | 1 |
| Deonarine, S | 1 |
| Holley, MP | 1 |
| Vaughn, CB | 1 |
| Chapman, J | 1 |
| Zaks, J | 1 |
| Young, S | 1 |
| Chinn, B | 1 |
| Enochs, K | 1 |
| Maniscalco, E | 1 |
| Duffin, H | 1 |
| Groshko, G | 1 |
| Reznik, S | 1 |
| Ridge, JA | 2 |
| Daly, JM | 2 |
| Stephens, FO | 1 |
| Crea, P | 1 |
| Walker, PJ | 1 |
| Bartkowski, R | 1 |
| Aguiar, JL | 1 |
| Henne, TH | 1 |
| Dörsam, J | 1 |
| Geelhaar, GH | 1 |
| Norton, JA | 1 |
| Sugarbaker, PH | 2 |
| Doppman, JL | 1 |
| Wesley, RA | 1 |
| Maton, PN | 1 |
| Gardner, JD | 1 |
| Jensen, RT | 1 |
| Clark, CG | 1 |
| Holl, E | 1 |
| Zänker, KS | 1 |
| Lange, J | 1 |
| Siewert, JR | 1 |
| Mouroux, J | 1 |
| Deixonne, B | 1 |
| Eledjam, JJ | 1 |
| Baumel, H | 1 |
| Raju, PI | 1 |
| DeSimone, P | 1 |
| MacDonald, J | 1 |
| Sleijfer, DT | 1 |
| Malik, ST | 1 |
| Wrigley, PF | 1 |
| Margreiter, R | 1 |
| Schmid, T | 1 |
| Steiner, E | 1 |
| Aigner, F | 1 |
| Then, P | 1 |
| Pernthaler, H | 1 |
| Cagnazzo, P | 1 |
| Cardi, G | 1 |
| Ricciuti, FP | 1 |
| Frati, L | 1 |
| Marchei, P | 1 |
| Muhrer, KH | 1 |
| Al-Idrissi, HY | 1 |
| Ibrahim, EM | 1 |
| Abdel Satir, A | 1 |
| Satti, MB | 1 |
| Al-Kasem, S | 1 |
| Al-Qurain, A | 1 |
| Vasen, HF | 1 |
| Sitsen, JM | 1 |
| Nortier, JW | 1 |
| Lips, CJ | 1 |
| Green, AA | 1 |
| Wrenn, E | 1 |
| Champion, J | 1 |
| Shipp, M | 1 |
| Ohtsuki, T | 1 |
| Obata, H | 1 |
| Tomimatsu, M | 1 |
| Ohnishi, K | 1 |
| O'Connell, TX | 1 |
| Kagan, AR | 1 |
| Steckel, RJ | 1 |
| Marymont, JV | 1 |
| Travers, H | 1 |
| Housholder, DF | 1 |
| Kawazoe, Y | 1 |
| Kumagai, M | 1 |
| Yoshioka, H | 1 |
| Wang, CE | 1 |
| Cao, XH | 1 |
| Zhen, YY | 1 |
| Fuse, M | 1 |
| Naitoh, A | 1 |
| Finney, K | 1 |
| Surdyke, M | 1 |
| Horikoshi, N | 1 |
| Mukaiyama, T | 1 |
| Miyaoka, K | 1 |
| Berger, T | 1 |
| Böse-Landgraf, J | 1 |
| Iwamura, F | 1 |
| Livraghi, T | 1 |
| Ravetto, C | 1 |
| Solbiati, L | 1 |
| Suter, F | 1 |
| Andersson, M | 1 |
| Billström, A | 1 |
| Domellöf, L | 1 |
| Ouchi, K | 1 |
| Saitoh, R | 1 |
| Miyoshi, S | 1 |
| Tarui, S | 1 |
| Imashuku, S | 1 |
| Bezwoda, WR | 1 |
| Weaving, A | 1 |
| Kew, M | 1 |
| Derman, DP | 1 |
| La Ciura, P | 1 |
| Nigra, E | 1 |
| Comandone, A | 1 |
| Grecchi, G | 1 |
| Leria, G | 1 |
| Calciati, A | 1 |
| Crown, J | 1 |
| McKenna, A | 1 |
| Hart, R | 1 |
| Sauter, ER | 1 |
| Farley, PC | 1 |
| McFaden, KH | 1 |
| Schaeffer, N | 1 |
| Higgins, J | 1 |
| Qazi, R | 1 |
| Rubins, J | 1 |
| Asbury, R | 1 |
| Watase, M | 1 |
| Shimano, T | 1 |
| Zinser, JW | 1 |
| Hortobagyi, GN | 2 |
| Buzdar, AU | 2 |
| Smith, TL | 1 |
| Fraschini, G | 1 |
| Jain, S | 1 |
| Seymour, AE | 1 |
| Mermillod, B | 1 |
| Gloor, F | 1 |
| Mueller, W | 1 |
| Rieck, B | 1 |
| Grace, RH | 1 |
| Scott, KW | 1 |
| Kitajima, Y | 1 |
| Leinonen, A | 1 |
| Niemelä, R | 1 |
| Kiviniemi, H | 1 |
| Siniluoto, T | 1 |
| Ståhlberg, M | 1 |
| Kin, R | 1 |
| Iwamori, S | 1 |
| Saeki, S | 1 |
| Nishimawari, K | 1 |
| Nagusa, Y | 1 |
| Sasao, T | 1 |
| Roethlin, M | 1 |
| Nehashi, Y | 1 |
| Reimann-Kirkowa, M | 1 |
| Guo, JY | 1 |
| Quebbeman, EJ | 1 |
| Jones, RB | 1 |
| Kaufman, SD | 1 |
| Wood, WC | 1 |
| Kienzle, HF | 1 |
| Wilhelm, S | 1 |
| Mack, P | 1 |
| Strenram, U | 1 |
| Widlus, D | 1 |
| Cox, JD | 1 |
| Wilson, JF | 1 |
| Mehta, MP | 1 |
| Shahabi, S | 1 |
| Mortimer, JE | 1 |
| Higano, C | 1 |
| Stevens, L | 1 |
| Datena, S | 1 |
| Graffis, R | 1 |
| Namer, M | 2 |
| Boublil, JL | 2 |
| Khater, R | 2 |
| Frenay, M | 1 |
| Thyss, A | 2 |
| Bourry, J | 2 |
| Philip, C | 2 |
| Bruneton, JN | 2 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Miller, RL | 1 |
| Andresen, S | 1 |
| Gahbauer, R | 1 |
| Persson, B | 1 |
| Nilsson, LG | 1 |
| Gustafson, T | 1 |
| Andersson, KE | 1 |
| Lieberman, DP | 1 |
| Tao, T | 1 |
| Xie, XH | 1 |
| Liu, KD | 1 |
| Lin, G | 1 |
| Eibl-Eibesfeldt, B | 1 |
| Storz, V | 1 |
| Kummermehr, J | 1 |
| Kuzuoka, M | 1 |
| Pagana, TJ | 1 |
| Bresadola, F | 1 |
| Virdis, A | 1 |
| Spissu, M | 1 |
| Soro, P | 1 |
| Masia, S | 1 |
| Trignano, M | 1 |
| Grieco, A | 1 |
| Cavallaro, A | 1 |
| Netri, G | 1 |
| Noviello, MR | 1 |
| Kolarić, K | 1 |
| Potrebica, V | 1 |
| Stanovnik, M | 1 |
| De Lisi, V | 1 |
| Cocconi, G | 1 |
| Tonato, M | 1 |
| Di Costanzo, F | 1 |
| Leonardi, F | 1 |
| Soldani, M | 1 |
| Edouard, D | 1 |
| Dinh, A | 1 |
| Paoli, D | 1 |
| Larrieu, H | 1 |
| Tajiri, H | 1 |
| Hijikata, A | 1 |
| Saito, D | 1 |
| Ohkura, H | 1 |
| Windle, R | 1 |
| Lubin, E | 1 |
| Neuman, M | 1 |
| Courtheoux, P | 1 |
| Berthelin, JL | 1 |
| Marchand, P | 1 |
| Gignoux, M | 1 |
| Verwaerde, JC | 1 |
| Mani, J | 1 |
| Théron, J | 1 |
| Nitenberg, G | 2 |
| Feil, H | 1 |
| Ruoff, G | 1 |
| Raina, A | 1 |
| Ferrante, F | 1 |
| Bisol, A | 1 |
| Fiori, G | 1 |
| Galeone, M | 1 |
| Richards, HK | 1 |
| Shrestha, RD | 1 |
| Kasanuki, J | 1 |
| Kokubun, M | 1 |
| Ichiki, N | 1 |
| Manegold, C | 1 |
| Thomas, H | 1 |
| Richter, C | 1 |
| Rettenmaier, G | 1 |
| Vyshinskaia, GV | 2 |
| Bassalyk, LS | 1 |
| Vasil'ev, SA | 1 |
| Gromova, NV | 1 |
| Nadezhdina, TM | 1 |
| Thirlwell, MP | 1 |
| Hollingsworth, LM | 1 |
| Herba, MJ | 1 |
| Boileau, G | 2 |
| Boos, G | 1 |
| MacFarlane, JK | 1 |
| Kawaura, Y | 1 |
| Kitagawa, S | 1 |
| Puntis, M | 1 |
| Hanff, G | 1 |
| Ranstam, J | 1 |
| Larroquette, CA | 1 |
| Holmes, FA | 1 |
| Gritsaĭ, AA | 1 |
| Lichinitser, MR | 1 |
| Kondrat'eva, AP | 1 |
| Aplevich, NN | 1 |
| Rotman, M | 1 |
| Kuruvilla, AM | 1 |
| Choi, K | 1 |
| Bhutiani, I | 1 |
| Aziz, H | 1 |
| Rosenthal, J | 1 |
| Braverman, A | 1 |
| Marti, J | 1 |
| Brandys, M | 1 |
| Machin, D | 1 |
| Mullee, M | 1 |
| Trotter, G | 1 |
| Cooke, T | 1 |
| Prorokov, VV | 1 |
| Ozhiganov, EL | 1 |
| Abramova, NA | 1 |
| Adson, MA | 1 |
| Ilstrup, DM | 1 |
| Hirahara, K | 1 |
| Aoki, S | 1 |
| Hori, M | 1 |
| Higuchi, M | 1 |
| Itoh, J | 1 |
| Narisawa, T | 1 |
| Koyama, K | 1 |
| Arizuka, S | 1 |
| Ashida, Y | 1 |
| Shiba, E | 1 |
| Wada, A | 1 |
| Escudier, B | 1 |
| Conscience, G | 1 |
| Nkam, M | 1 |
| Leclercq, B | 1 |
| Mancuso, L | 1 |
| Bondì, F | 1 |
| Marchì, S | 1 |
| Iacona, MA | 1 |
| Di Gregorio, L | 1 |
| Weatherall, TJ | 1 |
| Janaki, L | 1 |
| Boyer, C | 1 |
| Ottow, RT | 1 |
| Gianola, FJ | 1 |
| Schneider, PD | 1 |
| Goldberg, DA | 1 |
| Browning, S | 1 |
| Metter, GE | 1 |
| Miner, PJ | 1 |
| Ellison, NM | 1 |
| Servi, RJ | 1 |
| Fischer, HP | 1 |
| Juan, IK | 1 |
| Whitley, NO | 1 |
| Keramati, B | 1 |
| Jackson, AJ | 1 |
| Hebel, RJ | 1 |
| Jordan, TE | 1 |
| Panasci, L | 1 |
| Ford, J | 1 |
| Margolese, R | 1 |
| Williams, SD | 1 |
| Hui, SL | 1 |
| Nobile, MT | 1 |
| Sertoli, MR | 1 |
| Bruzzone, M | 1 |
| Tagarelli, G | 1 |
| Rubagotti, A | 1 |
| Massey, WH | 2 |
| Judkins, MP | 1 |
| Dennis, DL | 2 |
| Kanamoto, Y | 1 |
| Futorian, ES | 1 |
| Shubin, BM | 1 |
| Humphrey, LJ | 1 |
| Anderson, JM | 2 |
| Patrick, RS | 1 |
| Short, DW | 1 |
| Mackey, WA | 1 |
| McIntire, KR | 1 |
| Princler, GL | 1 |
| Patel, IR | 1 |
| Green, N | 1 |
| Beron, E | 1 |
| Melbye, RW | 1 |
| George, FW | 1 |
| Weiss, JW | 1 |
| Pitot, HC | 2 |
| Battersby, C | 1 |
| Egerton, WS | 1 |
| Rosengren, K | 1 |
| Wedel, N | 1 |
| MacDonald, JA | 1 |
| Fain, WR | 1 |
| Conn, JH | 1 |
| Chavez, CM | 1 |
| Provan, JL | 1 |
| Stokes, JF | 1 |
| Edwards, D | 1 |
| Kissel, P | 1 |
| Bessot, M | 4 |
| Duprez, A | 3 |
| Harris, HS | 2 |
| Geddes, EW | 1 |
| Parsons, VA | 1 |
| Blendis, LM | 1 |
| Dawson, JL | 1 |
| Rake, MO | 1 |
| Laws, JW | 1 |
| Takatani, O | 1 |
| Rochlin, DB | 1 |
| Smart, CR | 1 |
| Burrows, JH | 1 |
| Tucker, WG | 1 |
| Labelle, JJ | 1 |
| Lucas, RJ | 1 |
| Eisenstein, B | 1 |
| Reed, MD | 1 |
| Wilson, GS | 1 |
| Reitemeier, RJ | 1 |
| Meyza, J | 3 |
| Kaufman, S | 1 |
| Tashima, CK | 1 |
| Gorgun, B | 1 |
| Watne, AL | 1 |
| Champeau, M | 1 |
| Arsac, M | 2 |
| Pineau, P | 1 |
| Thevenin, F | 1 |
| Fays, J | 1 |
| Grilliat, JP | 1 |
| Bonnet, G | 1 |
| Mouzon, M | 1 |
| Tomoe, T | 1 |
| Terajima, S | 1 |
| Yamasato, M | 1 |
| Kondo, J | 1 |
| Earle, E | 1 |
| Butts, D | 1 |
| Hoaglin, LL | 1 |
| Katsuta, K | 1 |
| Hozumi, M | 1 |
| Pashintseva, LP | 1 |
| Krusanova, NI | 1 |
| Assekritova, IV | 1 |
| Thompson, RP | 1 |
| Nicholson, DC | 1 |
| Farnan, T | 1 |
| Whitmore, DN | 1 |
| Wolberg, WH | 1 |
| Sanderson, TA | 1 |
| Man, B | 1 |
| Kraus, L | 1 |
| Pikielny, S | 1 |
| Wood, DC | 1 |
| Mauuary, G | 1 |
| Winsback, AM | 1 |
| White, WD | 1 |
| Juniper, K | 1 |
| Daido, R | 1 |
| Koike, A | 1 |
| Nomiyama, Y | 1 |
| Francis, TI | 1 |
| Sugimura, M | 1 |
| Iwamura, K | 1 |
| Barclay, GA | 1 |
| al-Rais, SH | 1 |
| Harrison, NW | 1 |
| Dhru, D | 1 |
| Primack, A | 1 |
| Bhana, D | 1 |
| Kyalwazi, SK | 1 |
| Go, TS | 1 |
| Kithier, K | 1 |
| Scott, D | 1 |
| Theologides, A | 2 |
| Stehlin, JS | 1 |
| Greeff, PJ | 1 |
| Plagemann, PG | 1 |
| Erbe, J | 1 |
| Schulz, D | 1 |
| Young, HE | 1 |
| Linder, GT | 1 |
| Crook, JN | 1 |
| Cohn, I | 1 |
| Russell, DH | 1 |
| Marton, LJ | 1 |
| LeGendre, SM | 1 |
| Morris, HP | 2 |
| Lea, MA | 1 |
| Khalil, FL | 1 |
| Bullock, J | 1 |
| Mittelman, A | 1 |
| Koyama, S | 1 |
| Majima, S | 1 |
| Matsushige, H | 1 |
| Kinne, DW | 1 |
| Kim, DK | 1 |
| Castro, EB | 1 |
| Watson, RC | 1 |
| Howland, WS | 1 |
| Beattie, EJ | 1 |
| Mackman, S | 3 |
| Knock, FE | 1 |
| Galt, RM | 1 |
| Oester, YT | 1 |
| Sylvester, R | 1 |
| Andrews, JT | 2 |
| Cox, KR | 2 |
| Hare, WS | 2 |
| McConchie, IH | 1 |
| Vang, J | 1 |
| Lange, M | 1 |
| Geddes, E | 1 |
| Markoff, N | 1 |
| Djalaly, A | 1 |
| Johnson, EC | 1 |
| Priestman, TJ | 1 |
| Hanham, IW | 1 |
| Skarin, AT | 1 |
| Hirose, M | 1 |
| Takamatu, O | 1 |
| Tandon, RN | 1 |
| Bunnell, IL | 1 |
| Cooper, RG | 1 |
| Bevan, PG | 1 |
| Omura, GA | 1 |
| Roberts, GA | 1 |
| Huys, J | 1 |
| Otte, H | 1 |
| Gätera, G | 1 |
| Freyens, P | 1 |
| Berghe, GV | 1 |
| Dana, M | 1 |
| Hughes, J | 1 |
| Stoker, TA | 1 |
| Miyoshi, T | 1 |
| Akao, T | 1 |
| Ito, B | 1 |
| Creasey, WA | 1 |
| Tully, TE | 1 |
| Shafer, RB | 1 |
| Rozhold, J | 1 |
| Klucár, J | 1 |
| Witek, JT | 1 |
| Spencer, RP | 1 |
| Heidelberger, C | 1 |
| Johnston, GS | 1 |
| Jones, AE | 1 |
| Fortuny, IE | 1 |
| Skibba, JL | 2 |
| Sandler, M | 1 |
| Cheetham, HD | 1 |
| Watts, JA | 1 |
| Rudenstam, CM | 1 |
| Nilsson, LA | 1 |
| Lawton, RL | 1 |
| Condon, RE | 1 |
| Lahiri, SR | 1 |
| Aliapoulios, MA | 1 |
| Moore, FD | 1 |
| Freckman, HA | 1 |
| Carlberger, G | 1 |
| Ljungdahl, I | 1 |
| Yonemoto, RH | 1 |
| Byron, RL | 1 |
| Keating, JL | 1 |
| Alcini, E | 1 |
| Wiel Marin, A | 1 |
| Ronzoni, G | 1 |
| Pigliucci, GM | 1 |
| Fazio, M | 1 |
| Minetto, E | 1 |
| Cavallero, P | 1 |
| Sartoris, S | 1 |
| Van Way, CW | 1 |
| Reynolds, VH | 1 |
| Rapoport, AH | 1 |
| Burleson, RL | 1 |
| Mansfield, CM | 1 |
| Kramer, S | 1 |
| Southard, ME | 1 |
| Hornowski, S | 1 |
| Brix, M | 1 |
| Börjesson, B | 1 |
| Olsson, A | 1 |
| Szatkowska, R | 1 |
| Yamada, E | 1 |
| Miyaishi, S | 1 |
| Kuroyanagi, Y | 1 |
| Kaneko, M | 1 |
| Gofman, AM | 1 |
| Faĭn, SN | 1 |
| Takemae, T | 1 |
| Eras, P | 1 |
| Evseenko, LS | 1 |
| Orlova, RS | 1 |
| Barrett, O | 1 |
| Bernhardt, LC | 1 |
| Herter, FP | 1 |
| Mulcare, RJ | 1 |
| McCarthy, JG | 1 |
| Gump, FE | 1 |
| Ukai, M | 1 |
| Buckley, K | 1 |
| Wheeler, B | 1 |
| Harvey, ND | 1 |
| Spratt, JS | 1 |
| Zurek, WZ | 1 |
| Gonzalez, EM | 1 |
| Doehner, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patient[NCT04617457] | Phase 2 | 150 participants (Anticipated) | Interventional | 2021-10-10 | Recruiting | ||
| Phase II Trial of Hepatic Arterial inFusion Chemotherapy Sequential transaRterial Embolization cOmbined With leNvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma (FRONT Trial)[NCT05532319] | Phase 2 | 65 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma[NCT05609695] | 100 participants (Anticipated) | Observational | 2023-03-01 | Not yet recruiting | |||
| A Study of the Application of Hepatic Arterial Infusion in Advanced Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors and Antiangiogenic Agents[NCT05718492] | 100 participants (Anticipated) | Interventional | 2022-10-18 | Recruiting | |||
| Observation Study of Sequential Regorafenib Combined With Immunocheckpoint Inhibitors After Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma[NCT05573282] | 50 participants (Anticipated) | Observational | 2022-10-16 | Recruiting | |||
| A Phase III Randomized Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin With Sorafenib for Patients With Barcelona-Clinic Liver Cancer (BCLC)-C Stage Hepatocellular Carcinoma[NCT03164382] | Phase 3 | 262 participants (Actual) | Interventional | 2017-03-01 | Completed | ||
| Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver[NCT02885753] | Phase 3 | 348 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| [NCT01384994] | Phase 2 | 111 participants (Anticipated) | Interventional | 2011-08-31 | Recruiting | ||
| A Randomized Controlled Study of the Efficacy of Hepatic Arterial Perfusion Chemotherapy Concurrently Compared to Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable Intermediate and Advanced HCC[NCT06041477] | Phase 3 | 540 participants (Anticipated) | Interventional | 2023-09-30 | Recruiting | ||
| A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colore[NCT00819780] | Phase 2 | 285 participants (Actual) | Interventional | 2009-04-24 | Completed | ||
| A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer[NCT00508404] | Phase 2 | 154 participants (Actual) | Interventional | 2007-05-09 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| Drug Response in Patient-derived Organoids Models of Advanced or Recurrent Ovarian Cancer, an Exploratory Research[NCT05290961] | 30 participants (Anticipated) | Observational [Patient Registry] | 2022-03-09 | Recruiting | |||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy[NCT03783559] | Phase 3 | 168 participants (Actual) | Interventional | 2016-01-31 | Active, not recruiting | ||
| Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.[NCT01640405] | Phase 3 | 350 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells[NCT01640444] | Phase 2 | 240 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Safety and Efficacy of mFOLFOX6+ Bevacizumab+PD-1 Monoclonal Antibody Treatment Combinations in Patients With Local Advanced Microsatellite Stability Colorectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study (BASKETII)[NCT04895137] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study[NCT02826486] | Phase 2 | 80 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study[NCT01839877] | Phase 2 | 58 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases[NCT01972490] | Phase 4 | 241 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| The Effect and Safety on Unresectable CRLM From RFA in Combination With Second-line Chemotherapy and Bevacizumab Compared With the Combination of Second-line Chemotherapy and Bevacizumab: a Randomized and Controlled Clinical Trial[NCT03686254] | Phase 2/Phase 3 | 160 participants (Anticipated) | Interventional | 2018-07-16 | Recruiting | ||
| Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)[NCT03862911] | 330 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | |||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| Clinical Study of CT and MR in Staging and Prediction of Response in Patients With Gastric Cancer[NCT04028375] | 400 participants (Anticipated) | Observational | 2019-09-01 | Recruiting | |||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial[NCT06121700] | Phase 2 | 55 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004] | Phase 1 | 20 participants (Actual) | Interventional | 2020-03-11 | Completed | ||
| Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After Hepatic Artery Infusion Chemotherapy (HAIC) for Locally Advanced Hepatocellular Carcinoma (HCC)[NCT05002452] | 150 participants (Anticipated) | Observational | 2021-12-20 | Recruiting | |||
| An Open Label Pilot Study to Evaluate Efficacy and Safety of Durvalumab(MEDI 4736) With Hepatic Artery Infusion Chemotherapy (HAIC) in the Chinese Advanced HCC Patients With Severe Portal Vein Tumor Thrombosis (PVTT)(Vp3 or Vp4) DurHope[NCT04945720] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-11 | Recruiting | ||
| A Prospective, Multicenter, Phase III Clinical Study Comparing Continuous Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma[NCT05231382] | Phase 3 | 426 participants (Anticipated) | Interventional | 2022-03-28 | Recruiting | ||
| Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitor in Treating Potentially Resectable Locally Advanced Hepatocellular Carcinoma: A Prospective, Phase II Clinical Study[NCT03869034] | Phase 2 | 40 participants (Actual) | Interventional | 2019-03-25 | Active, not recruiting | ||
| An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer [NCT00885885] | Phase 2 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2021-07-01 | Enrolling by invitation | ||
| A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib and Camreli[NCT05313282] | Phase 3 | 140 participants (Anticipated) | Interventional | 2022-06-15 | Recruiting | ||
| A Prospective, Single-arm, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib-Mesylate Tablets and Camrelizumab for Injec[NCT04191889] | Phase 2 | 47 participants (Anticipated) | Interventional | 2020-04-13 | Recruiting | ||
| An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949] | Phase 1/Phase 2 | 39 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial[NCT02494973] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2015-05-26 | Suspended (stopped due to Recruitment too slow) | ||
| A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER[NCT00719797] | Phase 3 | 509 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927] | Phase 3 | 568 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| A Phase I/II Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma[NCT01047293] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer[NCT01765582] | Phase 2 | 280 participants (Actual) | Interventional | 2013-01-23 | Terminated | ||
| A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT01896531] | Phase 2 | 153 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.[NCT00145314] | Phase 3 | 571 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Neoadjuvant Radiotherapy for Patients With Hepatocellular Carcinoma Involving Type I Portal Vein Tumor Thrombus[NCT04025437] | Phase 2/Phase 3 | 214 participants (Anticipated) | Interventional | 2019-03-01 | Active, not recruiting | ||
| Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial[NCT02774187] | Phase 3 | 247 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Prospective, Single-armed, Multicentric, Explorative Phase II Clinical Research of Conversional Therapy With Combination of Hepatic Arterial Infusion Chemotherapy and Donafenib and Toripalimab for Unresectable Hepatocellular Carcinoma[NCT05493332] | Phase 2 | 93 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma[NCT01900717] | Phase 2 | 102 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer[NCT00952029] | Phase 2/Phase 3 | 492 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients[NCT04802954] | 400 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study[NCT01985763] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial[NCT02624726] | Phase 2 | 31 participants (Actual) | Interventional | 2016-01-31 | Active, not recruiting | ||
| Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer[NCT01836653] | Phase 2 | 122 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375] | Phase 2/Phase 3 | 192 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease[NCT00865709] | Phase 2 | 198 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer[NCT01564810] | Phase 4 | 150 participants (Anticipated) | Interventional | 2006-09-30 | Recruiting | ||
| The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection[NCT02738697] | Phase 3 | 290 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02585479] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to It doesn't meet the requirements of randomized trials) | ||
| A Randomized Controlled Trial of Radical Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma[NCT02584556] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn | ||
| Gemcitabine Plus Oxaliplatin (GEMOX) Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02534337] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-09-30 | Withdrawn (stopped due to It doesn't meet the requirements of randomized trials) | ||
| Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02527772] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-09-30 | Withdrawn (stopped due to It doesn't meet the requirements of randomized trials) | ||
| Hepatic Resection Combined With or Without Oxaliplatin+5-Fluorouracil/ Leucovorin(5-FU/LV)(FOLFOX4) for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT02452853] | Phase 2 | 51 participants (Anticipated) | Interventional | 2015-05-31 | Active, not recruiting | ||
| RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC:an Open Lable, Single-arm, Prospective Study[NCT02426450] | Phase 2 | 28 participants (Anticipated) | Interventional | 2015-04-30 | Active, not recruiting | ||
| A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer[NCT00484939] | Phase 3 | 280 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study[NCT00006479] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Active, not recruiting | ||
| Simultaneous RESEction of Colorectal Cancer With Synchronous Liver MeTastases (RESECT): A Feasibility Study[NCT02954913] | 41 participants (Actual) | Interventional | 2017-02-14 | Completed | |||
| Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial[NCT02912052] | Phase 3 | 240 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma[NCT05314400] | 300 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | |||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer[NCT00339183] | Phase 3 | 1,186 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| "Radical External Beam Chemoradiation in Patients With Rectal Cancer: a Wait-and-see Approach"[NCT03001362] | 48 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | |||
| Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial[NCT05338866] | 58 participants (Anticipated) | Observational | 2022-01-01 | Enrolling by invitation | |||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver [NCT00153998] | Phase 2 | 135 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes[NCT00492999] | Phase 2 | 64 participants (Anticipated) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-06-24 | Recruiting | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis[NCT03031444] | Phase 2/Phase 3 | 135 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Open Labeled, Multicenter Phase I/II Study Evaluating the Dose Escalation/Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan as First-Line Treatment of Metastatic Colorectal Cancer[NCT00422773] | Phase 1/Phase 2 | 21 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
| Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial[NCT00941655] | Phase 3 | 15 participants (Actual) | Interventional | 2009-07-22 | Completed | ||
| Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment[NCT00471965] | Phase 3 | 371 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.[NCT00970216] | 160 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Canc[NCT04659382] | Phase 2 | 52 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer: a Prospective Phase II Study[NCT06148402] | Phase 2 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Recruiting | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer[NCT02591667] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753] | Phase 1 | 14 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With RAS-mutated Metastatic Colorectal Cancer: a Dose-escalation, Phase I/II Trial[NCT03828799] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2019-05-17 | Active, not recruiting | ||
| Randomised Comparative Study Of Folfox6m Plus Sir-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma[NCT00724503] | 530 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus [NCT00778102] | Phase 2 | 80 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Bevacizumab Maintenance Versus no Maintenance After Stop of First-line Chemotherapy in Patients With Metastatic Colorectal Cancer. A Randomized Multicenter Phase III Non-inferiority Trial[NCT00544700] | Phase 3 | 265 participants (Actual) | Interventional | 2007-11-26 | Terminated (stopped due to Data collection is completed. As no changes in the endpoints were expected in the future, no further data is needed.) | ||
| A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice[NCT01460745] | 60 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.[NCT01490996] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Protocol for Evaluation of Oncological Treatment in Patients With CRLM Using Zebra Fish Avatars-may This Model Improve Resection Rates and Survival in Patients With Upfront Non-resectable Metastatic Disease?[NCT05289076] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2022-05-17 | Recruiting | ||
| Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)[NCT02162563] | Phase 3 | 564 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors[NCT00418938] | Phase 2 | 266 participants (Actual) | Interventional | 2006-11-01 | Completed | ||
| Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial[NCT00852228] | Phase 2 | 60 participants (Anticipated) | Interventional | 2008-07-31 | Active, not recruiting | ||
| Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0[NCT01621217] | Phase 1 | 21 participants (Anticipated) | Interventional | 2012-06-30 | Completed | ||
| Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer[NCT01219920] | Phase 3 | 244 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only[NCT01226719] | Phase 2 | 15 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer[NCT01523457] | Phase 2 | 75 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [NCT00594529] | Phase 2 | 27 participants (Anticipated) | Interventional | 2008-01-31 | Recruiting | ||
| Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction After Sphincter-preserving Surgery Among Rectal Cancer Patients[NCT03569488] | 1,100 participants (Anticipated) | Observational | 2020-01-24 | Recruiting | |||
| "Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: Trapianto di Fegato da Donatore Vivente Per Meta[NCT05186116] | 25 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Phase II Randomized Study of Maintenance Treatment With Bevacizumab or Bevacizumab Plus Metronomic Chemotherapy After First-line Induction FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer Patients[NCT02271464] | Phase 2 | 232 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer[NCT01163396] | Phase 2 | 57 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.[NCT00978107] | Phase 1 | 16 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.[NCT02460419] | Phase 3 | 104 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced HCC (Hepatocellular Carcinoma) Not Eligible to Curative Approach. A Phase II-b Study.[NCT00910572] | Phase 2 | 60 participants (Anticipated) | Interventional | 2007-07-31 | Completed | ||
| Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma[NCT02729506] | Phase 4 | 150 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294] | Phase 1 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver[NCT01785212] | 40 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma[NCT00168155] | Phase 2 | 70 participants | Interventional | 2002-01-31 | Completed | ||
| Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer[NCT00100815] | Phase 2 | 50 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737] | Phase 2 | 125 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Value of Contrast Enhanced Intraoperative Ultrasound Compared to Preoperative CEUS, CT and MRT in the Treatment of Colorectal Liver Metastases.[NCT01522209] | 59 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2[NCT05301010] | Phase 3 | 128 participants (Actual) | Interventional | 2018-02-02 | Completed | ||
| Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Pharmacokinetic Parameters, Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2.[NCT05301530] | Phase 1 | 50 participants (Actual) | Interventional | 2019-05-27 | Completed | ||
| A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Live[NCT00026234] | Phase 2 | 75 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer[NCT00193219] | Phase 2 | 36 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone[NCT00394992] | Phase 3 | 79 participants (Actual) | Interventional | 2006-12-31 | Terminated (stopped due to Data from the C08 study and Avant study) | ||
| Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal [NCT00125034] | Phase 2 | 344 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer[NCT01022541] | Phase 2 | 47 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-positive Gastric Cancer (JCOG9206-2)[NCT00147147] | Phase 3 | 280 participants | Interventional | 1993-01-31 | Completed | ||
| Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis (HELARC) ------ a Randomized Controlled Multicenter Clinical Study[NCT02886104] | 548 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | |||
| Treatment of Liver Metastases With Electrochemotherapy[NCT01264952] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II[NCT02352259] | Phase 2 | 23 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.[NCT00619541] | Phase 2 | 46 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
| Irreversible Electroporation for Treatment of Solid Abdominal Tumors[NCT03169439] | 25 participants (Anticipated) | Interventional | 2017-07-01 | Not yet recruiting | |||
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Clinical Study of Dynamic Contrast-enhanced Magnetic Resonance Imaging Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver Metastasis of Breast Cance[NCT05550090] | 40 participants (Anticipated) | Observational | 2022-09-16 | Recruiting | |||
| FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT01321957] | Phase 2 | 250 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Perioperative FOLFOXIRI and Bevacizumab Compared With Postoperative FOLFOX in Patients With Resectable Liver Metastases From Colorectal Cancer (PERIMAX). A Randomized, Multidisciplinary DGAV(CAO-V/CALGP)/AIO Phase II Trial[NCT01540435] | Phase 2 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to insufficient recruitment) | ||
| Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study[NCT03683004] | 40 participants (Actual) | Observational | 2018-01-22 | Completed | |||
| A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors[NCT02404480] | Phase 1 | 31 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma[NCT00752570] | Phase 2 | 144 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS[NCT00002544] | Phase 3 | 300 participants (Anticipated) | Interventional | 1993-05-31 | Completed | ||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases[NCT01336985] | Phase 1 | 5 participants (Actual) | Interventional | 2011-03-28 | Terminated | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427] | Phase 2 | 101 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms.[NCT00356161] | Phase 2 | 100 participants | Interventional | 2002-04-30 | Recruiting | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594] | Phase 3 | 1,691 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV[NCT00006050] | Phase 2 | 0 participants | Interventional | 1999-04-04 | Completed | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver[NCT00003834] | Phase 2 | 44 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER[NCT00002716] | Phase 3 | 135 participants (Actual) | Interventional | 1996-01-31 | Completed | ||
| A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin, and Bevacizumab for Resectable Colorectal Metastases in the Liver[NCT00118105] | Phase 2 | 0 participants (Actual) | Interventional | 2006-11-30 | Withdrawn (stopped due to Budget Constraints) | ||
| Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration[NCT02781285] | 1,500 participants (Anticipated) | Observational [Patient Registry] | 2014-12-31 | Recruiting | |||
| Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658] | 200 participants (Anticipated) | Observational | 2010-11-30 | Recruiting | |||
| A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553] | Phase 2 | 0 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2018-01-29 | Terminated (stopped due to Difficult to enrollment patient) | ||
| A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection[NCT05677113] | Phase 2 | 115 participants (Anticipated) | Interventional | 2023-08-30 | Recruiting | ||
| Construction and Evaluation of the Early Identification and Individualized Treatment for Oxaliplatin-induced Portal Hypertension[NCT04524676] | 25 participants (Anticipated) | Interventional | 2020-08-31 | Not yet recruiting | |||
| Construction and Evaluation of the Early Identification for Oxaliplatin Induced Portal Hypertension[NCT04524650] | 370 participants (Anticipated) | Observational | 2020-08-31 | Not yet recruiting | |||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Double-blind Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Per and Post Hepatectomy Infiltrations for Adult Pain Management[NCT01194843] | 85 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| A Randomized Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy Versus Standard Therapy in Women With Metastatic Breast Cancer Who Have Responded to Anthracycline or Taxane-Based Induction Chemotherapy[NCT00003032] | Phase 3 | 224 participants (Actual) | Interventional | 1997-04-25 | Completed | ||
| Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430] | 63 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement[NCT00003902] | Phase 1/Phase 2 | 110 participants (Anticipated) | Interventional | 1999-03-31 | Completed | ||
| A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168] | 0 participants | Expanded Access | No longer available | ||||
| Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience[NCT02557750] | 35 participants (Anticipated) | Observational | 2016-01-31 | Recruiting | |||
| Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma[NCT02981498] | Phase 2 | 35 participants (Anticipated) | Interventional | 2015-06-30 | Completed | ||
| First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809] | Phase 4 | 40 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Leas[NCT00510627] | Phase 4 | 0 participants (Actual) | Interventional | 2007-08-31 | Withdrawn (stopped due to Boston Scientific has decided to close the Study.) | ||
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166] | Phase 3 | 40 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| Prospective Registry Study of Neoadjuvant Therapy in Conjunction With Liver Transplantation for Cholangiocarcinoma[NCT00301379] | 59 participants (Actual) | Observational | 2005-08-12 | Terminated (stopped due to Low accrual) | |||
| Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis[NCT01357486] | Phase 2 | 160 participants (Actual) | Interventional | 2011-11-14 | Completed | ||
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| The Efficacy, Safety, and Patient Reported Outcomes of Different Regimens of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma[NCT00493402] | Phase 3 | 365 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy[NCT01097083] | Phase 2 | 20 participants | Interventional | 2010-04-30 | Terminated | ||
| MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171] | 180 participants (Anticipated) | Observational | 2022-10-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.0 |
| Bevacizumab Plus mFOLFOX6 | 9.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 25.4 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 57.75 |
| Bevacizumab Plus mFOLFOX6 | 53.52 |
"Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.~Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions." (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 60.49 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 61.54 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.9 |
| Bevacizumab Plus mFOLFOX6 | 10.1 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.1 |
| Bevacizumab Plus mFOLFOX6 | 9.7 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.0 |
| Bevacizumab Plus mFOLFOX6 | 9.5 |
The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 12.68 |
| Bevacizumab Plus mFOLFOX6 | 11.19 |
Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 11.0 |
| Bevacizumab Plus mFOLFOX6 | 11.1 |
For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 1.8 |
| Bevacizumab Plus mFOLFOX6 | 1.9 |
Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug. (NCT00819780)
Timeframe: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event (AE) | AE with worst grade of 3 | AE with worst grade of 4 | AE with worst grade of 5 | Serious adverse event (SAE) | AE leading to discontinuation of study drug | Any treatment-related adverse event (TRAE) | Treatment-related AE with worst grade of 3 | Treatment-related AE with worst grade of 4 | Treatment-related AE with worst grade of 5 | Serious treatment-related adverse event | TRAE leading to discontinuation of study drug | |
| Bevacizumab Plus mFOLFOX6 | 139 | 78 | 28 | 9 | 53 | 37 | 136 | 77 | 25 | 2 | 28 | 29 |
| Panitumumab Plus mFOLFOX6 | 139 | 88 | 31 | 7 | 61 | 34 | 138 | 92 | 24 | 3 | 37 | 28 |
"The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator.~Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 90.59 |
| Mutant KRAS | 89.66 |
Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 13.0 |
| Mutant KRAS | 7.4 |
Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 5.9 |
| Mutant KRAS | 6.1 |
The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. (NCT00508404)
Timeframe: Up to Week 17
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 49.41 |
| Mutant KRAS | 34.48 |
"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.~Complete Response (CR): disappearance of all target and non-target lesions and no new lesions.~Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 56.47 |
| Mutant KRAS | 37.93 |
Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 8.9 |
| Mutant KRAS | 7.2 |
The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 15.12 |
| Mutant KRAS | 6.78 |
Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 11.2 |
| Mutant KRAS | 7.3 |
Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | NA |
| Mutant KRAS | NA |
Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 3.8 |
| Mutant KRAS | NA |
Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 6.9 |
| Mutant KRAS | 5.8 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
Number of patients who experienced a Dose Limiting Toxicity (DLT). DLT will be assessed in the first 28 days of dosing. Patients need to get dosed with 2 rounds/sessions of all chemotherapy agents in the first 28 days in order to be evaluable for DLT assessment. The primary endpoint is safety as summarized by dose limiting toxicity (DLT). (NCT01047293)
Timeframe: December 2011
| Intervention | participants (Number) |
|---|---|
| ARM 1 RAD001 5 mg QOD | 0 |
| ARM 2 5mg RAD001 QD | 1 |
| ARM 3 10mg RAD001 QD | 1 |
(NCT01047293)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Patients | 87 |
OS was defined as the time from the date of randomization to the date of death from any cause. (NCT01765582)
Timeframe: Randomization until death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 33.97 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 28.32 |
| Arm C: FOLFOX + Bevacizumab | 30.65 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 28.32 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 100 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 98.9 |
| Arm C: FOLFOX + Bevacizumab | 100 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 99.4 |
ORR1 was the percentage of participants with complete response (CR) or partial response (PR) during first-line therapy as assessed by investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). CR was defined as disappearance of all extranodal target lesions and all pathological lymph nodes had to have decreased to <10 millimeter (mm) in short axis. PR was defined as at least a 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum diameters. ORR1 = CR + PR (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 72.0 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 72.8 |
| Arm C: FOLFOX + Bevacizumab | 62.1 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 72.4 |
PFS1 was defined as time from randomization to the first occurrence of disease progression during first-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5 mm. (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 11.86 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 11.37 |
| Arm C: FOLFOX + Bevacizumab | 9.46 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 11.70 |
The proportion of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases was calculated as follows: number of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases divided by total number of participants in each arm. This outcome represents a measure of the rate of conversion from unresectable to resectable disease. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 0.24 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 0.17 |
| Arm C: FOLFOX + Bevacizumab | 0.14 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 0.21 |
Reported here is the proportion of participants who underwent liver metastases resections calculated as follows: number of participants who underwent liver metastases resections divided by total number of participants in each arm. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 0.17 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 0.10 |
| Arm C: FOLFOX + Bevacizumab | 0.08 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 0.14 |
Time to PFS2 was defined as time from randomization to the first occurrence of disease progression after reinduction of second-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5mm. (NCT01765582)
Timeframe: Randomization up to disease progression during second-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 18.76 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 13.17 |
| Arm C: FOLFOX + Bevacizumab | 14.75 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 15.08 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. (NCT01896531)
Timeframe: Baseline until end of study (up to approximately 7.5 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Ipatasertib + mFOLFOX6 | 70 |
| Placebo + mFOLFOX6 | 80 |
Duration of objective tumor response in participants with measurable soft tissue disease at baseline was defined as the time from first observation of an objective tumor response until first observation of disease progression, as assessed by the investigator per modified RECIST Version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumor | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 4.63 | 4.70 | 4.70 |
| Placebo + mFOLFOX6 | 5.85 | 5.98 | 6.80 |
Objective Response Rate was defined as the percentage of participants achieving either a complete response (CR) or a partial response (PR) based on the investigator assessment using RECIST v 1.1. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 52.1 | 50.0 | 52.2 |
| Placebo + mFOLFOX6 | 57.3 | 73.3 | 56.5 |
OS was defined as the time from the date of randomization to the date of death from any cause. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Baseline up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 11.96 | 14.82 | 11.66 |
| Placebo + mFOLFOX6 | 15.31 | 21.78 | 17.22 |
PFS was defined as the time from randomization to the first occurrence of disease progression (as determined using RECIST Version 1.1 and assessed by the investigator), or death from any cause on study. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, assessed up to approximately 1.75 years
| Intervention | months (Median) | |
|---|---|---|
| All Randomized Participants | Participants With PTEN Loss Tumors | |
| Ipatasertib + mFOLFOX6 | 6.57 | 7.10 |
| Placebo + mFOLFOX6 | 7.52 | 7.39 |
(NCT01896531)
Timeframe: Day 1 at 1 hour and 4 hours post-dose; Day 5, pre-dose and 2 hours post-dose
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Day 1: 1 hour post-dose | Day 1: 4 hours post-dose | Day 5: pre-dose | Day 5: 2 hours post-dose | |
| Ipatasertib + mFOLFOX6 | 506 | 389 | 90.7 | 557 |
Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 6 |
The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 8 |
Overall Survival - Number of months still living since baseline (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 36.5 |
Percent change in tumor size after cycle 6. Each cycle is 21 days. (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Percent change (Median) |
|---|---|
| Genistein | -43.0 |
Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse. (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 11.5 |
"Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.~SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.~PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions." (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 6 | 3 | 2 | 2 |
Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle. (NCT01985763)
Timeframe: up to 6 months
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Genistein | 250 | 119 | 24 | 0 |
"Patients monitored for progression during the study period and 1 year following.~Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse." (NCT01985763)
Timeframe: 6 month and 12 month
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| Genistein | 69 | 38 |
"Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 8 | 1 | 2 | 2 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) was first documented or to the date of death, whichever occurred first according to Response Evaluation Criteria in Solid Tumors (RECIST). Subjects still having CR or PR and alive at the time of analysis were censored at their last date of tumor evaluation. CR was defined as disappearance of tumor lesions, PR as a decrease of at least 30% and PD as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks
| Intervention | months (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 7.5 |
| Matching Placebo + mFOLFOX6 | 6.7 |
Overall response of a subject was defined as the best tumor response (Complete Response (CR) or Partial Response (PR)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 45 |
| Matching Placebo + mFOLFOX6 | 61 |
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00865709)
Timeframe: From randomization of the first subject until 33 months later.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 535 |
| Matching Placebo + mFOLFOX6 | 552 |
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression or death due to any cause, whichever occurred first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.1 |
| Matching Placebo + mFOLFOX6 | 8.7 |
Time to progression (TTP) was defined as the time from date of randomization to disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.2 |
| Matching Placebo + mFOLFOX6 | 9.0 |
Duration of follow-up is defined as the time in days from randomization until disease progression or death, or time to censoring for overall survival. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Days (Mean) |
|---|---|
| Bevacizumab + Capecitabine | 540.5 |
| Capecitabine | 479.2 |
Duration of response was defined as the time in months from the first confirmed complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 9.7 |
| Capecitabine | 9.4 |
Overall survival was defined as the time in months from randomization to death from any cause. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 20.7 |
| Capecitabine | 17.0 |
Reported is the percentage of participants requiring additional treatment for malignancy in the survival follow-up period. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Bevacizumab + Capecitabine | 50.7 |
| Capecitabine | 49.3 |
Progression-free survival was defined as the time in months from the date of randomization to the date of disease progression or death from any cause, whichever occurred first. All measurable lesions (maximum of 5 per organ and 10 in total, those with the longest diameter and suitability for accurate repeated measurements) were identified as target lesions (TL). A sum of the longest diameter for all TLs was calculated and reported as the baseline sum longest diameter (SLD). All other lesions were identified as non-TLs and recorded at baseline. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 9.1 |
| Capecitabine | 5.1 |
Time to response was defined as the time in months from the date of first study treatment to the date of the first documentation of complete response (CR) or partial response (PR), whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. Participants who did not have a confirmed response were censored at the date of the last evaluable tumor assessment, or if that was unavailable, at the date of the first dose of study medication. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | NA |
| Capecitabine | NA |
BOR was defined as the best response (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], not evaluable [NE], or not assessed [NA]) recorded from the start of study treatment until disease progression (PD) or death. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not assessed | |
| Bevacizumab + Capecitabine | 2.9 | 17.1 | 54.3 | 10.0 | 15.7 |
| Capecitabine | 1.4 | 8.6 | 48.6 | 21.4 | 20.0 |
The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all predisease activities without restriction), 1=Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), 2=Symptomatic, < 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, > 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death. Reported is the percentage of participants in each of the 6 ECOG performance status categories. (NCT00484939)
Timeframe: Baseline to the Safety Follow-up which occurred 28 days after the last dose of treatment (up to 5 years 8 months).
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 7 ECOG = 0 (n=117,110) | Week 7 ECOG = 1 | Week 7 ECOG = 2 | Week 7 ECOG = 3 | Week 7 ECOG = 4 | Week 7 ECOG = 5 | Week 16 ECOG = 0 (n=88,77) | Week 16 ECOG = 1 | Week 16 ECOG = 2 | Week 16 ECOG = 3 | Week 16 ECOG = 4 | Week 16 ECOG = 5 | Week 25 ECOG = 0 (n=66,42) | Week 25 ECOG = 1 | Week 25 ECOG = 2 | Week 25 ECOG = 3 | Week 25 ECOG = 4 | Week 25 ECOG = 5 | Week 34 ECOG = 0 (n=48,24) | Week 34 ECOG = 1 | Week 34 ECOG = 2 | Week 34 ECOG = 3 | Week 34 ECOG = 4 | Week 34 ECOG = 5 | Safety Follow-up ECOG = 0 (n=89,82) | Safety Follow-up ECOG = 1 | Safety Follow-up ECOG = 2 | Safety Follow-up ECOG = 3 | Safety Follow-up ECOG = 4 | Safety Follow-up ECOG = 5 | |
| Bevacizumab + Capecitabine | 50.4 | 47.0 | 1.7 | 0.9 | 0.0 | 0.0 | 50.0 | 45.5 | 3.4 | 1.1 | 0.0 | 0.0 | 43.9 | 48.5 | 6.1 | 1.5 | 0.0 | 0.0 | 39.6 | 58.3 | 0.0 | 2.1 | 0.0 | 0.0 | 33.7 | 47.2 | 12.4 | 6.7 | 0.0 | 0.0 |
| Capecitabine | 34.5 | 58.2 | 5.5 | 1.8 | 0.0 | 0.0 | 36.4 | 51.9 | 11.7 | 0.0 | 0.0 | 0.0 | 45.2 | 45.2 | 9.5 | 0.0 | 0.0 | 0.0 | 33.3 | 58.3 | 8.3 | 0.0 | 0.0 | 0.0 | 32.9 | 45.1 | 14.6 | 4.9 | 1.2 | 1.2 |
"Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.6 |
| Wild-type KRAS - FOLFIRI Alone | 6.6 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 6.0 |
| Mutant KRAS - FOLFIRI Alone | 7.4 |
Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date. (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 14.5 |
| Wild-type KRAS - FOLFIRI Alone | 12.5 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 11.8 |
| Mutant KRAS - FOLFIRI Alone | 11.1 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00339183)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 35.35 |
| Wild-type KRAS - FOLFIRI Alone | 9.82 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 13.36 |
| Mutant KRAS - FOLFIRI Alone | 13.92 |
"Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 5.9 |
| Wild-type KRAS - FOLFIRI Alone | 3.9 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 5.0 |
| Mutant KRAS - FOLFIRI Alone | 4.9 |
"Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.3 |
| Wild-type KRAS - FOLFIRI Alone | 5.3 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 5.5 |
| Mutant KRAS - FOLFIRI Alone | 5.5 |
"A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFIRI Alone | 573 | 175 | 64 | 542 | 90 | 34 |
| Panitumumab Plus FOLFIRI | 584 | 232 | 123 | 577 | 124 | 97 |
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Participants who were alive and disease free at 12 months. DFS was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was disappearance of all target lesions. Partial response was at least a 30% decrease in target lesions. Progression was at least a 20% increase in target lesions and stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00941655)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 2 |
| Systemic Chemotherapy Alone | 0 |
Blood loss during surgery is related to complexity of the operation and via that to the stage of disease (more tumor to be cytoreduced, more blood loss). (NCT00941655)
Timeframe: Day 1
| Intervention | ml (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 650 |
Time it takes to perform this complex surgery and HIPEC to reduce tumor burden overall in this disease. (NCT00941655)
Timeframe: up to 12 hours
| Intervention | hours (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 10.1 |
Recuperation period following complex surgery for this disease. (NCT00941655)
Timeframe: 1-10 weeks
| Intervention | Days (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 17 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00941655)
Timeframe: Date treatment consent signed to date off study, approximately, 40.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 8 |
| Systemic Chemotherapy Alone | 5 |
CCR is assessed by Sugarbaker's criteria. CCR-0 is no residual tumor. CCR-1 is no residual nodules greater than 2.5 mm in diameter, CCR-2 is no residual nodules greater than 25 mm, and CCR-3 is residual nodules greater than 25 mm. (NCT00941655)
Timeframe: Day 1
| Intervention | Scores on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Gillys stage measures the completeness of the cytoreduction and is recorded before and after surgery. It is used to classify disease burden and determine prognosis. Stage 0 is no macroscopic signs of disease, stage 1 is nodules >5mm in one part of the abdomen, stage 2 is nodules >5 mm throughout the abdomen, stage 3 is nodules 5mm to 2 cm, and stage 4 is nodules < 2 cm. (NCT00941655)
Timeframe: Day 1
| Intervention | Stage (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 Before Surgery | Patient 1 After Surgery | Patient 2 Before Surgery | Patient 2 After Surgery | Patient 3 Before Surgery | Patient 3 After Surgery | Patient 4 Before Surgery | Patient 4 After Surgery | Patient 5 Before Surgery | Patient 5 After Surgery | Patient 6 Before Surgery | Patient 6 After Surgery | Patient 7 Before Surgery | Patient 7 After Surgery | Patient 8 Before Surgery | Paitent 8 After Surgery | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 |
Time between the first day of treatment and the date of death. (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient #1 | Patient #2 | Patient #4 | Patient #6 | Patient #7 | Patient #9 | Patient #11 | Patient #15 | |
| Surgery + HIPEC + Systemic Chemotherapy | 19 | 11 | 11 | 4 | 14 | 5 | 12 | 0 |
Time between the first day of treatment and the date of death (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Patient #3 | Patient #5 | Patient #8 | Patient #10 | Patient #12 | Patient #13 | Patient #14 | |
| Systemic Chemotherapy Alone | 17 | 6 | 10 | 0 | 0 | 8 | 0 |
(NCT00970216)
Timeframe: 48 weeks
| Intervention | participants (Number) |
|---|---|
| Chronic Hepatitis B | 79 |
Tumour Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR) - Disappearance of all target lesions which is confirmed if determined by two observations not less than 4 weeks apart; Partial Response (PR) - >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00724503)
Timeframe: Through study completion, up to 60 months
| Intervention | percentage of participants (Number) |
|---|---|
| B: FOLFOX + SIR-Spheres | 76.4 |
| A: FOLFOX Alone | 68.1 |
PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion. (NCT00724503)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
| Intervention | Months (Median) |
|---|---|
| mFOLFOX6 Plus SIRT | 10.7 |
| mFOLFOX6 Alone | 10.2 |
OS was defined as the time from randomization to death from any cause. For participants without an event of death, OS was censored at the last-known alive date. OS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 32.2 |
| Bevacizumab + FOLFOXIRI | NA |
PD was defined, using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. The percentage of participants experiencing PD or death was calculated as [number of participants with event divided by the number of participants analyzed] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 89.7 |
| Bevacizumab + FOLFOXIRI | 68.3 |
Among participants with curative resection (complete resection [R0] or microscopic residual tumor [R1]), relapse was defined as the first new occurrence of cancer or death. The percentage of participants who experienced relapse was calculated as [number of participants with a relapse event divided by the number of participants initially classified as R0 or R1 following resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 76.9 |
| Bevacizumab + FOLFOXIRI | 57.1 |
(NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 48.7 |
| Bevacizumab + FOLFOXIRI | 19.5 |
Using RECIST version 1.0, participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. The collective percentage of participants with confirmed best overall response of CR or PR was calculated as [number of participants meeting RECIST criteria for CR or PR divided by the number of participants analyzed] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 61.5 |
| Bevacizumab + FOLFOXIRI | 80.5 |
At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, as described previously. The collective percentage of participants assessed as having a complete or major response was calculated as [number of participants with complete or major response divided by the number of participants who completed the assessment] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 57.1 |
| Bevacizumab + FOLFOXIRI | 52.4 |
PFS was defined, using RECIST version 1.0, as the time from randomization to the date of first documented PD or death from any cause. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. For participants without documented PD or death, PFS was censored at the time of last tumor assessment. PFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 11.5 |
| Bevacizumab + FOLFOXIRI | 18.6 |
RFS was defined as the time from curative resection (complete resection [R0] or microscopic residual tumor [R1]) to the date of first diagnosis of relapse. For participants with curative resection and without relapse, RFS was censored at the last known relapse-free assessment. RFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 8.1 |
| Bevacizumab + FOLFOXIRI | 17.1 |
Time to resection was defined as the time from randomization to the date of first resective surgery. For participants who did not undergo resective surgery, time to resection was censored at Day 1. Time to resection was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; prior to each cycle, and within 7 days prior to surgery; and at time of surgery)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 4.4 |
| Bevacizumab + FOLFOXIRI | 4.3 |
Time to response according to RECIST version 1.0 was defined as the time from randomization to the date of first documented CR or PR. Participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. For participants who did not complete a confirmatory tumor assessment, time to response was censored at the date of last tumor assessment, or if unavailable, at the date of first dose. Time to response was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 3.1 |
| Bevacizumab + FOLFOXIRI | 3.1 |
Following resective surgery, participants were evaluated for complete resection (R0) or the presence of microscopic (R1) or macroscopic (R2) residual tumor. The percentage of participants within each residual tumor classification was calculated as [number of participants with R0, R1, and/or R2 divided by the total number of participants] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| R0, R1, or R2 | R0 or R1 | R0 | |
| Bevacizumab + FOLFOXIRI | 61.0 | 51.2 | 48.8 |
| Bevacizumab + mFOLFOX-6 | 48.7 | 33.3 | 23.1 |
Complications related to the first resective surgery were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, and classified according to severity. The NCI-CTCAE severity classification criteria are as follows: Grade 5 equals (=) resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild. The percentage of participants experiencing a given adverse event (AE) by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent first resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any complication, Total | Any complication, Grade 1 | Any complication, Grade 2 | Any complication, Grade 3 | Any complication, Grade 4 | Any complication, Grade 5 | Bleeding, Total | Bleeding, Grade 1 | Bleeding, Grade 2 | Bleeding, Grade 3 | Cardiovascular, Total | Cardiovascular, Grade 2 | Cardiovascular, Grade 3 | Cardiovascular, Grade 4 | Infections, Total | Infections, Grade 1 | Infections, Grade 2 | Infections, Grade 3 | Infections, Grade 4 | Liver insufficiency, Total | Liver insufficiency, Grade 5 | Neural disorder, Total | Neural disorder, Grade 2 | Noninfected perihepatic fluid collections, Total | Noninfected perihepatic fluid collections, Grade 2 | Other complication, Total | Other complication, Grade 1 | Other complication, Grade 2 | Other complication, Grade 3 | Other complication, Grade 4 | Pulmonary, Total | Pulmonary, Grade 3 | Renal impairment, Total | Renal impairment, Grade 2 | Renal impairment, Grade 4 | Wound healing, Total | Wound healing, Grade 1 | Wound healing, Grade 3 | Wound healing, Grade 4 | |
| Bevacizumab + FOLFOXIRI | 52.0 | 4.0 | 12.0 | 24.0 | 12.0 | 0 | 8.0 | 0 | 4.0 | 4.0 | 4.0 | 4.0 | 0 | 0 | 32.0 | 12.0 | 0 | 16.0 | 4.0 | 0 | 0 | 0 | 0 | 4.0 | 4.0 | 28.0 | 8.0 | 8.0 | 12.0 | 0 | 4.0 | 4.0 | 4.0 | 4.0 | 0 | 12.0 | 0 | 4.0 | 8.0 |
| Bevacizumab + mFOLFOX-6 | 73.7 | 15.8 | 36.8 | 10.5 | 0 | 10.5 | 15.8 | 5.3 | 5.3 | 5.3 | 10.5 | 0 | 5.3 | 5.3 | 26.3 | 10.5 | 5.3 | 5.3 | 5.3 | 10.5 | 10.5 | 5.3 | 5.3 | 0 | 0 | 52.6 | 26.3 | 21.1 | 0 | 5.3 | 5.3 | 5.3 | 10.5 | 5.3 | 5.3 | 5.3 | 5.3 | 0 | 0 |
Complications related to the second resective surgery were evaluated using the NCI-CTCAE version 3.0, and classified according to severity. The NCI-CTCAE severity classification criteria are as follows: Grade 5 = resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild. The percentage of participants experiencing a given AE by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent second resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any complication, Total | Any complication, Grade 1 | Any complication, Grade 2 | Any complication, Grade 3 | Any complication, Grade 3a | Bleeding, Total | Bleeding, Grade 1 | Bleeding, Grade 2 | |
| Bevacizumab + FOLFOXIRI | 66.7 | 33.3 | 0 | 33.3 | 0 | 33.3 | 33.3 | 0 |
| Bevacizumab + mFOLFOX-6 | 100.0 | 0 | 66.7 | 0 | 33.3 | 33.3 | 0 | 33.3 |
At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, where 'Complete response' was considered for those with 0 percent (%) viable tumor cells, 'Major response' for those with 1% to 49% viable tumor cells, 'Minor response' for 50% to 99% viable tumor cells, and 'No response' for 100% viable tumor cells. The response could not be determined in some cases and was documented as 'Unknown.' The percentage of participants within each response category was calculated as [number of participants with a given response divided by the number of participants who completed the assessment] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete response | Major response | Minor response | No response | Unknown | |
| Bevacizumab + FOLFOXIRI | 4.8 | 47.6 | 33.3 | 0 | 14.3 |
| Bevacizumab + mFOLFOX-6 | 0 | 57.1 | 28.6 | 0 | 14.3 |
Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | % of participants (Number) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 79.52 | 66.67 |
| Panitumumab Plus FOLFIRI | 72.41 | 52.94 |
Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 8.9 | 15.2 |
| Panitumumab Plus FOLFIRI | 12.7 | 10.2 |
Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | % of patients (Number) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 19.28 | 3.33 |
| Panitumumab Plus FOLFIRI | 32.18 | 11.76 |
Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 21.4 | 13.5 |
| Panitumumab Plus FOLFIRI | 18.0 | 8.7 |
Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 9.2 | 6.4 |
| Panitumumab Plus FOLFIRI | 7.7 | 3.7 |
Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS | Mutant KRAS | |
| Bevacizumab Plus FOLFIRI | 9.4 | 7.4 |
| Panitumumab Plus FOLFIRI | 11.1 | 4.5 |
Time to response is defined as time from the date of randomization to the date of first confirmed objective response (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 3.7 | 1.8 |
| Panitumumab Plus FOLFIRI | 2.1 | 2.2 |
The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01226719)
Timeframe: 18 months
| Intervention | percentage of evaluable participants (Number) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | 75 |
The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death (NCT01226719)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | NA |
The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01226719)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | 13.3 |
To determine the rate of complete (R0) resection for patients treated with this regimen. (NCT01226719)
Timeframe: 18 months
| Intervention | percentage of patients with surgery (Number) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | 100 |
The analyses of safety will be based on the frequency of adverse events and their severity for patients who received at least one dose of study treatment. (NCT01226719)
Timeframe: 18 months
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rash | Diarrhea | Fatigue | Nausea | Mucositis | Peripheral neuropathy | Vomiting | Anorexia | Cold sensitivity | Constipation | Dehydration | Leukopenia | Anemia | Hypokalemia | Hypomagnesemia | Nail changes | Neutropenia | Taste alteration | Thrombocytopenia | Weight loss | Abdominal pain | Alopecia | Depression | Dizziness | Insomnia | Alkaline phosphatase increased | ALT increased | Anxiety | AST increased | Asthenia | Back pain | Blood bicarbonate increased | Decreased ejection fraction | Dry mouth | Dysesthesia | Dyspepsia | Edema | Epistaxis | Flashers | Hand-foot syndrome | Hematochezia | Hemorrhoids | Hyperpigmentation | Hypertension | Hypoalbuminemia | Hyponatremia | Infection - other | Infusion related reaction | Memory loss | Oral infection | Paraphasia | Pruritus | Speech impairment | Swollen tongue | |
| FOLFOXIRI+Panitumumab Regimen | 12 | 9 | 8 | 8 | 7 | 6 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1 by independent radiology review) at 8 week intervals in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 35.1 |
| LAPC Modified FOLFIRINOX | 17.2 |
Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 81 |
| LAPC Modified FOLFIRINOX | 100 |
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Tumour response was determined according to RECIST 1.1 by independent radiology review. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 54 |
| LAPC Modified FOLFIRINOX | 97 |
The rate of surgical resection in the cohort of patients with locally advanced disease will be determined. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total | Unresectable | Borderline | |
| LAPC Modified FOLFIRINOX | 13 | 6 | 7 |
Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. Rates of grade 3 and 4 toxicities will be compared to historical controls. MPC and LAPC are combined because they were given the exact same medication. The study aimed to compare this dosage with historical dosage, so this comparison is the most appropriate. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | Febrile neutropenia | Diarrhea | Fatigue | Alanine aminotransferase (ALT) increased | Thromboembolic event | Peripheral sensory neuropathy | Vomiting | |
| LAPC Modified FOLFIRINOX | 5 | 2 | 2 | 2 | 4 | 4 | 0 | 0 | 0 | 1 |
| MPC Modified FOLFIRINOX | 4 | 5 | 2 | 1 | 8 | 5 | 3 | 3 | 2 | 1 |
Response was evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter; Overall Response (OR) = CR + PR. (NCT00100815)
Timeframe: Pre-treatment and every 6 weeks from treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 22.0 |
(NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 9.8 |
Grade 3, 4 or 5 toxicity rate (NCT00100815)
Timeframe: Subjects were evaluated for adverse events at each study visit for the duration of their participation in the study, up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 70 |
Quality of Life was assessed using EORTC QLQ-PAN26. All measures range in score from 1 to 4 as lower scores indicate better outcomes. The improved Quality of Life is defined as a greater than 5% decrease in 2 consecutive scores compared with the baseline score. (NCT00100815)
Timeframe: assessed at baseline then weekly for 3 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 56.0 |
Progressive Disease is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000], as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 5.7 |
The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00193219)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 31 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193219)
Timeframe: 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 55 |
Measured from the date of first treatment until the date of death from any cause (NCT00193219)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 25.7 |
Progression Free Survival (PFS) is defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death. (NCT00193219)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 9 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified World Health Organisation (WHO) criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 45.6 |
| FOLFOX-4 Alone | 35.7 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 57.3 |
| FOLFOX-4 Alone | 34.0 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 33.8 |
| FOLFOX-4 Alone | 52.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments as assessed by IRC (based on modified WHO criteria). (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 85.2 |
| FOLFOX-4 Alone | 81.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00125034)
Timeframe: Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 9.0 |
| FOLFOX-4 Alone | 5.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 18.3 |
| FOLFOX-4 Alone | 18.0 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 13.4 |
| FOLFOX-4 Alone | 17.5 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 22.8 |
| FOLFOX-4 Alone | 18.5 |
No residual tumor after on-study surgery for metastases. (NCT00125034)
Timeframe: Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 8 |
| FOLFOX-4 Alone | 4 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 7.2 |
| FOLFOX-4 Alone | 7.2 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 5.5 |
| FOLFOX-4 Alone | 8.6 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 8.3 |
| FOLFOX-4 Alone | 7.2 |
Please refer to Adverse Events section for further details (NCT00125034)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 170 |
| FOLFOX-4 Alone | 165 |
(NCT01264952)
Timeframe: After operation on day 7
| Intervention | events (Number) |
|---|---|
| Group I | 0 |
| Group II | 0 |
| Group III | 0 |
(NCT01264952)
Timeframe: After operation on tha days 2, 7, 30, monthly
| Intervention | patients with non-severe adverse events (Number) |
|---|---|
| Group I | 3 |
| Group II | 2 |
| Group III | 7 |
"Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI:~Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT01264952)
Timeframe: After operation or 1st day after operation, 7th day, 30th day, monthly
| Intervention | metastases (Number) |
|---|---|
| Group I | 10 |
| Group II | 1 |
| Group III | 10 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
300 reviews available for fluorouracil and Cancer of Liver
| Article | Year |
|---|---|
Intra-Arterial Therapy for Unresectable Colorectal Liver Metastases: Which and When? A Commentary on "Intra-Arterial Therapy for Unresectable Colorectal Liver Metastases: A Meta-Analysis".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2021 |
Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2022 |
Use of chemotherapy to treat hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2022 |
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 2022 |
Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy.
Topics: Animals; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Lipids | 2022 |
MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.
Topics: Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA, Long | 2022 |
Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2023 |
Combination Therapy Using Polyphenols: An Efficient Way to Improve Antitumoral Activity and Reduce Resistance.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; beta Catenin; Breast Neoplasms; Catechin; Curcumin; Cy | 2022 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2023 |
Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou | 2023 |
Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liv | 2023 |
Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Cisplatin in Liver Cancer Therapy.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Liver Ne | 2023 |
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Death; Cisplatin; Fluorouracil; Humans; Immunotherapy; Liver Neoplas | 2023 |
Oxaliplatin-Induced Multiple Focal Nodular Hyperplasia Masquerading as Colorectal Liver Metastasis-Case Report and Review of Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Digestive System S | 2020 |
Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Colorectal Neoplasms; Embolization, | 2020 |
Gastrointestinal malignancy in cystic fibrosis.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 2020 |
The actual management of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Electroporation; | 2020 |
Intraarterial Chemotherapy for Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep | 2021 |
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
Topics: Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined | 2021 |
[A Case of Liver Metastasis of Colorectal Cancer in a Hemodialysis Patient, Underwent Liver Resection and Chemotherapy after Colorectal Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Colorectal Neoplasms; Fluorouracil; | 2021 |
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2017 |
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and D | 2017 |
The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Carcinoma; C | 2017 |
Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Curcumin; Fluorouraci | 2018 |
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Cr | 2019 |
OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2003 |
Options for metastatic colorectal cancer beyond the second line of treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2014 |
[A case of metastatic colorectal cancer with icterus due to multiple liver metastases treated effectively by FOLFOX plus bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fata | 2013 |
Current chemotherapeutic approaches for hepatoblastoma.
Topics: Child; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Hepatoblastoma; | 2013 |
[A case of early colorectal cancer with synchronous multiple liver metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2013 |
[A case of advanced sigmoid colon cancer with metastases in the liver and the paraaortic lymph nodes successfully treated with 5-FU/l-LV and FOLFOX4 followed by S-1 leading to long-term complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil; Human | 2014 |
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2014 |
Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dise | 2014 |
[Penile metastasis from rectal carcinoma: a case report and literature review].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2014 |
Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Embolization, Ther | 2014 |
[A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour | 2014 |
Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2015 |
Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; | 2015 |
[A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothe | 2016 |
Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases.
Topics: Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive D | 2016 |
Liver Metastases in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2016 |
Progress in systemic therapy of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Fluorourac | 2016 |
Selective internal radiation therapy for liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Surv | 2016 |
Unresectable liver metastases in colorectal cancer: review of current strategies.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2016 |
A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2016 |
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; | 2017 |
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ch | 2017 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorect | 2008 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2008 |
[A case of alpha-fetoprotein-producing gastric cancer with hepatic metastasis successfully treated with combination chemotherapy].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2008 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial | 2008 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2009 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
Treatment of colorectal liver metastases: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasm | 2009 |
The multidisciplinary management of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnostic Imaging; Digestive System Surgic | 2009 |
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fatty Liver; Fluorouracil; Humans; Liver; Liver Neoplas | 2009 |
[Case of indwelling catheter dislocation into the duodenum during hepatic arterial infusion chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colonic Neoplasms; Duodenum; Fluorour | 2009 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycyt | 2009 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2009 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arr | 2009 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
The role of floxuridine in metastatic liver disease.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 2009 |
Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2009 |
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Selective internal radiation therapy for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2009 |
[A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2009 |
[Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Enzyme-Li | 2009 |
Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
Topics: Acidosis, Renal Tubular; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Surgical therapies in metastatic colorectal cancer with a potential for cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2011 |
Metastatic colorectal cancer: from improved survival to potential cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Catheter Ablation; | 2010 |
Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 2010 |
Meta-analysis: perioperative regional liver chemotherapy for improving survival and preventing liver metastases in patients with colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepa | 2010 |
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2010 |
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Chemotherapy, Adju | 2011 |
Atypical metastatic carcinoid of the uterine cervix and review of the literature.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemo | 2011 |
Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Huma | 2011 |
[Multimodal therapy for colon cancer: state of the art].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
[Rectal cancer: current status of multimodal therapy--when and how?].
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy, Adjuvant; Combine | 2011 |
[State of art of the radiofrequency ablation of colorectal liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheter Ablation; Colorec | 2011 |
A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; | 2012 |
[Neoadjuvant therapy concepts for liver metastases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[A case of sigmoid colon cancer invading urinary bladder treated with preoperative mFOLFOX6 and urinary bladder conserving surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2012 |
[A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 2012 |
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; C | 2012 |
[FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
[A case report of primary small cell esophageal carcinoma responding successfully to radiochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; | 2012 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluoro | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablati | 2013 |
Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2013 |
[Liver arterial infusion chemotherapy with adjuvant trastuzumab for the simultaneous treatment of liver and breast cancer-a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Ne | 2012 |
[Colorectal carcinoma: what's new?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Col | 2012 |
Oncological management of unresectable liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
[Angina attack caused by 5-fluorouracil infusion--report of a case and review of the literature].
Topics: Angina Pectoris; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Isosorbide Dinitrate; Live | 2002 |
Regional therapy of hepatic metastases.
Topics: Antineoplastic Agents; Catheter Ablation; Colorectal Neoplasms; Cryosurgery; Embolization, Therapeut | 2002 |
[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2002 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; | 2001 |
Complications of hepatic artery infusion: a review of 4580 reported cases.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Bone Marrow Diseases; Catheters, Indwe | 2001 |
[The role of the regional (intra-arterial) chemotherapy in the treatment of hepatic metastases of colorectal cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2003 |
Primary adenosquamous carcinoma of the liver: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Fatal Out | 2002 |
Fibrolamellar hepatocellular carcinoma in children and adolescents.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inh | 2003 |
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Flox | 2003 |
Hepatic resection after down-staging of unresectable hepatic colorectal metastases.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Liver Neop | 2003 |
Management of colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Balloon Occlusion; Catheter Ablation; Colorectal Neoplasms; Combine | 2003 |
Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonography, Computed Tomog | 2003 |
[Therapeutic strategies in colorectal cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 2003 |
[Colon cancer in pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cesarean Section; C | 2003 |
Induction therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Inf | 2003 |
Review article: colorectal cancer chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Ne | 2003 |
[Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Liver Neoplasms; Lun | 2003 |
[Application and problems in hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep | 2003 |
[Home chemotherapy and outpatient treatment for metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2003 |
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluor | 2003 |
[Treatment for recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2003 |
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula | 2003 |
[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colo | 2003 |
[A case of liver metastasis from gallbladder cancer with marked response to arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Combined Modality | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2003 |
[The chemotherapy for hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cis | 2003 |
First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; H | 2004 |
Isolated hepatic perfusion: experimental evidence and clinical utility.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perf | 2004 |
[Hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Ad | 2004 |
Systemic treatment of advanced colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
Current strategies in previously untreated advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C | 2004 |
Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorour | 2004 |
Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 2004 |
[Surgery of liver metastasis from colorectal cancer following irinotecan and 5FU-folinic acid].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Huma | 2004 |
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
[Recent progress in chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2004 |
[Chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine | 2004 |
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2005 |
[Surgical treatment of hepatic metastases of colorectal neoplasms].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2004 |
[Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Combined | 2004 |
Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
Hepatoblastoma: an oncological review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cisplatin; Clinical Trials as To | 2006 |
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemotherapy, Adjuv | 2006 |
[The modern treatment of colorectal cancer. Present and future].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2006 |
Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2006 |
First- and second-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug A | 2006 |
[FAIT (FU arterial infusion and interferon therapy) for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Synergism; Drug Th | 2006 |
[The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
[Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diseas | 2007 |
[Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2007 |
Presurgical chemotherapy in patients being considered for liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouraci | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Relate | 2007 |
Treatment of advanced colorectal cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2007 |
Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2008 |
[Recent developments in systemic chemotherapy for hepatocellular carcinoma].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabi | 2008 |
[Hepatic tumors].
Topics: alpha-Fetoproteins; Angiography; Breast Neoplasms; Bronchial Neoplasms; Carcinoembryonic Antigen; Ca | 1983 |
Treatment of the carcinoid tumor and the malignant carcinoid syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Ap | 1983 |
Intraarterial hepatic infusion chemotherapy in metastatic liver cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio | 1983 |
Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma.
Topics: Antineoplastic Agents; Catheterization; Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; F | 1983 |
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridin | 1984 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
[Treatment of metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Emboli | 1984 |
Systemic chemotherapy for advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio | 1980 |
Studies on the treatment and prevention of colorectal liver metastases.
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Hemodynamics; Humans; Liv | 1981 |
[Pharmacology of regional chemotherapy of colorectal liver metastases].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Dose | 1995 |
[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 1995 |
[What is the value of arterial chemotherapy in treatment of colorectal liver metastases].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Floxu | 1994 |
[Adjuvant and palliative regional therapy of liver metastases in colorectal tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 1995 |
Adjuvant chemotherapy for colon and rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1995 |
Update on regional treatments for hepatobiliary malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; | 1995 |
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bilirubin; Combined Modality Therapy; Fatal Outcome; Fe | 1995 |
Recurrent breast cancer: presentation, diagnosis, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast | 1993 |
Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemoembolization, Therapeuti | 1995 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Pancreatic N | 1994 |
Hepatic artery chemotherapy for colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu | 1995 |
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 1995 |
Medical treatment of hepatocellular carcinoma: any progress?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
Eyelid metastasis from breast cancer showing marked response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular | 1995 |
[Treatment of metastases of colorectal cancers].
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local | 1994 |
[Adjuvant chemotherapy in colonic cancers].
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Heparin; Humans; | 1994 |
Chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1994 |
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 1994 |
[Targeting therapy of gastric and colorectal cancer].
Topics: Colorectal Neoplasms; Drug Delivery Systems; Fat Emulsions, Intravenous; Fluorouracil; Humans; Infus | 1994 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1994 |
[Pharmacokinetics in arterial infusion chemotherapy].
Topics: Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver | 1993 |
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Health Care Costs; | 1996 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as | 1996 |
[Diagnosis and therapy for metastatic liver cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Colorectal Neoplasms; Co | 1996 |
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1995 |
Mitoxantrone, 5-FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg | 1996 |
Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 1996 |
Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 1996 |
Intra-hepatic arterial drug delivery.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Col | 1996 |
Hepatic arterial infusion for metastatic colorectal cancer: the price of "success".
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 1996 |
Isolated liver perfusion for liver metastases: pharmacokinetic advantage?
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 1996 |
Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1997 |
Pre- and/or post-operative immunochemotherapy for advanced digestive cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neopla | 1997 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic; | 1996 |
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 1998 |
[Treatment of patients with recurrent esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?
Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Ethanol; F | 1998 |
Colorectal cancer: treatment of advanced disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1998 |
[Multidisciplinary treatment for colorectal liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1998 |
Therapy for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1998 |
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Flu | 1998 |
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 1998 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1999 |
Colorectal cancer in adolescents.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon; Colore | 1999 |
Regional IL-2-based immunochemotherapy of colorectal liver metastases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
Adenosquamous carcinoma of the rectum showing endocrine-cell differentiation: report of a case.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Fluorouraci | 1999 |
Advanced colorectal cancer: which regimes should we recommend?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1999 |
[The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Administration, Oral; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therap | 1999 |
[Is portal infusion chemotherapy uneffective for hepatic recurrence after resection for colorectal cancer?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1999 |
[A case of liver metastases of rectal carcinoid successfully treated with hepatic arterial infusion of methotrexate and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Dr | 1999 |
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1999 |
[Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; F | 1999 |
[Improvements in palliative treatment of colorectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2000 |
Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Follow-Up Studies; | 2000 |
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 2000 |
[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Hepat | 2000 |
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; C | 2000 |
[Hepatic arterial infusion chemotherapy for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema | 2000 |
Adjuvant chemotherapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2001 |
Therapeutic approaches to metastasis confined to the liver.
Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal | 2001 |
Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as | 2000 |
[Multidisciplinary treatment for liver metastasis using cytokines].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2001 |
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector.
Topics: Adenoviruses, Human; alpha-Fetoproteins; Animals; Antineoplastic Protocols; Antiviral Agents; Carcin | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli | 2001 |
Systemic therapy for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2001 |
[A patient with small-cell carcinoma of the esophagus with synchronous liver metastasis surviving 48 months after surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Adminis | 2001 |
[A case of gastric cancer with multiple liver metastases that were completely responsive to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirub | 2001 |
[Hepatic arterial infusion chemotherapy using 'low dose FP'].
Topics: Administration, Sublingual; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2001 |
[Adverse reaction of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelling; Ci | 2001 |
[Hepatic arterial infusion chemotherapy combined with interferon-alpha for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2001 |
Hepatic artery infusional chemotherapy for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Equipm | 2001 |
[A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug | 2001 |
Bile duct infarction following intraarterial hepatic chemotherapy mimicking multiple liver metastasis: report of a case and review of the literature.
Topics: Adult; Antineoplastic Agents; Bile Ducts, Intrahepatic; Diagnosis, Differential; Female; Fluorouraci | 2002 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2002 |
[Evidence for and practical use of arterial infusion chemotherapy for liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2002 |
[A new regional arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Embolization, Therapeutic; Fluorouracil; | 2002 |
Randomized clinical trials in advanced and metastatic colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Evidence-Based Medicine; Fluorouracil; Humans | 2002 |
Intrahepatic arterial infusion of chemotherapy: pharmacologic principles.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fl | 2002 |
Intrahepatic arterial infusion of chemotherapy: clinical results.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2002 |
The treatment of advanced colorectal cancer: where are we now and where do we go?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2002 |
[Systemic chemotherapy for advanced colorectal cancer with liver metastasis].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusi | 2002 |
Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Carcinoma, | 1976 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
Nonsystemic treatment of metastatic tumors of the liver--a review.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1978 |
Therapeutic approaches to hepatoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Drug Synergism; Drug Therapy, Com | 1975 |
The biologic basis of malignant brain tumor therapy.
Topics: Animals; BCG Vaccine; Brain Neoplasms; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm; | 1976 |
[Selective chemotherapy of hepatocellular carcinomas].
Topics: Animals; Carcinoma, Hepatocellular; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Liver Neopla | 1978 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
[Ligation of the hepatic artery in the treatment of liver tumors (review of the literature)].
Topics: Adult; Anti-Bacterial Agents; Fluorouracil; Hemangioma; Hepatic Artery; Humans; Ligation; Liver Cirr | 1975 |
Adjuvant and palliative treatments of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!
Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
[Systemic chemotherapy in metastatic colorectal adenocarcinomas].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem | 1992 |
120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Colorectal Neopl | 1991 |
[Experimental models for hepatic metastases from colorectal tumors].
Topics: Animals; Azoxymethane; Colectomy; Colorectal Neoplasms; Cyclosporins; Disease Models, Animal; Fluoro | 1991 |
[Intra-arterial and intravenous chemotherapy in the treatment of hepatic metastases of colorectal origin: review of the literature and preliminary results].
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1990 |
[Treatment of hepatic metastases].
Topics: Adult; Aged; Female; Floxuridine; Fluorouracil; Hepatectomy; Humans; Infusion Pumps, Implantable; In | 1990 |
[Intra-arterial chemotherapy of the liver].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Floxuridine; Fluorouracil; He | 1990 |
Treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1989 |
[Interdisciplinary therapy concepts in primary and secondary neoplasms of the liver].
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Floxuridine; Fluorouracil; Follow-Up Studies; | 1989 |
[Chemotherapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Evaluatio | 1989 |
Status of ischemic therapy for hepatic tumors.
Topics: Combined Modality Therapy; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms; Postoper | 1989 |
Medical treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Co | 1987 |
Treatment of colorectal hepatic metastases.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; F | 1985 |
[Therapy concepts in colorectal liver metastases. What is proven, what is open to discussion?].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Hepatectomy; Humans; Inf | 1988 |
Adjuvant cytotoxic chemotherapy for colorectal cancer: the present position.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1988 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
Colorectal cancer: surgical management of recurrent and metastatic disease.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Rectal Neoplas | 1988 |
Colorectal cancer. Are adjuvant therapies beneficial?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 1988 |
Hepatic artery ligation or embolization and locoregional chemotherapy of liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Emboli | 1988 |
Evaluation and treatment of hepatic metastasis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1988 |
Liver cancer--present status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Fluorourac | 1988 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
[Adjuvant chemotherapy following radical operations for cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Com | 1985 |
[Chemotherapy of cancer of the rectum and the colon].
Topics: Antimetabolites; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Injections, I | 1970 |
5-Fluorouracil in the treatment of gastrointestinal neoplasia.
Topics: Administration, Oral; Antineoplastic Agents; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; | 1973 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
Present experiences with hepatic dearterialization in liver neoplasm.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Cathe | 1974 |
[Long-term therapy of liver diseases].
Topics: Aged; Anabolic Agents; Chronic Disease; Cortisone; Diet Therapy; Fatty Liver; Female; Fluorouracil; | 1972 |
Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges--G. H. A. Clowes Memorial Lecture.
Topics: Animals; Antineoplastic Agents; Arginase; Benz(a)Anthracenes; Benzopyrenes; Carcinogens; Cell Divisi | 1970 |
737 trials available for fluorouracil and Cancer of Liver
| Article | Year |
|---|---|
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Femal | 2021 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2022 |
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hep | 2022 |
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Surviv | 2022 |
A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2022 |
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2022 |
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 2022 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 2023 |
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2023 |
Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Treatment Outcome; Tretinoin | 2023 |
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human | 2023 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Femal | 2020 |
Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): Long-term results of survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2020 |
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic An | 2020 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; An | 2020 |
Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorec | 2020 |
A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Combined Modality T | 2020 |
Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; | 2020 |
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal | 2020 |
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2020 |
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic C | 2020 |
A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Drugs, Chin | 2021 |
Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeuti | 2021 |
Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2021 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2022 |
A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters; C | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2017 |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine | 2017 |
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deo | 2018 |
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2018 |
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocel | 2018 |
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2018 |
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cat | 2018 |
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as | 2018 |
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2018 |
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2019 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo | 2019 |
Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cetuxima | 2019 |
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2019 |
mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2019 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 | 2019 |
Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopl | 2019 |
All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Disease Progressio | 2019 |
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell-Free Nucleic Acids; Clinical | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Colorectal Neopla | 2019 |
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim | 2019 |
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camp | 2019 |
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capeci | 2013 |
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2013 |
Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2013 |
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoembryonic Antigen; C | 2013 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorou | 2013 |
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Topics: Ablation Techniques; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineop | 2013 |
[Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone | 2013 |
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepato | 2013 |
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2013 |
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Reg | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecit | 2013 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; | 2014 |
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2014 |
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2014 |
FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-on
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 2014 |
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorou | 2015 |
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet | 2014 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2014 |
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; Fluo | 2014 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2015 |
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Codon; Colorectal Neoplasms; Female | 2015 |
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2015 |
Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 2015 |
Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetam | 2015 |
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2015 |
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2015 |
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Ca | 2015 |
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colorectal Neoplasms; Curcumin; | 2015 |
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2016 |
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2015 |
Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Hep | 2014 |
[HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2015 |
Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
Topics: Adult; Aged; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antineoplastic | 2015 |
Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2015 |
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Live | 2015 |
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo | 2016 |
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetu | 2015 |
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Co | 2016 |
A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2016 |
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo | 2016 |
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cispl | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neo | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2016 |
Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2016 |
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2017 |
Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2017 |
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cytosine Deaminase; Female; Flucytosine; | 2017 |
High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2008 |
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
Topics: Adult; Aged; Brachytherapy; Embolization, Therapeutic; Female; Fluorouracil; Humans; Infusions, Intr | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2008 |
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2008 |
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2008 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytid | 2009 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C | 2009 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2009 |
A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; | 2009 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih | 2009 |
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot | 2009 |
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine | 2009 |
Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.
Topics: Adenoviruses, Human; Adult; Aged; Antimetabolites, Antineoplastic; Body Fluids; Carcinoma, Hepatocel | 2009 |
Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas | 2009 |
A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dis | 2009 |
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neopl | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2009 |
[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Australia; Brachytherapy; Camptothecin; Chemotherapy, | 2009 |
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2010 |
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2010 |
Clinical studies of laser ablation in treatment of primary liver carcinoma-associated portal vein tumor thrombus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2010 |
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxy | 2009 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cat | 2010 |
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2010 |
Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2010 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2010 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2010 |
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Emboliza | 2010 |
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; C | 2010 |
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2010 |
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin | 2011 |
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2011 |
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; F | 2012 |
Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group tri
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepat | 2011 |
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cos | 2010 |
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2010 |
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2012 |
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2011 |
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2011 |
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fl | 2011 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2011 |
[Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2011 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2012 |
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2011 |
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2012 |
Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2011 |
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 2012 |
Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hep | 2012 |
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2012 |
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2013 |
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe | 2012 |
Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: preliminary results of a prospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Early Detection of Cancer; Femal | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetax | 2012 |
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic | 2012 |
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradio | 2013 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2013 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2012 |
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined | 2013 |
Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2013 |
Effect of portal vein chemotherapy on liver metastasis after surgical resection of colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluoro | 2012 |
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2013 |
Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study.
Topics: Absorbable Implants; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Peripher | 2013 |
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camp | 2013 |
Continuation of regional chemotherapy of hepatic neoplasms despite occlusion of the hepatic artery-report of four cases.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arterial Occlusive Diseases; Catheterization | 2002 |
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Res | 2002 |
Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Dis | 2002 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2002 |
Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Cohort S | 2002 |
Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Disease Progres | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progress | 2002 |
[Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disea | 2002 |
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Topics: Adenoviruses, Human; Adult; Aged; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast | 2002 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 2001 |
[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer].
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Posto | 2002 |
Intravenous versus intrahepatic arterial 5-fluorouracil/leucovorin for treatment of colorectal cancer metastases.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Hepatic | 2002 |
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
[Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2003 |
[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Fluo | 2002 |
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2003 |
Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2003 |
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2003 |
[Clinical study on treatment of middle-advanced stage liver cancer by combined treatment of hepatic artery chemoembolization with gan'ai no. I and no. II].
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Ch | 2001 |
[Dynamics of clinical and biochemical indices in patients with primary liver cancer during endovascular chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2002 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capec | 2003 |
Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2003 |
Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2003 |
Fibrolamellar hepatocellular carcinoma in children and adolescents.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2003 |
PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorodeoxyglucose F18; Fluoro | 2003 |
Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2004 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2003 |
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2003 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2003 |
A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2003 |
Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2003 |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2003 |
[Interim analysis of a prospective, randomized multi-center study by the "Liver Metastases" Study Group: adjuvant intra-arterial chemotherapy after curative liver resection of colorectal metastases].
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1998 |
Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antin | 2003 |
Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronotherapy; Colorectal Neoplasm | 2003 |
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Fluoro | 2003 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chi-Square Distribution; Colectomy; Colonic Neoplasms; | 2004 |
Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Drug Adm | 2004 |
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Infusions | 2004 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2004 |
Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-R | 2004 |
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplas | 2004 |
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2004 |
A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Evaluation; Female; Fluorouracil; Human | 2004 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2004 |
Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheterization, Peripheral; Diseas | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
[Clinical observation on the treatment of middle-late stage liver carcinoma by combined therapy of hepato-arterial chemo-embolising and Chinese drugs for strengthening pi and regulating qi].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2004 |
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2004 |
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2004 |
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Canada; | 2005 |
[Capecitabine combined with TACE for advanced liver cancer].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoembolization, | 2004 |
[Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Cispla | 2004 |
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
[Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Dexame | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2005 |
[Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2005 |
Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2005 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2005 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Col | 2005 |
[Problems of case accumulation in a clinical trial of hepatic arterial infusion after resection of hepatic metastases: A summary of the study design and questionnaire survey of the participating centers in study no. 29-0003 of the Japanese Foundation for
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ | 2005 |
[Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronothe | 2005 |
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2005 |
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2005 |
Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemot | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; | 2005 |
Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2005 |
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2005 |
A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Colorectal Neoplasms; Disease-Free Survival; D | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bio | 2005 |
[A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 2005 |
Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M | 2006 |
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisp | 2006 |
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe | 2006 |
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dis | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; | 2006 |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; | 2006 |
A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2006 |
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms | 2006 |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2006 |
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci | 2006 |
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2006 |
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2007 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.
Topics: Administration, Inhalation; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carbon Diox | 2006 |
Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 2006 |
Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Ci | 2006 |
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Fem | 2006 |
Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Com | 2006 |
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free S | 2006 |
Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Che | 2006 |
Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relati | 2006 |
Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2006 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2006 |
[Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life].
Topics: Angiography; Catheterization; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, | 2006 |
Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cispla | 2007 |
FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2007 |
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorec | 2007 |
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austral | 2007 |
[Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient].
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Urea Nitrogen; Chem | 2006 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2007 |
[Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheterization; | 2007 |
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp | 2007 |
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2007 |
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2007 |
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptotheci | 2007 |
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2007 |
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2007 |
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2008 |
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2007 |
Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2007 |
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2008 |
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combi | 2008 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
[Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2007 |
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2008 |
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2007 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Ther | 2008 |
Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemothera | 2007 |
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2008 |
Perioperative chemotherapy for resectable hepatic metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 2007 |
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined Modality Therapy; Disease | 2008 |
[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
Topics: Adjuvants, Immunologic; Adult; Aged; Asthenia; CD4-Positive T-Lymphocytes; Chemoembolization, Therap | 2007 |
Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2008 |
Primary liver cancer. An Eastern Cooperative Oncology Group Trial.
Topics: Adenoma, Bile Duct; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body W | 1984 |
Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular | 1984 |
Newer techniques in cancer chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bleomycin; Bone Marrow Transplantation; Carcinoma; Ce | 1984 |
Chemotherapy of large bowel cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Floxuridine; Fluorouraci | 1982 |
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1983 |
Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cyclophosphamide; | 1982 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials a | 1984 |
[Clinical study on combination chemotherapy of primary liver cancer].
Topics: Adult; Aged; Azirines; Carbazilquinone; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Co | 1983 |
Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastroint
Topics: Adenocarcinoma; Clinical Trials as Topic; Colectomy; Combined Modality Therapy; Fluorouracil; Follow | 1984 |
[Joint clinical Phase II study of SF-SP].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation; Female; F | 1984 |
[Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin].
Topics: Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Leukocyte Cou | 1984 |
Clinical problems in radiotherapy of carcinoma of the pancreas.
Topics: Adenocarcinoma; Alpha Particles; Clinical Trials as Topic; Fluorouracil; Helium; Humans; Liver Neopl | 1982 |
Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Cyclop | 1980 |
MItomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; F | 1980 |
Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; Drug Therapy, Combination; Fluo | 1982 |
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hep | 1995 |
Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Hepatocellular; F | 1994 |
Electrochemical therapy of 74 cases of liver cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1994 |
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1995 |
Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, He | 1995 |
5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1995 |
[Intra-arterial 5-FU/intra-venous MTX therapy for metastatic liver lesions].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1995 |
[A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ | 1995 |
[Postoperative adjuvant arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 1995 |
[Preventive chemotherapy for residual liver after resection of hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Hu | 1995 |
[Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1995 |
[The study of continuous arterial infusion chemotherapy with CDDP and 5-FU in patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1995 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Su | 1995 |
[Hepatic arterial infusion therapy for gastric liver metastasis using implanted reservoir].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluoroura | 1995 |
[Assessment of serial carcinoembryonic antigen (CEA): monitor to evaluate efficacy of continuous intrahepatic chemotherapy for nonresectable liver metastases of colorectal carcinomas].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic | 1995 |
[The study of chemotherapy via the reservoir to colo-rectal cancer patients with liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1995 |
[Outcomes of effective treatment of cases of metastatic liver tumors by intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1995 |
[Efficacy of repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy for unresectable tumors of the liver].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi | 1995 |
[A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1995 |
[Clinical evaluation of anticancer effect of methionine-depleting total parenteral nutrition with 5-fluorouracil and/or mitomycin C].
Topics: Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; H | 1995 |
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
[Intraportal infusion of 5-FU and lipiodol-aclarubicin after hepatic resection for colorectal liver metastasis].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therape | 1995 |
Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.
Topics: Adenocarcinoma; Colonic Neoplasms; Fatty Liver; Female; Fluorouracil; Humans; Interferon alpha-2; In | 1995 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemoembolization, Therapeuti | 1995 |
Continuous hepatic arterial infusion of 5-fluorouracil for unresectable colorectal liver metastases: phase II study.
Topics: Abdominal Pain; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Stu | 1995 |
[Biochemically modulated chemotherapy with high-dose L-leucovorin and 5-fluorouracil for multiple liver metastasis from colorectal cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Live | 1995 |
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 1995 |
[Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer].
Topics: Adult; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Services, Ho | 1994 |
[Effect of prophylactic intra-arterial infusion of anticancer drugs on post hepatic resection for hepatic metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1994 |
[Home therapy approach in cancer patients-chemotherapy (case 2-2)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Home Infusion Th | 1994 |
Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 1995 |
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1995 |
5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1995 |
[Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1995 |
A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Mod | 1994 |
[Evaluation of cases of metastatic liver tumors resected following intra-arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colonic Neo | 1994 |
[The value of hepatic arterial infusion chemotherapy for liver metastases--discussion from viewpoints of prevention of hepatic death and QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Fl | 1994 |
[Efficacy of intrahepatic arterial chemotherapy to prevent recurrence of residual liver in metastatic liver cancer patients after hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Epirubicin; Female; Fluorou | 1994 |
[A study of regional chemotherapy: hepatic arterial infusion for metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepat | 1994 |
[Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Do | 1994 |
[Intraarterial infusion combination therapy with LV and 5-FU in hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
[Hepatic arterial infusion after hepatectomy for liver metastases of colorectal carcinoma to prevent residual hepatic recurrence].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Floxuridine; Flu | 1994 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
[The study of continuous arterial infusion chemotherapy with 5-FU and CDDP in patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1994 |
Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colo | 1994 |
[Intra-arterial chemotherapy for the treatment of advanced hepatocellular carcinoma through implantable port (reservoir)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1994 |
[A study of various complications in arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Catheters, Indwelling; | 1994 |
Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors.
Topics: Adenoma, Bile Duct; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorec | 1994 |
[Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
Hepatic arterial infusion chemotherapy for liver metastases from breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Fluoro | 1994 |
Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Emboliza | 1994 |
Local and systemic toxicity of intra-hepato-arterial chemotherapy for treatment of unresectable liver metastases of colorectal cancer with 5-Fluorouracil and high dose Leucovorin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Colore | 1993 |
[Concomitant arterial infusion chemotherapy with tamoxifen therapy for hepatic metastases from pancreatic adenocarcinoma--a preliminary report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Inject | 1993 |
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeabi | 1993 |
Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans | 1993 |
Re: "Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis".
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interferon Type I; Liver Neoplasms; Recombinant Proteins | 1994 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Female; Fluorouraci | 1994 |
Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 1993 |
[Intermittent hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-A | 1993 |
[A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Epir | 1993 |
[The efficacy of intra-arterial infusion chemotherapy in patients with non-resectable liver metastasis from colorectal cancer--a randomized study comparing FAM versus FEM].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ad | 1993 |
Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1993 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1993 |
Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H | 1993 |
Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1993 |
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; F | 1993 |
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1993 |
Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Inf | 1993 |
Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1995 |
Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Bone Marrow Tr | 1996 |
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Cohort Studies; Colorectal Neopl | 1995 |
A pilot study of interferon alpha and 5-fluorouracil in hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1996 |
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Flu | 1996 |
[Effect of leucovorin and 5-FU for advanced colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1996 |
Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Fluorouracil; | 1996 |
Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1996 |
A pilot study of adjuvant hepatic arterial infusion chemotherapy, associating 5-fluorouracil and leucovorin, after resection of colorectal cancer liver metastases.
Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fema | 1995 |
[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
[Continuous hepatic arterial infusion chemotherapy with low-dose CDDP plus 5-FU for liver metastases from colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A | 1996 |
[Clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Doxorubicin; | 1996 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer--the second report].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Human | 1996 |
[The preventive effect of weekly high-dose 5-FU infusion (WHF) after resection of hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; H | 1996 |
[The effect of intraportal chemotherapy in terms of administered dose of 5-FU].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl | 1996 |
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1996 |
Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
[Evaluation of hepatic arterial infusion chemotherapy for gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra | 1996 |
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 1996 |
Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; | 1997 |
Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasm | 1997 |
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1997 |
Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum | 1997 |
Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1997 |
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergi | 1997 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
Infusion pumps for systemic and intra-arterial chemotherapy of colorectal liver metastases.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cost Savings; E | 1997 |
Improved long-term survival with preoperative chemotherapy for hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Preschool; Cis | 1997 |
Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan.
Topics: Adjuvants, Immunologic; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 1997 |
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents | 1997 |
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe | 1997 |
[Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma 256, Walker; Chemotherapy | 1997 |
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 1997 |
Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H | 1997 |
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 1997 |
A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; In | 1997 |
[Evaluation of intra-arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Fema | 1997 |
[Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
Topics: Abdominal Pain; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Femal | 1997 |
[Usefulness of CA 15-3 antigen determination for evaluation of response to second-line chemotherapy in patients with breast cancer: preliminary study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclopho | 1997 |
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Sche | 1997 |
Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosph | 1998 |
[The evaluation of weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; F | 1998 |
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 1998 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 1998 |
[Method of preventing hepatic artery occlusion during continuous intrahepatic arterial infusion chemotherapy of 5-FU].
Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Colorectal N | 1998 |
[Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer].
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 1998 |
[Evaluation of hepatic arterial infusion chemotherapy using reservoir for liver metastases from gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubic | 1998 |
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di | 1998 |
Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Prot | 1998 |
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.
Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; Hepatic Artery; Humans; | 1998 |
Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 1996 |
Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1998 |
Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1999 |
[Multicenter phase II study of the Liver Metastases Study Group of weekly intra-arterial 24-hour high dose therapy with 5-FU and folinic acid (FA) in liver metastases of colorectal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1998 |
[Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
Topics: Adult; Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1998 |
A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubic | 1999 |
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antidotes; Antineoplastic Combined Chemotherapy P | 1999 |
[Biochemical modulation of 5-FU--effect of low dose CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin | 1999 |
Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility St | 1999 |
Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C | 1999 |
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1999 |
[Peripheral 5-FU blood concentration after high-dose injection into the hepatic artery: potential preventive effect on extrahepatic metastatic foci].
Topics: Adult; Aged; Area Under Curve; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Arte | 1999 |
Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1999 |
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Co | 1999 |
Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1999 |
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplat | 1999 |
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administrat | 1999 |
Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Islet Cell; | 1999 |
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Topics: Adult; Aged; Animals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; | 1999 |
Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1999 |
[Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1999 |
[Cooperative study of intraarterial preventive chemotherapy after resection of hepatic metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1999 |
[Clinical evaluation of intermittent hepatic arterial infusion therapy with CDDP and 5-FU for liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1999 |
[Weekly hepatic arterial infusion of high dose 5-fluorouracil for liver metastasis from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorourac | 1999 |
[Evaluation of the non-effective cases of irresectable multiple liver metastasis of colorectal cancer receiving hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorou | 1999 |
[Evaluation of intermittent hepatic arterial infusion chemotherapy for multiple liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Femal | 1999 |
[Efficacy of intra-arterial chemotherapy on life prolongation in patients with hepatic metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T | 1999 |
[Efficacy and side effect of continuous intra-arterial infusion of high-dose 5-FU for liver metastases of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal | 1999 |
[The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Administration, Oral; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therap | 1999 |
[Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 1999 |
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasm | 1999 |
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1999 |
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2000 |
Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug | 2000 |
[Prediction of the clinical efficacy of hepatic arterial chemotherapy for metastatic hepatic cancer by intraarterial infusion of 99mTc-MIBI].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorouracil; Hepat | 2000 |
Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Diseas | 2000 |
[Regional chemotherapy of the liver after resection of liver metastases in colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2000 |
Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: results with 10-year follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease-Free Survival; Female; Fluo | 2000 |
Gigantic hepatocellular carcinoma, treated by transcatheter oily chemoembolization (TOCE) and wedge hepatic resection.
Topics: Adult; Angiography; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality The | 2000 |
Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool | 2000 |
Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 2000 |
A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ductal, Breast; Cathet | 2000 |
Capecitabine in the treatment of metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Renal Cell; Deoxy | 2000 |
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 2000 |
The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival | 2000 |
Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |
Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Dr | 2000 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2000 |
[Phase I study of super high-dose chemotherapy for liver cancer with percutaneous isolated hepatic perfusion (PIHP) and peripheral blood stem cell transplantation (PBSCT)].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2000 |
[Evaluation of hepatic resection following hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 2000 |
[Indication for hepatic resection after hepatic arterial infusion chemotherapy for multiple liver metastases of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorourac | 2000 |
[Arterial infusion chemotherapy for liver metastases from colorectal cancer--therapeutic effects of different protocols].
Topics: Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; E | 2000 |
[Hepatic arterial injection therapy (HAI) for metastatic liver tumor from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hepatic Arter | 2000 |
Prevention of hepatic artery occlusion during continuous infusion of fluorouracil using liposteroid.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Colorectal Neoplasms; Dexamethasone; F | 2000 |
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2001 |
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplast | 2001 |
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2000 |
Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.
Topics: Abdominal Neoplasms; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined | 2001 |
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplast | 2001 |
Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Ar | 2001 |
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2001 |
A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2001 |
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 2001 |
[Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 2001 |
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; | 2001 |
A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2001 |
Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug R | 2001 |
Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Femal | 2002 |
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluo | 2001 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Fluorouracil; Human | 2002 |
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
Topics: Adenoviridae; Adenovirus E1B Proteins; Aged; Antibodies, Viral; Antineoplastic Combined Chemotherapy | 2001 |
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2002 |
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2002 |
Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2002 |
Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, | 2002 |
Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil.
Topics: Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Injection | 1976 |
5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Adminis | 1977 |
Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Aspartate Aminotransferases; Bilirubin; Carcinoma, H | 1977 |
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.
Topics: Adenoma, Bile Duct; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Clinical Trials a | 1978 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; England; Female; Fluorouracil; Follow-Up Studies; | 1977 |
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study.
Topics: Adenocarcinoma; Catheterization; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; | 1979 |
Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs.
Topics: Clinical Trials as Topic; Embolization, Therapeutic; Female; Fluorouracil; Hepatic Artery; Humans; I | 1979 |
Adjuvant cytotoxic liver perfusion for colorectal cancer.
Topics: Adenocarcinoma; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; England; Female; | 1979 |
Cytotoxic perfusion for colorectal liver metastases.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Evaluation Studies as Topi | 1978 |
Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
Topics: Aged; Body Weight; Bone Marrow Examination; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Fluor | 1976 |
A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studie | 1975 |
[Chemotherapy of metastasizing breast cancers. Indications and results].
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema | 1975 |
Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Epirubicin; | 1992 |
Intraperitoneal 5-fluorouracil in the management of colorectal liver cancer.
Topics: Adult; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Liver Neopla | 1992 |
Combination chemotherapy and radiation for palliation of hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 1992 |
Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report.
Topics: Administration, Cutaneous; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Dose-Response Rela | 1992 |
Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female | 1992 |
Continuous regional treatment with fluoropyrimidines for metastases from colorectal carcinomas: influence of modulation with leucovorin.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Hepatic Arter | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!
Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Dr | 1992 |
A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leuco | 1992 |
Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Liver | 1992 |
A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluatio | 1992 |
Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1992 |
Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intrav | 1992 |
High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801).
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil | 1992 |
A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.
Topics: Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Fluorouracil; | 1992 |
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms; | 1991 |
Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female; Floxu | 1991 |
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 1991 |
[Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients].
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouraci | 1991 |
Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and i.v. 5-fluorouracil (5-FU) chemotherapy for unresectable colorectal liver metastases: an alternative to FUdR-based regimens?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Floxuridine; | 1991 |
Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01.
Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Moda | 1991 |
A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepa | 1991 |
[Comparative evaluation of 2 schedules of administration of anti- neoplastic drugs by the CMF protocol in disseminated breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; Drug Ad | 1991 |
Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results.
Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Femal | 1991 |
[Oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in repeated arterial bolus chemotherapy in metastatic liver cancer of humans--preliminary randomized trial].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorub | 1991 |
Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1991 |
A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T | 1991 |
Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1991 |
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1991 |
A randomized study of on-line plasma perfusion over protein A-sepharose and 5-fluorouracil chemotherapy in patients with metastatic colorectal carcinoma.
Topics: Chromatography, Gel; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; | 1991 |
Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group).
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1991 |
The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Combined Modality Therapy; Deglutition Disorders; Esoph | 1991 |
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump | 1990 |
[Requirements for the randomized trial of i.a. vs. i.v. administration to reveal the impact of hepatic arterial infusion on survival in the treatment of liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Floxuri | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1990 |
Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases.
Topics: Adolescent; Adult; Aged; Colorectal Neoplasms; Embolization, Therapeutic; Female; Fluorouracil; Hepa | 1990 |
A randomized study of combined 5-fluorouracil and plasma perfusion over protein A-sepharose in human advanced colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Liver Ne | 1990 |
Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.
Topics: Adult; Aged; Albumins; Angiotensin II; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; Hepatic | 1990 |
Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1990 |
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venou | 1990 |
[Concepts in the prevention and treatment of liver metastases of colorectal cancer by regional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colonic Ne | 1988 |
[Intra-portal chemoprevention and therapy of liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Comb | 1989 |
[Is there a primary indication for regional therapy of liver metastases of gastrointestinal tumors?].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hu | 1989 |
[Can the occurrence of extrahepatic metastases in regional chemotherapy of the liver be prevented by adding systemic chemotherapy? A randomized multicenter study].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps | 1989 |
[Chemotherapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
[Effects of prophylactic intraportal chemotherapy on liver function, blood profile and survival in patients with colo-rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 1989 |
[Initial results of adjuvant portal liver infusion following radical surgery of colorectal cancer (Swiss Study Group for Epidemiologic and Clinical Cancer Research Study 40/81)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1989 |
Value of in vivo tissue testing in predicting the clinical response to regional perfusion chemotherapy in colorectal cancer patients with liver metastases.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorect | 1989 |
[Regional chemotherapy of liver metastases in colorectal carcinoma. Intra-arterial vs intravenous plus intra-arterial therapy].
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Evaluation Studies as Topic; Female; F | 1989 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1989 |
[European topic: liver surgery II--regional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 1989 |
Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Clinical Trials as Top | 1989 |
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
Topics: Aged; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Interaction | 1989 |
A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1989 |
Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study.
Topics: Adenocarcinoma; Blood Chemical Analysis; Colorectal Neoplasms; Combined Modality Therapy; Female; Fl | 1989 |
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Emboliz | 1988 |
Phase III trial of irradiation plus chemotherapy for patients with hepatic metastases and hepatoma: experience of the Northern California Oncology Group.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Female; | 1988 |
[The role of antineoplastic solution in transcatheter hepatic arterial embolization--in terms of survival rates affecting anticancer agents together with gelatin sponge].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization | 1988 |
A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cy | 1986 |
Systemic infusional chemotherapy for liver metastasis: an improved schedule for 5-fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Floxuridine; Fluorouracil | 1986 |
Regional infusion of fluoropyrimidines for hepatic metastases of colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu | 1988 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinica | 1987 |
5-Methyltetrahydrofolic acid (MFH4): an effective folate for the treatment of advanced colorectal cancer with 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; | 1988 |
Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1988 |
Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1987 |
Superselective intra-arterial chemotherapy with mitomycin C in liver and gallbladder cancer.
Topics: Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Gallbladder Neoplasms; Humans; I | 1988 |
Pilot study on the regional treatment of colorectal liver metastases by intermittent arterial ischaemia with degradable starch microspheres and arterial and portal infusion with mitomycin C plus 5-fluorouracil--a clinical trial led by the Gastrointestinal
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Emboliz | 1988 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; | 1986 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1986 |
Hepatic arterial ligation and portal vein infusion: a clinical trial by the Gastrointestinal Tract Cancer Group of the European Organization for Research and Treatment of Cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arter | 1986 |
A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1985 |
[Adjuvant chemotherapy following radical operations for cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Com | 1985 |
Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1985 |
Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis; Colonic Neoplasms; Combined Modality Therapy; F | 1985 |
Intra-arterial chemotherapy in the treatment of primary liver cancer.
Topics: Arteries; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Ma | 1974 |
2942 other studies available for fluorouracil and Cancer of Liver
| Article | Year |
|---|---|
Porphyrins containing nitric oxide donors: Synthesis and cancer cell-oriented NO release.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil | 2009 |
Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Ce | 2009 |
Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents.
Topics: Antineoplastic Agents; Cell Proliferation; Dioxanes; Drug Screening Assays, Antitumor; Focal Adhesio | 2011 |
Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells.
Topics: Adenosine; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cellular | 2012 |
Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azo Compounds; Carcinoma, Hepatocellular; Cell Line, Tumo | 2013 |
Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relat | 2013 |
Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplas | 2014 |
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, | 2015 |
Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Drug Screening Assays, A | 2015 |
Monoterpene indole alkaloid hydrazone derivatives with apoptosis inducing activity in human HCT116 colon and HepG2 liver carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Colon; Colonic Neoplasms; HCT116 Cells; Hep G2 Cells; | 2015 |
Combinatorial synthesis, in silico, molecular and biochemical studies of tetrazole-derived organic selenides with increased selectivity against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antioxidants; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry Techniqu | 2016 |
Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Glu | 2016 |
Phenylpropanoids from Juglans mandshurica exhibit cytotoxicities on liver cancer cell lines through apoptosis induction.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Hep G2 Cells; Humans; Juglans; Liver | 2017 |
Inhibition of invasion by N-trans-feruloyloctopamine via AKT, p38MAPK and EMT related signals in hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Coumaric Acids; Epithelial-Mesenchymal Transition; Huma | 2017 |
Cytotoxic clerodane diterpenoids from Croton crassifolius.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Croton; Diterpenes, Cler | 2017 |
Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Cycle Prot | 2017 |
Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment.
Topics: Acridones; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Des | 2017 |
Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line | 2017 |
Studies on anti-hepatoma activity of Annona squamosa L. pericarp extract.
Topics: Animals; Annona; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, | 2017 |
Autophagy antagonizes apoptosis induced by flavan enantiomers from Daphne giraldii in hepatic carcinoma cells in vitro.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, T | 2017 |
Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Caspase 3; Caspase 9; Cinnamates; Esterifica | 2017 |
Synthesis and biological evaluation of α-santonin derivatives as anti-hepatoma agents.
Topics: Antineoplastic Agents; Apoptosis; Drug Design; Humans; Inhibitory Concentration 50; Liver Neoplasms; | 2018 |
β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carbolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prol | 2019 |
Synthesis and biochemical studies of novel organic selenides with increased selectivity for hepatocellular carcinoma and breast adenocarcinoma.
Topics: Antineoplastic Agents; Antioxidants; Biphenyl Compounds; Breast Neoplasms; Carcinoma, Hepatocellular | 2019 |
Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Nucleus; Cell Proliferation; Dose- | 2019 |
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dos | 2020 |
Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach.
Topics: Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carcinoma, Hepatocellul | 2022 |
Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Camp | 2021 |
Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Respons | 2021 |
Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorou | 2022 |
Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2022 |
Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2021 |
[Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells].
Topics: Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Curcumin; Fluorouracil; Humans; L | 2021 |
FOLFOX-HAIC active in large HCC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liv | 2022 |
ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2022 |
Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2022 |
Neoadjuvant intra-arterial versus intravenous chemotherapy in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2021 |
Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2022 |
Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2022 |
Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neop | 2022 |
HAIC-FO improves outcomes in HCC.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Oxaliplatin; Sorafenib | 2022 |
[A Case of R0 Resection, with Preservation of Bladder Function, of Advanced Rectal Cancer Infiltrating the Bladder with a Single Metastatic Liver Tumor Due to Preoperative Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2021 |
[A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fem | 2021 |
[Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neopl | 2022 |
Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluor | 2022 |
Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2022 |
Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arteries; Carcinoma, Hepatocellular; Cisplatin; Dise | 2022 |
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
Topics: Ablation Techniques; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2022 |
[Prehepatectomy Chemotherapy Using Circadian Chrono-HAI for Liver Metastases from Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2022 |
CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Fluoroura | 2022 |
Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Flu | 2022 |
Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Galactosamine; Liver Neoplasms; | 2022 |
Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase.
Topics: Amphibian Venoms; Antineoplastic Agents; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; | 2022 |
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2022 |
Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hep | 2022 |
Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Drug Del | 2022 |
Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Topics: Adult; Carcinoma, Hepatocellular; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Liver Neo | 2022 |
Influence of 6-shogaol potentiated on 5-fluorouracil treatment of liver cancer by promoting apoptosis and cell cycle arrest by regulating AKT/mTOR/MRP1 signalling.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Catechols; Cell Cycle; Cell Cycl | 2022 |
Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female | 2022 |
Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Peptides; | 2022 |
Uricase sensitizes hepatocellular carcinoma cells to 5-fluorouracil through uricase-uric acid-UMP synthase axis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver | 2022 |
Cerium oxide decorated 5-fluorouracil loaded chitosan nanoparticles for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cerium; Chitosan; Fibroblasts; Fluorouracil; Liver Neoplasms; Ma | 2022 |
GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; | 2022 |
Effects of Liposome-Entrapped Muramyl Tripeptide Phosphatidylethanolamine (L-MTP-PE) on the Tumor Growth and Survival of Mice Bearing Syngeneic Tumor in Combination with a Chemotherapeutic or Immunomodulatory Agent.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Drug Carriers; Fluorouracil; Imm | 2022 |
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Port | 2022 |
Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy by Narayan et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2022 |
Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment.
Topics: Amino Acid Oxidoreductases; Collagen; Collagen Type I; Drug Resistance; Ecosystem; Fluorouracil; Hum | 2022 |
Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Leu | 2023 |
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Fluo | 2022 |
Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal N | 2022 |
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carci | 2022 |
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2023 |
Circ_0003998 upregulates ARK5 expression to elevate 5-Fluorouracil resistance in hepatocellular carcinoma through binding to miR-513a-5p.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Caspase 3; Cell Proliferation; Fl | 2022 |
[A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2022 |
One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2022 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
[Two Cases of Elderly Patients with Giant Intrahepatic Cholangiocarcinoma Treated with Multidisciplinary Therapy including Ablation Therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2022 |
[A Case of Liver Metastasis of Colorectal Cancer Successfully Treated with Hepatic Arterial Infusion Chemotherapy after Systemic Chemotherapy Was Difficult to Administer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Combinatorial treatment with Silybum marianum essential oil enhances the therapeutic efficacy of a 5-fluorouracil base therapy for hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Mice; NF-kappa B; Oils | 2023 |
[Two Cases of Transfusion-Free Hepatectomy Following Chemotherapy for H3 Grade of Simultaneous Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Femal | 2023 |
Efficient chemosensitizing and antimetastatic combinations of a naturally occurring trans-ferulic acid with different chemotherapies on an in vitro hepatocellular carcinoma model.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Doxorubicin; Fluorouraci | 2023 |
A comparative study of smart nanoformulations of diethyldithiocarbamate with Cu
Topics: Aldehyde Dehydrogenase; Animals; Ditiocarb; Female; Fetal Hypoxia; Fluorouracil; Humans; Liver Neopl | 2023 |
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Ind | 2023 |
[A Case of Recurrent Rectal Cancer with Acute Lower Extremity Arterial Occlusion during Treatment with Bevacizumab].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorourac | 2023 |
A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Novel Steroidal[17,16-
Topics: Androsterone; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation | 2023 |
Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ethiodized Oil; Fluoroura | 2022 |
Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colonic N | 2023 |
Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance | 2023 |
Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hep | 2023 |
pH-responsive chitosan/acrylamide/gold/nanocomposite supported with silver nanoparticles for controlled release of anticancer drug.
Topics: Acrylamides; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Chitosan; Delayed- | 2023 |
Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diseas | 2023 |
Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Adjuva | 2023 |
MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil.
Topics: Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Move | 2023 |
Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress.
Topics: Animals; Carcinoma, Hepatocellular; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorourac | 2022 |
IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Computational Biology; Fluorouracil; Humans; Liver Neoplasms | 2022 |
Initially unresectable colorectal liver metastases: the best therapeutic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum | 2023 |
Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interleukin-6; Liver Neoplasms; Organoids; Pentoxifyllin | 2023 |
Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
ASO Visual Abstract: Combined Hepatic Artery Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Novel ProTide prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of liver cancer.
Topics: Deoxyuridine; Fluorouracil; Humans; Liver Neoplasms; Prodrugs | 2023 |
ASO Visual Abstract: Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy-An International Survey of the HAI Consortium Research Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Adjuvant Hepatic Artery Infusion Chemotherapy: Still Swimming in Dark Water?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2024 |
Beta-Hydroxyisovaleryl-Shikonin Eradicates Epithelial Cell Adhesion Molecule-Positive Liver Cancer Stem Cells by Suppressing dUTP Pyrophosphatase Expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Epithelial Cell Adhesion Molecule; Fluorouracil; Humans | 2023 |
The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chol | 2019 |
Laparoscopic versus open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2019 |
Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Knockdown Technique | 2019 |
Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 2019 |
Dynamic Changes in Normal Liver Parenchymal Volume During Chemotherapy for Colorectal Cancer: Liver Atrophy as an Alternate Marker of Chemotherapy-Associated Liver Injury.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Bevacizumab | 2019 |
Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver | 2019 |
Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings.
Topics: Adult; Aged; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; N | 2019 |
A Complete Response Achieved in a Patient with Hepatic Metastasis from Sigmoid Colon Cancer by a Regimen Containing Ramucirumab: a Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Fluoroura | 2020 |
Anticancer Action of Psilostachyin-A in 5-Fluorouracil-Resistant Human Liver Carcinoma are Mediated Through Autophagy Induction, G2/M Phase Cell Cycle Arrest and Inhibiting Extracellular-Signal-Regulated Kinase/Mitogen Activated Protein Kinase (ERK/MAPK)
Topics: Antineoplastic Agents; Autophagy; Beclin-1; Cell Proliferation; Extracellular Signal-Regulated MAP K | 2019 |
Glycochenodeoxycholate induces cell survival and chemoresistance via phosphorylation of STAT3 at Ser727 site in HCC.
Topics: Carcinoma, Hepatocellular; Cell Survival; Drug Resistance, Neoplasm; Flavonoids; Fluorouracil; Gene | 2020 |
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sul | 2019 |
Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2019 |
Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cathepsin B; Chitosan; Chondroitin; Drug | 2020 |
H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzylisoquinolines; Carcinoma, Hep | 2019 |
Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fluo | 2020 |
A rectal cancer organoid platform to study individual responses to chemoradiation.
Topics: Animals; Chemoradiotherapy; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Neoplasm Me | 2019 |
Multicentre study of perioperative
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2019 |
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve | 2019 |
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve | 2019 |
Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Carcinoma, Ductal, Breast; Carcinoma, | 2019 |
Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2019 |
Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoferritins; Apoptosis; Binding Sites; Biomarkers, Tumor; | 2020 |
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Evolution; Clinical Trials, Phase III as | 2020 |
[A Case of FOLFOXIRI plus BV Therapy Responding to Liver Metastasis of Rectal Cancer with the Portal Venous Tumor Thrombi(Vp4)as Oncologic Emergency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatectom | 2019 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2020 |
NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; | 2020 |
Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Interle | 2020 |
Prognostic and Diagnostic Values of miR-506 and SPON 1 in Colorectal Cancer with Clinicopathological Considerations.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Chemotherap | 2021 |
Hepatic arterial infusion chemotherapy for colorectal liver metastases revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2020 |
Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoemb | 2020 |
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cetu | 2020 |
Phytochemical and Pharmacophoric Fragment Based Anticancer Drug Development.
Topics: Antineoplastic Agents; Chalcones; Colchicine; Drug Design; Drug Development; Drug Resistance, Multip | 2021 |
Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Re | 2020 |
Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatty Liver; Female; Fluorouracil; Humans; Irinoteca | 2020 |
Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition.
Topics: Carcinoma, Hepatocellular; Cholesterol; Drug Carriers; Fluorouracil; Hep G2 Cells; Humans; Liposomes | 2020 |
Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2020 |
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
[Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2019 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2020 |
IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2020 |
Comparative proteomic analysis of protein methylation provides insight into the resistance of hepatocellular carcinoma to 5-fluorouracil.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver | 2020 |
The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proli | 2020 |
Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Chemotherapy, Adjuvant; Col | 2020 |
Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; | 2020 |
Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; | 2020 |
Glycyrrhetinic acid modified MOFs for the treatment of liver cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Fluorouracil; Glycyrrhe | 2020 |
LGR5 marks targetable tumor-initiating cells in mouse liver cancer.
Topics: Ablation Techniques; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; C | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2020 |
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
[A Case of Ascending Colon Cancer with Synchronous Unresectable Liver Metastasis Maintaining a Long-Term Stable Disease State after Discontinuing Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colonic Neoplasms; Female; F | 2020 |
[Perioperative Chemotherapies for Patients with Colorectal Liver Metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Combined Modality | 2020 |
[A Case of Malignant Lymphoma Undergoing HAI Treatment for Multiple Liver Metastases of Carcinoid That Appeared about Nine Years after Resection of Rectal Carcinoid with Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemoembolization, Therapeuti | 2020 |
Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2020 |
CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Differentiation; Cyc | 2020 |
Defining Early Multidisciplinary Goals: NEXTO Trial in High-Risk Colorectal Cancer with Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Color | 2020 |
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fibroblast Growth Factor 2; Fibroblast | 2021 |
Challenges in Reirradiation of Intrahepatic Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2020 |
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2020 |
Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2020 |
Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hepatect | 2020 |
EGFR inhibition in colorectal cancer with liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluoro | 2020 |
Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor | 2020 |
Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antin | 2020 |
Ready to go 3D? A semi-automated protocol for microwell spheroid arrays to increase scalability and throughput of 3D cell culture testing.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Proliferat | 2020 |
Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease- | 2020 |
INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2020 |
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2020 |
ASO Author Reflections: Implementation of a New Hepatic Artery Infusion Program for Colorectal Liver Metastases is Safe, Feasible, and Effective.
Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplas | 2020 |
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2020 |
Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum | 2020 |
Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Membe | 2020 |
Mannose Conjugated Starch Nanoparticles for Preferential Targeting of Liver Cancer.
Topics: Drug Carriers; Drug Delivery Systems; Fluorouracil; Humans; Kinetics; Liver Neoplasms; Mannose; Nano | 2021 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross- | 2020 |
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellul | 2020 |
Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Liver Neoplasm | 2021 |
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2020 |
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Fluo | 2020 |
Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Su | 2020 |
Improved pharmacokinetic and biodistribution of 5-fluorouracil loaded biomimetic nanoerythrocytes decorated nanocarriers for liver cancer treatment.
Topics: Biomimetics; Drug Carriers; Fluorouracil; Humans; Liver Neoplasms; Nanoparticles; Particle Size; Tis | 2021 |
Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Extracellular Matrix; Extracel | 2020 |
MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Inducing Factor; Carcinoma, Hep | 2021 |
What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2021 |
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hepatocellular; C | 2021 |
Thiolated polymer nanocarrier reinforced with glycyrrhetinic acid for targeted delivery of 5-fluorouracil in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Fluorouracil; Glycyrrhetinic Acid; Liver Neoplasms; Polymers; Ra | 2021 |
[A Case of Colon Cancer with Synchronous Multiple Metastases Successfully Treated with Combined Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Fluorouracil; Hu | 2021 |
[Two Cases of Resectable Liver Metastasis from Colorectal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2020 |
[A Case of Pathological Complete Response of Colon Cancer after Systemic Chemotherapy with mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2020 |
[Laparoscopic Abdominoperineal Resection Following Intensive Chemotherapy for Stage Ⅳ Rectal Cancer with Unresectable Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2020 |
Who Will Benefit? Using Radiomics to Predict Response to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Liver Ne | 2021 |
Biological features, gene expression profile, and mechanisms of drug resistance of two- and three-dimensional hepatocellular carcinoma cell cultures.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tum | 2021 |
[Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice].
Topics: Animals; Capsules; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese H | 2020 |
Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chroma | 2021 |
Hepatectomy for liver metastasis from rectal cancer in a patient with mitochondrial disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diabetes Mellitus, Type 2; Fema | 2021 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Dox | 2021 |
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Depe | 2021 |
Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bl | 2021 |
Conversion therapy in patients with colorectal liver metastases.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineopl | 2021 |
Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Fluorouracil; Humans; Infusions, Intra-Ar | 2021 |
Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.
Topics: Animals; Carcinoma, Hepatocellular; Cell Survival; Drug Delivery Systems; Fluorouracil; Hep G2 Cells | 2021 |
Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
Topics: Acetylation; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dose-Response Relationship, | 2021 |
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cispla | 2021 |
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; DNA | 2021 |
Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2021 |
[Subarachnoid Hemorrhage Associated with Bevacizumab during Chemotherapy for Clinical Stage Ⅳ Sigmoid Colon Cancer-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Fluorouracil; Humans; Leucovori | 2021 |
Preparation, Synergism, and Biocompatibility of in situ Liquid Crystals Loaded with Sinomenine and 5-Fluorouracil for Treatment of Liver Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Carriers; Drug Liberatio | 2021 |
Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Fluorouracil; Hepatic Artery; Huma | 2021 |
Investigation of the Physical Properties and Clinical Application of Embosphere Microspheres.
Topics: Angiography; Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Carri | 2021 |
Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability.
Topics: Apoptosis; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; | 2021 |
Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in post-metastatic liver biochip modeling.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; | 2021 |
Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Heart Atria; Humans; Liver Neoplasms; Pulmonary Embolism; V | 2022 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pai | 2017 |
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop | 2017 |
Hepatoprotective Mongolian prescription II enhances the antitumor effects of chemotherapeutics in hepatocellular carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fluo | 2017 |
Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2017 |
Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relat | 2017 |
USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2017 |
Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevaci | 2017 |
Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Cur | 2017 |
Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; D | 2017 |
XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cell-Free System; Chemoemboliza | 2017 |
[A Case Report on a Successful Resection after FOLFIRI plus Cetuximab Therapy for Unresectable Colorectal Cancer with Multiple Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colectomy; Combined M | 2017 |
The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Argin | 2017 |
Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy.
Topics: Antineoplastic Agents; Bioreactors; Cells, Cultured; Colon; Colonic Neoplasms; Drug Discovery; Drug | 2017 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
A colon targeted drug delivery system based on alginate modificated graphene oxide for colorectal liver metastasis.
Topics: Alginates; Animals; Colon; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Glucuronic Aci | 2017 |
Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antibody-Dependent Cell Cytotoxicity; Antimetabolites, An | 2017 |
Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 2017 |
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Exons; Fluorouracil; Humans | 2017 |
A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelia | 2017 |
Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm | 2017 |
Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone | 2017 |
GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neo | 2017 |
Astragaloside IV downregulates the expression of MDR1 in Bel‑7402/FU human hepatic cancer cells by inhibiting the JNK/c‑Jun/AP‑1 signaling pathway.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Down-Regulat | 2017 |
Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Blood Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Mo | 2018 |
Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2017 |
The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Case-Co | 2018 |
Cytotoxic effects of Fritillaria imperialis L. extracts on human liver cancer cells, breast cancer cells and fibroblast-like cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation | 2017 |
Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2017 |
A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
Topics: Animals; Biopsy; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Cell Prolifer | 2017 |
Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellu | 2017 |
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2017 |
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; C | 2017 |
Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim | 2017 |
Arterioportal shunt incidental to treatment with oxaliplatin that mimics recurrent gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arteriovenous Fistula; Biopsy; Capecitabine; | 2017 |
Metastatic primary seminal vesicle adenocarcinoma: management of a rare tumour with multiagent chemotherapy and hormonal therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Genital Neoplasms, Mal | 2017 |
Early small bowel perforation due to aflibercept.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2017 |
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colec | 2017 |
BC-02 eradicates liver cancer stem cells by upregulating the ROS-dependent DNA damage.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Damage; Female; Fluor | 2017 |
The synergism and attenuation effect of Selenium (Se)-enriched Grifola frondosa (Se)-polysaccharide on 5-Fluorouracil (5-Fu) in Heps-bearing mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cell Proliferation; Drug Synergism; F | 2018 |
Novel mouse models of hepatic artery infusion.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; Hepatic A | 2017 |
The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Hep G2 Cells; Human | 2017 |
Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Dose-Res | 2017 |
Inhibition of autophagy in hepatocarcinoma cells promotes chemotherapeutic agent-induced apoptosis during nutrient deprivation.
Topics: Adenine; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepat | 2018 |
5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; H | 2018 |
Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, He | 2018 |
Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment.
Topics: Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regulation, Neoplasti | 2018 |
Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Caspases; CD8-Positive T-Lymphocytes; Cell D | 2018 |
[A Case of Fatal Interstitial Pneumonia during FOLFIRI plus Cetuximab Therapy for Liver Metastasis of Colon Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Fatal Outcome; Female | 2018 |
Effective Timing of Surgical Resection of Colorectal Cancer Liver Metastases During Chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; Colorectal Neoplasms; E2F1 Tr | 2018 |
[Experience of Ramucirumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer in Our Hospital].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2017 |
Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neopl | 2018 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Targeting PRPK Function Blocks Colon Cancer Metastasis.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic N | 2018 |
[A Case of a Long-Term Survivor Who Underwent Surgical Intervention for Hepatocellular Carcinoma Combined with Tumor Thrombus in the Main Trunkof the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cont | 2018 |
USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Movement; Cyclin E; Fluoroura | 2018 |
Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.
Topics: Adenocarcinoma; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diag | 2018 |
Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; bcl-X Protein; Carcin | 2018 |
Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2018 |
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi | 2018 |
Sorafenib and hepatic arterial infusion chemotherapy: another failed combination.
Topics: Adult; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Liver Neoplasms; Sorafenib | 2018 |
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Gastrointes | 2018 |
[A Case of Chemotherapy with FOLFOXIRI plus Cetuximab for Liver Metastasis of Sigmoid Colon Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; | 2018 |
[A Case of Colon Cancer with Brain, Liver and Lung Metastasis Successfully Treated with Bevacizumab plus Xelox Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Deoxycyt | 2018 |
Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Combined Modality Thera | 2019 |
RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.
Topics: Animals; Antigens, Nuclear; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell M | 2018 |
Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKα/NF-κB pathway.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; | 2018 |
Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinogenesis; Carcinoma, Hepatoc | 2018 |
Fast-Track Two-Stage Hepatectomy Using a Hybrid Interventional Radiology/Operating Suite as Alternative Option to Associated Liver Partition and Portal Vein Ligation for Staged Hepatectomy Procedure.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Embolization | 2018 |
Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cells.
Topics: Antigens, CD; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; | 2018 |
MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, | 2018 |
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2018 |
Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe | 2019 |
[A Case of Rectal Cancer and Multiple Liver Metastases Treated Using mFOLFOX and Bevacizumab under Maintenance Dialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fluorouracil; Glomerulonephritis, IGA; | 2018 |
Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141.
Topics: Carcinoma, Hepatocellular; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression | 2018 |
Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Disease Models, Ani | 2018 |
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cetuximab; Colorectal Neoplasms; Female; | 2018 |
[Primary Small Bowel Tumor with Simultaneous Lung Metastases from Rectal Cancer - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Intestinal Neoplasms; | 2018 |
High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Hepatocellular; Cohort Stu | 2018 |
Safety evaluation of simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluo | 2018 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Biotin; Cell Line; Cell Movement; Cell Proliferation; Chit | 2018 |
SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Endonucleases; Fluorouracil; Gene Expressi | 2018 |
ASO Author Reflections: Role of Preoperative Chemotherapy in the Treatment of Pancreatic Neuroendocrine Liver Metastases.
Topics: Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Pancreatic Neoplasms; Streptozocin | 2018 |
[A Case of Neuroendocrine Carcinoma of the Ascending Colon That Responded Completely to Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Neuroendocrine; Colectomy; C | 2018 |
Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biotin; Carcinoma, Hepatocellular; Curcumin | 2019 |
[A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Female; | 2018 |
Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2018 |
5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cardiotoxicity; Cardiovascular Diseases | 2019 |
Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell Surv | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cap | 2019 |
[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2018 |
[Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 2018 |
Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
Topics: Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy | 2019 |
Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Combined Modal | 2019 |
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2019 |
[A Very Elderly Patient Successfully Treated by Multimodality Treatment for Pancreas Cancer with Synchronous Multiple Liver Metastases and Liver Dysfunction].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatic Art | 2018 |
[A Case of Complete Pathological Response of Unresectable Synchronous Colorectal Hepatic Metastasis with Icterus after FOLFOX plus Panitumumab Therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatecto | 2018 |
[A Super-Elderly Patient with Recurrent Colon Cancer with Metastasis Effectively Treated with Capecitabine plus Bevacizumab Chemotherapy-A Case Report].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2018 |
[A Case of Long-Term Survival in a Patient with Ascending Colon Cancer and Synchronous Multiple Liver Metastases after Multimodality Therapy Including Multiple Hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colonic Neoplasms; Female; F | 2018 |
[A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le | 2018 |
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents, Immunological; An | 2019 |
Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Topics: ADAM17 Protein; Animals; Apoptosis; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Line; C | 2019 |
Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2019 |
High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases.
Topics: Aged; Animals; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Down-Regulati | 2019 |
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Clini | 2019 |
Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines.
Topics: Animals; Biomimetics; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Delayed-Action Pre | 2019 |
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2019 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Gypenoside L Inhibits Proliferation of Liver and Esophageal Cancer Cells by Inducing Senescence.
Topics: beta-Galactosidase; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescenc | 2019 |
Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemorad | 2019 |
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2019 |
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docet | 2019 |
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2019 |
Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells.
Topics: Aluminum Chloride; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; C | 2019 |
Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dr | 2019 |
Partial response after treatment with Conversion chemotherapy: A case report of a patient with colon cancer and unresectable hepatic metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms | 2019 |
Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
Topics: Animals; Aptamers, Nucleotide; Biomarkers, Pharmacological; Carcinoembryonic Antigen; Cell Adhesion; | 2019 |
Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
Topics: AC133 Antigen; AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Carcinoma, Hepatocellular; | 2019 |
Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China.
Topics: Carcinoma, Hepatocellular; China; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Po | 2019 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Hepatic arterial chemotherapy for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve | 2019 |
Spontaneous regression of pancreatic cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; | 2019 |
[Long-Term Effectiveness of Chemotherapy Containing mFOLFOX6 plus Panitumumab and 5-FU/l-LV plus Panitumumab after Primary Tumor Resection in a Case of Ascending Colon Carcinoma and Multiple Hepatic Metastases].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colo | 2019 |
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Topics: Abdominal Pain; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diabe | 2019 |
[A Case of Survival Following Fourth-Line Outpatient Chemotherapy 19 Months after Surgery for Small Intestinal Cancer with Multiple Liver Metastases in a Patient with Good General Condition].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Fluorouracil; Humans; Intestina | 2019 |
[Case of Hyperammonemia Induced by High-Dose Fluorouracil].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consciousness Disorders; Female; | 2019 |
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duc | 2019 |
Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2019 |
Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2019 |
Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report.
Topics: Abdominal Pain; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothe | 2020 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2019 |
TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromatin Immunoprecipitation; Epit | 2019 |
Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise | 2019 |
[Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2013 |
[A case with multiple liver metastases from rectal cancer responding completely to FOLFOX for a long duration without exacerbation of peripheral neuropathy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucovorin; Live | 2013 |
Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Analysis of Variance; Angiogenesis Inhibitors; | 2013 |
Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2013 |
hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Hepatocel | 2013 |
Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Car | 2013 |
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cation Transport | 2013 |
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2013 |
ALPPS procedure with the use of pneumoperitoneum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic | 2013 |
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Chemoradiotherapy; C | 2013 |
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
[Panitumumab-induced trichomegaly].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2013 |
PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral | 2013 |
Regression of liver metastases after treatment with oxaliplatin/capecitabine and development of a progressive multifocal leukoencephalopathy in a patient with advanced thymoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; L | 2013 |
Extracorporeal hepatic venous bypass during en bloc resection of right trisection, caudate lobe, and inferior vena cava: a novel technique to avoid hypothermic perfusion.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemothe | 2013 |
Efficient total synthesis and biological activities of 6-deoxyisojacareubin.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Fluorouracil; Humans; | 2013 |
Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Blotting, Western; Carcinoma, Hepatocellular; Cell L | 2014 |
Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette | 2013 |
Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2013 |
Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2013 |
Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; | 2013 |
High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Abla | 2013 |
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C | 2013 |
[Combination therapy herceptin+xeloda].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2002 |
Chemotherapy and resection for gastric cancer with synchronous liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations | 2013 |
[Secondary necrotizing fasciitis associated with panitumumab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Causal | 2013 |
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Cycle; Colorectal Neopla | 2013 |
Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic | 2013 |
Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques.
Topics: Animals; Antibodies; Antimetabolites, Antineoplastic; Cytokines; Female; Fluorouracil; Gene Knock-In | 2013 |
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2013 |
Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Influence of etiology on host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie | 2013 |
Cytotoxic withanolides from the leaves of Moroccan Withania frutescens.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Chromatography, High P | 2013 |
Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Enzyme Ac | 2013 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camp | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2013 |
Epigenetic silencing of DACH1 induces loss of transforming growth factor-β1 antiproliferative response in human hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Azacitidine; Carcinoma, Hepatocellular; DNA Methylation; Eye Proteins; Fema | 2013 |
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Curcumin; Drug Delivery | 2013 |
[Results of combined treatment of patients with metastatic gastric cancer. Case study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2013 |
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2013 |
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2013 |
[Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma].
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Charybdotoxin; Fluorouracil; Hypoxia-Inducible | 2013 |
Imaging analysis of hepatoblastoma resectability across neoadjuvant chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2013 |
[A case of relapsed colon cancer successfully treated by capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouraci | 2013 |
Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor | 2013 |
[Bevacizumab therapy for a colorectal cancer patient or hemodialysis with hepatic metastasis].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; | 2013 |
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell C | 2013 |
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2013 |
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chi-Square D | 2013 |
The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy | 2013 |
Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Oxaliplatin-induced liver injury mimicking metastatic tumor on images: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagno | 2013 |
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2014 |
[A case of advanced colon cancer with atrial fibrillation and the use of dabigatran for safe chemotherapy using fluoropyrimidine-based antitumor agents].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Benzimidazoles; Colonic N | 2013 |
[Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism].
Topics: Animals; Capecitabine; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; | 2013 |
The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinom | 2014 |
Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 2013 |
MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; beta Cate | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
[A preliminary study of the inhibitive efficacy of iodized linoleic acid and its fluorodeoxyuridine ester in hepatocellular cancer].
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Humans; Inhibitory Concentration | 2013 |
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fl | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2014 |
Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Deliv | 2013 |
Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tum | 2013 |
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
[Effect of plasmid transfected shMRE11 on the drug-resistance of BEL7402/5-FU hepatoma cells].
Topics: Carcinoma, Hepatocellular; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorouracil; Humans; Li | 2013 |
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemical and Drug Induced | 2013 |
Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Cholangitis, Scler | 2014 |
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Diarrhea; Disease- | 2013 |
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, | 2014 |
Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2013 |
Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response.
Topics: Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug | 2013 |
[A case study of stable disease after hepatic arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable hepatic metastases of colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Resistance, Neoplasm; | 2013 |
[A case of huge advanced hepatocellular carcinoma resected after hepatic arterial infusion therapy of 5-FU/LV/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal | 2013 |
Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Female; Fluorouracil; H | 2013 |
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2014 |
[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Cycle Proteins; Cel | 2014 |
Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; | 2013 |
Combination chemotherapy for metastatic extramammary Paget disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Neopla | 2014 |
[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
[A case of metastatic colorectal cancer with hyperammonemic encephalopathy induced by 5-FU in a patient continuously treated with XELOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabol | 2013 |
A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Coloni | 2013 |
Triptolide sensitizes liver cancer cell lines to chemotherapy in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell L | 2014 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
EpCAM-targeted therapy for human hepatocellular carcinoma.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2014 |
[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy].
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, The | 2013 |
[A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 2013 |
[Recurrent rectal cancer with multiple liver and lung metastases treated effectively with oxaliplatin and capecitabine plus bevacizumab chemotherapy-a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
[Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease | 2013 |
[A case in which XELOX plus bevacizumab chemotherapy was effective in an elderly patient with heart failure and multiple liver metastases after sigmoidectomy].
Topics: Abdominal Abscess; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
[A case of a recurrent hepatic metastasis occurred after curative resection of ascending colon cancer and a hepatic metastasis responding completely to capecitabine plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cysteine Endopeptidases; Drug Resistance, Neoplasm | 2014 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Differentiation; | 2014 |
Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellu | 2014 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2014 |
[A case of endocrine cell carcinoma of the ascending colon with liver metastasis treated with hepatectomy after excision of the primary lesion and systemic chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2014 |
Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; | 2014 |
Inhibition of p53 increases chemosensitivity to 5-FU in nutrient-deprived hepatocarcinoma cells by suppressing autophagy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Benzothiazoles; Carcinoma, Hepatocellular; Ce | 2014 |
Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid--enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemica | 2014 |
A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Ch | 2014 |
Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Diffusion; Drug Synergism; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo | 2014 |
Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Downregulation of Rap1 promotes 5-fluorouracil-induced apoptosis in hepatocellular carcinoma cell line HepG2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatoce | 2014 |
Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; | 2014 |
Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2014 |
Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Drug Therapy; Fluorouracil; | 2014 |
Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Combine | 2014 |
Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2014 |
Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2014 |
Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Ascites; Bilirubin; Colorectal Neoplasms; Combined Modality T | 2014 |
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell | 2014 |
Astragaloside Ⅳ reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biologic | 2014 |
IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.).
Topics: Animals; Antimetabolites, Antineoplastic; Camptothecin; Cell Line; Cell Line, Tumor; Colon; Cyclin-D | 2014 |
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2014 |
Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Delivery Systems; Fluorouracil; Hep | 2014 |
Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells.
Topics: Animals; Apolipoproteins A; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum | 2014 |
MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; D | 2014 |
[A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2014 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2016 |
Green synthesis of pullulan stabilized gold nanoparticles for cancer targeted drug delivery.
Topics: Adsorption; Animals; Biocompatible Materials; Biopolymers; Calorimetry, Differential Scanning; Carbo | 2014 |
Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Col | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma.
Topics: Analysis of Variance; Animals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Colony-Formi | 2014 |
Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2014 |
Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II.
Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Down | 2014 |
[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2014 |
[A case of pathological complete response of advanced rectal cancer with liver metastasis accompanied by tumor thrombus following treatment with bevacizumab/FOLFOX4 chemotherapy].
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
[Report of two cases of hepatitis B virus reactivation in primary liver carcinoma patients treated with the FOLFOX chemotherapy regimen].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatitis B virus; Humans; Leuc | 2014 |
HepG2 cells recovered from apoptosis show altered drug responses and invasiveness.
Topics: Ablation Techniques; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Dos | 2014 |
[Study on the mechanism of polypeptide extract from scorpion venom on inhibition of angiogenesis of H 22 hepatoma].
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Fluorouracil; Hypoxia-Inducible Factor 1, alpha | 2014 |
Radiation recall after a transarterial hepatic chemoembolization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; | 2014 |
Impact of liver-directed therapy in colorectal cancer liver metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Colorec | 2014 |
Polysaccharides from Tricholoma matsutake and Lentinus edodes enhance 5-fluorouracil-mediated H22 cell growth inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dow | 2014 |
Colon cancer, version 3.2014.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Co | 2014 |
FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2014 |
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperatu | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
The impact of pyrvinium pamoate on colon cancer cell viability.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell L | 2014 |
The synergistic effect of organic silicone quaternary ammonium salt and 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2014 |
Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif | 2014 |
Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2014 |
Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Topics: Aged; Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2014 |
Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2014 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemo | 2014 |
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2014 |
[Antitumor effect of Stichopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells].
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Fluorouracil; Glycosaminoglycans; L | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
Re-sensitization of 5-FU resistance by SPARC through negative regulation of glucose metabolism in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fema | 2015 |
Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2014 |
Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2014 |
In reply to Putnam.
Topics: Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Radiation-Sen | 2014 |
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of Yttrium-90 radioembolization: in regard to Hickey et al.
Topics: Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Radiation-Sen | 2014 |
Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells.
Topics: AMP-Activated Protein Kinases; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellu | 2014 |
Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Chem | 2014 |
Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; bcl-X Protein; Binding Sites; Carcinoma, H | 2015 |
[Long-term survival of a patient with sigmoid colon cancer showing multiple liver metastases treated by performing partial hepatectomy, five years after achieving a complete response via hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Fluorouracil; Hepatectomy; Humans; Infusions, | 2014 |
JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs.
Topics: Anthracenes; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Fluo | 2015 |
5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Carcinoma, Hepatocellu | 2015 |
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Comb | 2014 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2014 |
Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5-fluorouracil by regulating β-catenin and cyclin D1 expression.
Topics: Annexin A2; beta Catenin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Resistan | 2015 |
Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, H | 2015 |
[Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2015 |
Hepatic arterial infusion in hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Czech Republic; Disease-Fr | 2015 |
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2014 |
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto | 2015 |
Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellula | 2015 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatectomy; Hum | 2015 |
Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell | 2015 |
Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta-Thromboglobulin; Camptothecin; Capecitabine; Co | 2015 |
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Effectiveness of proton beam therapy on liver metastases of esophageal cancer: report of a case.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; | 2015 |
[Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Moda | 2014 |
[Preoperative chemotherapy with modified FOLFOX + panitumumab for the treatment of descending colon cancer with multiple liver metastases - a case study].
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colectomy; Co | 2015 |
Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2015 |
Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2015 |
Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Chemoembolization, Therapeutic; Disea | 2015 |
Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Prote | 2015 |
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2015 |
Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt | 2015 |
Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
[Preoperative chemotherapy enabled radical resection of tumors in a patient with multiple liver metastases].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2014 |
[A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2014 |
[A case of liver metastasis from sigmoid colon cancer treated effectively by second-line chemotherapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2014 |
[A case of long-term survival following chemotherapy after laparoscopic resection of sigmoid colon cancer with multiple liver metastases].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2014 |
[A case of descending colon cancer with multiple liver metastases effectively treated with capecitabine/oxaliplatin (CapeOX) and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2014 |
[Five-year-survival in a case of large synchronous liver metastases from colon cancer treated with local (operation, HAI, RFA, and TAE) and systemic combined therapy].
Topics: Antimetabolites, Antineoplastic; Catheter Ablation; Combined Modality Therapy; Embolization, Therape | 2014 |
[A case report of hepatectomy for liver metastasis of colon cancer after heavy particle radiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Ther | 2014 |
[Long-term survival in a patient receiving multidisciplinary therapy for hepatocellular carcinoma with left iliac bone metastasis].
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocell | 2014 |
[A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
[A case of advanced gastric cancer with liver metastasis involving curative surgery after neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2015 |
[A case of stage IV gastric cancer resected after chemotherapy with capecitabine plus cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; | 2015 |
Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bifidobacterium; Carcinoma, H | 2015 |
[Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Hyperammonemia; Inte | 2015 |
The Influence of Aging on Hepatic Regeneration and Early Outcome after Portal Vein Occlusion: A Case-Control Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro | 2015 |
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Colorectal Neo | 2015 |
Use of vinegar to relieve persistent hiccups in an advanced cancer patient.
Topics: Acetic Acid; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hiccup | 2015 |
Liver-Tumor Hybrid Organoids for Modeling Tumor Growth and Drug Response In Vitro.
Topics: Coculture Techniques; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; Hep G2 Cell | 2015 |
Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, T | 2015 |
Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2015 |
VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Gene Expression Regulation, Neopla | 2015 |
Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms; Female; Fluoroura | 2015 |
Advanced gastric cancer with liver and lymph node metastases successfully resected after induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Gastrectomy; Hum | 2014 |
[Outcome of hepatoblastoma: experience with 63 patients received chemotherapy with the regimen C5V].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Doxorubicin; Fem | 2015 |
A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Fatal Outcome; Fluorouracil; Gene Express | 2015 |
Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins - a case report.
Topics: Ablation Techniques; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neo | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
Topics: 3' Untranslated Regions; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down- | 2015 |
Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Proli | 2015 |
[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Capecitabine; Colecto | 2015 |
Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy | 2015 |
MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplas | 2015 |
Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Cholangiocarcinoma; Enbucrilate; Epirubicin; Female; Fl | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adju | 2015 |
A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Ph | 2015 |
Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
[Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism].
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplati | 2014 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Du | 2015 |
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy, Adjuv | 2015 |
Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2015 |
Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2015 |
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carci | 2015 |
Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Host Immunity Influences the Efficacy of Combined Intra-Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in Liver Cirrhosis Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2014 |
Education and Imaging. Hepatobiliary and Pancreatic: Complete remission after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with decompensated cirrhosis.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcino | 2016 |
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Che | 2015 |
[Rapidly Growing Interval Colon Cancer].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
[Novel hybrids of (phenylsulfonyl)furoxan and N-benzyl matrinol as anti-hepatocellular carcinoma agents].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Hep G2 Cells; Humans; Liver Neoplasm | 2015 |
MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Cisp | 2015 |
Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; alpha-Fetoproteins; Animals; Apoptosis Regulatory Proteins; bc | 2015 |
The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, | 2015 |
Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therap | 2015 |
Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Disease Models, Animal | 2016 |
High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2016 |
[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bi | 2015 |
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 2016 |
Significance of the Signal Intensity of Gadoxetic Acid-enhanced MR Imaging for Predicting the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic | 2016 |
GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; CSK Tyrosine-Protein Kinase; DN | 2015 |
Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Pr | 2015 |
Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2015 |
Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2015 |
MicroRNA-302b Enhances the Sensitivity of Hepatocellular Carcinoma Cell Lines to 5-FU via Targeting Mcl-1 and DPYD.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Dihyd | 2015 |
[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Elastomers; Fluorourac | 2015 |
[A Case of Radical Resection of Rectal Cancer with Multiple Liver and Lung Metastases after Preoperative Chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; F | 2015 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2015 |
Unilateral Capecitabine-related Hand-foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon | 2015 |
A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult.
Topics: Adult; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Diagnostic Errors; Doxorubicin; Dru | 2015 |
Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell | 2016 |
Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Primary Adenocarcinoma with Focal Choriocarcinomatous Differentiation in the Sigmoid Colon.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2015 |
Effect of luteolin on gene expression in mouse H22 hepatoma cells.
Topics: Animals; Carcinoma, Hepatocellular; CD58 Antigens; Cell Line, Tumor; Cell Proliferation; Fluorouraci | 2015 |
Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2016 |
The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cholesterol; Colorectal Neoplasms; Disease Models, | 2016 |
Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 | 2015 |
Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Blotting, Western; | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2015 |
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neo | 2015 |
Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 2016 |
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2017 |
[Pre-Operative Treatment with Transcatheter Arterial Chemoembolization (TACE) and Hepatic Arterial Infusion (HAI) for Liver Metastasis from Gastric Cancer--A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, | 2015 |
[XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Combined | 2015 |
[New FP Therapy Was Effective for a Case of Massive Hepatocellular Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal | 2015 |
[A Case of Simultaneous Laparoscopic Resection of Sigmoid Colon Cancer and Liver Metastases after Chemotherapy with Modified FOLFOX6 plus Panitumumab].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; | 2015 |
[A Case of Pathological Complete Response after Primary Tumor Resection Followed by Hepatectomy-A Sigmoid Colon Cancer with Synchronous Liver Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colectomy; Combined Modality Therapy; F | 2015 |
[A Case of Long-Term Survival of a Patient with Liver Metastasis of Colon Cancer and Suspected Inferior Vena Cava Invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Hum | 2015 |
[A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Chemotherapy, Adjuvant; Fl | 2015 |
[A Case of Liver Metastasis of Descending Colon Cancer with a Pathological Complete Response to mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon, Descending; Col | 2016 |
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ch | 2016 |
Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Dr | 2016 |
Inhibition of Growth and Metastasis of Colon Cancer by Delivering 5-Fluorouracil-loaded Pluronic P85 Copolymer Micelles.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; D | 2016 |
Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M | 2016 |
Hepatic Arterial Infusion Chemotherapy for Life Threatening Patients due to Liver Metastases from Colorectal Cancer with Cetuximab.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal N | 2015 |
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Second-Line Modified FOLFOX6 Regimen in The Patients with Metastatic Esophagus Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
[Fluoroscopy-induced Subacute Radiation Dermatitis in Patient with Hepatocellular Carcinoma].
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluoroscopy; Fluorouracil; Gamma Rays; Humans; | 2016 |
ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun.
Topics: Animals; Annexins; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumo | 2016 |
Multidisciplinary effort in treating children with hepatoblastoma in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Preschool; Chi | 2016 |
Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C | 2016 |
[Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Coculture Techniques; Culture Me | 2015 |
Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.
Topics: Carcinoma, Hepatocellular; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Epithel | 2016 |
Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Core | 2016 |
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2016 |
[A Case of Double Cancer of Initially Unresectable Sigmoid Colon Cancer and Advanced Gastric Cancer Treated with Curative Resection after mFOLFOX6 Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Fluorouracil; Hum | 2016 |
Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorect | 2016 |
Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2016 |
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; | 2016 |
Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
Topics: Acetylcysteine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepat | 2016 |
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Abl | 2016 |
Safety of implanting sustained-release 5-fluorouracil into hepatic cross-section and omentum majus after primary liver cancer resection.
Topics: Alanine Transaminase; alpha-Fetoproteins; Aspartate Aminotransferases; Delayed-Action Preparations; | 2016 |
[A Case of Unresectable Rectal Cancer with Multiple Liver Metastases Treated Effectively with 22 Courses of XELOX Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; L | 2016 |
[A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2016 |
Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; | 2016 |
Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepato | 2016 |
Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer.
Topics: Aged; Animals; Antineoplastic Agents; Cell Differentiation; Cellular Reprogramming; Cisplatin; Doxor | 2016 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
The Effects and Mechanisms of Periplaneta americana Extract Reversal of Multi-Drug Resistance in BEL-7402/5-FU Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Tr | 2016 |
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
Topics: Adult; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluor | 2016 |
Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor | 2016 |
Fractal Dimension of Tc-99m DTPA GSA Estimates Pathologic Liver Injury due to Chemotherapy in Liver Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemic | 2016 |
Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Deliver | 2016 |
Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, | 2016 |
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Co | 2016 |
Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasms; Disease Model | 2016 |
Robotic-Assisted Placement of an Hepatic Artery Infusion Pump and Catheter for Regional Chemotherapy of the Liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2016 |
Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
Topics: Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorourac | 2016 |
The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy.
Topics: Autophagy; Base Sequence; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; C | 2016 |
Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
Topics: Adaptor Proteins, Signal Transducing; Aged; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2016 |
[A Case of Liver Metastasis from Colorectal Cancer That Showed a Pathological Complete Response to mFOLFOX6 plus Cetuximab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Combined Modality Therapy; Fluorour | 2016 |
Capecitabine and the Risk of Fingerprint Loss.
Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil | 2017 |
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Colorectal Neo | 2016 |
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bili | 2017 |
Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2016 |
The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma.
Topics: Adult; Aged; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Female; | 2016 |
Use of 5-Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmac | 2017 |
Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associ | 2016 |
Management of rectal cancer: the 2016 French guidelines.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Chemoradiotherap | 2017 |
miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5‑fluorouracil by targeting EIF4E.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Down-Regulation; Drug Resistance, Ne | 2017 |
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemo | 2016 |
Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow; Bone | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
"
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal | 2016 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorec | 2017 |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic | 2017 |
Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2.
Topics: Carcinoma, Hepatocellular; Down-Regulation; Fluorouracil; Gene Knockdown Techniques; Hep G2 Cells; H | 2017 |
Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Topics: Actins; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2017 |
FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2017 |
Studies of anticancer drug cytotoxicity based on long-term HepG2 spheroid culture in a microfluidic system.
Topics: Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; Fluorouracil; Hep G2 Cells; Humans; | 2017 |
Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Arginase; Carcinoma, Hepatocellu | 2017 |
[Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorourac | 2016 |
[Long-Term Survival in a Case of Sigmoid Colon Cancer with Multiple Liver Metastases Treated with Repeated Hepatectomies].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Fluorouraci | 2016 |
[Pathological Complete Response in a Case of Multiple Liver Metastases from Rectal Cancer Treated with XELOX plus Bevacizumab(Bev)Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Combined Modal | 2016 |
[A Case of Rectal Cancer with Unresectable Liver Metastasis Responding to Rechallenge with FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Fluorouracil; | 2016 |
A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheter Ablation | 2017 |
Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2017 |
Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cetuximab; Colorectal Neop | 2017 |
In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
Topics: A549 Cells; Absorption, Physiological; Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatoce | 2017 |
Astragaloside II sensitizes human hepatocellular carcinoma cells to 5-fluorouracil via suppression of autophagy.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Line, | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2017 |
Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: is it really the end of an era?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluoroura | 2008 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Granulocyte-colony stimulating factor producing rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colectomy; Fatal Outcome; | 2008 |
Liver resection for colorectal liver metastases in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2008 |
Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell | 2008 |
Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Combined M | 2008 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; F | 2008 |
Mesojejunoileac liposarcoma with intrahepatic metastasis in a dog.
Topics: Animals; Capecitabine; Deoxycytidine; Dog Diseases; Dogs; Doxorubicin; Fatal Outcome; Fluorouracil; | 2008 |
[Efficacy of 5-FU hepatic arterial infusion with l-leucovorin for patients with unresectable colorectal liver metastasis].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hum | 2008 |
[5-FU/LV therapy for a rectal cancer patient undergoing continuous hemodialysis with multiple hepatic metastases--a case report].
Topics: Biomarkers, Tumor; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Rectal Neop | 2008 |
Significance of trans-hepatic arterial chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2008 |
[The study of Rougan Jiedu formula anti-liver cancer in vivtro].
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif | 2008 |
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2009 |
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leuc | 2008 |
Management of colorectal liver metastases after complete response to neoadjuvant chemotherapy. A case of computertomography-guided wire marking of the liver tumor.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemo | 2008 |
[A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Docetaxel; Esophageal | 2008 |
Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2008 |
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Haplotypes; H | 2008 |
Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellula | 2008 |
Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
Topics: Absorbable Implants; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Down-regulation of Sonic hedgehog signaling pathway activity is involved in 5-fluorouracil-induced apoptosis and motility inhibition in Hep3B cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Down-Regulation; Fluorouracil | 2008 |
Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre | 2009 |
Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Transplantat | 2008 |
Hepatocellular carcinoma-related gene targeting using the large circular antisense library.
Topics: Antisense Elements (Genetics); Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Surviva | 2008 |
[The combined treatment of colorectal cancer with liver metastases].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptotheci | 2009 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2008 |
[Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU].
Topics: Anticarcinogenic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatoc | 2008 |
The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion; Cell Proliferation; Colla | 2008 |
Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Rel | 2008 |
[A case with liver resection of metastasis from rectal cancer after FOLFOX4+bevacizumab treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capec | 2008 |
Hepatic arterial infusion chemotherapy combined with venous embolization in a patient with hepatic metastases with an arteriovenous shunt.
Topics: Angiography; Antimetabolites, Antineoplastic; Arteriovenous Fistula; Combined Modality Therapy; Cont | 2009 |
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
Topics: Aged; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Embolization, Therapeutic; Fluorode | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
[Cytotoxicity of the secondary metabolites of Marine Mangrove Fungus Paecilomyces sp. tree 1-7 on human hepatoma cell line HepG2].
Topics: Antineoplastic Agents; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-R | 2008 |
What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2009 |
[A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptotheci | 2008 |
[Epiphora in a patient receiving FOLFOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Lacrimal Apparatus Disea | 2008 |
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie | 2009 |
Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; DNA-Binding Protein | 2008 |
Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Chemoembolization, Therape | 2008 |
Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colo | 2009 |
Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2009 |
Small-vessel vasculitis following treatment with combination 5-fluorouracil/folinic acid and oxaliplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leuco | 2009 |
Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; E | 2009 |
Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Thera | 2008 |
Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 8; | 2009 |
[Elderly patient with metastatic gallbladder cancer treated by cisplatin, epirubicin and continuous infusion 5-fluorouracil].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Epi | 2008 |
Sequential or combination chemotherapy for a patient with mCRC?
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabo | 2008 |
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2008 |
Recurrent disease four years after surgery and adjuvant chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2008 |
[A long-term survival case of gastric cancer with liver metastases treated by hepatic arterial infusion chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Doxorubicin; Female; | 2008 |
[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chola | 2008 |
[Modified FOLFOX6 treatment for obstructive jaundice caused by hepatic lymph-node metastasis from liver metastases of rectal cancer--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil; Huma | 2008 |
[A case report of complete remission of relapsed rectal cancer liver metastasis after systemic chemotherapy successfully treated by radiofrequency ablation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Fluorouracil; Humans; Leucovorin; | 2008 |
[Hepatic artery infusion chemotherapy to three liver metastasis cases in which systemic chemotherapy was impossible or ineffective].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Female; Fluorouracil; Hepa | 2008 |
[Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2009 |
[Pharmacokinetic monitoring of 5-fluorouracil may improve the clinical benefit with an individualized regimen-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Monitoring; Fluorouracil; Humans; Liver N | 2009 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2008 |
[Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
[Comparison between pathological findings and MR diffusion-weighted imaging in primary hepatocellular carcinoma after transcatheter arterial chemoembolization].
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Diffusion M | 2008 |
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2009 |
Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cathet | 2009 |
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro.
Topics: Adenoviridae; Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorescent | 2009 |
Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement | 2009 |
[Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX)].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; L | 2009 |
[A case of metastatic breast cancer with liver metastasis effectively treated with capecitabine and vinorelbine].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasm | 2009 |
[Indications and results of palliative gastric resection in advanced gastric carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy, Adjuvant; Female; Flu | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
[Preparation of floxuridine loaded polycation and its antitumor activity].
Topics: Antimetabolites, Antineoplastic; beta-Cyclodextrins; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2009 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2009 |
[A case of resection of synchronous multiple liver metastases from colorectal cancer after FOLFOX chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; L | 2009 |
Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Colorectal Neoplasms; D | 2009 |
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined C | 2009 |
[Expression of ERK5 in multidrug-resistant hepatocellular carcinoma cell line].
Topics: Carcinoma, Hepatocellular; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoro | 2009 |
A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization.
Topics: Adenoviruses, Human; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2009 |
Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profilin | 2009 |
A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antimetabolites, Antineoplastic; beta-Galactosidase; | 2009 |
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2009 |
ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 6; Cell Cycle; Cell Death; Cell Line, Tumo | 2009 |
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
[Advanced hepatic resection for malignancy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 2009 |
[A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Duodenal Neoplasms; Duodenoscopy; | 2009 |
[A successfully resected case of rectal cancer with liver metastases treated with mFOLFOX6 and bevacizumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex | 2009 |
Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Drug Resistan | 2009 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 2009 |
Perforating dermatosis in a patient receiving bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; E | 2009 |
[Effect of HBx gene RNA interference combined with chemotherapy on hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C | 2009 |
Deriving the intrahepatic arteriovenous shunt rate from CT images and biochemical data instead of from arterial perfusion scintigraphy in hepatic arterial infusion chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Catheters, Indwelling; Colorectal Neoplasm | 2009 |
Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Abla | 2009 |
A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; DNA-Binding Proteins; Dru | 2009 |
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2009 |
[Hepatic cystoadenocarcinoma. Differential diagnosis of hepatic cystic tumors].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcino | 2009 |
Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 2009 |
Hepatocellular carcinoma in membranous obstruction of the inferior vena cava--a causal or a casual presentation.
Topics: Adult; Angioplasty, Balloon; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Flu | 2009 |
Long-term results of hepatectomy after hepatic arterial infusion chemotherapy for initially unresectable hepatic colorectal metastases.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorou | 2009 |
[A case of advanced hepatocellular carcinoma effectively treated with 5-fluorouracil and high-concentration cisplatin suspended in lipiodol by short-term hepatic arterial infusion chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; | 2009 |
Identification of genes conferring resistance to 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell L | 2009 |
Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum | 2009 |
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellu | 2009 |
Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Combined Moda | 2009 |
Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2009 |
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2009 |
Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cyclooxygenase 2; Down-Regulation; Drug | 2009 |
[Role of DNA topoisomerase II alpha in intrinsic and acquired drug resistance of liver cancer].
Topics: Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2009 |
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
Topics: Adult; Aged; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modal | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2009 |
[A case of rectal cancer with liver metastases successfully treated with modified FOLFOX6 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; He | 2009 |
N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2010 |
Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2009 |
Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.
Topics: Angiogenic Proteins; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Prolif | 2009 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2009 |
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2010 |
[A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2009 |
Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; D | 2009 |
Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX).
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2009 |
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Hist | 2009 |
[Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathy, Dilated; Dacarbazine; Female; | 2010 |
Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2010 |
Gallbladder squamous cell carcinoma in the setting of low-dose methotrexate use.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholecystectomy, Lap | 2009 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2010 |
Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Carboplatin; Carcinom | 2009 |
[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2009 |
[A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
[Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances the cell chemosensitivity to 5-Fu].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2009 |
Acute tumor lysis syndrome in a 7-month-old with hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disseminated Intravascular Coagulation; F | 2010 |
Improved first-line chemotherapy: a better chance for surgery?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hep | 2010 |
Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2009 |
Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Fo | 2010 |
[Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2009 |
[A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2009 |
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Line, Tumo | 2009 |
[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2009 |
[Evaluation of hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intr | 2009 |
[Hepatic metastatectomy of colorectal cancer following mFOLFOX6 treatment--analysis of 7 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2009 |
[Switching to direct intrahepatic arterial infusion of 5-FU after a progression of liver metastases from colorectal carcinoma treated with systemic infusion of FOLFOX].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2009 |
[A case of duodenal penetration by indwelling catheter during hepatic arterial infusion chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Catheters, In | 2009 |
[A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2009 |
[A case report of metastatic liver tumor from rectosigmoid colon cancer demonstrating a pathological complete response with FOLFOX and FOLFIRI treatment].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2009 |
[A case of liver metastasis of rectal cancer demonstrating complete response for more than two years to mFOLFOX6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; M | 2009 |
[A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
[A new method of short-term high volume (6 g of 5-FU in a week) intermittent hepatic arterial infusion using repeated transient catheter insertion].
Topics: Aged; Antimetabolites, Antineoplastic; Catheterization; Fluorouracil; Hepatic Artery; Humans; Infusi | 2009 |
[A case of advanced rectal cancer with severe liver dysfunction due to multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans; Infusion | 2009 |
[A case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Female; Fluorour | 2009 |
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
[Two case reports of metastatic liver carcinoma with the effective treatment of radiofrequency ablation and intraarterial chemotherapy].
Topics: Aged; Catheter Ablation; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Infu | 2009 |
[A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast | 2009 |
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A long-term survival case of hepatocellular carcinoma with lymph node metastasis on the posterior surface of the pancreas head and portal vein tumor thrombus successfully treated with hepatopancreatoduodenectomy and adjuvant interferon-alpha and 5-fluoro
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 2009 |
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents | 2010 |
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Ca | 2010 |
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2010 |
Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemothera | 2007 |
[A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Combin | 2010 |
Implantation of port-catheter system for hepatic arterial infusion chemotherapy with catheter tip fixation in a patient with celiac arterial obstruction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoma, Hepato | 2010 |
Establishment of a cisplatin-induced multidrug resistance cell line SK-Hep1/DDP.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Ass | 2010 |
[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2009 |
[A case of advanced ascending colon cancer, curatively resected after complete response in left supraclavicular and paraaortic lymph nodes and liver metastases to FOLFOX4 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonic Neoplasms; Combined Modality Therapy | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Cisplatin; | 2010 |
[Long-term response of liver metastases of breast cancer to capecitabine--case report].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycyt | 2010 |
[A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoembryonic Antigen | 2010 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2010 |
Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2010 |
Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Topics: Aneurysm; Angiogenesis Inhibitors; Angiomyolipoma; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2010 |
Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2010 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2011 |
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2010 |
[A case of recurrent breast cancer with life-threatening liver metastasis remarkably responding to classical CMF].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; F | 2010 |
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2010 |
Role of local liver therapy for hepatic metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Fluorouraci | 2009 |
Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Ca | 2010 |
FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2010 |
Steroids, cancer and vertebral fractures: a dreaded combination.
Topics: Adrenal Cortex Hormones; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2011 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deox | 2010 |
Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2010 |
Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2010 |
[Pathologically complete response of multiple liver metastases from rectal cancer treated with mFOLFOX6 plus bevacizumab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2010 |
Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2010 |
Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2010 |
In defense of hepatic arterial infusion for hepatic metastases of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2010 |
Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cause of Death; Cis | 2010 |
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Su | 2011 |
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2011 |
Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cell Line, Tumor; Chromatography, High Pressu | 2010 |
Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2011 |
Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Fluoroura | 2011 |
[A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colectomy; Colonic Neoplasms; Female; | 2010 |
[A case or resection of synchronous multiple liver metastases from rectal cancer after FOLFOX4 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2010 |
[A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma; Cell Migration Assays; Cell Transformation, Neopla | 2010 |
Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2010 |
[HAI chemotherapy for liver metastases of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2010 |
[Two cases of unstable angina in patients treated with bevacizumab].
Topics: Aged; Angina, Unstable; Angiogenesis Inhibitors; Angiography; Antibodies, Monoclonal; Antibodies, Mo | 2010 |
[A recurrence after surgery for colon cancer with metastases of the liver and periaortic lymph nodes, with CR achieved by using bevacizumab+mFOLFOX6].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog | 2010 |
Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2010 |
Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2010 |
CD13 is a therapeutic target in human liver cancer stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; CD13 Antige | 2010 |
Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2010 |
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistan | 2010 |
The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2011 |
Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2011 |
Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 2012 |
Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral | 2011 |
Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carbon Dioxide; Colon; Colorectal N | 2011 |
Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug | 2010 |
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Perirenal hematoma associated with bevacizumab treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutat | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; | 2010 |
Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Atractylodes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholan | 2010 |
Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Combi | 2011 |
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoradiotherapy; Duodenal Ulcer | 2011 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Susceptibility of Hep3B cells in different phases of cell cycle to tBid.
Topics: Antimetabolites, Antineoplastic; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Blotting, | 2011 |
Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Fluorouracil; H | 2010 |
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2011 |
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; DNA Primers; Drug Evaluation, Precl | 2010 |
Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
Topics: Adenoviridae; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bioma | 2011 |
[Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
[Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2010 |
Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2011 |
Chemoresistant hepatoblastoma in a patient with mosaic trisomy 18 treated with orthotopic liver transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Chromosomes, H | 2011 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2011 |
Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2010 |
Hepar lobatum carcinomatosum associated with metastatic rectal carcinoma: an unusual cause of liver dysmorphy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Liver; Liver Neoplasms; Male; | 2011 |
[A case of liver metastases from rectal cancer showed a complete response by FOLFIRI and bevacizumab chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F | 2011 |
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up | 2010 |
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
[Prehepatectomy chemotherapy using hepatic artery infusion plus systemic chemotherapy for liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2010 |
[An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
[Efficacy of short-term high volume (6 g of 5-FU in a week) hepatic arterial infusion for synchronous diffuse liver metastases of sigmoid colon cancer with over 40 thousand ng/mL of CEA of ascites].
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; Ascitic Fluid; Carcinoembryonic Antigen; Colon, Si | 2010 |
[A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
[A case of multiple liver metastases from nonfunctioning neuroendocrine pancreatic tumor curatively resected after successful intra-arterial chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Neuroendocrine; Combined Modality Therapy; Female | 2010 |
[Regional treatment of esophageal liver metastasis by intra-arterial low-dose 5-FU therapy].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Esophageal Neoplasms; Female; Fluorouracil | 2010 |
[A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Live | 2010 |
[A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
[A case of sigmoid colon cancer with synchronous multiple liver and lung metastases, who survived 25-month after combination of chemotherapy and metastasectomy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
[A case of lung metastasis from colon cancer controlled effectively by the stereotactic radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2010 |
[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, | 2010 |
[Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2010 |
[Two-stage hepatectomy combined with converting chemotherapy achieved a successful treatment for initially unresectable multiple bilobar colorectal liver metastases].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[Roles of hepatectomy for colorectal liver metastases with necrotic foci caused by prior anti-cancer therapies].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
[A long-term survival after hepatectomy combined with hepatic arterial infusion chemotherapy for hepatic metastasis of colon cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
[Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2010 |
[Idiopathic thrombocytopenic purpura during chemotherapy for liver metastasis of rectal cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[A case of rectal cancer with synchronous multiple liver metastases successfully treated with combined chemotherapy of modified FOLFOX6 and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[Long-term survival case after liver resection and postoperative hepatic arterial infusion for multiple liver metastases from rectal cancer].
Topics: Antimetabolites, Antineoplastic; Disease-Free Survival; Fluorouracil; Hepatectomy; Humans; Infusions | 2010 |
[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolizati | 2011 |
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antin | 2011 |
5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Capecitabine; Deoxycytidine; | 2011 |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2011 |
R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2011 |
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
The design and cytotoxic evaluation of some 1-aryl-3-isopropylamino-1-propanone hydrochlorides towards human Huh-7 hepatoma cells.
Topics: Acetone; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Crystallography, X-Ray; | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients.
Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
Antitumor effect of Croatian propolis as a consequence of diverse sex-related dihydropyrimidine dehydrogenase (DPD) protein expression.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (N | 2011 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Di | 2010 |
Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Fluorouracil; Hepatic Ar | 2012 |
[Effective cetuximab monotherapy for a case of recurrence rectal cancer after multiple previous chemotherapy treatment (FOLFOX, FOLFIRI)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[A case of synchronous multiple liver metastasis of sigmoid colon cancer with a pathological complete response to combination chemotherapy of 5-FU/LV and bevacizumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2012 |
Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis.
Topics: Adenocarcinoma; Animals; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Drug Resistan | 2011 |
Which treatment modality should we choose for advanced hepatocellular carcinoma?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2010 |
[Effect of bushen jianpi decoction and its disassemble recipes on tumor growth in mice with transplanted primary hepatic carcinoma].
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drugs, Chinese Herbal; Fluorouracil | 2011 |
Efficacy and safety of hepatic arterial infusion of fluorouracil with leucovorin as salvage treatment for refractory liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Protocols; Dise | 2011 |
Biodistribution and improved anticancer effect of NIK-siRNA in combination with 5-FU for hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2011 |
18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
Topics: Adult; Aged; Analysis of Variance; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease- | 2011 |
The influence of toxicity constraints in models of chemotherapeutic protocol escalation.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Cell Cycle; Colorectal Neoplasms; Drug Administrati | 2011 |
Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro.
Topics: Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Calcium; Carcinoma, Hepatoce | 2011 |
Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
Topics: Carcinoma, Hepatocellular; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Imm | 2011 |
Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brachytherapy; Chemotherapy, | 2011 |
Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines.
Topics: Antigens, CD; Antineoplastic Agents; Artemisinins; ATP Binding Cassette Transporter, Subfamily B; AT | 2011 |
Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice.
Topics: Adjuvants, Immunologic; Animals; Antigens, CD19; Antineoplastic Agents, Phytogenic; Boraginaceae; Ca | 2012 |
[A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Diss | 2011 |
Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2012 |
Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Female; F | 2012 |
COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocar | 2011 |
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2011 |
Reversal effect of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Chalcones; Chromatogra | 2011 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Type IV collagen as a tumour marker for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, | 2011 |
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[The inhibitory effect of RNA interference on STAT3 expression in liver cancer cell line SMMC7721].
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gene Knockdown Techni | 2011 |
Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci | 2011 |
Hepatocellular carcinoma HepG2 cell apoptosis and caspase-8 and Bcl-2 expression induced by injectable seed extract of Coix lacryma-jobi.
Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 8; Cell Separation; Coix | 2011 |
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACH
Topics: Adenocarcinoma; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA-Binding | 2012 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Dea | 2011 |
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecit | 2011 |
Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispla | 2011 |
Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, He | 2011 |
Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2011 |
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2011 |
Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2011 |
[A case of metastatic esophageal cancer - endoscopic resection of the primary site following systemic chemotherapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Endoscopy; Eso | 2011 |
FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Eighty-five-year-old patient with recurrent rectal cancer effectively treated with CapeOX chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Deo | 2011 |
Multidrug resistance reversal effect of DMC derived from buds of Cleistocalyx operculatus in human hepatocellular tumor xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3 | 2012 |
[End results of combined treatment in metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Chemot | 2011 |
[Pilot study of preoperative mFOLFOX6 chemotherapy for advanced rectal cancers which were difficult to ensure surgical margins].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Leu | 2011 |
Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; | 2011 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; | 2011 |
[A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens].
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Re | 2011 |
[Recurrent liver sigmoid cancer responding remarkably to neoadjuvant chemotherapy using bevacizumab/XELOX: report of a case].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Blotting, Western; Carcinoma, Hepatocellular; | 2012 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2012 |
A patient with a metastatic gastroenteropancreatic endocrine carcinoma causing hyperinsulinaemic hypoglycaemia and the carcinoid syndrome.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Fl | 2011 |
Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Enhancement of carboplatin- and quercetin-induced cell death by roscovitine is Akt dependent and p53 independent in hepatoma cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Carboplatin; Carcinoma, Hepatocellular; Caspase 3; C | 2011 |
mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dihydrouracil D | 2011 |
Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo.
Topics: Abietanes; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; bcl-2-Associ | 2012 |
The value of palliative gastrectomy in gastric cancer with distant metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2012 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2011 |
Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit Analy | 2012 |
[A successful treatment of conversion chemotherapy by mFOLFOX6 plus cetuximab for initially unresectable synchronous colorectal liver metastases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspas | 2011 |
Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dia | 2011 |
Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Drug Resistanc | 2012 |
Hepatic arterial infusion chemotherapy with a coaxial reservoir system using a non-braided spiral tip microcatheter.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Catheter | 2012 |
Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cytosine Deaminase; Endothelial Cel | 2012 |
Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; | 2012 |
Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line.
Topics: Adult; Aged; Annexin A3; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Re | 2012 |
[A case of breast cancer postoperative metastases to the liver obtained cCR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Cyclophosphamide; Epirubic | 2011 |
[A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2011 |
[Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
[Recurrance of disappearing colorectal liver metastases after mFOLFOX6 regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
[The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
[Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion o
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
[A case of colonic neuroendocrine carcinoma with severe liver dysfunction by multiple liver metastases successfully treated with hepatic arterial infusion].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Neuroendocrine; Colonic Neoplasms; Combined Modality The | 2011 |
[Repeated resections for originally unresectable liver metastasis from colorectal cancer after multiagent chemotherapy].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
[A case of no recurrence over 10 years in advanced rectal cancer with bleeding treated by urgent arterial embolization followed by synchronous liver resection and extended lymph node dissection].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Combined Modality Therapy; Fe | 2011 |
[A case of encephalopathy that was suspected to be caused by chemotherapy for colon cancer].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2011 |
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2011 |
Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2012 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distributi | 2012 |
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes.
Topics: Carcinoma; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluo | 2012 |
Analysis of local control in patients receiving IMRT for resected pancreatic cancers.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.
Topics: Adult; Aged; Analysis of Variance; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycyt | 2012 |
Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Adhes | 2012 |
Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; C | 2012 |
Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2012 |
[Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biop | 2012 |
Irreversible electroporation for focal ablation at the porta hepatis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contrast Media; Electropo | 2012 |
Effect of neoadjuvant chemotherapy in hepatic steatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatty Liver; Female; Fluorouracil; Huma | 2012 |
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Topics: Acetone; Amines; Antineoplastic Agents; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Dela | 2012 |
Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbo | 2012 |
Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin | 2012 |
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose F | 2012 |
[A case of resected rectal cancer with hepatic node and multiple liver metastases effectively treated by preoperative modified FOLFOX6 and sLV5FU2 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Human | 2012 |
[Chemoembolization of liver metastasis].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolizati | 2012 |
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2012 |
A case of type 2 diabetes and metastatic liver cancer exhibiting hypercholesterolemia with abnormal lipoproteins.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure | 2012 |
Safety and optimal management of hepatic arterial infusion chemotherapy after pancreatectomy for pancreatobiliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Biliary Tract Neoplasms; Chi-Squar | 2012 |
Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cel | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; | 2012 |
Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
Topics: Administration, Metronomic; Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepat | 2012 |
Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Fluorouraci | 2012 |
Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 | 2012 |
[Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2012 |
Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization | 2012 |
Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Prot | 2013 |
Inadvertent severe acute kidney injury and oxaliplatin.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorecta | 2013 |
Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Fluorouracil; Hepatic Arter | 2012 |
[A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluorour | 2012 |
Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2013 |
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma | 2012 |
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Mon | 2012 |
Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Colo | 2012 |
Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Proc | 2012 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2013 |
Onset of segmental colitis associated with diverticulosis after treatment with bevacizumab for metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2012 |
A complex oncosurgical approach to increasing the resectability of colorectal cancer metastases - a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Emboliza | 2014 |
Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2012 |
Prospective impact of 5-FU in the induction of endoplasmic reticulum stress, modulation of GRP78 expression and autophagy in Sk-Hep1 cells.
Topics: Apoptosis; Autophagy; Calcium; Carcinoma, Hepatocellular; Caspase 12; Cell Line, Tumor; Endoplasmic | 2012 |
Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; Enzyme Inhibi | 2012 |
Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence | 2012 |
[A case of advanced primary colorectal carcinoma accompanied by liver metastasis in which ileus developed due to marked fibrosis with cicatricial formation in primary colorectal cancer treated by chemotherapy including bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2012 |
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Transformat | 2012 |
[A case of response to panitumumab as third-line chemotherapy for multiple liver metastases and portal venal tumor embolus of rectal cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Embol | 2012 |
[A case of pathologically by complete response in advanced sigmoid colon cancer with multiple metastases of lung and Liver, left hydronephrosis after chemotherapy including bevacizumab/FOLFOX6].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fema | 2012 |
Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Capecitabine; Carcinoma, Hepatocellular; Cell Death; Cell Prolifer | 2012 |
Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2012 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemoth | 2013 |
Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2012 |
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2012 |
A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2012 |
New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.
Topics: Antineoplastic Agents; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorou | 2012 |
Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; De | 2013 |
[Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Reversal effect of melanoma differentiation associated gene-7/interleukin-24 on multidrug resistance in human hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Doxorubicin; Drug Resistance, Mul | 2012 |
[A case of reversible posterior leukoencephalopathy syndrome(RPLS)induced by modified FOLFOX6].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Fluorouracil; Humans; | 2012 |
A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
[Therapy traces on hands and feet in a patient with colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnosis, Di | 2012 |
In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal | 2012 |
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma | 2012 |
Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2013 |
Dual-phase CT angiography through the port-catheter system for hepatic arterial infusion chemotherapy using multislice CT: assessment of system dysfunction and impact on predicting clinical problems.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatoc | 2012 |
Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Lin | 2012 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, | 2012 |
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2012 |
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2012 |
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer.
Topics: Activities of Daily Living; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineopla | 2012 |
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2013 |
[Multimodality therapy containing hepatic arterial infusion chemotherapy for liver metastasis of esophageal cancer-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Combined Modality Therap | 2012 |
[A case of intussusception due to sigmoid colon cancer during mFOLFOX6 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Intussusception; Leuco | 2012 |
[A case of unresectable multiple hepatic metastases from ascending colon cancer successfully treated with panitumumab and FOLFIRI(5-FU/LV/irinotecan)therapy].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic | 2012 |
Pathological complete response and two-year disease-free survival in a primary gastric choriocarcinoma patient with advanced liver metastases treated with germ cell tumor-based chemotherapy: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Choriocarcinoma, Non-gestat | 2012 |
Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Car | 2012 |
5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatoce | 2012 |
Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases.
Topics: Adult; Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2013 |
Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 2012 |
Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combi | 2013 |
TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2013 |
Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Astragalus Plant; ATP Binding Ca | 2012 |
How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adj | 2012 |
[Evaluation of the efficacy and prognostic factors for colorectal liver metastases treated with transcatheter arterial chemoembolization].
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; | 2012 |
Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2012 |
Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Asso | 2012 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers | 2012 |
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
[A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2013 |
Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Hepatocellular; Cell | 2013 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Hepatocellular carcinoma and chemotherapy: the role of p53.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, | 2012 |
Cervical extravasation of bevacizumab.
Topics: Adenocarcinoma; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antin | 2013 |
Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2013 |
[Two cases of long-term survival of metastatic colorectal cancer following treatment with polysaccharide K and mFOLFOX6 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2012 |
[Two long-term survival cases of unresectable intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy and radiation therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2012 |
[Predictive value of Köhne's index on the efficacy of FOLFIRI regimen in the treatment of unresectable liver metastatsis of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
[Two cases of interstitial pneumonia caused by cetuximab plus mFOLFOX6 therapy in metastatic colorectal cancer patients].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
[Liver damage detected after a hepatectomy for liver metastasis after 12 courses of mFOLFOX6 therapy as an adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemical and Drug Induced Liver Injury; C | 2012 |
[A case of a colon cancer patient with liver metastasis subjected to hepatectomy after achieving radiographic complete response with preoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Hepat | 2012 |
[A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
[A long-term survivor of colorectal cancer associated with multiple liver metastases and peritoneal carcinomatosis treated through a multidisciplinary approach].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Human | 2012 |
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemo | 2012 |
RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2013 |
Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic | 2013 |
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcin | 2013 |
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiothe | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2013 |
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2012 |
Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 2002 |
Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hepat | 1996 |
Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2002 |
[Preliminary clinical evaluation of low-dose cisplatin and continuous infusion of 5-FU (LFP) chemotherapy after weekly high-dose 5-FU therapy for the treatment of liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dose-Response | 2002 |
Mechanism of apoptotic effects induced by 5-fluorouracil on human liver carcinoma Bel7402 cell line.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Arginine; Fluorouracil; Humans; Immunohistochemistry; Li | 2002 |
Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2002 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combine | 2002 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
[A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 2002 |
[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2002 |
[A case of gastric cancer with multiple liver metastases responding to combined hepatic arterial and aortic infusion chemotherapy with cisplatinum, 5-fluorouracil, and levofolinate calcium].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 2002 |
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2002 |
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 2002 |
Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Thera | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres | 2002 |
Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).
Topics: Buthionine Sulfoximine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fluorescein; Fluoroura | 2002 |
Superior venocaval obstruction secondary to central venous catheter-related thromboses in two patients with metastatic colorectal carcinoma receiving weekly 5-flurouracil. Should adjusted-dose warfarin be used as thromboprophylaxis?
Topics: Aged; Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Colorectal Neoplasms; | 2002 |
Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Sq | 2001 |
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorourac | 2001 |
[A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Col | 2002 |
[A case of postoperative hepatic metastasis from gastric cancer responding to hepatic arterial infusion chemotherapy of paclitaxel].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dru | 2002 |
[A case report of intra-hepatic arterial infusion of mitomycin C with degradable starch microspheres for liver metastases of sigmoid colon carcinoma].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biodegradation, Enviro | 2002 |
[Evaluation of intra-arterial infusion chemotherapy for liver metastasis from gastric cancer FEM--combination therapy of 5 FU, Epirubicin and MMC].
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Hepatectomy; Humans; Infus | 2002 |
[Effect of hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin | 2002 |
[Resection made possible following hepatic arterial infusion in 2 cases of hepatic metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Hepat | 2002 |
[5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Hepatectomy and intraarterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, | 2002 |
[Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2002 |
[Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Female; F | 2002 |
[A case of multiple liver metastases from breast cancer in which we confirmed disappearance of cancer cells after hepatic resection following hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Infusions, Intra | 2002 |
[Hepatic arterial infusion of high-dose 5-FU to liver metastases--case reports of 6 patients with abnormal laboratory data on liver function].
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intr | 2002 |
[A case of esophageal cancer successfully treated by chemoradiotherapy after resection for multiple liver metastasis of sigmoid colon cancer].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Infus | 2002 |
[A case of postoperative multiple hepatic metastasis from gastric cancer successfully treated by percutaneous microwave coagulation therapy and hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi | 2002 |
[A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes].
Topics: Carcinoid Tumor; Combined Modality Therapy; Doxorubicin; Electrocoagulation; Female; Fluorouracil; H | 2002 |
[A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
[Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combina | 2002 |
[Pancreatic islet cell carcinoma with multiple hepatic metastases successfully treated with a streptozocin/5-FU regimen--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Drug Administration Schedule; | 2002 |
[Rules to carry out hepatic arterial infusion chemotherapy at home for patients with liver metastasis of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepat | 2002 |
Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2001 |
Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect | 2003 |
Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Catheterization; Colorectal Neoplasms; Disease-Free Survival; Femal | 2003 |
Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; | 2003 |
Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; F | 2002 |
Hepatic artery infusion for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2003 |
Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Cell Survival; Colorectal Neoplasms; End | 2003 |
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Drug Interac | 2003 |
[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2003 |
Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Flu | 2003 |
Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2003 |
Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gas | 2003 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics.
Topics: Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver; Liver Neoplasms; Male; Middle | 2003 |
Resection of hepatocellular carcinoma with tumor thrombus of the portal vein after neoadjuvant regional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2002 |
[Clinical efficiency of chemotherapy in primary liver cancer depending on the state of blood coagulation system].
Topics: Adolescent; Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagu | 2002 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2003 |
A case of aggressive neuroendocrine carcinoma of the stomach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
[A case of advanced hepatocelluar carcinoma achieving a complete response following the hepatic arterial infusion chemotherapy and subsequent lipiodolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2003 |
[Clinical outcome of intra-hepatic arterial infusion therapy for multiple liver metastases from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 2003 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; C | 2003 |
Physical training during intrahepatic chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Exercise Therapy; Fluorouracil; Forced Expiratory V | 2003 |
High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
Topics: Animals; Antineoplastic Agents; Arabinonucleosides; Cell Division; Colonic Neoplasms; Cytosine; Deox | 2003 |
5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2003 |
Hepatic artery chemotherapy and colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Floxuridine; Fluor | 2003 |
Hepatic artery chemotherapy and colorectal liver mestastases.
Topics: Antineoplastic Agents; Catheters, Indwelling; Colorectal Neoplasms; Controlled Clinical Trials as To | 2003 |
Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Res | 2003 |
[Role of caspase-8 and caspase-3 in hepatoma cells apoptosis induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspase | 2003 |
S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colo | 2003 |
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2003 |
Is liver disease an octreotide side effect?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Drug | 2003 |
[First-line metastatic cancer of the colon].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio | 2003 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Resistance, | 2003 |
[Modeling 5-FU clearance during a chronomodulated infusion].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chronothe | 2003 |
Trace elements improve survival of DTIC-treated mice with overt liver metastases of Lewis lung carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carcinoma, Lewis Lung; Dacarbazin | 2003 |
Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Moda | 2003 |
Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver.
Topics: Antimetabolites, Antineoplastic; beta-Alanine; Fluorine Radioisotopes; Fluorouracil; Humans; Liver; | 2003 |
[A case report of complete remission of liver metastases from colorectal cancer treated with continuous hepatic arterial infusion].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 2003 |
[Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cyclo | 2003 |
Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinosarcoma; Delayed-Action Preparations; Fluorouracil; | 2003 |
Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; F | 2003 |
[Regional arterial chemoembolisation and chemoimmunoembolisation in combined treatment of colon cancer with hepatic metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Doxoru | 2003 |
[A clinical study of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for liver metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluor | 2003 |
[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; | 2003 |
[A case of effective weekly paclitaxel administration for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 2003 |
A case report of primary hepatic squamous cell carcinoma that remarkably responded to low dose arterial injection of anti-cancer drugs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2003 |
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Floxuridine; Fluorouraci | 2003 |
Arterial infusion chemotherapy for the patient of unresectable pancreatic carcinoma with multiple liver metastases: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fatal Outcome; Fluo | 2003 |
Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Hepatocellular; | 2003 |
Fluorinated pyrimidines in treatment of breast cancer patients with liver metastases.
Topics: Breast Neoplasms; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Pyrimidines | 1963 |
TREATMENT OF DISSEMINATED CARCINOID TUMORS INCLUDING HEPATIC-ARTERY CATHETERIZATION.
Topics: Antineoplastic Agents; Carcinoid Tumor; Catheterization; Fluorouracil; Hepatic Artery; Humans; Liver | 1963 |
5-FLUOROURACIL TREATMENT OF LIVER METASTASES BY CONTINUOUS HEPATIC ARTERY INFUSION VIA COURNAND CATHETER: RESULTS AND SUITABILITY FOR INTENSIVE POSTSURGICAL ADJUVANT CHEMOTHERAPY.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Gast | 1963 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
GROWTH INHIBITION OF A SPECTRUM OF TRANSPLANTED MOUSE TUMORS BY COMBINATIONS OF INHIBITORS OF NUCLEIC ACID BIOSYNTHESIS AND ALKYLATING AGENTS.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tumor; | 1963 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
HEPATIC CHEMOTHERAPY BY ARTERIAL AND VENOUS INFUSION.
Topics: Catheterization; Clinical Enzyme Tests; Dogs; Fluorouracil; Hepatic Artery; Hepatic Veins; Infusions | 1964 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
CHEMOTHERAPEUTIC STUDIES WITH OSTEOGENIC SARCOMA HE10734.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Fl | 1964 |
ACUTE GASTRITIS RESULTING FROM REGIONAL INFUSION OF AN ANTIMETABOLITE.
Topics: Adenocarcinoma; Angiography; Antimetabolites; Chemotherapy, Cancer, Regional Perfusion; Diagnosis, D | 1963 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; L | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci | 1964 |
[FRICTION RUB SOUNDS IN THE ABDOMEN].
Topics: Abdomen; Auscultation; Blood Protein Electrophoresis; Cyclophosphamide; Fluorouracil; Friction; Geri | 1964 |
HEPATIC OUTFLOW OCCLUSION DURING HEPATIC ARTERY INFUSION WITH CHEMOTHERAPEUTIC AGENTS.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Carotid Arteries; Dogs; Fluorouracil; Hepatic Artery | 1964 |
SELECTIVE CONCENTRATION OF ANTICANCER DRUGS IN THE LIVER: HEPATIC-ARTERY INFUSION AND INDUCED HEPATIC OUTFLOW BLOCK.
Topics: Animals; Antineoplastic Agents; Arteries; Biomedical Research; Chemotherapy, Cancer, Regional Perfus | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2003 |
Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Drug Adminis | 2003 |
Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterization, Pe | 2003 |
Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2003 |
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Cyclooxyg | 2003 |
[Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorectal Neoplasms; D | 2003 |
Caspase-8 in apoptosis of hepatoma cell induced by 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Caspase 9; Caspase | 2003 |
[Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2003 |
[Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplati | 2003 |
[Postoperative adjuvant intraarterial chemotherapy of combined cisplatin and 5-FU for advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2003 |
[Evaluation of intraarterial infusion chemotherapy for liver metastasis from gastric cancer FEM: combination therapy of 5-FU, epirubicin and MMC].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Female; Fl | 2003 |
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2003 |
[Evaluation of arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 2003 |
[Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; | 2003 |
[Relationship between effectiveness of hepatic artery injection chemotherapy and serum VEGF].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Chemoembo | 2003 |
[Efficacy of circadian chronotherapy via hepatic arterial infusion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Female; F | 2003 |
[Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2003 |
[A case of successful treatment of advanced hepatocellular carcinoma with tumor thrombi in the major portal branches and inferior vena cava with combined intraarterial 5-fluorouracil, adriamycin and cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi | 2003 |
[A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2003 |
[A case of liver and lung metastases of rectal cancer responding well to 5-FU hepato-arterial infusion (HAI) with combined use of oral UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2003 |
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2003 |
[A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Admini | 2003 |
[Pancytopenia and ARDS with high dose hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Cisplatin; Drug Combinations; Female; Fluorouracil; Gastrecto | 2003 |
[A case of spinal infarction related to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec | 2003 |
[A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 2003 |
Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; DNA, Complementary; Fas | 2003 |
In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl | 2003 |
Complete response of brain metastases originating in breast cancer to capecitabine therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Drug Administration | 2003 |
[A case of multiple hepatic metastases from colorectal cancer effectively treated by arterial infusion therapy with Leucovorin/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Drug Administration Schedule; Fluoro | 2003 |
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line, Tumor; Cell Movem | 2004 |
Rectal adenocarcinoma with germ-cell differentiation: report of a case.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 2003 |
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Fluo | 2003 |
The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Cisplatin; | 2004 |
[Synergism of an antisense oligodeoxynucleotides targeted to hTERT in combination with chemotherapeutic drugs on inhibiting the proliferation of HepG2 cells].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA-Binding Proteins; Doxorubicin; Drug Synergis | 2003 |
Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Multiple; Drug Resista | 2004 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2003 |
[A case of parotid carcinoma with hepatic metastasis that responded remarkably to combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2003 |
[A case of advanced gastric cancer with multiple liver metastases responding completely to hepatic arterial infusion and systemic chemotherapies].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2003 |
[Application of arsenic trioxide in comprehensive therapy of liver carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma | 2003 |
Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Collagen; Colonic Neop | 2004 |
[Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2004 |
18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorodeoxyglucos | 2004 |
First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2004 |
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
Topics: Chromosomes, Human, Pair 18; Colorectal Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Electro | 2004 |
Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colorectal Neop | 2004 |
[Hepatic arterial infusion therapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Hepatic Artery; Humans; In | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Aorta, Thoracic; Colonic Neoplasms; Deoxyr | 2004 |
19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neopl | 2004 |
An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line | 2003 |
[A case of gastric cancer with a synchronous hepatic metastasis responding to postoperative oral administration of UFT and intermittent intrahepatic arterial chemotherapy of 5-FU].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dru | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Coloni | 2004 |
Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-R | 2004 |
Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, | 2004 |
A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Epirubicin; Femal | 2004 |
Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemoembolization, Therapeutic; Colonic | 2004 |
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; En | 2004 |
[Colorectal cancer: what should be the management of primary tumour?].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon; Colonoscopy; Colorectal Neoplasms; D | 2004 |
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apop | 2004 |
A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex).
Topics: Adenocarcinoma; Aged; Alloys; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2004 |
[Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2004 |
Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cell Division; Cell Line, Tumor; | 2004 |
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2004 |
Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2004 |
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colo | 2004 |
Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Doxorubicin; Esophageal Neoplasms; Fluorourac | 2004 |
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Desen | 2004 |
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeuti | 2004 |
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Profiling; H | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular | 2004 |
Liver insufficiency due to breast cancer metastases--fast biological response with capecitabine.
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Failure; Li | 2004 |
A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma.
Topics: Alkaline Phosphatase; Antimetabolites, Antineoplastic; Bilirubin; Carcinoma, Hepatocellular; Cerulop | 2004 |
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
[Successful treatment of 5-FU intraarterial infusion on the third postoperative day for a patient with multiple liver metastases from colon cancer and high risk of liver failure].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Benzimidazoles; Colectomy; Colonic Neoplasms; | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2004 |
Hepatic artery infusion chemotherapy for metastatic colorectal cancer to the liver at the lahey clinic: comparison between two methods of treatment, surgical versus percutaneous catheter placement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachial Artery; Catheterization, Peripheral; Colorect | 2004 |
Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colon; Colorectal Neoplasms; Enzyme-Linked Immuno | 2004 |
Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2004 |
Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, I | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Sig | 2004 |
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxyc | 2004 |
Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2004 |
Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Topics: Administration, Oral; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Kidney | 2004 |
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2004 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colon, Sigm | 2004 |
[Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2004 |
Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fatal Outcome; Fluorourac | 2004 |
Effect of resveratrol and in combination with 5-FU on murine liver cancer.
Topics: Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell C | 2004 |
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2004 |
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwe | 2004 |
Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2004 |
Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; D | 2004 |
Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dr | 2004 |
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq | 2004 |
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dihydrouracil De | 2004 |
[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration | 2004 |
[A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2004 |
5-fluorouracil and hydroxyurea enhance adenovirus-mediated transgene expression in colon and hepatocellular carcinoma cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; beta-Galactosidase; Carcinoma, | 2005 |
[A case of the 5-year survivor of ascending colon cancer associated with synchronous multiple liver metastasis and peritoneal dissemination successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colonic Neoplasms; Embolization, Therapeutic | 2004 |
[Two cases of resection of synchronous bilobar multiple liver metastases from colorectal cancer after hepatic arterial infusion chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infu | 2004 |
[Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
[Two case reports of complete regression of liver metastases from colorectal cancer after locoregional immunochemotherapy].
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorect | 2004 |
[Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion].
Topics: Administration, Oral; Adult; Aged; Agmatine; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2004 |
[A case report of the 8 year survivor--unresectable liver metastases from advanced gastric cancer (Stage IV) were completely responsive, after 4 years from a total sequential gastrectomy, combining docetaxel treatment to regress the recurrence].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 2004 |
[Three successful case reports of advanced gastric cancer with chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2004 |
[Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2004 |
[Evaluation of hepatic artery infusion chemotherapy for liver metastasis of colorectal cancer using a side-hole catheter].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catheterization; Catheterization, Peripheral; | 2004 |
[A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; | 2004 |
[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2004 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after curative hepatectomy for metastatic colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Art | 2004 |
[A case of postoperative pelvic metastasis and multiple liver metastases of the rectal cancer successfully treated by arterial infusion therapy with 5-FU/leucovorin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans; Iliac Artery; | 2004 |
[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration | 2004 |
[Cases of postoperative hepatic metastasis from gastric cancer in which hepatic arterial infusion chemotherapy with 5-FU, adriamycin and cisplatin was performed after TS-1 chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fluorouracil; Hepatic | 2004 |
[A case of unresectable multiple liver metastases from colon cancer successfully treated by hepatic arterial infusion chemotherapy and systemic immunotherapy (IFNANK) followed by hepatic resection].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2004 |
[The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient].
Topics: Catheter Ablation; Colorectal Neoplasms; Fluorouracil; Hepatitis B; Humans; Infusions, Intra-Arteria | 2004 |
[A case report--Efficacy of combination therapy to unresectable advanced gall bladder carcinoma--palliative operation, hepatic arterial infusion therapy, and radiation therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati | 2004 |
[The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2004 |
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2004 |
5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Huma | 2004 |
Adjuvant hepatic arterial infusion after curative resection of colorectal liver metastases using removable intra-arterial catheters with shape-memory alloy.
Topics: Adult; Aged; Alloys; Antimetabolites, Antineoplastic; Catheters, Indwelling; Chemotherapy, Adjuvant; | 2004 |
[Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2004 |
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contraindication | 2004 |
Endoscopic stenting of the common bile duct allows successful treatment of a breast cancer patient with excessive liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Common | 2004 |
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2004 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidin | 2004 |
[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2004 |
[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2004 |
[Hepatic arterial infusion chemotherapy (HAIC)--hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response | 2004 |
[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Collagen; Culture Med | 2004 |
Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, | 2004 |
Adjuvant portal vein cytotoxic infusion for curatively resected colon cancer--is it obsolete?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 2005 |
[The present and future of home care chemotherapy for patients with advanced and recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2004 |
Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; Humans; Idoxuridine; Iod | 2005 |
A huge primary peritoneal papillary adenocarcinoma which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor: report of a case.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Cisplatin; Diagnosis, Differential; Female; | 2005 |
[Two cases of gastric cancer with multiple liver metastases responding to TS-1 with hepatic arterial infusion of CDDP following low-dose 5-FU and CDDP chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relat | 2005 |
Estimation of the time of pulmonary metastasis in colorectal cancer patients with isolated synchronous liver metastasis.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep | 2005 |
Concurrent proton beam radiotherapy and systemic chemotherapy for the metastatic liver tumor of gastric carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2005 |
Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2005 |
Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2005 |
Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carcinoma, Hepatocellular; | 2005 |
Hepatic arterial infusion after liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dex | 2005 |
[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Epirubicin; | 2005 |
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2004 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, | 2005 |
[A case of liver metastases from cecal cancer successfully treated with fluorouracil and folinic acid (UFT/LV)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy, | 2005 |
[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2005 |
[A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined | 2005 |
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; | 2005 |
CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.
Topics: Animals; Carcinoma, Hepatocellular; Combined Modality Therapy; CpG Islands; Fluorouracil; Genetic Th | 2005 |
[Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2005 |
Intraarterial chemotherapy: another choice for unresectable advanced hepatocellular carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2004 |
Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 2004 |
[Three cases of multiple colorectal liver metastases responding to hepatic arterial infusion chemotherapy undergoing liver resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colon, Sigmoid; Colonic Neoplasms; | 2005 |
[A case of bilateral multiple liver metastases with distant lymph node metastases due to rectal cancer successfully treated with hepatic arterial infusion (HAI) of levofolinate (l-LV)/5-fluorouracil (5-FU) and radiotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2005 |
Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Catheters, Indwe | 2005 |
Images of interest. Hepatobiliary and pancreatic: Tumor thrombi in esophageal varices.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Endoscopy; Eso | 2005 |
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle Proteins; Colorectal | 2005 |
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colo | 2005 |
[Systemic therapy for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluo | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA | 2005 |
[A case of hepatocellular carcinoma with tumor thrombi in the first branch of the portal vein and hepatic vein trunks treated by transcatheter hepatic arterial chemoembolization and hepatic arterial infusion chemotherapy--two years and six months follow-u
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane Permeability; Cyt | 2005 |
5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorour | 2005 |
Prophylactic hepatic irradiation following curative resection of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2005 |
Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2005 |
Slow evolution of liver metastasis from colon cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Colectomy; Colorectal Neoplasms; Disease-Free Survival; | 2005 |
Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells: a comparative study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocell | 2005 |
Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Back Pa | 2005 |
Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2005 |
Rectal cancer clinical practice guidelines in oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Live | 2005 |
[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
[Combined chemotherapy with oral leucovorin (LV) + tegafur/uracil (UFT) and hepatic arterial infusion (HAI) therapy for liver metastasis of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2005 |
[A case of cerebral infarction caused by disseminated intravascular coagulation during hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebral Infarction; Colorectal Neoplasms; Dis | 2005 |
Long-term complete remission of metastatic gastric cancer after weekly docetaxel, 24 h infusion of high-dose 5-FU/leucovorin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Digestive System Surgical Procedures; Doc | 2005 |
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Prog | 2005 |
[Transcatheter hepatic arterial chemoembolization on recurrent hepatocellular carcinoma after resection].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2005 |
[A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Deoxycyti | 2005 |
[A case of hepatic metastases of ampullary carcinoma which completely responded to intrahepatic infusion of 5-FU with low-dose l-leucovorin].
Topics: Aged; Ampulla of Vater; Duodenal Neoplasms; Duodenum; Fluorouracil; Humans; Infusions, Intra-Arteria | 2005 |
Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2005 |
5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Hepatocel | 2005 |
Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha.
Topics: Aged; Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Co | 2005 |
[A case of colon cancer with liver and lung metastases-efficacy of CPT-11/5-FU/l-LV (IFL) as part of ambulatory treatment].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Drug Admin | 2005 |
Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Re | 2006 |
[Case report--postoperative continuous intraarterial infusion of small doses of 5-FU successfully controlled residual tumor and liver metastasis of stage IV gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Combi | 2005 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bac | 2003 |
Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2005 |
[A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cecal | 2005 |
[A clinical study of hepatic arterial infusion chemotherapy with low-dose CDDP and 5-FU for liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta | 2005 |
[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response | 2005 |
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellul | 2006 |
Perfusion chemotherapy for colorectal liver metastases: a randomized study comparing FUDR against 5-FU/BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neoplasms; Floxuridine; Fluor | 1989 |
Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Diges | 2005 |
[Radiofrequency ablation (RFA) in colorectal cancer with hepatic metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasm | 2005 |
[Chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2005 |
[A case report of hepatocellular carcinoma (Vp4)--an attempt to reduce residual tumor thrombus using combination therapy (hepatic arterial infusion, hepatic arterial embolization and radiation)].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluorouracil; | 2005 |
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined | 2005 |
[Hepatic arterial infusion (HAI) chemotherapy achieved a complete response (CR) for multiple liver metastases of colorectal cancer--two case reports].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2005 |
[The hepatic artery injection chemotherapy and prostaglandin E1 administration for hepatocellular carcinoma invading the biliary tract with jaundice].
Topics: Aged; Alprostadil; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
[Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopl | 2005 |
[A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2005 |
Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy, Needle; Carcinoma, Squamous | 2005 |
[Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma].
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2005 |
Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2006 |
5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Topics: Aged; Antimetabolites, Antineoplastic; beta-Alanine; Cardiovascular Diseases; Colonic Neoplasms; Dru | 2005 |
Unresectable hepatic colorectal metastases: need for new surgical strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2006 |
Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastase
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cryotherapy; Female; Fluorouracil; Foll | 2006 |
[Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 2006 |
[A case of successful treatment by low-dose 5-fluorouracil and cisplatin for liver metastases of esophageal adenosquamous carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Dose-Response R | 2006 |
Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Fluorouracil; Genetic Vector | 2006 |
[Investigation of bile duct injury after transcatheter arterial chemoembolization].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Carcinom | 2005 |
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
Topics: Acetates; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; | 2006 |
Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Cytokines; Dihydrour | 2006 |
[Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarr | 2006 |
[A case of postoperative liver metastasis from bile duct carcinoma responding to transarterial chemoembolization].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoembo | 2006 |
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycy | 2006 |
Acute coronary syndrome induced by oral capecitabine.
Topics: Acute Disease; Administration, Oral; Adult; Angina, Unstable; Antimetabolites, Antineoplastic; Bone | 2006 |
Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colorec | 2006 |
[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer].
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Therapy, Combination; | 2006 |
[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2006 |
5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis.
Topics: Aged; Aged, 80 and over; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fl | 2006 |
Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2006 |
Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothe | 2006 |
Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer.
Topics: Antineoplastic Agents; Chemoembolization, Therapeutic; Cisplatin; Female; Fluorouracil; Humans; Iodi | 2006 |
Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreat | 2006 |
Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capec | 2006 |
A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Comb | 2006 |
Intraventricular metastases from rectal-sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiac Tamponad | 2006 |
[A case of hepatic metastases of sigmoid colon cancer which completely responded to systemic l-leucovorin/5-FU therapy and oral LV/UFT combination therapy].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2006 |
[Treatment efficacy of surgical management for liver metastasis from colorectal cancer--a report of 198 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2006 |
[Establishment of a multidrug-resistant cell line BEL-7402/5-FU of human hepatocellular carcinoma and its biological characteristics].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Do | 2006 |
Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemother | 2006 |
Neoadjuvant therapy with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
[Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2006 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capeci | 2006 |
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
Topics: Acetyltransferases; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Wes | 2006 |
[Blood supply of pulmonary metastases and its clinical significance].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2006 |
Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Hepa | 2006 |
Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2006 |
[A case of gastric endocrine cell carcinoma with liver metastasis showing rapid growth during pregnancy and marked reduction by systemic chemotherapy after delivery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Delivery, Obstetric; Dr | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2006 |
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Che | 2006 |
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; | 2006 |
Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Capecit | 2006 |
[Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimet | 2006 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2006 |
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardi | 2006 |
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
Topics: Adult; Aged; Colorectal Neoplasms; Contrast Media; Female; Fluorouracil; Gadolinium DTPA; Humans; Im | 2007 |
Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cas | 2006 |
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
[A case of effective multidisciplinary treatment with hepatic resection for synchronous multiple liver metastases from rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubic | 2006 |
[Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemoth
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2006 |
Bcl-XL small interfering RNA enhances sensitivity of Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and hydroxycamptothecin.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; bcl-X Protein; Camptothecin; Car | 2006 |
Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Genotype; Hepati | 2006 |
Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Topics: Antibodies; Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; CASP8 and FA | 2007 |
alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand.
Topics: alpha-Fetoproteins; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; C | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies | 2007 |
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2006 |
Benefits and risks of neoadjuvant therapy for liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Processes; Ce | 2006 |
Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Ce | 2006 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
[Partial response of liver metastasis from colon cancer following intermittent oral administration of TS-1 after intra-hepatic arterial single injection of CDDP, doxorubicin and 5-FU].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2006 |
Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; | 2006 |
FDG-PET in colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinic | 2006 |
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St | 2006 |
[Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; D | 2006 |
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC recovery by joint administration of 5-FU and paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bo | 2006 |
[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2006 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2006 |
[Management and prognosis in stage IV gestational trophoblastic neoplasia patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Fema | 2006 |
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Combined | 2007 |
Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 2006 |
[A case of an elderly patient having advanced hepatocellular carcinoma with tumor thrombus in the inferior vena cava treated with chemo-radio-therapy--intraarterial infusion of weekly high dose 5-FU (WHF)].
Topics: Aged, 80 and over; Carcinoma, Hepatocellular; Combined Modality Therapy; Fluorouracil; Humans; Infus | 2006 |
[A long-term survival case of liver and mediastinal LN metastases from colon cancer treated with intensive multimodal therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2006 |
[A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
Topics: Adenocarcinoma; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Fluorouracil; Hepatectomy; Human | 2006 |
[Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2006 |
[Hepatic arterial infusion of low-dose leucovorin/5-FU chemotherapy for unresectable hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2006 |
[The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic | 2006 |
[Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatectomy; Human | 2006 |
A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ant | 2006 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2006 |
[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, | 2006 |
[A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].
Topics: Aged; Camptothecin; Carcinoma; Colectomy; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Art | 2006 |
[A case of colon cancer liver metastases treated by combined therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Colon, Si | 2006 |
[A case report of successful local control with chemoradiation for unresectable rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; M | 2006 |
Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Fluor | 2006 |
[Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2007 |
[A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispl | 2007 |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neopl | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2007 |
Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU.
Topics: Adenoviridae; Adoptive Transfer; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Carcinoma, H | 2007 |
A successful treatment for metastatic liver tumors from endocrine carcinoma of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endocrine | 2007 |
Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters.
Topics: Aged; Angiography; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Car | 2007 |
[A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluoroura | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitab | 2008 |
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Hepatectomy | 2007 |
Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor | 2007 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplast | 2007 |
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor | 2007 |
[A case report of a patient with advanced rectal cancer who was administered chemotherapy in collaboration with a clinical pathway and visiting nursing care].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Community Health Nurs | 2006 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distribution; Color | 2007 |
[Anti-tumor effect of interferon for hepatocellular carcinoma-from the clinical consideration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2007 |
The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Panitumumab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 2007 |
Liver resection after FOLFOX with bevacizumab.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2007 |
[Comparisons of standard treatments for colorectal cancer between Japan and Western Countries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2007 |
[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2007 |
Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas.
Topics: Alternative Splicing; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, He | 2007 |
Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dose-Response Relat | 2007 |
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2007 |
[A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2007 |
[Long survival of a colon cancer case with multiple liver metastases cured by multidisciplinary therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cisplatin; Co | 2007 |
[Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Dihydro | 2007 |
Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX2 tumor in rabbits by intravenous injection.
Topics: Animals; Antimetabolites, Antineoplastic; Biocompatible Materials; Cell Proliferation; Disease Model | 2007 |
Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Progression; Female; Fluorou | 2007 |
Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendo | 2007 |
Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2007 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
[Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2007 |
[A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Combined Modality Therapy; Contrast Media; Female; Fl | 2007 |
Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2007 |
Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antidotes; Antimetabolites, Antineoplastic; Antineopl | 2007 |
Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Therapy, | 2007 |
[A case of chronic hepatitis C virus-related advanced hepatocelluar carcinoma surviving more than 8 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 2007 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2007 |
Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemot | 2007 |
[Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
Topics: Antibodies, Monoclonal; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
[Diagnosis and prognosis study of breast carcinoma with micropapillary component].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2007 |
Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targetting intervention radiology.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Medi | 2007 |
Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Genes, Reporter; Hepatitis B virus; Human | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Topics: Angiopoietins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepato | 2007 |
Regression of radiation-induced macular edema after systemic bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab | 2007 |
Bevacizumab-associated reversible hypotension.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2006 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2007 |
Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
Topics: Adenocarcinoma; Amyotrophic Lateral Sclerosis; Antineoplastic Combined Chemotherapy Protocols; Campt | 2007 |
[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined | 2007 |
Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2007 |
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Feasibility Studi | 2008 |
Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumo | 2007 |
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2008 |
Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit | 2007 |
[A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2007 |
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cohort Studi | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2007 |
Liver perfusion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adj | 2007 |
Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2007 |
[Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Sy | 2007 |
Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; Gene Expressi | 2007 |
Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; DNA, Complementary; Female; Fluoro | 2007 |
Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorecta | 2007 |
Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Colon; Colonic Polyps; Colonoscopy; Colorectal | 2007 |
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2007 |
Synthesis and bioevaluation of 5-fluorouracil derivatives.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Drug Screening Assays, Antitu | 2007 |
Effects of endogenous nitric oxide induced by 5-fluorouracil and L-Arg on liver carcinoma in nude mice.
Topics: Animals; Antimetabolites; Apoptosis; Arginine; bcl-2-Associated X Protein; Carcinoma, Hepatocellular | 2007 |
Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Senescence; Fluorouracil; Humans; L | 2008 |
Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Cryptogenic Organizing | 2007 |
[A case report--combination chemotherapy with oral UFT and CPT-11, 5-FU, l-LV by hepatic arterial infusion for multiple hepatic metastasis from sigmoid colon cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2007 |
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; | 2008 |
[Influence of neoadjuvant chemotherapy on liver integrity and ischemic tolerance].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Chemotherapy, Adjuvant; | 2008 |
Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2008 |
[Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusio | 2008 |
Cytotoxic effects and in vitro reversal of multidrug resistance by therapeutic ultrasound in human hepatocarcinoma cell line (HepG2).
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug | 2008 |
Oxaliplatin-induced immune mediated thrombocytopenia.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Plat | 2008 |
[A long-term survival case of unresectable hepatohilar bile duct cancer treated with radiotherapy and hepatic arterial infusion chemotherapy ].
Topics: Aged; Bile Duct Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 2007 |
[A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Fluorouracil; Human | 2007 |
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; C | 2008 |
Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2008 |
Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue.
Topics: Carcinoma, Hepatocellular; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expression | 2007 |
Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Mon | 2008 |
[It's a good ability to keep all your bases covered].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Liver Neoplasms; N | 2008 |
Capecitabine for treatment of advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycyti | 2007 |
Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
Topics: Angiotensin II; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA- | 2007 |
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[Treatment of colonic cancer and follow up].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colon; Colonic Neoplasms; Colost | 2007 |
Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2008 |
[A case of advanced gastric cancer effectively treated with combination of weekly paclitaxel and hepatic arterial infusion of 5-FU/LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil; Gastr | 2008 |
[Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Sepsis from liver abscesses in metastatic colorectal carcinoma after chemoimmunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
Systemic therapy for metastatic colorectal cancer: current questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Clinical Trial | 2008 |
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi | 2009 |
A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cellul | 2008 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colonoscopy; Colore | 2008 |
Administration of oxaliplatin to a pregnant woman with rectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival | 2009 |
Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Capecitabine; Deoxycytidine; Dose-Response Rel | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De | 2008 |
Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2008 |
[Evaluation of efficacy and influence factors of transarterial interventional therapy in patients with liver metastasis from malignancy of alimentary tract].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, T | 2007 |
[A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Esophageal Neoplasms; | 2008 |
[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 2008 |
[A case of liver metastasis of rectal cancer demonstrating complete response for three years to 5-FU/l-leucovorin].
Topics: Aged; Carcinoembryonic Antigen; Colonoscopy; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; | 2008 |
[Transcatheter treatment of liver metastases from breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antineoplastic Agents; Breast Neoplasms; Chemoembolizat | 2008 |
Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; | 2009 |
Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2008 |
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2008 |
Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells.
Topics: Acetophenones; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell P | 2008 |
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; F | 2008 |
[Patient of advanced age with synclonus liver metastases from colon cancer effectively treated with intraarterial chemotherapy of 5-FU].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Hepatic Artery; | 2008 |
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gem | 2008 |
Chemotherapy for malignancy of the liver by short-term direct infusion of the hepatic artery.
Topics: Adult; Aged; Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arteri | 1967 |
Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Cholestasis, Extrahepatic; Combined Modality Therapy; Doxorubicin; | 1984 |
[Studies on the new long-acting anti-cancer preparation, 5-fluorouracil-polyglycolic acid composite].
Topics: Aged; Delayed-Action Preparations; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Needl | 1984 |
[Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxoru | 1984 |
[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorou | 1984 |
[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 1984 |
[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Sched | 1984 |
Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dronabinol; Female; Fluorouracil; Gastr | 1984 |
[Studies on the new anticancer preparation, 5-fluorouracil-polyglycolic acid-composite and its therapeutic evaluation].
Topics: Aged; Animals; Delayed-Action Preparations; Drug Implants; Female; Fluorouracil; Humans; Liver Neopl | 1984 |
[Therapeutic measures in liver metastases].
Topics: Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms | 1980 |
Virilizing hepatoblastoma--significance of alpha-1-fetoprotein and human chorionic gonadotropin as tumor markers in diagnosis and follow-up.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Chorionic Gonadotropin; Cyclophosphamide; Doxorubicin | 1981 |
Adjuvant and palliative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Humans; Liver | 1981 |
Hepatic artery infusion with 5-fluorouracil and mitomycin-C in metastatic colorectal carcinoma phase II study.
Topics: Adult; Aged; Catheterization; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; | 1982 |
[Treatment of inoperable liver metastasis. Preliminary results with intrahepatic chemotherapy via a new type of indwelling catheter].
Topics: Adult; Aged; Catheters, Indwelling; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver N | 1982 |
[Therapy of carcinoid and the carcinoid syndrome].
Topics: Aminocaproic Acid; Aprotinin; Carcinoma, Squamous Cell; Cyproheptadine; Doxorubicin; Embolization, T | 1983 |
[Clinical evaluation of chemotherapeutic agents in the treatment of primary liver cancer].
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluor | 1982 |
Continuous intra-arterial infusion chemotherapy of hepatoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Fema | 1983 |
[The clinical effect of hyperthermia combined with induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Pressure; Cisplatin | 1984 |
Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases.
Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Drug Admin | 1982 |
Intraarterial infusion chemotherapy in the treatment of liver metastases from ovarian cancer.
Topics: Antineoplastic Agents; Cystadenocarcinoma; Doxorubicin; Drug Therapy, Combination; Endometriosis; Fe | 1981 |
Effective retreatment of patients with colorectal cancer and liver metastases.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Resistan | 1983 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1983 |
Intrahepatic chemotherapy in isolated liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Floxuridine; Fluoro | 1983 |
[Local infusion therapy in liver metastases of colorectal cancers. Results of a phase-II study].
Topics: Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio | 1984 |
Regional chemotherapy: application in hepatic metastases.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1984 |
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1984 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
[Up-date of the chemotherapy of carcinoma of the colo-rectum: our experience with 5-fluorouracil and folinic acid in high doses].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Leu | 1984 |
Tumor cell lipid composition and sensitivity to humoral immune killing. I. Modification of cellular lipid and fatty acid content by metabolic inhibitors and hormones.
Topics: Animals; Carcinoma, Hepatocellular; Cardiolipins; Cattle; Cholesterol; Cytotoxicity, Immunologic; Da | 1980 |
Adriamycin in the treatment of resectible and irresectible primary hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Therapy, Combination; Fluorourac | 1980 |
Therapy of hepatocellular cancer with combined intrahepatic arterial chemotherapy and whole liver irradiation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Evaluation; | 1980 |
[Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)].
Topics: Antineoplastic Agents; Asialoglycoproteins; Azo Compounds; Carcinoma, Hepatocellular; Cell Membrane | 1981 |
Fulminant lung metastases from cancer of the breast.
Topics: Adult; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclophosphamide; Female; Fluorour | 1981 |
A non-resectable hepatoma after hepatic artery ligation combined with infusion chemotherapy--an eight-year survival.
Topics: Aged; Carcinoma, Hepatocellular; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Ligation; | 1981 |
[Advanced liver neoplasms in children].
Topics: Adolescent; Carcinoma, Hepatocellular; Child; Child, Preschool; Female; Fluorouracil; Humans; Infant | 1981 |
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular | 1982 |
Preoperative chemotherapy for unresectable primary hepatic malignancies in children.
Topics: Adolescent; Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Child, Preschool; Cyclophospham | 1982 |
Clinical and chemotherapeutic study of hepatocellular carcinoma in Malaysia: a comparison with African and American patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neopl | 1982 |
Prolonged survival with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Time Factors | 1982 |
Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Th | 1983 |
Glucagonoma and its angiographic diagnosis.
Topics: Adenoma, Islet Cell; Adult; Aged; Angiography; Antineoplastic Agents; Dacarbazine; Drug Therapy, Com | 1982 |
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa | 1983 |
Pharmacokinetics of ftorafur after intravenous and oral administration.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Half-Life; Human | 1983 |
Surgical considerations in the management of hepatic neoplasia.
Topics: Adenoma, Bile Duct; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Floxuridine; | 1983 |
The effectiveness of hepatic artery infusion in treatment of primary hepatobiliary tumors.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Fluorouracil; Hepati | 1983 |
[HBs antigen-positive adult type liver cancer in a child with sustained remission induced by infusion of antineoplastic agents into the hepatic artery].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Fluorouracil | 1983 |
[Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil].
Topics: Aged; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Female; Fl | 1982 |
[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1982 |
[Chemotherapy of gastrointestinal cancer in elderly patients--evaluation of combination therapy with mitomycin C and 5-fluorouracil].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Colonic Neoplasms; Drug Synergism; Dru | 1983 |
Unsuccessful DTIC treatment of a patient with glucagonoma syndrome.
Topics: Adenoma, Islet Cell; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Glucagonoma; Humans; Live | 1983 |
[Evaluation of chemotherapy in hepatocellular carcinoma with liver cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1983 |
Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1984 |
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy.
Topics: Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Colonic Neoplasms; Combined Modali | 1984 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
[Isolated liver perfusion in advanced metastases of colorectal cancers].
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; | 1984 |
[Results of intermittent intra-arterial chemotherapy with 5-FU in liver metastases and inoperable tumors of the gastrointestinal and urogenital tracts].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Drug Tolerance; Female; Fluorouracil; Gastroi | 1984 |
[Enzymatic conversion of tegafur in human tumor tissue].
Topics: Adult; Female; Fluorouracil; Humans; In Vitro Techniques; Liver Neoplasms; Middle Aged; Stomach Neop | 1983 |
[Chemotherapy of gastric cancer patients with hepatic metastases].
Topics: Administration, Oral; Antibiotics, Antineoplastic; Fluorouracil; Humans; Liver Neoplasms; Mitomycin; | 1983 |
[Intra-arterial infusion chemotherapy for metastatic hepatic tumor of colo-rectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1983 |
Phase II study of orally and rectally administered Tegafur in liver metastases from gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Liver Neoplasms; M | 1984 |
[Basic and clinical studies on metastatic cancer--with special reference of multidisciplinary treatment of gastric and colorectal cancer patients with hepatic metastasis].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Ar | 1983 |
Combination of hepatic arterial infusion and systemic chemotherapy for gastric cancer with synchronous hepatic metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatic Artery; H | 1984 |
Liver calcifications following hepatic artery infusion with 5-fluorouracil, adriamycin and mitomycin C (FAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Chemical and Drug Induced Liver Injury; | 1984 |
[Intra-hepato-arterial administration of cis-diammine-dichloroplatinum II (CDDP) for primary or metastatic hepatic cancer].
Topics: Adult; Aged; Carcinoembryonic Antigen; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; F | 1984 |
[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
Topics: Administration, Oral; Adult; Aged; Capsules; Colonic Neoplasms; Delayed-Action Preparations; Drug Ev | 1984 |
Hepatic artery ligation and portal vein infusion for liver metastases from colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Hepat | 1984 |
Hepatic arterial infusion chemotherapy for cancer of the liver.
Topics: Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms | 1980 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1984 |
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; D | 1984 |
Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; | 1984 |
Improving cancer patients' adjustment to infusion chemotherapy: evaluation of a patient education program.
Topics: Adult; Evaluation Studies as Topic; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1983 |
Remission of metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Humans; Intestinal Poly | 1983 |
Kinetics of methotrexate, dacarbazine and 5-fluorouracil during isolated liver perfusion.
Topics: Animals; Biotransformation; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Dogs; Dose-Respon | 1983 |
First histologic findings in metastases of colorectal carcinoma following isolated liver perfusion with cytostatics.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; L | 1983 |
Transient repeated dearterialization combined with intra-arterial infusion of oncolytic drugs in the treatment of liver tumors.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Cyclophosphamide; Duod | 1983 |
Intra-arterial chemotherapy of the liver with transient, repeated hypoxia.
Topics: Adult; Aged; Catheterization; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Human | 1983 |
First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary.
Topics: Animals; Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Colonic N | 1983 |
Ultrastructural changes in the dog liver cell after isolated liver perfusion with various cytotoxins.
Topics: Animals; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Do | 1983 |
Hepatic artery chemotherapy: the relative importance of direct organ distribution vs. the constant-infusion schedule.
Topics: Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Liver Neopla | 1984 |
The natural history of gastric cancer and prognostic factors influencing survival.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic M | 1984 |
Adjuvant intrahepatic cytotoxic liver infusion for colon cancer. Catheter placement technique.
Topics: Catheterization; Colonic Neoplasms; Fluorouracil; Heparin; Humans; Liver Neoplasms; Portal System | 1984 |
Comparative efficacy of antitumor treatment for liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1981 |
Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.
Topics: Adenocarcinoma; Colonic Neoplasms; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; | 1981 |
Intrahepatic artery 5-fluorouracil and mitomycin-C in previously untreated patients with hepatic metastases from colorectal carcinoma.
Topics: Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Mitomyci | 1982 |
[Effect of cancer chemotherapy for unresectable cancer of the pancreas].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Mal | 1982 |
[Antitumor treatment for synchronous hepatic metastasis from stomach cancer].
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver N | 1982 |
[Treatment of unresectable liver cancer with intrahepatic arterial infusion chemotherapy].
Topics: Adult; Aged; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middl | 1982 |
[Clinical experiences with UFD-1].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combination | 1982 |
Nursing implications of hepatic artery infusion.
Topics: Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Patient Education | 1982 |
Rectal adenocarcinoma treated with intra-arterial 5-fluorouracil. Prolonged remission.
Topics: Adenocarcinoma; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neop | 1982 |
Intraarterial yttrium 90 in the treatment of hepatic malignancy.
Topics: Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Microsp | 1982 |
Intra-arterial chemotherapy of liver tumors.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusions, Intra-Arte | 1982 |
Adenocarcinoma of the colon with hepatic metastases. Fifteen-year survival.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Prognosis; | 1982 |
Fluorouracil for colorectal cancer: a sobering look.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Rectal Neoplasms | 1982 |
Dosimetry and preliminary human studies of 18F-5-fluorouracil.
Topics: Animals; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Fluorine; Fluorouracil; Half-Life; Hu | 1982 |
Long-term, ambulatory, continuous intravenous infusion of 5-fluorouracil for the treatment of metastatic adenocarcinoma in the liver.
Topics: Adenocarcinoma; Aged; Ambulatory Care; Cecal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; | 1982 |
[Vascular isolation and perfusion of the liver in clinical practice].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Colonic Neop | 1982 |
Endocrine ablation and hepatic artery infusion in the treatment of metastases to the liver from carcinoma of the breast.
Topics: Adrenalectomy; Antineoplastic Agents; Breast Neoplasms; Castration; Doxorubicin; Estrogen Antagonist | 1982 |
Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Intra-Arterial; | 1982 |
Colorectal cancer. Chemotherapy.
Topics: Adjuvants, Pharmaceutic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; | 1982 |
Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate.
Topics: Aged; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver | 1982 |
Effect of surgery on liver function in patients with liver cancer.
Topics: Adult; Aged; Antipyrine; Female; Fluorouracil; Humans; Ligation; Liver; Liver Function Tests; Liver | 1982 |
[Isolated liver perfusion with 5-fluorouracil (5-FU) in the human].
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neo | 1982 |
[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].
Topics: Adult; Aged; Blood Platelets; Drug Evaluation; Female; Fluorouracil; Humans; Intestinal Neoplasms; I | 1982 |
Treatment of asymptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes.
Topics: Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Colonic Neoplasms; Drug Therapy, Combinatio | 1982 |
Angiography after temporary inhibition of blood flow followed by intraarterial 5-FU infusion in the treatment of liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-A | 1981 |
[Treatment of inoperable liver metastases: preliminary results with intrahepatic chemotherapy via a new type of indwelling catheter (author's transl)].
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1981 |
[Ligation and catheterization of the hepatic artery in the chemotherapy of primary and secondary hepatic tumors].
Topics: Adult; Aged; Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arteria | 1981 |
Transfemoral hepatic artery infusion for metastatic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Female; Femoral Artery; Fluorour | 1981 |
Hepatic artery occlusion with perfusion in the treatment of carcinoid syndrome.
Topics: Adult; Aged; Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; Liver Neoplasms; Male; M | 1981 |
Concomitant hepatic radiation and intraarterial fluorinated pyrimidine therapy: correlation of liver scan, liver function tests, and plasma CEA with tumor response.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Carcinoembryonic Antigen; Fluorouracil; Humans; I | 1981 |
Uptake of 5-fluorouracil during isolated perfusion of the canine liver.
Topics: Animals; Disease Models, Animal; Dogs; Fluorouracil; Liver; Liver Neoplasms; Perfusion | 1980 |
Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man.
Topics: Administration, Oral; Adult; Biological Availability; Fluorouracil; Humans; Injections, Intravenous; | 1980 |
[Regional cytostatic infusion therapy in patients with inoperable gastrointestinal carcinomas and metastases in the liver (author's transl)].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Colostomy; Fluorouracil; Gastrointestinal Neo | 1980 |
Chemotherapy for gastrointestinal malignancy.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Fluoroura | 1980 |
Transient hepatic dearterialization followed by regional intra-arterial 5-fluorouracil infusion as treatment for liver tumors.
Topics: Adult; Aged; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Ligation; Live | 1981 |
5-Fluorouracil/levamisole induced intrahepatic fat infiltration imitating liver metastasis.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Diagnosis, Differential; Fatty Liver; Fluorour | 1995 |
[Regional therapy breast cancer liver metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1995 |
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Brain Diseases; Cecal Neoplasms; Dihydrourac | 1995 |
Clostridium septicum abscess in hepatic metastases: successful medical management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
[Hepatocellular carcinoma in pregnancy].
Topics: Adult; Carcinoma, Hepatocellular; Cesarean Section; Chemotherapy, Adjuvant; Combined Modality Therap | 1994 |
Whole abdominal radiotherapy and concomitant 5-fluorouracil as adjuvant therapy in advanced colon cancer.
Topics: Abdomen; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hum | 1995 |
[Intra-arterial infusion chemotherapy for advanced liver metastases from lung cancer via implantable vascular access: report of six cases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplat | 1995 |
[A case of intrahepatic infusion chemotherapy with angiotensin II human for liver metastasis from early gastric cancer].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure | 1995 |
[Long-term survival in two cases of multiple liver metastasis successfully treated with intraoperative ultrasound-guided microwave tumor coagulation (MTC)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi | 1995 |
[Sclerosing cholangitis-induced biliary cyst formation: complication of hepatic artery infusion chemotherapy].
Topics: Adenocarcinoma; Biliary Tract Diseases; Cholangitis, Sclerosing; Cysts; Fluorouracil; Hepatic Artery | 1995 |
[A case report of far advanced gastric cancer with multiple liver metastasis (H3) treated with transarterial intermittent chemotherapy and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Enterobacteriaceae; Epirubicin; Fluorouracil; | 1995 |
[Chronochemotherapy in two cases of metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Administration Sch | 1995 |
[A case of advanced gastric cancer treated effectively with neo-adjuvant chemotherapy using l-leucovorin and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 1995 |
[Efficacy of treatment with frequent and low-dose epirubicin in two cases of pulmonary metastases after surgery of liver cancer].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Epirubic | 1995 |
Long-term survival in two cases of colorectal carcinoma following a new chemotherapy regimen and subsequent metastasectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 1995 |
New versus old: pancreatic cancer and chemoradiation attempts.
Topics: Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; Liver; Liver Neoplasms; Panc | 1995 |
Effective treatment of liver metastases from colon cancer with a combination of gamma-interferon and cisplatin chemotherapy: report of a case.
Topics: Adenocarcinoma; Administration, Oral; Cisplatin; Colectomy; Drug Therapy, Combination; Fluorouracil; | 1995 |
The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat.
Topics: Administration, Topical; Animals; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fl | 1995 |
Exceptional toxicity of 5-fluorouracil and interferon-alpha in a patient with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Interferon-gamma; Liver Neoplasms; Male | 1995 |
A 10-year survivor with unresectable hepatic metastases from sigmoid colon carcinoma treated with regional chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans | 1995 |
[Hepatic artery chemotherapy-embolization and biological response modifiers for late hepatic carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Combine | 1995 |
Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer.
Topics: Animals; Colorectal Neoplasms; Fluorouracil; Infusions, Intravenous; Liver Neoplasms; Male; Mice; Mi | 1994 |
[A case of liver metastasis of gastric cancer with portal vein tumor thrombosis responding to chemotherapy with 5-FU and epirubicin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Huma | 1995 |
[Palliative therapy of primary liver tumors].
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; alpha-Fetoproteins; Angiography; Antineoplastic Combine | 1993 |
Transcatheter chemoembolization of progressive carcinoid liver metastasis.
Topics: Adult; Aged; Carcinoid Tumor; Catheterization; Chemoembolization, Therapeutic; Cisplatin; Doxorubici | 1993 |
Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Che | 1995 |
[Evaluation of 5-FU, leucovorin, etoposide, and cisplatin (FLEP) chemotherapy by hepatic artery injection in the treatment of multiple liver metastases from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluorouracil; Hepatic | 1995 |
Influence of 5-fluorouracil on serum lipids.
Topics: Aged; Animals; Breast Neoplasms; Cholesterol; Cholesterol, HDL; Colonic Neoplasms; Female; Fluoroura | 1995 |
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
Topics: Carcinoma; Catheterization, Peripheral; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Stability | 1995 |
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzofurans; Biological Transport; Carc | 1995 |
[Neoadjuvant chemotherapy of liver tumors metastasized by sigmoid colon cancer: a case report of CDDP/5-FU intraarterial infusion therapy followed by hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouraci | 1995 |
[Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Servic | 1994 |
[Home therapy approach in cancer patients-chemotherapy (case 2-1)].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac | 1994 |
[Home therapy approach in cancer patients-chemotherapy (case 2-3)--intra-arterial infusion cancer chemotherapy for hepatic metastasis of colorectal cancer--case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic | 1994 |
The significance of anatomical variations of hepatic artery and multiple arterial supplies in embolization of liver tumors.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Female; Fluorouracil; Hepatic Artery; Humans; Liver Cir | 1994 |
New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Fatal | 1995 |
[Combination therapy of 5-FU and low dose CDDP for advanced and recurrence gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 1995 |
[Surgical therapy of liver metastases. Therapeutic procedures, results and prognostic factors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chem | 1994 |
[Cardiac toxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Cardiomyopathies; Cecal Neoplasms; Colonic Neoplasms; Death, Sudden | 1994 |
[A case of multiple liver metastasis from remnant gastric cancer responding to leucovorin.5-FU+UFT therapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 1995 |
The significance of portal vein chemotherapy for liver micrometastases: an experimental study of a rat model.
Topics: Animals; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorouracil; Heparin; Infusions, Int | 1994 |
[A case report: multiple liver metastasis from gastric cancer responding to intraarterial infusion of sequential low-dose MTX and 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; Hu | 1994 |
[A long-survival case of unresectable liver metastasis of colon cancer by hepatic arterial intermittent multidrug infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxoru | 1994 |
[Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 1994 |
[A case of liver metastasis from bile duct cancer effectively treated with hepatic artery infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Drug Administration Schedule; E | 1994 |
[A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cy | 1994 |
Treatment of patients with irresectable liver metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver | 1994 |
Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome.
Topics: Adult; Carcinoid Tumor; Drug Therapy, Combination; Fluorouracil; Humans; Hypoxia; Liver Neoplasms; L | 1994 |
[Prinzmetal's angina pectoris caused by exercise during therapy with 5-fluorouracil. A proposition of therapeutic protocol].
Topics: Angina Pectoris, Variant; Exercise Test; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged | 1994 |
[A case of advanced gastric cancer successfully treated with resection after FEP (5-FU, epirubicin, CDDP) combined chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 1994 |
[A case of poorly differentiated hepatic cell carcinoma which showed 90% decrease in size after chemotherapy with intraarterial infusion of mitomycin C and oral administration of tegafur].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1994 |
Management of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; H | 1994 |
Regional chemotherapy for colorectal liver metastases: thirty years without patient benefit.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Incidence; Infusions, Intra | 1994 |
[A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administrati | 1994 |
Adjuvant therapy with fluorouracil and levamisole and liver ultrasound mimicking liver metastases.
Topics: Adult; Colonic Neoplasms; Diagnosis, Differential; Fatty Liver; Female; Fluorouracil; Humans; Levami | 1994 |
5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin.
Topics: Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouraci | 1994 |
Intra-arterial infusion of Tc-99m MAA: a case of highly selective targeting of liver metastases and shunting.
Topics: Enalapril; Fluorouracil; Hepatic Artery; Humans; Hypertension; Infusions, Intra-Arterial; Liver Neop | 1994 |
[The evolution of the liver metastases from colorectal carcinoma treated with hepatic intra-arterial chemotherapy. The echographic and CT aspects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Floxuridine; Fluoro | 1994 |
Interleukin-2 in neoadjuvant therapy potentiates inhibitory activity of 5-fluorouracil and interferon in experimental liver metastases.
Topics: Animals; Combined Modality Therapy; Drug Synergism; Female; Fluorouracil; Interferon alpha-2; Interf | 1994 |
Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1994 |
[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1994 |
[The concentration of FT in peripheral blood and portal blood after oral, intravenous or rectal administration].
Topics: Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplas | 1994 |
High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Brain Neoplasms; | 1994 |
Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 1994 |
Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1994 |
Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1994 |
[A comparative study on the serum and tissue 5-FU concentrations in patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5'-DFUR].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1994 |
[Application of crossed assay design in test of drug sensitivity in vitro in combined chemotherapy of liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1993 |
[A case of advanced gastric cancer complicated with multiple liver metastasis successfully treated with l-LV and 5-FU combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administrati | 1994 |
Local and systemic toxicity of intra-hepatic-arterial 5-FU and high-dose or low-dose leucovorin for liver metastases of colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1994 |
Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytotoxicity, Immunologic; Fluo | 1994 |
A procedure for the determination of 5-fluorouracil in tissue using microbore HPLC and fluorescence detection.
Topics: Calibration; Chromatography, High Pressure Liquid; Fluorouracil; Humans; Liver; Liver Neoplasms; Ref | 1994 |
[Weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouraci | 1993 |
Selective 19F MR imaging of 5-fluorouracil and alpha-fluoro-beta-alanine.
Topics: Artifacts; beta-Alanine; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Magnetic | 1993 |
[Treatment of liver metastases of colorectal tumors using intra-arterial fluorouracil to the liver, administered with a completely implantable access system and a portable infusion pump].
Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arteria | 1993 |
Diagnosis and therapy for primary hepatic carcinoma: transcatheter inferior phrenic arteriography and chemoembolization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 1993 |
[5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma.
Topics: Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Liver; Liver Neoplasms; | 1993 |
[Are there prognostic parameters for predicting the success of regional chemotherapy in nonresectable liver metastases of colorectal cancer?].
Topics: Adult; Aged; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouraci | 1993 |
[A case of nonresectable esophageal cancer treated by the combination of cisplatin, 5-fluorouracil and THP-adriamycin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1993 |
The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1993 |
Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Drug | 1993 |
[Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Doxorubicin; Fluorouracil; Humans; Immuno | 1993 |
[Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases].
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion Pum | 1993 |
[Complications of intra-arterial chemo-infusion using implantable vascular access system].
Topics: Breast Neoplasms; Colonic Neoplasms; Equipment Failure; Evaluation Studies as Topic; Female; Fluorou | 1993 |
[Arterial infusion chemotherapy of 5-FU and leucovorin for patients with liver metastases from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1993 |
[Intra-arterial chemotherapy with 5-FU (weekly high dose 5-FU HAI) for the prevention of tumor recurrence in residual liver after hepatic resection of metastasis from colorectal cancer].
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; | 1993 |
[Intermittent intra-arterial infusion chemotherapy of 5-FU and carboplatin for unresectable liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Drug Administration | 1993 |
[Clinical study on the effect of continuous transarterial infusion chemotherapy of CDDP for metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Admi | 1993 |
[Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal | 1993 |
[Importance of systemic administration of pyrimidine after thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gas | 1993 |
[Intraarterial infusion chemotherapy for recurrent or unresectable gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 1993 |
[A case of complete response by intermittent intra-arterial injection of 5-fluorouracil and carboplatin for liver metastases due to pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluorouracil; H | 1993 |
[Advanced breast cancer with onset of multi-organ metastases successfully treated with combined loco-regional therapies: a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Ch | 1993 |
[Two cases of intrahepatic biloma during hepatic arterial infusion chemotherapy proved by CT-Scan].
Topics: Adult; Bile; Bile Duct Diseases; Bile Ducts, Intrahepatic; Colonic Neoplasms; Female; Fluorouracil; | 1993 |
Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study.
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1993 |
Improved survival for hepatocellular cancer with combination surgery and multimodality treatment.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combi | 1993 |
[The present status of chemotherapy for hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1993 |
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; | 1993 |
[Pathomorphological study of resected hepatocellular carcinoma after transcatheter hepatic arterial chemo-embolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 1993 |
[The study of continuous local arterial-infusion chemotherapy with 5-FU + CDDP for patients with severely advanced HCC--for the elongation of the life-span and the improvement of QOL].
Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1993 |
[Complication of gastro-duodenum with intra-hepatic arterial infusion chemotherapy using implantable reservoir system for hepatic tumors].
Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Administration Schedule; Duodenal Diseases; Female; Fluor | 1993 |
[Clinical study of continuous local arterial-infusion chemotherapy for severely advanced hepatocellular carcinoma (HCC) using reservoir].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 1993 |
Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2(15)O and [18F]uracil positron emission tomography (PET).
Topics: Colorectal Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neoplasms; Oxygen Radioiso | 1993 |
Percutaneous hepatic arterial chemotherapy and chemoembolization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 1993 |
Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 1993 |
Dose-intensive therapy for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Bra | 1993 |
[The treatment of liver metastases of colorectal tumors using intra-arterial fluorouracil via hepatic artery, administered with a completely implantable access system and a portable infusion pump].
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Inf | 1993 |
Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.
Topics: Adult; Aged; Animals; Colorectal Neoplasms; Female; Fluorodeoxyuridylate; Fluorouracil; Gas Chromato | 1993 |
[Experimental and clinical study in vitro chemosensitivity test for succinate dehydrogenase inhibition test].
Topics: Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopla | 1993 |
[Metachronous liver metastases treated with repeated liver resections and chemotherapy].
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neop | 1993 |
Experimental cancer chemotherapy using a liver metastatic model of human colon cancer transplanted into the spleen of severe combined immunodeficient mice.
Topics: Animals; Colonic Neoplasms; Fluorouracil; Humans; Isoenzymes; L-Lactate Dehydrogenase; Liver; Liver | 1993 |
[A case of advance colon cancer responding to sequential methotrexate and 5-fluorouracil therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 1993 |
Response of soluble IL-2 receptor levels to repeated cycles of IL-2 immunotherapy/chemotherapy.
Topics: Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Interleukin-2; Leukocy | 1993 |
Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, | 1993 |
[Follow up of liver metastases using computed tomography in colorectal cancer treated with interferon-alpha and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-U | 1993 |
Pellagra secondary to 5-fluorouracil.
Topics: Aged; Biliary Tract Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Nicotinic Acids; Pellagr | 1993 |
[A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro | 1993 |
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; In | 1996 |
Bioavailability of subcutaneous 5-fluorouracil: a case report.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma; Colorectal Neoplasms | 1996 |
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P | 1996 |
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Body Weight; Colorectal Neoplasms; Deoxygluc | 1996 |
Re: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 1996 |
Adenocarcinoma of the duodenum with liver metastases. Complete remission and long-term survival with 5-fluorouracil chemotherapy--a case report.
Topics: Adenocarcinoma; Adult; Duodenal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Remission | 1996 |
[The clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer employing an implanted port system].
Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantabl | 1996 |
Carcinoma colon with mandible and liver metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1996 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
[A case of advanced gastric cancer responding to chemotherapy and radiotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cispl | 1996 |
[A case of advanced gastric cancer with lung and liver metastasis treated by CDDP and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 1996 |
[A case of advanced gastric cancer with liver metastasis with no recurrence and long survival].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1996 |
Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation.
Topics: Actuarial Analysis; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineop | 1996 |
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo | 1996 |
Response to regional chemotherapy in patients with variant hepatic arterial anatomy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusio | 1996 |
A prospective evaluation of the treatment of primary or metastatic liver carcinoma with hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1996 |
Thymidylate synthase in advanced gastrointestinal and breast cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Colonic Neoplasms; Fem | 1996 |
[Individual therapeutic procedure in metastatic carcinoid of the small intestine].
Topics: Carcinoid Tumor; Colectomy; Combined Modality Therapy; Female; Fluorouracil; Humans; Ileal Neoplasms | 1996 |
[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration S | 1996 |
[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluorou | 1996 |
Canities--reversal with chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 1995 |
[Two cases of multiple liver metastases (H3) from colon cancer treated by home hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Fluorouracil; Hepati | 1995 |
Comparison by carcinoembryonic antigen doubling time of hepatic injection and infusion for unresectable hepatic metastasis from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; Female; F | 1995 |
Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemoemboliz | 1996 |
[Usefulness of continuous arterial infusion chemotherapy for post operative multiple recurrence and residual hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 1996 |
[Locoregional therapy for liver metastases of colorectal cancer].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 1996 |
[Hepatic intra-arterial 5-fluorouracil and CDDP administration in patients with colorectal cancer metastasis to the liver].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta | 1996 |
[Indication of prophylactic hepatic arterial-infusion chemotherapy after hepatic resection for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusi | 1996 |
[Intra-arterial infusion chemotherapy for liver metastases from breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul | 1996 |
[Induced hypertensive chemotherapy with angiotensin-II for liver metastases from gastric cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Female; Fluoro | 1996 |
[A case of Borrmann type 4 gastric cancer successfully treated with MTX and 5-FU therapy through the hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 1996 |
[A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 1996 |
Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar | 1996 |
Accumulation of Tc-99m HMDP in hepatic metastasis from colon carcinoma without detectable calcification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Calcinosis; Cisplatin; Colonic Neopl | 1996 |
Continuous infusional 5-fluorouracil chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; | 1996 |
Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Cisplatin; | 1996 |
Cardiac perforation associated with continuous infusional chemotherapy.
Topics: Antineoplastic Agents; Catheterization, Central Venous; Colonic Neoplasms; Fluorouracil; Heart Injur | 1996 |
[Clinical study of home hepatic arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disposable Eq | 1996 |
Major upper gastrointestinal haemorrhage associated with hepatic arterial chemoperfusion.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Duodenal Ulcer; Female; Fluorouracil; Gastrointestina | 1996 |
[Chemosensitivity test on hepatocellular carcinoma (HCC) and drug resistance].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocel | 1996 |
Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility Studies; Fluorouracil; Huma | 1996 |
[Characterization of spontaneous liver metastatic model of BALB/c retroperitoneal sarcoma (LMFS) injected in footpad and antitumor effects of HCFU].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Liver; Liver Neoplasms; Mic | 1997 |
Role of portal vein chemotherapy following failure of previous treatment for advanced colorectal hepatic metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, | 1997 |
[A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluor | 1997 |
Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Chemotherapy, Adjuvant; Colorect | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Ad | 1997 |
[Secondary hepatic resections in a case of sigmoid colon cancer with multiple liver metastasis (H3) after successful continuous hepatic artery infusion chemotherapy oriented by in vitro chemosensitivity test].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug | 1997 |
Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorine Radioisotopes; | 1997 |
[Combined intra-arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic | 1997 |
[A case of papillary adenocarcinoma of the stomach with liver metastases and carcinomatous peritonitis treated effectively by methotrexate/5-fluorouracil sequential chemotherapy].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; D | 1997 |
[Cisplatin/5-fluorouracil intraperitoneal administration superior to intravenous administration for liver metastases of colonic carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1997 |
[Hepatic arterial chemotherapy for liver cancer over a period of 8 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Epirubicin; Female; | 1997 |
[Continuous arterial infusion of low-dose cisplatin, 5-fluorouracil as adjuvant therapy in cytoreductive surgery for advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1997 |
[Continuous hepatic arterial infusion of fluorouracil with leucovorin for liver metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Colorectal Neoplasms; Drug Administ | 1997 |
[Evaluation of hepatic resection and hepatic arterial infusion chemotherapy for multiple liver metastases from colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1997 |
[The study of continuous infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with primary liver cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cholangiocarcinoma; | 1997 |
[A case of advanced hepatocellular carcinoma with portal invasion effectively treated by continuous intra-arterial chemotherapy with 5-fluorouracil].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, I | 1997 |
[Evaluation of CTA for arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hep | 1997 |
[A new two-part therapy for multiple bilobar liver metastases of colorectal cancer--treatment of one lobe with partial hepatectomy and the other with arterial chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1997 |
[A case of huge liver metastasis from colon cancer successfully treated by hepatic intraarterial infusion of low-dose 5-FU].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil | 1997 |
[A case of multiple liver metastasis and local recurrence from rectal cancer effectively treated by arterial infusion chemotherapy using low-dose 5-fluorouracil, cisplatin and LV].
Topics: Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sch | 1997 |
[Hepatectomy and intra-arterial infusion chemotherapy for hepatic metastasis of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorourac | 1997 |
[Combination hepatic intra-arterial 5-fluorouracil and CDDP administration with oral regimen in patients with colorectal cancer metastasis to the liver].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 1997 |
[A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Co | 1997 |
[Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Fadrozole; Femal | 1997 |
[Liver abscess caused by hepatic artery infusion chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatec | 1997 |
[Extra-arterial dislocation of indwelling catheter in hepatic arterial infusion chemotherapy--special reference to tissue destruction by 5-fluorouracil].
Topics: Aged; Aneurysm, False; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 1997 |
[Complication due to arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Choles | 1997 |
[Complication of reservoir hepatic artery infusion chemotherapy and additional treatments].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Embolization, Therapeutic; Epiru | 1997 |
[Circadian chemotherapy in cancer patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Circadian Rhythm; Drug Administration Schedule; Female | 1997 |
[Correlation between anti-tumor effects and serum hepatocyte growth factor level in patients with liver metastases from gastric cancer treated by induced hypertensive chemotherapy with angiotensin II].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Press | 1997 |
[Long-term complete response in two cases of liver metastases from rectal and gastric cancer treated with intra-arterial infusion chemotherapy of leucovorin and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1997 |
[A case of postoperative recurrence of hepatocellular carcinoma successfully treated with arterial infusion chemotherapy using cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1997 |
A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 1997 |
Prolonged survival in a nasopharyngeal carcinoma patient with multiple metastases: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1997 |
Previous intravenous chemotherapy does not alter response rate or survival time of patients with hepatic metastases from colorectal cancer treated by hepatic artery chemotherapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Fluorour | 1997 |
Cutaneous metastasis as a complication of hepatic intra-arterial chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac | 1997 |
[Penetrating duodenal ulcer as a complication of a hepatic artery port catheter in hepatic metastasis of sigmoid carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Duodena | 1997 |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1998 |
[A case of hepatic metastasis of rectal cancer with familial adenomatous polyposis treated by transarterial administration of low-dose leucovorin and 5-FU].
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1998 |
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electrocardiography; Female; Fluorouracil; Heart; H | 1998 |
Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F1 | 1998 |
[A case of multiple liver metastasis of gastric cancer responding to hepatic arterial infusion chronotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Ad | 1998 |
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Colo | 1998 |
[Continuous intraportal chemotherapy for prevention of metachronous hepatic metastasis in colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 1998 |
[A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 1998 |
In vitro demonstration of synergy between radionuclide and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dose-Response | 1998 |
Successful right trisegmentectomy for ruptured hepatoblastoma with preoperative transcatheter arterial embolization.
Topics: Angiography; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Embo | 1998 |
Diagnosis and management of metastatic gastrinoma by multimodality treatment including liver transplantation: report of a case.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fema | 1998 |
[Combined therapy of metastatic liver neoplasms: intrahepatic chemoembolization and systemic chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 1998 |
[A comparative assessment of the effectiveness of dearterialization of the liver and intraorgan chemotherapy in patients with liver cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Embolization, Therapeutic; | 1998 |
Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Topics: Adenoviridae; Animals; Antimetabolites; Colonic Neoplasms; Cytosine Deaminase; Escherichia coli; Flu | 1998 |
[Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 1998 |
[Experimental study on 5-FU intraperitoneal injection for liver metastasis].
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Injections, Intraperitoneal; Injections, Int | 1998 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B | 1998 |
Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans; | 1998 |
18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.
Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Drug Interactions | 1998 |
[Percutaneous positioning of port catheter in the hepatic artery for chemotherapy of metastases using the Arai technique].
Topics: Adult; Aged; Angiography; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; A | 1998 |
[Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 1998 |
[Intra-arterial preventive chemotherapy for residual liver after resection of hepatic metastasis from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorou | 1998 |
[Efficacy of combination therapy (hepatectomy and prophylactic arterial chemoinfusion) for liver metastases of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Drug Administratio | 1998 |
[Intrahepatic arterial infusion chemotherapy with angiotensin II for liver metastasis from gastric cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administr | 1998 |
[Appearance of extrahepatic lesions in the superior lip and orbit of a patient with liver metastases of gastric cancer following partial response by hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Fluo | 1998 |
[p53 expression and response to hepatic intraarterial infusion chemotherapy in patients with colorectal cancer metastasis to liver].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1998 |
[Preoperative CEA level predicts outcomes of hepatic resection for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Comb | 1998 |
Radiologically placed hepatic artery catheter allows selection of patients with high-volume liver metastases for regional chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Catheterization, Peripheral; | 1998 |
[Long-term follow-up and therapeutic control of a hepatic metastatic acinar cell carcinoma of the pancreas using FDG PET].
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Fatal Outcome; Female; Fluorodeoxygl | 1998 |
Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Dose-Respons | 1998 |
[Adjuvant regional arterial port chemotherapy after resection of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 1998 |
[Membranous lipodystrophy caused by chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 1998 |
[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug | 1998 |
[Complete remission of liver metastasis from rectal cancer following continuous oral administration of tegafur-uracil after intrahepatic arterial single injection of CDDP and 5-FU].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinat | 1998 |
[The major response of metastatic kidney cancer to the combination of oxaliplatin, 5-fluorouracil and folinic acid (FOX-FOL)].
Topics: Adenocarcinoma, Clear Cell; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antin | 1998 |
Patterns of serum CEA fall after hepatic arterial chemotherapy as sole therapy and combined with cryotherapy for colorectal metastases.
Topics: Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality T | 1998 |
[Resection of primary liver cancer following transcatheter arterial chemoembolization: clinicopathological features and postoperative course in cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterizat | 1997 |
Alcohol consumption enhances liver metastasis in colorectal carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Analysis of Variance; Antineoplastic Agents; Blood | 1998 |
Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; China; Dihydrouracil Dehydrogenas | 1997 |
Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Colonic Neoplasms; Col | 1997 |
Clinical applications of the histoculture drug response assay.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1995 |
CT of calcified liver metastases in colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Calcinosis; Colorectal Neoplasms; Fluorouracil; Humans; Liver Disea | 1998 |
Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance.
Topics: Animals; Butyrates; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Interleukin-2; Li | 1998 |
Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways.
Topics: Antibodies; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Cisplatin; f | 1999 |
Biochemical modulation therapy for pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplati | 1998 |
[Current approaches to surgical treatment of liver tumors].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuva | 1998 |
The natural history of liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1998 |
Detection of multiple hepatic micrometastases in pancreatic adenocarcinoma with a solitary liver metastasis by direct sequencing of the K-ras gene: a case report.
Topics: Adenocarcinoma; Aged; Base Sequence; Combined Modality Therapy; Dose Fractionation, Radiation; Femal | 1999 |
Hepatic cryotherapy and subsequent hepatic arterial chemotherapy for colorectal metastases to the liver.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Femal | 1998 |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight | 1998 |
[A case of unresectable pancreatic cancer responding to MTX/5-FU sequential therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1999 |
Rationale of the so-called extended resection for pancreatic invasive ductal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Femal | 1999 |
[A case of multiple liver metastases showing good response by administration of carmofur alone in an aged patient with colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neopla | 1999 |
The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Casset | 1999 |
A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Asialoglycoprotein Receptor; Cell Membrane; Co | 1999 |
[Experimental study on intraperitoneal administration of 5-fluorouracil for liver metastasis in comparison with intravenous administration].
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Infusions, Intravenous; I | 1999 |
Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi | 1999 |
Noradrenaline improves the tumour to normal blood flow ratio and drug delivery in a model of liver metastases.
Topics: Animals; Antimetabolites, Antineoplastic; Blood Flow Velocity; Chemotherapy, Cancer, Regional Perfus | 1999 |
Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Aorta; Colorectal Neoplasms; Female; Fluorine Ra | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Second line therapies move to the forefront in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, C | 1999 |
Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic | 1999 |
[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1999 |
[A case of advanced hepatocellular carcinoma treated by repeated arterial infusion chemotherapy of 5-FU, LV, CDDP with an implanted reservoir].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1999 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Ne | 1999 |
[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 1999 |
[A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II].
Topics: Aged; Angiotensin II; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic C | 1999 |
Adjuvant regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 1999 |
Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellu | 1999 |
Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Be | 1999 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 1999 |
Advanced gallbladder carcinoma with liver metastasis showing a favorable response after intra-arterial infusion chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 1999 |
[Efficacy of adjuvant hepatic arterial infusion chemotherapy following resection of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1999 |
[Intraarterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fe | 1999 |
[Complete responses in patients with unresectable liver metastases from colorectal cancer with weekly high-dose 5-FU plus one-shot CDDP HAI].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ | 1999 |
[Management after hepatectomy of colorectal cancer metastases to the liver--intrahepatic arterial infusion chemotherapy and repeated hepatectomy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1999 |
[Clinical evaluation of weekly hepatic arterial infusion chemotherapy in patients with unresectable metastatic liver cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Ad | 1999 |
[Percutaneous ethanol injection therapy with hepatic arterial infusion chemotherapy for liver metastases from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Ethanol; Fluorouracil; Hepatic Art | 1999 |
[Efficacy and problems of hepatic arterial chemotherapy with angiotensin II for liver metastasis from gastric cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administr | 1999 |
[Experimental study on intraperitoneal and intravenous administration of anti-tumor agents for liver metastasis].
Topics: Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Infusions, | 1999 |
[Hepatic arterial infusion of low-dose cisplatin, 5-fluorouracil for hepatocellular carcinoma with tumor thrombi in the portal vein].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 1999 |
[Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1999 |
[Complications related to hepatic arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 1999 |
[A case report of hepatocellular carcinoma with hepatic and portal venous tumor thrombus and multiple intrahepatic metastasis who survived over 1 year after the operation with combined locoregional chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined | 1999 |
[Long partial response (PR) in a case of multiple liver metastasis from colon cancer effectively treated by continuous hepatic intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1999 |
[A long-survival case of gastric cancer with multiple liver metastasis: usefulness of intraoperative multimodality therapy and post-operative intra-arterial chemotherapy for liver lesions].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Sche | 1999 |
[An effective case of arterial infusion therapy of low-dose CDDP and continuous 5-FU for isolated hepatic recurrence of gastric carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1999 |
Anaphylactic reaction to oxaliplatin: a case report.
Topics: Adenocarcinoma; Anaphylaxis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1999 |
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect.
Topics: Animals; Antifungal Agents; Antimetabolites; Antineoplastic Agents; Cancer Vaccines; Colonic Neoplas | 1999 |
[Effects of HCFU and TNP 470 on liver metastasis of BALB/c retroperitoneal sarcoma (LMFS)].
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cyclohexanes; | 1999 |
Optimal injection protocol for CT evaluation during hepatic arterial infusion chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouraci | 1999 |
[Hemodynamics at hepatoarterial infusion of 5-FU in a chronic renal failure patient maintained by hemodialysis].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; I | 1999 |
Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Interferon-alpha; Jejun | 2000 |
Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
[A case of gastric cancer with liver metastasis responding to low-dose CDDP/5-FU combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Admi | 2000 |
[Complete remission in a case of sigmoid colon cancer with multiple liver metastases-treatment with arterial chemotherapy and percutaneous microwave coagulation therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2000 |
[Evaluation of hepatic toxicity following high-dose 5-FU arterial infusion chemotherapy: analysis of 42 cases of colorectal liver metastases].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Atrophy; Chemical and Drug Induced Liver Injury; Color | 2000 |
Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase.
Topics: Adenoviridae; Animals; Bacterial Proteins; Colonic Neoplasms; Cytosine Deaminase; Dose-Response Rela | 2000 |
[A case of multiple liver metastases from colon cancer successfully operated after intraarterial chemotherapy performed in home].
Topics: Catheters, Indwelling; Chemotherapy, Adjuvant; Fluorouracil; Hepatic Artery; Home Nursing; Humans; I | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpret | 2000 |
Targeted chemoembolization of tumors with poly(2-hydroxyethyl methacrylate) particles.
Topics: Anticoagulants; Carcinoid Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Dalteparin; Doxo | 2000 |
Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Cholangiocarcinoma; Disease Progression; Disease-Fre | 2000 |
[A case study of alpha feto protein (AFP)-producing gastric carcinoma with multiple liver metastases, in which chemotherapy was effective enough to once save a life in rapid decline].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluor | 2000 |
[A case of biloma caused by early complications of hepatic artery infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile; Cisplatin; Fluorouracil; Hepatectomy; He | 2000 |
[A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mo | 2000 |
[A case of gastric cancer with multiple liver metastasis responding to combined chemotherapy with low-dose cisplatin and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2000 |
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; | 2000 |
Technetium-99m labelled macroaggregated albumin arterial catheter perfusion scintigraphy: prediction of gastrointestinal toxicity in hepatic arterial chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catheterization, Peripheral; Colorectal Neopl | 2000 |
Hepatic artery access ports: recognizing and avoiding the problems.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Catheters, Indwelling; Collateral Circu | 2000 |
Perfusion of the oesophagus and stomach during hepatic artery chemotherapy via an aberrant gastric artery.
Topics: Adenocarcinoma; Angiography; Antimetabolites, Antineoplastic; Catheterization; Colonic Neoplasms; Em | 1999 |
Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Divi | 2000 |
Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benchmarking; C | 2000 |
Squamous cell carcinoma of the pancreas with cystic degeneration.
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamou | 2000 |
[Two cases of advanced gastric cancer responding to TS-1: a novel oral formation of 5-fluorouracil].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2000 |
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Drug Resistance; | 2000 |
A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.
Topics: 5' Untranslated Regions; Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; | 2000 |
[Hepatic arterial infusion chemotherapy using totally implantable port system].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 2000 |
[A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
[A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 2000 |
[A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2000 |
[A case of colonic cancer with multiple liver metastases effectively treated by intra-arterial chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Femal | 2000 |
Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2000 |
Palliation of unresectable hilar cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Cholangiocarcinoma; Fluorouracil; Humans; Liver Neoplasms; Palliati | 2000 |
[A study of liver metastasis from colorectal cancer in which hepatic resection was performed after hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modalit | 2000 |
[Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; | 2000 |
[A successful case of preoperative intermittent hepatic arterial infusion of high-dose 5-FU and pharmacokinetic modulating chemotherapy against unresectable liver metastasis of colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2000 |
[Case report--efficacy of short-term intraarterial 5-fluorouracil for liver metastasis from colorectal cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Dr | 2000 |
[Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fl | 2000 |
[Intra-arterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neop | 2000 |
[Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; Hepati | 2000 |
[Continuous hepatic arterial infusion of 5-fluorouracil with leucovorin for unresectable liver metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 2000 |
[Efficacy of combination therapy for multiple liver metastases of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality T | 2000 |
[Hepatic arterial infusion chemotherapy for liver metastasis from esophageal squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2000 |
[Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 2000 |
[Hepatocellular carcinoma with tumor thrombus in the portal and hepatic veins treated successfully with hepatectomy and chemotherapy--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 2000 |
[Three cases in which CR was obtained in residual metastatic lesions by intrahepatic arterial infusion after resection of hepatic metastases from colorectal carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Drug Adminis | 2000 |
[Evaluation by FDG-PET of arterial infusion chemotherapy for unresectable metastatic liver tumor].
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorodeoxyglucose F18; Fluorouracil; Hepatic Artery; | 2000 |
[Repetitive chemo-embolization with degradable starch microspheres (DSM) to each left and replaced right hepatic artery in a patient with multiple liver metastases of colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colonic Neoplasms; E | 2000 |
[A case of locally advanced rectal carcinoma with liver metastasis treated with a combination of CRT, HAI, and systemic chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Combined Modality | 2000 |
[Complications related to arterial infusion chemotherapy in patients with hepatic metastasis from colorectal cancer].
Topics: Adult; Aged; Arterial Occlusive Diseases; Biliary Fistula; Colorectal Neoplasms; Common Bile Duct; E | 2000 |
[Two cases of chemotherapy related death associated with acute depression of consciousness complicating hepatic arterial infusion chemotherapy (5-FU and CDDP) for liver metastases from gastric cancer].
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consciousness Disord | 2000 |
A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2000 |
[A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined M | 2000 |
[Effect of Ruboxyl (nitroxyl derivative of daunorubicin) on hepatic metastases of colorectal carcinoma].
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Daunoru | 2000 |
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Cohort Studie | 2001 |
[Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluorouracil; He | 2000 |
Advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-FU, MMC and peroral administration of 5-FU: a case report.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; | 2000 |
[Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2001 |
[Ambulatory chemotherapy schedule for metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2001 |
[The expression of platelet-derived endothelial cell growth factor in liver cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; En | 2000 |
Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2001 |
[A case of gastric cancer with liver metastases successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopla | 2001 |
[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil].
Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Fluorouracil; Hepatitis C, Ch | 2001 |
[Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2001 |
[A case of advanced gastric cancer complicated with liver metastases responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin, with UFT and low-dose cisplatin for maintenance on an outpatient basis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil | 2001 |
Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2000 |
Metastatic in-situ perianal Paget's disease.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Fluorourac | 2001 |
Endovascular occlusion of branches of hepatic artery with poly(2-hydroxyethyl methacrylate) emboli as a single occlusive measure in hepatology.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Arterial Occlusive Diseases; Carcinoid Tumor; Carcinom | 2000 |
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomark | 2001 |
Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2001 |
Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma.
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplast | 2001 |
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colectomy; Colorec | 2001 |
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Combinations; Drug Screening Assays, Antitum | 2001 |
[Successful resection of multiple liver metastases from rectal cancer following initial treatment using hepatic arterial infusion chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 2001 |
Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
[Results and limitations of arterial infusion therapy for liver metastases from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 2001 |
[A case of multiple liver metastases from rectal carcinoid tumor successfully treated with arterial infusion chemotherapy using degradable starch microspheres (DSM)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cisplatin; Drug Administration Sche | 2001 |
Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Fluorine Rad | 2001 |
[A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration | 2001 |
Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuva | 2001 |
[Intermittent administration of 5-FU and isovorin to patients with advanced and recurrent colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2001 |
Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
Topics: Adult; Aged; Cell Cycle Proteins; Colorectal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasm | 2001 |
Esophagectomy and hepatic arterial chemotherapy following hepatic resection for esophageal cancer with liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 2001 |
Intra-arterial hepatic chemotherapy (IAHC) for liver metastases from colorectal cancer: need of guidelines for catheter positioning, port management, and anti-coagulant therapy.
Topics: Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluorouracil; Hepatic | 2001 |
[Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Severe anaphylactic reaction to oxaliplatin.
Topics: Adult; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluoroura | 2001 |
Expression of metallothionein in colorectal cancers and synchronous liver metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2001 |
[Surgical and adjuvant therapy of neuroendocrine tumors of the gastrointestinal tract and their metastases. A retrospective analysis of personal patient group].
Topics: Adult; Aged; Antineoplastic Agents; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Combined | 2001 |
Transcatheter therapy for liver metastasis from gastric cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 2000 |
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
[A case of advanced hepatocellular carcinoma (Vp3) with right adrenal gland metastasis successfully treated with repeated arterial infusion chemotherapy using low dose CDDP and 5-FU through an implanted reservoir].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2001 |
Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth.
Topics: alpha-Fetoproteins; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Division; Fluor | 1999 |
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb | 2001 |
Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorectal Neoplasms | 2001 |
Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model.
Topics: Animals; Antimetabolites, Antineoplastic; Antipyrine; Calibration; Colorectal Neoplasms; Fluorouraci | 2000 |
[Adjuvant short-term continuous hepatoarterial infusion of 5-FU for advanced colorectal cancer using a removable hepatoarterial catheter].
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Catheterization; Chemotherapy, Adjuv | 2001 |
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Dehydrogen | 2001 |
[A case of postoperative multiple hepatic metastasis from esophageal cancer successfully treated by surgical resection and hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
[Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour | 2001 |
[A case of hepatocellular carcinoma responding to hepatic arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelli | 2001 |
[Usefulness of hepatic arterial infusion chemotherapy for liver metastasis in gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hepatic Arter | 2001 |
[Efficacy of continuous hepatic arterial infusion of high-dose 5-FU for liver metastases of gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Fluorouracil; Hepatic Artery; H | 2001 |
[A case of advanced gastric cancer with multiple liver metastases partially responding to combination intra-arterial chemotherapy via the hepatic artery and abdominal aorta].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cisplatin; Drug Administration Sch | 2001 |
[Hepatic resection for synchronous liver metastases of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatectomy; Hepatic Art | 2001 |
[Sigmoid colon cancer with multiple liver metastasis (H3) effectively treated with CPT-11 and DSM (degradable starch microsphere) HAI therapy and intensive high dosage 5-FU HAI therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; | 2001 |
[Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; | 2001 |
[Two cases of multiple liver metastases of colon cancer with systemic irinotecan and hepatic arterial injection of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administ | 2001 |
[A case of multiple liver metastases from sigmoid colon cancer effectively treated by hepatic intra-arterial administration of levoforinate and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatic Artery; Humans; Infusi | 2001 |
[Clinical experience of intra-arterial chemotherapy for liver metastases of breast cancer patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Doxo | 2001 |
[Pharmacokinetics of "subselective" arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Catheters, Indwelling; Drug Administration Sc | 2001 |
[Examination of in vitro chemosensitivity test using methylthiazole tetrazolium bromide chemosensitivity (MTT) test with combined drugs in hepatic arterial infusion chemotherapy for carcinoma of the liver].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Color | 2001 |
Preoperative administration of 5-FU and interferon beta may prevent recurrence of hepatitis B and C virus.
Topics: Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorouracil | 2002 |
[A case of spindle cell type hepatocellular carcinoma responding to hepatic intra-arterial infusion chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dru | 2002 |
Selective approaches to gastric cancer patients with liver metastases: role of liver-directed chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Humans; Infusi | 2001 |
Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2001 |
[Personal experience with intra-arterial locoregional chemotherapy of liver metastases from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Doxorubicin; Female | 2001 |
Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2001 |
Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Bystander Effect; Colonic Neoplasms; Cytosine Deaminase; D | 2002 |
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2002 |
[Implanted percutaneous continuous hepatic arterial infusion system for nonresectable liver metastasis].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus | 2001 |
Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2002 |
Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2002 |
Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases.
Topics: Adult; Aged; Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Ducts, Extrah | 2002 |
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 2002 |
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Hepat | 2002 |
[A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality | 2002 |
Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Female; Flox | 2002 |
Resistance to apoptosis is increased during metastatic dissemination of colon cancer.
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; bcl | 2002 |
[A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 2002 |
[A case of advanced gastric carcinoma with liver metastasis with no recurrence and long survival by means of surgery and postoperative chemotherapy].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
[A case of complete response (CR) persisting for 2 years and 10 months from UFT-E in a patient with liver metastasis of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2002 |
[A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug C | 2002 |
Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
Topics: Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2002 |
A breakthrough in cryosurgery.
Topics: Antimetabolites, Antineoplastic; Bronchial Fistula; Carcinoma; Cryosurgery; Fistula; Fluorouracil; H | 2002 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine | 2002 |
[A case treated successfully with low-dose CDDP and 5-FU for the treatment of liver and para-aortic lymph node metastases and second metastasis to anterior mediastinum lymph nodes from gastric cancer after gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administration Schedule; Fluo | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
[A case report of both CAF and docetaxel-resistant breast cancer responding to paclitaxel weekly therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2002 |
Is the NICE process flawed?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Liver Ne | 2002 |
[Treatment for patients with liver metastasis from colorectal cancer--expansion of hepatic arterial infusion therapy].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver | 2002 |
Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2002 |
[Apoptosis effects of human liver carcinoma cells induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Enzyme Inhibitors; Fluorourac | 2002 |
[The interaction between 5-fluorouracil and marini on QGY cell line in vitro].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Dose-Response Relationship, Drug; D | 2002 |
Effect of concanavalin A on tyrosine aminotransferase in rat hepatoma tissue culture cells. Rapid reversible inactivation of soluble enzyme.
Topics: Alanine Transaminase; Animals; Carcinoma, Hepatocellular; Cell Line; Concanavalin A; Cyclic AMP; Cyc | 1977 |
Chemotherapeutic drugs increase killing of tumor cells by antibody and complement.
Topics: Animals; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; | 1975 |
Hepatic artery ligation and cytotoxic infusion in treatment of liver neoplasms.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Fluorouracil; Hepatic Artery; Humans; Infusions, | 1975 |
Enhancing effect by metabolic inhibitors on the killing of tumor cells by antibody and complement.
Topics: Animals; Antibodies, Neoplasm; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carci | 1975 |
Effect of antitumor agents on sarcoma-180 tumor cells transplanted to liver, kidney, and lung.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Dactinomycin; Daunorubicin; Fluorouraci | 1975 |
Hepatic artery ligation and prolonged cytotoxic therapy in advanced primary and secondary liver tumours.
Topics: Adult; Aged; Antineoplastic Agents; Bilirubin; Biopsy; Catheterization; Female; Fluorouracil; Hepati | 1975 |
Beta-glucuronidase activity of Yoshida ascites hepatomas of different drug-sensitivity and its change after treatment of host rats with various anticancer agents.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carbazilquinone; Carcinoma, Hepatocellular; Chromomycins; | 1976 |
Evaluation of hepatoma chemotherapy by alpha-fetoprotein determination.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion | 1976 |
Hepatic dearterialization for nonrespectable primary and secondary tumors of the liver.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; Fluorouracil; Hemangiosarcoma; H | 1976 |
Primary sarcoma of the liver. Report of a case with excellent response to hepatic artery ligation and infusion chemotherapy.
Topics: Aged; Female; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms; Palliative Care; Sarc | 1978 |
Enhancement of the cancer chemotherapeutic effect by anticancer agents in the form of fat emulsion.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carcinoma, | 1977 |
Palliation of hepatic metastasis.
Topics: Female; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Palliative Care; Radiother | 1978 |
Treatment of liver cancer with regional intraarterial 5-FU infusion.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle | 1978 |
[Chemotherapy for digestive carcinomas. Results of a phase II clinical trial (author's transl)].
Topics: Bile Duct Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Esophageal Neopl | 1979 |
Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1979 |
[Treatment of primary and secondary liver tumors using a combination of chemotherapy and surgery].
Topics: Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Floxuridine; Fluorouracil; Humans; Leu | 1975 |
[Hepatic metastases of cancers of the large intestine. Results of arterial chemotherapeutic treatment].
Topics: Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Intestinal Neoplasms; Intesti | 1976 |
Chemotherapy of gastrointestinal cancer.
Topics: Doxorubicin; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Mitomyc | 1976 |
Complications of long term transbrachial hepatic arterial infusion chemotherapy.
Topics: Adolescent; Adult; Aged; Brachial Artery; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio | 1977 |
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.
Topics: Adult; Aged; Drug Evaluation; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, | 1978 |
[Chemotherapy of gastrointestinal cancer (author's transl)].
Topics: Carcinoid Tumor; Doxorubicin; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Neo | 1978 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusi | 1979 |
A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Drug Therapy | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Current management of hepatic tumors.
Topics: Angiography; Biopsy, Needle; Blood Platelet Disorders; Carcinoma, Hepatocellular; Child; Child, Pres | 1975 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
A study of trace and minor elements in the solid tumor model 3924A hepatoma before and after treatment with t-fluorouracil.
Topics: Animals; Carcinoma, Hepatocellular; Cattle; Disease Models, Animal; Female; Fluorouracil; Liver; Liv | 1975 |
Effects of 5-fluorouracil on the cell kinetic and growth parameters of hepatoma 3924A.
Topics: Animals; Carcinoma, Hepatocellular; Cell Count; Connective Tissue; Deoxyuridine; DNA, Neoplasm; Dose | 1975 |
Increased urinary excretion of cyclic guanosine monophosphate in rats bearing Morris hepatoma 3924A.
Topics: Animals; Carcinoma, Hepatocellular; Cyclic AMP; Cyclic GMP; Female; Fluorouracil; Liver Neoplasms; N | 1975 |
The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Floxuridine; Fluorouracil; In Vitro Techniques; | 1975 |
[Studies on the fate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207), a carcinostatic agent. III. Absorption, distribution, excretion and metabolism after rectal administration of FT-207 (author's transl)].
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Male; Neop | 1975 |
Experimental study on drug sensitivity of the rat ascites hepatoma cells in embryonated eggs.
Topics: Animals; Carcinoma, Hepatocellular; Chick Embryo; Drug Evaluation, Preclinical; Fluorouracil; Liver | 1975 |
Malignant hepatoma associated with acquired hepatic cutaneous porphyria.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Feces; Female; Fluorouracil; Hu | 1976 |
Complications of percutaneous transaxillary catheterization for arteriography and selective chemotherapy.
Topics: Adult; Aged; Angiography; Aortography; Arterial Occlusive Diseases; Axillary Artery; Catheterization | 1976 |
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Dacarbazine; Dactinomycin; Do | 1976 |
Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Colect | 1976 |
Primary carcinoma of the liver.
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Hepatocellular; Child; Child, Pre | 1976 |
Combination chemotherapy with 5--fluorouracil, amethopterin (methotrexate) and prednisolone (FAP protocol) in the therapy of cholangiocarcinoma.
Topics: Adenoma, Bile Duct; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Male; Methotre | 1976 |
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car | 1976 |
Solid tumour models for the assessment of different treatment modalities: IV. the combined effects of radiation and 5-fluorouracil.
Topics: Animals; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Dose-Response Relationship, Ra | 1976 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Utilization of 3H from deoxyuridine and thymidine for synthesis of DNA and tother macromolecules in various organs of the rat.
Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; Deoxyuridine; DNA; Fluorouracil; Intestinal Mucosa; | 1977 |
Observations on the postoperative tumor growth behavior of certain islet cell tumors.
Topics: Adenoma, Islet Cell; Fasting; Fluorouracil; Gastrins; Humans; Liver Neoplasms; Neoplasm Metastasis; | 1976 |
Differential recovery of intestine, bone marrow, and thymus of rats with solid tumors following 5-fluorouracil administration.
Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; Deoxyuridine; DNA; Dose-Response Relationship, Drug | 1976 |
Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line; Deoxyuridine; DNA Replication; Drug Re | 1977 |
Hepatocellular carcinoma in association with androgen therapy.
Topics: Adult; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Male; Methyltestosterone | 1977 |
Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; H | 1977 |
Oral fluorouracil therapy of hepatoma.
Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; | 1977 |
Futraful therapy on liver cancer.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Drug Administrat | 1977 |
Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy.
Topics: Animals; Carcinoma, Hepatocellular; Female; Fluorouracil; Liver Neoplasms; Neoplasms, Experimental; | 1977 |
Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Drug Resistance; Female; Fluorouracil; Isoenzymes; Ki | 1977 |
A case report of hepatoblastoma treated by chemotherapy and hepatic lobectomy.
Topics: Carcinoma, Hepatocellular; Child, Preschool; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Huma | 1977 |
[Effect of 5-fluorouracil and thiophosphamide on the activity and fractional content of phosphatases of Zajdela hepatoma].
Topics: Adenosine Triphosphatases; Animals; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Lysoso | 1977 |
Evidence for role of purine nucleoside phosphorylase in sensitivity of Novikoff hepatoma cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line; DNA, Neoplasm; Fluorouracil; | 1976 |
Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Female; Fluorourac | 1977 |
[Fluorinated pyrimidines administered by percutaneous arterial perfusion in primary or secondary cancers of the liver].
Topics: Carcinoma, Hepatocellular; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neopl | 1977 |
Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fem | 1977 |
Case report: Liver scintigraphy in the follow-up of a patient on cytotoxic therapy.
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Fluorouracil; Humans; | 1976 |
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Carcinoid | 1977 |
[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; | 1977 |
Chemotherapy studies in autochthonous rat tumors: hepatomas.
Topics: Animals; Carcinogens; Carcinoma, Hepatocellular; Cyclophosphamide; Doxorubicin; Female; Fluorouracil | 1977 |
Synchronization of host and tumor responses for sequential therapy in experimental solid tumors.
Topics: Animals; Bone Marrow Diseases; Carcinoma, Hepatocellular; Cell Cycle; DNA, Neoplasm; Drug Administra | 1978 |
Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts.
Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; DNA; Drug Administration Schedule; Fluorouracil; Li | 1978 |
Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Fluo | 1978 |
Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives.
Topics: Adult; Carcinoma, Hepatocellular; Carmustine; Contraceptives, Oral; Contraceptives, Oral, Combined; | 1978 |
Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Hepatocellular; Disseminated Intravascular Co | 1978 |
Evaluation of a chemotherapeutic regimen for primary liver cancer in children.
Topics: Adolescent; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Child; Doxorubicin; Drug E | 1978 |
[Characteristic pharmacodynamic in 1-(2-tetrahydrofuryl)-5-fluorouracil metabolism and its clinical efficacy in patients with primary hepatoma (author's transl)].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Li | 1978 |
Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: a case report.
Topics: Adenoma, Bile Duct; Adult; Carcinoembryonic Antigen; Doxorubicin; Drug Therapy, Combination; Female; | 1979 |
Treatment of primary liver cancer: response to regional chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg | 1979 |
Clinical studies in Asian patients with irresectible primary hepatocellular carcinoma treated by adriamycin and prednisolone alone or in combination with 5-fluorouracil, vincristine and prednisolone.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Child; Doxorubicin; Drug Therapy, Combination; F | 1978 |
Hepatocellular carcinoma associated with erythrocytosis. A nine year survival after successful chemotherapy and left lateral hepatectomy.
Topics: Carcinoma, Hepatocellular; Erythropoietin; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male; | 1979 |
Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Indomethacin; Kinetics; Liver Cirrhosis; Liver Neop | 1979 |
[Oral 5-fluorouracil therapy in liver metastasis].
Topics: Administration, Oral; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Huma | 1979 |
Leucovorin in combination chemotherapy of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Le | 1977 |
Treatment of hepatic metastases by percutaneous hepatic arterial infusion.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastroint | 1979 |
Effect of infusion chemotherapy and hepatic artery ligation on normal liver: experimental study in the cat.
Topics: Animals; Cats; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Ligation; Li | 1979 |
Heparinized catheters for long-term intraarterial infusion of 5-fluorouracil in liver metastases.
Topics: Aged; Catheters, Indwelling; Female; Fluorouracil; Heparin; Humans; Infusions, Intra-Arterial; Liver | 1979 |
Combination infusional 5-fluorouracil and radiation therapy for the treatment of metastatic carcinoma of the colon to the liver.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Liver Neo | 1979 |
[Intra-arterial infusion chemotherapy for metastatic liver cancer (author's transl)].
Topics: Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Mitomycins | 1979 |
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil vs. intravenous 5-fluorouracil in patients with hepatic metastases from colo-rectal cancer: a Central Oncology Group Study (COG 7032).
Topics: Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Hepatic Artery; Humans; Infusions, Int | 1979 |
The carcinoid syndrome: methods of treatment and recent experience with hepatic artery ligation and infusion.
Topics: Female; Fluorouracil; Heart Failure; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Ileum; Intest | 1977 |
Iatrogenic liver abscesses. A complication of hepatic artery ligation for tumor.
Topics: Arteriovenous Shunt, Surgical; Biliary Fistula; Bronchial Fistula; Female; Fluorouracil; Hepatic Art | 1978 |
Effect of 5-fluorouracil on liver regeneration and metabolism after partial hepatectomy in the rat.
Topics: Animals; Body Weight; Female; Fluorouracil; Hepatectomy; Lipids; Liver; Liver Neoplasms; Liver Regen | 1978 |
Treatment of hepatic metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1978 |
Fundamental investigations on local chemotherapy for liver cancer.
Topics: Animals; Dogs; Fluorouracil; Humans; In Vitro Techniques; Liver; Liver Neoplasms; Mitomycins | 1978 |
Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes.
Topics: Catheters, Indwelling; Colonic Neoplasms; Femoral Artery; Fluorouracil; Hepatic Artery; Humans; Infu | 1978 |
The clinical results of 5-fluorouracil intrahepatic arterial infusion in 528 patients with metastatic cancer to the liver.
Topics: Diarrhea; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 1978 |
Primary malignant hemangioendothelioma of the liver: survival following nonoperative treatment.
Topics: Fluorouracil; Hemangioendothelioma; Humans; Liver Neoplasms; Male; Middle Aged; Optic Neuritis | 1978 |
Cancer of the pancreas in young adults.
Topics: Adenocarcinoma; Adult; Biopsy, Needle; Female; Fluorouracil; Humans; Laparotomy; Liver Neoplasms; Ne | 1978 |
Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immune | 1975 |
Hypoglycemia secondary to metastases to the liver. A case report and review of the literature.
Topics: Aged; Cyclophosphamide; Fluorouracil; Humans; Hypoglycemia; Liver Neoplasms; Male; Neoplasm Metastas | 1977 |
Management of hepatic metastases.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional P | 1977 |
Cyclic combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1977 |
Results of liver dearterialization combined with regional infusion of 5-fluorouracil for liver cancer.
Topics: Adult; Aged; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Ligation; Liver Ci | 1976 |
Treatment of experimental liver tumors by continuous intra-arterial chemotherapy.
Topics: Administration, Oral; Animals; Carcinoma 256, Walker; Fluorouracil; Hepatic Artery; Infusions, Paren | 1976 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
Basal-cell carcinoma. A case unmasked by systemic fluorouracil therapy.
Topics: Administration, Topical; Carcinoma, Basal Cell; Diarrhea; Fluorouracil; Humans; Injections, Intraven | 1976 |
Hemangiosarcoma of liver and spleen treated by hepatic artery ligation, intraportal infusion chemotherapy, and splenectomy.
Topics: Adult; Female; Fluorouracil; Hemangiosarcoma; Hepatic Artery; Humans; Ligation; Liver Neoplasms; Spl | 1976 |
The role of nonspecific immunotherapy in the treatment of breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer.
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoro | 1976 |
Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infu | 1976 |
Survival among patients with liver metastases from cancer of the colon and rectum.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Bilirubin; Colonic Neoplasms; F | 1976 |
Hepatic artery ligation in treatment of carcinoid syndrome.
Topics: Aged; Angiography; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Hydroxyindoleacet | 1975 |
Hepatic artery ligation and postoperative chemotherapy for hepatic metastases: clinical and pathophysiological results.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Carbon Dioxide; Colonic Neoplasms; Female; Fluorouracil; | 1975 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
[Clinical and experimental aspects of intra-arterial treatment of malignant neoplasms of the liver in children].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Drug Evaluation; Fluorouracil; Humans; Injections, | 1975 |
[Digestive tract cancer: planning of chemotherapy].
Topics: Bile Duct Neoplasms; Cytarabine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Hum | 1975 |
["MFC" therapy for advanced gastrointestinal cancer (author's transl)].
Topics: Cytarabine; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasm | 1975 |
Intra arterial chemotherapy in malignant tumours of liver (a preliminary report).
Topics: Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Methotrex | 1975 |
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil.
Topics: Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Liver Neoplasms; Neoplasm Metastasis | 1975 |
Concentration of biologically active 5-fluorouracil in general circulation during continuous portal infusion in man: a preliminary report.
Topics: Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Portal Vein | 1975 |
Evaluation of the ligation of the hepatic artery and regional arterial chemotherapy in the treatment of primary and secondary cancer of the liver.
Topics: Adolescent; Adult; Evaluation Studies as Topic; Female; Fluorouracil; Hepatic Artery; Humans; Ligati | 1975 |
Adriamycin in the treatment of cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1976 |
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Li | 1976 |
Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
Topics: Adult; Aged; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Ligation; Liver Ne | 1976 |
[Pancreatic endocrine tumor with metastases and increase of alpha-fetoprotein. A case report].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fatal Outcome; Fluoroura | 1992 |
Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouraci | 1992 |
Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; | 1992 |
Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; Gastroin | 1992 |
[Hepatic blood flow in patients treated by continuous hepatic artery infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 1992 |
[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut | 1992 |
5-Fluorouracil and leucovorin in hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fe | 1992 |
[Treatment of hepatic malignant tumors with percutaneous echoguided injections of absolute alcohol and 5 FU- folinic acid-ultrafluid lipiodol combination. Preliminary results in 17 patients].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drug Therapy, Combina | 1992 |
[Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Liver Neoplasms; | 1992 |
[The efficacy of transarterial immuno-embolization therapy in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fibrinogen; Fluoro | 1992 |
[Effects of intra-arterial infusion chemotherapy with radiation therapy for advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1992 |
[Prophylactic chemotherapy by regional arterial infusion in resected hepatoma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1992 |
[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
Chemotherapy can convert unresectable hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
[Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using implantable drug delivery system].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubic | 1992 |
Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1992 |
[Clinical evaluation of operative and non-operative treatment in hepatocellular carcinoma with main portal vein tumor thrombus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
[Orthotopic liver transplantation for metastases of bronchial carcinoid tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoid Tumor; Combine | 1992 |
Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate.
Topics: Carcinoid Tumor; Chemoembolization, Therapeutic; Combined Modality Therapy; Fluorouracil; Humans; In | 1992 |
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepa | 1992 |
[The efficacy of transcatheter arterial infusion chemotherapy in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Doxorubicin; Femal | 1992 |
[Hepatic arterial infusion chemotherapy plus embolization for unresectable liver cancer--a report on 40 patients].
Topics: Adult; Aged; Chemoembolization, Therapeutic; Cisplatin; Female; Fluorouracil; Hepatic Artery; Humans | 1992 |
Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination.
Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1992 |
Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; | 1992 |
[A case report of metastatic colonic carcinoma in the liver effectively treated by long-term, ambulatory and continuous, intra-hepatic-arterial infusion of 5-fluorouracil using disposable multi-day-type infusor].
Topics: Adult; Ambulatory Care; Colectomy; Colostomy; Disposable Equipment; Drug Administration Schedule; Fe | 1992 |
[Intermittent intra-arterial infusion chemotherapy using implantable reservoir for the treatment of hepatic metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 1992 |
[Evaluation of implantation of a cancer chemotherapeutic vascular access device: report of 91 cases].
Topics: Catheters, Indwelling; Cisplatin; Evaluation Studies as Topic; Femoral Artery; Fluorouracil; Humans; | 1992 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
[Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer].
Topics: Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps; Infusions, In | 1992 |
[Treatment of liver metastases from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 1992 |
[Superior mesenteric arterial infusion chemotherapy in patient with both peritoneal carcinomatosis and liver metastasis].
Topics: Animals; Fluorouracil; Infusions, Intra-Arterial; Intestine, Small; Liver; Liver Neoplasms; Mesenter | 1992 |
[Effective treatment of liver metastasis and peritoneal dissemination of gastric cancer using intra-arterial therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administration Schedule; Fluoro | 1992 |
[Rapid complete regression of liver, brain and bone metastases from previously treated breast cancer, with combination of platin, fluorouracil and lomustine].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neopl | 1992 |
[A case of recurrent liver tumor from gastric cancer responding remarkably to hepatic arterial infusion of large doses of mitomycin C and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gastrectomy; Hepatic Artery; Hum | 1992 |
[Indication for chemoembolization of liver tumors. An interdisciplinary concept and initial results].
Topics: Adult; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Fluorouracil; Germany, West; Human | 1992 |
[Pharmacokinetic study of tegafur in the hepatic tissue obtained from the patients with liver cancer].
Topics: Aged; Colonic Neoplasms; Fluorouracil; Humans; Liver; Liver Neoplasms; Middle Aged; Stomach Neoplasm | 1992 |
[A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion | 1992 |
Regression of liver metastases following treatment with yttrium-90 microspheres.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Chemotherapy, Cancer, Regional Perfusion; Col | 1992 |
Promotion of hepatic metastases by liver resection in the rat.
Topics: Animals; Fluorouracil; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Mi | 1992 |
Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response.
Topics: Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; Liver Neoplasms; Rectal Neoplasms; Re | 1992 |
[Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report].
Topics: Adult; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies | 1991 |
[A case of recurrent hepatocellular carcinoma after hepatic resection surviving over five years by hepatic arterial infusion of lipiodol-anticancer drug suspension].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1991 |
[Efficacy of anticancer agent-lipiodol emulsion for hepatic arterial infusion and regional hyperthermia in patients with nonresectable hepatoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal | 1991 |
[Intra-arterial infusion chemotherapy for unresectable hepatocellular carcinoma using an implantable reservoir].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; D | 1991 |
[Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 1991 |
[Effects of intraarterial infusion chemotherapy on liver function in patients with hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cytarabine; | 1991 |
Complete disappearance of unresectable hepatoblastoma by continuous infusion therapy through hepatic artery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1991 |
Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1991 |
The incorporation of 5-fluorouracil into rat liver tumor and normal tissues after administration by the hepatic artery during temporary portal vein clamping.
Topics: Adenosine Triphosphate; Animals; Constriction; DNA; Fluorouracil; Hepatic Artery; Intestinal Mucosa; | 1990 |
Combination chemotherapy in the treatment of hepatoblastoma.
Topics: Adenomatous Polyposis Coli; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biom | 1990 |
Alpha-interferon and oral fluorouracil in the treatment of unremovable and/or metastatic renal cancer.
Topics: Adult; Aged; Bone Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Interferon-alp | 1991 |
[Nutritional support for cancer bearing patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Home Nursing; Humans | 1991 |
Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
Effects of combined therapies with protein-bound polysaccharide (PSK, Krestin) and fluorinated pyrimidine derivatives on experimental liver metastases and on the immunologic capacities of the hosts.
Topics: Adjuvants, Immunologic; Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; | 1991 |
Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy.
Topics: Colonic Neoplasms; Female; Fluorouracil; Hemofiltration; Hemoperfusion; Humans; Infusions, Intra-Art | 1991 |
High total dose 5-fluorouracil treatment during pregnancy.
Topics: Adult; Breast Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Pregnancy; Pregnancy Complic | 1991 |
Isolated liver perfusion versus hepatic artery infusion with 5-fluorouracil in a rat model; effects on thymidylate synthase.
Topics: Animals; Binding Sites; Bone Marrow; Cell Line; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouraci | 1991 |
Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings.
Topics: Aged; Carcinoma; Duodenitis; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Ileitis; Inf | 1991 |
Colorectal metastases to the liver: present results and future strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1991 |
The role of interferons in the management of carcinoid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Int | 1991 |
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hep | 1991 |
[Regional chemotherapy of diffuse liver metastases of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1991 |
[A combined method for treating metastases of colorectal carcinoma to the liver].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 1991 |
Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Screening Assays, Antitumo | 1991 |
Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Animals; Azoxymethane; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dise | 1991 |
[Hepatic arterial infusion of high dose 5-FU in weekly schedule for liver metastases from colorectal cancer employing a newly developed pump "Koken Infusor"].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouraci | 1991 |
[Loco-regional cancer therapy for hepatic metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamid | 1991 |
[Five-hour hepatic arterial infusion of high-dose 5-FU on weekly schedule for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Fluorouracil; Humans; Infusions | 1991 |
[Evaluation of continuous intra-arterial infusion chemotherapy after hepatic resection of liver metastases in colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1991 |
[Regional immunochemotherapy for liver metastasis of esophageal cancer in a patient with variant hepatic artery].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1991 |
[Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubic | 1991 |
Kinetic modeling of in vivo--nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors.
Topics: Adult; Aged; beta-Alanine; Female; Fluorine; Fluorouracil; Humans; Least-Squares Analysis; Liver; Li | 1991 |
[Hepatic arterial infusion chemotherapy and loco-regional treatment and irradiation of pancreas tumor in non-resectable pancreas cancer with liver metastases].
Topics: Administration, Oral; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; | 1991 |
[Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colo | 1991 |
[Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Colorectal Neop | 1991 |
[Effects and complications of continuous hepatic arterial infusion chemotherapy using implantable reservoir for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Drug Administ | 1991 |
[Hepatic arterial infusion of farmorubicin (FARM) and 5-fluorouracil (5-FU) in a patient with massive hepatic metastasis from gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorourac | 1991 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
[Splenic or hepatic arterial injections of interleukin-2 with chemotherapeutic agents for hepatic metastases].
Topics: Aged; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; In | 1991 |
[Combined regional chemotherapy and radiotherapy of liver metastases].
Topics: Catheters, Indwelling; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intra-Arterial; L | 1990 |
A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorour | 1991 |
Colorectal liver metastases.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Microspheres | 1991 |
[Value of CEA determination in follow-up of patients with liver metastasis of colorectal cancers with loco-regional chemotherapy].
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1991 |
[Myocardial infarcts within the scope of 5-fluorouracil therapy].
Topics: Adenocarcinoma; Adult; Electrocardiography; Fluorouracil; Humans; Infusions, Intravenous; Liver Neop | 1990 |
[Intrahepatic arterial infusion chemotherapy in primary and metastatic cancer of the liver].
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil; Hepatic Artery; | 1990 |
Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy.
Topics: Adult; Aged; beta-Alanine; Female; Fluorine; Fluorouracil; Humans; Liver; Liver Neoplasms; Magnetic | 1990 |
[A case of unresectable liver metastasis from leiomyosarcoma of the stomach successfully treated by intra hepato-arterial chemotherapy with Infuse-A-Port].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Hepatic Artery; Humans; I | 1990 |
[Combined treatment by hepatectomy and postoperative chemotherapy via a catheter in the hepatic artery of metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fluorouracil | 1990 |
[Treatment of liver metastases from colorectal cancer--major hepatic resection and continuous hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hep | 1990 |
Serious chemical sclerosing cholangitis associated with hepatic arterial 5FU and MMC chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrogra | 1990 |
[Tissue UFT distribution and histological changes following UFT administration in metastatic liver cancer cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Human | 1990 |
[Evaluation of the liver and peritoneal metastasis in the treatment of gastric carcinoma with intra-arterial injection in terms of survival period].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Int | 1990 |
[A study of low-dose intermittent intra-arterial infusion chemotherapy for liver metastasis in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1990 |
[Clinical evaluation and problem of intra-arterial infusion chemotherapy of liver metastasis from digestive organ cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl | 1990 |
[Hepatic arterial infusion chemotherapy using implantable reservoir in colorectal liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Doxorubicin; Fluoro | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
[Continuous hepatic arterial infusion chemotherapy using implantable reservoir in liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Drug | 1990 |
[Successful treatment of advanced gastric cancer with multiple liver metastasis by combination chemotherapy using mitomycin C, 5-fluorouracil, and high-dose leucovorin: a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1990 |
[Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Scree | 1990 |
Hepatic artery infusion pumps: cannulation techniques and other surgical considerations.
Topics: Animals; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, | 1990 |
Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antiviral Agents; Bromodeoxyuridine; Colonic Neoplas | 1990 |
Regional chemotherapy in liver metastases of colorectal carcinoma: monitoring with arterial computed tomography.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorub | 1990 |
Localized skin toxicity from 5-fluorouracil after paravenous infusion of leukovorin calcium.
Topics: Drug Eruptions; Fluorouracil; Humans; Injections, Subcutaneous; Leucovorin; Liver Neoplasms; Male; M | 1990 |
[Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1990 |
[Intra-hepato-arterial infusion chemotherapy using catheter inserted and placed in hepatic artery via the left radial artery on liver malignancy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1990 |
[Clinical efficacy of ifosfamide for liver metastasis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Breast Neoplasms; Doxorubicin; Drug Ad | 1990 |
Cytocidal activity of a synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1990 |
Application of traditional Chinese drugs in comprehensive treatment of primary liver cancer.
Topics: Carcinoma, Hepatocellular; Cobalt Radioisotopes; Combined Modality Therapy; Doxorubicin; Drugs, Chin | 1990 |
[Primary and metastatic liver tumors--evaluation of tumor regression and response with regional cytostatic drug therapy by sonography and fine needle puncture histology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Carmustin | 1990 |
[Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer].
Topics: Adenoma, Bile Duct; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile | 1990 |
Repeated dearterialization of hepatic tumors with an implantable occluder.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheterization; Catheters, Indwelling; Colonic Neoplasms; E | 1990 |
[A case of nonresectable gastric cancer completely responding to combined chemotherapy according to the mode of progression].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
Toxicities of trichosanthin and alpha-momorcharin, abortifacient proteins from Chinese medicinal plants, on cultured tumor cell lines.
Topics: Abortifacient Agents, Nonsteroidal; Animals; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Ce | 1990 |
Rapid chemosensitivity assay with human normal and tumor cells in vitro.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Survival; Cells, Cultured; Cisplatin; Dose-Re | 1990 |
A comparison of regional and systemic chemotherapy for hepatic metastases.
Topics: Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Art | 1990 |
[A case of esophageal carcinoma with the lung and liver metastases surviving more than 3 years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Ci | 1990 |
Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. The Swiss Group for Clinical and Epidemiological Cancer Research (SAKK).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1990 |
A simple high pressure liquid chromatographic method for the determination of fluorouracil to monitor patients on regional infusion for hepatic metastases.
Topics: Chromatography, High Pressure Liquid; Fluorouracil; Humans; Indicators and Reagents; Infusions, Intr | 1990 |
Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients.
Topics: Fluorouracil; Humans; Hyaluronoglucosaminidase; Injections, Intra-Arterial; Liver Neoplasms; Male; M | 1990 |
Comparison of portal vein chemotherapy with hepatic artery chemotherapy in the treatment of liver micrometastases.
Topics: Animals; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Infusions, I | 1990 |
Hepatic arterial infusion (HAI) chemotherapy for liver metastases of colorectal cancer using 5-FU.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra | 1990 |
The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplas | 1990 |
[Transcatheter hepatic artery chemoembolization in the treatment of liver cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Embolization, Therapeutic; | 1990 |
[Intraarterial and intraportal infusion chemotherapy to prevent hepatic metastasis after curative resection of pancreatic cancer].
Topics: Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; P | 1990 |
[Evaluation of reservoir inserted for the prevention of liver metastasis of colorectal cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatectomy; Humans; Infusion Pump | 1990 |
Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases.
Topics: Animals; Catheterization; Colonic Neoplasms; Fluorouracil; Liver Neoplasms; Male; Neoplasm Transplan | 1990 |
[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Hepatocellular; Combined | 1985 |
Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biodegradation, Env | 1985 |
[Current status of diagnosis and treatment of metastatic liver cancer].
Topics: alpha-Fetoproteins; Angiography; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antin | 1987 |
Conventional fractionation radiotherapy combined with 5-fluorouracil for metastatic malignant melanoma.
Topics: Abdominal Neoplasms; Adult; Aged; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Liver Neoplasm | 1987 |
5-Fluorouracil incorporation into RNA of a rat liver adenocarcinoma after hepatic artery injection together with degradable starch microspheres.
Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Female; Fluorouracil; Injections, Intra-Arterial; Liver | 1987 |
Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1988 |
[Favorable response of advanced hepatocellular carcinoma to proper hepatic arterial administration of cytokines and the significance of the administration].
Topics: Animals; Carcinoma, Hepatocellular; Drug Combinations; Fluorouracil; Hepatic Artery; Humans; Injecti | 1988 |
Effective palliation of metastatic adenocarcinoma to the liver: a case report.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, | 1988 |
Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Carcinoma, Hepatocellular; | 1989 |
The combined effect of interferon and 5-FU on tumor-cell metastasis in the nude mouse.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluor | 1989 |
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1989 |
Effects of chemotherapeutic agents on alpha-fetoprotein secretion and growth of human hepatoma cell lines in vitro.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cisp | 1989 |
[Clinical use of magnetic resonance spectroscopy and positron emission tomography in oncology].
Topics: Colorectal Neoplasms; Energy Metabolism; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance S | 1989 |
[Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children].
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1989 |
Treatment of hepatic cancer by hepatic arterial infusion chemotherapy.
Topics: Embolization, Therapeutic; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Ne | 1989 |
Non-homogeneous intrahepatic drug distribution in intraportal infusional chemotherapy demonstrated by Tc-99m-MAA perfusion SPECT.
Topics: Aged; Catheterization, Central Venous; Chemotherapy, Cancer, Regional Perfusion; Combined Modality T | 1989 |
[Conservative treatment of malignant liver tumors].
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Methotr | 1989 |
[Chemotherapeutic effect on metastatic tumors].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Fluorou | 1989 |
[Locoregional chemotherapy of liver tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1989 |
[Preventive hepatic arterial infusion in high risk cases of liver metastasis from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluation; Fluorour | 1989 |
[Availability of intermittent chemotherapy by reservoir in liver metastasis of colo-rectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Evaluation Studie | 1989 |
[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Combined Moda | 1989 |
[Over two years survival of intra-arterial infusion chemotherapy in gastric cancer with liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fluoro | 1989 |
[Arterial infusion chemotherapy in patients with gastric cancer in liver metastasis and long-term survival after treatment].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Aorta; Doxorubicin; Fluorouracil; He | 1989 |
[Study of long-survival cases with liver metastasis of colorectal cancer by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Doxo | 1989 |
[Reservoir implanted arterial infusion therapy in liver cancer with replaced right hepatic artery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi | 1989 |
[Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cholangitis, Sclerosin | 1989 |
[Three cases of effective hepatic arterial infusion with OK-432, mitomycin C and 5-fluorouracil in liver metastasis from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatic Artery; Humans; | 1989 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1989 |
Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1989 |
[Evaluation of long survival cases treated with intra-arterial cancer chemotherapy using implantable reservoirs].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxor | 1989 |
Regional chemotherapy for hepatic metastases from colorectal carcinoma.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms | 1989 |
Treatment of liver metastases from colorectal cancer with continuous high dose intra-arterial floxuridine (FUDR) and systemic fluorouracil: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1989 |
[A case of hepatocellular carcinoma (HCC) with lung metastasis which responded to chemotherapy with a single use of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Lung Neopla | 1989 |
Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheterization, Peripheral; Doxorubicin; Embolization, Ther | 1989 |
[Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Combined Modality Therapy; Doxorubicin; | 1989 |
[Clinical studies of intermittent hepatic arterial occlusion with infusion chemotherapy for unresectable hepatocellular carcinoma associated with arterioportal or arteriovenous shunts].
Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluor | 1989 |
[Metastatic liver cancer from the stomach successfully treated by combined immunochemotherapy and transarterial embolization].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabin | 1989 |
Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Liver Cirrhosis; Liv | 1989 |
[Preliminary study of traditional Chinese medicine-Western medicine treatment of patients with primary liver carcinoma].
Topics: Adjuvants, Immunologic; Adult; Camptothecin; Carcinoma, Hepatocellular; Cimetidine; Drugs, Chinese H | 1989 |
[Intra-arterial infusion chemotherapy in non-resectable pancreatic cancer using angiotensin-II and implantable drug delivery system].
Topics: Adenoma, Bile Duct; Adult; Aged; Aged, 80 and over; Angiotensin II; Antineoplastic Combined Chemothe | 1989 |
[New approach for unresectable primary liver cancer--intra-arterial combination chemotherapy during and after operation with local injection of ethanol].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 1989 |
[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Com | 1989 |
[Hepatic arterial infusion chemotherapy of hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug E | 1989 |
[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combin | 1989 |
[A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 1989 |
[A long-survival case of hepatocellular carcinoma treated by intra-arterial chemotherapy and immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Hepatocellular | 1989 |
[Analysis of prognostic factors in patients with hepatocellular cancer treated by hepatic arterial infusion chemotherapy].
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1989 |
[The study of transcatheter arterial chemo-lipiodol administration in liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1989 |
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 1989 |
[A case of hepatocellular carcinoma effectively treated by intraarterial infusion of CDDP and other agents].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Emboliza | 1989 |
Intraarterial infusion chemotherapy for metastatic liver tumors using multiple anti-cancer agents suspended in a lipid contrast medium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Diatrizoate M | 1989 |
[Hepatic artery embolization for primary hepatic carcinoma].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Embolization, Therapeutic; Female; Fluorouracil | 1989 |
[Advanced hepatocellular carcinoma: value of systemic chemotherapy combining adriamycin, amiodarone and 5-fluorouracil].
Topics: Adult; Aged; Amiodarone; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1989 |
[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1989 |
[Two cases of digestive cancer demonstrated remarkable regression by hyperthermia with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic N | 1989 |
[The clinical studies of intermittent hepatic artery occlusion with infusion chemotherapy--19 cases of unresectable hepatocellular carcinoma and 14 cases of metastatic liver cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterizat | 1989 |
[Ablative hormone therapy and chemotherapy of metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1989 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
In vitro and in vivo inhibition of thymidylate synthase of human colon cancer by 5-fluorouracil.
Topics: Colonic Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Liver Neoplasms; Thymidylate Synthase | 1989 |
[Synchronous hepatic metastases of colorectal adenocarcinoma: what is the course? Apropos of 36 cases].
Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, In | 1989 |
[Early adjuvant intraportal chemotherapy with 5-fluorouracil after hepatic resection of colorectal metastasis: a preliminary clinical and pharmacokinetic study].
Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; I | 1989 |
A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female; | 1989 |
[Positron emission tomography following brief infusion of 5-[18F]uracil: linear model for the kinetics of 18F radioactivity in tumors].
Topics: Colonic Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neoplasms; Tomography, Emissi | 1989 |
[Experiences with intra-arterial tumor chemotherapy of malignant liver tumors via totally implantable catheter systems].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; C | 1989 |
5-Fluorouracil-induced angina.
Topics: Aged; Angina Pectoris; Coronary Vasospasm; Female; Fluorouracil; Humans; Liver Neoplasms; Platelet A | 1989 |
[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Flu | 1989 |
[Hepatic arterial infusion chemotherapy using totally implantable reservoir in liver metastases in colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoemb | 1989 |
[Intra-arterial chemotherapy with angiotensin II in metastatic carcinoma of the liver using implantable pump].
Topics: Adult; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Doxo | 1989 |
[Portal vein infusion therapy of the prevention of liver metastasis from colorectal carcinomas].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouraci | 1989 |
[Intra-hepato-arterial chemotherapy combined with hyperthermic treatment: clinical results of metastatic cancer of the liver and effects on correct (but not at all necessary) hepatic blood flow].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1989 |
[Arterial infusion cancer chemotherapy in liver tumor using implantable reservoir].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1989 |
Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Art | 1989 |
Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dogs; Drug Evaluation; Female; Fluorouracil | 1989 |
[1-Hexylcarbamoyl-5-fluorouracil (HCFU) effective in hepatocellular carcinoma metastatic to the lungs--a case report].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1987 |
Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1987 |
[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Fluoro | 1987 |
Clinical management of recurrent hepatocellular carcinoma after primary resection.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fluorouracil; Follow-Up S | 1988 |
Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluat | 1988 |
Intrahepatic chemotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; | 1988 |
[5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver; Liver Neoplasms | 1988 |
Treatment of unresectable hepatoblastoma with cisplatin, vincristine and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child, Preschool; Cisplat | 1988 |
[Combined hepatic arterial infusion chemotherapy with transcatheter arterial embolization and hyperthermia in primary liver cancer].
Topics: Adenoma, Bile Duct; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, | 1988 |
[Arterial infusion of anticancer agent and lipiodol using a totally implanted drug delivery system].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Combinations; Emulsions; Fluoroura | 1988 |
[Accumulation of lipiodol in hepatocellular carcinoma after transarterial chemoembolization with 5 FU-lipiodol-emulsion].
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Emulsions; Fluorouracil; Hepatic Artery; Human | 1988 |
[Trans-arterial embolization or transarterial infusion of anti-cancer drugs suspended in a lipid contrast medium against unresectable metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Embolization, Therapeutic; Fluorouracil | 1988 |
[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combin | 1988 |
[Hepatic arterial chemotherapy combined with hyperthermia or arterial embolization in unresectable liver tumor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Hepatocellular; Cispla | 1988 |
Sensitivity to six antitumor drugs differs between primary and metastatic liver cancers.
Topics: Aclarubicin; Antineoplastic Agents; Carbazilquinone; Carcinoma, Hepatocellular; Cisplatin; Doxorubic | 1988 |
[Olive oil-lipiodol mixture and anticancer agents (5FU, MMC) emulsion as a chemoembolic agent].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Emboliza | 1988 |
Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 1986 |
Assessment of serial carcinoembryonic antigen: determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy.
Topics: Adult; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Cancer, Regional Perfusion; Cohort | 1989 |
Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A | 1989 |
Epithelioid haemangioendothelioma of the liver: objective response to hepatic intra-arterial 5-FU.
Topics: Female; Fluorouracil; Hemangioendothelioma; Hepatic Artery; Humans; Injections, Intra-Arterial; Lapa | 1989 |
Hepatic arterial and systemic chemotherapy for the treatment of primary and secondary malignancies of the liver.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; Fl | 1985 |
Hepatic artery infusion chemotherapy for colorectal metastases: a personal experience.
Topics: Adult; Aged; Carcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans | 1985 |
The implantable "Infusaid" infusion pump. The Sydney experience using 5-fluorouracil.
Topics: Australia; Colonic Neoplasms; Floxuridine; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Infusi | 1986 |
Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2'-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model.
Topics: Animals; DNA, Neoplasm; Floxuridine; Fluorouracil; Liver; Liver Neoplasms; Liver Neoplasms, Experime | 1986 |
Aggressive resection of metastatic disease in selected patients with malignant gastrinoma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Combin | 1986 |
Implantable vascular access devices in the treatment of colorectal liver metastases.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arter | 1986 |
On the differential affinities of two anticancer analogues to their target.
Topics: Adenocarcinoma; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Floxuridine; Fluoro | 1985 |
An implantable pump for regional chemotherapy of liver metastases.
Topics: Adult; Aged; Catheters, Indwelling; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arte | 1986 |
[Chemoprophylaxis of liver metastasis of colonic and rectal cancers].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Portal Vein; Rectal N | 1986 |
Treatment of liver metastases with a combination of chemotherapy and hyperfractionated external radiation therapy.
Topics: Combined Modality Therapy; Floxuridine; Fluorouracil; Humans; Liver; Liver Neoplasms | 1987 |
Regional and systemic chemotherapy for colorectal metastases to the liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans | 1987 |
[Locoregional chemotherapy of hepatic metastases of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Infusion Pumps; I | 1987 |
Intra-arterial hepatic chemotherapy for liver malignancy.
Topics: Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Liver Neoplasms | 1988 |
[Our therapy concept in nonresectable liver metastases].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Com | 1988 |
[Rationale and current results of loco-regional chemotherapy in hepatic metastases of colorectal carcinoma].
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Colorectal Neoplasms; Doxorubicin; Floxuridine; Fluoro | 1987 |
Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1985 |
Chemotherapy of metastatic islet cell carcinoma. Report of 4 cases and review of the literature.
Topics: Adenoma, Islet Cell; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Ne | 1985 |
Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child, Preschool; Cisplat | 1985 |
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Fluorouracil; | 1985 |
Primary liver tumor in a young man: a brief review of diagnostic strategies and treatment options.
Topics: Adult; Carcinoma, Hepatocellular; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Male; Parenter | 1985 |
Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arteritis; Carcinoma, Hepatocellular; Cholecystitis; Ch | 1985 |
[Low-dose intermittent intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dox | 1985 |
[Basic and clinical study of liver cancer using intra-arterial infusion of an emulsion of the oily contrast medium lipiodol with 5-FU].
Topics: Animals; Emulsions; Fluorouracil; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; R | 1985 |
[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization | 1985 |
Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Hepato | 1985 |
[Physiologic hepatic dearterialization and 5-FU intra-arterial perfusion in primary hepatic carcinoma].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Int | 1985 |
[Blood level of 5-fluorouracil (5-FU) by oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and tegafur in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1985 |
[Evaluation of intermittent hepatic arterial occlusion with infusion chemotherapy of unresectable hepatocellular carcinoma].
Topics: Aged; Animals; Carcinoma, Hepatocellular; Dogs; Embolization, Therapeutic; Female; Fluorouracil; Hep | 1986 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
Combined use of drugs and radiation in the treatment of liver metastases.
Topics: Amifostine; Bromodeoxyuridine; Combined Modality Therapy; Floxuridine; Fluorouracil; Humans; Infusio | 1986 |
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.
Topics: Animals; Antibodies; Biliary Tract Neoplasms; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; C | 1986 |
[Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 1986 |
[Angiographic and computed tomographic findings in intra-arterial cytostasis of colorectal liver metastases].
Topics: Angiography; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arteri | 1986 |
[A case of hepatoma effectively treated by TAE and intra-arterial and intraportal infusion chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 1986 |
Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance.
Topics: Administration, Cutaneous; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Hepatocellular; Fluorou | 1986 |
Cardio-pulmonary elimination of 5-fluorouracil after bolus injection in the hepatic artery.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatic Artery; Humans; Injections, In | 1987 |
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile; Carcinoma, Hepatocellula | 1987 |
Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Therapy, Computer-Assisted; Fluorouracil; Humans; In Vitro Tec | 1987 |
Combination chemotherapy for unresectable hepatoblastoma in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1987 |
Intraarterial injection of anti-tumor drugs dispersed in lipid contrast medium: a choice for initially unresectable hepatoblastoma in infants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1987 |
Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Fluorouracil; Follow- | 1986 |
Combination chemotherapy for advanced colorectal cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
[A case of multiple liver metastases from sigmoid carcinoma treated successfully with arterial infusion chemotherapy].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Dru | 1986 |
Requirements and results of liver perfusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Follow-Up Studies; Humans; Infusions, | 1986 |
[The features of liver metastasis of breast cancer on imaging and its response to arterial infusion chemotherapy].
Topics: Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubi | 1986 |
Clinical course of breast cancer patients with liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; | 1987 |
Mitomycin C associated hemolytic uremic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Hemolyti | 1987 |
Rationale and indications for perfusion in liver tumors: current data.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1987 |
[A case of gastric cancer with marked response to intra-arterial infusion of cisplatinum, mitomycin C and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Infusions, | 1987 |
Successful treatment of multiple liver metastases by liver perfusion.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Heparin; | 1987 |
[A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU].
Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Fluorouracil; Humans; Interferon-gamma; Liver Neopl | 1987 |
[Clinical observations of hepatic artery infusion therapy combined with hepatic artery ligation in metastatic liver cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug Adminis | 1988 |
[Intra-arterial chemotherapy of colorectal liver metastases with 5-fluorouracil (5-FU) and mitomycin C (MMC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1987 |
[Results of intra-arterial infusion chemotherapy in colorectal cancer patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Colonic Neoplasms; Combined Modality Th | 1988 |
[Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion | 1988 |
[Regional therapy of isolated liver metastases from breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling | 1988 |
[Hepatic artery chemoembolization in the treatment of primary liver cancer].
Topics: Adult; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluorouracil; Gelatin Sponge, A | 1988 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
Treatment of hepatic metastases.
Topics: Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Floxuridine; Fluorouracil; Huma | 1985 |
Treatment of colorectal cancer hepatic metastases by hepatic artery chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Floxuridine; Fluorour | 1985 |
[Portable infusion pump for ambulatory cytostatic therapy in inoperable liver metastases].
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Infusion Pumps; Live | 1988 |
RNA labelling with 3H-orotic acid and 3H-fluorouracil of rat liver tumour following transient hepatic arterial ischaemia.
Topics: Animals; DNA, Neoplasm; Fluorouracil; Hepatic Artery; Ischemia; Liver Neoplasms; Male; Orotic Acid; | 1988 |
Phase I-II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Humans; Liver Neoplasms; Middl | 1988 |
Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5-fluorouracil infusion and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Humans | 1988 |
[Intra-arterial 5-fluorouracil chemotherapy in liver metastases of colorectal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arter | 1988 |
Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1988 |
Regional therapy of malignant liver tumors.
Topics: Animals; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasm | 1988 |
Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.
Topics: Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorouracil; Humans; Kin | 1987 |
Phase II evaluation of sequential hepatic artery infusion of 5-fluorouracil and hepatic irradiation in metastatic colorectal carcinoma.
Topics: Colonic Neoplasms; Combined Modality Therapy; Drug Evaluation; Female; Fluorouracil; Humans; Infusio | 1988 |
Intraperitoneal infusion of 5-FU in liver metastases from colorectal cancer.
Topics: Abdomen; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Liver Neoplasms; Mal | 1988 |
Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
Topics: Albumins; Angiotensin II; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Injections, Intra | 1988 |
[Clinical results and problems of total-body thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Ther | 1988 |
Salvage of blocked hepatic artery infusion catheters for regional therapy of metastatic liver disease.
Topics: Arterial Occlusive Diseases; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Coloni | 1988 |
[Study on microspheres for embolization of the hepatic artery].
Topics: Animals; Delayed-Action Preparations; Dogs; Embolization, Therapeutic; Fluorouracil; Gelatin; Hepati | 1988 |
Hepatic arterial ligation with and without portal infusion in metastatic colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Hum | 1988 |
Basic investigations on interaction of 5-fluorouracil and tumor ischemia in the treatment of liver malignancies.
Topics: Adenocarcinoma; Animals; Combined Modality Therapy; Female; Fluorouracil; Humans; Ischemia; Liver Ne | 1988 |
[5-FU/ADR/MMC combined hepatic infusion in liver metastases from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Doxorubicin; Drug Evaluation; Fem | 1988 |
[Transcatheter arterial chemoembolization and selective hepatic arterial infusion using totally implantable reservoir].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Embolization, Therap | 1988 |
Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1988 |
A new technique for hepatic infusional chemotherapy.
Topics: Catheterization, Peripheral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1986 |
[Prevention of hepatic metastasis in patients operated on for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Epirubicin; Fluorour | 1987 |
The rationale for intra-arterial chemotherapy.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Epirubicin; Fluorouracil; Humans; Injections, Intra-Art | 1987 |
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fl | 1987 |
[Response to hepatic intra-arterial chemotherapy for metastases of colorectal cancer. Anatomo-pathological evaluation apropos of 3 cases of secondary hepatic excision].
Topics: Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intra-Arteria | 1987 |
A case of pancreatic cancer with liver metastasis which responded to chemotherapy.
Topics: Cisplatin; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1987 |
Cannulation of the portal vein for cytotoxic liver perfusion in colorectal carcinomas: an alternative approach.
Topics: Adenocarcinoma; Antineoplastic Agents; Catheterization; Colonic Neoplasms; Fluorouracil; Humans; Liv | 1987 |
Technetium-99m macroaggregates for the study of the distribution of arterial infusion chemotherapy in the liver.
Topics: Adolescent; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Mi | 1987 |
[Chemoembolization of hepatic metastases. Preliminary study].
Topics: Adult; Aged; Antineoplastic Agents; Doxorubicin; Embolization, Therapeutic; Female; Fluorouracil; He | 1987 |
Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Inf | 1987 |
[Preliminary results of a phase II study of 5-FU, adriamycin, and mitomycin C (FAM) in combined hepatic infusion in patients with non-resectable metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Dr | 1987 |
[Regional intra-arterial infusion in combination chemotherapy with IFN-beta, MMC and 5-FU (beta-MF chemotherapy) in liver tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Injections, Intr | 1987 |
[The effect and CT imaging of FAM hepatic infusion chemotherapy in patients with liver metastasis from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil | 1987 |
[Home treatment of cancer: experiences with ambulatory intra-arterial chemotherapy of liver metastases].
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Home Care Services; Hum | 1987 |
Cardiotoxicity during chemotherapy for advanced gastroenteric tumors.
Topics: Adult; Antineoplastic Agents; Doxorubicin; Female; Fluorouracil; Heart; Humans; Liver Neoplasms; Mal | 1987 |
Temporary blood flow stasis with degradable starch microspheres (DSM) for liver metastases in a rat model.
Topics: Animals; Disease Models, Animal; Drug Carriers; Fluorouracil; Hemostasis; Hepatic Artery; Injections | 1987 |
Tumor and liver drug uptake following hepatic artery and portal vein infusion.
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; In | 1987 |
Gastric cancer with synchronous unresectable hepatic metastasis and a positive response to chemotherapy--report of two cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Humans; In | 1987 |
[Angina pectoris during regional chemotherapy of liver metastases].
Topics: Angina Pectoris; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms | 1987 |
Survival following self-administered chemotherapy for liver metastases.
Topics: Catheters, Indwelling; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Prognosis; Self Adm | 1987 |
[Clinico-biochemical findings in malignant carcinoid during cytostatic therapy (description of a case)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; | 1986 |
Ambulatory hepatic artery infusion chemotherapy for cancer of the liver.
Topics: Adult; Aged; Ambulatory Care; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Gastro | 1986 |
[A new anticancer preparation, 5-fluorouracil-poly-L-lactic acid microcapsule, and its therapeutic evaluation].
Topics: Adult; Aged; Animals; Capsules; Delayed-Action Preparations; Embolization, Therapeutic; Female; Fluo | 1986 |
Hepatic dearterialization in cancer: new perspectives.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Fluorour | 1986 |
Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: a multivariate analysis.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion | 1986 |
Permanent hepatic artery ligation versus temporary dearterialization in the treatment of hepatic tumors.
Topics: Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Liver Neoplasms | 1986 |
[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Parenter | 1986 |
Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ev | 1986 |
Subclinical hepatic toxicity during combination chemotherapy for breast cancer.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; B | 1986 |
[4-component chemotherapy and radiation therapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality | 1986 |
Response of colo-rectal hepatic metastases to concomitant radiotherapy and intravenous infusion 5 fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1986 |
[Intrahepatic-artery infusion of cis-diamminedichloroplatinum (II) and 5-fluorouracil in primary or metastatic liver cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hepati | 1987 |
[Intra-arterial infusion chemotherapy using a subcutaneously implanted silicone reservoir--with reference to the chemotherapy protocol].
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cytarabi | 1985 |
[A case of complete regression of gastric carcinoma and liver metastases by treatment with tegafur].
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Liver Neoplasms; Male; Stomach Neoplasms; Tegafur | 1985 |
[Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas].
Topics: Biliary Tract Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Lymph Nodes; Pancreatic Neoplasms; P | 1985 |
Long-term survivors of colorectal cancer with unresectable hepatic metastases.
Topics: Administration, Oral; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Human | 1985 |
[A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Colonic Neoplasms; Fluor | 1985 |
[Intra-arterial infusion chemotherapy of hepatic carcinoma using a totally-implantable Infusaid pump].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Catheterization; Fluorouraci | 1985 |
[Intra-arterial continuous infusion in patients with advanced and recurrent cancer of the digestive system].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1985 |
[Multimodality therapy of colorectal cancer].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Emboliz | 1985 |
[A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cy | 1985 |
[Cardiotoxicity of 5-fluorouracil. Apropos of a new case].
Topics: Coronary Disease; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged | 1985 |
Cardiac toxicity of 5-fluorouracil. Report of a case of spontaneous angina.
Topics: Angina Pectoris; Colonic Neoplasms; Electrocardiography; Fluorouracil; Humans; Liver Neoplasms; Male | 1986 |
Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1985 |
Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modal | 1985 |
Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic N | 1985 |
[Therapy-induced tumor regression. Morphological findings in malignant primary and secondary liver tumors following intensive regional cytostatic treatment].
Topics: Adenocarcinoma; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Doxoru | 1985 |
Evaluation of treatment for gastric cancer with liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Evaluation Studies as Topic; Female; Fl | 1985 |
Unresectable hepatic metastases from carcinoma of the colon and rectum.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Carcinoembryon | 1985 |
Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.
Topics: Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Hepatic Artery; Hum | 1985 |
A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Ev | 1985 |
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1985 |
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, | 1971 |
Effect of various anticancer agents on DNA polymerase.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Bone | 1971 |
[Selection of a method for treating cancer of the pancreaticoduodenal region].
Topics: Bile Duct Neoplasms; Cyclophosphamide; Duodenal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Huma | 1971 |
Prolonged intermittent arterial infusion for metastatic carcinoma of the liver.
Topics: Adult; Aged; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Hepati | 1972 |
Disappearance of hepatic cancer after intra-arterial fluorouracil.
Topics: Autopsy; Bile Ducts; Fluorouracil; Humans; Injections, Intra-Arterial; Liver; Liver Neoplasms; Lymph | 1972 |
Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma.
Topics: Adolescent; Adult; Age Factors; Alpha-Globulins; Blood Transfusion; Carcinoma, Hepatocellular; Femal | 1972 |
Carcinoma of pancreas--palliative radiotherapy.
Topics: Carcinoma; Cobalt Isotopes; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Palliative C | 1973 |
Inhibition of ribosomal ribonucleic acid maturation by 5-azacytidine and 8-azaguanine in Novikoff hepatoma cells.
Topics: Animals; Azacitidine; Azaguanine; Carcinoma, Hepatocellular; Cells, Cultured; Cytidine; Dactinomycin | 1974 |
[Cytostatic treatment of liver cancer].
Topics: Fluorouracil; Humans; Liver Neoplasms; Palliative Care | 1974 |
A carcinoid saga.
Topics: Anesthesia, General; Aprotinin; Carcinoid Tumor; Female; Fluorouracil; Hepatectomy; Humans; Hydroxyi | 1974 |
Response of alpha-fetoprotein to chemotherapy in patients with hepatomas.
Topics: Adult; Aged; Alpha-Globulins; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; | 1974 |
[Attack on liver cancer--what's the value of diagnosis and treatment?].
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Middle | 1974 |
[Intra-arterial treatment of malignant neoplasms in children (author's transl)].
Topics: Adolescent; Carcinoma, Hepatocellular; Child; Female; Fluorouracil; Humans; Injections, Intra-Arteri | 1972 |
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female; | 1970 |
Palliative treatment of metastatic carcinoma of the liver by hepatic artery infusion with 5-fluorouracil: report of a case.
Topics: Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neo | 1967 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
Hepatic artery infusion chemotherapy in hepatoma.
Topics: Aged; Alkaline Phosphatase; Angiography; Aorta; Brachial Artery; Carcinoma, Hepatocellular; Catheter | 1968 |
[Loco-regional and sequential chemotherapy of advanced cancer].
Topics: Adult; Carcinoma; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Dysgerminoma; | 1968 |
Metastatic colorectal carcinoma. Response to hepatic infusion. A review.
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms | 1970 |
Malignant hepatoma in the Bantu.
Topics: Adenoma, Bile Duct; Africa, Eastern; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotra | 1970 |
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs.
Topics: Adenocarcinoma; Aged; Angiography; Aortography; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perf | 1970 |
Echographic evaluation of abdominal tumor regression during antineoplastic treatment.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorub | 1974 |
An evaluation of 51 patients with hepatic artery infusion.
Topics: Antineoplastic Agents; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepat | 1966 |
Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver.
Topics: Adenocarcinoma; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arte | 1967 |
Hepatic artery catheterization for chemotherapy.
Topics: Angiography; Catheterization; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenter | 1968 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Practical aspects of investigation and treatment of colorectal cancer.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Parenteral; Liver Function | 1972 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon.
Topics: Age Factors; Aspartate Aminotransferases; Catheterization; Chemotherapy, Cancer, Regional Perfusion; | 1974 |
Hypercalcemia in cancer: response to therapy.
Topics: Adenocarcinoma; Adult; Allopurinol; Antineoplastic Agents; Calcium; Cyclophosphamide; Fluorouracil; | 1974 |
Infusion chemotherapy in hepatoma and metastatic liver tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; | 1967 |
Infusion of liver tumours.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Floxurid | 1968 |
[Primary cancer of the liver in a child detected by angiography and treated by exeresis and antimitotics].
Topics: Adolescent; Angiography; Carcinoma, Hepatocellular; Cholangiography; Diagnosis, Differential; Echino | 1968 |
[Apropos of a hepatoma: rôle of regional chemotherapy].
Topics: Adult; Carcinoma, Hepatocellular; Fluorouracil; Hepatomegaly; Humans; Liver Neoplasms; Male; Perfusi | 1968 |
[Cancer of the body of the pancreas with hepatic metastases].
Topics: Abdomen; Blindness; Catheterization; Cholangiography; Coma; Diagnosis, Differential; Fluorouracil; H | 1968 |
Infusion of liver tumours.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Hepatomegaly; Hum | 1968 |
[Treatment of cancer of the liver by regional perfusion].
Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci | 1968 |
[Comments on the treatment of solid tumors with 5-fluorouracil].
Topics: Adenocarcinoma, Scirrhous; Adult; Breast Neoplasms; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1969 |
[Clinical study on continuous 5-FU infusion for the treatment of primary liver cancer].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Injections, Intra-Arterial; In | 1970 |
Metabolically active liver metastases treated by 5-fluorouracil hepatic artery infusion.
Topics: Adenoma, Islet Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Hepatic Artery; Hormones, Ectop | 1970 |
[Autopsy case of liver cancer undetected until the terminal stage].
Topics: Aged; Antineoplastic Agents; Autopsy; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Functio | 1970 |
[Some data from a biochemical study of patients with primary cancer of the liver during chemotherapy].
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms | 1970 |
Hepatoma: long-term survival with disseminated tumor treated with 5-fluorouracil.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Long-Term Care; Lung Neoplasms; Ma | 1970 |
Cutaneous porphyria due to a malignant primary hepatoma.
Topics: Aged; Carcinoma, Hepatocellular; Feces; Female; Fluorouracil; Humans; Liver Neoplasms; Photosensitiv | 1970 |
Considerations in the development of a predictive system for cancer chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; DNA; Floxuridine; Fluorouracil; Liver N | 1971 |
Experience with hepatic arterial infusions.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall | 1971 |
Catheterization of the umbilical vein and its use for hepatography.
Topics: Adenocarcinoma; Adult; Aged; Angiography; Breast Neoplasms; Catheterization; Diatrizoate; Female; Fl | 1971 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
[Study in man of recirculation and tissue uptake of 5-FU 6 H3].
Topics: Adenoma, Bile Duct; Antimetabolites; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfu | 1971 |
Primary cancer of the liver: a review of 25 cases and report of two prolonged survivals.
Topics: Adult; Aged; Body Weight; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatectomy; Humans; Live | 1972 |
[Effects of selective administration of anticancer agents in massive dosage combined with fibrolytic enzyme (urokinase) in hepatic cancer].
Topics: Carcinoma, Hepatocellular; Fibrinolytic Agents; Fluorouracil; Humans; Liver Neoplasms; Male; Middle | 1972 |
Continuous prolonged intrahepatic infusion of 5-fluorouracil in the treatment of hepatoma in Ibadan.
Topics: Adult; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Li | 1972 |
[Intra-arterial chemotherapy of primary hepatoma and changes in -fetoprotein levels].
Topics: Aged; Carcinoma, Hepatocellular; Female; Fetal Proteins; Fluorouracil; Humans; Injections, Intra-Art | 1972 |
[Clinical studies of primary hepatic carcinoma].
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Alkaline Phosphatase; Autopsy; Biopsy; Carcinoma, Hepat | 1971 |
Malignant insulinoma with hepatic secondaries treated with hepatic artery ligation.
Topics: Adenoma, Islet Cell; Aged; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms; Male; Ne | 1973 |
Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine.
Topics: Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Cell Line; Electrophoresis; Fluorine; Fluoroura | 1973 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
The surgical management of primary hepatocellular carcinoma in Uganda.
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Catheterization; Female; Fluorouracil; Hepatectomy; He | 1973 |
Proceedings: Primary liver cancer. A review of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases.
Topics: ABO Blood-Group System; Adenoma, Bile Duct; Adolescent; Adult; Aged; Alanine Transaminase; Alkaline | 1974 |
Hepatoma, erythrocytosis and increased serum erythropoietin developing in long-standing hemochromatosis.
Topics: Aged; Animals; Biopsy, Needle; Carcinoma, Hepatocellular; Chronic Disease; Erythropoietin; Female; F | 1974 |
Experience with infusion and resection in cancer of the liver.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Female | 1974 |
The deoxyribonucleoside transport systems of cultured Novikoff rat hepatoma cells.
Topics: Animals; Biological Transport; Carcinoma, Hepatocellular; Cell Line; Cell Membrane Permeability; Cel | 1974 |
Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1974 |
Primary liver carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular; | 1974 |
Polyamine depletion of tumor tissue and subsequent elevation of spermidine in the sera of rats with 3924A hepatomas after 5-fluorouracil administration.
Topics: Animals; Carcinoma, Hepatocellular; Female; Fluorouracil; Liver; Liver Neoplasms; Neoplasms, Experim | 1974 |
Incorporation of precursors and inhibitors of nucleic acid synthesis into hepatomas and liver of the rat.
Topics: Amino Acids; Animals; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Line; Fluorouracil; Inje | 1974 |
Metabolic studies of 5-fluorouracil. II. Influence of the route of administration on the dynamics of distribution in man.
Topics: Administration, Oral; Bile; Carbon Radioisotopes; Carcinoma, Hepatocellular; Chromatography, Thin La | 1974 |
[Treatment of liver cancer with oral administration of N-(2'-furanidyl)-5 fluorouracil (FT207) (author's transl)].
Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver N | 1974 |
Studies on the mechanism and prevention of local recurrence of carcinoma at the suture line after colonic resection.
Topics: Animals; Carcinoma, Hepatocellular; Colon; Colonic Neoplasms; Fluorouracil; Intestinal Mucosa; Liver | 1971 |
Major hepatic resection using vascular isolation and hypothermic perfusion.
Topics: Cyclophosphamide; Dactinomycin; Fluorouracil; Hepatectomy; Hepatic Veins; Humans; Hypothermia, Induc | 1974 |
A second look at the second operation in colonic cancer after the administration of fluorouracil.
Topics: Biopsy; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphat | 1974 |
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi | 1974 |
Systemic 5-fluorouracil in hepatic metastases from primary colon or rectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Hepatic metastases from rectal and colon cancers. Treatment by infusion of 5-fluorouracil into umbilical vein.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Liver scanning for the detection of metastases following colo-rectal cancer surgery.
Topics: Adenocarcinoma; Adult; Celiac Artery; Colonic Neoplasms; Female; Fluorouracil; Gold Isotopes; Hepate | 1973 |
Multiple arterial infusions with 5-fluorouracil.
Topics: Catheterization; Clinical Enzyme Tests; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Li | 1972 |
Results of 27 cases with hepatic metastases treated by combination chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Humans; | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
One shot administration of antineoplastic agents in massive doses via the celiac artery for inoperable cancer of the liver.
Topics: Angiography; Celiac Artery; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intra-Arterial; | 1972 |
The treatment of metastatic carcinoma of the liver by the percutaneous selective hepatic artery infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Injections, Intra-Arter | 1973 |
Cytotoxic perfusion of the liver via the umbilical vein for liver metastases in carcinoma of the colon.
Topics: Aged; Blood Sedimentation; Cholestasis; Colonic Neoplasms; Diarrhea; Fluorouracil; Humans; Leukocyte | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
[Intraportal chemotherapy for hepatic metastases].
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Humans; Injections, Intraveno | 1973 |
Radiotherapy for bronchogenic carcinoma: actual difficulties and plans for the future.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide | 1973 |
The treatment of jaundice due to liver metastases by quadruple chemotherapy.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Jaundice; Liver Neoplasms; Meth | 1973 |
Comparison of hepatic angiography with reticuloendothelial and transcatheter macroaggregated radioisotope scanning.
Topics: Angiography; Catheterization; Fluorouracil; Humans; Liver Neoplasms; Radionuclide Imaging | 1973 |
Intra-arterial cancer chemotherapy with combined anticancer agents.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Deoxycytidine; Drug Therapy, Combination | 1973 |
The administration of 5-fluorouracil by mouth.
Topics: Adenocarcinoma; Administration, Oral; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart | 1974 |
Serial liver scanning. Metastatic disease.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injectio | 1974 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
[Cytostatics in the regional chemotherapy of malignant tumors of the abdominal organs and of their liver metastases].
Topics: Abdominal Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Humans; Liver N | 1974 |
Scan evidence of decrease in size of intrahepatic tumors after chemotherapy. A case report.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cecal Neoplasms; Doxorubicin; Female; Fluorouracil; Human | 1974 |
Sequential liver scanning.
Topics: Adult; Breast Neoplasms; Chloroquine; Colonic Neoplasms; Dactinomycin; Emetine; Estrogens; Female; F | 1969 |
Cancer of the liver. Intra-arterial infusion.
Topics: Adult; Aged; Catheterization; Celiac Artery; Female; Fluorouracil; Hepatic Artery; Humans; Injection | 1972 |
Intrahepatic arterial infusion with 5-fluorouracil.
Topics: Fluorouracil; Injections, Intra-Arterial; Injections, Intraperitoneal; Liver Neoplasms | 1972 |
5-Hydroxyindole-secreting rectal carcinoid tumour.
Topics: Adult; Carcinoid Tumor; Duodenal Ulcer; Female; Fluorouracil; Humans; Hydroxyindoleacetic Acid; Live | 1972 |
Evaluation of hepatic dearterialization in primary and secondary cancer of the liver.
Topics: Adult; Aged; Female; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver; Liver Neoplasms; Lymphom | 1972 |
Hepatic artery ligation and cytotoxic infusion in treatment of liver metastases.
Topics: Aged; Alkaline Phosphatase; Female; Fluorouracil; Gallbladder Neoplasms; Hepatic Artery; Humans; Inj | 1972 |
Treatment of hepatic tumours by ligation of the hepatic artery and infusion of cytotoxic drugs.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1972 |
[Local intra-arterial infusion chemotherapy of malignant tumor--successful treatment by intra-arterial infusion of 5-fluorouracil and mitomycin C in cases of unresectable cancer of the liver, stomach, colon and rectum].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infant; Injections, Intra-Arterial; Li | 1971 |
Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth.
Topics: Administration, Oral; Aged; Bone Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver C | 1971 |
Treatment of metastatic breast cancer with a combination of adrenalectomy and 5-fluorouracil. Progress report.
Topics: Adrenalectomy; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Huma | 1971 |
Intrahepatic arterial infusion with 5-fluorouracil.
Topics: Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Hepatic Artery; Humans; Liver Neoplasms; Neo | 1971 |
Chemotherapy for metastatic colorectal liver carcinoma by intra-aortic infusion.
Topics: Antineoplastic Agents; Aorta, Abdominal; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms | 1971 |
[5-FU excretion in anticarcinogenic therapy in liver cancer].
Topics: Carbon Isotopes; DNA; Endoplasmic Reticulum; Fluorouracil; Humans; Liver Neoplasms; Uracil Nucleotid | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
[Loco-regional intra-arterial therapy of liver neoplasms].
Topics: Adult; Aged; Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; Liver Circulation; Liver | 1969 |
[Polychemotherapy of bronchial carcinoma].
Topics: Aged; Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Fluorouracil; | 1970 |
A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Fluorouraci | 1970 |
Survival of patients treated with systemic fluorouracil for hepatic metastases.
Topics: Adult; Age Factors; Aged; Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hum | 1970 |
The influence of treatment on the survival of patients with hepatic metastases diagnosed by liver scanning.
Topics: Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Hepatectomy; Humans; | 1970 |
Infusion chemotherapy for metastatic liver cancer.
Topics: Adolescent; Antineoplastic Agents; Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; In | 1970 |
Treatment of hepatic tumours.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Hepatic Artery; Humans; Laparotomy; Lei | 1970 |
[Treatment of metastases to the liver in the course of sigmoid and rectal cancer].
Topics: Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Methods; Neoplasm Metastasis | 1970 |
One-shot infusion of non-surgically administered mitomycin C in the celiac artery for liver metastases. Clinical effects.
Topics: Adult; Aged; Angiography; Blood Cell Count; Blood Platelets; Celiac Artery; Colonic Neoplasms; Femal | 1970 |
[Intra-portal infusion of 5-fluorouracil for metastasis of rectal cancer into the liver].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Liver Neoplasms; Middle | 1970 |
[Chemotherapy of hepatic cancer--evaluation of local administration via porta vain].
Topics: Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Injections, Intra-Arterial; Injection | 1970 |
Hepatic coma secondary to metastatic liver disease.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Breast Neoplasms; Colonic Neoplasms; Fluorouracil | 1971 |
[On a method of treating patients with cancer of the stomach with 5-fluorouracil].
Topics: Aged; Duodenal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Stomac | 1967 |
Liver regeneration after major hepatectomy. Effect of chemotherapy on growth and function--case report.
Topics: Adenocarcinoma; Female; Fluorouracil; Gallbladder Neoplasms; Gold Isotopes; Hepatectomy; Humans; Liv | 1968 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
A radioisotopic method for determining optimum non-surgical therapy for advanced cancer. II. Clinical experience.
Topics: Adenocarcinoma; Breast Neoplasms; Diethylstilbestrol; Female; Fluorouracil; Fluoxymesterone; Gastroi | 1968 |
Infusion of liver tumours.
Topics: Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Liver Neoplasms | 1968 |
[Topical intra-arterial infusion of antineoplastic agents].
Topics: Adult; Aged; Antimetabolites; Catheterization; Female; Femoral Neoplasms; Fluorouracil; Humans; Inje | 1968 |
Prolonged continuous hepatic infusion. Results with fluorouracil for primary and metastatic cancer in the liver.
Topics: Adult; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorou | 1969 |
[Local arterial infusion of antineoplastic agents and its application, with special reference to chemotherapy of liver tumors by hepatic artery infusion of 5FU].
Topics: Antineoplastic Agents; Catheterization; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arte | 1969 |
Chemotherapy for liver cancer by protracted ambulatory infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans | 1965 |
Augmentation of lymphatic uptake of chemotherapeutic agents by induced hepatic outflow block.
Topics: Animals; Carbon Isotopes; Chemotherapy, Cancer, Regional Perfusion; Dogs; Fluorouracil; Hepatic Arte | 1966 |